
ENVIRONMENTAL ENTERIC DYSFUNCTION: ADVANCING CURRENT KNOWLEDGE

**Donna M. Denno M.D. M.P.H., Kelley M. VanBuskirk Ph.D. M.P.H.,
Zakia C. Nelson M.P.H., Christine A. Musser B.F.A., Phillip I. Tarr M.D.**

Copyright © 2016 Donna M. Denno, Kelley M. VanBuskirk, Zakia C. Nelson, Christine A. Musser and Phillip I. Tarr

Except otherwise noted, this work is made available under a Creative Commons Attribution License. <http://creativecommons.org/licenses/by/4.0/>

The image on p. 63 is excluded from the Creative Commons Attribution License. The image on p. 63 is reproduced from *Gut*, Booth, C.C., Vol. 5, p. 46, 1964 with permission from BMJ Publishing Group Ltd.

You are free to:

- **Share** — copy and redistribute the material in any medium or format
- **Adapt** — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.

Under the following terms:

- **Attribution** — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Attribute as follows:

“Denno, DM, VanBuskirk, KM, Nelson, ZC, Musser, CA, Tarr, PI. (2016). Environmental enteric dysfunction: Advancing current knowledge. St. Louis, MO: Washington University Libraries. <http://dx.doi.org/10.7936/K7WQ0228>

This work is licensed under a Creative Commons Attribution License. <http://creativecommons.org/licenses/by/4.0/> This is an [edited or unedited] version of the original.”

- **No additional restrictions** — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

Notices:

- You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation.
- No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.

TABLE OF CONTENTS

ACKNOWLEDGMENTS	viii
ABBREVIATIONS	ix
SYNOPSIS	xi
CHAPTER 1. ENVIRONMENTAL ENTERIC DYSFUNCTION (EED) BACKGROUND	1
1.1 EED HISTORY AND OVERVIEW	1
1.2 AN OLD PROBLEM REQUIRING NEW KNOWLEDGE	3
1.3 PATHOPHYSIOLOGIC PROCESSES AND CONSEQUENCES OF EED	7
1.4 THE ROLE OF BIOMARKERS AND DIAGNOSTICS IN EED	12
1.5 SCIENTIFIC BASIS FOR THIS REVIEW	13
CHAPTER 2. METHODOLOGY: BUILDING THE EED LIBRARY AND UNDERTAKING A SYSTEMATIC REVIEW OF EED BIOMARKERS/ DIAGNOSTICS	15
2.1 EED: A BROAD FIELD, MANY UNANSWERED QUESTIONS	15
2.2 CONSTRUCTING A SYSTEMATIC SEARCH STRATEGY: OPTIMIZING SENSITIVITY	20
2.3 REFERENCE VOLUME MITIGATION	23
2.4 BUILDING THE EED LIBRARY	25
CHAPTER 3. EED LIBRARY AS A BASIS FOR SYSTEMATIC REVIEWS	34
3.1 DEFINING SYSTEMATIC REVIEW QUESTION PRIORITIES	34
3.2 DETERMINING RELEVANCE TO THE SYSTEMATIC REVIEW	36
3.3 ACQUISITION OF REFERENCES AND COPYRIGHT FAIR USE COMPLIANCE	42
3.4 DOCUMENTING RELEVANCE TO THE SYSTEMATIC REVIEW	42

3.5 DATA EXTRACTION FOR THE SYSTEMATIC REVIEW	43
3.6 EED LIBRARY: SEARCH RESULTS OVERVIEW	44
3.7 QUALITY CONTROL	45
3.8 EED LIBRARY STATUS	46
CHAPTER 4. SYSTEMATIC REVIEW OF EED BIOMARKERS/ DIAGNOSTIC TESTS: RESULTS SYNOPSIS	48
4.1 BIOMARKERS AND DIAGNOSTICS SYSTEMATIC SEARCH RESULTS	48
4.2 CHARACTERISTICS OF REFERENCES INCLUDED IN THE SYSTEMATIC REVIEW	50
4.3 CLASSIFICATION OF BIOMARKERS AND DIAGNOSTIC TESTS	61
CHAPTER 5. SYSTEMATIC REVIEW RESULTS BY BIOMARKER CLASSIFICATIONS	63
5.1 MARKERS OF ABSORPTION AND PERMEABILITY: OVERVIEW	63
5.1.1 SUGARS AS TRACERS OF INTESTINAL FUNCTION	64
5.1.2 ENDOMOLECULAR NUTRIENTS AS TRACERS OF INTESTINAL FUNCTION	68
5.2 MARKERS OF ABSORPTION	69
5.2.1 D-XYLOSE	83
5.2.2 ENDOMOLECULAR CHALLENGE ABSORPTION TESTS	85
5.2.3 ENTEROCYTE-SPECIFIC PROTEINS	86
5.2.4 FECAL FAT	87
5.2.5 SUMMARY OF MARKERS OF ABSORPTION	88
5.3 MARKERS OF PERMEABILITY	90
5.3.1 THE URINARY LACTULOSE:MANNITOL RATIO (L:M)	124
5.3.1.1 TECHNICAL ISSUES WITH THE L:M TEST	124
5.3.1.2 RANGE OF L:M VALUES REPORTED	138
5.3.1.3 ASSOCIATIONS BETWEEN L:M AND GROWTH OUTCOMES	141
5.3.1.4 ASSOCIATIONS BETWEEN L:M AND OTHER OUTCOMES	144
5.3.1.5 USE OF THE L:M TEST AS AN ENDPOINT FOR INTERVENTION TRIALS	145
5.3.1.6 ASSOCIATIONS BETWEEN L:M AND OTHER MARKERS	147
5.3.2 THE LACTULOSE:RHAMNOSE RATIO (L:R)	147
5.3.2.1 THE L:R TEST AS A REFLECTION OF ISSUES IN SERUM OR URINE SUGAR TESTING IN CHILDREN	148
5.3.2.2 RANGE OF L:R VALUES REPORTED AND ASSOCIATIONS WITH GROWTH OUTCOMES	150
5.3.2.3 ASSOCIATIONS BETWEEN L:R AND OTHER MARKERS	152
5.3.2.4 METHODOLOGICAL ISSUES WITH THE L:R TEST	152
5.3.3 SERUM AND URINARY LACTOSE	153

5.3.4 SUMMARY OF MARKERS OF PERMEABILITY	154
5.4 MARKERS OF DIGESTION	157
5.4.1 SUCROSE AND LACTOSE BREATH TESTS	172
5.4.2 STOOL REDUCING SUBSTANCES	174
5.4.3 INTESTINAL DISACCHARIDASES	175
5.4.4 ¹³ C ASSESSMENT IN STOOL AFTER LIPID ADMINISTRATION	176
5.4.5 URINARY LACTOSE:LACTULOSE RATIO	176
5.4.6 SUMMARY OF MARKERS OF DIGESTION	177
5.5 MARKERS OF INTESTINAL INFLAMMATION AND INTESTINAL IMMUNE ACTIVATION	178
5.5.1 FECAL LACTOFERRIN	195
5.5.1.1 PREVALENCE OF FECAL LACTOFERRIN	195
5.5.1.2 ASSOCIATIONS BETWEEN FECAL LACTOFERRIN AND GROWTH OR OTHER OUTCOMES	196
5.5.1.3 ASSOCIATION BETWEEN FECAL LACTOFERRIN AND OTHER MARKERS	197
5.5.1.4 METHODOLOGICAL ISSUES WITH THE FECAL LACTOFERRIN TEST	197
5.5.2 FECAL CYTOKINES	198
5.5.2.1 PREVALENCE OF FECAL CYTOKINES	198
5.5.2.2 ASSOCIATIONS BETWEEN FECAL CYTOKINES AND GROWTH OR OTHER OUTCOMES	199
5.5.2.3 ASSOCIATIONS BETWEEN FECAL CYTOKINES AND OTHER MARKERS	200
5.5.3 FECAL LEUKOCYTES	200
5.5.4 FECAL NEOPTERIN	201
5.5.5 FECAL IgE	201
5.5.6 INFLAMMATORY INTESTINAL CELL MARKERS	201
5.5.7 INTESTINAL TISSUE CYTOKINES AND IMMUNE MARKERS	202
5.5.8 DUODENAL ASPIRATES FOR IMMUNOGLOBULINS	203
5.5.9 SUMMARY OF MARKERS OF INTESTINAL INFLAMMATION	203
5.6 MARKERS OF SYSTEMIC INFLAMMATION AND SYSTEMIC IMMUNE ACTIVATION	204
5.7 MARKERS OF MICROBIAL DRIVERS	232
5.7.1 LACTULOSE HYDROGEN BREATH TEST (HBT)	238
5.7.2 ¹³ CO ₂ IN BREATH OR STOOL AFTER ADMINISTRATION OF ¹³ C GLYCOCHOLATE AS MARKER FOR SBBO	238
5.7.3 INTESTINAL ASPIRATES FOR BACTERIAL CONCENTRATIONS	239
5.8 MARKERS OF NONSPECIFIC INTESTINAL INJURY	239
5.9 MARKERS OF EXTRA-SMALL INTESTINAL FUNCTION	262
5.10 RELATIONSHIPS BETWEEN MARKERS OF EED, INCLUDING HISTOPATHOLOGY	270
5.11 RELATIONSHIPS BETWEEN EED BIOMARKERS AND GROWTH OR OTHER OUTCOMES OF INTEREST	272
CHAPTER 6. CONCLUSIONS AND FUTURE IMPLICATIONS	277

6.1 SUMMARY OF FINDINGS	277
6.2 FUTURE BIOMARKER AND DIAGNOSTICS RESEARCH	277
APPENDICES	288
REFERENCES	395

LIST OF FIGURES

FIGURE 1. LIST OF PLAUSIBLY RELEVANT LITERATURE FROM 1980 TO 2010.....	4
FIGURE 2. THE VICIOUS CYCLE OF INTESTINAL DYSFUNCTION, INFECTIOUS DISEASE SUSCEPTIBILITY, POOR GROWTH, AND DEVELOPMENT.....	9
FIGURE 3. EED-RELATED PATHOPHYSIOLOGICAL PROCESSES RESULT IN STUNTING AND/OR GROWTH SHORTFALL.	10
FIGURE 4. EED SYSTEMATIC REVIEW PROCESSES FLOW CHART.....	21
FIGURE 5. EED LIBRARY INCLUSION SCHEMATIC.	29
FIGURE 6. FLOWCHART OF PROJECT PROCEDURE RESULTS.....	45
FIGURE 7. GEOGRAPHIC MAPPING OF STUDY SITES.	54

LIST OF TABLES

TABLE 1. SPECTRUM OF ETIOLOGIES, OUTCOMES, AND BIOMARKERS/DIAGNOSTICS IN EED.	14
TABLE 2. TOPIC AREAS AND QUESTIONS.....	16
TABLE 3. SUMMARY OF ANALYSIS OPTIONS.....	25
TABLE 4. SUMMARY OF EED LIBRARY INCLUSION/EXCLUSION INSTRUCTIONS TO RESEARCH ANALYSTS.....	27
TABLE 5. ADDITIONAL EED LIBRARY INCLUSION/EXCLUSION GUIDANCE AND TIPS.....	30
TABLE 6. GUIDELINES FOR SYSTEMATIC REVIEW INCLUSION/EXCLUSION DETERMINATION AND DATA EXTRACTION.....	39
TABLE 7. ACCURACY RATES FOR INCLUSION AND EXCLUSION.....	46
TABLE 8. BREAKDOWN OF PUBLICATIONS IN EXCLUDED LANGUAGES OF POTENTIAL RELEVANCE TO THE SYSTEMATIC REVIEW.	48
TABLE 9. ARTICLES PERTINENT TO THE SYSTEMATIC REVIEW.	50
TABLE 10. OVERVIEW OF STUDIES.....	55
TABLE 11. STUDY TIMING ANALYSIS.	60
TABLE 12. CLASSIFICATION FRAMEWORK FOR BIOMARKERS OF INTESTINAL FUNCTION/DYSFUNCTION AND INFLAMMATION.....	62
TABLE 13. SUGAR PROBES.	65

TABLE 14. COMPARISONS OF L:M TEST STUDY METHODS AND REPORTING FRAMEWORKS.....	125
TABLE 15. ASSOCIATIONS BETWEEN ANTHROPOMETRIC INDICATORS AND BIOMARKERS OF EED.....	143
TABLE 16. ANALYTE ATTRIBUTES.....	284

LIST OF CATEGORY-SPECIFIC EVIDENCE TABLES

EVIDENCE TABLE 1. MARKERS OF ABSORPTION.....	70
EVIDENCE TABLE 2. MARKERS OF PERMEABILITY.....	91
EVIDENCE TABLE 3. MARKERS OF DIGESTION.....	158
EVIDENCE TABLE 4. MARKERS OF INTESTINAL INFLAMMATION AND INTESTINAL IMMUNE ACTIVATION.....	179
EVIDENCE TABLE 5. MARKERS OF SYSTEMIC INFLAMMATION AND SYSTEMIC IMMUNE ACTIVATION.....	209
EVIDENCE TABLE 6. MARKERS OF MICROBIAL DRIVERS.....	233
EVIDENCE TABLE 7. MARKERS OF NON-SPECIFIC INTESTINAL INJURY.....	241
EVIDENCE TABLE 8. MARKERS OF EXTRA-SMALL INTESTINAL FUNCTION.....	264

LIST OF APPENDICES

APPENDIX 1. SEARCH TERMS FOR EED ARTICLES OF INTEREST.....	288
APPENDIX 2. REFERENCES USED TO TEST SYSTEMATIC SEARCH.....	303
APPENDIX 3. SUMMARY OF SAMPLED REFERENCES PUBLISHED BETWEEN 1990-1999.....	305
APPENDIX 4. SAMPLE REDCAP TEMPLATE.....	307
APPENDIX 5. HIGHLY CONSIDERED BUT EXCLUDED REFERENCES.....	308
APPENDIX 6. REVIEW ARTICLES WITH INFORMATION OF RELEVANCE TO THE SYSTEMATIC REVIEW.....	310
APPENDIX 7. EVIDENCE TABLE OF ALL STUDIES INCLUDED IN THE REVIEW.....	311

Acknowledgments

We would like to thank the Gates Foundation for their generous support of this project. We also thank Foundation program officers Dr. Debbie Burgess, Dr. Thomas Brewer, and Dr. Yiwu He, for sharing their valuable ideas.

We would also like to thank members of our research staff: Xeno Acharya, Nicole Basta, Kathryn Bergh, Jennifer Berthiaume, Tonya Cooksey, Teja Dyamenahalli, Diane Friedman, Marta Haftek, Christopher Kemp, Alastair Matheson, Jean McDougall, Majdi Osman, Anna Talman, Anjali Truitt, and Ngoc Wasson; as well as the members of our administrative staff: Cindy Bohse, Adrienne Genise, Alison Griffith, Ariana Jasarevic, Maida Redzic, and Jeanette Smith. We appreciate your dedication to the project.

We thank Tomas Allen of the World Health Organization for assistance in building the systematic search strategy. The project also benefitted from the database expertise of J. Kevan Essmyer of REDCap and Harry Stevens.

Many thanks to the Washington University librarians Cathy Sarli and Amy Suiter, who facilitated the e-publication process.

We would like to extend our thanks to those not named here who contributed to the project in various ways.

Abbreviations

ΔHAZ	delta height-for-age Z-(score)
ΔWAZ	delta weight-for-age Z-(score)
ΔWHZ	delta weight-for-height Z-(score)
AGP	alpha-1-acid glycoprotein
ANOVA	analysis of variance
CF	cystic fibrosis
CI	confidence interval
CMPA	cow's milk protein allergy
CONSORT	Consolidated Standards of Reporting Trials
CRP	C-reactive protein
ED	enteric dysfunction
EE	environmental enteropathy
EED	environmental enteric dysfunction
ESR	erythrocyte sedimentation rate
ETEC	enterotoxigenic <i>E. coli</i>
FA	fatty acid
GAG	glycosaminoglycan
GCA	glycocholate
HAZ	height-for-age Z-(score)
HBT	hydrogen breath test
HCT	hematocrit
HGB	hemoglobin
HLA-DR	human leukocyte antigen DR-1
HPLC	high-performance liquid chromatography
HSPG	heparan sulfate proteoglycan
IEL	intraepithelial lymphocytes
IFN-γ	interferon gamma
IL	interleukin
IBD	inflammatory bowel disease
L:Cr	lactose:creatinine ratio
L:M	lactulose:mannitol ratio
L:R	lactulose:rhamnose ratio

LBW	low birth weight
MCV	mean corpuscular volume
MGA	maltase-glucoamylase
MN	micronutrient
mRNA	messenger RNA
NCD	non-communicable disease
OR	odds ratio
ORT	oral rehydration therapy
PD	persistent diarrhea
PDF	portable document format files
PEM	protein energy malnutrition
PICO	population intervention comparison outcome
RA	research analyst
RBC	red blood cell
RR	relative risk
SBBO	small bowel bacterial overgrowth
SBT	sucrose breath test
SCL:L	sucralose:lactulose ratio
SEM	scanning electron microscopy
SES	socioeconomic status
SGA	small for gestational age
STARD	Standards for Reporting of Diagnostic Accuracy
SUC:L	sucrose:lactulose ratio
TE	tropical enteropathy
TG	triglyceride
TGF- β	tumor growth factor- β
TMS	tropical malabsorption syndrome
TNF	tumor necrosis factor
TNF- α RI	tumor necrosis factor- α receptor I
TS	tropical sprue
UK	United Kingdom
WaSH	water, sanitation and hygiene
WAZ	weight-for-age Z-score
WBC	white blood cell
WHO	World Health Organization
WHZ	weight-for-height Z-score

Synopsis

Purpose of Project: Gut dysfunction in children in resource-poor environments is well documented. The precipitant of this dysfunction is unknown. However, infections, nonspecific inflammation, malabsorption, and leakiness of mucosa are frequently incriminated as processes that underlie this dysfunction. Major consequences of this dysfunction have been postulated, the most critical of which is poor growth, especially stunting. The study of gut dysfunction in children would have as its ultimate goal the prevention of growth consequences. In this project, we have collated literature published between 2000 and 2010, with the purpose of guiding near-term research into the causes and pathophysiology of enteric dysfunction. In particular, we have attempted to identify biomarkers with which to detect this dysfunction.

Rationale for seeking biomarkers: Theoretically, tissue from the small bowel, the organ of greatest interest, could shed light on the underlying pathophysiology. However, analyzing this tissue poses challenges. These challenges include the practicalities of gaining access to this organ, incomplete confidence regarding sampling strategies to pursue, risk of sampling error, and the yet-to-be-determined value of the information that would be obtained. Thus, the more readily obtained and potentially more informative biomarkers found in stool or blood could feasibly advance the field.

Methods: A systematic literature review was performed by trained research analysts, two physicians, and two epidemiologists. Materials were collated in a master, highly inclusive database of publications relevant to environmental enteric dysfunction (EED) in children in resource-poor settings. This process was undertaken for two reasons. First, because search terms sensitive and specific for “enteropathy” and “enteric dysfunction” are not well indexed in literature databases (including PubMed), we had to create a resource with which to find data related to biomarkers. Second, the project was built to address multiple and different inquiries

related to the topic. Development of an internal library was the most efficient preparation for multiple interrogations, including those seeking to identify publications relevant to the following systematic review question, which is a main focus of this book:

What biomarkers or diagnostic tests have been used to identify, or have been shown to be associated with, mucosal dysfunction of the small intestine or host inflammation in children less than five years of age from developing-country settings?

Findings: 67,903 unique references were obtained from PubMed, Embase, Global Health and World Health Organization (WHO) Regional Libraries (1980-2010). 9,675 of these publications met EED Library inclusion criteria and 374 between 2000 and 2010 were potentially relevant to the systematic review question. Of these, 77 met the review inclusion criteria.

Each relevant publication was thoroughly and systematically reviewed and summarized in evidence table format. Biomarkers were categorized as being relevant to one of eight processes that could underlie, be associated with, or reflect enteric function/dysfunction in children: (1) absorption; (2) porosity/permeability; (3) digestion; (4) intestinal inflammation and/or intestinal immune activation; (5) systemic inflammation and/or systemic immune activation; (6) microbial drivers; (7) nonspecific intestinal injury, and (8) non-small intestinal organ function. A meta-analysis of pooled data from these publications was not possible because of the heterogeneity of study populations and methods, non-standardized information portrayal, scant attempts to correlate biomarkers to intestinal pathology (and where this was attempted, correlation was lacking), small population sizes, and limited relation of biomarkers with outcomes of interest, i.e., stunting. However, the data do strongly suggest the presence of broad categories of intestinal dysfunction, and imply a high prevalence of poorly functioning guts, in children in resource-poor environments. It is quite likely that a panel of biomarkers reflecting multiple physiologic derangements might predict intestinal injury.

Conclusions: Our novel search and EED construction methodology effectively identified a diffusely defined and poorly indexed (in the literature)—but nevertheless important—public health problem. Our EED Library format permits efficient information retrieval for multiple EED-related inquiries and the methodology can be applied to other health issues that face similar definition and search/retrieval issues.

Using this comprehensive data collation and extraction system, we found no evidence of a globally applicable, simple, single-purpose biomarker that reliably correlates with intestinal dysfunction in children or to growth faltering mediated by such a lesion. The studies that are available were often not performed with this goal in mind. However, there is a large body of evidence that enteric dysfunction in children is highly prevalent in resource-poor settings, and that this dysfunction could be an important, and potentially remediable, cause of stunting.

Therefore, we urge that future research on biomarkers in human populations be pursued. We also urge that future work adheres to the following principles:

1. Assess function-related candidate biomarkers.
2. Relate the biomarker data to consequential outcomes.
3. Rigorously describe the study design and methodology underlying the data produced.
4. Provide robust data repositories. Employ best practices publication guidelines, such as those endorsed by the Consolidated Standards of Reporting Trials (CONSORT) system including the Standards for Reporting of Diagnostic Accuracy (STARD) Initiative.
5. Consider indices of enteric dysfunction, incorporating “stacking” multiple biomarkers representing diverse pathophysiologic processes, potentially also including non-laboratory test derived clinical characteristics.
6. Explore invasive, field-adaptable, host assessments (e.g., saliva, transcutaneous), even if technology needs to be developed or adapted.

Chapter 1. Environmental Enteric Dysfunction (EED) Background

1.1 EED History and Overview

For many years it has been known that the digestive system, and in particular the small bowel, of people who reside in poor regions do not function well. The first English language description of this disorder was written by William Hillary in the mid-1700s. His case series of malabsorption in European expatriates in Barbados [2] (reviewed by Booth [3]) also reported glossitis (most likely caused by concomitant folate deficiency) and diarrhea. Over a century later, Patrick Manson re-described this disorder, again focusing on expatriates in the Dutch West Indies, and used the term tropical “Sprouw,” from a Dutch word describing what was almost certainly celiac disease (gluten-sensitive enteropathy) in Europe [4]. The onset of this malady in previously healthy Europeans residing in the tropics, and reports of epidemic malabsorption in Allied troops in Southern Asia during the Second World War [5, 6], gave rise to the concept of gut lesions caused by “environmental” factors. Therefore, this enteropathy was modeled as an acquired, likely infectious, problem [7]. This acquired/environmental concept was reinforced by secular variances in the incidence of tropical malabsorption syndromes, alternately referred to as tropical enteropathy (TE), in areas previously endemic for this disorder [8, 9].

The early descriptions of tropical enteropathy did not define the true extent of the problem. Most notably, these initial reports focused on adults. The realization that children were affected by what was probably the same disorder was delayed. Second, while various causes of this intestinal dysfunction have been postulated, the definitive cause or causes remain(s)

elusive. Indeed, interest and investigation into the problem itself waxes and wanes with discoveries of new enteric pathogens. This has implications for our systematic review of the problem. For example, giardiasis would be a lead candidate as a cause of tropical enteropathy in view of the chronicity of the illnesses it can cause, and the ability of *Giardia* to injure the mucosa of the small bowel. However, *Giardia lamblia* was not widely accepted as a human pathogen until the 1970s. Hence, prior investigations would have discounted this agent as being a cause of enteropathy. Third, there have been regional differences in the reported incidence of tropical enteropathy. Early communications suggested that individuals in Africa were seemingly less affected than were individuals in other areas, and that many cases of adult malabsorption were attributed to biliary and pancreatic disorders [10]. However, more recent reports suggest that Africans are, indeed, susceptible to tropical enteropathy [11-15]. Also, diagnosis in early studies was made by varying methodologies, including those based on response to empiric treatments (antibiotics, antiparasitics, micronutrients) and repatriation to countries in which tropical enteropathy is not endemic; it is often unclear from which intervention(s) responders benefitted. Finally, enteric dysfunction in resource-poor settings has often eluded, and continues to elude, useful definition. Instead, we are forced to rely on histopathologic findings from the small bowel, and these findings are variably specific. These abnormalities include villous blunting, increased crypt:villous ratios, and presence of intraepithelial lymphocytes (IEL). However, the reliance on biopsies skews disease detection and data acquisition towards adults who more frequently undergo invasive testing [16]. These definitional issues continue to hinder advancement in the field, and to impose challenges in identifying useful biomarkers.

The nomenclature used to describe the entity of interest has shifted in response to ongoing efforts to better understand and describe the disease. As early as 1984, the term “environmental enteropathy” was used synonymously with “tropical enteropathy” [17], although not commonly until 2004 [18]. Most recently, “environmental enteric dysfunction” (EED) has

been suggested as nomenclature for the entity of interest [16]. We adopt this term in this book as it provides specificity with regards to the origin of intestinal dysfunction (i.e., environmental opposed to genetic or other factors) and focuses on functional alterations of consequence [19]. The term EED refers to functional shortcomings of the gut with and/or without histological correlates, and obviates the need to rely on the histology inferred by the term “enteropathy”¹. We acknowledge that EED might differ in disease burden, etiology, and effects in children and adults in different regions. However, independent of case definition or underlying criteria, suboptimal intestinal function in children in resource-poor environments is common, and it is important to determine its true incidence, spectrum of host injury, mechanisms of pathophysiology, diagnostic ascertainment, clinical consequences, and mitigation via interventions whether prevention or treatment. Therefore, it is now time to measure the extent of this dysfunction and its consequences. To do so, we need to consider the technology that will be required to investigate the problem.


1.2 An Old Problem Requiring New Knowledge

There is a compelling need for research on enteric dysfunction in children in resource-poor environments, but scientific advancement in the field has been, in fact, quite modest. The Web of Science (formerly ISI Web of Knowledge) demonstrates a paucity of publications related to EED (Figure 1).

¹ Strictly speaking, the “-pathy” suffix is from the Greek word for disease or suffering, but in many connotations refers to histopathologically defined disorders.

Figure 1. List of plausibly relevant literature from 1980 to 2010.

A search of *Thomson Reuters Web of Science™* ALL Databases Collection¹ on 27 August 2014, spanning 1980-2010 and using any of the following search terms: "tropical enteropathy", "environmental enteropathy", "tropical sprue", "environmental enteric dysfunction", "tropical malabsorption syndrome", or "tropical malabsorption." Topic was used for the query, with the phrase enclosed in quotation marks. Search filters for language or document type were not applied.



The lack of progress on EED contrasts with recent dramatic advances in mortality reduction caused by acute enteric infections. The annual number of deaths attributed to diarrhea among children under five years of age fell from an estimated 4.6 million in 1980 [20] to about 700,000 in 2011 [21]. Most of the mortality reduction in the latter two decades of the past century was likely a result of refinements in, and/or increased use of, oral rehydration

¹ Searches were conducted using the *Thomson Reuters Web of Science™* ALL Databases Collection and reflect only the data as indexed by the database. Publication data may be incomplete. The *Thomson Reuters Web of Science™* ALL Databases Collection consisted of Inspec® (1898-present), MEDLINE® (1950-present), SciELO Citation Index (1997-present), Science Citation Index Expanded (1970-present), Social Sciences Citation Index (1970-present) and Art & Humanities Citation Index (1975-present).

therapy(ORT) [22, 23]. Globally, current ORT coverage rates are moderate and have stabilized over the past decade [24]; more recent reductions in diarrhea-related mortality likely stem from general improvements in socioeconomic development, nutrition, and water/sanitation infrastructure [25]. Coverage rates for access to improved water sources, particularly in urban settings, are on track to meet international development goals [26]. However, access to adequate quantities of water, water of sufficient quality for drinking, and improved sanitation facilities are limited and only slowly improving [26-28]; the same lack of progress applies to hand hygiene prevalences [29]. Improved water sources, sanitation, and hygiene can avert 58% of childhood diarrhea-related deaths in low- and middle-income countries [27]. A 34% reduction in risk of diarrheal disease has been demonstrated with interventions to improve water quality, and a 28% reduction in diarrheal disease has been observed with improvements in sanitation, particularly sewer interventions [30]. Promotion of hand hygiene with soap is estimated to contribute to a 23% reduction in diarrheal disease risk [29].

Treatment with zinc can reduce the duration and severity of acute episodes of diarrhea and reduce the risk of future episodes [31-33]. Since 2004, zinc has been a recommended therapeutic for children suffering from diarrheal episodes in resource-limited settings. Safe and effective rotavirus vaccines are now available and recommended for widespread use [34-36]. Coverage rates for these relatively “new” interventions are low, but their implementation is accelerating. Major advances might also be on the horizon in the form of effective cholera, typhoid, *Shigella*, and enterotoxigenic *Escherichia coli* (ETEC) vaccines [37-39].

Despite reductions in mortality risk associated with acute diarrhea, enteric infections remain prevalent. Over 1.7 billion episodes of diarrhea occur among children under five years of age each year [21] and incidence rates have not changed markedly in the past several decades [40]. Repeated episodes of infection in the developing gut are probably deleterious [41]. Expanded implementation of prevention and treatment measures could further diminish diarrhea

mortality and could additionally reduce morbidity and disease burden. However, these advances against acute enteric infections now raise the relative importance of chronic intestinal dysfunction as a hindrance to optimal childhood health [42].

However, this problem is much more complex: emphasis on acute enteric infection fails to address the consequences of recurrent, persistent, and chronic diarrhea, as well as the long-term consequences of diarrhea on stunting and on disability-adjusted life years. Also, a new variety of agents, in particular enteroaggregative *Escherichia coli*, and *Cryptosporidia* spp., which each require special technologies to identify, have recently and repeatedly been associated with persistent diarrhea and stunting. Additionally, several epidemiologic studies suggested that the frequency of episodes of acute diarrhea impairs long-term health in populations outside Brazil [18, 43, 44]. In view of the successes of oral rehydration and the rotavirus vaccine, it was reasonable to assume that the problem of enteric infections in children would be solved. Moreover, simple infrastructural management strategies, particularly the provision of appropriate village waste containment facilities [45] were determined to be important protective measures against chronic diarrhea. We now recognize that enteric inflammation is a determinant of stunting and long-term gastrointestinal dysfunction, even independent of the presence of the more easily enumerable episodes of diarrhea [45].

The renewed interest in EED is aptly timed for many different reasons. As noted above, we are in an era in which we know how to treat and prevent acute diarrhea. Therefore, chronic intestinal injury and inflammation now pose larger proportional threats to population and childhood well-being. Also, translational research has created new proteomic, metabolomic, and genomic technology with which to study human pathophysiology. The value of re-examining and expanding diagnostic capabilities is two-fold. First, such efforts will shed light on incidence rates within communities and assess factors associated with differences in disease rates in various

populations. Second, such tools might accurately identify children at risk of developing EED, who have EED (at its various clinical stages), and as a way to monitor treatment for EED.

We recognize that other priorities compete with EED for resources in the field of child health. First, there is the imperative to continue to reduce mortality from acute diarrhea. Indeed, the Child Health and Nutrition Research Initiative of the Global Forum for Health Research methodology de-emphasized research on chronic enteric conditions in favor of implementing available strategies to continue to reduce acute childhood diarrhea mortality [46, 47]. That analysis was weighted towards interventions that could be implemented by 2015 to meet Millennium Development Goals. EED intervention studies require longer investigation periods than do disorders with known etiologies and outcomes that are apparent in the short term. For example, the pathophysiology of EED is not well understood, technologies sufficient to assess the process in individual hosts or within populations are not broadly available, and interventions to mitigate consequences of clinical importance are not yet established. Work to understand and control EED should be viewed as complementing, rather than competing with, continued efforts to reduce the burden of acute enteric illnesses. It was with this concept in mind that we embarked on our review of the EED literature, with a goal of providing a platform on which future EED efforts, especially those related to biomarkers and diagnostics, could be built.

1.3 Pathophysiologic Processes and Consequences of EED


The gut is an organ that is central to health and development. Healthy intestinal functioning optimizes childhood physical and intellectual well-being and development, and enables children to achieve adult stature. Several lines of evidence indicate that suboptimal functioning of the human gut, manifesting as EED, leads to poor health for children in resource-poor settings. First, investigators in Fortaleza, Brazil have demonstrated that episodes of

recurrent or persistent diarrhea are major determinants of childhood growth impairment [48], and subsequent reduced growth and intellectual capacity at school entrance [49, 50]. These investigations were seminal because they provided a new metric for calculating the burden of enteric-related disease other than counting deaths or numbers of episodes of loose stools. This is also important because stunting can be associated with subclinical intestinal inflammation [15, 51].

Multiple aspects of intestinal pathophysiology contribute to poor health, growth and development (Figure 2) and physiologic derangements in these processes are deleterious (Figure 3). First, injured intestinal mucosa absorbs nutrients poorly [52] and represents one potential EED-mediated growth-failure pathway [15, 53]. Chronic intestinal inflammation is very common in the tropics [54] and can damage intestinal epithelial integrity and disrupt tight junctions, resulting in intestinal permeability defects. Multiple studies demonstrate increased intestinal porosity in children in the tropics [15, 44, 55-58]. Increased intestinal permeability can, in turn, lead to translocation or the nonphysiologic uptake of intestinal luminal contents, including microbes and microbial products, into the bloodstream [59]. Microbial translocation can, in turn, mediate systemic inflammation as can chronic intestinal inflammation. Stunting is often associated with subclinical intestinal inflammation [15, 51]. Systemic inflammation can penalize growth by interrupting bone growth potential, release of growth hormone binding proteins at the level of the liver [60], suppressing appetite, and increasing metabolic requirements [61]. Such mechanistic attribution remains hypothetical at this juncture.

Figure 2. The vicious cycle of intestinal dysfunction, infectious disease susceptibility, poor growth, and development.


NCDs= non-communicable diseases. WaSH=water, sanitation and hygiene. EED= environmental enteric dysfunction.



Adapted from Denno DM [62], Guerrant RL, et al. [63] and Mata L [64].

Figure 3. EED-related pathophysiological processes result in stunting and/or growth shortfall.

Growth can be affected by disturbances in a variety of intestinal and other physiologic processes resulting from EED. GH=growth hormone.



The first several years of childhood represent a critical period that influences life-long nutritional and health status and human potential [65]. Stunting is an especially important cause of adverse consequences in resource-poor regions, and stunting that occurs in the first two

years of life is particularly consequential [48, 66-72]. Childhood stunting is associated with cognitive impairment, poor school performance, and reduced adult capacity [73-76]. Clinical complications of childhood stunting also include predisposition to obesity and diabetes and other chronic diseases in later adulthood—a double burden increasingly afflicting populations in resource-limited settings [65]. Moreover, undernutrition contributes to over one-third of childhood deaths [77].

Poor nutrition among girls can have a particularly profound effect on future reproductive and fetal/neonatal health. For example, maternal stunting can be a risk factor for obstructed labor, stillbirth, and neonatal mortality [78]. Furthermore, maternal anthropometry also influences future generational growth, morbidity and mortality [79].

Dysfunctional guts can hinder the efficacy of oral vaccinations and absorption of medications. This may pose a threat to oral enteric vaccine strategies and absorption of medications for chronic infections such as tuberculosis and HIV/AIDS [80]. Indeed, failure of oral polio vaccine to induce protective immunity in children at risk is a major challenge to disease eradication [81].

Increasing dietary nutrient provision does not necessarily or completely resolve growth failure in resource-poor settings [82]. Gut function is an important antecedent to healthy human growth and development. Strategies are needed to ascertain gut inflammation, increased permeability, and decreased absorption. Strategies are also needed to measure and address the persistence, progression, and resolution of these types of dysfunction. Chronic intestinal inflammation and inability to absorb nutrients may be the most actionable manifestations of enteric dysfunction in children. Intervention studies to mitigate EED will require appropriate, robust and reproducible methods to identify children with intestinal dysfunction, ideally before penalties to growth and development accrue.

A coordinated effort to control EED in children in resource-poor regions could markedly reduce childhood undernutrition, poor development, and mortality. In the past decade, we have seen an explosion in our understanding and abilities to diagnose an analogous disorder, i.e., celiac disease, which has histopathologic similarities to EED. We have learned the genetic and environmental, i.e., dietary, risk factors for celiac disease, and also determined that this disorder is not confined to individuals of northern European ancestry, as previously thought. Furthermore, the diagnosis and management of celiac disease, including partial mitigation of growth consequences, has advanced, at least in high-income countries. Similar data are emerging regarding the more challenging disorders of inflammatory bowel disease, i.e., Crohn's disease and ulcerative colitis [83]. We can apply lessons learned from these chronic intestinal inflammatory states to the study of EED.

There is reason to be optimistic about renewed research and development relevant to EED. Emerging technologies can interrogate human processes and microbial populations to an extent not predicted even a few years ago. These technologies can shed new light on EED, an entity that has traditionally required tissue for diagnosis.

1.4 The Role of Biomarkers and Diagnostics in EED

Much as pioneering studies on mechanisms of intestinal secretion in cholera [84] formed the basis for giving oral rehydration solution to children with diarrhea worldwide, it is critical to identify the mechanisms underlying intestinal dysfunction in children in resource-poor areas. Beyond searches for specific etiologic pathogens or nutritional deficiencies, biomarkers and diagnostics will need to be broadly considered in favor of pursuing a better understanding of EED as a disorder. "Discovery" efforts will be needed to generate sufficient information to move forward.

Broad-based research is urgently needed to invigorate the field. For example, multi-dimensional assessments of individuals and populations will be necessary to measure intestinal dysfunction, and identify factors that precipitate and perpetuate EED. We believe that the utility of biomarkers in EED needs to extend beyond the concept of diagnostics. Diagnostics, as most commonly used to assess the human gut, usually seek specific pathogens, or belong to a limited panel of tests of gut inflammation and/or absorptive function. It is likely that rigorous and systematic analyses of EED require a better understanding of the microbial population in the gut and detailed assessments of intestinal inflammation, absorption, permeability, translocation, and subsequent systemic inflammatory cascade as well as the precipitants and consequences of EED, such as nutrient deficiencies. As such, we sought to systematically search, review and portray the existing diagnostics/biomarkers literature related to EED as a basis of knowledge to leverage further investigation.

1.5 Scientific Basis for this Review

In view of increasing understanding of the role of gut health and function in promoting overall health and development in childhood and beyond, it is logical to catalyze efforts to accurately identify and predict children with EED and to refine the sensitivity and specificity of promising biomarkers. While a single marker with optimal operating characteristics would be a welcome tool, it is unlikely that a single test can be used worldwide to detect and predict EED with the necessary precision. A panel of tests, perhaps in conjunction with clinical characteristics, may be necessary, akin to the Jones criteria used to diagnose acute rheumatic fever.

Currently, there is no consensus on the best way to measure intestinal function either invasively or noninvasively. Additionally, there is no evidence that the entities of interest, i.e., intestinal inflammation and/or poor function associated with stunting, are caused by a single

etiology or that a common pathogenesis underlies all cases. Also, we do not know if intestinal inflammation precedes growth failure, if the disorder might actually begin *in utero*, or if any therapies can reliably and uniformly restore linear growth. Nonetheless, there is now consensus that stunted children are not only at risk for unhealthy consequences during childhood, they are more likely than their non-stunted peers to develop chronic disorders that extend into adulthood, including obesity, type II diabetes, and hypertension [85, 86]. Clearly there is a need to reassess whether existing markers of intestinal dysfunction can better define the disorder of interest, and anticipate its development in children. We therefore attempted to first identify the current state of the knowledge, then delineate gaps in that knowledge, and, finally, sought to determine which tests might have the most utility.

Table 1. Spectrum of etiologies, outcomes, and biomarkers/diagnostics in EED.

These lists of causes, results, and techniques to identify EED were used to define manuscripts of potential interest in the list generated by the search terms.

Potential drivers (causes) of EED	Pathogens, food insecurity, immune activation, specific nutrient deficiencies, environmental hygiene
Potential consequences of EED	Recurrent diarrhea, persistent diarrhea, intestinal inflammation with and without diarrhea, stunting
Possible biomarkers/diagnostics of EED	Biopsies, sugar clearance tests (measuring absorption and permeability of the gut), breath hydrogen tests, nutrient challenge tests, fecal analyses for leakage or non-absorption, serologic analyses for inflammation or evidence of gut permeability

Chapter 2. Methodology: Building the EED Library and Undertaking a Systematic Review of EED Biomarkers/Diagnostics

2.1 EED: A Broad Field, Many Unanswered Questions

First, in collaboration with experts in the field, we developed a set of questions that would be of primary importance to better understand and control EED. The scope was broad and included environmental, nutritional, and other factors that might underlie EED, as well as information related to EED pathogenesis. We framed these questions within six “topic areas” (Table 2). We used these questions to guide our systematic literature search, seeking to identify all references that could contribute to answering them. Prior to searching the literature for relevant EED references, a search of the Cochrane Database of Systematic Reviews found no Cochrane Reviews related to EED.

Table 2. Topic areas and questions.

The left column lists inclusive but circumscribed areas of relevance to EED, and the right column presents questions relevant to each topic area. These formed the basis for the literature search terms (Appendix 1).

Topic area	Questions
I. Epidemiology of EED	<p data-bbox="414 443 1421 478">What is the burden of disease represented by EED?</p> <p data-bbox="414 510 1421 577">What is the prevalence of EED (including as measured by tests of gut dysfunction or inflammation)?</p> <ol data-bbox="462 609 1421 787" style="list-style-type: none"> <li data-bbox="462 609 1421 745">1. What proportion of stunted/malnourished children have EED (as measured by gut dysfunction/inflammation or infection with specific microbes or identifiable microbial populations) or have a past history of EED? <li data-bbox="462 745 1421 787">2. Other
<p data-bbox="180 814 397 913">II. EED, malnutrition as an outcome.</p> <p data-bbox="180 945 397 1182">Associations, risk factors, protective factors, causes of acquisition of EED, malnutrition</p>	<p data-bbox="414 814 1421 982">What exposures/variables are associated with EED (including as measured by tests of gut dysfunction or inflammation) or malnutrition/stunting? What are the effect sizes (e.g., relative risk (RR), odd ratio (OR)) of the associations? What are the causal pathways/mechanisms? <i>Exclude exposures related to food security/caloric density.</i> Include:</p> <ol data-bbox="462 1014 1421 1885" style="list-style-type: none"> <li data-bbox="462 1014 1421 1113">3. Is infection with specific enteric pathogens (e.g., subsets of diarrheagenic <i>E. coli</i>, <i>Cryptosporidium</i>, <i>Giardia</i>) associated with EED or malnutrition/stunting? <li data-bbox="462 1113 1421 1182">4. Are recurrent acute enteric infections/recurrent episodes of diarrhea associated with EED or malnutrition/stunting? <li data-bbox="462 1182 1421 1251">5. Are persistent or chronic enteric infections/persistent diarrheal episodes associated with EED or malnutrition/stunting? <li data-bbox="462 1251 1421 1350">6. Is exposure to/ingestion of fecal microbial populations (e.g., in settings with lack of access to improved sanitation) associated with EED or malnutrition/stunting? <li data-bbox="462 1350 1421 1449">7. Are other diseases/conditions including infections not predominantly enteric in origin/manifestation (e.g., HIV, tuberculosis, malaria) associated with EED or malnutrition/stunting? <li data-bbox="462 1449 1421 1518">8. Are environmental (e.g., water, sanitation, hygiene) factors associated with EED or malnutrition/stunting? <li data-bbox="462 1518 1421 1617">9. Are social (e.g., socioeconomic status (SES), household characteristics) or geographic (e.g., rural/urban) factors associated with EED or malnutrition/stunting? <li data-bbox="462 1617 1421 1652">10. Are genetic factors associated with EED or malnutrition/stunting? <li data-bbox="462 1652 1421 1751">11. Are specific foods or nutrients (e.g., micronutrients (MNs), lack of specific foods or nutrients, or specific feeding practices associated with EED or malnutrition/stunting? <li data-bbox="462 1751 1421 1820">12. Are maternal factors (e.g., anemia in pregnancy, maternal short stature) associated with EED or malnutrition/stunting? <li data-bbox="462 1820 1421 1885">13. Is low birth weight (LBW) or small for gestational age (SGA) associated with EED or malnutrition/stunting?

Topic area	Questions
	<p>14. Are microbially contaminated foods/lack of food safety or contaminated bottles, feeding utensils, etc. associated with EED or malnutrition/stunting?</p> <p>15. Is malnutrition a risk factor for EED?</p> <p>16. Other</p>
<p>III. EED as an exposure.</p> <p>EED association with, risk factor for, a cause of subsequent other child health problems.</p>	<p>What outcomes are associated with EED (including as measured by gut dysfunction or inflammation or infection with specific microbes or identifiable microbial populations)?</p> <p>17. Is EED a risk factor for malnutrition/stunting?</p> <p>18. Is EED a risk factor for MN deficiencies—either multiple deficiencies or isolated deficiencies (including zinc, vitamin A, iron, vitamin D, folate, vitamin B12)?</p> <p>19. Is EED a risk factor for overnutrition (including overweight and obesity), especially later in childhood/adulthood?</p> <p>20. Is EED a risk factor for subsequent enteric infections/diarrheal illness, either in general or as caused by specific pathogens?</p> <p>21. Is EED a risk factor for decreased oral vaccine efficacy or oral drug efficacy?</p> <p>22. Is EED a risk factor for diminished cognitive function or developmental delay?</p> <p>23. Other</p>
<p>IV. Assessment, biomarkers, and diagnostics of EED or malnutrition</p>	<p>24. What diagnostic tools or biomarkers are available to assess for EED or malnutrition¹? What biomarkers are manifest during the EED clinical state that could be utilized to develop a diagnostic test?</p> <p>Subquestions:</p> <p>24a. How sensitive and specific is the test/biomarker in identifying the child with EED compared to villous blunting with crypt hyperplasia on histologic examination of small bowel biopsy intestinal biopsy? In the absence of comparison to histology, how does the test/marker compare to other diagnostic tests of gut function/dysfunction including permeability, inflammation, or nutrient uptake?</p> <p>24b. Does the marker or diagnostic allow grading of disease severity or gut dysfunction?</p> <p>24c. Is the diagnostic or biomarker field-friendly?</p> <p>24d. What are the costs associated with the diagnostic/marker?</p> <p>25. Other</p>
<p>V. EED Clinical course, pathophysiology</p>	<p>26. What is the clinical course of EED (e.g., clinical symptoms, signs and laboratory findings)? What are the underlying mechanisms/pathways of these clinical changes?</p> <p>27. What nutritional changes/abnormalities occur in EED including</p>

Topic area	Questions
	<p>energy metabolism, MN uptake, bioavailability and metabolism?</p> <p>28. What gut pathophysiology, histology or cellular changes are found in EED?</p> <p>29. Other</p>
VI. EED, malnutrition interventions—prevention and treatment	<p>What interventions can prevent, treat or mitigate EED (including as measured by tests of gut dysfunction or inflammation) or stunting/malnutrition? What is the effect² of interventions in reducing prevalence of EED or malnutrition among children (compared to no intervention or placebo intervention)? What is the effect of interventions on treating or mitigating the impact of EED (<i>outcomes could include diminished gut inflammation, diminished microbial content in host guts, improved gut function</i>) or stunting/malnutrition (<i>outcomes could include improved linear growth or weight gain</i>) among individual children? For each treatment intervention identified, what is the effect in impacting outcomes compared to no intervention or placebo intervention³?</p> <p>Exclude interventions related to increased calorie intake or food security. Interventions include:</p> <p>Population-based interventions among asymptomatic children in developing-country settings:</p> <p>30. Zinc, vitamin A, folic acid, vitamin B12 supplementation or fortification⁴ (or supplementation or fortification with other MNs or with multiple MNs)</p> <p>31. Interventions related to breastfeeding</p> <p>32. Nutritional interventions such as introduction of or increased consumption of certain foods, including weaning or complementary foods</p> <p>33. Feeding practices (e.g., responsive feeding practices among caretakers)</p> <p>34. Improved food safety (e.g., boiling eating utensils, improved food storage and reheating)</p> <p>35. Improved water, sanitation, hygiene</p> <p>36. Prebiotics, probiotics</p> <p>37. Maternal interventions (e.g., prenatal iron/folate supplements in pregnancy and examination of impact on EED or malnutrition in offspring)</p> <p>38. Health services interventions (e.g., implementation of growth monitoring programs, cash transfers in return for care-seeking)</p> <p>39. Other</p> <p>Interventions to prevent EED implemented among children in developing-country settings with specific symptoms (e.g., diarrhea):</p> <p>40. Zinc, vitamin A, folic acid, vitamin B12, or other MNs (e.g., for treatment of diarrhea)</p> <p>41. Prebiotics, probiotics (e.g., for treatment diarrhea)</p>

Topic area	Questions
	42. Management/treatment of other conditions (e.g., antitubercular agents, tuberculosis, antiretrovirals for HIV, antimalarials to treat malaria infections, intermittent preventive treatment of malaria) 43. Other
	Among children identified/diagnosed as having EED or malnutrition: 44. Treatment with specific MNs including: iron, zinc, vitamin A, vitamin D, folic acid, vitamin B12 45. Treatment with multiple MN preparations (e.g., Sprinkles) 46. Treatment with antibiotics 47. Treatment with probiotics 48. Nutritional interventions such as introduction or increased consumption of specific foods; ready-to-use therapeutic or supplementary foods; related nutritional therapeutics 49. Feeding practices (e.g., responsive feeding practices among caretakers) 50. Other

¹ Not including measures of physical growth (e.g., height, weight, mid upper arm circumference), indices calculated from measures of physical growth (e.g., body surface area), or use of growth charts or growth standards.

² Including any potential harms identified with the intervention. Furthermore, cost information should be captured where available.

³ Where possible, also identify the best stage in the EED clinical spectrum in which to intervene and at which stage does therapeutic effect have the greatest impact on outcomes compared to other stages?

⁴ Supplementation defined as administration of MNs to a population subgroup based on age or other life cycle factors. E.g., prenatal vitamins, giving 6-36 month-olds vitamin A capsule every six months. Fortification defined as adding MNs to food staples such as the addition of folate to flour.


A “wide-net” broadly inclusive systematic search strategy was considered necessary at project inception in order to capture sufficient references of relevance for four reasons: (1) a wide scope and breadth of questions were deemed of interest for potential systematic investigation; (2) we believed that there would likely be modified or derivative questions after the initial review was performed; (3) EED has a broad, indistinct, and historically variable definition; and (4) specific search terms for EED, ED or even enteropathy do not exist in the medical and health databases. Because the effort involved in searching for articles solely related to one EED systematic review question would only be marginally more compared to searching more broadly for articles to address a wide range of EED-related questions, we opted for an infrastructure that could produce a systematic review product efficiently and expediently.

2.2 Constructing a Systematic Search Strategy: Optimizing Sensitivity

We devised a systematic and comprehensive search, extraction, and analysis strategy. Our overall procedure is depicted in Figure 4. We now describe the process components.

The first step was the construction of a comprehensive, systematic search strategy. We developed individual search strategies for each database with the assistance of a research librarian at the World Health Organization in Geneva. We devised a two-step search strategy that was extensive due to the broadly defined nature of EED and the lack of robust indexing of search terms across databases (as described above) (Appendix 1). In the first step, we used broad terms to capture all references related to EED, including similar or identical disorders ('tropical enteropathy', 'environmental enteropathy', 'tropical sprue', 'tropical malabsorption syndrome', and 'malabsorption', 'enteropathy', or 'intestinal dysfunction' in the tropics). At first pass, we included any age group and any setting (e.g., returned travelers), because these publications could conceivably contain data that provide some understanding of aspects of EED. We were also interested in other enteropathies among children under five years of age in developing countries, such as celiac disease or Crohn's disease, because these disorders might have been misdiagnosed EED, or because tests employed could be relevant to EED in children at risk in resource-poor areas of the world.

Figure 4. EED systematic review processes flow chart.



As the second step, we identified references about malnutrition or nutritional status (as measured by anthropometrics) among children under five years of age in developing countries. The goal was to identify scenarios where EED is an intermediary: nutritional status as an outcome of enteric dysfunction, biochemical or radiologic biomarkers/diagnostics of nutritional status, or interventions to prevent or treat malnutrition. For nutritional outcomes, we limited our search to effects on anthropometric indices (e.g., height-for-age, weight-for-age, weight-for-height, mid-upper arm circumference, and growth velocity). We excluded articles strictly about prevalence or incidence of malnutrition (i.e., containing no information about risk factors associated with nutritional status), articles about non-EED outcomes of malnutrition/nutritional status, and articles examining the utility of anthropometric measures.

Next, we constructed search strategies to query the most relevant medical and health databases: PubMed (<http://www.ncbi.nlm.nih.gov/pubmed/>), Embase (<http://www.embase.com/>), Global Health (database published by Centre for Agriculture and Biosciences International (CABI)), and the WHO regional databases. We included Global Health and the WHO databases because of their higher proportions of articles from resource-poor regions, which are often not published in journals that are indexed in PubMed and Embase. Additionally, the WHO regional databases contain much “gray” literature from government and nongovernmental organizations that could have been of relevance.

To ensure that our search adequately identified relevant references, we developed a test set of references obtained by identifying 20 key EED references in collaboration with two external advisors with content expertise (Appendix 2).

We sought to retain as many relevant references in our search results as possible, while minimizing extraneous and irrelevant information. To maintain specificity, we filtered the references for data from developing countries, tropical settings, or indigenous populations.

However, universal use of this filter resulted in test EED references being missed. We were, however, able to use the filter on the malnutrition search strategy without losing relevant articles. We were able to apply another filter to restrict malnutrition articles to those related to children. We did not restrict language or year of publication. After these modifications to our search strategy, 18 of the 20 test references were captured. To detect the remaining two articles, we would have needed to use a strategy that yielded a ten-fold increase in the number of articles returned in the search. On further scrutiny, this problem was caused by a lack of sensitive index terms for one article [87] and lack of child terms for the other [57] (Appendix 2). We accepted this compromise, recognizing that the “snowball” technique (described below) would increase our search sensitivity.

With our approach, we were able to interrogate the literature on a topic that is both poorly defined and poorly indexed. Our comprehensive, rigorously evaluated, and reproducible methodology can be utilized as a systematic search model approach for other topics that are similarly broad and/or diffusely defined or cataloged, for which standard systematic search techniques would be insufficient and imprecise.

2.3 Reference Volume Mitigation

The systematic search, completed June 2010, identified a total of 85,334 references (after identifying and removing references that were duplicated within the four databases that were searched), dating back to 1910 (discussed further in Results section). This overwhelming volume of potentially relevant literature was unexpected, and we briefly considered using only references from recent review articles on the topic. This was not possible, however, because no previous systematic reviews had been published with which to identify biomarkers that could be used to prevent and treat, or to guide rehabilitation from, intestinal dysfunction in children in resource-limited countries. Some reviews [8, 45, 88-93] either focused on adults or on narrow

components of the problems, and not diagnostic strategies. Hence, this “look back” literature review strategy would not have yielded the information we were seeking.

We next considered two options relevant to processing the ca. 85,000 titles. The first option was to scrutinize this very long list with only one or two questions in mind, and vote on each as presumptive “include” or “exclude” related only to the limited inquiry, and ignore all irrelevant topic areas and corresponding questions (“limited-use scrutiny”). The second option was to build an EED Library with references with notation of its relevance to any of the potential topic area(s) and questions (“future use scrutiny”). The third option was to scrutinize each reference, and then note the relevance only at the topic level, and not identify the specific questions that each reference might address. Table 3 summarizes the advantages and disadvantages of each approach.

After careful consideration, we decided to use a “modified future use” approach, i.e., examine each reference for its relevance to each of the six target areas, but not drill down to the question level. However, we left questions available to the analysts as guides to the potential utility of each document. We recognized that this approach entailed more analyst labor, i.e., approximately 200 additional person hours (assuming two readings of each listing) compared to the first strategy in Table 3 (these estimates are limited to the review of the reference lists). However, the hours of effort per question potentially answered would be considerably fewer, when considering that the comprehensive scoring would encompass topic areas that include a total of 49 potentially useful questions.

Table 3. Summary of analysis options.

Advantages and disadvantages of comprehensive versus targeted analysis of literature produced by search terms are portrayed.

Strategy	Advantages	Disadvantages
1. Targeted (“single use”) scrutiny of 85,000 references (focus on only 1 or 2 possible uses of/questions for database)	Reduced time per reference, based on an estimate of 0.75 hour for 1 analyst to scrutinize 200 references, and all references are independently reviewed by two analysts, for a total of 637 person hours	Cannot be used for more than a very limited number of questions (estimated 2 at most)
2. Broad (“future use”) scrutiny (focus on all possible topic areas, and denote particular questions)	Diminishes need to repeat scrutiny of references, and generates candidate documents for all potential topic areas and questions	Extended time per reference compared to strategy 1 (based on an estimate of 1.75 hours for 1 analyst to scrutinize 200 references, and all references are reviewed by two analysts), for a total of 1488 hours
3. Broad (“modified future use”) scrutiny (focus on all possible topic areas, but do not denote particular questions)	Diminishes need to repeat scrutiny of references, and generates candidate documents for all potential topic areas, but not questions	Extended time per reference compared to strategy 1 (based on an estimate of 1.25 hours for 1 analyst to scrutinize 200 references, and all references are reviewed by two analysts), for a total of 1,063 person hours

2.4 Building the EED Library

The initial list of approximately 85,000 references from the processes described above contained the following information from the databases searched: title, authors, journal, and to varying extents, abstracts. We exported the references from PubMed, EMBASE and Global Health into EndNote software (ca. 81,000); this was not possible with the references from the WHO Regional libraries (ca. 4,000) because of the format in which these references were exported from the search engine.

References from all of these sources were reviewed by research analyst (RA) pairs comprised of individuals trained in epidemiology or nutritional sciences, and who received extensive training in our protocol for inclusion/exclusion of studies.

Per standard systematic review methodology, each reference (title, keywords, and abstract when available) was reviewed by two analysts to determine inclusion status for the EED Library. Dual review reduces bias and inaccuracies in the systematic review process. The principal investigators (DMD and PIT) initially piloted the Library inclusion process, until 100% concordance was achieved upon independent review of 1,300 consecutive references. A series of training sessions to convey the goals of the project, along with a protocol with which to determine inclusion of a reference in the EED Library, were provided to the team of RAs. Verbal and written instructions were conveyed to the analysts (Table 4), and a schematic regarding articles to include, and under what category, was also provided (Figure 5).

Table 4. Summary of EED Library inclusion/exclusion instructions to research analysts.

Each analyst was instructed in the scope of interest of the EED Library, and how to code, tag and label data related to each reference included in the EED Library.

A reference was included if it pertained to any of the following conditions:

- Environmental Enteric Dysfunction
- Tropical Enteropathy
- Tropical Sprue
- Environmental Enteropathy
- Tropical Malabsorption Syndrome
- Malabsorption/Enteropathy/Enteric Dysfunction in resource-limited settings

Any age group and any setting (e.g., travelers) were eligible for this filter step.

References about other enteropathies were included *only if* among children under five in developing countries (e.g., celiac disease, inflammatory bowel disease (IBD)).

Nutrition-related articles were included if:

- Malnutrition or nutritional status (as measured by anthropometrics) among children under five in developing country was an outcome
- The study pertained to biochemical diagnostics or biomarkers or radiographic or other imaging among children under five in a developing country
- The study used interventions to prevent or treat malnutrition, even if the outcome was something other than change in nutritional status or prevalence of malnutrition. Interventions were eligible only if they started among children under five years, even if outcomes were measured at a later age.

A separate category of inclusion captured relevant reviews; this was defined broadly to include review articles, meta-analyses, editorials, commentaries, compendia or conference proceedings, letters, books, or book chapters.

Exclusions:

- prevalence, incidence, etc. of malnutrition if there was no information about factors (other than caloric insufficiency/food insecurity) associated with nutritional status
- outcomes specifically due to malnutrition/nutritional status
- the utilization of anthropometric measures

Further delineation of relevance to our systematic review

Topic areas:

I. Epidemiology of EED

II. EED or malnutrition as an outcome

Any associations, risk factors, protective factors, causes of acquisition of EED, malnutrition (except for food insecurity/inadequate calories associated with malnutrition).

III. EED as an exposure

EED as an association with, risk factor for, or cause of subsequent other child health problems.

IV. Assessment, biomarkers, and diagnostics of EED or malnutrition

V. EED clinical course, pathophysiology

VI. EED or malnutrition interventions

Relevant studies included in the EED Library:


- Exposures, risk factors, protective factors, host factors, prevention or treatment interventions (other than those related to caloric density or food security), and their impact on EED or malnutrition outcomes.
- Diagnostic tests or biomarkers related to, or to assess for, EED or malnutrition.
- Interventions (other than those related to caloric density or food security) to prevent or treat malnutrition in children under five years, even if the outcome was something other than change in prevalence of malnutrition or change in nutritional status of individual children. Outcomes could include, for example, change in case fatality rate. Outcomes measured beyond five years were also included.
- Prevalence, clinical course, and pathophysiology of EED.

References we excluded from the EED Library:

- Malnutrition as a risk factor for other morbidities/outcomes (e.g., malnutrition as a risk factor for pneumonia, stunting as a risk factor for obesity or mortality in adulthood, malnutrition as a risk factor for childhood mortality) unless the outcome was EED (e.g., malnutrition as a risk factor for poor intestinal function was included)
 - Malnutrition prevalence studies--unless they also examined risk factors for malnutrition or were intervention studies where change in prevalence of malnutrition is an outcome.
 - Measures/indices of physical growth such as growth charts or use of new indices calculated based on height, weight, or other physical measurements.
-

Figure 5. EED Library inclusion schematic.

Analysts used this as a guide in determining which references should be included in the EED Library.



Abbreviations: EE-environmental enteropathy, EED-environmental enteric dysfunction, PEM-protein energy malnutrition, TE-tropical enteropathy, TMS-tropical malabsorption syndrome, TS-tropical sprue

Feedback on nuances of the inclusion protocol was communicated to the analysts on a regular basis for the duration of the project. Table 5 contains samples of such guidance.

Table 5. Additional EED Library inclusion/exclusion guidance and tips.

The EED category was intentionally defined broadly. The term environmental enteric dysfunction (EED) has several potential equivalents in the literature, including tropical enteropathy, environmental enteropathy, tropical sprue, and tropical malabsorption syndrome. We also included references about enteric dysfunction and any other enteropathy impacting children in developing countries. These enteric conditions included kwashiorkor enteropathy, HIV enteropathy, tuberculosis enteropathy, celiac disease, inflammatory bowel disease, and other enteropathies, assuming they occurred in a developing-country setting.

References were included even if our outcomes of interest were not the study's primary focus.

If the title or abstract clearly indicated that the outcome was acute diarrhea, acute gastroenteritis or an acute enteric infection, we excluded it. If the reference noted they specifically examined persistent or chronic diarrhea as an outcome, it was included. Even if the main outcome studied was acute diarrhea, the reference was included if it examined EED or persistent/chronic diarrhea as a "minor" outcome. If an outcome of "diarrhea" was not specified as either acute or persistent/chronic, we assumed the article referred to acute diarrhea and we excluded it. References about acute diarrhea were included when they examined the impact of acute diarrheal illness or acute gastroenteritis on EED or malnutrition.

References about children with IBD or celiac disease originating in a developing country were included (but excluded if the study was conducted in a developed country). Even though the origin of IBD and celiac disease is distinct from EED, we included it from developing-country settings for two reasons:

a. Celiac disease or IBD in developing countries may truly be misdiagnosed EED, a fact we will be better able to judge when reading the study methodology.

b. We are attempting to look at enteric dysfunction in developing settings more broadly and with fresh perspectives, to allow new observations of underlying patterns.

While enteropathy is not always a manifestation of tuberculosis, HIV, or kwashiorkor, if a study in a developing country discussed enteric dysfunction or enteropathy related to these conditions, we included it.

We excluded studies that reported prevalence of infection with a specific pathogen. If a study examined a pathogen's association with EED or other outcomes of interest as previously specified, then we included it.

We focused on small intestine pathology; therefore, we excluded studies looking at gastric/colonic pathology unless they also examined outcomes pertaining to the small intestine.

References about gastrointestinal problems that are not EED-related were excluded; a non-exhaustive list of commonly encountered conditions not included in our review includes:

- Appendicitis
- Blind loop syndrome
- Colonic atresia
- Duodenal atresia
- Dyspepsia

- Hemolytic uremic syndrome
- Henoch-Schonlein purpura
- Hirschsprung's disease
- Intestinal obstruction
- Intussusception
- Irritable bowel syndrome
- Malrotation
- Necrotizing enterocolitis
- Perirectal abscess
- Peritonitis
- Primary bile acid malabsorption
- Pseudomembranous colitis
- Rectal prolapse
- Short bowel syndrome
- Volvulus

We included studies examining potential risk/protective factors for stunting, wasting or other forms of malnutrition, except those related to food security or caloric density. We excluded studies where any type of malnutrition was considered the exposure, unless EED was an outcome.

Articles examining factors associated with anthropometric/growth outcomes were included even if not related to malnutrition. We did not include articles that solely examined the outcomes of overweight and obesity (unless related to EED), but studies of changes in growth status among children under five in developing countries were included. We excluded anthropometric data collected for the purpose of evaluating national statistics (e.g., in relation to WHO child growth standards) and studies of malnutrition or nutritional status prevalence unless the studies also looked at risk or protective factors associated with EED.

Growth outcomes among children with common chronic infectious diseases such as HIV or hepatitis were considered outcomes of interest.

We included any potential risk or protective factors for EED, malnutrition, or other outcomes of interest, even if they are not necessarily directly related to gut dysfunction, e.g., poverty, domestic violence, maternal anemia, small for gestational age (SGA), or low birth weight (LBW). We excluded studies where SGA or LBW was the study outcome, however.

We included genetic risk factors for EED, malnutrition, or another related outcome of interest as long the study was conducted in a developing-country setting.

Many studies contain relevant information about children under five even though they are not restricted to— or even focusing on— that age group. If any children under five were included, we included the reference.

If a relevant study was conducted in a year when the study country was on the developing country list, it was included.

We excluded case reports (or in vitro lab or animal model studies) even if relevant to EED.

The analysts were provided guidelines on inclusion and exclusion criteria. They were further instructed to: include only references from work performed in low- and middle-income countries (per World Bank definitions during the time that the data in the reference were collected) or among marginalized or indigenous populations in developed countries (e.g., Aboriginal Australian children) [94, 95]; to include references related to EED or conditions identical to or very consistent with EED (e.g., environmental enteropathy, tropical enteropathy, persistent diarrhea) among any age group in a setting of interest, and references related to other enteropathies or to nutritional conditions of interest among children under five years of age in a setting of interest.

The refinements in the inclusion/exclusion instructions regarding other enteropathies were implemented because there is accumulating evidence that celiac disease is not confined to individuals of northern European descent residing in industrialized countries, but is instead a worldwide problem, including in regions in which EED is endemic, such as South Asia [96]. Second, there is increasing recognition of inflammatory bowel diseases (i.e., Crohn's disease and ulcerative colitis) in these regions [97], though most cases of intestinal inflammation in these populations are not related to idiopathic inflammatory bowel diseases in children under five years of age. Third, we wished to include references on malnutrition and nutritional status where EED could act as an intermediary while excluding references that examined other aspects of malnutrition. For example, while food insecurity commonly affects populations at risk for EED, studies of nutritional deficits by themselves, including surveys of such deficiencies, were designated to be beyond the scope of our project. In another example, iron deficiency can be caused by a multitude of factors including defective absorptive capacity in the small bowel. To capture only the references relating to intestinal absorptive function, we excluded references if iron deficiency was studied outside the context of intestinal uptake assessment or another process related to EED.

Progressing in reverse chronological order, virtually all references between 1980 and 2010 were evaluated as to whether or not they should be included or excluded from the EED Library, or whether or not additional information from the full text (particularly when the abstract was not initially available from the medical/health databases searched) was needed to make the determination. If included in the Library, references were assigned tags as to whether the reference contained information about: 1) enteropathy or enteric function/dysfunction, 2) nutritional status or malnutrition, and/or 3) enteric microbes. By using the topic areas and tags, we could then formulate queries to apply to our EED Library to identify articles potentially relevant to specific review questions that are contained in Table 2 or identified in the future. Additionally, topic areas (Table 2) covered in each reference were noted, as well as an indication whether the reference was a review or otherwise did not present primary data.

Each reference published between 1980 and 2010 was reviewed for inclusion by two analysts according to the written guidelines and instructions. A principal investigator or lead analyst reviewed all references for which the analysts were discordant on Library inclusion, topic area, or other determinations, and provided final decisions. Furthermore, to verify that systematic errors did not occur in the exclusion of references, a random subset of references excluded by both analysts was scrutinized by a lead analyst. Percent error rate for this subset was calculated.

The kappa statistic was used to evaluate reliability of individual analyst responses against final inclusion/exclusion determinations. Interpretation of kappa was performed using the following guidelines as described by Koepsell and Weiss [98]: agreement of >0.80 was deemed excellent, $0.61-0.80$ substantial, $0.41-0.60$ moderate, $0.21-0.40$ fair, $0.00-0.20$ slight, and <0.00 poor.

Chapter 3. EED Library as a Basis for Systematic Reviews

3.1 Defining Systematic Review Question Priorities

Evidence related to any topic area and addressing questions raised in Table 2 has potential to move the EED field forward. While an argument could be made to pursue any of the topic areas/questions, we had to define a starting question to address and had to develop a prioritization scheme given the importance of many of the topic areas/questions. Descriptive epidemiology (topic area I in Table 2), for example, would certainly be useful to gauge the scope of the problem, but would probably not produce useful recommendations. We considered developing a review that considered EED as a dependent variable (i.e., an outcome) of processes and risk factors (topic area II in Table 2). Such a characterization might be used to develop preventive interventions for EED. We next formulated a model of EED as an event that causes many injuries in the host (topic area III in Table 2), such as stunting and micronutrient deficiencies. A review based on this model could be considered an analysis of its consequences by focusing on host injuries and population impact. Biomarkers of EED as a subject for review (topic area IV in Table 2) could provide a compendium of tools that could be used to detect EED, and possibly to shed light on its origin. Consideration was additionally given to reporting the clinical course and pathophysiology of EED (topic area V in Table 2), to summarize the state of knowledge about cellular and organ processes that underlie its disease course. Finally, we considered reviewing existing treatment or prevention interventions for EED (topic area VI in Table 2).

To provide direction for our initial efforts, we decided that it was important to select areas in which a sufficient body of data is likely to exist. An additional attribute for a useful review is that the resulting analysis can be used for disease control.

With these considerations in mind, we narrowed the set to four lead questions:

1. What is the evidence that EED is caused by (an) identifiable pathogen(s), microbial populations, environmental or other identifiable factors?
2. What is the evidence that EED can be prevented by any interventions?
3. What is the evidence that EED can be noninvasively diagnosed?
4. What is the evidence regarding efficacy/effectiveness of treatment interventions for EED?

Based on deliberations amongst the co-authors, and engagement with the Bill & Melinda Gates Foundation, as well as discussions at the Gut Integrity Workshop held in Seattle, Washington in December 2010, we focused on noninvasive diagnosis of EED as a priority systematic review question.

3.2 Determining Relevance to the Systematic Review

We carefully considered the specifics of the review question and framed the question for consistency with the Population Intervention Comparison Outcome (PICO) framework for systematic review questions [99]:

What biomarkers or diagnostic tests¹ have been used to identify or have been shown to be associated with mucosal dysfunction of the small intestine² or host inflammation³ in children under five years of age from developing-country settings⁴?

For the purpose of this systematic review question, dysfunction was defined as manifestation of increased small intestinal permeability, decreased absorption of nutrients, enteric inflammation, or abnormal enterocyte metabolism or cell function. These conditions could be present in children with environmental enteric dysfunction based on histology or persistent diarrhea or those with malnutrition, or who were clinically asymptomatic. Evaluation of asymptomatic or “normal” subjects without overt clinical evidence of enteric dysfunction or those with acute diarrhea was of interest as long as they were evaluated for tests of mucosal small intestinal dysfunction (e.g., endoscopy, histology, or markers of permeability or absorption from serum, urine, or stool) or they were being tested in the same study as children with persistent diarrhea. Gastrointestinal dysfunction or enteropathy related to celiac disease, cow's milk protein allergy (CMPA), inflammatory bowel disease, or cystic fibrosis, as well as primary

¹ Assessments of host biological materials or imaging assessments (e.g. radiologic) of the host.

² Including increased small intestinal permeability, decreased absorption of nutrients, enteric inflammation, or abnormal enterocyte metabolism or cell function among those with enteropathy (e.g. environmental enteric dysfunction (EED) based on histology or persistent diarrhea) or children with malnutrition or clinically asymptomatic children.

³ Laboratory confirmed generalized or tissue inflammation, but not necessarily specifically measuring gut-specific inflammation, e.g. C-reactive protein (CRP), IL-6.

⁴ Defined as low or middle income country as determined by World Bank or among marginalized or indigenous populations in a developed country.

immunodeficiency disorders (e.g., X-linked agammaglobulinemia, common variable immunodeficiency, IgA deficiency, IgG subclass deficiency) were excluded from this systematic review.

Studies that used tests or markers specifically related to small intestinal mucosal function (except for the aforementioned excluded specific enteropathies) among children under five years of age from a developing country setting were included. These tests include biopsy, tests of nutrient absorption (e.g., iron absorption), tests of gut permeability and/or absorption (e.g., D-xylose, lactulose:mannitol ratio [L:M]), and stool markers (e.g., fecal fat, reducing substances). Articles describing tests or markers of systemic inflammation that can be affected by mucosal intestinal function (e.g., IL-6, C-reactive protein (CRP), blood counts) were also included as long as they were conducted: a) among children with EED or enteric dysfunction consistent with EED (e.g., those with persistent diarrhea and without an excluded enteropathy), b) among acute diarrhea or asymptomatic patients in a study that compared results to subjects with a small intestinal mucosal disorder of interest, or c) in association with a test of mucosal small intestinal function. Articles that were limited to tests of micronutrient status, celiac or CMPA disease-specific tests, or tests for specific pathogens were excluded from the systematic review.

We decided to restrict this analysis to articles published between 2000 and 2010 in the interest of producing an expedited analysis of a well-defined literature set. We retain the ability to apply this methodology to the literature identified for prior intervals. We also performed an assessment of 10 references chosen at random that were published between 1990 and 1999 to determine the scope of additional information that an analysis of the literature prior to our restricted time block might provide (Appendix 3). Of the 10 articles, only one had a sample size of 100 or more subjects under five years of age. Overall, these articles do not lend substantial or novel data to content already derived from the 2000-2010 analysis.

We acknowledge that delving back to prior decades could provide additional informative data. This is especially true because much study regarding EED occurred in the 1970s and 1980s and waned in the subsequent decades, and because technology is not evolving rapidly in this field. However, secular trends in socioeconomic, environmental, nutritional, and disease conditions as well as improvements in laboratory, epidemiologic, and biostatistical methods complicate comparison of data across studies from different time periods. Also, earlier studies focused on adults.

The team included analysts knowledgeable in German, French, Spanish, Italian, and Portuguese; thus, we were able to thoroughly dissect articles in these languages. References in other languages were excluded as we were not able to translate other languages in detail sufficient for the purposes of thorough extraction and analysis.

A summary of inclusion/exclusion criteria and of the instructions given to analysts is provided in Table 6.

Table 6. Guidelines for systematic review inclusion/exclusion determination and data extraction.

Biomarkers and Diagnostics Systematic Review Question:

What biomarkers or diagnostic tests¹ have been used to identify or have been shown to be associated with mucosal dysfunction² of the small intestine or host inflammation³ in children under five years of age from developing-country settings⁴?

¹ Assessments of host biological materials or imaging (e.g., radiologic) assessments of the host.

² Dysfunction can be related to increased small intestinal permeability, decreased absorption of nutrients, enteric inflammation, or abnormal enterocyte metabolism or cell function among those with enteropathy (e.g., EED based on histology, persistent diarrhea) or children with malnutrition or clinically asymptomatic children.

³ Laboratory-confirmed generalized or tissue inflammation, but not necessarily specifically measuring gut-specific inflammation (e.g. CRP, IL-6).

⁴ Developing-country setting is defined as a low- or middle-income country (as classified by World Bank) or among indigenous populations in a developed country.

Excludable conditions (non-EED enteropathies)

Celiac disease, IBD, CMPA, cystic fibrosis (CF) (diagnosed by abnormal sweat test), as well as primary immunodeficiency disorders (e.g., X-Linked agammaglobulinemia, common variable immunodeficiency, IgA deficiency, IgG subclass deficiency) were not conditions of interest for this review unless the following circumstances existed:

1. The study had controls or other subjects of interest who underwent diagnostic tests that are of interest to us (see "Category I Tests," below).
2. The condition (i.e., celiac disease, CMPA, IBD) did not meet our systematic review criteria for defining or diagnosing that condition. In other words, these disorders may have been incorrectly diagnosed and could actually have been an enteric dysfunction of interest.

Asymptomatic children and children with acute diarrhea:

Evaluation of asymptomatic or 'normal' subjects without overt clinical evidence of enteropathy or those with acute diarrhea was pertinent to our review as long as the included tests of mucosal small intestinal dysfunction (e.g., endoscopy, histology, or serum, urine, or stool markers of permeability or absorption). We were not interested in asymptomatic children or those with acute diarrhea if tested for only systemic markers, unless they were tested in the same study as children with EED or persistent diarrhea (PD). We were interested in the comparison of systemic tests in patients who are asymptomatic and/or have acute diarrhea vs. PD. For example, if a systemic marker was measured in subjects who were asymptomatic or had acute diarrhea, we did not include these data. However, if these tests were also performed in a PD group, then we included the data from all of these subjects— acute diarrhea, PD, and asymptomatic subjects— taking care to separate findings by these categories.

We did not include references about children who presented with abdominal pain, vomiting, anemia, rectal bleeding, gastroesophageal reflux, etc., unless they reported to have also had EED, tropical enteropathy (TE), environmental enteropathy (EE), PD, malabsorption, or other symptoms suggesting small intestinal mucosal dysfunction.

Tests to Include:

Tests specific to intestinal dysfunction: We included biomarkers and diagnostic tests specifically related to small intestinal mucosal function if other inclusion criteria were met (i.e., age under 5, developing-country setting, etc.). We included these types of tests:

- Endoscopy
- Intestinal biopsy or lavage
- Lactose/sucrose load test

Tests of nutrient absorption (not static blood levels; see Excludable Diagnostic Tests, below), such as the following:

- B12 absorption
- Iron absorption
- Calcium absorption
- ¹³C sucrose or hydrogen breath test (HBT)

Urine markers of gut permeability or absorption:

- D-xylose
- Creatinine, fraction excretion
- Lactulose, fraction excretion
- Sucrose, fraction excretion
- Sucralose, fraction excretion
- Mannitol, fraction excretion
- L:M (lactulose:mannitol) ratio
- Sucrose:lactulose ratio
- Sucralose:lactulose ratio
- Urea:creatinine ratio
- Lactose:creatinine ratio

Any stool markers (except those testing for specific micro-organisms; see Excludable Diagnostic Tests, below), such as the following:

- Alpha-1-antitrypsin
- Calprotectin
- Fecal fat
- Lactoferrin
- Neopterin
- Myeloperoxidase
- pH
- Reducing substances
- Leukocytes (i.e., white blood cells (WBCs) by microscopy
- Occult blood testing (including guiac)
- Red blood cells (RBCs) by microscopy

Systemic, Non-specific Tests: Many biomarkers and diagnostic tests, including the below list of systemic markers of inflammation, can be impacted by mucosal intestinal function, but they can also be impacted by other non-gastrointestinal disorders.

For these tests, we only included if one or more of the following conditions were met:

1. They were conducted among patients with a mucosal small intestinal disorder of interest (e.g., EED, PD, or among asymptomatic or acute diarrhea subjects in a study that also examined subjects with mucosal small intestinal disorder of interest).
2. The tests were reported in relation to a test of mucosal small intestinal function (see list above).

Examples of systemic, non-specific tests are the following:

- Hemoglobin (HGB), hematocrit (HCT) (blood cell counts)
- Total serum proteins and other serum proteins such as albumin, pre-albumin
- Serum lipids and lipoproteins
- Liver function tests (e.g., alanine transaminase)
- Urine sodium (Na)
- Urine pH
- Systemic inflammatory markers such as:
 - C-reactive protein (CRP)
 - Erythrocyte sedimentation rate (ESR)
 - Tumor necrosis factor (TNF)
 - Interleukin-6 (IL-6)
 - Interferon-gamma (IFN-gamma)
 - Alpha-1-acid glycoprotein (AGP)
 - Serum immunoglobulins
 - Immune cell subsets
 - Ferritin

Algorithm for our inclusion/exclusion decisions on tests/markers:

1. Was the test performed on children under five years in a developing-country setting? If no, exclude. If yes, continue.
2. Is the test on the list of excludable tests? If yes, exclude. If no, continue.
3. Is the test potentially related to small intestinal mucosal function? If no, exclude. If yes, continue.
4. Is the test specific for small intestinal mucosal function? If yes, include and extract data. If no, continue.
5. Is the test a more general test that could be related to dysfunction of other organ systems? If no, exclude. If yes, continue.
6. Was the test assessed among children with mucosal small intestinal dysfunction or among children who have been assessed for mucosal small intestinal dysfunction? If no, exclude. If yes, include and extract data.

3.3 Acquisition of References and Copyright Fair Use Compliance

References potentially relevant to the systematic review were determined by querying the EED Library Access database. The query identified references tagged as explicitly EED-related and relevant to or possibly relevant to topic area IV (i.e., diagnostic tests and biomarkers).

Starting in reverse chronological order, full texts of references that were identified as potentially relevant to the systematic review were obtained as Portable Document Format files (PDFs) and deposited into a central repository on Google Drive.

We maintained compliance with Fair Use obligations of U.S. Copyright Law, watermarking all PDFs and making the Google Drive repository available only to team members. Furthermore, analysts who performed data extraction indicated their compliance with fair use when logging into the data entry system, via a checkbox that stated “I agree to use this article according to US copyright law.”

3.4 Documenting Relevance to the Systematic Review

Two principal investigators (DMD, PIT) and/or lead analysts (ZCN, KMV) reviewed discordant decisions made by research analysts (RAs) to determine relevance of references to the systematic review according to written guidelines (Table 6). In addition, a subset of concordant decisions (with an emphasis on excluded references) was reviewed for quality control.

After the systematic search of the EED Library, we employed the "snowball technique" to identify further articles relevant to the systematic review. The snowball technique involves review of bibliographies of references determined as relevant to the systematic review, and cited articles were cross-checked against the EED Library. If not already included in the Library, the article was evaluated for inclusion in the Library and the systematic review.

3.5 Data Extraction for the Systematic Review

For data extraction, presentation, and analysis, we utilized the REDCap (Research Electronic Data Capture) system (<http://project-redcap.org/>). REDCap is a secure, web-based application for construction and management of online surveys and databases from multiple users [100]. A sample REDCap template for data extracted from systematic review references can be found in Appendix 4.

After inclusion/exclusion decisions for the review were finalized, six analysts extracted data from studies into REDCap. The analysts were provided written guidelines on the type of data to be extracted (Table 6). Conference call training sessions were employed to reinforce guidelines and to address questions. Analysts were instructed to extract data on relevant facets including: study objectives, outcome of relevance to review question, setting, study design, subject description, case definition for subjects of interest, age groups and age range, study population, sample size for review question, biomarkers or diagnostic tests, test conditions and specifications, and results, as well as provide their impression of the evidence quality and a study synopsis. Extracted data were reviewed for accuracy and completeness by lead analysts, who made edits as needed and provided feedback to the RAs to increase efficiency and accuracy.

We exported specific fields of data from REDCap, facilitating analyses and data presentation in evidence table format. From these characterizations, we portrayed the spectrum of responses in quantitative and free-text formats as needed.


It is important to note that the EED Library, with references from PubMed, EMBASE, Global Health, and WHO Regional databases that were published between 1980 and 2010, remains available for research relevant to enteric dysfunction in children in resource-poor environments.

3.6 EED Library: Search Results Overview

The systematic search of PubMed, Embase, WHO Regional, and Global Health databases yielded 85,334 references of potential relevance to the EED Library. 17,431 references that were published before 1980 have not been assessed for inclusion in the Library. 67,903 references published between 1980 and 2010 are depicted in Figure 6. A small portion of this set was not reviewed because full text was necessary for determination, but was not available (i.e., we were unable to retrieve 89 articles published between 2000 and 2010).

66,541 references were dual-reviewed against EED Library inclusion criteria with 9,669 admitted to the project Library. Fifteen percent of those included were reviews, commentaries, abstract proceedings, books, or editorials, and the remainder were references with primary data. To conserve project resources, approximately 1,350 articles from the original systematic search that were published before 2000 were not reviewed for library inclusion.

Figure 6. Flowchart of project procedure results.



3.7 Quality Control

Accuracy and completeness in coding inclusion/exclusion and labels, tags, and topic areas by analysts were closely monitored. Means for the percent of inaccurate exclusion and inclusion and for kappa statistics were weighted based on the number of reference spreadsheets reviewed by each analyst. The overall inaccurate exclusion and inclusion rates were 2.2% and 2.7%, respectively. The kappa average for the group of analysts was 0.76, which is considered to be in the "substantial concordance" range [98]. In addition, 1,200 references that were concordantly excluded by two analysts were reviewed by a lead analyst; the exclusion error rate for these references was 0.5% (Table 7).

Table 7. Accuracy rates for inclusion and exclusion.

Concordance/discordance between analysts and study investigators on an evaluation set of 12,000 references. Analysts who completed only a limited number of references are not included.

Analyst	Inaccurate Exclude (%)	Inaccurate Include (%)	Kappa (mean)	Number of references analyzed for quality control
A	5.2	3.4	0.46	1800
B	0.9	3.2	0.83	11400
C	2.9	0.9	0.78	2000
D	1.9	2.9	0.78	7800
E	2.9	1.3	0.74	6400
F	5.8	6.4	0.50	600
G	6.4	3.7	0.61	200
H	2.9	3.3	0.75	600
I	4.2	6.5	0.67	800
J	3.3	0.7	0.79	600

Group metrics:	Weighted average inaccurate exclude	Weighted average inaccurate include	Weighted average kappa	Concordant exclusion error rate
	2.2	2.7	0.76	0.5 %

3.8 EED Library Status

Twenty percent of all of the references derived from our initial systematic search of the PubMed, Embase, and Global Health databases were published between 2006 and 2010. The discordance between the abundance of references that we found in our search and the paucity of references found in the ISI query suggest that relevant literature is indexed with search terms

that are neither sensitive nor specific. The inclusive approach using terms that broadened the scope of papers identified was therefore warranted, even though such broadening obligated the inclusion of over 85,000 references.

Furthermore, careful documentation of our search terms allows reproducibility despite the complex nature of our strategy. The search strategy can be replicated and resultant references run through our project procedures to update the Library at any time. In addition, the search strategy designed for this project can be modified if related searches are needed.

The EED Library, as derived from PubMed, EMBASE, Global Health and WHO Regional databases and published between 1980 and 2010, was designed to be a resource for scientists, public health and clinical practitioners working on a variety of EED investigations. In fact, we have interrogated our EED Library for several groups of researchers in the field:

1. Dr. David Rudnick at Washington University in St. Louis requested assistance in his work on liver function and growth in resource-limited settings, and we queried the database as regards the role of aflatoxin and growth as reflected in the literature.
2. We provided a list of references from the last decade that reported use of biopsies among children in resource-limited settings to Dr. James Lavery's team in Toronto to assist in their examination of ethical considerations of invasive and noninvasive assessments of what they termed "tropical enteropathy/enteric enteropathy."
3. We provided data from our database to Dr. Gerald Keusch's team (which includes co-authors Drs. Denno and Tarr) who were building a working definition of EED.
4. The master evidence table was made available to all of the participants of the Bill and Melinda Gates Foundation Grand Challenges Gut Function Biomarker Shaping Meeting in London in June 2012.
5. We performed a pilot project for the Bill and Melinda Gates Foundation to determine the number of studies in the EED database that involved interventions. We further determined how many of these were clinical trials vs. treatment studies, categorized the interventions, and tallied the number of studies per category.

The EED Library can be searched using the codes, labels and tags that our Research Analyst team assigned to EED Library records. Continued assembly of literature post-2010 would add value if the database is to be further utilized to address other queries.

Chapter 4. Systematic Review of EED Biomarkers/Diagnostic Tests: Results Synopsis

4.1 Biomarkers and Diagnostics Systematic Search Results

The query of our EED Library to identify references potentially relevant to the systematic review produced 361 citations for the time period between 2000 and 2010. The "snowball" technique identified 13 additional potentially relevant publications that were not found through the original systematic search. Thirty-three of the 374 potentially relevant publications were in languages other than those that we included for this review—English, French, German, Italian, Portuguese, and Spanish (Table 8).

Table 8. Breakdown of publications in excluded languages of potential relevance to the systematic review.

Language	Number potentially relevant	Number sufficiently reviewed and excluded for reasons other than language
Arabic	1	0
Chinese	3	1
Croatian	2	2
Czech	2	1
Norwegian	1	0
Polish	14	10
Russian	9	6
Turkish	1	1
Totals	33	21

However, we were able to determine (via translation and/or English language abstract) that 21 of the 33 did not meet our other systematic review inclusion criteria. We were unable to sufficiently translate the remaining 12 papers to determine their relevance or, if they were relevant, to extract data. These papers were in Arabic (n=1), Chinese (n=2), Czech (n=1), Norwegian (n=1), Polish (n=4), and Russian (n=3). Two-hundred and fifty publications were eliminated for various reasons, including their focus on celiac disease, cow's milk protein allergy, or inflammatory bowel disease; lack of at least three subjects of interest under five years of age; or they did not assess biomarkers or diagnostic tests related to small intestinal function or inflammation. One potentially relevant article was thought to be pertinent to the systematic review based on the abstract, and another article required full text for further determination; however, the full texts for these two articles could not be found.

An additional 12 references were highly considered for inclusion, but ultimately excluded from the review for reasons including insufficient subjects in the specified age range, inadequate relevant data on appropriately-aged subjects, or uncertainty about the setting in which the study was performed (Appendix 5).

We identified 20 review articles with content that addressed or discussed material of relevance to our systematic review question (Appendix 6); however, we identified no systematic review that had been conducted on biomarkers or diagnostic tests related to EED.

4.2 Characteristics of References Included in the Systematic Review

The remaining 77 references included in the systematic review (Table 9) describe research that was performed in 22 different countries. Figure 7 maps the sites where the studies were performed.

Table 9. Articles pertinent to the systematic review.

These were determined to be the publications of interest between 2000 and 2010.

Alcantara CS, et al. Interleukin-8, tumor necrosis factor-alpha, and lactoferrin in immunocompetent hosts with experimental and Brazilian children with acquired cryptosporidiosis. 2003. [101]
Alves GM, et al. Nutritional status and breath hydrogen test with lactose and lactulose in Terena Indian children. 2002. [102]
Amadi B, et al. Reduced production of sulfated glycosaminoglycans occurs in Zambian children with kwashiorkor but not marasmus. 2009. [103]
Azim T, et al. Immune response of Bangladeshi children with AD who subsequently have persistent diarrhea. 2000. [104]
Bhatnagar S, et al. Celiac disease with mild to moderate histological changes is a common cause of chronic diarrhea in Indian children. 2005. [105]
Bitarakwate E, et al. Serum zinc status of children with persistent diarrhoea admitted to the diarrhoea management unit of Mulago Hospital, Uganda. 2003. [106]
Bukhari AS, et al. DNA damage and plasma homocysteine levels are associated with serum metabolites and mineral constituents' profiles in children with persistent diarrhea. 2010. [107]
Bushen OY, et al. Heavy cryptosporidial infections in children in northeast Brazil: comparison of <i>Cryptosporidium hominis</i> and <i>Cryptosporidium parvum</i> . 2007. [108]
Bustos M, et al. Disaccharidase deficiency in Bolivian children with persistent diarrhea. 2003. [109]
Campbell DI, et al. Intestinal inflammation measured by fecal neopterin in Gambian children with enteropathy: association with growth failure, <i>Giardia lamblia</i> , and intestinal permeability. 2004. [15]
Campbell DI, et al. Growth faltering in rural Gambian infants is associated with impaired small intestinal barrier function, leading to endotoxemia and systemic inflammation. 2003. [110]
Campbell DI, et al. Chronic T cell-mediated enteropathy in rural west African children: relationship with nutritional status and small bowel function. 2003. [111]
Campbell DI, et al. Age-related association of small intestinal mucosal enteropathy with nutritional status in rural Gambian children. 2002. [112]
Chen P, et al. Association of vitamin A and zinc status with altered intestinal permeability: analyses of cohort data from northeastern Brazil. 2003. [113]

Clark TD, et al. Risk factors and cumulative incidence of anaemia among human immunodeficiency virus-infected children in Uganda. 2002. [114]

Darboe MK, et al. Effectiveness of an early supplementation scheme of high-dose vitamin A versus standard WHO protocol in Gambian mothers and infants: a randomised controlled trial. 2007. [115]

Dini E, et al. Sudan III and steatocrit in the detection of fecal fat in malnourished children. 2002. [116]

El Mouzan MI, et al. Endoscopic duodenal biopsy in children. 2006. [117]

Fagundes-Neto U, et al. Studies of the small bowel surface by scanning electron microscopy in infants with persistent diarrhea. 2000. [118]

Filteau SM, et al. The effect of antenatal vitamin A and (beta)-carotene supplementation on gut integrity of infants of HIV-infected South African women. 2001. [119]

Galpin L, et al. Effect of *Lactobacillus* GG on intestinal integrity in Malawian children at risk of tropical enteropathy. 2005. [120]

Gandolfi L, et al. Antiendomysial antibody test reliability in children with frequent diarrhea and malnutrition: is it celiac disease? 2001. [121]

Goto R, et al. Impact of anti-*Giardia* and anthelmintic treatment on infant growth and intestinal permeability in rural Bangladesh: a randomised double-blind controlled study. 2008. [122]

Goto R, et al. Impact of intestinal permeability, inflammation status and parasitic infections on infant growth faltering in rural Bangladesh. 2008. [123]

Goto R, et al. Poor intestinal permeability in mildly stunted Nepali children: Associations with weaning practices and *Giardia lamblia* infection. 2002. [124]

Haase A, et al. Dual sugar permeability testing in diarrheal disease. 2000. [125]

Hafeez A, et al. An audit of pediatric upper gastrointestinal endoscopies. 2000. [126]

Jain S, et al. Fecal occult blood screening in children with severe malnutrition. 2007. [127]

Kapoor L, et al. Giardiasis--clinical and diagnostic perspective. 2001. [128]

Kapoor S, et al. Detecting protein losing enteropathy by Tc-99m dextran scintigraphy: A novel experience. 2002. [129]

Kirkpatrick BD, et al. Serum mannose-binding lectin deficiency is associated with cryptosporidiosis in young Haitian children. 2006. [130]

Kirkpatrick BD, et al. Childhood cryptosporidiosis is associated with a persistent systemic inflammatory response. 2006. [131]

Kirkpatrick BD, et al. Cryptosporidiosis stimulates an inflammatory intestinal response in malnourished Haitian children. 2002. [132]

Kohli A, et al. *Giardia duodenalis* assemblage, clinical presentation and markers of intestinal inflammation in Brazilian children. 2008. [133]

Kukuruzovic R, et al. Increased nitric oxide production in AD is associated with abnormal gut permeability, hypokalemia and malnutrition in tropical Australian aboriginal children. 2003. [43]

Kukuruzovic R, et al. Milk formulas in acute gastroenteritis and malnutrition: a randomized trial. 2002. [134]

Kukuruzovic R, et al. Small bowel intestinal permeability in Australian aboriginal children. 2002. [58]


Laadhar L, et al. Determination of anti-transglutaminase antibodies in the diagnosis of celiac disease in children: results of a five year prospective study. 2004. [135]

Leite CA, et al. Functional, microbiological and morphological intestinal findings among human immunodeficiency virus infected children. 2006. [136]

-
- Lima AA, et al. Effects of vitamin A supplementation on intestinal barrier function, growth, total parasitic, and specific *Giardia* spp infections in Brazilian children: a prospective randomized, double-blind, placebo-controlled trial. 2010. [137]
-
- Lima AA, et al. Intestinal barrier function and weight gain in malnourished children taking glutamine supplemented enteral formula. 2005. [138]
-
- Lima NL, et al. Wasting and intestinal barrier function in children taking alanyl-glutamine-supplemented enteral formula. 2007. [139]
-
- Long KZ, et al. The effect of vitamin A supplementation on the intestinal immune response in Mexican children is modified by pathogen infections and diarrhea. 2006. [140]
-
- López de Romaña D, et al. Longitudinal measurements of zinc absorption in Peruvian children consuming wheat products fortified with iron only or iron and 1 of 2 amounts of zinc. 2005. [141]
-
- Mahmud MA, et al. Sociodemographic, environmental and clinical risk factors for developing persistent diarrhea among infants in a rural community of Egypt. 2001. [142]
-
- Mahmud MA, et al. Increased fecal IgE among infants in a rural community of Egypt: an analysis of associated risk factors. 2001. [143]
-
- Manary ML, et al. Zinc homeostasis in Malawian children consuming a high-phytate, maize-based diet. 2002. [144]
-
- Mishra OP, et al. Endoscopic and histopathological evaluation of preschool children with chronic diarrhea. 2001. [145]
-
- Mittal SK, et al. Tropical Sprue in North Indian Children. 2001. [146]
-
- Moya-Camarena SY, et al. Effects of asymptomatic *Giardia intestinalis* infection on carbohydrate absorption in well-nourished Mexican children. 2002. [147]
-
- Murphy JL, et al. Maldigestion and malabsorption of dietary lipid during severe childhood malnutrition. 2002. [148]
-
- Murphy JL, et al. Gastrointestinal handling and metabolic disposal of ¹³C-labelled tripalmitin during rehabilitation from childhood malnutrition. 2001. [149]
-
- Nichols B, et al. Contribution of villous atrophy to reduced intestinal maltase in infants with malnutrition. 2000. [53]
-
- Northrop-Clewes CA, et al. Anthelmintic treatment of rural Bangladeshi children: effect on host physiology, growth, and biochemical status. 2001. [150]
-
- Panter-Brick C, et al. Pathways leading to early growth faltering: An investigation into the importance of mucosal damage and immunostimulation in different socio-economic groups in Nepal. 2009. [151]
-
- Perin NM, et al. Intestinal absorption of D-xylose in children infected with the human immunodeficiency virus. 2001. [152]
-
- Pires AL, et al. Digital morphometric and stereologic analysis of small intestinal mucosa in well-nourished and malnourished children with persistent diarrhea. 2003. [153]
-
- Poddar U, et al. Is tissue transglutaminase autoantibody the best for diagnosing celiac disease in children of developing countries? 2008. [154]
-
- Poddar U, et al. Celiac disease in India: Are they true cases of celiac disease? 2002. [155]
-
- Quadro L, et al. Retinol and retinol-binding protein: gut integrity and circulating immunoglobulins. 2000. [156]
-
- Rabbani GH, et al. Green banana and pectin improve small intestinal permeability and reduce fluid loss in Bangladeshi children with persistent diarrhea. 2004. [157]
-

-
- Rabbani GH, et al. Increased nitrite and nitrate concentrations in sera and urine of patients with cholera or shigellosis. 2001. [158]
-
- Ritchie BK, et al. ¹³C-sucrose breath test: novel use of a noninvasive biomarker of environmental gut health. 2009. [159]
-
- Rollins NC, et al. Feeding mode, intestinal permeability, and neopterin excretion: A longitudinal study in infants of HIV-infected South African women. 2001. [160]
-
- Rollins NC, et al. Vitamin A supplementation of South African children with diarrhea: optimum timing for improving biochemical and clinical recovery and subsequent vitamin A status. 2000. [161]
-
- Samie A, et al. *Cryptosporidium* species: preliminary descriptions of the prevalence and genotype distribution among school children and hospital patients in the Venda region, Limpopo Province, South Africa. 2006. [162]
-
- Sarker SA, et al. *Helicobacter pylori* infection, iron absorption, and gastric acid secretion in Bangladeshi children. 2004. [163]
-
- Sheng XY, et al. Major variables of zinc homeostasis in Chinese toddlers. 2006. [164]
-
- Sherwani K, et al. Prevalence of iron deficiency anemia in chronic diarrhoea and celiac disease - A western UP experience. 2008. [165]
-
- Soliman SM, et al. Role of micronutrient mixture in acute and persistent diarrhea in infants and its impact on nutritional status. 2003. [166]
-
- Tassara O, et al. Gastrointestinal diseases in children infected with the human immunodeficiency virus. 2003. [167]
-
- Thurnham DI, et al. Innate immunity, gut integrity, and vitamin A in Gambian and Indian infants. 2000. [168]
-
- Trehan I, et al. A randomized, double-blind, placebo-controlled trial of rifaximin, a nonabsorbable antibiotic, in the treatment of tropical enteropathy. 2009. [13]
-
- Vieira MM, et al. Carotenoids, retinol, and intestinal barrier function in children from northeastern Brazil. 2008. [169]
-
- Williams EA, et al. A double-blind, placebo-controlled, glutamine-supplementation trial in growth-faltering Gambian infants. 2007. [170]
-
- Willumsen JF, et al. Subclinical mastitis as a risk factor for mother-infant HIV transmission. 2000. [171]
-
- Zhang Y, et al. Lactulose-mannitol intestinal permeability test in children with diarrhea caused by rotavirus and *Cryptosporidium*. 2000. [172]
-

Figure 7. Geographic mapping of study sites
Number of studies by country included in the systematic review.



*One of the studies attributed only to The Gambia in this map had two study locations: The Gambia and India.

Aggregated characteristics of the included studies are presented in Table 10. Details of the data from each article are reported in the Evidence Table of all studies included in the review (Appendix 7). Data are also presented in individual Evidence Tables based on category of biomarker (Evidence Tables 1-8). It is important to note that we only include data from articles that pertain to our review question. No identified study was explicitly designed to assess the accuracy of the diagnostic tests or biomarkers that they employed among children in developing-country settings. While this does not detract from their intrinsic value, it does pose an additional challenge to our goal of evaluating diagnostics for EED. For example, we did not find data pertaining specifically to standard measures of diagnostic test evaluation, such as positive or negative predictive values, or receiver operating characteristic curves. We assessed the use of the biomarkers as they were employed and extracted data relevant to the markers themselves, even if these data were not the primary focus of the studies.

Table 10. Overview of studies.

Characteristics of studies are provided and demonstrate broad-based nature of current and recent data.

Study sites by WHO regions, countries: Number of studies

WPRO: China (1), Australia (5)
 AMRO: Brazil (16), Haiti (3), Mexico (2), Peru (2),
 Venezuela (1), Chile (1), Bolivia (1), Jamaica (2)
 AFRO: Zambia (1), Malawi (3), The Gambia (6),
 South Africa (5), Uganda (2)
 EMRO: Saudi Arabia (1), Pakistan (2), Egypt (3), Tunisia (1)
 SEARO: India (10), Bangladesh (7), Nepal (2)

Publication year: Number of studies

2000:10	2006:7
2001:12	2007:5
2002:13	2008:7
2003:10	2009:3
2004:4	2010:2
2005:4	

Language of Publication: Number of studies

French: 1
 Portuguese: 2
 Spanish: 3
 English: 71

Study durations: Time period for subject enrollment	Median: 502 days Range: 28 days – 17 years Not specified: 27 studies
Publication Lag: Time from study enrollment to publication	Median: 4 years Range: 1 year – 15 years Not specified: 37 studies
Study setting: Number of studies	Urban: 49 Peri-urban: 5 Rural: 16 Urban slum ¹ : 7
Study designs: Number of studies	Case-controls: 25 Longitudinal cohort: 14 Randomized controlled trial: 16 Cross-sectional: 12 Case-series: 10
Sample size of subjects of interest: Number of subjects in all studies combined	Total: 7730 Interquartile Range: 104 Median: 75 Range: 3-318
Age range of subjects investigated in all studies combined	Range: birth-88 years
Subjects of interest to this review under five years of age: Number of subjects all studies combined	Total: 5419 ² Interquartile range: 119 Median: 71 Range: 3-306
Presenting conditions of study subjects of interest at the time of recruitment: Number of studies ³	Acute Diarrhea: 27 Persistent Diarrhea: 30 Infection with specific enteric pathogens: 28 <i>Cryptosporidium</i> (8) <i>Giardia</i> (11) Helminths (4) <i>Helicobacter pylori</i> (3) Other (13) Malnutrition: 45 Infected with HIV or Tuberculosis: 9 Healthy / asymptomatic: 40 Other: 18

¹ This comprises any study noted as being conducted in a slum, shantytown, or urban squatter settlement.

² Excluding 22 studies that do not specify subjects ≤ 4 and 5 years.

³ Number >77 because some studies included more than one condition or test.

Types of specimens and biomarkers reported: Number of studies⁴

<p><u>Blood</u> (25) Hemoglobin: 10 Albumin: 9 Immunoglobulins: 7 Lactulose:rhamnose ratio (L:R): 5 α-1-acid glycoprotein: 4 CRP: 5 Red blood cell indices (e.g., Mean corpuscular volume): 4 WBC: 4 Total protein: 3 D-xylose: 2 Transferrin (saturation): 2 α-1-antichymotrypsin: 2 Cytokines: 1 Immune function assays: 1 Mannose-binding lectin: 1 Nitric oxide: 1 Oxidative stress markers, DNA damage to lymphocytes, liver enzymes, thyroid hormones: 1 Radiolabeled iron challenge: 1</p> <p><u>Breath</u> (4) ¹³C lipid breath test: 1 ¹³C sucrose breath test: 1 Hydrogen breath test Lactose: 2 Lactulose: 1 Xylose: 1</p>	<p><u>Urine</u> (32) Lactulose:mannitol (L:M): 25⁵ Radiolabeled zinc or lipid challenge: 3 Neopterin: 2 Nitric oxide: 2 Sucrose:lactulose ratio: 2⁶ D-xylose: 1 Lactose:lactulose ratio: 1⁷ Lactulose:rhamnose (L:R): 1 Sucralose:lactulose ratio: 1⁸</p> <p><u>Stool</u> (24) Lactoferrin: 9 Leukocytes: 4 Cytokines: 5 Fecal fat: 3 Radiolabeled zinc or lipid challenge: 4 Reducing substances: 4 Occult blood/RBCs by microscopy: 3 IgE: 2 Neopterin: 1</p>	<p><u>Small intestinal aspirates</u> (2) Concentrations of immunoglobulins (Ig) IgA, IgG, and IgM: 1 Microbial concentrations: 1</p> <p><u>Small intestinal endoscopic gross visualization</u> (4)</p> <p><u>Small intestinal tissue</u> (18) Histopathology: 17 Disaccharidases: 2 Protein and inflammatory markers: 2 Messenger RNA abundances: 1</p> <p><u>Site not specified</u> (2) D-xylose: 2</p>
---	---	---

For studies that included small intestinal biopsy, characteristics specific to biopsy results:

Total subjects of interest: 996

Subjects of interest under five years of age: 8 studies specified (n=311), 10 did not specify

Site of small intestinal biopsy: Number of studies

- Duodenum: 11
- Jejunum or ileum: 4
- Not specified: 3

Esophagus or stomach also biopsied: 1

Large intestine or rectum also biopsied: 2

⁴ Number >77 because some studies included more than one condition or test.

⁵ 18 of the 25 studies include fractional excretion of the individual components.

⁶ Includes fractional excretion of the individual components.

⁷ Includes fractional excretion of the individual components; there was also one study that measured lactose excretion individually without relationship to another sugar.

⁸ Includes fractional excretion of the individual components.

Comparison of biomarkers to histopathology: Number of studies	Yes: 3 studies compared extra-intestinal tissue markers to histopathology: D-xylose (2) ⁹ ; Fecal fat (1); L:M (1) ¹⁰
	Yes: 3 studies compared endoscopic visualization or intestinal tissue markers to histopathology: Intestinal maltase activity and various intestinal mRNA abundances (1), endoscopic gross visualization (1), scanning electron microscopy (compared to light microscopy) (1)
	No: 71 studies
Comparison of extra-intestinal tissue biomarkers to other extra-intestinal tissue biomarkers: Number of studies	Yes: 12 studies ¹¹ comparing: L:M vs. albumin (1), Immunoglobulins (2), Alpha-1-acid glycoprotein AGP (1), Endotoxin and IgG endotoxin core antibody (1) Fecal neopterin (1); Lactose and Lactose:lactulose (1)
	Serum L:R vs. urinary L:R (1), sucrose breath test (1), urinary nitric oxide (1), serum lactose (1), reducing substances (1), red cell indices (1) Fecal lactoferrin vs. TNF- α receptor I (1), Urinary lactose:creatinine vs. hemoglobin (1); Urinary nitrites vs. stool reducing substances (1); Serum nitrites vs. WBC (1)
	No: 65 studies

We calculated that in the 77 papers analyzed, a total of 5,410 children under five years of age were studied for any biomarker plausibly related to EED, and an additional 2,311 children were studied, among whom the number of subjects aged under five years could not be determined (Table 10). More than 50 different biomarkers were studied. These biomarkers were obtained by study of urine, stool, blood, breath, and intestinal tissue. Eighteen studies examined the histopathology of biopsied intestinal tissue, but only three studies compared intestinal histopathology to non-intestinal tissue biomarkers (D-xylose; fecal fat; urinary L:M [111, 136, 155]). One additional study compared results of intestinal tissue markers (maltase activity and intestinal mRNA abundances for various markers) to histopathology [53]. Notably, few small

⁹ One study compared D-xylose as well as fecal fat.

¹⁰ This study compared the lactulose:mannitol ratio (L:M) to morphometric analysis of biopsy tissue.

¹¹ Number of comparisons listed is >12 because some studies included more than one comparison.

bowel biopsies (the “gold standard” diagnostic) among children under five years of age in developing-country settings are included in this cohort of studies from the past eleven years. Indeed, small bowel biopsies from only 311 children under five years of age in eight studies were reported, and an additional 685 children in 10 other studies had small bowel biopsies but the number of those who were under five years of age could not be determined.

We were also interested in the lag time between study enrollment and publication, and examined a subset of the first 24 articles relevant to the systematic review. Table 11 provides intervals between enrollment, study start and close, study duration, and year of publication for a subset of the first 24 articles that we reviewed. There were, in general, long delays in cohort enrollment and dissemination of primary data (up to 19 years, and often over a decade).

Table 11. Study timing analysis.

Dates of publication, enrollment, and performance of a subset of publications. Seven of 24 studies did not specify study time interval.

Publication Year	Study enrollment years	Range of study intervals
2006	Aug 1994-May 1995	1991-2002
	30 days – date not specified	
	1993-2002	
	Not specified	
	9 months – date not specified	
	15 months – date not specified	
	Not specified	
1991-2001		
2007	Sept 2001-October 2004	2001-2004
	July 2003-November 2004	
	5 years – date not specified	
2008	June 2003-February 2004	1989-2004
	June 2003-April 2004	
	Jan 2000-Dec 2002	
	Not specified	
	Aug 1989-Apr 1993 (current study 2004)	
July 2000-Aug 2001		
2009	3 days- date not specified	1998-2007
	Date not specified	
	2005 – 7 months	
	Sept 2007	
2010	1998-2000	2000-2004
	June 2000-Aug 2004	
	Not specified	

4.3 Classification of Biomarkers and Diagnostic Tests

The “job description” of the small bowel can be reduced to a circumscribed set of tasks: break down specific nutrients using enzymes in the intestinal lining or by micellization of lipophilic substances; extract nutrients from food; exclude the food components that have no nutritive value and propel them distally for elimination; retain (i.e., not leak into the gut) molecules used (and often synthesized) by the host; and resist microbial breach of the barrier. Hence, the intestinal mucosa serves as a specialized transporting organ as well as a physical, physiologic, and antimicrobial interface between the host and the environment which in this case consists of ingested food and water, but also other potentially highly contaminated materials (e.g., soil) [173], given the oral-motor activities of infants and toddlers. The cells and submucosa that line the small bowel are, therefore, critical for assimilation of nutrients, maintenance of structural integrity, and protection against microbial assault. In injury, substances are absorbed by barrier breach rather than by physiologic transport or diffusion.

We strove to take an unbiased and uniform approach to classifying the EED markers. Our classification system was blinded to the assertions of study authors regarding marker category; however we did find that investigators’ categorizations were largely consistent with ours. Our classification system was based on the primary function/dysfunction that the test is likely to measure or the underlying pathophysiology and pathogenesis that the test may likely reflect. For example, the amount of D-xylose that is absorbed after an oral challenge is believed to reflect gut absorptive capacity, and D-xylose uptake from the challenge, measured either in the blood or urine, is therefore classified as a test of gut absorption. We also aimed to unambiguously place a marker in one group based on best fit when possible, though we recognize that markers might detect derangements of multiple functions. For example, the

presence of lactose in the blood or urine likely indicates a loss of lactase enzyme in the intestinal brush border, and thus can be a marker of abnormal digestion or nonspecific intestinal injury. However, for lactose to traverse the mucosa and gain access to the systemic circulation, a porosity defect is needed. Hence, we chose to place this marker in the permeability category.

Finally, we recognize that many tests reflect nonspecific injury and processes, which cannot be so easily binned into mechanistic or pathophysiologic categories. For example, while measures of surface area on a biopsy provide a general impression of absorptive capacity, we categorize histopathology as a measure of nonspecific injury, as the visualization of tissue portrays a general picture of derangements in architecture without specifying function.

With these factors in mind, we formulated eight test categories, classified in Table 12, and constructed evidence tables based on these classifications.

Table 12. Classification framework for biomarkers of intestinal function/dysfunction and inflammation.


Evidence Table	Type of Functional Measure
1	Absorption
2	Porosity/permeability (with or without assessment of absorption)
3	Digestion
4	Intestinal inflammation and/or intestinal immune activation
5	Systemic inflammation and/or systemic immune activation
6	Microbial drivers
7	Nonspecific intestinal injury
8	Non-small intestine organ function

Chapter 5. Systematic Review Results by Biomarker Classifications

5.1 Markers of Absorption and Permeability: Overview

Tests of gut permeability and of absorption often overlap in concept, and are frequently performed simultaneously. For this reason, it is appropriate to provide background in tandem.

Proper functioning of the intestine depends on sufficient absorptive surface area and maintaining the barrier function and structural integrity of the lining of this organ. Absorptive surface is a function of individual villous surface area, as depicted in the photos below [3], and of gut length, which is probably not compromised in post-natally-acquired enteropathic syndromes. Absorption depends on the ability of various cellular mechanisms to assimilate nutrients from food that is ingested, using processes that rely on specialized pumps, pathways,



Microvilli of the small bowel, as seen with a magnifying lens [3]. Normal finger-like projections are presented in the top panel. Enteropathy is characterized by flattened villi (bottom panel). Reproduced from *Gut*, Booth, C.C., Vol. 5, p. 46, 1964 with permission from BMJ Publishing Group Ltd.

and degradation. Integrity reflects sieve size, and presumably passive diffusion of large molecules across non-intact epithelia. To varying extents, these functionalities are hindered in EED, celiac disease, and small bowel Crohn's disease, among other disorders.




To perform its functions, the intestinal epithelium utilizes a layer of

highly specialized columnar epithelial cells connected by the apical junctional complex of tight junctions and adherens junctions. Theoretically, specific molecules can be chosen strategically to interrogate these various attributes. For example, breaches in integrity that enable passive diffusion into the host could be measured by ingesting a substance that is not found in the diet, and measuring its concentration in the blood or urine. Another detection strategy would be to use a molecule that is easily absorbed in health and disease, but where absorption is limited only by mucosal surface availability, and, similarly, measure this tracer in urine and blood. The optimal challenge substances would resist digestion in the gut, be nontoxic, and be easily measured. Ideally, one attribute (surface area) can and should be measured in parallel with the other (specific uptake). Lastly, it might be difficult to separate one function (i.e., permeability) from the other (absorption); therefore these two processes are discussed in tandem in this section.

5.1.1 Sugars as Tracers of Intestinal Function





Historically, sugars have served well as tracers of intestinal function. These substances are nontoxic, easily detected in blood or urine, and, most importantly, neither made, nor degraded, by the host, so their presence in the body reflects gut uptake. Most of these sugars are assayed after ingestion of a load. Some of these sugars are “endomolecular,” i.e., consumed as part of a normal diet, but most are “xenomolecular,” i.e., foreign to natural diets, not metabolically necessary for the host, and absorbed without the benefit of specific transporters. Because they are foreign to the human diet, their use as a marker of intestinal function requires administration of a load to assay presence in body fluids. Moreover, depending on their size and the physiology of their assimilation, these sugars can be used to probe either amalgamated function, or specific processes or lesions (see Table 13).

Table 13. Sugar probes.

Sugar	Molecular weight	Molecular structure	Chemical (IUPAC) name	Formula	Endo- vs. Xeno-molecular ¹	Primary function assessed when found in blood and/or urine / Other comments
D-xylose	150.13	[174] 	D-xylose	HOCH ₂ (CH (OH)) ₃ CHO	Xeno-molecular	Measure of small bowel (perhaps primarily jejunal) absorptive capacity. Sugar synthesized by wood.
Lactose	342.3	[175] 	β -D-galactopyranosyl-(1 \rightarrow 4)-D-glucose	C ₁₂ H ₂₂ O ₁₁	Endo-molecular	Measure of small bowel permeability, although might also reflect lactase deficiency.
Lactulose	342.30	[176] 	4-O- β -D-galactopyranosyl-D-fructofuranose	C ₁₂ H ₂₂ O ₁₁	Xeno-molecular	Measure of small bowel permeability. Usually normalized to mannitol.

¹ We use the term xenomolecular for probes that would not be ingested in a normal dietary environment, while endomolecular probes are common and/or necessary dietary constituents. Therefore, endomolecular probes or their breakdown products are typical constituents in body analytes.

Table 13. Sugar probes.

Sugar	Molecular weight	Molecular structure	Chemical (IUPAC) name	Formula	Endo- vs. Xeno-molecular ¹	Primary function assessed when found in blood and/or urine / Other comments
Mannitol	182.17	[177] 	(2R,3R,4R,5R)-Hexan-1,2,3,4,5,6-hexol	C ₆ H ₁₄ O ₆	Xeno-molecular	Measure of total small bowel absorptive capacity.
Rhamnose	164.16	[178] 	2R,3R,4R,5R,6S)-6-methyloxane-2,3,4,5-tetrol	C ₆ H ₁₂ O ₅ · H ₂ O	Xeno-molecular	Has been used in lieu of mannitol as a measure of total small bowel absorptive capacity.
Sucralose	397.64	[179] 	1,6-Dichloro-1,6-dideoxy-β-D-fructofuranosyl-4-chloro-4-deoxy-α-D-galactopyranoside	C ₁₂ H ₁₉ .Cl ₃ O ₈	Xeno-molecular	Measure of colonic permeability. Active ingredient in Splenda ^R .
Sucrose	342.30	[180] 	Structural α-D-glucopyranosyl-(1→2)-β-D-fructofuranoside	C ₁₂ H ₂₂ .O ₁₁	Endo-molecular	Measure of gastric permeability.

An early sugar that was employed as an indicator of intestinal function was D-xylose [181, 182], a pentose, which remains a standard for single sugar absorption testing worldwide. Humans do not synthesize D-xylose isomerase. Following an enteral challenge, the molecule is eliminated intact by renal clearance, after circulating in the blood. It is largely passively absorbed in the small bowel. The mechanism of clearance is glomerular filtration without demonstrated tubular reabsorption or renal tubular excretion. Hence, uptake of D-xylose can be assayed by seeking the peak in the serum or by collecting urine for assay. The assay for D-xylose currently relies on isotopic or photometric assays [183]. Its main limitation is that a single sugar cannot differentiate loss of absorptive function from loss of absorptive area (e.g., due to shortened bowel length). Other single sugars that indicate absorptive function include mannitol and rhamnose. Sugars that are not absorbed by an intact healthy gastrointestinal tract better reflect porosity including lactose and lactulose in the small intestine, sucrose in the stomach, and sucralose in the large intestine.

The second class of sugar absorption tests utilizes two sugars. One sugar reflects total small bowel absorptive capacity, and is most often mannitol or, occasionally, rhamnose. This "denominator" sugar requires no specific uptake mechanisms or host attributes except for available surface area. The "numerator" sugar in these dual tests is most often lactulose although lactose, sucrose, and sucralose have also been used. These large molecules enter the host by passive diffusion in the presence of alterations of the integrity of the small bowel (lactulose and lactose), stomach (sucrose), or colon (sucralose).

Dual sugar tests have additional advantages. A single molecule might be affected by factors that are not related to the permeability process, e.g., rates of gastric emptying and intestinal transit, bacterial degradation, or the sufficiency of urine collection. In contrast, a ratio of excretion of two molecules is not susceptible to these factors, because such processes act on both molecules similarly, and the ratio is the key retained metric. However, absolute values

might be low in these situations, and dynamic ranges for uptake are not well established. Finally, in adults, some data suggest that the use of hyperosmolar fluids (i.e., lactulose and mannitol) might affect absorption via solvent drag [184]. For purposes of comparison, the four grams of lactulose and one gram of mannitol dissolved in five milliliters of water, a commonly employed formulation [185] produces a solution that is 4,629 mOsm/kg as compared to normal plasma osmolality of 270-285 mOsm/kg.

Variations on the challenge and recover motif used in the classic sugar absorption studies warrant discussion. Some studies use indirect assessments of uptake. For example, non-absorbed D-xylose can be metabolized by microbes in the bacteria-rich colon, and possibly also in small bowel bacterial overgrowth, and measured as exhaled carbon dioxide.

We reviewed 36 studies that assessed small intestinal absorption or permeability using sugars as absorbed probes. Three studies measured lactose, an endomolecular sugar, either in the serum (n=1) or urine (n=2) among breastfeeding children. Of the 36 studies, 35 assessed malabsorption/permeability deficits by administering xenomolecular sugar challenges using lactulose, mannitol, rhamnose, or xylose (including one study each that also measured serum and urinary lactose). We reviewed five studies that reported xenomolecular probe results of single-only sugar tests, and 30 studies that reported results of dual sugar tests. The dual sugar tests included urinary L:M (n=25 studies), urinary or serum L:R (n=5), and urinary lactose:lactulose (n=1). The single sugar assay was used in six studies: urinary lactose (n=1) and D-xylose (two using serum measures, one using urine as a substrate, and two in which the body fluid from which the sugar was measured was not reported).

5.1.2 Endomolecular Nutrients as Tracers of Intestinal Function

Essential nutrients that are absorbed by healthy small intestine provide another opportunity to assess gut absorptive function. These types of marker assessments can provide

especially valuable information regarding the role of derangement of gut function among children with nutrient deficiencies, i.e., how much of the deficiency is because of lack of intake rather than malabsorption. Since these molecules are naturally found in body analytes, load administration requires tagging such as with the use of radiolabeled molecules, quantification of which can then be assessed in breath, blood, urine, and/or stool as surrogate markers of absorptive capacity. We reviewed six studies that utilized such methodologies including assessments of zinc (n=3), lipid (n=2) and iron (n=1) absorption.

We present in Evidence Tables 1 and 2 data from publications that utilized markers of absorption and permeability, respectively. Evidence Table 1 depicts data related to the systematic review from the articles that reported results of markers that were principally related to absorptive functions (such as D-xylose and fecal fat). Evidence Table 2 contains data on markers related to porosity or permeability. However, tests of gut permeability are often assessed simultaneously with markers of absorption. For example, the lactulose:mannitol ratio (L:M) and lactulose:rhamnose ratio (L:R) are often described as tests of permeability; however, by their nature they do include measures of absorption (via mannitol and rhamnose, respectively). For this reason, we present markers of permeability with or without concomitant assessment of absorption in Evidence Table 2. We identified 44 publications that assessed small intestinal absorption (13 studies) or permeability (primarily, sometimes also with some assessment of absorption based on dual sugar testing; 31 studies) in children in resource-poor settings.

5.2 Markers of Absorption

Data regarding markers of absorption are presented in Evidence Table 1.

Evidence Table 1. Markers of absorption.

Biomarkers in bold are primarily markers of malabsorption.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
<p>2002</p> <p>Dini E et al.</p> <p>Sudan III and steatocrit in the detection of fecal fat in malnourished children</p> <p>Fecal fat by four different testing methods as a marker of malabsorption among children with varying nutritional status and well-nourished controls</p>	<p>Caracas, Venezuela</p> <p>6 mo-9 yr olds with recruited from an outpatient nutrition center and well-nourished controls.</p>	<p>Case-control</p> <p>n=129;</p> <p>n=99 cases:</p> <ul style="list-style-type: none"> • 30 with subclinical malnutrition • 34 with mild malnutrition • 30 with moderate malnutrition • 5 with severe malnutrition <p>n=30 controls</p>	<p><u>Stool Test:</u></p> <p>Fecal fat, by method:</p> <ul style="list-style-type: none"> • Sudan III classic • Sudan III modified • Steatocrit classic • Steatocrit acid <p>Each subject underwent testing for all four methods.</p>	<p>Proportions testing positive for fecal fat ranged from 33%-41% overall, depending on test method used.</p> <p>The proportion testing positive varied by nutritional status across testing methods:</p> <ul style="list-style-type: none"> • 80%-100% of severely malnourished subjects had a positive test • Similar proportions of subjects with subclinical, mild or moderate malnutrition tested positive, ranging from 30%-47% • 13%-27% of controls tested positive <p>These differences appeared to be significant, but statistical comparison results were not entirely clear.</p> <p>Fecal fat did not vary based on quantity of fat intake.</p> <p>By all four methods, a high percentage of children with parasites tested positive (~60%) compared to children without parasites (25%).</p> <p>Associations were observed between infection with <i>Giardia lamblia</i> or <i>Blastocystis hominis</i> and fecal fat ($p < 0.05$); this held true across diagnostic methods.</p> <p>The presence of diarrhea at time of testing was positively associated with fecal fat by all test methods ($p < 0.02$ for all except steatocrit classic,</p>	<p>A majority of children studied tested negative for fecal fat.</p> <p>The highest percent testing positive was in those with severe malnutrition, followed by those with subclinical-moderate malnutrition. Controls had the lowest percent testing positive.</p> <p>Subjects with enteric parasites or those experiencing diarrhea at time of testing excreted fat significantly more often than uninfected children without diarrhea, although the magnitude of difference was not reported.</p> <p>There was some variation between the different testing methods, for example their relationship with a history of diarrhea in the year prior to testing.</p>	<p>Spanish language article.</p> <p>Control recruitment strategy was not well described.</p> <p>Proportions positive for fecal fat by history of diarrhea (current or previous) were not provided.</p> <p>Authors reported percent agreement between tests but did not report results of statistical testing of these estimates.</p> <p>Test results varied by subject characteristics; however, assessments adjusting for potential confounding were not reported.</p>

Evidence Table 1. Markers of absorption.

Biomarkers in bold are primarily markers of malabsorption.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
				<p>p=0.06).</p> <p>The relationship between fecal fat and history of diarrhea in the year prior to testing varied by test method:</p> <ul style="list-style-type: none"> • Sudan III classic: p=0.134 • Sudan III modified: p<0.001 • Steatocrit classic: p=0.14 • Steatocrit acid: p=0.015 <p>Agreement between all four methods was 72%. Agreement between at least three was 91.5%.</p>		
<p>2006</p> <p>Leite CA et al.</p> <p>Functional, microbiological and morphological intestinal findings among human immunodeficiency virus infected children</p> <p>Small intestinal and rectal biopsy to assess morphology and D-xylose as a marker of malabsorption among HIV-infected children</p>	<p>Sao Paulo, Brazil</p> <p>5 mo-12 yr old (median 24 mo) HIV-infected subjects recruited from a hospital and clinic.</p> <p>All subjects had some degree of protein-energy malnutrition.</p>	<p>Cohort</p> <p>n=11;</p> <p>n=5 patients with current or recent episode of diarrhea</p> <p>n=6 patients with no diarrhea in the 30 days preceding enrollment</p>	<p>Blood Test: D-xylose (9 tested)</p> <p><u>Biopsy of small intestine by tethered capsule or endoscopy:</u> Histopathology (10 tested)</p> <p><u>Rectal biopsy:</u> Histopathology (6 tested)</p>	<p>100% had low D-xylose absorption:</p> <ul style="list-style-type: none"> • Mean: 15.6 mg/dL • SD: 5 • Range: 8.9-24.4 • Median: 14.2 <p>Small intestinal biopsy:</p> <ul style="list-style-type: none"> • 100% had some degree of villous atrophy based on a I-IV grading system: <ul style="list-style-type: none"> • Grade I: 3 • Grade I/II: 2 • Grade II: 1 • Grade II/III: 1 • Grade III/IV: 1 • 2 samples were too superficial to assess • Intraepithelial lymphocytes were increased in half of the biopsies. • Lymphocytic and polymorphonuclear (PMN) infiltration of the lamina propria were present in 10/10 and 7/10 biopsies, respectively. 	<p>There was a high prevalence (100%) of abnormal D-xylose results among HIV-infected children, regardless of diarrhea status.</p> <p>All patients also had cellular infiltration of the lamina propria and varying degrees of villous atrophy.</p> <p>There was no correlation between D-xylose and degree of villous atrophy on biopsy.</p>	<p>Portuguese language article.</p> <p>D-xylose <25 mg/dL was defined as indicative of malabsorption. This value is higher than what some references have noted as a cut-point [186]</p> <p>Investigators used a well-articulated system of grading villous atrophy.</p> <p>Results were not presented by diarrhea status, perhaps due to small sample size.</p>

Evidence Table 1. Markers of absorption.

Biomarkers in bold are primarily markers of malabsorption.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
				Rectal biopsy: <ul style="list-style-type: none"> 100% had normal architecture Lymphocytic and PMN infiltration were present in 6/6 and 4/6, respectively.		
2005 López de Romaña D et al. Longitudinal measurements of zinc absorption in Peruvian children consuming wheat products fortified with iron only or iron and 1 of 2 amounts of zinc Zinc absorption among stunted, anemic children receiving zinc as well as iron and/or iron/zinc-fortified foods	Lima, Peru 3-4 yr olds residing in a poor community at the periphery of Lima with stunting and moderate anemia as a surrogate risk factor for zinc deficiency.	RCT n=41; (31 completed both initial and follow-up absorption assay at 2 mo) Group 1: n=14 received wheat flour with iron fortification only (10 completed follow-up) Group 2: n=12 received wheat flour with iron and 3mg zinc/100g flour (9 completed follow-up) Group 3: n=15 wheat flour with iron and 9mg zinc/100g flour (12 completed follow-up)	Urine Test: Zinc excretion to measure fractional absorption of zinc (FAZ) and total absorbed zinc (TAZ) following radiolabeled zinc administration	Mean zinc parameters (SD) at initial assessment: <ul style="list-style-type: none"> FAZ: <ul style="list-style-type: none"> Group 1: 0.34 (0.11) Group 2: 0.24 (0.05) Group 3: 0.13 (0.04) TAZ (mg/d): <ul style="list-style-type: none"> Group 1: 0.71 (0.18) Group 2: 1.11 (0.21) Group 3: 1.34 (0.47) Neither mean FAZ nor TAZ changed significantly at subsequent assessments in any treatment group. In both the initial and subsequent assays, mean TAZ from zinc-fortified meals increased with increasing amounts of fortification ($p < 0.001$). However mean FAZ was inversely related to zinc intake from these meals ($p < 0.001$). Non-fortified dinner FAZ and TAZ were significantly lower in the group receiving the most zinc-supplementation at the initial assay ($p = 0.015$ and $p = 0.012$, respectively) despite no difference in zinc intakes from the unfortified dinner by treatment group. This relationship between groups was not observed at the second assay; however, a significant decrease of 16% in mean FAZ	Despite a reduction in FAZ with increasing fortification, TAZ increased as more zinc was consumed and with increasing concentrations of zinc fortification. Authors speculate that reduction in FAZ with increasing fortification could be due to factors such as saturation kinetics. Authors described an unexpected finding: subjects consuming more zinc from the zinc-fortified breakfast and lunch meals absorbed less zinc from the unfortified dinners during the initial absorption assay.	Intestinal function could play a role in zinc (or other micronutrient) absorption; such factors were not explored in this study. The principal aim of this study was to determine appropriate extent of zinc fortification of a staple food in a specific community; we present only results relevant to this review.

Evidence Table 1. Markers of absorption.

Biomarkers in bold are primarily markers of malabsorption.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
				<p>and TAZ from the unfortified dinners was observed between initial and subsequent assays ($p < 0.001$).</p> <p>Mean plasma zinc concentrations did not differ between treatment groups throughout the study period. The proportion with low fasting plasma zinc concentrations ($< 65 \mu\text{g/dL}$) was lower at the end of the study (3.3% vs. 20.5% initially, $p = 0.046$).</p>		
<p>2002</p> <p>Manary ML et al.</p> <p>Zinc homeostasis in Malawian children consuming a high-phytate, maize-based diet</p> <p>Zinc absorption in a sample of 10 asymptomatic children</p>	<p>Blantyre, Malawi</p> <p>2–5 yr olds (mean age 43.6 mo, SD 7.7) from rural area attending immunization clinic.</p> <p>There was a high prevalence of stunting and low plasma zinc in this series.</p>	<p>Case-series</p> <p>n=10</p>	<p><u>Stool Test:</u> Endogenous fecal zinc (EFZ)</p> <p><u>Urine Test:</u> Zinc excretion to measure fractional absorption (FAZ) and total absorption (TAZ) following radiolabeled zinc administration</p>	<p>Mean (SD):</p> <ul style="list-style-type: none"> • FAZ: 0.24 (0.04) • TAZ (mg/d): 1.30 (0.33) • EFZ (mg/d): 1.15 (0.33) <p>Language in the discussion section strongly suggests, but does not explicitly state, that TAZ and EFZ were not correlated. Correlation analysis for these parameters was not reported.</p>	<p>EFZ was higher than would be expected for a zinc deficient cohort, and EFZ was not correlated with TAZ as would have been expected. While high-phytate diets leading to poor zinc absorption might explain these findings, the authors note that in a previous study (among a somewhat older age group) there were no differences in EFZ among children consuming high- or low-phytate diets [187]. They note that such perturbations in EFZ have also been reported in children with enteropathy due to cystic fibrosis [188] and suggest that a similar process could be going on in these Malawian children due to TE.</p>	<p>Authors note that the lack of comparable data from children of the age range in this study limits data interpretation. They also provide results per body weight due to presumed relationship; validity of such measures has not been established.</p> <p>Authors comment that the methods used for calculating absorption measures are sensitive and accurate, but quite difficult to conduct, especially among children.</p>

Evidence Table 1. Markers of absorption.

Biomarkers in bold are primarily markers of malabsorption.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
2001 Mittal SK et al. Tropical sprue in north Indian children D-xylose and duodenal biopsy as markers of TS	New Delhi, India 0-15 yr old gastroenterology clinic patients with PD. Those with abnormal morphology on biopsy, abnormal D-xylose test, and clinical response to antibiotics were diagnosed as having TS. Those with abnormal morphology and response to gluten-free diet were diagnosed with CD. We include data on these subjects for comparative reasons.	Case-series n=94; (38 with repeat biopsies) <5 yr old: n=44	<u>Duodenal biopsy, method not specified:</u> Histopathology <u>Blood Tests:</u> • Hemoglobin • D-xylose* * Not specified whether from urine or serum, and units of measurement not provided.	36 (38.3%) were diagnosed with TS including 14/44 (31.8%) who were under 5 years of age. 18 (19.1%) were diagnosed with CD. Degree of villous atrophy among TS vs. CD patients: • Mild in 8/36 (22.2%) vs. 0 • Moderate in 23/36 (63.9%) vs. 4/18 (22.2%) • Severe in 5/36 (13.9%) vs. 14/18 (77.8%) Mean hemoglobin concentration (range) among TS patients was 8.3 g/dL (5.5-11) and did not differ from values of those with CD. Among the 22 TS patients, repeat biopsies showed: • 16 with normalization • 5 with improvement • 1 worsened despite marked clinical improvement The D-xylose test was abnormal in all TS patients by diagnostic definition.	More than half of the GI clinic patients with PD had some degree of villous atrophy. More than one-third and almost one-fifth of subjects were diagnosed with TS and CD, respectively. By study diagnostic definition, all TS patients improved with treatment. Among those who had repeat biopsies, almost three-quarters showed normalization of histology, while 23% had partial improvement and 1 patient had worsened pathology.	Biopsy results were not provided for patients without TS or CD. It was unclear if there were patients with abnormal D-xylose and histology who did not respond to antibiotic therapy and therefore were not diagnosed with TS. Cut-off points used to define abnormal D-xylose tests were not provided.
2002 Moya-Camarena SY et al. Effects of asymptomatic <i>Giardia intestinalis</i> infection on carbohydrate	Hermosillo, Sonora, Mexico 3-6 yr olds in a periurban setting attending preschool centers meeting inclusion criteria of no GI symptoms, no antibiotics in the	Case-control n=13; <5 yr old: n=5 n=7 asymptomatic cases infected	<u>Breath Tests*:</u> • Lactose HBT • D-Xylose HBT** <u>Urine Test:</u> D-xylose**¹ * Reported as parts	Mean lactose HBT (SE): • Cases pre-treatment: 3.6 (0.75) ppm • Cases post-treatment: -0.85 (0.75) ppm (p<0.05 compared to pre-treatment) • Controls: 0.19 (0.81) ppm (p<0.05 compared to pre-treatment cases)	Lactose HBT concentrations were normal according to established cut-points among all subjects. However, lactose HBT was significantly higher among cases compared to controls and there	Statistical methods might not have been adequate to account for intra-subject correlation when comparing the same group of subjects (cases) before and after treatment.

¹ D-xylose results were expressed as % of dose administered.

Evidence Table 1. Markers of absorption.

Biomarkers in bold are primarily markers of malabsorption.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
absorption in well-nourished Mexican children Lactose hydrogen breath test (HBT) as a marker of lactose absorption, and xylose breath test and urinary excretion as markers of xylose absorption in well-nourished children with asymptomatic giardiasis and non-infected controls	preceding 3 wk, and no SBBO by lactulose HBT and Indican test.	only with <i>G. intestinalis</i> n=6 controls without <i>Giardia</i> Cases were evaluated before and 3 wk after treatment with tinidazole. Post-treatment stools were verified for absence of parasites.	per million (ppm) post-substrate ingestion after subtraction of baseline, pre-substrate H ₂ concentrations. A positive HBT is considered to be a rise of ≥ 20 ppm in breath H ₂ above baseline H ₂ concentration. ** Investigators did not specify the xylose enantiomer used, however test functionality characteristics lead us to assume that it was the dextrorotary (D) enantiomer.	Mean xylose HBT (SE): • Cases pre-treatment: 2.2 (0.69) ppm for infected group • Cases post-treatment: -4.16 (0.69) ppm (p<0.05 compared to pre-treatment) • Controls: 1.13 (0.74) ppm (NS compared to pre-treatment cases) Mean urinary excretion of xylose (SE) among cases pre-treatment and post-treatment was 34% (3) and 46% (11), respectively (NS), well above cut-offs indicative of malabsorption.	was also a significant decrease in lactose HBT among cases after treatment. The clinical relevance of such mildly elevated HBT results in asymptotically infected children is unclear. Results did not demonstrate xylose malabsorption by either urinary or breath measures among any group. While urinary results did not differ before and after treatment, case xylose HBT was significantly lower after treatment; again the clinical significance of such results is not apparent.	Investigators wished to exclude children with SBBO. As such, inclusion criteria restricted participants to those with adequate production of H ₂ following ingestion of lactulose and with minimal urinary indoxyl sulfate excretion. The number of children excluded due to failure to meet these criteria was not reported.
2002 Murphy JL et al. Maldigestion and malabsorption of dietary lipid during severe childhood malnutrition Stool recovery of radiolabeled products as markers of lipid digestion and absorption, and bile salt deconjugation as a marker of SBBO among children with severe	Kingston, Jamaica 5-23 mo olds admitted to the Tropical Metabolism Research Unit of the University of the West Indies with severe malnutrition.	Case-series n=24 Subjects were divided into 3 groups of 8 children, each group receiving a different labeled triglyceride. Data were collected in three separate phases as described above in JL Murphy et al. 2001 [149].	Stool Tests: • Total and fractionated ¹³C following ingestion of one of three ¹³C labeled triglycerides (TG): trilaurin, triolein, or trilinolein* • ¹³ C stool assay following administration of labeled fatty acid ¹³ C glycocholate** * To assess fat excretion as a % of	Median total stool excretion of ¹³ C in phase 1 was 9% (range: 1%-29%) and did not vary between TG groups. Median ¹³ C excretion dropped 33%-99% in phase 2 and 86%-95% in phase 3 compared to phase 1 (p<0.05 each). Over the study period, there were significant associations between total lipid and the amount of ¹³ C labeled TGs in stool for some groups, but not for others. Median ¹³ C in TG and FA was similar across TG groups in all phases. ¹³ C FA recovery was	High concentrations of ¹³ C (compared to healthy UK children) [190] were observed in half of the subjects at admission, reflecting impaired digestion or absorption. The differences in stool ¹³ C were wide but not as extreme as in a previous study by same investigators (also examined in this review) using a different TG (tripalmitin) substrate [149].	Authors state that the study was not powered to compare the different TGs, but they contend that medium chain trilaurin did not appear to be processed differently than the longer chain TGs triolein and trilinolein. Authors did not describe the method used to assign subjects to

Evidence Table 1. Markers of absorption.

Biomarkers in bold are primarily markers of malabsorption.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
malnutrition			dose administered. Also assessed proportion of ¹³ C in triglyceride (TG) and fatty acid (FA) fractions to distinguish excretion caused impaired digestion (presence of TG) vs. poor absorption (presence of FA). ** To assess bile salt deconjugation in the bowel caused by SBBO; conducted after the TG assessment and a 3 day washout period.	similar and reduced by ~2/3 compared to Phase 1. ¹³ C TG was not detectable in Phases 2 or 3. Statistical comparisons between phases were not reported. ¹³ C after radiolabeled glycocholate administration was detected in stool at quantities considered to be in excess of the 7% recovery of dose administered upper limit of normal in U.S. adults in [189]: • Phase 1: 13/24 (54%) • Phase 2: 5/24 (20.8%) Phase 3: 3/24 (12.5%)	¹³ C excretion did not significantly differ between TG groups and declined with improving clinical course. Similar to their previous study, significantly more ¹³ C in stool was recovered as FA than TG, reflecting impaired absorption over poor lipid digestion/ hydrolysis. Unlike in their previous study, there was evidence of SBBO as measured post-ingestion of ¹³ C glycocholate.	different TG groups. While it was noted that some subjects had positive stool cultures, details were not provided on the nature of the enteric infections.
2001 Murphy JL et al. Gastrointestinal handling and metabolic disposal of ¹³ C-labelled tripalmitin during rehabilitation from childhood malnutrition Fecal fat, stool recovery of radiolabeled products, and breath tests as markers of lipid digestion and absorption and bile salt deconjugation as a marker of SBBO among	Kingston, Jamaica 7-23 mo olds with malnutrition admitted to the University of the West Indies.	Case-series n=8 Data were collected in three separate phases (each lasting 9 days): 1. Within 48 hours of admission 2. During early rehabilitation 3. During late rehabilitation	Stool Tests: • Fecal fat* • Total and fractionated ¹³C assay after administration of ¹³C tripalmitin (TP)** • ¹³ C assay after administration of ¹³ C glycocholate (GCA)*** Breath Tests: • ¹³ CO ₂ after administration of ¹³ C glycocholate (GCA)*** or ¹³ C TP**** * In 72 hour stool collection (measured as total grams and as	Mean fecal fat (SD): • Phase 1: 2.4 g/day (3.6) or 5.9% (9.4) of dietary lipid intake • Phase 2: 1.7 (0.9) g/day, or 3.3% (2.4) of intake • Phase 3: 0.9 (0.6) g/day, or 1.4% (0.7) of intake • Differences between phases were not statistically significant. Total excretion of ¹³ C in stool also varied widely across patients (0%-44%) and did not differ between study phases. Correlation between fecal fat and ¹³ C (r=0.48; p<0.05) was observed. Lack of lipid digestion and absorption were assessed by	Mean fecal fat was not elevated compared to published norms [191, 192], during any study phase. There was wide variation in fecal fat at presentation, and wide variations in stool ¹³ C across subjects. Authors indicate that this is the first such assessment in malnourished children; previous studies on healthy children from the UK demonstrated average excretion of 6% [190]. The majority of excreted ¹³ C was in the form of FA rather than TG.	Statistical methods might be inappropriate for a small sample. All subjects were treated with antibiotics including metronidazole for presumptive SBBO; this might have affected GCA testing.

Evidence Table 1. Markers of absorption.

Biomarkers in bold are primarily markers of malabsorption.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
children with severe malnutrition			<p>% of dietary fat intake).</p> <p>** To assess fat excretion as a % of dose administered. Also assessed proportion of ¹³C in triglyceride (TG) and fatty acid (FA) fractions to distinguish excretion caused by impaired digestion (presence of TG) vs. poor absorption (presence of FA).</p> <p>*** To assess bile salt deconjugation in the bowel caused by SBBO; conducted after the TG assessment and a 3 day washout period.</p> <p>**** Expressed as a percentage of absorbed label (dose administered - label recovered in stool) to assess oxidation for acute energy needs.</p>	<p>measuring TG and FA fractions, respectively. Mean ¹³C TG recovery (SD) (% of administered dose), number of patients excreting TG:</p> <ul style="list-style-type: none"> Phase 1: 0.7% (1.6), n=3 Phase 2: 0.9% (2.8), n=1 Phase 3: no recovery from any subjects, differences between phases were NS <p>¹³C FA fraction in stool declined during rehabilitation. Mean ¹³C FA recovery (SD):</p> <ul style="list-style-type: none"> Phase 1: 6.0% (7.3) Phase 2: 4.8% (3.7) Phase 3: 3.3% (3.8), differences between phases were NS <p>Mean FA values were ~9x (NS), 5x (p<0.001), and 3x (p<0.05) higher than mean TG values in Phases 1, 2, and 3, respectively.</p> <p>Following administration of labeled TP, absorbed ¹³C label by breath analysis was ~5% (range 0%-21.2%) and similar across study phases.</p> <p>Following the administration of labeled GCA, there was either no or minimal recovery of ¹³C in stool and ¹³CO₂ on breath (as % of dose administered) in all phases.</p>	<p>Authors interpreted this to reflect failure of lipid absorption in the face of adequate digestion/ hydrolysis. Each form (FA and TG) was found in decreasing values as the study phases progressed, suggesting improved digestion and absorption, although results did not differ significantly.</p> <p>Fecal fat was correlated with concentrations of ¹³C in stool.</p> <p>There was no evidence of SBBO or bile acid malabsorption.</p> <p>¹³CO₂ excretion following administration of ¹³C TP was minimal, suggesting a propensity for deposition in adipose tissues rather than oxidation for immediate energy needs. The authors report that this breath test has not been widely used, but that healthy UK children have breath excretion values from 15%-43% [190], compared to a mean of 5% and range 0%-21% in this cohort; the latter findings were more similar to results from kwashiorkor patients where ¹³C-labeled oleic acid was</p>	

Evidence Table 1. Markers of absorption.

Biomarkers in bold are primarily markers of malabsorption.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
					used as substrate [193].	
<p>2000</p> <p>Nichols B et al.</p> <p>Contribution of villous atrophy to reduced intestinal maltase in infants with malnutrition</p> <p>Jejunal biopsy, maltase activity, and enzyme messenger RNAs among malnourished and well-nourished children. Assessed association between maltase and villous atrophy and other mucosal intestinal markers indicative of loss of enterocytes and enterocytic function.</p>	<p>Sao Paulo, Brazil</p> <p>Cases were children (mean age 9.9 mo, SD 8.1) hospitalized with malnutrition refractory to dietary rehabilitation.</p> <p>Controls were children (mean age 3.6 mo, SD 1.0) with HAZ and WAZ scores >-2 and normal intestinal mucosa on biopsy, hospitalized for Kasai procedure for biliary atresia.</p>	<p>Case-control</p> <p>n=33; n=24 cases n=9 controls</p> <p>Subjects were matched on height and weight; ages differed within matched sets.</p>	<p><u>Jejunal capsule biopsy:</u></p> <ul style="list-style-type: none"> • Histopathology* • Maltase activity • Intestinal messenger RNA (mRNA) abundances: <ul style="list-style-type: none"> • Maltase-glucoamylase (MGA) • Sucrase-isomaltase (SI) • Villin, a structural protein expressed only in enterocytes • Sodium-activated luminal glucose-galactose transporter 1 (SGLT), a functional protein expressed only in enterocytes • β-actin <p>* Mucosal atrophy was scored on a scale of 1 (absence of atrophy compared to an organ donor) to 4 (similar to children with active CD).</p>	<p>Mean villous atrophy score (SD):</p> <ul style="list-style-type: none"> • Cases: 2.6 (0.8) • Controls: 1.2 (0.5), p=0.006 <p>WAZ score was correlated with villous atrophy (r=0.65, p-value not reported).</p> <p>13/25 [sic] cases and 0/5 controls had subnormal (defined as <94U/g protein) of maltase activity; mean maltase was 34% lower among cases (p=0.11). Maltase activity did not appear to decrease with WAZ score (further details not provided).</p> <p>However, in sub-analyses among those samples with an adequate β-actin, a housekeeping gene message, (n=10 cases, n=9 controls), cases' findings expressed as a mean percent of controls' (SD) included:</p> <ul style="list-style-type: none"> • Villous length (reciprocal of atrophy score): 38.9 (41.6), p=0.004 • Maltase activity: 37.1 (23.2), p=0.001 • MGA mRNA: 45.1 (36.4), p=0.016 • Villin mRNA: 52.5 (22.6), p=0.003 • SGLT mRNA: 66.6 (23.1), p=0.057 • β-actin: 88.2 (15.8), p=0.189 <p>Both villous length and maltase activity in a subset of cases were less than 40% of control values.</p>	<p>The malnourished children had significantly greater villous atrophy than the younger controls.</p> <p>Among the subset tested for mRNA messages, maltase activity as well as the mRNA abundances for MGA, villin and SGLT were significantly correlated with case status and were correlated with villous atrophy.</p> <p>While maltase deficiency has been reported in malnutrition in other studies, authors assert that these are the first results that directly support the hypothesis that reductions in maltase activity are due to villous atrophy. This study also nicely correlates mRNA relative abundance with function.</p>	<p>Tissue from patients requiring intestinal resection as part of their biliary atresia management provides an opportunity to assess presumably "normal" intestinal architecture. However, unless they mocked up ex vivo mucosal biopsies in these controls, resections will have lower proportions of villous to submucosa tissue compared to cases' samples derived from mucosal biopsies. While this probably doesn't affect histology, it might affect enterocyte functional assays and mRNA determination, as transmural tissue will bring in more diverse populations of cells; only some of them might have transcripts of interest. However, the bias is likely in a direction that would reduce effect size.</p>

Evidence Table 1. Markers of absorption.

Biomarkers in bold are primarily markers of malabsorption.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
			Histology among controls was on surgically resected tissue.	MGA, villin, and SGLT mRNA abundances were correlated with villous atrophy score (r=0.73), (r=0.76), and (r=0.54), respectively (p-values not reported) ¹ . MGA mRNA abundance was correlated with maltase activity (r=0.32).		It was unclear if control inclusion criteria included absence of atrophy or if all potential controls lacked atrophy. Statistical methods might not have adequately taken into account the small sample size and matching scheme. Subsets of subjects were investigated for various tests. For example, 10 cases had mRNA analyses based on β-actin adequacy. Another instance of selected testing was the subset of 22 and 15 cases that had WAZ score to histology and mRNA correlation analyses, respectively. Rationale for subset selection was not thoroughly described.
2001 Perin NM et al. Intestinal absorption	Florianopolis, Brazil 18 mo-14 yr old HIV-infected children with GI and non-GI	Cross-sectional n=104	<u>Blood Test:</u> D-xylose	Prevalence of an abnormal D-xylose result was 7.7%. Mean D-xylose (SD, range): 42.8mg/dL (14.4mg/dL, 16-73	D-xylose showed substantial variation across individuals.	Portuguese language article. D-xylose <25 mg/dL was defined as

¹ Villin and SGLT1 were assessed as a ratio with housekeeper gene β-actin.

Evidence Table 1. Markers of absorption.

Biomarkers in bold are primarily markers of malabsorption.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
of D-xylose in children infected with the human immunodeficiency virus D-xylose as a marker of intestinal absorption among HIV-infected children with and without GI symptoms	symptoms of HIV infection recruited from a pediatric AIDS center.			mg/dL) D-xylose was not associated with age. Of the 8 children with abnormal results, 1 had diarrhea. Of 19 with diarrhea, 1 had an abnormal result. Of those with abnormal results, 50% had <i>Cryptosporidium</i> infection. Of the 33 subjects with <i>Cryptosporidium</i> infection, 4 had abnormal D-xylose results.		indicative of malabsorption.
2002 Poddar U et al. Celiac disease in India: Are they true cases of celiac disease? Duodenal biopsy, D-xylose, and fecal fat in children with symptoms of CD but normal mucosal biopsy results	Chandigarh, India 18 mo-14 yr olds with PD, FTT, or pallor from a hospital pediatric gastroenterology unit. Subjects with normal crypt:villous ratio on biopsy were of interest for this review.	Case-control n=47	<u>Endoscopic duodenal biopsy:</u> Histopathology <u>Stool Tests:</u> • Fecal fat* • D-xylose** * In 72-hour stool collection. ** Not specified whether from urine or serum, and units of measurement not provided.	38% had chronic inflammatory cell infiltrates in the lamina propria. 55% had abnormal D-xylose concentrations. 20% had abnormal fecal fat test. No results beyond proportion positive were reported for any of the above markers.	Among controls with normal mucosal architecture by biopsy, more than one-third had PD. D-xylose and fecal fat might not correlate well with duodenal biopsy results.	Relationships between fecal fat, D-xylose and biopsy results were not reported. While 38% of controls had PD, results for the markers studied were not stratified by PD for this group. Seven children with biopsies consistent with CD did not respond to gluten-free diet and were excluded from the study. Cut-off points used to define abnormal D-xylose tests were not provided.

Evidence Table 1. Markers of absorption.

Biomarkers in bold are primarily markers of malabsorption.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
<p>2004</p> <p>Sarker SA et al.</p> <p><i>Helicobacter pylori</i> infection, iron absorption, and gastric acid secretion in Bangladeshi children</p> <p>Iron absorption among children with iron deficiency anemia with and without <i>H. pylori</i> infection</p>	<p>Dhaka, Bangladesh</p> <p>2-5 yr old apparently healthy children from a periurban setting, screened for iron deficiency and <i>H. pylori</i>.</p>	<p>Case-control</p> <p>n=25: n=13 cases infected with <i>H. pylori</i> n=12 controls not infected with <i>H. pylori</i></p>	<p>Blood Test: Iron (absorption test)</p>	<p>Mean¹ iron absorption from ferrous (Fe) sulfate and Fe fumarate:</p> <ul style="list-style-type: none"> • Uninfected children: 15.6% and 5.4%, (p<0.001) • Infected children before treatment: 19.7% and 5.3%, (p<0.0001) • Infected children after treatment: 22.5% and 6.4%, (p<0.0001) • <i>H. pylori</i> treatment did not significantly affect absorption (Fe sulfate or fumarate), p=0.3 	<p>Iron absorption from Fe fumarate was significantly lower than from Fe sulfate.</p> <p>Results do not support the hypothesis that <i>H. pylori</i> infection influences absorption of water-soluble (Fe sulfate) or non-water-soluble (Fe fumarate) iron compounds.</p>	<p>Data on iron absorption among 2-5 yr olds are limited, making comparison of results from this study setting difficult.</p>
<p>2006</p> <p>Sheng XY et al.</p> <p>Major variables of zinc homeostasis in Chinese toddlers</p> <p>Differences in zinc absorption in healthy toddlers with a high prevalence of zinc deficiency.</p>	<p>Xi-Chou (town) & Yun-Nan (province), China</p> <p>19-25 mo olds recruited from a remote small town and 2 surrounding rural villages.</p> <p>48% of children had plasma zinc concentrations below 2.5th percentile. Dietary zinc intake was low.</p> <p>There was a high prevalence of stunting among the subjects.</p>	<p>Cross-sectional</p> <p>n=43</p>	<p>Stool Test: Endogenous fecal zinc (EFZ)</p> <p>Urine Test: Zinc excretion to measure fractional absorption of zinc (FAZ) and total absorbed zinc (TAZ) following radiolabeled zinc administration</p>	<p>Mean (SD):</p> <ul style="list-style-type: none"> • FAZ: 0.35 (0.12) • AZ (mg/d): 0.63 (0.24) • EFZ (mg/d): 0.67 (0.23) <p>The quantity of absorbed zinc was lower than physiologic requirements.</p> <p>There was no statistically significant difference in any laboratory value between the town and village groups.</p> <p>Zinc absorption was ~80% of estimated physiologic requirement and equivalent to the amount of endogenous zinc excreted via the intestine; it was expected that absorbed zinc would exceed excreted zinc [144, 187, 194, 195]</p>	<p>Zinc absorption was lower than physiologic requirements and EFZ was higher than expected.</p> <p>The authors note that the results are difficult to explain and specifically state that they do not think (though without clear justification) that enteropathy is prevalent in the population and therefore could not be a contributing factor.</p>	

Notes: Some studies included subjects ≥5 yr of age. Where these studies provided data separately for children <5 yr, we present results for only those subjects. Where these studies did not stratify results by age, but did report the number of children <5 yr included in the study, we provide a breakdown of under-5s.

¹ Geometric mean.

Evidence Table 1. Markers of absorption.

Biomarkers in bold are primarily markers of malabsorption.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
<p>All studies reporting lactulose:ramnose ratio results presented values multiplied by a factor of 100 for ease of reporting.</p> <p>Abbreviations: AD=acute diarrhea, ALT=alanine aminotransferase, AST=aspartate aminotransferase, CBC=complete blood count, CD=celiac disease, CI=95% confidence interval, Cr=creatinine, Δ=change in, EED=environmental enteric dysfunction, FTT=failure to thrive, GI=gastrointestinal, HAZ=height-for-age Z-(score), HDL=high density lipoproteins, HIV=human immunodeficiency virus, HLA=human leukocyte antigen, IEL=intraepithelial lymphocytes, IgA=immunoglobulin A, IgE=immunoglobulin E, IgG=immunoglobulin G, IgM=immunoglobulin M, IL=interleukin, IFN=interferon, LDL=low density lipoproteins, L:M=lactulose:mannitol ratio, mo=month(s), NS=not statistically significant, PD=persistent diarrhea, RCT=randomized controlled trial, SBBO=small bowel bacterial overgrowth, SD=standard deviation, SE=standard error, SES=socioeconomic status, Tc-99m=technetium 99, T3=triiodothyronine, T4=thyroxine, TE=tropical enteropathy, TGF=transforming growth factor, TNF=tumor necrosis factor, TS=tropical sprue, WAZ=weight-for-age Z-(score), WBC=white blood cell count, WFA=weight-for-age, WHZ=weight-for-height Z-(score), wk=week(s), yr=year(s)</p>						

Thirteen studies used markers of intestinal absorption among children in resource-limited settings. The range of markers included urinary, breath and serum markers of sugar absorption, fecal fat as a marker of lipid absorption, measures of endomolecular absorption, and presence of messenger RNAs in intestinal tissue as markers of intestinal surface area, and, by inference, absorptive capacity.

5.2.1 D-Xylose

While single molecule tests have disadvantages compared with dual molecule tests, as discussed above, the D-xylose test has been commonly used to assess malabsorption in developing settings. There has been further criticism of this test, including its potential hepatic metabolism of the sugar [196] and jejunal absorption [197].

D-Xylose was the most commonly reported measure of small bowel absorption in the literature that we reviewed and was employed in five studies. It was assessed either in serum (n=2) [136, 152] or urine (n=1) [147], although in two studies the substrate from which D-xylose was measured was not reported [146, 155]. Although one of these reports did not specify the xylose enantiomer [147], test functionality characteristics led us to assume it was the dextrorotary (D) enantiomer, as was used in the other studies. This study, in addition to assessment of urinary excretion of the sugar, also measured hydrogen excretion in breath before and after administration of the xylose. Three of the studies [136, 146, 147] provided demographic information stratified by age group and together included 58 children under five years of age. However, none of the studies presented D-xylose data by age group. Overall, the five studies included D-xylose results for 267 children up to the age of 14 years.

Two of the studies investigated the association of D-xylose with degree of villous atrophy on biopsy. One of these studies performed D-xylose tests in children with symptoms of celiac disease and normal architecture on duodenal biopsy, although approximately one-third had

chronic inflammatory cell infiltrates in the lamina propria [155]. This publication reported abnormal D-xylose results in 55% of these subjects (but did not provide information on the range of normal and abnormal concentrations, sampling site, or units of measure of D-xylose). Their results suggested that the D-xylose test might not correlate well with intestinal histopathology, especially crypt:villous architecture. The other study was among HIV-infected children with protein-energy malnutrition in Brazil [136]. All subjects' tissue had cellular infiltration of the lamina propria and varying degrees of villous atrophy on biopsy, and all subjects also had abnormally low D-xylose absorption (based on authors' reported cutoff value of <25 mg/dL). However, there was no correlation between the proportion of serum D-xylose absorption and the degree of villous atrophy on biopsy.

Another Brazilian study used the same definition of normal range for serum D-xylose among HIV-infected children with and without gastrointestinal symptoms. Eight percent of the children had D-xylose below the "normal" range in their blood following challenge [152]. The authors also examined the relationships between D-xylose absorption and history of diarrhea and *Cryptosporidium* infection. Of the eight children with abnormal D-xylose, one had diarrhea, and of 19 subjects with diarrhea, one had an abnormal result for D-xylose. Among subjects with abnormal results, 50% had *Cryptosporidium* infection, and of the 33 with *Cryptosporidium* infection (many of whom did not have diarrhea), four had an abnormal D-xylose test. They did not report statistical testing of association, but these clinical factors do not appear to be associated with D-xylose absorption in this cohort.

Moya-Camarena et al. performed urinary D-xylose and xylose breath hydrogen tests in well-nourished children with asymptomatic *Giardia intestinalis* infection and healthy controls recruited from preschool centers [147]. Results did not demonstrate any disturbance in urinary xylose absorption among infected cases or healthy controls. Urinary results did not differ before and after treatment for *Giardia*. Breath hydrogen levels decreased significantly with treatment,

indicating improvement. The clinical and physiologic implications of this difference, in the face of hydrogen breath test results well within the range of normal, are not apparent. The investigators did not report on the relationship between breath and urinary D-xylose results.

Finally, Mittal et al. used the D-xylose absorption test as part of their diagnostic criteria for tropical sprue among gastroenterology clinic patients presenting with persistent diarrhea. By definition, all of the children had abnormal xylose absorption results; however, information about the D-xylose dose, units of measure, cutoff point for normal, and even the identity of the sampled fluid (urine or serum) were not provided [146].

Methods of test performance and cutoff points were often not described adequately to enable comparing results across studies. For example, in two instances D-xylose abnormal cut points were specifically defined as <25 mg/dL [136, 152]. This is higher than some references suggest as a cutoff point among infants and children [186]. Insufficient data were reported in these two studies for readers to assess how the proportion of those with D-xylose malabsorption might have shifted with differing cut points. In two other studies D-xylose results were only reported as normal or abnormal without defining a cutoff point [146, 155].

5.2.2 Endomolecular Challenge Absorption Tests

Six studies assessed absorption after administering labelled endomolecules (zinc (n=3), iron (n=1), and lipids (n=2)). These investigations rely on challenge with the molecule of interest, which is generally a stable isotope, and measure urinary excretion as an indicator of absorption, or fecal excretion, as an indicator of non-absorption. When examining stool, it is important to note that the fecal concentration could potentially represent uptake and subsequent excretion by the host. In one Peruvian study, there appeared to be saturation kinetics at high doses of zinc, and zinc dosing early in the day was related to diminished absorption of this divalent cation from unfortified foods later in the day [141]. Manary et al. identified an unexpectedly high fractional

excretion of the challenge zinc in children in Malawi [144]. In China, Sheng et al. demonstrated unexpectedly high fractional excretion of zinc in stool, and inferred diminished uptake of this nutrient, but also speculated that their population of children were not suffering from enteropathy [164]. Murphy et al. used ^{13}C labeled triglycerides (TG) as trilaurin, triolein, or trilinolein, and determined that in a group of Jamaican children, many of whom had bacterial overgrowth, the uptake of challenge lipids was impaired, but that the defect was not related to impaired intestinal lipolysis [148]. Earlier, Murphy et al. demonstrated that during acute malnutrition, there is impaired lipid uptake from the gut, and that this defect improved during rehabilitation [149]. Unlike in the cohort in their later study, small bowel bacterial overgrowth was not an issue in this cohort. Sarker et al. studied labeled iron uptake in children with and without *Helicobacter pylori* infection, and found no evidence for diminished uptake among the infected children [163]. Similarly, treatment of the *H. pylori* infection did not improve uptake. They inferred that this gastric infection did not play a role in diminished uptake of iron by children in Bangladesh, but did note that there are limited data on the physiology of normal iron uptake in children in the age group studied (2-5 year olds).

5.2.3 Enterocyte-specific Proteins

Nichols et al. assessed intestinal tissue markers of digestion (see Evidence Table 3) as well as two markers of absorption: intestinal messenger RNA (mRNA) abundances of villin and sodium-activated luminal glucose-galactose transporter 1 transcripts [53]. These are structural proteins expressed only in enterocytes. mRNAs for these proteins are found in reduced quantities if intestinal surface area is diminished and hence reflect absorptive capacity. Nichols et al. compared the mRNA abundances in intestinal biopsies of children with refractory malnutrition to values found in controls that were neither stunted nor wasted, and found a reduction of more than 50% in mRNA abundances for both proteins among cases. It is important to note that the controls were children with biliary atresia who, as part of their

management for the condition, underwent intestinal resection. Without having performed an *ex vivo* mucosal biopsy in the control subjects, it is not possible to rule out a lower ratio of villous to submucosa tissue present in resected tissue which might affect mRNA determinations, as transmural tissue can be expected to contain a more diverse population of cells, only some of which might contain the transcripts of interest. However, the bias, if any, is likely in the direction that would reduce effect size.

5.2.4 Fecal Fat

Data on fecal fat was reported in three studies as a marker of malabsorption, including one study that measured the fat by four different methods, with a high degree of consistency in results across techniques [116]. That study, conducted among children with varying nutritional status in Venezuela, and another study conducted in India among children with symptoms consistent with and being evaluated for celiac disease [155], reported results as percent of subjects that tested positive while another study of severely malnourished Jamaican children [149] presented results as mean fecal fat excretion in grams per day and as percent of intake; hence, the results of this third study could not be compared to the other two. Positive results among the Venezuelan children varied from 13-27% (depending on laboratory method) among well-nourished children to 80-100% (again, depending on method) among the most severely malnourished children [116], while the Indian study detected fat in the stools of 20% of the children [155].

The Jamaican study found the fecal fat results to correlate with recovery of radiolabeled lipids in the stool after administration of ^{13}C tripalmitin. The Indian study found that 55% of subjects with symptoms of celiac disease but a negative serologic evaluation for that disorder had abnormal D-xylose absorption (although the authors did not report the units of measure,

cutoff point of normal-abnormal results, or whether or not they measured the sugar in the urine or serum) and 20% had abnormal fecal fat results; correlation testing was not reported.

5.2.5 Summary of Markers of Absorption

The assessed markers demonstrated normal and abnormal enteric function, depending on the marker and the study. The proportion of abnormal urinary D-xylose excretion results ranged from none among well-nourished children with asymptomatic *Giardia intestinalis* infection and healthy controls [147] to 100% among HIV-infected children in Brazil with protein-energy malnutrition [136]. Endomolecular markers also yielded varying results in different study populations. Apparent malabsorption was observed based on lipid uptake in a cohort of Jamaican children, some of whom had small bowel bacterial overgrowth [149]. In contrast, a study of iron uptake among children with and without *Helicobacter pylori* infection found no evidence of impaired absorption [163]. Malnourished children had reduced absorptive capacity relative to controls as inferred from reduced abundance of messenger RNA in biopsies for enterocyte-specific proteins [53]. Similarly malnourished children showed absorptive derangement by fecal fat test, with a notably higher proportion of positive tests than among well-nourished children [116].

Two of the fecal fat studies were the only ones that assessed more than one marker that is primarily a measure of absorptive capacity. The Jamaican study was the only one that reported testing for correlation between these tests of absorption [149]. Several studies compared the relationship of markers of absorption to biopsy. D-xylose [136, 146, 155] and fecal fat [155] corresponded poorly with histopathology. The papers suggested that there was only a short interval between the performance of these tests and the biopsies, but the exact length of time was not provided. Abundance of messenger RNA for two enterocyte-specific proteins, villin and sodium-activated luminal glucose-galactose transporter 1, did correlate with

villous atrophy in a study examining biopsy-derived markers [53]. None of the studies compared markers of absorption to other types of markers of enteric dysfunction (i.e., other than to biopsy or other measures of absorptive function).

Only one study reported data on an absorption marker in relation to the presence of diarrhea, finding no apparent association with D-xylose absorption, although this was not analyzed statistically [152]. None of the studies examined the association between absorption markers and growth outcomes. A Peruvian study was the only one to report an absorption marker as a clinical endpoint of an intervention trial, in this case a randomized, controlled trial of zinc supplementation [141]. It was also the only study to measure intra-individual longitudinal change outside of the context of intervention or convalescence. These investigators assessed zinc absorption longitudinally in controls without zinc supplementation and observed no change in absorption of this pentose sugar.

These absorption tests showed a range of logistical challenges for deployment in resource-limited settings. When methods were described, the D-xylose test was conducted by colorimetric or spectrophotometric means, whereas the tests of endomolecules involved more complex laboratory methods and the intestinal tissue markers, requiring biopsy, were most technically complicated and invasive. The D-xylose studies generally did not cite reference standards or compare their results to those from other studies. Two studies compared their fecal fat results to those in other published studies [116, 149]. One of these studies also conducted a lipid breath test and compared results to those previously published [149]. All of the zinc absorption studies discussed results in relation to expected values based on reference indices and other studies of zinc homeostasis [141, 144, 164]. In the iron absorption study, authors cited a lack of data available in the literature for subjects of similar age for comparison [163].

5.3 Markers of Permeability

Data regarding markers of permeability are presented in Evidence Table 2. As discussed above, many of the tests that assess permeability also entail a test component that assesses absorptive function.

Thirty-one studies assessed markers of intestinal permeability. All but one of these included assessments of dual sugar tests as either lactulose:mannitol (L:M) (n=25) or lactulose:rhamnose (L:R) (n=5); the other reported measures of lactose in the urine as lactose:creatinine. Two studies reporting L:M test results also reported other markers of permeability, either urinary lactose and lactose:lactulose or plasma endotoxin and IgG endotoxin-core antibody.

Evidence Table 2. Markers of permeability.

This category includes markers with dual assessment of absorption and permeability. Biomarkers in bold are primarily markers of permeability (with or without dual assessment of absorption).

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
<p>2004</p> <p>Campbell DI et al.</p> <p>Intestinal inflammation measured by fecal neopterin in Gambian children with enteropathy: association with growth failure, <i>Giardia lamblia</i>, and intestinal permeability</p> <p>Fecal neopterin and L:M as markers of intestinal inflammation and permeability, respectively, and their correlation with growth status and <i>Giardia</i> recovery in the stool</p>	<p>Keneba, Gambia</p> <p>2 mo olds from rural area followed until 15 mo of age.</p>	<p>Cohort</p> <p>n=72</p> <p>Subjects were evaluated with twice-weekly questionnaire to determine diarrhea morbidity, clinic assessments of growth, and screening laboratory tests every 2 mo.</p>	<p>Stool Test: Neopterin</p> <p>Urine Tests: <ul style="list-style-type: none"> • Lactulose¹ • Mannitol • L:M </p>	<p>Mean neopterin concentration was negatively correlated with long-term height ($r=-0.29$, $p<0.009$) and weight ($r=-0.36$, $p<0.007$) gain, but not with giardiasis.</p> <p>Mean² L:M (CI): 0.31 (0.26, 0.34).</p> <p>Mean excretion of lactulose (CI): 0.20 (0.18, 0.23).</p> <p>Mean excretion of mannitol (CI): 3.0 (2.8, 3.2).</p> <p>Mean L:M was negatively correlated with long-term height gain (r value not provided, $p<0.0001$), but was not correlated with presence of <i>Giardia</i>.</p> <p>L:M and fecal neopterin were not correlated ($p=0.11$).</p>	<p>L:M and mean fecal neopterin concentration were not correlated.</p> <p>Mean L:M in the Gambian children was substantially higher than normal values in children in the UK. These high L:M ratios appear to be driven by mannitol excretion.</p>	<p>Study population might have some overlap with that of Campbell et al. also included in this review [110].</p>
<p>2003</p> <p>Campbell DI et al.</p> <p>Growth faltering in rural Gambian infants is associated with impaired small intestinal barrier function, leading to endotoxemia and systemic inflammation</p> <p>L:M as a marker of</p>	<p>Keneba, The Gambia</p> <p>All 2-11 mo olds were recruited from this rural village and followed up to 14 mo of age.</p>	<p>Cohort</p> <p>n=71</p>	<p>Urine Tests: <ul style="list-style-type: none"> • Lactulose³ (53 tested) • Mannitol (52 tested) • L:M (52 tested) <p>Blood tests: <ul style="list-style-type: none"> • Albumin • CBC • C-reactive protein (CRP) </p> </p>	<p>At 8 wk of age:</p> <ul style="list-style-type: none"> • Mean⁴ L:M: 0.169 (CI: 0.145, 0.198; range: 0.058-0.657) • Mean lactulose recovery: 0.202 (SD=0.159; range: 0.009-0.640) • Mean mannitol recovery: 3.80 (SD=2.35; range: 0.52-8.58) <p>L:M more than doubled between 12 wk-1 yr of age ($r=0.44$, $p<0.001$) and was driven by both increasing lactulose ($r=0.18$, $p<0.001$) and decreasing mannitol ($r=-0.14$, $p<0.01$) excretion with age.</p>	<p>Mean L:M ratios were elevated at 8 weeks of age, and more than doubled in the first year of life.</p> <p>Many markers of inflammation and endotoxin release were significantly correlated with L:M and lactulose recovery.</p>	<p>Presence of malaria parasites was assessed by blood smear at each study visit; the only parameter associated with malaria was CRP.</p> <p>Authors did not report investigating relationships between certain serum parameters</p>

¹ Lactulose and mannitol results were expressed as % of dose administered.

² Type of mean not specified.

³ For lactulose and mannitol results, excretion measurement was not specified.

⁴ Geometric mean.

Evidence Table 2. Markers of permeability.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
intestinal permeability and its relationship with various inflammatory markers and endotoxin			<ul style="list-style-type: none"> • IgA • IgM • IgG • Plasma endotoxin • IgG endotoxin-core antibody 	<p>WAZ and HAZ scores were negatively correlated with L:M ($r=-0.41$, $p<0.001$), and primarily driven by lactulose excretion ($r=-0.39$, $p<0.001$).</p> <p>Laboratory values were consistent with chronic, low level immunostimulation:</p> <ul style="list-style-type: none"> • 50% of platelet and 39% of leukocyte counts were elevated, especially mean lymphocyte counts which were almost twice expected values [198]. • While the mean¹ CRP was within the normal range, 25% of values were above the upper limit of normal (5 mg/L), and 17% were >10 mg/L [198]. • Mean IgG, IgA and IgM concentrations were near normal at 8 wk of age, but increased rapidly; all three were elevated above expected values in all other age groups [198, 199] • Mean² free plasma endotoxin concentration was twice the upper limit of normal [200] and IgG endotoxin-core antibody concentrations were also elevated [198] • However, mean albumin concentrations (and concentrations within SD) were generally within normal range [198]. <p>L:M was correlated with IgG and IgA ($r=0.41$ and 0.41,</p>	Poor growth was significantly correlated with L:M ratios, primarily due to lactulose excretion.	<p>(blood counts, CRP concentrations) and L:M.</p> <p>Authors postulate that while general markers of inflammation cannot be specifically ascribed to a gut source, endotoxin and its related core antibody are potentially a direct measure of intestinal inflammation due to gut gram negatives as a primary source of endotoxin release among subjects without sources of extra-intestinal gram negative infection.</p> <p>Study population might have overlap with that of Campbell et al. 2004 also included in this review [15].</p>

¹ Geometric mean.

² Geometric mean.

Evidence Table 2. Markers of permeability.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
				<p>respectively, $p < 0.001$), and IgM ($r = 0.28$, $p < 0.02$).</p> <p>IgG and IgA were also correlated with lactulose recovery ($r = 0.26$ and 0.25, respectively, $p < 0.02$).</p> <p>IgG endotoxin core antibody concentration was correlated with L:M and driven by lactulose recovery, ($r = 0.35$, $p < 0.005$ for both).</p> <p>Endotoxin concentrations were correlated with lactulose recovery ($r = 0.36$, $p < 0.02$) only.</p>		
<p>2003</p> <p>Campbell DI et al.</p> <p>Chronic T cell-mediated enteropathy in rural west African children: relationship with nutritional status and small bowel function</p> <p>L:M as a marker of intestinal permeability, small bowel biopsy with assessment of intestinal immune markers, and computerized morphometric analysis among rural Gambian children with differing degrees of malnutrition and compared to well-nourished UK children</p>	<p>Fajara and Sibanar, The Gambia</p> <p>6 mo-3 yr old hospital- and clinic-based cases from rural communities.</p> <p>Case groups based on differences in nutritional status:</p> <ol style="list-style-type: none"> 1. WAZ score > -2, with GI complaints other than diarrhea 2. Grade I protein energy malnutrition (PEM) (WAZ score -2 to -4) and unresponsive to nutritional supplements, 	<p>Case-control</p> <p>n=40 cases:</p> <ul style="list-style-type: none"> • Group 1: n=4 • Group 2: n=11 (7 with diarrhea) • Group 3: n=25 (18 with diarrhea) <p>n=34 with case tissue samples sufficient for cytokine immuno-reactivity tests:</p> <ul style="list-style-type: none"> • Group 1: n=3 • Group 2: n=8 • Group 3: n=23 	<p><u>Endoscopic small bowel biopsy, site not specified:</u></p> <ul style="list-style-type: none"> • Histopathology • Morphometric assessment by computer analysis* • Intestinal tissue cytokines and immune markers: • CD-3 • CD-4 • CD-8 • CD-19 • CD-25 • HLA-DR • Perforin • $\gamma\delta$ T-cell receptor • Syndecan-1 • TNF-α • IFN-γ • TGF-β • IL-10 	<p>Crypt-hyperplasia and villous atrophy were observed among all Gambian subjects, and the degree of histopathology did not differ among cases with differing nutritional status, nor was there a correlation with diarrhea.</p> <p>IEL¹ means were ~3-fold higher in Gambian than UK children.</p> <p>Median CD3, CD4, CD8, CD19, and CD25 cell counts were significantly higher (2-5x higher) among each case group compared to the UK controls.</p> <p>IEL, $\gamma\delta$, syndecan-1, HLA-DR, and perforin were detected among the Gambian children in varying degrees but were not reported for UK controls. Syndecan, CD3, and CD8 displayed a gradient proportional to malnutrition severity.</p> <p>All Gambian groups showed higher lamina propria cytokine-</p>	<p>All Gambian subjects had evidence of enteropathy with crypt-hyperplasia and villous atrophy, and mean IELs > 2 SD above UK norms, independent of nutritional status and diarrhea history.</p> <p>Elevation of cell-mediated intestinal markers and mucosal proinflammatory cytokines was present across the 3 Gambian groups, variably correlated with nutritional status.</p> <p>L:M ratios were elevated in all Gambian groups,</p>	<p>Statistical methodology was not sufficiently detailed to determine what was compared (e.g. type of central tendency measure and variance calculations for L:M not stated).</p> <p>Duration of diarrhea not specified, but assumed to be persistent.</p> <p>Mucosal lymphocyte densities, cytokine immuno-reactivity, and L:M results were not stratified by history of diarrhea.</p>

¹ These figures are presumed to represent IEL means; however, this was not explicitly stated.

Evidence Table 2. Markers of permeability.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
	<p>with or without diarrhea</p> <p>3. Grade II PEM (WAZ score <-4) with or without diarrhea</p> <p>Controls from UK* who were well nourished children with GI complaints other than diarrhea and with normal endoscopy results were also studied.</p> <p>* UK subjects are presented in this table due to comparisons of interest made in the review. However we do not include these subjects in the sample size for this review.</p>		<p><u>Urine Tests:</u></p> <ul style="list-style-type: none"> • Lactulose² • Mannitol • L:M <p>* Biopsy involved morphometric assessment by computer analysis of villous height, crypt depth, villous:crypt ratio, and intraepithelial lymphocyte (IEL) density (per 100 epithelial cells).</p>	<p>immunoreactive mononuclear cell density (~200-450/mm²) than UK controls (30-80/mm²).</p> <p>Among subjects with elevated cytokines, similar densities were seen for both pro-inflammatory (IFN-γ and TNF-α) and putative regulatory (IL-10 and TGF-β) cytokines. Epithelial expression of TGF-β was also enhanced compared to UK controls, but subjects with poorer nutritional status had lower densities of mucosal TGF-β+ cells, with median densities of 420 and 250 cells/mm² in the grade I and grade II PEM groups, respectively.</p> <p>L:M values¹:</p> <ul style="list-style-type: none"> • Group 1: 0.53 (0.4-1.3) • Group 2: 0.47 (0.02-2.20) • Group 3: 0.73 (0.14-2.2) • Not assessed among the UK controls <p>Nutritional status was not associated with L:M, recoveries of lactulose or mannitol.</p> <p>L:M was correlated with mucosal B lymphocyte density (r=0.57, p<0.05), IEL (r=0.51, p<0.02), and perforin+ IEL (r=-0.64, p<0.03).</p>	without apparent correlation to host nutritional status.	
<p>2002</p> <p>Campbell DI et al.</p> <p>Age-related association of small</p>	<p>Keneba, The Gambia and surrounding villages</p> <p>2-60 yr olds</p>	<p>Cohort</p> <p>n=162;</p> <p><5 yr old: n=26</p>	<p><u>Urine Tests:</u></p> <ul style="list-style-type: none"> • Lactulose² • Mannitol • L:M 	<p>Mean³ L:M (SE) in 2-5 yr old group: 0.353 (0.022).</p> <p>Mean lactulose and mannitol % recovery was ~0.45 and ~0.65, respectively.</p>	<p>Mean L:M in asymptomatic 2 to 5 yr olds was high and decreased significantly with increasing age, but</p>	<p>Subjects were free from diarrhea symptoms for at least one week prior to urinary assessments.</p>

¹ Not clearly indicated if these figures represent mean (CI) or another measure of central tendency.

² Lactulose and mannitol results were expressed as % of dose administered.

³ Type of mean not specified.

Evidence Table 2. Markers of permeability.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
<p>intestinal mucosal enteropathy with nutritional status in rural Gambian children</p> <p>L:M and urinary lactulose and mannitol recovery as a marker of intestinal permeability and its association with nutritional status at varying ages. Also assessed correlation of change in L:M with nutritional status at 3.5 mo re-visit.</p>	<p>randomly selected from rural communities.</p>	<p>(23 were re-assessed)</p>		<p>L:M was highest in 2-5 yr age group and decreased with increasing age (up to age 20) ($p < 0.001$), but never fell within referenced UK normal ranges [201].</p> <p>Most of the improvement in L:M was driven by a reduction in lactulose excretion ($p < 0.001$), which fell within expected UK ranges by age 10 yr.</p> <p>In contrast, although mannitol excretion slightly decreased with age, this trend did not reach statistical significance. In fact, excretion proportions were at all times $\frac{1}{2}$ - $\frac{1}{3}$ of expected UK values [201].</p> <p>L:M was inversely correlated with HAZ score¹ ($r = -0.31$, $p < 0.001$), but not with WAZ or body mass index (BMI) Z- scores. The correlation with HAZ score was mainly due to the higher lactulose excretion in subjects with poorer HAZ scores ($r = -0.22$, $p = 0.001$) and held across all age groups.</p> <p>There was a small improvement in mean L:M (SE) between the two study time points from 0.198 (0.018) to 0.172 (0.010) ($p = 0.026$ for change in L:M), driven by an improvement in mannitol recovery with no change in lactulose excretion.</p> <p>Indices of intestinal permeability within subjects showed a high</p>	<p>never fell within expected range of values.</p> <p>Among all age groups, L:M showed significant intra-subject correlation between tests conducted 3.5 months apart.</p> <p>Among all age groups, L:M was significantly inversely correlated with HAZ score, primarily driven by lactulose excretion.</p>	<p>The authors sought correlation between the mean L:M of the two visits and ΔBMIZ, ΔHAZ and ΔWAZ scores, but statistical calculations were not provided.</p>

¹ Reported results were adjusted for age, sex, and visit.

Evidence Table 2. Markers of permeability.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
				<p>degree of correlation between the two visits:</p> <ul style="list-style-type: none"> • Lactulose: $r=0.55$, $p<0.001$ • Mannitol: $r=0.24$, $p<0.05$ • L:M: $r=0.66$, $p<0.001$ <p>Change in measures between visits (analysis not stratified by age):</p> <ul style="list-style-type: none"> • Mean L:M (SD): <ul style="list-style-type: none"> • Visit 1: -1.62 (0.66) • Visit 2: -1.76 (0.55), ($p=0.026$) • Mean mannitol recovery (SD): <ul style="list-style-type: none"> • Visit 1: 5.25 (2.69) • Visit 2: 6.28 (3.03), ($p=0.006$) • Mean lactulose recovery (SD): <ul style="list-style-type: none"> • Visit 1: 0.28 (0.20) • Visit 2: 0.29 (0.18), NS (p-value not specified) 		
<p>2003</p> <p>Chen P et al.</p> <p>Association of vitamin A and zinc status with altered intestinal permeability: analyses of cohort data from northeastern Brazil</p> <p>L:M as a marker of intestinal permeability pre- and post-vitamin A and zinc supplementation among children with history of PD or low WAZ score</p>	<p>Goncalves Dias favela in Fortaleza, Brazil</p> <p>2-97 mo olds recruited from an urban shantytown.</p>	<p>Cohort</p> <p>$n=75$ with pre-supplement L:M and retinol concentrations measured:</p> <ul style="list-style-type: none"> • 51 with pre-supplement circulating zinc concentrations measured • 20 with post-intervention* longitudinal follow-up of subset with history of PD or low WAZ score 	<p>Urine Tests:</p> <ul style="list-style-type: none"> • Lactulose¹ • Mannitol • L:M 	<p>Baseline mean (SD):</p> <ul style="list-style-type: none"> • L:M²: 0.29 (0.16) • Lactulose: 0.54 (0.29) • Mannitol: 2.07 (0.88) <p>L:M was not correlated with age. L:M was inversely correlated with retinol ($r=-0.55$, $p<0.0005$), including after adjustment for zinc concentration and stratification on retinol concentrations.</p> <p>Retinol was correlated with mannitol ($r=0.28$, $p=0.017$) and lactulose ($r=-0.22$, $p<0.063$) excretion.</p> <p>Lactulose, mannitol and their combined ratio were not correlated with zinc concentrations.</p>	<p>Supplementation of vitamin A and zinc resulted in significant improvements in L:M among the cohort of children with a history of PD or low WAZ score who received post-supplementation assessment. Less than one-third of the subjects had post-intervention L:M assessments.</p>	<p>Longitudinal data were not reported stratifying on underlying condition (i.e. PD history vs. WAZ score).</p> <p>Follow-up data on L:M were not provided for the children with normal WAZ score or no history of PD.</p> <p>Unclear how long after supplementation the L:M testing was done.</p>

¹ For lactulose and mannitol results, excretion measurement was not specified.

² Type of mean not specified.

Evidence Table 2. Markers of permeability.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
		* These subjects received a single oral dose of vitamin A and a 2-wk course of daily zinc supplements.		L:M improved after supplementation for the cohort of 20 children followed longitudinally with PD or low WAZ score: L:M mean (SD): • Pre-treatment: 0.28 (0.12) • Post-treatment: 0.19 (0.07) However, lactulose and mannitol excretion did not change significantly.		Post-supplementation L:M results in the text of the publication differed somewhat from what was reported in the publication table.
2007 Darboe MK et al. Effectiveness of an early supplementation scheme of high-dose vitamin A versus standard WHO protocol in Gambian mothers and infants: a randomised controlled trial L:M as a marker of intestinal epithelial integrity among infants receiving high-dose vitamin A or standard vitamin A protocol	Keneba, The Gambia Subjects recruited at birth from rural community. Age range during study was 0-12 mo.	RCT n=197 n=99 received high dose vitamin A protocol n=98 received standard dose vitamin A protocol	<u>Urine Test:</u> L:M	Mean ¹ L:M and proportion with values >0.30 among those receiving standard doses of vitamin A, by age: • 2 mo: 0.195, 12% • 5 mo: 0.197, 13% • 7 mo: 0.212, 22% • 9 mo: 0.286, 30% • 12 mo: 0.322, 34% Mean L:M differed between the two groups only at 7 mo (0.276 in high-dose vitamin A group, p=0.014), although there was no difference in percentages with L:M >0.30.	L:M values rose by ~50% from age 2 mo to 1 yr and were not affected by dosing of vitamin A.	The L:M normal cutoff was defined higher than for most other L:M studies, as 0.30. This was derived from the mean plus 2 SD from a study of UK infants [202].
2001 Filteau SM et al. The effect of antenatal vitamin A and (beta)-carotene supplementation on gut integrity of infants	Durban, South Africa Pregnant, HIV-infected women between 28-32 wk gestation recruited from antenatal clinic. Infants were	RCT n=238 n=119 received vitamin A supplements (26 with HIV infection)	<u>Urine Tests:</u> • Lactulose ² • Mannitol • L:M Subjects tested: • 1 wk: • Treatment:	Mean L:M ³ (CI) at 1 wk among infants without reports of illness was 0.12 (0.08, 0.17). L:M did not change with increasing age and did not significantly increase with reported morbidity. While a history of ever having been breastfed was an important	Mean L:M overall was within normal range. However, mean L:M for placebo-treated, HIV-infected infants by 14 weeks was significantly elevated to almost 0.5.	Specific sugar excretion was normalized to urinary creatinine to control for variation in renal function.

¹ Geometric mean.

² For lactulose and mannitol results, excretion measurement was not specified.

³ Geometric mean.

Evidence Table 2. Markers of permeability.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
of HIV-infected South African women L:M as a marker of intestinal permeability among infants of HIV-infected mothers enrolled in a vitamin A trial	followed until 14 wk of age.	n=119 received placebo (29 with HIV infection) Treatment involved maternal vitamin A supplements during pregnancy and at delivery.	n=104 <ul style="list-style-type: none"> • Placebo: n=104 6 wk: <ul style="list-style-type: none"> • Treatment: n=100 • Placebo: n=105 14 wk: <ul style="list-style-type: none"> • Treatment: n=99 • Placebo: n=95 	<p>contributor to L:M at 1 wk ($\Delta R^2=0.22$, $p=0.008$), a significant effect was not seen at 6 and 14 weeks¹. Current feeding status had a modest effect on L:M only at 14 wk ($\Delta R^2=0.06$, $p=0.04$).</p> <p>Birth weight contributed significantly at 1 wk ($\Delta R^2=0.07$, $p=0.02$), but current weight did not contribute significantly to L:M at any time point.</p> <p>HIV infection status by 14 wk was the major factor contributing to L:M at 6 wk ($\Delta R^2=0.22$, $p=0.008$) and 14 wk ($\Delta R^2=0.21$, $p=0.01$).</p> <p>Maternal HIV viral load during pregnancy was not consistently significantly correlated with infant L:M. Maternal lymphocyte counts and plasma retinol concentrations were not associated with infant L:M.</p> <p>While maternal vitamin A supplementation had no effect on L:M of uninfected infants, it appeared to prevent the increase in L:M of HIV-infected infants²:</p> <p>Mean L:M (CI):</p> <ul style="list-style-type: none"> • Uninfected: <ul style="list-style-type: none"> • Vitamin A group: 0.11 (0.08, 0.15) • Placebo group: 0.09 (0.06, 0.12) • HIV-infected: <ul style="list-style-type: none"> • Vitamin A group: 0.17 (0.13, 0.23) • Placebo group: 0.50 (0.37, 0.68) 	While HIV infection did not affect mannitol excretion, it was associated with increased lactulose excretion.	

¹ Reported results were adjusted for confounding variables, unless otherwise noted.

² Reported results were adjusted for confounding variables included an interaction with HIV infection.

Evidence Table 2. Markers of permeability.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
				<p>Mannitol was not affected by vitamin A. HIV infection was not consistently significantly associated with mannitol across age groups.</p> <p>Lactulose also did not consistently differ between treatment groups or by HIV-status, although vitamin A prevention of increase in lactulose among HIV-infected infants neared significance at 14 wk (p=0.058)¹.</p>		
<p>2005</p> <p>Galpin L et al.</p> <p>Effect of <i>Lactobacillus</i> GG on intestinal integrity in Malawian children at risk of tropical enteropathy</p> <p>L:M and sucrose: lactulose ratio (SUC:L) as markers of intestinal and gastric permeability, respectively, in asymptomatic children presumed at risk of EED</p>	<p>Mwenye, Malawi</p> <p>36-60 mo olds recruited from a rural community, excluding children with severe acute malnutrition or severe chronic illnesses.</p> <p>Subjects were considered at risk for EED due to residence in a location with high prevalence of EED.</p> <p>Presumed that if SBBO is etiology for EED, treatment with <i>Lactobacillus</i> will result in improved gut integrity.</p>	<p>RCT</p> <p>n=164;</p> <p>n=81 received <i>Lactobacillus</i> GG (80 completed the study)</p> <p>n=83 received placebo (81 completed the study)</p> <p>Subjects received 30-days of <i>Lactobacillus</i> GG or placebo. Only the 161 subjects who completed the study had repeat testing.</p>	<p>Urine Tests:</p> <ul style="list-style-type: none"> • Lactulose² • Mannitol • Sucrose (SUC) • L:M • SUC:L 	<p>At enrollment:</p> <ul style="list-style-type: none"> • 73% had L:M >0.10 • 40% had L:M >0.20 • Mean³ L:M (SD): <ul style="list-style-type: none"> • Treatment: 0.18 (0.16) • Placebo: 0.22 (0.20) • Mean lactulose (SD) in treatment group: 0.25 (0.17) • Mean mannitol (SD) in treatment group: 8.0 (4.5) • Mean SUC:L (SD): <ul style="list-style-type: none"> • Treatment: 0.58 (0.64) • Placebo: 0.60 (0.64) <p>Mean excretion of sucrose (SD) increased from 0.057 (0.042) to 0.078 (0.058) in the treatment group (p=0.01), but similar results were observed in the placebo group. Otherwise there were no changes in lactulose, mannitol, L:M, or SUC:L after treatment or placebo.</p>	<p>A high baseline prevalence of abnormal L:M was observed, with no change after intervention.</p> <p>High mannitol excretion (relative to UK norms) drove the abnormal L:M.</p> <p>There was little effect on SUC:L with intervention; sucrose excretion increased in both treatment and control groups.</p>	<p>Difficult to interpret sucrose tests because there are limited data on laboratory values for these tests in young children.</p>
<p>2008</p>	<p>Dhamrai Upazila, Bangladesh</p>	<p>RCT</p>	<p>Urine Test:</p>	<p>Mean L:M¹ (SD) at baseline was 0.18 (0.24) in treatment groups, with</p>	<p>High L:M ratios overall with</p>	<p>High L:M ratios were defined as</p>

¹ P-values are from reported results that were adjusted for confounding variables.

² Lactulose, mannitol, and sucrose results were expressed as % of dose administered.

³ Arithmetic mean.

Evidence Table 2. Markers of permeability.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
<p>Goto R et al.</p> <p>Impact of anti-<i>Giardia</i> and anthelmintic treatment on infant growth and intestinal permeability in rural Bangladesh: a randomised double-blind controlled study</p> <p>L:M as a marker of intestinal permeability, IgG as a marker of chronic immune stimulation, and α-1-acid glycoprotein as an acute phase reactant among children undergoing anti-parasitic presumptive treatment vs. placebo. Also assessed markers' associations with growth parameters.</p>	<p>3-15 mo olds from a rural area were enrolled and followed in a 9-mo trial.</p> <p>There was a high prevalence of malnutrition in the study population.</p>	<p>n=222*</p> <p>n=75 received anti-<i>Giardia</i> and anthelmintic treatment</p> <p>n=59 received anti-<i>Giardia</i> treatment only</p> <p>n=88 received placebo</p> <p>* Those who fully participated and for whom data were analyzed are included in this review.</p>	<p>• L:M</p> <p><u>Blood Tests:</u></p> <ul style="list-style-type: none"> • α-1-acid glycoprotein (AGP) • IgG • Albumin 	<p>no significant difference in placebo group or in testing post-intervention.</p> <p>Proportion with elevated L:M at any study time point varied between 58%-74%. >57% consistently elevated L:M ratios.</p> <p>Seasonal variation in L:M was observed (p <0.001), with highest mean values in the monsoon season.</p> <p>L:M was associated with ΔWAZ and ΔWHZ scores at 24 weeks (p=0.001 and p<0.001, respectively, point estimates not provided.)</p> <p>Serum immune marker values were similar in all groups and did not change substantially with interventions.</p> <p>AGP concentrations were negatively associated with ΔWAZ score at 24 weeks (p=0.004, point estimate not provided), and were associated with ΔWHZ score at 12 weeks but not at 24 weeks.</p>	<p>substantial seasonal and within-infant variability.</p> <p>Interventions did not impact L:M or serum immune markers.</p> <p>There was improvement in weight with better L:M values, the degree to which this occurred was not reported.</p>	<p>greater than the upper CI for UK infants.</p> <p>Same study population as reported by this group in another study also included in this review [123].</p>
<p>2008</p> <p>Goto R et al.</p> <p>Impact of intestinal permeability, inflammation status and parasitic infections on infant growth faltering in rural Bangladesh</p>	<p>Dhamrai Upazila, Bangladesh</p> <p>3-15 mo olds from a rural area were enrolled and followed in a 9-mo trial.</p> <p>There was a high prevalence of</p>	<p>Longitudinal data extracted from an RCT [122].</p> <p>n=298</p> <p>Urine and blood samples were collected every 3 mo and</p>	<p><u>Urine Test:</u></p> <p>L:M</p> <p><u>Blood Tests:</u></p> <ul style="list-style-type: none"> • α-1-acid glycoprotein (AGP) • IgG • Albumin • Hemoglobin 	<p>Mean² L:M: 0.15</p> <p>L:M showed a decreasing trend with age (p=0.003), and was associated with female gender (p=0.004), HAZ score (p=0.039), and WAZ score (p=0.019), but not with giardiasis or any of the serum immune markers.</p> <p>IgG, AGP, and albumin were associated with giardiasis, but</p>	<p>Mean L:M was elevated. L:M was not associated with any of the tested serum markers of inflammation or with giardiasis.</p> <p>IgG rose with increasing age at the rate expected</p>	<p>Helminthiasis prevalence was very low; testing for association with markers was not performed.</p> <p>Giardiasis was defined as presence of a <i>Giardia</i>-specific IgM</p>

¹ Geometric mean.

² Geometric mean.

Evidence Table 2. Markers of permeability.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
L:M as a marker of intestinal permeability, IgG as a marker of chronic immune stimulation, and α -1-acid glycoprotein as an acute phase reactant. Also assessed laboratory values' associations with giardiasis and growth parameters.	malnutrition in the study population.	anthropometric measurements were collected monthly.		hemoglobin was not. Mean circulating albumin concentration was normal for age [203]. Compared to UK age-matched reference [199], rate of rise in IgG with increasing age was similar, but concentrations were consistently ~3g/L higher. IgG was not associated with growth parameters. Albumin was associated with HAZ score only (p=0.016). AGP was inversely associated with HAZ (p=0.011) and WAZ (p=0.005) scores.	(compared to UK norms) [199] but at higher concentrations across all ages.	response. Same study population as reported by this group in another study also included in this review [122]. Cut-off values representing elevated concentrations have not been determined for AGP. UK norms for 10 mo olds-adults are 0.88 g/L mean (0.21 SD) [204].
2002 Goto R et al. Poor intestinal permeability in mildly stunted Nepali children: Associations with weaning practices and <i>Giardia lamblia</i> infection L:M as a marker of intestinal permeability, and assessment of association with giardiasis, helminthiasis, nutritional practices, and growth status.	Kathmandu, Nepal 0-5 yr olds (mean age 3.8 yr) from two urban squatter settlements. 37% and 33% of subjects were stunted and underweight, respectively.	Cross-sectional n=210	Urine Tests: • Lactulose ¹ • Mannitol • Lactose ² (168 tested) • L:M (158 tested) • Lactose:lactulose ratio (157 tested)	L:M: • 92% had values >UK norms • Mean ³ L:M (SD, range): 0.26 (0.21, 0.04-1.71). • <i>Giardia</i> -infected versus uninfected means: 0.43 vs. 0.25, p=0.014 The duration of ingestion of solid foods (with or without concurrent breastfeeding) was not associated with L:M in multivariate analysis. L:M was correlated with longer duration of breastfeeding (r=0.27, p<0.019). Specifically, children who breastfed for >2 yr had higher L:M ratios than children who breastfed for shorter times (data not provided). L:M was not associated with:	L:M ratios were high overall. Wide individual variation was observed in L:M ratios. L:M was associated with giardiasis but not helminthiasis. Urinary lactose concentrations and lactose:lactulose ratios were significantly higher in breastfed subjects than in those that were not breastfed,	Low lactase activity was defined as lactose:lactulose ratio >0.4. Specific L:M data by WAZ and HAZ scores were not reported, although authors state that L:M was not associated with "growth status."

¹ Lactulose and mannitol results were expressed as % of dose administered.

² Lactose results were expressed in mg/L.

³ Geometric mean.

Evidence Table 2. Markers of permeability.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
				<ul style="list-style-type: none"> • History of diarrhea in the week preceding testing • Helminthiasis • Age • WAZ or HAZ scores <p>Lactulose excretion ranged from 0.02–15.00. Mannitol excretion ranged from 0.5–15.00.</p> <p>47% showed low lactase activity. Lactose values and lactose:lactulose ratios decreased with age ($R^2=28\%$, $p<0.0001$), but were not associated with sex, ethnicity, and location nor were they associated with L:M.</p> <p>Mean¹ urinary lactose concentrations (mg/L) by feeding mode:</p> <ul style="list-style-type: none"> • Breastfed: 172.5 • Non-breastfed: 44.5, $p<0.0001$ corrected for infant age <p>Mean² lactose:lactulose ratio by feeding mode:</p> <ul style="list-style-type: none"> • Breastfed: 2.76 • Non-breastfed: 0.31, $p<0.0001$ corrected for infant age <p>Mean L:M by feeding mode:</p> <ul style="list-style-type: none"> • Breastfed: 0.23 • Non-breastfed: 0.28, non-significant, p-value not specified 	<p>despite similar intestinal permeability values.</p> <p>There were some unexpected findings: the duration of breastfeeding, and not the timing of introduction of solid foods, was correlated with L:M, and the correlation was direct, not inverse. Authors speculate that this could be due to higher mean age of their cohort compared to another study that demonstrated beneficial effect of duration of breastfeeding on reduced L:M in Guatemala [205].</p>	
2000 Haase A et al. Dual sugar	Darwin, Australia Cases were >4 months admitted to Royal Darwin	Case-control n=264; n=150 cases with	<u>Blood Test:</u> L:R <u>Urine Test:</u>	<p>Among the subset with both blood and urine specimens:</p> <ul style="list-style-type: none"> • Urine L:R: <ul style="list-style-type: none"> • Mean³ (CI): <ul style="list-style-type: none"> • Cases: 12.4 (9.3, 16.5) 	Children with diarrhea had significantly higher L:R ratios by both blood and urine	Authors used data from non-diarrheal controls from their clinical practice to derive cut-points for

¹ Geometric mean.

² Geometric mean.

³ Geometric mean.

Evidence Table 2. Markers of permeability.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
<p>permeability testing in diarrheal disease</p> <p>Lactulose: rhamnose ratio (L:R) as a marker of intestinal permeability in children with or without diarrhea. Also directly compared blood and urine methods of L:R testing in a subset of subjects.</p>	<p>Hospital with diarrhea. Controls were patients admitted with non-GI illness.</p> <p>More than 75% of cases and controls were Aboriginal.</p>	<p>AD</p> <p>n=114 controls with no diarrhea</p>	<p>L:R</p> <p>Among cases:</p> <ul style="list-style-type: none"> • 24 had both blood and urine L:R • 98 had blood L:R only • 28 had urine L:R only <p>Among controls:</p> <ul style="list-style-type: none"> • 25 had both blood and urine L:R • 36 had blood L:R only • 53 had urine L:R only <p>A total of 49 subjects were tested with both blood and urine L:R methods to allow direct comparison of values.</p>	<ul style="list-style-type: none"> • Controls: 6.7 (5.0, 8.8), p=0.004 • Distribution across ratios: <ul style="list-style-type: none"> • Low: n=31 • Intermediate: n=9 • High: n=9 • Blood L:R: <ul style="list-style-type: none"> • Mean¹ (CI): <ul style="list-style-type: none"> • Cases: 9.4 (6.7, 13.1) • Controls: 5.9 (4.4, 7.8), p=0.04 • Distribution across ratios: <ul style="list-style-type: none"> • Low: n=27 • Intermediate: n=11 • High: n=11 <p>Among subjects with only urine tested: Mean² urine L:R (CI):</p> <ul style="list-style-type: none"> • Cases: 15.7 (12.6, 19.6) • Controls: 6.7 (5.7, 8.0), p<0.0001 <p>Among subjects with only blood tested: Mean³ blood L:R (CI):</p> <ul style="list-style-type: none"> • Cases: 12.8 (10.3, 16.0) • Controls: 3.7 (2.8, 4.9), p<0.0001 <p>Even though blood L:R was consistently lower than urine L:R by a geometric mean (CI) of 1.09 (1.02, 1.16), there was strong correlation between L:R ratios in blood and urine as measured by:</p> <ul style="list-style-type: none"> • Concordance correlation coefficient for agreement (CI) of 0.76 (0.64, 0.88) • Kappa statistic (CI) of 0.71 (0.51, 	<p>testing compared with controls without GI illness.</p> <p>There was substantial agreement between urine and blood L:R tests in the same subjects.</p> <p>Urine has been an established substrate for sugar excretion assessment as an indication of intestinal permeability. However, timed collection of urine is not a trivial task, especially among female children, and contamination with stool is problematic, especially in children with diarrhea. However, the much lower concentrations of probe sugars in blood compared to urine had posed a challenge to sensitive detection in blood. High performance liquid chromatography (HPLC) methods, as</p>	<p>L:R ratios used in this study:</p> <ul style="list-style-type: none"> • Blood L:R: <ul style="list-style-type: none"> • Low= <7 • Intermediate= 7-12.5 • High= >12.5 • Urinary L:R: <ul style="list-style-type: none"> • Low= <10 • Intermediate= 10-18 • High= >18 <p>Controls were significantly older than the cases, but authors suggest that age differences do not impact L:R test performance.</p> <p>Numbers of subjects do not always match up (e.g. numerator in test failure rate calculations does not match other such reported numbers).</p> <p>Analyses of those subjects who had both blood and urine testing were conducted on combined cases and controls.</p> <p>Analyses of those</p>

¹ Geometric mean.

² Geometric mean.

³ Geometric mean.

Evidence Table 2. Markers of permeability.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
				<p>0.92) (when L:R ratios are divided into 3 ordered categories)</p> <ul style="list-style-type: none"> • Sensitivity and specificity of blood tests of 81% (25/31) and 89% (16/18), respectively, when using the urine testing as the standard. <p>The failure rate* for serum L:R testing (20/197, 10%) was lower than for urine testing (86/234, 37%) (p<0.0001).</p> <p>* Defined as emesis with rhamnase/lactulose oral challenge (same dose for urine and serum testing), urine leakage or contamination with stool, or plasma quantity from blood draw of insufficient quantity for analysis.</p>	<p>used in this study, now provide a more sensitive method of assessing blood specimens.</p> <p>The failure rate of L:R blood testing was significantly lower than that of urine testing.</p>	<p>with and without diarrhea would have been of interest. One would expect children with diarrhea to have higher rates of urine test failure due to contamination with stool and to have higher failure rates using either analytes due to higher rates of emesis.</p> <p>Spot blood testing might be more feasible than timed urine collections, but HPLC might not be feasible in resource-poor settings.</p> <p>This study appears to report on the same population as two other studies in this review which also assessed serum L:R as a marker of intestinal permeability [43, 58].</p>
<p>2003</p> <p>Kukuruzovic R et al.</p> <p>Increased nitric oxide production in acute diarrhea is associated with abnormal gut</p>	<p>Darwin, Australia</p> <p>1-6 yr old Aboriginal and non-Aboriginal hospital inpatients.</p>	<p>Case-control</p> <p>n=318;</p> <p>n=169 cases with AD (154 Aboriginal)</p>	<p><u>Urine Test:</u> Nitric Oxide (NO)*</p> <p><u>Blood Tests:</u></p> <ul style="list-style-type: none"> • L:R • Mean corpuscular volume (MCV) 	<p>NO among Aboriginal children with diarrhea was >3x higher than any other group and >5x higher than in non-Aboriginal controls.</p> <ul style="list-style-type: none"> • NO was >3x and >2x higher among Aboriginal than non-Aboriginal children in the diarrhea (p<0.001) and no infections groups 	<p>NO₂ + NO₃:Cr ratio, as a measure of endogenous nitric oxide production, was used as a marker of gut permeability and inflammation, with</p>	<p>Positive stool RS was defined as ≥0.5%.</p> <p>Abnormal L:R was defined as >7.6; no reference or derivation was</p>

Evidence Table 2. Markers of permeability.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
<p>permeability, hypokalemia and malnutrition in tropical Australian aboriginal children</p> <p>Nitric oxide (NO) as a marker of intestinal permeability and inflammation, and lactulose:rhamnose ratio (L:R) as a marker of intestinal permeability and the relationship between NO and L:R, growth parameters, mean corpuscular volume (as a surrogate of iron deficiency), and stool reducing substances among children with and without diarrhea</p>	<p>Subjects were grouped as follows:</p> <ol style="list-style-type: none"> 1. Children with AD 2. Children with no diarrhea but with non-GI infectious conditions 3. Children without GI or infectious conditions 	<p>n=149 controls:</p> <ul style="list-style-type: none"> • 73 with non-GI infections (49 Aboriginal) • 76 with no infections (29 Aboriginal) 	<p><u>Stool Test:</u> Reducing substances (RS)** (169 cases tested)</p> <p>* NO is an unstable free radical and is converted to nitrite and nitrate. Urine nitrate (NO₃) + nitrite (NO₂) was expressed as a ratio with urine creatinine (NO₂ + NO₃:Cr) in order to account for differences in urine concentration.</p> <p>** Measured only among children with profuse diarrhea.</p>	<p>(p<0.001), respectively, but there was no difference between them in the non-GI infections group.</p> <ul style="list-style-type: none"> • NO was >3x and ~2x higher in the diarrhea compared to the no infections group among Aboriginals (p<0.001) and non-Aboriginals (p<0.03), respectively. • NO was virtually the same among the Aboriginal non-GI infections and no infections groups, as well as among the non-Aboriginal diarrhea and non-GI infections groups. <p>112/152 (74%) and 31/169 (18%) of children with AD had abnormal L:R ratios¹ and positive stool RS, respectively.</p> <p>NO and L:R were measured at "convalescence" on Day 5 among those with diarrhea: the mean improvement in NO was 21.7% compared with 54.6% for L:R (p=0.01).</p> <p>NO and L:R were correlated (n=193, r=0.37, p<0.001)¹; the correlation was stronger for lactulose (effect ratio=1.47, p<0.001) than for rhamnose (effect ratio=0.80, p=0.02²).</p> <p>NO was not correlated with stool RS³ or MCV, but was correlated with lower WAZ score (effect ratio=0.88, p=0.05).</p>	<p>an attempt to identify how much more it reflects as response to inflammation from GI vs. non-GI infections.</p> <p>Among non-Aboriginal controls, NO production was the same among those with diarrhea and non-GI infections (and higher compared to controls). NO was highest by far among Aboriginal children with diarrhea compared to any other group. Authors suggest that high basal concentrations of NO among Aboriginal children due to (clinically silent) enteropathy could explain the concentrations seen among Aboriginal controls in this study.</p> <p>NO appeared to decrease significantly more slowly than L:R among children</p>	<p>provided for this cut-point.</p> <p>Study population appears to be the same as in another Kukuruzovic, et al. study also included in this review which assessed serum lactulose:rhamnose as a marker of intestinal permeability [58].</p>

¹ Reported results appear to have been adjusted for age and race.

² Reported results were adjusted for age and race.

³ Reported results among children with diarrhea were adjusted for age and race.

Evidence Table 2. Markers of permeability.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
					recovering from diarrhea. NO was found to correlate with L:R. NO was more strongly correlated with lactulose than rhamnose.	
2002 Kukuruzovic RH et al. Milk formulas in acute gastroenteritis and malnutrition: a randomized trial Lactulose:rhamnose ratio (L:R) as a marker of intestinal permeability among children with diarrhea and/or malnutrition treated with milk formulas of varying composition and osmolality	Darwin, Australia Inpatient Aboriginal children <3 yr old with AD and/or WAZ score <-2. 60% of subjects had low WAZ score and 90% had diarrhea.	RCT n=177; n=60 received De-Lact formula n=65 received O-Lac formula n=52 received Alfaré formula Subjects were treated with one of three low-lactose formulas: • De-Lact, low-osmolality lactose-free formula • O-Lac, lactose-free formula • Alfaré, partially hydrolyzed formula	<u>Blood Test:</u> L:R L:R testing was repeated in 150 subjects at day 5: • De-Lact: n=48 • O-Lac: n=52 • Alfaré: n=50	Baseline mean ¹ L:R (CI) in De-Lact group was 14.9 (10.4, 21.5), with no difference between groups. The mean improvement* in L:R (CI) was 13.0 (9.3, 16.6) with some significant differences between the various formulas: • De-Lact: 18.6 (10.6, 26.6) • O-Lac: 12.0 (7.5, 16.6), p=0.15 compared to De-Lact • Alfaré: 8.5 (2.1, 14.9), p=0.049 compared to De-Lact * Improvement in L:R was calculated as baseline L:R minus repeat L:R.	Authors noted that treatment with all of the low-lactose formulas studied resulted in improved L:R among this population at risk for enteropathy and growth failure. Improvement was most marked with the low osmolality formula, De-Lact.	Reported results did not appear to be harmonized with the method described for calculating improvement in L:R. Fully breastfed children were excluded. The study did not include a control arm (of standard care) to which change in L:R could be compared. Authors reiterate the advantages of serum over timed urine collection for assessment of L:R as discussed in another publication in this review [125].
2002 Kukuruzovic RH et al.	Darwin, Australia Cases were Aboriginal and	Case-control n=375 admissions for 306 children;	<u>Blood Tests:</u> • Lactose • Lactulose ² • Rhamnose	27/75 (36%) of Aboriginal controls and 0 non-Aboriginal controls had abnormal L:R ratios.	Mean L:R ratios of Aboriginal children were approximately double those of non-	Positive stool RS was defined as ≥0.5%.

¹ Geometric mean.

² Lactulose and rhamnose results were expressed as % of dose administered.

Evidence Table 2. Markers of permeability.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
Small bowel intestinal permeability in Australian Aboriginal children Serum lactulose: rhamnose ratio (L:R), serum lactose, and stool reducing substances as markers of intestinal permeability among Aboriginal and non-Aboriginal children with and without diarrhea	non-Aboriginal children admitted to hospital with diarrhea. Controls were Aboriginal and non-Aboriginal children admitted without GI illnesses.	n=285 case admissions for AD (264 Aboriginal) n=90 control admissions with no diarrhea (74 Aboriginal)	<ul style="list-style-type: none"> • L:R • Hemoglobin • Mean corpuscular volume (MCV) <p>Stool Test: Reducing substances (RS)*</p> <p>L:R testing was repeated on day 5 for a subset of Aboriginal subjects: <ul style="list-style-type: none"> • 174/264 admissions for acute diarrhea • 25/74 control admissions </p> <p>* Measured only among children with profuse diarrhea when "clinically indicated." Number tested not provided.</p>	<p>Mean¹ L:R at baseline: Cases:</p> <ul style="list-style-type: none"> • Aboriginal: 16.4 • Non-Aboriginal: 7.9, p=0.002 compared to Aboriginal cases <p>Controls:</p> <ul style="list-style-type: none"> • Aboriginal: 4.6 • Non-Aboriginal: 2.5, p=0.02 compared to Aboriginal controls <p>Mean improvement² in L:R (CI) at day 5 among those with repeat testing:</p> <ul style="list-style-type: none"> • Aboriginal cases: 14.6 (11.2, 18.0) • Aboriginal controls: -0.63 (-4.0, 2.7) <p>Mean lactulose recovery³:</p> <ul style="list-style-type: none"> • Cases day 1: 0.085 (0.070–0.103) • Cases day 5: 0.039 (0.033–0.046) • Controls: 0.024 (0.019–0.029) <p>All 3 values significantly differed from one another.</p> <p>Mean rhamnose recovery:</p> <ul style="list-style-type: none"> • Cases day 1: 0.479 (0.424–0.542) • Cases day 5: 0.555 (0.498–0.616) • Controls: 0.585 (0.500–0.685) <p>These values did not significantly differ from one another.</p> <p>Confidence intervals (CIs) in the authors' graphical representation of mean L:R at admission did not overlap, and the difference in means was particularly evident between Aboriginal and non-Aboriginal subjects.</p>	<p>Aboriginal children both among those with and without diarrhea, consistent with authors' suggestion that clinically silent enteropathy is prevalent among Aboriginal children.</p> <p>Mean L:R significantly improved over 5 days among Aboriginal cases. Children with severe diarrhea had higher mean L:R.</p> <p>Higher case L:R was driven more by high lactulose than by low rhamnose. Similarly, improvement in L:R among cases was primarily due to decreased lactulose.</p> <p>Stool RS and serum lactose were found in approximately one-quarter and one-third of Aboriginal cases, respectively. The latter was weakly associated with</p>	<p>Abnormal L:R was defined as >5.6, derived from 2 SD above the arithmetic mean for non-Aboriginal controls in this study. The rationale for the choice of 2 SD above the arithmetic, instead of the geometric, mean is not clear. Proportions of cases with abnormal concentrations were not reported.</p> <p>Analysis included data for 69 children with repeat admissions; this might violate independence assumptions for their statistical analysis methods.</p> <p>Repeat L:R testing was conducted on controls of both racial groups, but among cases it was only conducted on Aboriginal cases.</p> <p>This study appears to report on the</p>

¹ Geometric mean.

² Improvement in L:R appears to have been calculated as baseline L:R minus repeat L:R, as described in another publication in this review; however, this was not expressly stated. Reference 134. Kukuruzovic RH, Brewster DR. Milk formulas in acute gastroenteritis and malnutrition: a randomized trial. J Paediatr Child Health, 2002. 38(6):571-577.

³ Figures reported parenthetically after the mean percent recoveries of lactulose and rhamnose were not specified as ranges or CIs.

Evidence Table 2. Markers of permeability.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
				<p>Factors associated with L:R among cases were¹:</p> <ul style="list-style-type: none"> • Acidosis (p=0.007) • Hypokalemia (p=0.035) • Diarrhea severity (p=0.001) <p>Age and malnutrition were not associated with L:R.</p> <p>38% and 27% of Aboriginal cases had positive serum lactose and stool RS, respectively. 12% of Aboriginal and non-Aboriginal controls combined had lactosemia.</p> <p>Presence of lactosemia was associated with L:R, adjusted relative risk (CI)=1.06 (1.03, 1.10)². Stool RS, anemia, and MCV were not associated with L:R.</p>	increased lactulose.	<p>same population as in the Kukuruzovic, et al. 2003 reference also included in this review, which assessed nitric oxide excretion [43].</p> <p>Authors reiterate the advantages of serum over timed urine collection for assessment of L:R, as discussed in another publication in this review [125].</p>
<p>2010</p> <p>Lima AA et al.</p> <p>Effects of vitamin A supplementation on intestinal barrier function, growth, total parasitic, and specific <i>Giardia</i> spp infections in Brazilian children: a prospective randomized, double-blind, placebo-controlled trial</p> <p>L:M as a marker of intestinal barrier function, and stool</p>	<p>Fortaleza, Brazil</p> <p>2 mo-9 yr olds (mean 43 mo) from an impoverished urban community, eligible if HAZ score was <median for their community.</p> <p>Subjects were screened for intestinal parasites, and longitudinal anthropometrics were assessed.</p>	<p>RCT</p> <p>n=79;</p> <p>n=40 received placebo (tocopherol)</p> <p>n=39 received vitamin A (retinyl palmitate)</p> <p>Subjects were treated every 4 mo.</p>	<p>Urine Tests:</p> <ul style="list-style-type: none"> • Lactulose³ • Mannitol • L:M <p>Stool Tests:</p> <ul style="list-style-type: none"> • Lactoferrin • Cytokines: <ul style="list-style-type: none"> • IFN-γ • TNF-α • IL-4 • IL-10 	<p>Median L:M at baseline was 0.089. There was no significant change in L:M at 4 mo follow-up within either treatment group.</p> <p>No significant difference in L:M was observed between treatment groups.</p> <p>Both median lactulose and mannitol excretions decreased at 4 mo follow-up among the vitamin A compared to the placebo group:</p> <ul style="list-style-type: none"> • Lactulose: 0.21 to 0.74, p=0.042 • Mannitol: 3.06 to 8.25, p=0.008 <p>Overall proportion of lactoferrin was 23% initially. At 1 mo follow-up, there was no difference in prevalence between vitamin A (33%) and</p>	<p>Frequency of stool lactoferrin varied between 23%-32%.</p> <p>While vitamin A supplementation was associated with reduced lactulose excretion, it was also associated with reduced mannitol excretion, with no overall effect on L:M.</p> <p>Vitamin A supplementation was not associated with presence of lactoferrin or</p>	<p>Authors did not report testing for associations between urinary markers of intestinal permeability and concentrations of fecal cytokines, or between these markers and growth parameters or parasitosis.</p> <p>Cut-point values for lactoferrin positivity and abnormal L:M were not described.</p>

¹ Reported results were adjusted for confounding variables, unless otherwise noted.

² Reported results were adjusted for severity of diarrhea, acidosis, hypokalemia, and age.

³ For lactulose and mannitol results, excretion measurement was not specified.

Evidence Table 2. Markers of permeability.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
lactoferrin and specific intestinal immunological cytokines as markers of intestinal inflammation among nutritionally at-risk children who received either vitamin A or placebo				placebo (31%) groups. Cytokine concentrations did not significantly differ between placebo and vitamin A groups.	intestinal cytokine response.	Exclusively breastfed children were excluded from study participation due to assessment of stool lactoferrin.
2005 Lima AA et al. Intestinal barrier function and weight gain in malnourished children taking glutamine-supplemented enteral formula L:M as a marker of intestinal permeability and various stool tests among children with malnutrition or PD who received either glycine or glutamine supplemented formula or placebo	Fortaleza, Brazil 2-60 mo olds hospitalized with WAZ score <-2, ~70% of whom had PD.	RCT n=80; n=53 received supplemented formula <ul style="list-style-type: none"> • 27 with glycine • 26 with glutamine n=27 received nonsupplemented formula	<u>Urine Tests*</u> : <ul style="list-style-type: none"> • Lactulose¹ • Mannitol • L:M <u>Stool Tests**</u> : <ul style="list-style-type: none"> • Lactoferrin • Leukocytes • Occult blood • Reducing substances (RS) * n=80 tested at enrollment, n=65 tested at day 10. ** n=60 tested.	Mean ² L:M (SE): <ul style="list-style-type: none"> • Glutamine group: <ul style="list-style-type: none"> • Baseline: 0.31 (0.10) (similar in all three groups) • Day 10: 0.10 (0.02); significant decrease, (p=0.01) • No significant decrease in L:M in glycine and nonsupplemented formula groups at day 10 Mean lactulose (SE): <ul style="list-style-type: none"> • Glutamine group: <ul style="list-style-type: none"> • Baseline: 0.97 (0.46) (similar in all three groups) • Day 10: NS decrease in all 3 groups Mean mannitol (SE): <ul style="list-style-type: none"> • Glutamine group: <ul style="list-style-type: none"> • Baseline: 3.42 (0.64) (similar in all three groups) • Day 10: NS decrease in all 3 groups Proportion of stool markers at baseline among all subjects: <ul style="list-style-type: none"> • Lactoferrin: 53.3% • Leukocytes: 11.7% • RS: 3.3% • Occult blood: 5.0% 	L:M significantly improved in the glutamine group only. >50% of subjects had intestinal inflammation by stool lactoferrin. Fecal leukocytes, RS, and occult blood were detected in fewer subjects than lactoferrin.	The relationship between stool markers and L:M was not reported. Data were not stratified by history of PD. Fecal fat was assessed, but results were not reported. Cut-off values for lactoferrin positivity were not described. Exclusively breastfed children were excluded from study participation due to assessment of stool lactoferrin.

¹ Lactulose and mannitol results were expressed as % of dose administered.

² Type of mean not specified.

Evidence Table 2. Markers of permeability.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
<p>2007</p> <p>Lima NL et al.</p> <p>Wasting and intestinal barrier function in children taking alanyl-glutamine-supplemented enteral formula</p> <p>L:M as a marker of intestinal permeability in assessing alanyl-glutamine supplement to improve intestinal barrier function in malnourished children compared to glycine-containing placebo supplement</p>	<p>Parque Universitario, Fortaleza, Brazil</p> <p>6 mo-8 yr olds (mean age 3.5 yr) from an urban setting with HAZ, WAZ, or WHZ scores <-1.</p>	<p>RCT</p> <p>n=107;</p> <p>n=51 received alanyl-glutamine treatment</p> <p>n=56 received glycine placebo</p>	<p><u>Urine Tests:</u></p> <ul style="list-style-type: none"> • Lactulose¹ • Mannitol • L:M 	<p>L:M median (range) at baseline:</p> <ul style="list-style-type: none"> • Treatment: 0.0385 (0.8922 [sic]) • Placebo: 0.0302 (5.5812 [sic]) <p>Lactulose and mannitol excretion both significantly decreased in the treatment group only (p=0.05 for both sugars)². L:M did not change significantly within or across groups days after treatment.</p> <p>Lactulose excretion was not associated with WHZ, WAZ or HAZ scores in either group³. Mannitol was not associated with growth parameters in the control group, but was associated with WHZ (r²=-0.386, p=0.027) and WAZ (r²=-0.385, p=0.027) scores in the supplemented group. Data for L:M and growth parameter association was not provided.</p>	<p>Even though lactulose excretion improved in the treatment group, mannitol excretion worsened with overall L:M not changing.</p> <p>Lactulose, mannitol and L:M did not change significantly in the placebo group.</p>	<p>Authors state that L:M median and range values were within the confidence interval for values of healthy children in the study community; no reference was cited.</p> <p>Although the authors defined persistent and chronic diarrhea in their methods, they did not report data stratified according to these conditions.</p> <p>Authors provide negative R² values when reporting Pearson's correlation analysis results; these likely actually represent r values.</p>
<p>2001</p> <p>Northrop-Clewes CA et al.</p> <p>Anthelmintic treatment of rural Bangladeshi children: effect on host physiology, growth, and biochemical status</p>	<p>Jamalpur district, northern Bangladesh</p> <p>2-5 yr olds from poor rural villages, sampled randomly from a larger cohort study.</p>	<p>RCT*</p> <p>n=109;</p> <p>n=54 received bimonthly empiric antihelminthic treatment</p> <p>n=55 received</p>	<p><u>Blood Tests</u></p> <ul style="list-style-type: none"> • α 1-antichymotrypsin • Albumin • Total protein <p><u>Urine Test:</u></p> <p>L:M</p>	<p>Mean L:M⁴ at baseline:</p> <ul style="list-style-type: none"> • Treatment: 0.22 • Placebo: 0.25 <p>Seasonal variation in L:M was observed, with highest values following the monsoon season.</p> <p>Within-subject L:M analysis showed</p>	<p>L:M ratios were high overall and demonstrated seasonal variation.</p> <p>Intra-individual L:M values did not change significantly over time, nor were they associated with</p>	<p>Baseline study data were lost, so analysis began with samples taken at month 2.</p> <p>The relationship between the serum markers and intestinal</p>

¹ Lactulose and mannitol results were expressed as % of dose administered.

² Reported results were adjusted for age and season.

³ Reported results were adjusted for age and season.

⁴ Geometric mean.

Evidence Table 2. Markers of permeability.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
L:M as a marker of intestinal permeability, and α 1-antichymotrypsin as a marker of inflammation and immune activation to treatment among children randomized to bimonthly antihelminthics or placebo.	Stools were assessed for helminthiasis and giardiasis. Growth was followed longitudinally.	placebo * Randomized at the village level.	Among 93 subjects with L:M at baseline: • 46 received treatment • 47 received placebo Among 66 subjects with repeated L:M testing: • 34 received treatment • 32 received placebo	no significant association with intestinal helminthiasis and no significant improvement in treatment or placebo groups over 1 yr. L:M was generally not associated with giardiasis (with the exception of one group at one study interval). L:M was inversely correlated with Δ HAZ and Δ WAZ scores at some of the follow-up intervals ($r=-0.22$, $p<0.02$ and $r=-0.21$, $p<0.05$, respectively, at 12 mo follow-up visit). Mean serum ACT, albumin and total protein were within normal ranges and were not associated with growth parameters. ACT and albumin concentrations did not significantly change with treatment, whereas total protein concentrations did ($p<0.001$).	helminthiasis or consistently associated with giardiasis. Inverse correlations were seen between L:M and growth parameters. Serum markers were within normal range. The only significant change in these markers was a decrease in total protein in the treatment group without concomitant change in albumin; this suggested a decrease in globulins (not directly measured), perhaps due to decreased inflammation.	permeability was not reported.
2009 Panter-Brick C et al. Pathways leading to early growth faltering: An investigation into the importance of mucosal damage and immunostimulation in different socio-economic groups in Nepal	Kathmandu, Nepal 3-18 mo olds in two cohorts: 1. All children in target age range from four squatter settlements Randomly selected, age-matched cohort from lower middle-class, periurban	Cohort n=86; n=48 in squatter cohort n=38 in lower middle-class cohort	Urine Test: Lactose:Cr Blood Test: Hemoglobin	Mean ¹ Lactose:Cr (CI): • Squatter: 0.14 (0.12, 0.16) • Middle Class: 0.08 (0.07, 0.10) • Statistically significant difference between the 2 groups among the 6-12 mo olds ($p=0.007$) and 18-24 mo olds ($p=0.002$), but not among 12-18 mo olds. • For both SES groups, Lactose:Cr values decreased with increasing age ($p<0.001$). HAZ, WAZ, WHZ, and Δ WAZ scores were strongly associated with mean	Authors speculate that Lactose:Cr accounted for less of the deterioration in nutritional status among the squatter children because of several factors, including poorer nutritional intake, that impact the nutritional status of children with lower socio-economic	Specific sugar excretion was normalized to urinary creatinine to control for variation in renal function. Authors suggest that while Lactose:Cr might not be as accurate as L:M, it might be a more field-friendly assessment of

¹ Geometric mean.

Evidence Table 2. Markers of permeability.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
Lactose:creatinine ratio (Lactose:Cr) as a marker of intestinal permeability and hemoglobin, albumin, α -1-acid glycoprotein, and IgG as markers of immunostimulation. The latter were also assessed for their relationship to nutritional status.	households			Lactose:Cr ($p < 0.001$ each) as was Δ HAZ score ($p = 0.004$); Δ WHZ score was not. The strength and magnitude of association between Δ WAZ score and Lactose:Cr was most pronounced among the wealthier cohort and there was no association between Δ HAZ score and Lactose:Cr among the squatter children. Hemoglobin concentrations were inversely related to Lactose:Cr ($r^2 = 0.018$, $p < 0.001$).	status.	mucosal damage compared to L:M, requiring only spot urine collection and no substrate dosing. However, L:M was not assessed in this study; direct comparison of the two tests was not possible. While hemoglobin concentration was inversely related to Lactose:Cr, testing for associations of other measured blood markers (IgG, AGP and albumin) with Lactose:Cr was not reported.
2000 Quadro L et al. Retinol and retinol-binding protein: gut integrity and circulating immunoglobulins L:M as a marker of small intestinal permeability, and its correlation with serum retinol among mildly malnourished children	Goncalves Dias favela in Fortaleza, Brazil 1-9 yr olds with mild malnutrition selected from a large cohort of children from an urban slum. They were recruited at birth and followed longitudinally. 19 (63%) had some degree of vitamin A deficiency—all of	Cross-sectional n =30	<u>Urine Tests:</u> • Lactulose ¹ • Mannitol • L:M	80% of subjects had abnormal L:M, defined as ≥ 0.030 . Serum retinol was: • Inversely correlated with L:M ($r = 0.46$, $p = 0.012$) • Directly correlated with mannitol ($r = 0.66$, $p < 0.01$) Not correlated with lactulose (data not reported)	Children with low serum retinol had higher L:M, apparently mediated by mannitol excretion.	The L:M normal cutoff was defined lower than for most other L:M studies, as 0.030. The authors reference several studies regarding use of this cut point.

¹ Lactulose and mannitol results were expressed as % of dose administered.

Evidence Table 2. Markers of permeability.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
	these had mild deficiency, except for 2 with moderately low concentrations.					
<p>2004</p> <p>Rabbani GH et al.</p> <p>Green banana and pectin improve small intestinal permeability and reduce fluid loss in Bangladeshi children with persistent diarrhea</p> <p>L:M as a marker of intestinal permeability among infants with PD who are treated with green banana, pectin, or rice diet</p>	<p>Dhaka, Bangladesh</p> <p>5-12 mo old males admitted to the hospital of the International Centre for Diarrhoeal Disease Research with PD but without other illnesses.</p>	<p>RCT</p> <p>n=57;</p> <p>n=19 received green banana and rice</p> <p>n=17 received pectin and rice</p> <p>n=21 received rice alone (placebo)</p>	<p>Urine Tests:</p> <ul style="list-style-type: none"> • Lactulose¹ • Mannitol • L:M 	<p>Mean L:M (SD) by treatment group, pre- and post-treatment:</p> <ul style="list-style-type: none"> • Banana: pre=0.50 (0.14), post=0.21 (0.12), p<0.01 • Pectin: pre=0.54 (0.17), post=0.23 (0.09), p<0.01 • Placebo: pre=0.41 (0.11), post=0.45 (0.13), p>0.6 <p>Lactulose and mannitol excretion did not differ between groups at baseline.</p> <p>Lactulose excretion was not significantly reduced after intervention in the placebo group.</p> <p>Mean (SD):</p> <ul style="list-style-type: none"> • Pre-treatment: 1.45 (0.12) • Post-treatment: 1.35 (0.15) <p>Both treatment groups had 70-80% reduced lactulose excretion following treatment (p<0.01).</p> <p>Mannitol excretion increased in all groups compared to their pre-treatment values, but only significantly so in the banana and pectin groups (p<0.05).</p> <p>Mean mannitol % excretion (SD), pre- vs. post-treatment:</p> <ul style="list-style-type: none"> • Banana: 1.82 (0.13) vs. 3.21 (0.16) • Pectin: 1.91 (0.12) vs. 3.2 (0.18) • Placebo: 2.10 (0.11) vs. 2.33 	<p>L:M values were high at baseline among the study population of inpatient young children with PD. Mean L:M significantly improved with the green banana or pectin intervention but were still above normal range following 7 days of treatment. The improvements in L:M were driven by both mannitol and lactulose, with the latter having an impact of greater magnitude.</p> <p>Authors cite studies postulating that the effectiveness of green banana in reducing diarrheal fluid loss is due to its high content of amylase-resistant starch, which undergoes bacterial fermentation into short-chain fatty</p>	

¹ Lactulose and mannitol results were expressed as % of dose administered.

Evidence Table 2. Markers of permeability.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
				(0.18) The banana and pectin groups stopped having diarrhea more often compared to controls (e.g. $p < 0.01$ by day 4). Among the banana and pectin groups, stool reductions were associated with percent change in L:M before and after treatment ($R^2 = 0.84$ for pectin and $R^2 = 0.86$ for banana; $p < 0.05$ for each).	acids in the colon, stimulating colonic salt and water absorption. Pectin is thought to work by a similar mechanism. Authors also suggest that short chain fatty acids might affect entero-hormones and growth factors, resulting in the observed changes in intestinal permeability [206].	
2009 Ritchie BK et al. 13C-sucrose breath test: novel use of a noninvasive biomarker of environmental gut health Sucrose breath test (SBT) as a marker of small bowel mucosal damage vis a vis sucrose activity among an Australian Aboriginal population. Also compared SBT with serum lactulose:rhamnose ratio (L:R)	Darwin and Adelaide, Australia 4 mo-5 yr old Aboriginal children admitted to hospital with diarrhea. Two control groups: 1. Aboriginal controls admitted to hospital with non-GI symptoms (50% had pneumonia) 2. Healthy, non-Aboriginal controls recruited from community	Case-control n=43; n=18 Aboriginal cases with AD n=25 controls: • 18 Aboriginal, without diarrhea • 7 non-Aboriginal, healthy	<u>Blood Tests:</u> • L:R (32 Aboriginal cases and controls tested) • C-reactive protein (CRP) • Mean Corpuscular Volume (MCV) • Hemoglobin <u>Breath Test:</u> ¹³ C sucrose breath test (SBT)	20/32 (63%) of Aboriginal children had abnormal L:R ratios. Mean ¹ L:R (CI): • Diarrhea cases: 31.8 (24.9, 40.7) • Aboriginal controls without diarrhea: 11.4 (8.5, 15.5), significant difference ($p < 0.0001$) SBT Mean (CI): • Diarrhea cases: 1.9% (0.9, 3.0), $p < 0.0001$ compared to non-Aboriginal controls and $p = 0.004$ compared to Aboriginal controls • Aboriginal controls: 4.1% (3.0, 5.2), $p = 0.032$ compared to non-Aboriginal controls • Non-Aboriginal controls: 6.1% (4.8, 7.3) Significant differences were observed between all three groups. SBT results were not associated with wasting or with patient age or breastfeeding status.	SBT values were significantly lower and L:R values were significantly higher among Aboriginal children with diarrhea than among those without GI symptoms. SBT was also significantly lower among Aboriginal controls than among non-Aboriginal children without diarrhea. This is consistent with previous reports of high prevalence of clinically silent TE in this population. SBT was significantly inversely correlated with L:R.	Abnormal L:R ratios were defined as > 16 ; no reference or derivation was provided for this cut-point. L:R test was not conducted among the non-Aboriginal controls. SBT/L:R correlation analysis was based on data for Aboriginal cases and controls combined; stratified analysis was not reported and could be of interest considering the large difference in L:R observed between these

¹ Geometric mean.

Evidence Table 2. Markers of permeability.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
				<p>SBT and L:R were inversely correlated ($r=0.67$; CI: 0.42, 0.62; $p<0.0001$). L:R explained 45% of the variance in SBT; diarrhea explained 28% of variance.</p> <p>SBT was associated with increased MCV, relative risk (CI)=3.9 (2.8, 5.0). SBT was not associated with hemoglobin or CRP.</p>		<p>groups.</p> <p>Associations of MCV, CRP, and hemoglobin with SBT after adjusting for potentially confounding variables were not reported.</p>
<p>2001</p> <p>Rollins NC et al.</p> <p>Feeding mode, intestinal permeability, and neopterin excretion: A longitudinal study in infants of HIV-infected South African women</p> <p>L:M as a marker of gut mucosal integrity and urinary neopterin excretion as a marker of cell-mediated immunity in infants with and without HIV infection</p>	<p>Durban, South Africa</p> <p>1, 6, and 14 wk old infants born to HIV-infected mothers.</p>	<p>Cohort</p> <p>n=272</p>	<p>Urine Tests:</p> <ul style="list-style-type: none"> • Lactulose¹ • Mannitol • L:M • Neopterin 	<p>Mean² L:M (CI):</p> <ul style="list-style-type: none"> • HIV-infected subjects: <ul style="list-style-type: none"> • 1 wk: 0.12 (0.06, 0.27) • 6 wk: 0.24 (0.15, 0.38) • 14 wk: 0.24 (0.14, 0.44) • Uninfected subjects: <ul style="list-style-type: none"> • 1 wk: 0.13 (0.09, 0.19) • 6 wk: 0.08 (0.06, 0.11) • 14 wk: 0.09 (0.07, 0.13) <p>HIV-infection by 14 wk of age was significantly associated with increased L:M.</p> <p>A non-significant, positive trend in neopterin excretion was observed among HIV-infected infants.</p>	<p>L:M was generally normal (compared to UK values) for non-HIV-infected infants, but significantly increased among HIV-infected subjects, especially after 6 weeks.</p> <p>The increased L:M in HIV-infected infants was primarily driven by lactulose rather than mannitol.</p> <p>Higher neopterin excretion by HIV-infected infants was observed but this was not statistically significant.</p>	<p>Assessment of association between L:M and neopterin was not reported.</p>
<p>2000</p> <p>Rollins NC et al.</p> <p>Vitamin A</p>	<p>Durban, South Africa</p> <p>6-60 mo old inpatients or</p>	<p>RCT</p> <p>n=139;</p> <p>n=66 received</p>	<p>Urine Tests:</p> <ul style="list-style-type: none"> • Lactulose³ • Mannitol • L:M • Neopterin 	<p>Mean⁴ L:M:</p> <ul style="list-style-type: none"> • Group 1: <ul style="list-style-type: none"> • Day 0: ~1.8 • Day 3: ~2.4 • Group 2: 	<p>Mean L:M ratios were very high (~10x) (at baseline and at day 3 in both groups) compared to</p>	<p>Urine testing could only be conducted in the laboratory on certain days; hence only a subset of</p>

¹ Lactulose and mannitol results were expressed in mg.

² Geometric mean.

³ For lactulose, mannitol, and neopterin results, excretion measurement was not specified.

⁴ Geometric mean.

Evidence Table 2. Markers of permeability.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
<p>supplementation of South African children with diarrhea: optimum timing for improving biochemical and clinical recovery and subsequent vitamin A status</p> <p>L:M as a marker of intestinal permeability and urinary neopterin, serum α-1 acid glycoprotein, and C-reactive protein as markers of inflammation among children with severe diarrhea</p>	<p>outpatients with severe diarrhea.</p>	<p>vitamin A on admission (group 1)</p> <p>n=73 received vitamin A after clinical improvement (group 2)</p> <p>Treatment involved vitamin A supplementation either on the day of admission or after acute diarrheal symptoms had resolved.</p>	<p><u>Blood Tests:</u></p> <ul style="list-style-type: none"> • C-reactive protein (CRP) • α-1 acid glycoprotein (AGP) <p>49 subjects received urine testing:</p> <ul style="list-style-type: none"> • Group 1: n=25 • Group 2: n=24 <p>Blood and urine were tested on days 0 and 3.</p>	<ul style="list-style-type: none"> • Day 0: ~1.2 • Day 3: ~0.7 <p>There were no differences in mean L:M between groups or within groups between days 0 and 3, although there was a significant difference in paired analysis within individuals at the two time points (data not presented, and direction, magnitude and degree of significance not reported).</p> <p>Lactulose and mannitol excretion were assessed only in the paired analysis. Lactulose excretion decreased between days 0 and 3 (magnitude of effect and degree of significance not reported), while mannitol excretion showed no change.</p> <p>Mean¹ neopterin and AGP concentrations did not differ between groups or within groups on the different study days or in the paired analysis. When initial CRP (~2x higher in Group 2 compared to Group 1, p<0.004) was taken into account, mean CRP on day 3 did not differ between the 2 groups. However in the paired analysis, CRP concentrations were significantly different between days 0 and 3.</p>	<p>other studies in this review. Study authors suggested (via personal correspondence) that this could have been due to the severity of illness in the sample population (children hospitalized for diarrhea).</p> <p>Vitamin A administration did not result in significant improvement in L:M, neopterin, or AGP regardless of timing of vitamin A administration.</p>	<p>subjects underwent those tests.</p> <p>Group 2 patients had significantly higher CRP, non-significantly higher WBCs and AGP, and lower retinol and retinol-binding protein concentration compared to group 1 at baseline. Authors note that these parameters suggest that Group 2 patients might have been more ill at baseline. For the subset of 49 patients undergoing urine testing, the mean L:M and neopterin concentrations were lower among Group 2 than Group 1 subjects (NS). However, baseline differences in acute phase and vitamin A markers at baseline were not reported separately for these 49 subjects.</p> <p>Data for lactulose and mannitol excretion were not</p>

¹ Geometric mean.

Evidence Table 2. Markers of permeability.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
						<p>reported separately. Rationale for additional analyses of these molecules expressed as ratios with creatinine was not explained.</p> <p>Authors suggest that their 3-day testing period (based on their previous work in a different setting [207] might have been too short to identify effect as demonstrated by McCullough et al. at 10 days after presentation [208].</p>
<p>2000</p> <p>Thurnham DI et al.</p> <p>Innate immunity, gut integrity, and vitamin A in Gambian and Indian infants</p> <p>L:M as a marker of intestinal integrity among children receiving vitamin A supplementation</p>	<p>Orissa State, India</p> <p>Subjects were recruited from 2 sources:</p> <ol style="list-style-type: none"> Hospital-based infants admitted for "diarrheal or respiratory disease," mean age 9 mo Clinic-based infants with "minor ailments", age not specified 	<p>RCT</p> <p>n=174;</p> <p>n=94 hospital-based</p> <ul style="list-style-type: none"> 31 received vitamin A at day 1 32 received vitamin A at discharge (up to day 5) 31 received placebo <p>n=80 clinic-based*</p> <p>Clinic-based subjects were</p>	<p>Urine Test: L:M</p> <p>For hospital-based subjects, L:M was assessed at baseline, discharge from hospital, and 10 or 30 days after discharge.</p> <p>For clinic-based subjects, L:M was assessed at baseline, 4, and 8 wk.</p>	<p>Mean L:M was ~3-fold higher among hospitalized compared to clinic patients at baseline. Within the allocation groups, mean baseline L:M did not differ for either the hospitalized or clinic subjects.</p> <p>Among the hospital cohort, mean L:M declined significantly in the two vitamin A groups compared to the placebo group, and remained lower at day 30 among the treatment groups, but the difference was no longer significant compared to the placebo group.</p> <p>Among the clinic cohort, mean L:M reduction was accelerated in vitamin A-supplemented children. However, mean L:M did not significantly differ between treatment groups at any time point.</p>	<p>Mean L:M values, including post-intervention values, were 2-5 times higher than those observed in the UK [209].</p> <p>L:M reduction was accelerated among vitamin A-supplemented children, but end-of-study mean values did not differ statistically between allocation groups in either the clinic or the hospital cohorts.</p>	<p>Precise numerical values were not reported, rather L:M results were portrayed in figures with units expressed in mg, making it difficult to compare these results to those of other studies.</p> <p>Information on study design, such as randomization scheme, was limited.</p> <p>The article also reported re-analyzed data from a 1991 report from</p>

Evidence Table 2. Markers of permeability.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
		<p>randomized to receive vitamin A weekly for 8 wk or placebo.</p> <p>* Number of subjects in each treatment group was not specified.</p>		<p>The rate of decline in L:M was most steep among the vitamin A-treated hospitalized patients, in whom the mean L:M value decreased by 63% over 30 days, followed by placebo-treated hospitalized patients, with a decrease of 38% over 30 days. Mean L:M decreased by 57% in the vitamin A-treated clinic patients, while there was no change in L:M among the clinic placebo group.</p>		The Gambia [209].
<p>2009</p> <p>Trehan I et al.</p> <p>A randomized, double-blind, placebo-controlled trial of rifaximin, a nonabsorbable antibiotic, in the treatment of tropical enteropathy</p> <p>L:M, sucrose:lactulose, and sucralose:lactulose as markers of small intestinal, gastric, and colonic permeability, respectively, among those receiving rifaximin or placebo</p>	<p>Limela, Malawi</p> <p>All 3-5 yr olds from the village were recruited.</p>	<p>RCT</p> <p>n=144;</p> <p>n=72 received rifaximin for 7 days</p> <p>n=72 received placebo</p> <p>It was presumed that if SBBO is the etiology for enteropathy, treatment with rifaximin would result in improved intestinal integrity.</p>	<p><u>Urine Tests</u></p> <ul style="list-style-type: none"> • Lactulose¹ • Mannitol • Sucrose (SUC) • Sucralose (SCL) • L:M² • Sucrose:lactulose ratio (SUC:L) • Sucralose:lactulose ratio (SCL:L) <p>Subjects were tested before and after treatment.</p>	<p>At enrollment:</p> <ul style="list-style-type: none"> • Mean mannitol (SD): <ul style="list-style-type: none"> • Treatment: 9.57 (5.24) • Placebo: 10.29 (6.62) • Mean lactulose (SD): <ul style="list-style-type: none"> • Treatment: 0.30 (0.18) • Placebo: 0.34 (0.25) • Mean SUC (SD): <ul style="list-style-type: none"> • Treatment: 0.062 (0.04) • Placebo: 0.074 (0.058) • Mean SCL (SD): <ul style="list-style-type: none"> • Treatment: 0.51 (0.29) • Placebo: 0.58 (0.53) • Mean L:M (SD): <ul style="list-style-type: none"> • Treatment: 0.18 (0.12) • Placebo: 0.17 (0.09) • Mean SUC:L (SD): <ul style="list-style-type: none"> • Treatment: 0.50 (0.34) • Placebo: 0.64 (0.90) • Mean SCL:L (SD): <ul style="list-style-type: none"> • Treatment: 0.42 (0.32) • Placebo: 0.39 (0.23) • For both groups combined: <ul style="list-style-type: none"> • 76% had L:M >0.10 • 34% had L:M >0.20 <p>No significant post- intervention</p>	<p>There was a high proportion with elevated L:M which did not change with rifaximin treatment.</p> <p>Baseline L:M measurements in this study resembled those of another Malawian population in similar environmental conditions [120].</p> <p>SCL excretion in this population was similar to that found in healthy American children (0.4%), while SCL:L was comparatively lower (0.8) and driven by lactulose [210]. SCL:L might be a better marker of colonic permeability [211-213]. Results</p>	<p>Methodological differences in specimen collection and testing, in particular for SCL excretion, might account for some differences in values compared to other studies.</p> <p>This was the first use of SCL for site-specific absorption testing in a developing country setting.</p>

¹ Lactulose, mannitol, SUC, and SCL results were expressed as % of dose administered.

² Type of mean for sugar ratios not specified.

Evidence Table 2. Markers of permeability.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
				differences were observed in any fractional sugar excretion or dual sugar test, including among children with elevated pre-intervention L:M.	<p>from this study potentially indicate that colonic permeability was normal.</p> <p>Few data exist on SUC excretion. Results in this trial are similar to those found in another Malawian population (0.06% SUC excretion) [120] and high compared to healthy older children from developed country settings (0.02-0.03%) [210, 212].</p>	
<p>2008</p> <p>Vieira MM et al.</p> <p>Carotenoids, retinol, and intestinal barrier function in children from northeastern Brazil</p> <p>L:M as marker of intestinal barrier function, fecal lactoferrin and leukocytes as markers of intestinal inflammation, and CRP and AGP as acute phase reactants among children with varying vitamin A</p>	<p>Fortaleza, Brazil</p> <p>2 mo-9 yr olds (mean age 41 mo) from an impoverished urban community, eligible if HAZ score <median for their community.</p>	<p>Cross-sectional</p> <p>n=102</p>	<p><u>Urine Tests:</u></p> <ul style="list-style-type: none"> • Lactulose¹ • Mannitol • L:M (97 tested) <p><u>Stool Tests:</u></p> <ul style="list-style-type: none"> • Lactoferrin (93 tested) • Leukocytes <p><u>Blood Tests:</u></p> <ul style="list-style-type: none"> • C-reactive protein (CRP) • α-1-acid glycoprotein (AGP) 	<p>48.5% had abnormal L:M.</p> <p>L:M and excretion of each sugar separately did not vary with retinol concentration.</p> <p>L:M was associated with levels of common dietary carotenoids, primarily driven by lactulose. However, the association was not always statistically significant, and the direction of association varied depending on precursor.</p> <p>40% of stool samples were positive for lactoferrin.</p> <p>1% of stool samples were positive for fecal leukocytes.</p> <p>30% of stool samples were positive</p>	<p>Almost half of subjects had increased L:M, and ~40% of subjects had increased lactoferrin.</p> <p>While serum retinol concentrations were not associated with L:M, serum carotenoids were; authors suggest that these retinol precursors might be more sensitive predictors of impaired intestinal function. However, the reported direction of</p>	<p>L:M threshold for abnormal values was defined as ≥ 0.0864 [214]. Cut-off values for lactoferrin positivity were not described.</p> <p>Relationships between acute phase proteins and measures of intestinal permeability or inflammation were not reported. Relationships between L:M and lactoferrin or fecal leukocytes as well as those between</p>

¹ Lactulose and mannitol results were expressed as % of dose administered.

Evidence Table 2. Markers of permeability.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
status				for parasites but this had no impact on L:M results, lactoferrin, or acute phase reactants.	association varied, making interpretation of these results unclear.	retinol or carotenoids and lactoferrin or fecal leukocytes were not reported. Exclusively breastfed children were excluded from study participation due to assessment of stool lactoferrin.
2007 Williams EA et al. A double-blind, placebo-controlled, glutamine-supplementation trial in growth-faltering Gambian infants L:M and plasma immunoglobulins and acute phase reactant proteins (albumin, C-reactive protein, and alpha-1-antichymotrypsin) in community-based Gambian infants enrolled in a glutamine trial	West Kiang region, Gambia 4-10 mo olds from a rural area followed during the 5-month rainy season and for 6 months afterward.	Cohort n=72 Glutamine or placebo of nonessential amino acids was orally administered twice daily during rainy season; L:M ratio was measured monthly, and plasma samples were collected 3 times.	<u>Urine Tests:</u> • Lactulose ¹ • Mannitol • L:M <u>Blood markers</u> • C-reactive protein (CRP) • Alpha-1 antichymotrypsin (ACT) • IgA • IgG • IgM • Albumin	Mean ² L:M (CI): • Baseline: • Glutamine group: 0.33 (0.25, 0.43) • Placebo group: 0.33 (0.26, 0.41) • Post-intervention: • Glutamine group: 0.29 (0.23, 0.35) • Placebo group: 0.26 (0.21, 0.32) Mean excretion of lactulose (CI): • Baseline: • Glutamine group: 0.21 (0.16, 0.28) • Placebo group: 0.20 (0.15, 0.26) • Post-intervention: • Glutamine group: 0.17 (0.13, 0.21) • Placebo group: 0.14 (0.11, 0.18) Mean excretion of mannitol (CI): • Baseline: • Glutamine group: 2.65 (2.02,	L:M values were elevated in this population, with no significant change after the intervention. None of the plasma markers differed significantly between treatment and placebo groups, either at baseline or at the end of supplementation. Growth outcomes did not differ significantly across treatment groups.	The relationships between L:M and growth parameters, immuno-globulins, and acute phase proteins were not reported.

¹ Lactulose and mannitol results were expressed as % of dose administered.

² Geometric mean.

Evidence Table 2. Markers of permeability.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
				<p>3.48)</p> <ul style="list-style-type: none"> • Placebo group: 2.50 (1.87, 3.36) • Post-intervention: <ul style="list-style-type: none"> • Glutamine group: 2.48 (1.99, 3.11) • Placebo group: 2.14 (1.62, 2.82) <p>L:M values did not differ significantly between treatment groups before or following intervention. However, a repeated measures ANOVA showed that during supplementation, L:M values were borderline elevated among the glutamine-supplemented group relative to the placebo group (p=0.05), counter to expectation.</p> <p>Neither ACT, CRP, albumin, nor immunoglobulins IgA, IgG, or IgM differed significantly between treatment and placebo groups, either at baseline or at the end of supplementation.</p> <p>Mean levels of IgA and IgG increased during the study (p <0.001), while IgM levels did not. Concentrations of each of these immunoglobulins did not differ between treatment and placebo groups.</p> <p>Plasma albumin, ACT, and CRP values showed no change over the course of the study.</p> <p>Proportions of children with elevated CRP ranged from 30-41% at different collection time points. The glutamine intervention had no effect on proportion of children with</p>		

Evidence Table 2. Markers of permeability.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
				<p>elevated CRP.</p> <p>Treatment and placebo groups experienced decreases in WAZ, HAZ, and MUAC coinciding with the rainy season; however, there was no significant difference observed between the groups for any of these parameters.</p> <p>Treatment and placebo groups did not differ in morbidity indices (i.e. percentage of time reported with a particular illness or illness overall).</p>		
<p>2000</p> <p>Willumsen JF et al.</p> <p>Subclinical mastitis as a risk factor for mother-infant HIV transmission</p> <p>L:M as a marker of infant intestinal permeability and its relationship with subclinical maternal mastitis</p>	<p>Durban, South Africa</p> <p>HIV-infected breastfeeding mothers and their infants followed up to 14 wk of age.</p> <p>Women recruited from antenatal clinic via a vitamin A supplementation trial to reduce mother-to-child HIV transmission.</p>	<p>Cross-sectional analysis of baseline data prior to randomization for an RCT</p> <p>n=104 mothers</p> <p>n=108 infants (4 pairs of twins), (26 were HIV-infected by 3 mo of age)</p>	<p>Urine Test:</p> <p>L:M</p>	<p>There was no significant association between L:M and subclinical mastitis as measured by milk Na/K.</p>	<p>Subclinical mastitis was not associated with magnitude of L:M.</p>	<p>Actual L:M values were not reported but are found in a companion study, also included in this review [119]. The study group in Willumsen, et al. represents a subsample of the study population reported in the companion study.</p>
<p>2000</p> <p>Zhang Y et al.</p> <p>Lactulose-mannitol intestinal permeability test in children with diarrhea caused by rotavirus and <i>Cryptosporidium</i></p>	<p>Lima, Peru</p> <p>0-36 mo olds with watery diarrhea admitted to oral rehydration unit of hospital.</p>	<p>Case-control</p> <p>n=36;</p> <p>n=29 cases:</p> <ul style="list-style-type: none"> • 15 with <i>C. parvum</i> alone • 7 with rotavirus alone • 7 with bacteria (alone or with 	<p>Urine Test:</p> <p>L:M</p> <p>Enrollment and convalescent (at day 20) L:M ratios were assessed.</p>	<p>Mean¹ L:M (SE) at day 1, day 20:</p> <ul style="list-style-type: none"> • Rotavirus only: 0.67 (0.38), 0.19 (0.09) • <i>Cryptosporidium</i> only: 0.76 (0.43), 0.28 (0.14) • Bacterial infection: ranged from 0.2-0.87, 0.11-0.99 • Unknown etiology: 0.26 (0.12), 0.29 (0.18) <p>Mean L:M ratios significantly</p>	<p>L:M ratios were significantly elevated in children with rotavirus or <i>Cryptosporidium</i> infection compared to those with diarrhea not caused by rotavirus, <i>Cryptosporidium</i>, or identifiable bacteria.</p>	

¹ Arithmetic mean.

Evidence Table 2. Markers of permeability.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
L:M as a marker of intestinal permeability in children with diarrhea		rotavirus or <i>Cryptosporidium</i>) n=7 controls with unknown etiology		differed between the unknown etiology and both the rotavirus ($p < 0.01$) and <i>Cryptosporidium</i> groups ($p < 0.05$) at baseline, but not at day 20. Mean L:M ratios decreased between baseline and day 20 for both the rotavirus ($p < 0.001$) and <i>Cryptosporidium</i> ($p < 0.05$) groups. Among the group of subjects with enteric bacterial infections, the causative agents identified and mean L:M ratios (baseline, day 20) were: <i>Campylobacter jejuni</i> and rotavirus infection (0.86, 0.18), <i>C. jejuni</i> and <i>Cryptosporidium</i> infection (0.87, 0.53), <i>Salmonella</i> sp. (0.2, 0.11), <i>C. jejuni</i> (0.69, 0.99), and <i>Aeromonas</i> sp. (0.38, 0.11). The L:M ratios of this group of seven infants were not included in the statistical analyses.	Mean L:M did not change significantly among those with diarrhea of unknown etiology, but did significantly decrease among those infected with rotavirus or <i>Cryptosporidium</i> , reaching ratios similar to those with diarrhea of unknown etiology.	

Notes: Some studies included subjects ≥ 5 yr of age. Where these studies provided data separately for children < 5 yr, we present results for only those subjects. Where these studies did not stratify results by age, but did report the number of children < 5 yr included in the study, we provide a breakdown of under-5s. All studies reporting lactulose:rhamnose ratio results presented values multiplied by a factor of 100 for ease of reporting. Further details on L:M studies can be found in Table 19.

Abbreviations: AD=acute diarrhea, ALT=alanine aminotransferase, AST=aspartate aminotransferase, CBC=complete blood count, CD=celiac disease, CI=95% confidence interval, Cr=creatinine, Δ =change in, EED=environmental enteric dysfunction, FTT=failure to thrive, GI=gastrointestinal, HAZ=height-for-age Z-(score), HDL=high density lipoproteins, HIV=human immunodeficiency virus, HLA=human leukocyte antigen, IEL=intraepithelial lymphocytes, IgA=immunoglobulin A, IgE=immunoglobulin E, IgG=immunoglobulin G, IgM=immunoglobulin M, IL=interleukin, IFN=interferon, LDL=low density lipoproteins, L:M=lactulose:mannitol ratio, mo=month(s), NS=not statistically significant, PD=persistent diarrhea, RCT=randomized controlled trial, SBBO=small bowel bacterial overgrowth, SD=standard deviation, SE=standard error, SES=socioeconomic status, Tc-99m=technetium 99, T3=triiodothyronine, T4=thyroxine, TE=tropical enteropathy, TGF=transforming growth factor, TNF=tumor necrosis factor, TS=tropical sprue, WAZ=weight-for-age Z-(score), WBC=white blood cell count, WFA=weight-for-age, WHZ=weight-for-height Z-(score), wk=week(s), yr=year(s)

5.3.1 The Urinary Lactulose:Mannitol Ratio (L:M)

The urine L:M test is the permeability test that has been most extensively used to measure gut function in children in the literature identified for this review. This noninvasive test involves oral administration of a dose of both sugars (i.e., lactulose and mannitol), followed by a timed urine collection. As reviewed above, lactulose is a large sugar (a disaccharide) that is minimally absorbed from an intact small intestine. However, if permeability is altered, this disaccharide traverses intracellular spaces of the gut, is then cleared by glomerular filtration without renal tubular reabsorption, and becomes measurable in the urine. Mannitol is a sugar alcohol that is absorbed (via transcellular pathways) proportional to the small bowel absorptive capacity (i.e. surface area). Shortened microvilli diminish uptake and subsequent urinary excretion of mannitol, which, like lactulose, is filtered and not reabsorbed.

5.3.1.1 Technical Issues with the L:M Test

Prior to delving into the results of the L:M tests, it is important to note that all of the biomarkers examined in this review have particular and general performance considerations, perhaps none more so than the L:M test. These considerations for the L:M test are summarized in Table 14, which demonstrates the tremendous variability in methods, citation of methods, ranges of purported normal values of abnormal cutoff points, and the way that results were reported across the 25 studies that we reviewed that used L:M as a marker.

Table 14. Comparisons of L:M test study methods and reporting frameworks.

Reference ¹	Population	Exclusion/ Inclusion Criteria	Fasting	Loading Doses of Lactulose and Mannitol ²	Urine Collection Post Loading Dose Time Interval ³	Laboratory Analysis Method ⁴	Central Tendency Measure for L:M	Comparisons to Other Studies ⁵
2004 Campbell DI et al. Intestinal inflammation measured by fecal neopterin in Gambian children with enteropathy	2 mo olds from a rural area followed until 15 mo of age.	Not specified	1 hr after loading dose	A	5 hr	Enzymatic assay per Northrop CA et al. [215] and Lunn PG et al. [216]	Mean, type not specified, (CI)	
Normal value cut points⁶: <0.10 based on UK norm. Campbell DI et al. cited Travis & Menzies et al. [201] but it was unclear if the citation was related to normal values for lactulose and mannitol individually or also for L:M. Travis & Menzies did not report primary L:M data, but cited a mean (type not specified) of 0.016 (SEM 0.002), per Juby et al. [217], as normal.								
2003 Campbell DI et al. Growth faltering in rural Gambian infants is associated with impaired small intestinal barrier function	2-11 mo olds from a rural village followed up to 14 mo of age.	Not specified	2 hr after loading dose	A	5 hr	Enzymatic assay per Northrop CA et al. [215] and Lunn & Northrop-Clewes [218]	Geometric mean (CI, range)	Gambian children [209]
Normal value cut points: Based on UK norms, value was not specified, per Freeman JV et al. [219], Weaver [220], Lunn PG et al. [202], and Lunn [52]. Freeman JV et al. [219] reported no data relevant to L:M. Weaver reported data for breastfed English infants and a derived median L:M from this data of ~0.2. Lunn PG et al. [202] reported a mean (SEM) L:M for UK 3-15 mo olds of 0.12 (0.02) based on “data from [their] laboratory”, but did not portray the data or cite another reference. Text suggests this was a geometric mean, but this was not clearly stated. Lunn [52] described L:M patterns, but not specific values.								

¹ Some titles are abbreviated.

² A = 400 mg/kg of lactulose, 100 mg/kg of mannitol, B = not reported, C = 4 g lactulose, 1 g mannitol, D = 5 g lactulose, 1 g mannitol, E = 200 mg/kg of lactulose, 50 mg/kg of mannitol, F = 400 mg/kg of lactulose, 100 mg/kg of mannitol, G = 400 mg/kg of lactulose (maximum 4 g), 100 mg/kg of mannitol (maximum 1 g), H = 500 mg/kg of lactulose (maximum 5 g), 100 mg/kg of mannitol (maximum 1 g).

³ Where authors cited references for these parameters, they are provided.

⁴ Where authors cited references for these parameters, they are provided.

⁵ Other than studies presented within the “Normal value cut points” row.

⁶ Where authors cited references for normal value cut-points, they are provided along with the relevant information from those citations.

Table 14. Comparisons of L:M test study methods and reporting frameworks.

Reference ¹	Population	Exclusion/ Inclusion Criteria	Fasting	Loading Doses of Lactulose and Mannitol ²	Urine Collection Post Loading Dose Time Interval ³	Laboratory Analysis Method ⁴	Central Tendency Measure for L:M	Comparisons to Other Studies ⁵
2003 Campbell DI et al. Chronic T cell-mediated enteropathy in rural west African children: relationship with nutritional status and small bowel function	6 mo-3 yr old malnourished in- and out-patients from rural areas. Compared to well-nourished UK children with GI complaints other than diarrhea.	Not specified	Not reported	B	5 hr	Enzymatic assay per Sullivan PB et al. [221] and Lunn PG et al. [209]	Not clearly indicated	Asymptomatic Gambian children [209]
<p>Normal value cut points: <0.10 based on UK norms, per Fagundes-Neto U et al. [17] and Beattie RM et al. [222]. We were unable to obtain the article by Fagundes-Neto U et al. to verify. No relevant L:M data were found in Beattie RM et al.</p>								
2002 Campbell DI et al. Age-related association of small intestinal mucosal enteropathy with nutritional status in rural Gambian children	2-60 yr olds from rural communities.	Not specified	Not reported	C	5 hr	Enzymatic assay per Northrop CA et al. [215], and Lunn & Northrop-Clewes [218]	Mean, type not specified, (SE)	Adults in UK & tropics [57] and previous results in Gambian & UK subjects [202]
<p>Normal value cut points: <0.10 based on UK norm per Freeman JV et al. [219] and Travis & Menzies [201]. Freeman JV et al. reported no relevant data. Travis & Menzies cited a mean (type not specified) L:M ratio of 0.016 (SEM 0.002), per Juby LD et al. [217], as normal.</p>								
2003 Chen P et al. Association of vitamin A and zinc status with altered intestinal permeability	2-97 mo olds from an urban shantytown.	Not specified	Not reported	D	5 hr	HPLC per Barboza MS et al. [214]	Mean, type not specified (SD)	
<p>Normal value cut points: Not reported.</p>								

Table 14. Comparisons of L:M test study methods and reporting frameworks.

Reference ¹	Population	Exclusion/ Inclusion Criteria	Fasting	Loading Doses of Lactulose and Mannitol ²	Urine Collection Post Loading Dose Time Interval ³	Laboratory Analysis Method ⁴	Central Tendency Measure for L:M	Comparisons to Other Studies ⁵
2007 Darboe MK et al. Effectiveness of an early supplementation scheme of high-dose vitamin A versus standard WHO protocol in Gambian mothers and infants	0-12 mo olds from a rural community.	Inclusion: successfully obtained cord blood sample Exclusion: birth weight <2.2 kg, <37 wk gestation, congenital anomalies or severe peripartum illness	Not reported	E	5 hr	Enzymatic assay per Lunn PG et al. [209]	Geometric mean	

Normal value cut points: <0.30, authors derived this from Lunn PG et al. [202] UK infants' mean plus 2 SD. Lunn PG et al. stated a mean (type not specified) (SE) of 0.12 (0.02) based on "most recent data from this laboratory", data not shown or cited.

2001 Filteau SM et al. The effect of antenatal vitamin A and (beta)-carotene supplementation on gut integrity of infants of HIV-infected South African women	Infants of HIV- infected women recruited from antenatal clinic and followed until 14 wk of age.	Not specified	Not reported	A	5 hr	Enzymatic assay per Lunn PG et al. [209] and Willumsen JF et al. [207]	Geometric mean (CI)	
--	--	---------------	--------------	---	------	--	------------------------	--

Normal value cut points: Based on norms, values not specified, per Catassi C et al. [223] and Lunn PG et al. [209]. Catassi C et al. reported data from 72 Italian infants. Their L:M values were calculated in two ways: 1) absolute ratio of lactulose and mannitol in mg/dl with L:M mean (type not specified) (SD) ranging from 1.27 (0.73)-0.22 (0.21) and 2) ratio of lactulose and mannitol as percent dose ingested with L:M mean (type not specified) (SD) of 0.09 (0.08). Lunn PG et al. stated that UK infants' norm as a mean (type not specified) (SD) of 0.12 (0.09), but did not portray the related data or cite another reference for this UK norm.

Table 14. Comparisons of L:M test study methods and reporting frameworks.

Reference ¹	Population	Exclusion/ Inclusion Criteria	Fasting	Loading Doses of Lactulose and Mannitol ²	Urine Collection Post Loading Dose Time Interval ³	Laboratory Analysis Method ⁴	Central Tendency Measure for L:M	Comparisons to Other Studies ⁵
2005 Galpin L et al. Effect of Lactobacillus GG on intestinal integrity in Malawian children at risk of tropical enteropathy	36-60 mo olds from a rural community.	Exclusion: evidence of severe acute malnutrition or severe chronic illness	Overnight	D	3 hr	Cation-exchange column and refractometer by modified method of Catassi C et al. [224] and Shulman RJ et al. [225]	Arithmetic mean (SD)	
<p>Normal value cut points: <0.10 based on developed world norms between 0.03-0.12, per Goto R et al. [205], van Elburg RM et al. [226], Campbell DI et al. [112]. Goto R et al. reported data based on 158 Guatemalan infants aged 0-11 mo without diarrhea in preceding week; the L:M median ranged from 0.41-0.54. They also used 0.07 as a cut point for normal L:M based on another reference by Ford RP et al. [227] which did not report data relevant to L:M. van Elburg RM et al. reported L:M based on 30 Dutch 0-16 yr olds. L:M was calculated in two ways: 1) absolute ratio of lactulose and mannitol in mmol/mol creatinine with L:M mean (type not specified) (SD) 0.043 (0.045) and 2) ratio of lactulose and mannitol as percent dose ingested with L:M mean (type not specified) (SD) 0.034 (0.033). Campbell DI et al. reported mean (type not specified) (SE) L:M of 0.353 (0.022) based on 26 Gambian 2-5 yr olds without diarrhea. They also reference UK norms but do not report specific values (see above).</p>								
2008 Goto R et al. Impact of anti- <i>Giardia</i> and anthelmintic treatment on infant growth and intestinal permeability in rural Bangladesh	3-15 mo olds from a rural community followed over 9 mos. Malnutrition was prevalent.	Not specified	Not reported	A	Usually 3 hr, but up to 5-6 hr if no urine output within 3 hr per Akram S et al. [228]	Enzymatic assay per Lunn PG et al. [216] and Northrop CA et al. [215].	Geometric mean (SD)	Gambian and Bangladeshi subjects per Lunn PG et al. [209] and Rousham EK et al. [229]
<p>Normal value cut points: < upper CI for UK infants, value not specified, per Lunn PG et al. [209]. Lunn PG et al. stated that UK infants' norm as a mean (type not specified) (SD) of 0.12 (0.09), but did not portray the related data or cite another reference for this UK norm.</p>								

Table 14. Comparisons of L:M test study methods and reporting frameworks.

Reference ¹	Population	Exclusion/ Inclusion Criteria	Fasting	Loading Doses of Lactulose and Mannitol ²	Urine Collection Post Loading Dose Time Interval ³	Laboratory Analysis Method ⁴	Central Tendency Measure for L:M	Comparisons to Other Studies ⁵
2008 Goto R et al. Impact of intestinal permeability, inflammation status and parasitic infections on infant growth faltering in rural Bangladesh	3-15 mo olds from a rural community followed over 9 mos. Malnutrition was prevalent.	Not specified	1 hr before load	A	5 hr for first exam. Reduced to 3 hr subsequently if subject voided within first 90 minutes per Akram S et al. [228]	Enzymatic assay per Lunn PG et al. [216] and Northrop CA et al. [215]	Geometric mean, mean log L:M ⁷ (SD reported for logged value)	Gambian and Bangladeshi subjects per Lunn PG et al. [209] and Rousham EK et al. [229]
Normal value cut points: Geometric mean 0.12 for UK infants per Lunn PG et al. [209]. Lunn PG et al. stated that UK infants' norm as a mean (type not specified) (SD) of 0.12 (0.09), but did not portray the related data or cite another reference for this UK norm.								
2002 Goto R et al. Poor intestinal permeability in mildly stunted Nepali children: Associations with weaning practices and <i>Giardia lamblia</i> infection	0-5 yr olds from two urban squatter settlements. Malnutrition was prevalent.	Not specified	1 hr after load (with the exception of breastfeeding)	A	5 hr	Enzymatic assay per Lunn PG et al. [216]; Northrop CA et al. [215]; Blood et al. [230]; Lunn & Northrop-Clewes [218]	Geometric mean (range, geometric SE ⁸)	Bangladeshi subjects per Northrop-Clewes CA et al. [150] and Rousham EK et al. [229]. Gambian subjects per Lunn PG et al. [202] and Behrens RH et al. [231]. Guatemalan subjects ⁹ per Goto R et al. [205]
Normal value cut points: <0.12 based on UK geometric mean per Lunn PG et al. [202]. Lunn et al. stated that UK infants' norm as a mean (type not specified) (SD) of 0.12 (0.09), but did not portray the related data or cite another reference for this UK norm.								

⁷ Authors present positive log L:M values, however, logged values would be expected to be negative for ratios between 0-1 as is the case for L:M ratios.

⁸ Authors calculated the geometric standard error using the formula: antilog (mean + standard error of logged values) - geometric mean.

⁹ For this study, medians were reported rather than means.

Table 14. Comparisons of L:M test study methods and reporting frameworks.

Reference ¹	Population	Exclusion/ Inclusion Criteria	Fasting	Loading Doses of Lactulose and Mannitol ²	Urine Collection Post Loading Dose Time Interval ³	Laboratory Analysis Method ⁴	Central Tendency Measure for L:M	Comparisons to Other Studies ⁵
2010 Lima AA et al. Effects of vitamin A supplementation on intestinal barrier function, growth, total parasitic, and specific <i>Giardia</i> spp infections in Brazilian children	2 mo-9 yr olds from an impoverished urban community.	Inclusion: HAZ score <community median Exclusion: exclusively breast-fed, participant in another study in past 2 yr, or febrile illness at enrollment	Not reported	F	Per Barboza MS et al. [214]	Per Lunn PG et al. [216] and Northrop CA et al. [215]	Median (range ¹⁰)	
Normal value cut points: Not reported.								
2005 Lima AA et al. Intestinal barrier function and weight gain in malnourished children taking glutamine- supplemented enteral formula	2-60 mo olds hospitalized with malnutrition, ~70% of whom had PD.	Inclusion: history of PD or WAZ score <-2 and consent to 10-day hospital stay Exclusion: exclusively breast-fed, intolerant to cow's milk, participant in another study in past 2 yr, illness at enrollment	3 hr before load	G	5 hr	HPLC per Barboza MS et al. [214]	Mean, type not specified, (SE)	
Normal value cut points: Not reported.								

¹⁰ Authors used the term "range," but for some of the L:M medians, only one value was reported, apparently the maximum L:M value observed.

Table 14. Comparisons of L:M test study methods and reporting frameworks.

Reference ¹	Population	Exclusion/ Inclusion Criteria	Fasting	Loading Doses of Lactulose and Mannitol ²	Urine Collection Post Loading Dose Time Interval ³	Laboratory Analysis Method ⁴	Central Tendency Measure for L:M	Comparisons to Other Studies ⁵
2007 Lima NL et al. Wasting and intestinal barrier function in children taking alanyl- glutamine-supplemented enteral formula	6 mo-8 yr olds from an urban setting with HAZ, WAZ, or WHZ scores <-1.	Exclusion: exclusively breast-fed, participant in another study in the past 2 yr, sibling enrolled in this study, chronic or severe or febrile illness at enrollment	3 hr before load	D	5 hr	HPLC per Barboza MS et al. [214]	Median (range) ⁱ	
Normal value cut points: Within the CI for values of healthy children in the community, values were not reported and no reference was provided.								
2001 Northrop-Clewes CA et al. Anthelmintic treatment of rural Bangladeshi children: effect on host physiology, growth, and biochemical status	2-5 yr olds from poor rural villages.	Not specified	2 hr before and after load	C	5 hr	Enzymatic assay per Northrop CA et al. [215], and Lunn & Northrop-Clewes [218]	Geometric mean, mean log L:M (SE reported for logged value)	Bangladeshi subjects per Northrop CA et al. [232]
Normal value cut points: <~0.15 based on UK norm per Lunn PG et al. [209]. Lunn PG et al. stated that UK infants' norm as a mean (type not specified) (SD) of 0.12 (0.09), but did not portray the related data or cite another reference for this UK norm.								
2000 Quadro L et al. Retinol and retinol-binding protein: gut integrity and circulating immunoglobulins	1-9 yr olds with mild malnutrition from an urban slum. Vitamin A deficiency was prevalent.	Inclusion: no sign of infection or other obvious illness	Overnight	D	5 hr	HPLC per Bao Y et al. [233]	None reported	
Normal value cut points: <0.030 based on norms per Lima AA et al. [234], Deitch [235], Ukabam & Cooper [236], Wyatt J et al. [237], Pearson AD et al. [238], and Ford RP et al. [227] Lima AA et al. reported mean L:M (type not specified) (SE) of 0.017 (0.002) based on data from 13 Brazilian adults without HIV infection. Deitch reported mean L:M from 8 healthy American adult controls. Mean L:M was 1.7; SE was only presented graphically. L:M was expressed as lactulose/mannitol x 100 and the ratio was calculated as units rather than % dose administered; type of mean was not otherwise specified. Baseline values of mannitol (from pre-test samples) were subtracted from test samples. Ukabam & Cooper reported separate lactulose and mannitol excretion means for 25 healthy adult controls, presumably from the UK based on address of corresponding author. They did not report data on the L:M ratio. Wyatt J et al. reported mean (type not specified) L:M (SE) of 0.018 (0.002) based on data from 30 healthy adults (presumably in Austria based on corresponding author's address.) They defined a normal cutoff of 0.030 based on mean L:M + 2 SD. Pearson AD et al. reported mean L:M (type not specified) (range) of 0.018 (0.005-0.028) based on data from 31 healthy 2-13 yr olds (presumably in UK based on corresponding author's address.) Ford RP et al. reported no data relevant to L:M.								

Table 14. Comparisons of L:M test study methods and reporting frameworks.

Reference ¹	Population	Exclusion/ Inclusion Criteria	Fasting	Loading Doses of Lactulose and Mannitol ²	Urine Collection Post Loading Dose Time Interval ³	Laboratory Analysis Method ⁴	Central Tendency Measure for L:M	Comparisons to Other Studies ⁵
2004 Rabbani GH et al. Green banana and pectin improve small intestinal permeability and reduce fluid loss in Bangladeshi children with persistent diarrhea	5-12 mo old males admitted to hospital with PD but without other concurrent illnesses.	Inclusion: male, PD Exclusion: concurrent illness	3 hr before load	D	5 hr	Enzymatic assay per Behrens et al. [239], and Yamanaka [240]	Mean, type not specified (SD)	
<p>Normal value cut points: Based on norms, value not specified, per Lunn PG et al. [209], Barboza MS et al. [214], Behrens RH et al. [231], Roy SK et al. [241], Ford RP et al. [227]. Lunn PG et al. stated that UK infants' normal values are: mean (type not specified) (SD) 0.12 (0.09), but did not portray the related data or cite another reference for this UK value. Barboza MS et al. reported mean L:M (type not specified) (SD) of 0.0394 (0.0235) based on 15 Brazilian under-5s from a low SES area without diarrhea in the preceding 2 weeks. Behrens RH et al. reported mean L:M (type not specified) (+/-2SD) of 0.42 (0.2, 1.4) and 0.52 (0.2, 2.2) based on 255 tests on 60 healthy Gambian 0-18 mo olds with HFA >80% of NCHS median and 45 tests on 15 Gambian 0-18 mo olds with HFA between 60-80% of NCHS median. Roy SK et al. reported geometric mean L:M (CI) of 0.13 (0.1, 0.16) based on 53 asymptomatic Bangladeshi controls. Ages of controls were not described but diarrheal cases were aged 3-24 mo. Ford RP et al. reported no data relevant to L:M.</p>								
2001 Rollins NC et al. Feeding mode, intestinal permeability, and neopterin excretion: A longitudinal study in infants of HIV-infected South African women	1, 6, and 14 wk old infants born to HIV- infected mothers.	Not specified	Not reported	A	5 hr	Enzymatic assay per Willumsen JF et al. [207]	Geometric mean (CI)	
<p>Normal value cut points: Based on norms, value not specified, per Catassi C et al. [223] and Behrens RH et al. [231]. Catassi C et al. reported mean L:M based on data from 72 Italian infants. Their L:M values were calculated in two ways: 1) absolute ratio of lactulose and mannitol in mg/dl with L:M mean (type not specified) (SD) ranging from 1.27 (0.73)-0.22 (0.21) and 2) ratio of lactulose and mannitol as percent dose ingested with L:M mean (type not specified) (SD) of 0.09 (0.08). Behrens RH et al. reported mean L:M (type not specified) (+/-2SD) of 0.42 (0.2, 1.4) and 0.52 (0.2, 2.2) based on 255 tests on 60 healthy Gambian 0-18 mo olds with HFA >80% of NCHS median and 45 tests on 15 Gambian 0-18 mo olds with HFA between 60-80% of NCHS median.</p>								

Table 14. Comparisons of L:M test study methods and reporting frameworks.

Reference ¹	Population	Exclusion/ Inclusion Criteria	Fasting	Loading Doses of Lactulose and Mannitol ²	Urine Collection Post Loading Dose Time Interval ³	Laboratory Analysis Method ⁴	Central Tendency Measure for L:M	Comparisons to Other Studies ⁵
2000 Rollins NC et al. Vitamin A supplementation of South African children with diarrhea: optimum timing for improving biochemical and clinical recovery and subsequent vitamin A status	6-60 mo old in- or out-patients with severe diarrhea. Intestinal permeability tests could be performed only for a subset of inpatients.	Exclusion: children with dysentery, metabolic acidosis, circulatory impairment, severe electrolyte disturbances, or inability to take oral fluids	Not reported	A	5 hr	Enzymatic assay per Willumsen JF et al. [207]	Geometric mean (CI)	
Normal value cut points: Not reported.								
2000 Thurnham DI et al. Innate immunity, gut integrity, and vitamin A in Gambian and Indian infants	Inpatients with diarrheal or respiratory disease, mean age 9 mos. And out-patients with "minor ailments", age not specified.	Not specified	Not reported	B	5 hr	Not specified per Lunn PG et al. [209]	Mean, type not specified (SE)	
Normal value cut points: <0.12 based on UK norm per Lunn PG et al. [209]. Lunn PG et al. stated that UK infants' norm as a mean (type not specified) (SD) of 0.12 (0.09), but did not portray the related data or cite another reference for this UK norm.								
2009 Trehan I et al. A randomized, double-blind, placebo-controlled trial of rifaximin, a nonabsorbable antibiotic, in the treatment of tropical enteropathy	3-5 yr olds from a rural village.	Exclusion: chronic debilitating illness, congenital abnormalities, or severe acute malnutrition	Overnight	D	4 hr	HPLC per Shulman RJ et al. [212] and Scarpignato C et al. [242]	Mean, type not specified (SD)	
Normal value cut points: <0.10 based on norms of 0.03-0.12 per Campbell DI et al. [112], Goto R et al. [205], and Galpin L et al. [120]. Campbell DI et al. reported mean (type not specified) (SE) L:M of 0.353 (0.022) based on 26 Gambian 2-5 yr olds without diarrhea. They also reference UK norms but do not report specific values (see above). Goto R et al. reported L:M values based on 158 Guatemalan infants aged 0-11 mo without diarrhea in preceding week. L:M median ranged from 0.41-0.54. They also used 0.07 as a cut point for normal L:M based on another reference by Ford RP et al. [227] which did not report data relevant to L:M. Galpin L et al. reported arithmetic mean (SD) L:M of 0.18 (0.16) and 0.22 (0.20) based on 2 groups of 80 and 81 healthy Malawian 3-5 yr old children, respectively.								

Table 14. Comparisons of L:M test study methods and reporting frameworks.

Reference ¹	Population	Exclusion/ Inclusion Criteria	Fasting	Loading Doses of Lactulose and Mannitol ²	Urine Collection Post Loading Dose Time Interval ³	Laboratory Analysis Method ⁴	Central Tendency Measure for L:M	Comparisons to Other Studies ⁵
2008 Vieira MM et al. Carotenoids, retinol, and intestinal barrier function in children from northeastern Brazil	2 mo-9 yr olds from an impoverished urban community.	Inclusion: HAZ score <community median Exclusion: exclusively breast-fed, participants in another study in past 2 yr or febrile illness at enrollment	1 hr after load, fasted prior as well, but duration not specified.	H	5 hr	HPLC per Bao Y et al. [233], Lima, et al. [234], and Barboza MS et al. [214]	Mean (SD); however, only the proportion of normal values was reported rather than the mean	
Normal value cut points: <0.0864, calculated as mean + 2SD based on data from Barboza MS et al. [214]: mean L:M (type not specified) (SD) of 0.0394 (0.0235) based on 15 Brazilian under-5s from low SES area without diarrhea in preceding 2 weeks.								
2007 Williams EA et al. A double-blind, placebo- controlled, glutamine- supplementation trial in growth-faltering Gambian infants	4-10 mo olds from a rural area followed during the 5-month rainy season and for 6 months afterward	All age-eligible children in the study villages were included	None pre- dose (stating ethical considera- tions); 2 hr post- dose (exception of water allowed)	F	5 hr	Not specified. Williams et al. cited Travis and Menzies [201] generally regarding L:M assessment of intestinal permeability; it was unclear which aspects of Travis and Menzies' methods were being referenced.	Geometric mean, (CI)	
Normal value cut points: Not reported.								
2000 Willumsen JF et al. Subclinical mastitis as a risk factor for mother-infant HIV transmission	Infants of HIV- infected breastfeeding mothers, followed up to 14 wk of age.	Inclusion: breastfeeding	Not reported	B	Not specified	Enzymatic assay per Willumsen JF et al. [207]	None reported	
Normal value cut points: Not reported.								

Table 14. Comparisons of L:M test study methods and reporting frameworks.

Reference ¹	Population	Exclusion/ Inclusion Criteria	Fasting	Loading Doses of Lactulose and Mannitol ²	Urine Collection Post Loading Dose Time Interval ³	Laboratory Analysis Method ⁴	Central Tendency Measure for L:M	Comparisons to Other Studies ⁵
2000 Zhang Y et al. Lactulose-mannitol intestinal permeability test in children with diarrhea caused by rotavirus and <i>Cryptosporidium</i>	0-36 mo olds with watery diarrhea admitted to a hospital oral rehydration unit.	Inclusion: watery diarrhea and stool positive for rotavirus or <i>Cryptosporidium</i> Exclusion: dysentery, history of renal disease, or current antibiotic use	Not reported	A	5 hr	Enzymatic assay and spectrophotometer.	Arithmetic mean (SE). Also reported raw data allowing for further analysis by the reader.	
Normal value cut points: Not reported.								

Abbreviations: AIDS=Acquired immune deficiency syndrome, CI=95% confidence interval, GI=Gastrointestinal, HAZ=Height-for-age Z (score), HFA=Height-for-age, HIV=Human immunodeficiency virus, HPLC=High performance liquid chromatography, hr=Hour(s), L=Lactulose, L:M=lactulose:mannitol, M=Mannitol, mo=Month(s), PD=Persistent diarrhea, SD=Standard deviation, SE=Standard error, TB=Tuberculosis, UK=United Kingdom, WAZ=Weight-for-age Z (score), WFA=Weight-for-age, WHZ=Weight-for-height Z (score), wk=Week(s), yr=Year(s)

An important initial methodological consideration is that administration of a loading dose is required; dosing among the studies we reviewed varied. Ideally, the dosing should be related to body mass, or at least to body weight, in view of the large range in body size and composition of the subjects to whom it is administered. Such dosing was reported to have been performed in only 13 of the 25 L:M studies we reviewed. It should be noted that either or both of these molecules can cause diarrhea via their hyperosmolar properties, and that sometimes the load causes vomiting. These side effects, although not serious, might be more prominent among children with certain characteristics thus skewing results. Indeed, the hyperosmolar effect is proposed to potentially interfere with absorption by causing solvent drag (retention of the measured solute in the gut), and has prompted consideration of a liquid meal with which to administer these exomolecular probes of intestinal absorption and permeability [184].

Because gastric emptying could delay kinetics of absorption, a standard and perhaps prolonged fasting interval should be employed. This presents a challenge when testing infants who cannot tolerate fasts of greater than 3-6 hours depending on age, especially if exclusively breastfed since breastmilk is easily and relatively quickly digested. Furthermore, even a three-hour fasting interval may not be tolerated among acutely malnourished children. However, fasting is most important for assessment of individual component measurements. Twelve of the 25 reviewed studies reported that the children were fasted prior to challenge, but the duration of fasting differed across studies.

There are additional theoretical concerns with hyperosmolar sugar absorption tests. First, there is evidence in humans that intestinal permeability can be altered by the administration of such solutes [243, 244]. Second, there is a small degree of endogenous mannitol production and excretion [243]. Third, the use of lactulose can accelerate orocecal transit time [245]. None of these factors were mentioned by any of these studies. These potential technical limitations have also not received much attention outside of the field of

environmental enteric dysfunction in the last two decades. Both the individual mannitol and lactulose component measures provide unique information as mentioned above, and thus should be reported separately; nearly three-quarters of the studies we reviewed did so. Ideally, the individual components should be presented as percent of dose administered, and also as an (ideally standardized) osmolarity of the ingested probe. Of the 18 studies reporting that components were measured separately, 11 presented results as such. Indeed, the report of Lima et al. exemplifies the merit of reporting such metadata, as a paradoxically inverse relationship between mannitol uptake and poor growth was identified [139].

Five-hour timed urine collections are considered standard. Timed urine collection among infants and young children presents a challenge in the best of circumstances and it can be even more challenging when subjects have loose stools, as is often the case among the very cohort of children for whom assessment of intestinal permeability is desired. Urine collection times varied across the studies in this review, and two did not report the information. Additionally, urinary bacteria, either representing clinical bacteriuria or contamination and replication prior to freezing, could alter sugar concentrations [246].

Laboratory detection method varied as described in Table 14. Limits of normal results have not been determined for populations in resource-limited settings. Comparisons are made to those derived from developed-country settings. Table 14 demonstrates the various norms, primarily from the United Kingdom (UK), that were cited and referenced within the studies that we reviewed. Furthermore, the results were reported in varying ways. For example, L:M values can change with age of the subject, and in the setting of low urinary flow, as in dehydration, the impermeability of the proximal tubule has not been adequately assessed in children. Stratification of results based on age was often non-existent or suboptimal for determining its contribution to high L:M values. Also, it was difficult to compare the same age groups between studies. Perhaps the most striking deficiency was the lack of standard reporting of central

tendency measures, which were variably provided as medians or means. The latter were calculated as arithmetic or geometric means; the geometric method is more appropriate for ratio measures such as L:M. Some studies did not report central tendency measures but only the proportion with abnormal results. Among the 25 L:M studies we reviewed, three reported no central tendency values, two reported medians, and 20 reported means. Of the studies reporting means, 10 reported the geometric mean, which is a mathematically preferred expression of a mean for ratios, while two reported arithmetic means, and eight reported means without specifying their type. Clearly, despite the relative abundance of recent L:M data, the wide variation in study and reporting methods hamper our ability to make inter-study comparisons.

5.3.1.2 Range of L:M Values Reported

The majority of studies that we reviewed found elevated L:M values in their subjects, consistent with reports from before the interval of publication of papers that we assessed for this systematic review (i.e., studies published prior to 2000). These elevated L:M values were largely compared to norms reported for Western (primarily from the UK) childhood values [201, 217, 220, 223, 226, 235, 237, 238] and less often related to presumed norms of children in developing-country settings [112, 120, 205, 214, 231, 234, 241].

Delineation of normal values is a challenge for several reasons. Normative curves are often established based on assessments among a small sample of children in a developed country. Two standard deviations are frequently used as cutoff point to define normal/abnormal levels. However, this may not always be an appropriate method for a variety of reasons. Genetic factors might or might not influence test results. Marker response to environmental exposures might, at least initially, reflect adaptive rather than pathologic responses.

As noted above, comparison of L:M values across the 25 studies that we reviewed was also challenged by differences in the way the values were reported (see Table 14). Among

studies reporting the ratio results as geometric means, the values (ratios) ranged from 0.08 to 2.4 and both extremes were published by the same author group in two different studies, although among different populations. The lowest (i.e. least abnormal) values were reported among HIV-negative South African infants under four months of age born to HIV-infected mothers [160, 161], while the highest values were found in children aged six to 60 months hospitalized with severe diarrhea, also in South Africa [161]. The fact that the highest values were an order of magnitude higher than in other studies reviewed led us to speculate that L:M values might have been expressed as a multiple for portrayal on the same graph with urinary neopterin and serum retinol-binding data.

Among children in rural Bangladesh, one study found a geometric mean L:M value of 0.15 [123]. In two different rural Bangladesh intervention trials, baseline L:M values were 0.18 in each of the anti-helminthic treatment groups and 0.16 in the placebo group in the same setting [122], but were 0.22 and 0.25 in a different rural setting also among anti-helminthic treatment and placebo groups, respectively [150].

In Nepal, the mean L:M value among mildly stunted children aged 0-60 months was 0.26, but did significantly differ between those infected with *Giardia* (0.43) vs. those without evidence of giardiasis (0.25) [124]. A series of studies conducted in The Gambia reported L:M geometric mean values of 0.169 [110], 0.353 [112], and 0.31 [15]. Another study demonstrated similar results, ranging from 0.26 to 0.37 in placebo-treated children, depending on month of the study [170]. These studies support the concept of widespread intestinal permeability issues among children in developing settings with considerable variation between studies, generally finding a greater degree of permeability in central African settings.

However, in contrast to the Asian and central African studies, some South African [119, 160] studies found L:M values that were similar to established norms (i.e., mean values from

healthy children in developed settings). These apparent contradictions could reflect the emergence of the economies in which these children reside, with concomitant improvement in gut health. Three [119, 160, 161] of the four L:M studies from South Africa presented geometric means (notably, each of these four studies were performed by the same investigator group). The fourth study [171] presented a subset of data published by Filteau et al. [119]. Filteau et al. [119] and Rollins et al. [160] assessed L:M among infants born to HIV-infected mothers and generally found normal values that did not increase with age. Filteau et al. also noted no change in L:M measures with increasing morbidity. However, in both studies the mean value of L:M for the infants who became infected with HIV was increased; the Rollins et al. observational study reported a mean of 0.24 and the Filteau et al. intervention trial reported a mean of almost 0.5 among those whose mothers had not received vitamin A supplementation.

Similarly, some South American [137, 139] studies found L:M values that were similar to mean values for healthy children. Six L:M studies from Brazil were conducted by one team of investigators [113, 137-139, 156, 169]. Three of the studies reported baseline L:M values but did not classify them as normal or abnormal [113, 137, 138]. Two studies assessing similar populations of mildly malnourished children from an impoverished urban community in Brazil [156, 169] reported that a high proportion of their subjects had abnormal L:M values. L:M median and range data collected a few years later in the same setting and with the same inclusion criteria were noted by the authors to be within the confidence interval for values of healthy children in the study community [139] (the reference for this confidence interval was not cited).

Several studies measured the variability of L:M values between and within individuals. Some of these identified wide ranges [122, 124], and Campbell et al. [112] found that L:M showed significant intra-subject correlation between tests conducted 3.5 months apart. In contrast, Northrop-Clewes et al. [150] observed that intra-individual L:M values in the placebo

group of an anti-helminthic trial did not change significantly over 12 months. Of note, L:M values might change with increasing age because of normal changes of physiologic maturation. However, the studies that we reviewed rarely reported data stratified by age, thereby prohibiting rigorous comparisons from one study to the next.

Very few studies investigated longitudinal change in a measure of central tendency of L:M values for their study sample. Campbell et al. found a small but significant improvement in mean L:M value between the two study time points (from 0.198 to 0.172, type of mean not mentioned), driven by an improvement in mannitol recovery with no change in lactulose excretion [112]. The interval between sampling was 3.5 months.

Three studies observed seasonal variation in L:M values. Two of these studies were conducted in rural Bangladesh; the timing of peak L:M values differed slightly between them. In one study [122], the highest values were observed during the monsoon season while in the other [150], the peak followed the monsoon season. A study in The Gambia reported monthly variation in geometric mean L:M values, ranging from 0.37 in July to 0.26 in October in placebo-treated children [170].

5.3.1.3 Associations between L:M and Growth Outcomes

The L:M test has been used extensively to assess small intestinal function in relation to nutritional status in children in resource-limited settings. Several studies have found inverse relationships between L:M and growth parameters, while others have not (Table 15). Goto et al. [123] and Campbell et al. [110] found that L:M was inversely associated with height-for-age Z-scores (HAZ) and weight-for-age Z-scores (WAZ). A longitudinal study by Goto et al. [122] found associations between change in L:M and changes in weight-for-age Z-scores (Δ WAZ) and weight-for-height Z-scores (Δ WHZ), showing improvement in growth parameters with decreased L:M values. A later study by Campbell et al. [15] found that long-term height gain was negatively

associated with mean L:M value. Northrop-Clewes et al. [150] observed that L:M was inversely correlated with change in height-for-age Z- (Δ HAZ) and Δ WAZ scores at 12 months of follow-up.

However, several studies did not find an association between L:M and growth parameters. Goto et al. [124] reported no association between L:M values and growth status, although they did not specify which of the assessed growth measures (HAZ and WAZ) were used to evaluate this. A 2003 study by Campbell et al. similarly found no association between L:M and grade of protein energy malnutrition [111]. The same group earlier demonstrated that L:M was inversely associated with HAZ after correcting for age, gender, and study visit, but not with WAZ or body mass index z-scores [112]. In these studies, the association with HAZ was mainly attributed to the greater lactulose excretion in subjects with poorer HAZ scores and was constant across all age groups. There was no significant association between L:M calculated as the mean of the two data collection points and change in nutritional status parameters.

Several factors complicate comparison of the relationship between L:M and growth parameters across studies. Anthropometric indices used in these assessments varied. Markers were sometimes associated with different anthropometric measures within the same study. In one instance [112], a relationship was identified between L:M and HAZ score but not WAZ score. When the relationship between L:M values and growth parameters is not reported, it is not clear if the anthropometric indicator was either not evaluated or whether a significant relationship was not identified (i.e., only positive results were presented). One study assessed association with single sugar excretion only, reporting no significant associations between HAZ, WAZ, or weight-for-height Z- (WHZ) scores and lactulose, but significant associations with both WAZ and WHZ scores and mannitol [139]. The article did not mention HAZ score when reporting the results of mannitol analyses, leaving unspecified whether the relationship was assessed and found to be nonsignificant, or not assessed at all.

Table 15. Associations between anthropometric indicators and biomarkers of EED.

Data presented are from one study unless otherwise indicated in parentheses.

Anthropometric Z- score	L:M	Lactulose	Mannitol	Lactose:creatinine	Stool lactoferrin	Stool neopterin	Urine nitric oxide	Intestinal maltase activity	Intestinal lactase activity	Histopathology
HAZ	Y (3) N (1)	N		Y					Y	By 2 of 3 digital morphometric measures ¹ : Y
ΔHAZ	Y (2)			Y	N	Y				
WAZ	Y (2) N (3)	N	Y	Y			N	N	Y	By 2 of 3 digital morphometric measures*: Y Endoscopy: N Histopathology: N (2) Y (1)
ΔWAZ	Y (2)			Y		Y				
WHZ	Y	N	Y	Y						By 2 of 3 digital morphometric measures ¹ : Y
ΔWHZ				Y						
BMI	N									

Y=yes, a statistically significant relationship was found.
N=no, a statistically significant relationship was not found.

¹ The three digital morphometry measures included enterocyte height, enterocyte brush border, and enterocyte nucleus height. The two measures that were significantly associated with anthropometric indicators differed for each type of anthropometric indicator assessed.

5.3.1.4 Associations between L:M and Other Outcomes

Four studies assessed the potential association between L:M values and *Giardia* infection. Two found no association [15, 123]. A Bangladeshi antihelminthic trial [150] found that L:M and giardiasis were not associated overall; they only identified an association among the treatment group in their intervention trial at a single time point over the course of the 12-month study period. In the fourth study, the geometric mean L:M among mildly stunted Nepalese children from urban squatter settlements aged five years and under was 0.26, but statistically significantly differed between *Giardia*-infected and non-infected children (0.43 vs. 0.25, respectively) [124].

Several studies investigated the relationship between subject age and L:M values; three found no association [113, 119, 124]. Goto et al. demonstrated a decreasing L:M trend with age among a cohort of Bangladeshi 3-15 month olds [123]. Campbell et al. [112] compared Gambian 2-5 year olds with older children and found a significant association between age and L:M values as well as a small but statistically significant improvement in mean L:M over 3.5 months driven by improved mannitol excretion without change in lactulose excretion. They later [110] reported study results among another cohort of Gambian children that showed that L:M values showed a large and statistically significant increase between 12 weeks and one year of age, a change driven by both increasing lactulose and decreasing mannitol excretion. Darboe et al. [115] observed that L:M values rose by about 50% from age two months to one year, but did not analyze the trend statistically.

Various studies examined the L:M marker in the context of other conditions. No association was found between L:M and diarrhea history [124] or helminthiasis [150, 205]. Associations were found between L:M and infection with HIV [119, 160] and *Cryptosporidium* and rotavirus [172]. Two studies reported seasonal L:M variation in rural Bangladesh, with peaks during [122] or following [150] monsoon season.

5.3.1.5 Use of the L:M Test as an Endpoint for Intervention Trials

Multiple studies have used the L:M marker as an endpoint to assess intestinal permeability in randomized, controlled trials. The specific interventions varied widely, including micronutrient supplementation, probiotics, therapeutic diets, and antibiotic and anti-helminthic drug administration.

Four studies utilized L:M as an outcome in vitamin A supplementation intervention trials and found no association with L:M overall [115, 119, 137, 168] although Filteau et al. did identify a significant reduction in L:M values among HIV-infected children treated with vitamin A [119]. While Darboe et al. noted that a vitamin A-supplemented group experienced a reduction in lactulose uptake, they also observed an accompanying decrease in mannitol absorption; therefore the ratio of the two sugars did not change [115]. This finding demonstrates the value of reporting the absorption of the two sugars separately, in addition to reporting the ratio. In contrast, Chen et al. observed improved L:M values after treating a cohort with persistent diarrhea or low WAZ with a single dose of vitamin A and a two-week course of daily zinc [113].

Lima et al. conducted two studies using L:M as an outcome to assess the beneficial effects of formulas of different compositions used in therapeutic rehabilitation of children with persistent diarrhea and/or malnutrition. In the study assessing glycine-supplemented formula, L:M values improved in the treatment group [138]. However in a trial in which this group examined alanyl-glutamine-supplemented formula, even though lactulose excretion improved, mannitol excretion worsened and therefore L:M values did not change after the intervention [139]. In another trial of glutamine supplementation, conducted by Williams et al. in The Gambia, the intervention did not improve L:M values; in fact, analysis by repeated measures analysis of variance (ANOVA) indicated that L:M values were borderline elevated in the glutamine-supplemented group ($p=0.05$), contrary to what was expected [170].

Another dietary intervention trial examined the efficacy of green banana and pectin among children with persistent diarrhea [157]. While post-intervention L:M values were still elevated, both lactulose and mannitol excretion improved after treatment, with lactulose being the primary driver of the improvements seen in the ratio of these two sugars.

Four other trials examined the degree to which L:M values improved as a result of various interventions, with no effect observed: probiotics [120] and antibiotics (rifaximin) [13] to target small bowel bacterial overgrowth as a potential cause of impaired intestinal integrity in Malawi, and various anti-helminthic and anti-*Giardia* treatments in Bangladesh [122, 150]. Interestingly, a Brazilian vitamin A trial demonstrated reduced lactulose as well as mannitol excretion, but an unchanged overall ratio [137], thereby highlighting the value of reporting absorption of the sugars separately.

In many of these studies, power considerations were not addressed at all, or incompletely addressed, and were often subordinated to study realities. Several examples illustrate the issue. Goto et al. recruited 222 children, into two treatment groups and one placebo group [122]. They estimated their sample size based on baseline recent Bangladeshi infant data [247]. They calculated that to improve HAZ by 33%, a sample size of 68 was needed (using an α of 0.05, and 80% power). For WAZ, the sample size needed was 73. So, after allowing for attrition, they aimed to recruit approximately 100 infants in each group. The anti-*Giardia* treatment used in this study, secnidazole, is unpalatable, so there was concern that there might be more attrition in those receiving this treatment. Therefore the treatment groups were increased by about 10% relative to the control group (n = 142, 141 and 127, respectively). However, because of large loss of subjects to follow-up as well as other methodological issues, including inaccurate dosing by many subjects and switching to analysis on actual treatment received rather than on an "intent-to-treat" basis, the final group sizes were 75 (secnidazole & albendazole), 59 (secnidazole only), and 88 (control). Hence, the size of the second group fell

below sample size targets for adequate power, while the other groups were still of sufficient size for projected HAZ and WAZ outcomes.

Northrop-Clewes et al. [150] did not report sample size calculations, indicating that their target sample size of 120 was based on logistical reasons. They went on to state “the null effect of deworming in this study could perhaps have stemmed from an inadequate sample size or duration of follow-up. However, significant improvements were observed in studies with smaller samples (e.g., n = 23, n = 55, and n = 72; 42, 10, 11) and of much shorter duration (seven and nine weeks) [248-250]”. This comparison draws attention to the potential role of publication bias in any review of the literature.

5.3.1.6 Associations between L:M and Other Markers

Five of the 25 publications examined L:M results in relation to other potential markers of intestinal dysfunction, including one study that found that it was not correlated with urinary lactose or lactose:lactulose [124]. Two studies assessed L:M and markers of systemic inflammation and found differing results [110, 123]. A fourth study found no correlation with stool neopterin [15]. The only study that we reviewed that examined L:M in relation to intestinal tissue reported a variety of intestinal tissue measurements by morphometry and reported positive correlation with mucosal B-lymphocyte density, intraepithelial lymphocytes (IEL), and IELs staining positive for perforin [111]. It is not clear if the other intestinal markers were not correlated or merely not assessed for correlation.

5.3.2 The Lactulose:Rhamnose Ratio (L:R)

Similar to the L:M, the lactulose:rhamnose ratio (L:R) has been used as an index of gut mucosal function. As in the L:M test, lactulose is used as the measure of barrier function, but rhamnose replaces mannitol as the marker of absorptive capacity. L:M is performed on urine samples and, as mentioned above, in timed collections, ranging from three to six hours. The L:R

test had been performed on similarly timed urine specimens as well. To our knowledge, there are no published data comparing rhamnose directly to mannitol in children with enteric dysfunction, but in adults with inflammatory bowel disease the two sugars are absorbed comparably [251].

5.3.2.1 The L:R Test as a Reflection of Issues in Serum or Urine Sugar Testing in Children

Recent advances in high-performance liquid chromatography (HPLC) now permit sensitive detection of lactulose, mannitol and rhamnose in the blood. While timed blood specimens have been evaluated in animals and human adults [252-256], the invasiveness of repeated phlebotomies presents practical and ethical challenges in pediatric research. However, collection of urine over a period of time in young children, while less invasive, is not a trivial task either. While application of urine “bag” collectors permits noninvasive capture of urine, loss of urine because of leakage around the bag is common, as is contamination by stool, especially among children with diarrhea. Indeed, it should be noted that the children in most need of intestinal function testing often have diarrhea, and the ingestion of the sugar loads themselves can lead to osmotic diarrhea.

Haase et al. compared the validity of L:R testing on one-time collections of blood to 5-hour urine collections [125] in children. They found that blood L:R values were consistently lower than urine L:R values by a geometric mean (95% confidence interval (CI)) of 1.09 (1.02, 1.16). There was substantial agreement between the two tests as measured by a kappa statistic of concordance (95% CIs) of 0.71 (0.51, 0.92). Assuming urine L:R as a gold standard, Haase et al. calculated sensitivity and specificity of blood L:R as 81% and 89% respectively.

As discussed above, test failure can occur for various reasons when tests rely on urine samples, particularly timed samples. However, test failure can also occur with blood specimens because of insufficient volumes collected to run the assay, and potentially from edema if blood

is obtained by finger stick [257]. In addition, the assay cannot be performed using either analyte if children vomit, or refuse to ingest, the sugars. Haase et al. defined test “failure” as emesis of the sugar load, urine leakage or contamination with stool, or blood collection insufficient for analysis (<0.25 mL of plasma). While they did not delineate the reasons for failure among the blood vs. the urine collections, they did observe a significantly higher failure rate for the urine (37%) compared to the blood assays (10%) ($p < 0.0001$). Interestingly, a study published in 1999 (and therefore not included in the analysis of this systematic review) by the same authors also reported a 37% failure rate for urine L:R testing and in this earlier study they specified the proportions by cause of failure. They noted that the failure rate for a five-hour urine collection varied between 47% (32 of 68) in girls with acute diarrhea to 17% (14 of 82) in non-diarrheal controls. They also noted that causes of test failure consisted of vomiting or refusal to drink the probe sugar solution in 21 (9%) of the tests [258].

The remaining four studies that used L:R as a marker of gut permeability measured these ratios in blood specimens. We found that rates of technical failure of testing were not often reported in the sugar absorption/permeability studies that we reviewed. Of the four studies using serum L:R, two discussed failure to complete testing. One study specifically reported difficulty with venipuncture in two of 34 subjects [159]. In the other study, L:R was measured at baseline as well as following an intervention with specific milk formulas [134]. It was not entirely clear, but it did seem that baseline L:R testing was successfully completed on all subjects while there was a reported “failure” of post-intervention testing among 10 of 150 children. Reasons for test failure in the second determination were not reported. Among the five studies that used D-xylose (either urine or serum) [136, 146, 147, 152, 155] no mention was made of lack of completion of testing among the subjects enrolled. Only seven [124, 138, 139, 150, 161, 169, 172] of the 25 urinary L:M studies included in this review specifically mentioned the number of children who completed L:M testing compared to the number recruited into the study. It was not

always clear why incomplete L:M testing occurred, but it appears that in five of these studies there was a failure in testing because of improper compounding of the sugar solution, inability to collect urine during the testing period, urine leakage or stool contamination, or refusal to ingest the sugar solution. Similar to the study that expressly measured and reported failure rates in L:R testing [125], Goto et al. reported in 1999 (and therefore not included in this review) that the L:M test failure rates were 32% [205].

It should be noted that each of the five L:R studies in this review was conducted by the same researchers in Darwin, Northern Territories, Australia (one of their studies also included subjects from Adelaide, South Australia, Australia). It appears that some of the studies might represent data from overlapping cohorts of children. It should also be noted that while Australia clearly falls within the classification of a high income country, our inclusion definition of children in “developing-country setting” included marginalized or indigenous populations in a developed country who are plausibly exposed to the same environmental and/or infectious risks for EED as children in developed-country settings. In fact, research among Aboriginal populations in Australia has contributed a great deal to the EED field [58, 258].

5.3.2.2 Range of L:R Values Reported and Associations with Growth Outcomes

Many investigators report the L:R value multiplied by 100 for ease of reporting; this convention was followed within the articles examined for this review. The geometric mean was the measure of central tendency consistently used in these studies, facilitating comparison of results. However, while the L:M studies referenced various ranges of normal standards, none of the L:R studies cited such reference standards. Furthermore, the three studies that reported the proportion of children with abnormal L:R results used different cutoff points and did not cite references for these demarcations of normal and abnormal values that they employed. One study defined an abnormal L:R value as >16 , with 20 of 32 children (63%) exhibiting values

above this threshold [159], another used 7.2 as their defined cutoff point with 112 of 152 subjects (74%) above that threshold [43], and a third explained the derivation of its cutoff point of >5.6 as two standard deviations above the arithmetic mean for non-Aboriginal children without diarrhea [58]. No citation was given for this standard value, implying that it might have been derived from the data collected in this study. However, the authors reported that none of the study's non-Aboriginal children without diarrhea had abnormal permeability values, suggesting that perhaps the cutoff point was derived from a different study. While their study included Aboriginal children with diarrhea, they did not report proportions of children with L:R values >5.6 for this group.

Three studies compared serum L:R values among primarily Aboriginal cases with diarrhea and controls without this disorder. Baseline geometric means for L:R (95% CIs) in the two studies ranged from 3.7 (2.8, 4.9) [134] to 5.9 (4.4, 7.8) [125] to 11.4 (8.5, 15.5) [159] among controls and 9.4 (6.7, 13.1) [125] to 12.8 (10.3, 16.0) [134] to 31.8 (24.9, 40.7) [159] among cases.

In a randomized trial of three different milk formulas in Aboriginal children with malnutrition and/or diarrhea, baseline geometric mean L:R values (95% CIs) were 14.9 (10.4, 21.5) in one treatment group; baseline values were similar in the other groups [134]. Although subjects were randomized to treatment groups, the study did not include a control arm of standard care to which change in L:R could be compared. Mean improvement in L:R (95% CIs) was 13.0 (9.3, 16.6) with some significant differences across treatment groups. This was the only study in this review using L:R as an outcome measure in an intervention trial.

A similar study reported that mean L:R values among Aboriginal children were approximately double those of non-Aboriginal children, whether examining across groups of subjects either with or without diarrhea, consistent with the authors' suggestion that clinically

silent enteric dysfunction is prevalent among Aboriginal children [58]. Geometric mean L:R among the children without diarrhea was 2.5 and 4.6 among non-Aboriginal and Aboriginals, respectively ($p=0.02$). Geometric mean L:R among those with diarrhea was 7.9 and 16.4 among non-Aboriginals and Aboriginals, respectively ($p=0.002$).

One study examined the relationship between L:R and growth and found no association with nutritional status or age. Associations were, however, found between high L:R and acidosis ($p=0.007$), hypokalemia ($p=0.035$) and diarrhea severity ($p=0.001$) among children with diarrhea [58].

5.3.2.3 Associations between L:R and Other Markers

Serum L:R was compared to other biomarkers for EED in three of the other four studies. Ritchie et al. found L:R to be significantly inversely correlated with the ^{13}C sucrose breath test ($r=0.67$; CI: 0.42, 0.62; $p<0.0001$) [159]. Kukuruzovic et al. studied urinary nitric oxide excretion in relation to L:R in Aboriginal and non-Aboriginal in-patients with acute diarrhea, non-gastrointestinal infections, or without infections or diarrhea [43]. They found that NO_2/NO_3 :creatinine and L:R were correlated ($r=0.37$, $p<0.001$), after adjusting for age and race. The association was stronger for lactulose permeability, with an effect ratio (95% CIs) of 1.47 (1.29, 1.66), than it was for rhamnose malabsorption, with an effect ratio (95% CIs) of 0.80, (0.67, 0.97). NO_2/NO_3 concentrations decreased significantly less rapidly than L:R values among children recovering from diarrhea. Another study by Kukuruzovic et al. assessed the association between L:R and red cell indices, stool reducing substances, and lactosemia and identified an association only with the latter, but the degree of correlation was minimal [58].

5.3.2.4 Methodological Issues with the L:R Test

Overall, there were fewer issues with consistency in reporting of L:R results across studies, perhaps because all of the L:R studies in our review were performed by the same group

of investigators. Four of the five studies reported a measure of central tendency for L:R and it was consistently in the form of a geometric mean multiplied by 100. Dosing of the sugars was the same across the studies. The timing for serum sampling was similar, with most using a collection time of 90 minutes following administration of the dose; only one study differed slightly, with testing occurring in a range between 90 to 120 minutes. HPLC was the test method for the serum L:R throughout. However, in striking contrast to the L:M studies, reference standards for L:R values were not cited. The three studies that reported proportions with abnormal L:R values used markedly different cutoff values that were either not defined or given insufficient explanation.

The urinary L:R test has disadvantages typical of any urinary method for dual-sugar permeability testing; the serum method avoids these issues, and, indeed, Haase et al. found a lower test failure rate with this method.

5.3.3 Serum and Urinary Lactose

As mentioned above, we assigned markers to categories based on their best fit, recognizing that biomarkers could indicate derangement of more than one function. For example, lactose is not normally absorbed across the intestine, but rather requires breakdown to products that are absorbed, namely galactose and glucose. This digestion is catalyzed by lactase, an intestinal brush border enzyme. While the presence of lactose in the serum or urine would in most instances indicate a lack of lactase (as opposed to presence of lactose excessive to lactase saturation), it also, and primarily, reflects a permeability defect, because even if lactose is not broken down, its size should preclude traversing the mucosa unless a porosity defect also exists.

We identified three studies that measured lactose in the blood (n=1) or urine (n=2) in the context of putative intestinal injury. Kukuruzovic et al. tested markers of intestinal permeability,

including serum lactose, among hospitalized Aboriginal and non-Aboriginal children with and without diarrhea [58]. Circulating lactose was detected in 38% of Aboriginal cases and 12% of controls (Aboriginal and non-Aboriginal combined). Lactosemia was weakly associated with an abnormal L:R. Another study of children from two urban squatter settlements with high rates of malnutrition primarily focused on identifying lactase deficiency via urinary lactose:lactulose, finding that nearly half of subjects had low lactase activity [124]. Urinary lactose concentration, as well as lactose:lactulose ratio, decreased with increasing age, but neither was associated with the L:M. The authors noted that lactose concentrations and lactose:lactulose ratios were significantly higher in breastfed subjects than those not breastfed, despite similar L:M values. However, the paper did not specify the nature of the dietary lactose sources in the non-breastfed babies. That is to say, if the bioavailability of the lactose or the quantity ingested is low, mucosal function could appear to be inappropriately normal. The final study measured the lactose:creatinine (L:Cr) ratio in Nepali children living either in squatter settlements or lower middle-class periurban households [151]. Mean L:Cr was significantly higher among the squatter compared to the lower-middle class group. For both SES groups, L:Cr values decreased with increasing age ($p < 0.001$). HAZ, WAZ, WHZ, and Δ WAZ scores were strongly associated with mean L:Cr ($p < 0.001$ for each parameter) as was Δ HAZ score ($p = 0.004$); Δ WHZ score was not. Interestingly, the strength and magnitude of association between Δ WAZ score and L:Cr was most pronounced among the wealthier cohort and there was no association between Δ HAZ score and L:Cr among the squatter children, perhaps because of poor diets accounting for more of an effect among the squatter children.

5.3.4 Summary of Markers of Permeability

Despite logistical challenges, the L:M and L:R tests and other tests of permeability have been utilized extensively to assess intestinal function in children in resource-limited settings.

L:M values were often, but not always, elevated above published developed country norms in community-based studies of asymptomatic children in resource-limited settings. The other tests of permeability generally were not compared to a reference standard, limiting comparison of results across studies and different settings.

The L:M test was more extensively studied than the other permeability markers and was used more widely as an endpoint for intervention trials, including evaluation of micronutrient supplementation, dietary interventions and probiotics, and anti-bacterial and anti-parasitic drug treatments. L:R was used as an outcome measure for one intervention study. With new HPLC laboratory methods that are sufficiently sensitive to detect lactulose, rhamnose and other sugars, dual sugar tests might become more widely used.

While we identified two studies that compared serum L:R to serum lactose [58] and L:M to urinary lactose and lactose:lactulose [124], we did not find comparisons of L:M and L:R test results; a head-to-head comparison of the two most extensively used permeability tests would be informative.

The relationship between L:M and age varied across studies; some observed an association [110, 112, 115, 123], while others did not [113, 119, 124]. The single study that investigated the relationship between L:R and age did not find an association [58]. Furthermore, while most studies found an inverse association between L:M and anthropometric status, results were mixed. One study investigated the relationship between L:R and growth, and did not observe an association [58].

As with the D-xylose and endomolecular tests of absorption, lack of consistency in what was used as a cutoff point for normal (or what was reported to have been used) in the dual sugar permeability tests made it very difficult to compare results from one study to the next. Across permeability tests, we found a wide spectrum of depth of reporting and insufficient

details were often provided. The L:M studies best portrayed issues with methodology, reporting, and poor comparability caused by wide differences in how the test was performed across studies, differences in subject preparation and feeding mode, dosage of test sugars, and timing of urine collection, all of which can influence test results. Further complicating comparability, the measures of central tendency for reporting L:M varied.

While L:R tests have been conducted by evaluating the different biological sampling media of urine or serum, the serum test was used much more widely in the last decade and serum tests have been conducted in a much more standard manner than the urinary L:M test. Urinary L:R has disadvantages typical of any urinary method for dual-sugar permeability testing; the serum method avoids these, and Haase et al. [125] found fewer test failures with this method.

We found only one example of the urinary lactose:creatinine test having been employed in a pediatric population in a resource-limited setting [151]. The lactose in the urine is waste from endogenous metabolism of ingested material, and the creatinine is also a waste product naturally present in the urine. Testing endogenous metabolites eliminates the need for a loading dose as well as a post-dose delay of multiple hours for sample collection, which are inherent parameters of dual-sugar tests. These aspects of the L:Cr test could provide advantages compared to dual-sugar tests in resource-limited settings. However, in comparing the tests, it will be important to consider other parameters such as sample processing, as well as the comparative accuracy and reproducibility of the different tests. Recent data on the use of the L:Cr ratio to assess intestinal permeability in pediatric populations in resource-limited settings is scarce. None of the studies from our review assessed both L:M and L:Cr ratios in the same individuals, so it is not possible to compare the tests directly from the available data.

It should be noted that many elements of this chapter, especially pertaining to the L:M test, were published in 2014 [185].

5.4 Markers of Digestion

Twelve studies [43, 53, 58, 102, 109, 124, 132, 138, 147-149, 159] utilized a variety of markers that reflect intestinal digestive function. The particular data relevant to this review are listed for each of these studies in Evidence Table 3. Thirteen markers were assessed across the studies: eleven and two were markers of carbohydrate and lipid digestion, respectively. Testing for reducing substances in the stool was used in four studies as a marker of nonspecific poor digestion of sugars [43, 58, 132, 138]. Two other studies used biopsied intestinal tissue to measure specific disaccharidase activity or mRNA abundances [53, 109]. Three studies tested exhaled breath to assess maldigestion of lactose or sucrose [102, 147, 159].

One study employed urine lactose:lactulose ratio as a marker of lactase function [124]. Lastly, two studies, both by the same investigators, assessed intestinal lipid digestive capacity by measuring total triglyceride compared to fatty acids in the stool [148, 149].

Evidence Table 3. Markers of digestion.

Biomarkers in bold are categorized as primarily markers of digestion.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
2002 Alves GM et al. Nutritional status and breath hydrogen test with lactose and lactulose in Terena Indian children Lactose hydrogen breath test (HBT) as a marker of lactase activity, and lactulose HBT as a marker of SBBO	Limão Verde and Córrego Seco, Mato Grosso do Sul, Brazil All children <10 yr old were recruited from these rural villages.	Cross-sectional n=264; <5 yr old: n=145 (However results were provided by <4 and ≥4 yr old age groups.)	<u>Breath Tests:</u> • Lactose HBT (251 tested) • Lactulose HBT (252 tested)	Lactose HBT: • Elevated: 27.1% among all subjects • Borderline: 43.0% among all subjects • 0% of subjects <4 yr had elevated or borderline results Lactulose HBT positive: • 11.5% of all subjects 8.6% of subjects <4 yr	The prevalence of lactase deficiency as measured by lactose HBT was >25%, but non-existent among those <4 yr of age. Prevalence of SBBO as assessed by lactulose HBT was ~10%.	Assessment of association between lactulose and lactose absorption was not reported.
2003 Bustos M et al. Disaccharidase deficiency in Bolivian children with persistent diarrhea Jejunal biopsy and disaccharidase activities in children with PD and different forms of malnutrition	Cochabamba, Bolivia 3-34 mo old Amerindians hospitalized with PD and moderate or severe malnutrition in an urban setting.	Cohort n=42 cases with PD and malnutrition: • 2 with kwashiorkor • 20 with marasmus • 20 with marasmic-kwashiorkor Children were assessed on admission and at three weeks, after diarrhea had resolved and anthropometrics were improving.	<u>Jejunal tethered capsule biopsy:</u> • Histopathology • Disaccharidase activity: • Lactase • Sucrose-Isomaltase • Maltase Histology was scored on a scale of 1 (normal) to 4 (severe morphological damage or flat mucosa).	Most subjects had mild to moderate (score of 2-3) histological abnormalities, with one kwashiorkor patient having completely flat villi. Second biopsy showed a trend of improved mucosa, but difference was not significant based on histology score, intraepithelial lymphocyte density, or degree of infiltration of lamina propria. Percentages with enzymatic activity below normal at baseline, discharge: • Lactase: 64%, 59% • Sucrase-isomaltase: 97%, 90% • Maltase: 45%, 52% All changes were statistically significant. Lactase recovery was associated with admission HAZ (p=0.05) and WAZ (p=0.03) scores.	Patients had diminished intestinal disaccharidase activity and substantial pathology on biopsy at admission and at three weeks, despite clinical improvements and tolerance of lactose-containing formula.	Spanish language article. Values for subnormal disaccharidase activity were not provided. The magnitude of lactase inverse association with growth parameters was not reported. Authors did not report whether they had tested for associations between maltase or sucrose-isomaltase and growth parameters.

Evidence Table 3. Markers of digestion.

Biomarkers in bold are categorized as primarily markers of digestion.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
				Despite continued high disaccharidase deficiency prevalence at discharge, all children tolerated the lactose-containing formula challenge.		
<p>2002</p> <p>Goto R et al.</p> <p>Poor intestinal permeability in mildly stunted Nepali children: Associations with weaning practices and <i>Giardia lamblia</i> infection</p> <p>L:M as a marker of intestinal permeability, and assessment of association with giardiasis, helminthiasis, nutritional practices, and growth status.</p>	<p>Kathmandu, Nepal</p> <p>0-5 yr olds (mean age 3.8 yr) from two urban squatter settlements.</p> <p>37% and 33% of subjects were stunted and underweight, respectively.</p>	<p>Cross-sectional</p> <p>n=210</p>	<p><u>Urine Tests:</u></p> <ul style="list-style-type: none"> • Lactulose¹ • Mannitol • Lactose² (168 tested) • L:M (158 tested) • Lactose:lactulose ratio (157 tested) 	<p>L:M:</p> <ul style="list-style-type: none"> • 92% had values >UK norms • Mean³ L:M (SD, range): 0.26 (0.21, 0.04-1.71). • <i>Giardia</i>-infected versus uninfected means: 0.43 vs. 0.25, p=0.014 <p>The duration of ingestion of solid foods (with or without concurrent breastfeeding) was not associated with L:M in multivariate analysis.</p> <p>L:M was correlated with longer duration of breastfeeding (r=0.27, p<0.019). Specifically, children who breastfed for >2 yr had higher L:M ratios than children who breastfed for shorter times (data not provided).</p> <p>L:M was not associated with:</p> <ul style="list-style-type: none"> • History of diarrhea in the week preceding testing • Helminthiasis • Age • WAZ or HAZ scores <p>Lactulose excretion ranged from 0.02–15.00. Mannitol excretion ranged from 0.5–15.00.</p>	<p>L:M ratios were high overall.</p> <p>Wide individual variation was observed in L:M ratios.</p> <p>L:M was associated with giardiasis but not helminthiasis.</p> <p>Urinary lactose concentrations and lactose:lactulose ratios were significantly higher in breastfed subjects than in those that were not breastfed, despite similar intestinal permeability values.</p> <p>There were some unexpected findings: the duration of breastfeeding, and not the timing of introduction of solid foods, was correlated with L:M, and the correlation was direct, not inverse.</p> <p>Authors speculate that this could be due to higher mean age of their</p>	<p>Low lactase activity was defined as lactose:lactulose ratio >0.4.</p> <p>Specific L:M data by WAZ and HAZ scores were not reported, although authors state that L:M was not associated with “growth status.”</p>

¹ Lactulose and mannitol results were expressed as % of dose administered.

² Lactose results were expressed in mg/L.

³ Geometric mean.

Evidence Table 3. Markers of digestion.

Biomarkers in bold are categorized as primarily markers of digestion.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
				<p>47% showed low lactase activity. Lactose values and lactose:lactulose ratios decreased with age ($R^2=28\%$, $p<0.0001$), but were not associated with sex, ethnicity, and location nor were they associated with L:M.</p> <p>Mean¹ urinary lactose concentrations (mg/L) by feeding mode:</p> <ul style="list-style-type: none"> • Breastfed: 172.5 • Non-breastfed: 44.5, $p<0.0001$ corrected for infant age <p>Mean² lactose:lactulose ratio by feeding mode:</p> <ul style="list-style-type: none"> • Breastfed: 2.76 • Non-breastfed: 0.31, $p<0.0001$ corrected for infant age <p>Mean L:M by feeding mode:</p> <ul style="list-style-type: none"> • Breastfed: 0.23 • Non-breastfed: 0.28, non-significant, p-value not specified 	cohort compared to another study that demonstrated beneficial effect of duration of breastfeeding on reduced L:M in Guatemala [205].	
2002 Kirkpatrick BD et al. Cryptosporidiosis stimulates an inflammatory intestinal response in malnourished Haitian children	Port-au-Prince, Haiti <18 mo olds from a low SES setting recruited from the rehydration unit of GHESKIO HIV Center ³ with diarrhea and <i>Cryptosporidium</i> infection. Controls	Case-control n=49; n=17 cases with <i>Cryptosporidium</i> and diarrhea (5 with PD) n=32 controls without	Stool Tests: <ul style="list-style-type: none"> • Reducing substances (RS) • Lactoferrin • Cytokines: <ul style="list-style-type: none"> • TNF-α receptor I • IL-4 • IL-8 • IL-10 • IL-13 	Proportion RS-positive: <ul style="list-style-type: none"> • 33.3% cases • 64.7% diarrhea controls • 46.7% healthy controls, ($p=0.2$) Proportion lactoferrin-positive: <ul style="list-style-type: none"> • 83.3% cases • 60.0% diarrhea controls • 28.6% healthy controls, ($p=0.01$) 	Fecal lactoferrin was identified most often in children with diarrhea, especially in those with <i>Cryptosporidium</i> . While some fecal cytokines were detected in as many as 40% of healthy controls and 70% of controls with diarrhea, they were generally	Reported results were not stratified by persistent vs. acute diarrhea status. Cut-off values for lactoferrin positivity were not described. Stools from children

¹ Geometric mean.² Geometric mean.³ The Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections.

Evidence Table 3. Markers of digestion.

Biomarkers in bold are categorized as primarily markers of digestion.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
Stool lactoferrin, reducing substances, leukocytes and cytokines as markers of intestinal inflammation of children with and without <i>Cryptosporidium</i> infection	recruited from an outpatient clinic without <i>Cryptosporidium</i> infection included those with and without diarrhea.	<i>Cryptosporidium</i> ; • 17 with diarrhea (5 with PD) • 15 healthy	• IFN- γ <u>Blood Test:</u> WBC	IFN- γ was not recovered in any stools. All other fecal cytokines were significantly associated with <i>Cryptosporidium</i> cases compared to diarrhea and healthy controls. Additionally, TNF- α receptor I, IL-8, IL-13 were found in diarrhea and healthy controls, while IL-4 and IL-10 were not. Fecal lactoferrin was associated with the presence of TNF- α receptor I (point estimate not provided, p=0.03). Mean WBC counts were within normal range in all 3 groups.	associated with <i>Cryptosporidium</i> infection. The other stool tests did not discriminate by diarrhea or <i>Cryptosporidium</i> status.	who were breastfeeding were not tested for lactoferrin.
2003 Kukuruzovic R et al. Increased nitric oxide production in acute diarrhea is associated with abnormal gut permeability, hypokalemia and malnutrition in tropical Australian aboriginal children Nitric oxide (NO) as a marker of intestinal permeability and inflammation, and lactulose:rhamnose ratio (L:R) as a marker of intestinal	Darwin, Australia 1-6 yr old Aboriginal and non-Aboriginal hospital inpatients. Subjects were grouped as follows: 1. Children with AD 2. Children with no diarrhea but with non-GI infectious conditions 3. Children without GI or infectious conditions	Case-control n=318; n=169 cases with AD (154 Aboriginal) n=149 controls: • 73 with non-GI infections (49 Aboriginal) • 76 with no infections (29 Aboriginal)	<u>Urine Test:</u> Nitric Oxide (NO)* <u>Blood Tests:</u> • L:R • Mean corpuscular volume (MCV) <u>Stool Test:</u> Reducing substances (RS)** (169 cases tested) * NO is an unstable free radical and is converted to nitrite and nitrate. Urine nitrate (NO ₃) + nitrite (NO ₂) was expressed	NO among Aboriginal children with diarrhea was >3x higher than any other group and >5x higher than in non-Aboriginal controls. • NO was >3x and >2x higher among Aboriginal than non-Aboriginal children in the diarrhea (p<0.001) and no infections groups (p<0.001), respectively, but there was no difference between them in the non-GI infections group. • NO was >3x and ~2x higher in the diarrhea compared to the no infections group among Aboriginals (p<0.001) and non-Aboriginals (p<0.03), respectively. • NO was virtually the same	NO ₂ + NO ₃ :Cr ratio, as a measure of endogenous nitric oxide production, was used as a marker of gut permeability and inflammation, with an attempt to identify how much more it reflects as response to inflammation from GI vs. non-GI infections. Among non-Aboriginal controls, NO production was the same among those with diarrhea and non-GI infections (and higher compared to controls). NO was highest by far among Aboriginal children with diarrhea compared to	Positive stool RS was defined as $\geq 0.5\%$. Abnormal L:R was defined as >7.6; no reference or derivation was provided for this cut-point. Study population appears to be the same as in another Kukuruzovic, et al. study also included in this review which assessed serum lactulose:rhamnose as a marker of intestinal permeability [58].

Evidence Table 3. Markers of digestion.

Biomarkers in bold are categorized as primarily markers of digestion.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
permeability and the relationship between NO and L:R, growth parameters, mean corpuscular volume (as a surrogate of iron deficiency), and stool reducing substances among children with and without diarrhea			as a ratio with urine creatinine (NO ₂ + NO ₃ :Cr) in order to account for differences in urine concentration. ** Measured only among children with profuse diarrhea.	among the Aboriginal non-GI infections and no infections groups, as well as among the non-Aboriginal diarrhea and non-GI infections groups. 112/152 (74%) and 31/169 (18%) of children with AD had abnormal L:R ratios and positive stool RS, respectively. NO and L:R were measured at "convalescence" on Day 5 among those with diarrhea: the mean improvement in NO was 21.7% compared with 54.6% for L:R (p=0.01). NO and L:R were correlated (n=193, r=0.37, p<0.001) ¹ ; the correlation was stronger for lactulose (effect ratio=1.47, p<0.001) than for rhamnose (effect ratio=0.80, p=0.02 ²). NO was not correlated with stool RS ³ or MCV, but was correlated with lower WAZ score (effect ratio=0.88, p=0.05).	any other group. Authors suggest that high basal concentrations of NO among Aboriginal children due to (clinically silent) enteropathy could explain the concentrations seen among Aboriginal controls in this study. NO appeared to decrease significantly more slowly than L:R among children recovering from diarrhea. NO was found to correlate with L:R. NO was more strongly correlated with lactulose than rhamnose.	
2002 Kukuruzovic RH et al. Small bowel intestinal permeability in	Darwin, Australia Cases were Aboriginal and non-Aboriginal children admitted to hospital with diarrhea. Controls were	Case-control n=375 admissions for 306 children; n=285 case admissions for AD (264	Blood Tests: • Lactose • Lactulose ⁴ • Rhamnose • L:R • Hemoglobin • Mean corpuscular	27/75 (36%) of Aboriginal controls and 0 non-Aboriginal controls had abnormal L:R ratios. Mean ⁵ L:R at baseline: Cases: • Aboriginal: 16.4	Mean L:R ratios of Aboriginal children were approximately double those of non-Aboriginal children both among those with and without diarrhea, consistent with authors' suggestion that	Positive stool RS was defined as ≥0.5%. Abnormal L:R was defined as >5.6, derived from 2 SD above the

¹ Reported results appear to have been adjusted for age and race.

² Reported results were adjusted for age and race.

³ Reported results among children with diarrhea were adjusted for age and race.

⁴ Lactulose and rhamnose results were expressed as % of dose administered.

⁵ Geometric mean.

Evidence Table 3. Markers of digestion.

Biomarkers in bold are categorized as primarily markers of digestion.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
<p>Australian Aboriginal children</p> <p>Serum lactulose: rhamnose ratio (L:R), serum lactose, and stool reducing substances as markers of intestinal permeability among Aboriginal and non-Aboriginal children with and without diarrhea</p>	<p>Aboriginal and non-Aboriginal children admitted without GI illnesses.</p>	<p>Aboriginal) n=90 control admissions with no diarrhea (74 Aboriginal)</p>	<p>volume (MCV)</p> <p>Stool Test: Reducing substances (RS)*</p> <p>L:R testing was repeated on day 5 for a subset of Aboriginal subjects: <ul style="list-style-type: none"> • 174/264 admissions for acute diarrhea • 25/74 control admissions </p> <p>* Measured only among children with profuse diarrhea when "clinically indicated". Number tested not provided.</p>	<ul style="list-style-type: none"> • Non-Aboriginal: 7.9, p=0.002 compared to Aboriginal cases <p>Controls:</p> <ul style="list-style-type: none"> • Aboriginal: 4.6 • Non-Aboriginal: 2.5, p=0.02 compared to Aboriginal controls <p>Mean improvement¹ in L:R (CI) at day 5 among those with repeat testing:</p> <ul style="list-style-type: none"> • Aboriginal cases: 14.6 (11.2, 18.0) • Aboriginal controls: -0.63 (-4.0, 2.7) <p>Mean lactulose recovery²:</p> <ul style="list-style-type: none"> • Cases day 1: 0.085 (0.070–0.103) • Cases day 5: 0.039 (0.033–0.046) • Controls: 0.024 (0.019–0.029) <p>All 3 values significantly differed from one another.</p> <p>Mean rhamnose recovery:</p> <ul style="list-style-type: none"> • Cases day 1: 0.479 (0.424–0.542) • Cases day 5: 0.555 (0.498–0.616) • Controls: 0.585 (0.500–0.685) <p>These values did not significantly differ from one another.</p> <p>Confidence intervals (CIs) in the authors' graphical representation of mean L:R at admission did not overlap, and the difference in</p>	<p>clinically silent enteropathy is prevalent among Aboriginal children.</p> <p>Mean L:R significantly improved over 5 days among Aboriginal cases. Children with severe diarrhea had higher mean L:R.</p> <p>Higher case L:R was driven more by high lactulose than by low rhamnose. Similarly, improvement in L:R among cases was primarily due to decreased lactulose.</p> <p>Stool RS and serum lactose were found in approximately one-quarter and one-third of Aboriginal cases, respectively. The latter was weakly associated with increased lactulose.</p>	<p>arithmetic mean for non-Aboriginal controls in this study. The rationale for the choice of 2 SD above the arithmetic, instead of the geometric, mean is not clear. Proportions of cases with abnormal concentrations were not reported.</p> <p>Analysis included data for 69 children with repeat admissions; this might violate independence assumptions for their statistical analysis methods.</p> <p>Repeat L:R testing was conducted on controls of both racial groups, but among cases it was only conducted on Aboriginal cases.</p> <p>This study appears to report on the same population as in the Kukuruzovic, et al. 2003 reference also</p>

¹ Improvement in L:R appears to have been calculated as baseline L:R minus repeat L:R, as described in another publication in this review; however, this was not expressly stated. Reference 134. Kukuruzovic RH, Brewster DR. Milk formulas in acute gastroenteritis and malnutrition: a randomized trial. J Paediatr Child Health, 2002. 38(6):571-577.

² Figures reported parenthetically after the mean percent recoveries of lactulose and rhamnose were not specified as ranges or CIs.

Evidence Table 3. Markers of digestion.

Biomarkers in bold are categorized as primarily markers of digestion.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
				<p>means was particularly evident between Aboriginal and non-Aboriginal subjects.</p> <p>Factors associated with L:R among cases were ¹:</p> <ul style="list-style-type: none"> • Acidosis (p=0.007) • Hypokalemia (p=0.035) • Diarrhea severity (p=0.001) <p>Age and malnutrition were not associated with L:R.</p> <p>38% and 27% of Aboriginal cases had positive serum lactose and stool RS, respectively. 12% of Aboriginal and non-Aboriginal controls combined had lactosemia.</p> <p>Presence of lactosemia was associated with L:R, adjusted relative risk (CI)=1.06 (1.03, 1.10)². Stool RS, anemia, and MCV were not associated with L:R.</p>		<p>included in this review, which assessed nitric oxide excretion [43].</p> <p>Authors reiterate the advantages of serum over timed urine collection for assessment of L:R, as discussed in another publication in this review [125]</p>
<p>2005</p> <p>Lima AA et al.</p> <p>Intestinal barrier function and weight gain in malnourished children taking glutamine-supplemented enteral formula</p> <p>L:M as a marker of</p>	<p>Fortaleza, Brazil</p> <p>2-60 mo olds hospitalized with WAZ score <-2, ~70% of whom had PD.</p>	<p>RCT</p> <p>n=80;</p> <p>n=53 received supplemented formula</p> <ul style="list-style-type: none"> • 27 with glycine • 26 with glutamine <p>n=27 received</p>	<p><u>Urine Tests*</u>:</p> <ul style="list-style-type: none"> • Lactulose³ • Mannitol • L:M <p><u>Stool Tests**:</u></p> <ul style="list-style-type: none"> • Lactoferrin • Leukocytes • Occult blood • Reducing substances (RS) 	<p>Mean⁴ L:M (SE):</p> <ul style="list-style-type: none"> • Glutamine group: <ul style="list-style-type: none"> • Baseline: 0.31 (0.10) (similar in all three groups) • Day 10: 0.10 (0.02); significant decrease, (p=0.01) • No significant decrease in L:M in glycine and nonsupplemented formula groups at day 10 	<p>L:M significantly improved in the glutamine group only.</p> <p>>50% of subjects had intestinal inflammation by stool lactoferrin. Fecal leukocytes, RS, and occult blood were detected in fewer subjects than lactoferrin.</p>	<p>The relationship between stool markers and L:M was not reported.</p> <p>Data were not stratified by history of PD.</p> <p>Fecal fat was assessed, but results were not reported.</p>

¹ Reported results were adjusted for confounding variables, unless otherwise noted.

² Reported results were adjusted for severity of diarrhea, acidosis, hypokalemia, and age.

³ Lactulose and mannitol results were expressed as % of dose administered.

⁴ Type of mean not specified.

Evidence Table 3. Markers of digestion.

Biomarkers in bold are categorized as primarily markers of digestion.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
intestinal permeability and various stool tests among children with malnutrition or PD who received either glycine or glutamine supplemented formula or placebo		nonsupplemented formula	* n=80 tested at enrollment, n=65 tested at day 10. ** n=60 tested.	Mean lactulose (SE): • Glutamine group: • Baseline: 0.97 (0.46) (similar in all three groups) • Day 10: NS decrease in all 3 groups Mean mannitol (SE): • Glutamine group: • Baseline: 3.42 (0.64) (similar in all three groups) • Day 10: NS decrease in all 3 groups Proportion of stool markers at baseline among all subjects: • Lactoferrin: 53.3% • Leukocytes: 11.7% • RS: 3.3% Occult blood: 5.0%		Cut-off values for lactoferrin positivity were not described. Exclusively breastfed children were excluded from study participation due to assessment of stool lactoferrin.
2002 Moya-Camarena SY et al. Effects of asymptomatic <i>Giardia intestinalis</i> infection on carbohydrate absorption in well-nourished Mexican children Lactose hydrogen breath test (HBT) as a marker of lactose absorption, and xylose breath test and urinary excretion as markers of xylose	Hermosillo, Sonora, Mexico 3-6 yr olds in a periurban setting attending preschool centers meeting inclusion criteria of no GI symptoms, no antibiotics in the preceding 3 wk, and no SBBO by lactulose HBT and Indican test.	Case-control n=13; <5 yr old: n=5 n=7 asymptomatic cases infected only with <i>G. intestinalis</i> n=6 controls without <i>Giardia</i> Cases were evaluated before and 3 wk after treatment with	Breath Tests* : • Lactose HBT • D-Xylose HBT** Urine Test: D-xylose**. ¹ * Reported as parts per million (ppm) post-substrate ingestion after subtraction of baseline, pre-substrate H ₂ concentrations. A positive HBT is considered to be a rise of ≥20ppm in breath H ₂ above	Mean lactose HBT (SE): • Cases pre-treatment: 3.6 (0.75) ppm • Cases post-treatment: -0.85 (0.75) ppm (p<0.05 compared to pre-treatment) • Controls: 0.19 (0.81) ppm (p<0.05 compared to pre-treatment cases) Mean xylose HBT (SE): • Cases pre-treatment: 2.2 (0.69) ppm for infected group • Cases post-treatment: -4.16 (0.69) ppm (p<0.05 compared to pre-treatment) • Controls: 1.13 (0.74) ppm (NS compared to pre-treatment cases) Mean urinary excretion of xylose	Lactose HBT concentrations were normal according to established cut-points among all subjects. However, lactose HBT was significantly higher among cases compared to controls and there was also a significant decrease in lactose HBT among cases after treatment. The clinical relevance of such mildly elevated HBT results in asymptotically infected children is unclear. Results did not	Statistical methods might not have been adequate to account for intra-subject correlation when comparing the same group of subjects (cases) before and after treatment. Investigators wished to exclude children with SBBO. As such, inclusion criteria restricted participants to those with adequate production of H ₂ following ingestion

¹ D-xylose results were expressed as % of dose administered.

Evidence Table 3. Markers of digestion.

Biomarkers in bold are categorized as primarily markers of digestion.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
absorption in well-nourished children with asymptomatic giardiasis and non-infected controls		tinidazole. Post-treatment stools were verified for absence of parasites.	baseline H ₂ concentration. ** Investigators did not specify the xylose enantiomer used, however test functionality characteristics lead us to assume that it was the dextrorotary (D) enantiomer.	(SE) among cases pre-treatment and post-treatment was 34% (3) and 46% (11), respectively (NS), well above cut-offs indicative of malabsorption.	demonstrate xylose malabsorption by either urinary or breath measures among any group. While urinary results did not differ before and after treatment, case xylose HBT was significantly lower after treatment; again the clinical significance of such results is not apparent.	of lactulose and with minimal urinary indoxyl sulfate excretion. The number of children excluded due to failure to meet these criteria was not reported.
2002 Murphy JL et al. Maldigestion and malabsorption of dietary lipid during severe childhood malnutrition Stool recovery of radiolabeled products as markers of lipid digestion and absorption, and bile salt deconjugation as a marker of SBBO among children with severe malnutrition	Kingston, Jamaica 5-23 mo olds admitted to the Tropical Metabolism Research Unit of the University of the West Indies with severe malnutrition.	Case-series n=24 Subjects were divided into 3 groups of 8 children, each group receiving a different labeled triglyceride. Data were collected in three separate phases as described above in JL Murphy et al. 2001 [149].	<u>Stool Tests:</u> • Total and fractionated ¹³C following ingestion of one of three ¹³C labeled triglycerides (TG): trilaurin, triolein, or trilinolein* • ¹³ C stool assay following administration of labeled fatty acid ¹³ C glycocholate** * To assess fat excretion as a % of dose administered. Also assessed proportion of ¹³ C in triglyceride (TG) and fatty acid (FA) fractions to distinguish excretion caused impaired digestion (presence of TG) vs. poor absorption (presence	Median total stool excretion of ¹³ C in phase 1 was 9% (range: 1%-29%) and did not vary between TG groups. Median ¹³ C excretion dropped 33%-99% in phase 2 and 86%-95% in phase 3 compared to phase 1 (p<0.05 each). Over the study period, there were significant associations between total lipid and the amount of ¹³ C labeled TGs in stool for some groups, but not for others. Median ¹³ C in TG and FA was similar across TG groups in all phases. ¹³ C FA recovery was similar and reduced by ~2/3 compared to Phase 1. ¹³ C TG was not detectable in Phases 2 or 3. Statistical comparisons between phases were not reported. ¹³ C after radiolabeled glycocholate administration was detected in stool at quantities considered to be in excess of	High concentrations of ¹³ C (compared to healthy UK children) [190] were observed in half of the subjects at admission, reflecting impaired digestion or absorption. The differences in stool ¹³ C were wide but not as extreme as in a previous study by same investigators (also examined in this review) using a different TG (tripalmitin) substrate [149]. ¹³ C excretion did not significantly differ between TG groups and declined with improving clinical course. Similar to their previous study, significantly more ¹³ C in stool was recovered as FA than TG, reflecting impaired	Authors state that the study was not powered to compare the different TGs, but they contend that medium chain trilaurin did not appear to be processed differently than the longer chain TGs triolein and trilinolein. Authors did not describe the method used to assign subjects to different TG groups. While it was noted that some subjects had positive stool cultures, details were not provided on the nature of the enteric infections.

Evidence Table 3. Markers of digestion.

Biomarkers in bold are categorized as primarily markers of digestion.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
			of FA). ** To assess bile salt deconjugation in the bowel caused by SBBO; conducted after the TG assessment and a 3 day washout period.	the 7% recovery of dose administered upper limit of normal in U.S. adults in [189]: <ul style="list-style-type: none"> Phase 1: 13/24 (54%) Phase 2: 5/24 (20.8%) Phase 3: 3/24 (12.5%) 	absorption over poor lipid digestion/ hydrolysis. Unlike in their previous study, there was evidence of SBBO as measured post-ingestion of ¹³ C glycocholate.	
2001 Murphy JL et al. Gastrointestinal handling and metabolic disposal of ¹³ C-labelled tripalmitin during rehabilitation from childhood malnutrition Fecal fat, stool recovery of radiolabeled products, and breath tests as markers of lipid digestion and absorption and bile salt deconjugation as a marker of SBBO among children with severe malnutrition	Kingston, Jamaica 7-23 mo olds with malnutrition admitted to the University of the West Indies.	Case-series n=8 Data were collected in three separate phases (each lasting 9 days): 1. Within 48 hours of admission 2. During early rehabilitation 3. During late rehabilitation	Stool Tests: <ul style="list-style-type: none"> Fecal fat* Total and fractionated ¹³C assay after administration of ¹³C tripalmitin (TP)** ¹³C assay after administration of ¹³C glycocholate (GCA)*** Breath Tests: <ul style="list-style-type: none"> ¹³CO₂ after administration of ¹³C glycocholate (GCA)*** ¹³CO₂ after administration of ¹³C TP**** * In 72 hour stool collection (measured as total grams and as % of dietary fat intake). ** To assess fat excretion as a % of dose administered. Also assessed	Mean fecal fat (SD): <ul style="list-style-type: none"> Phase 1: 2.4 g/day (3.6) or 5.9% (9.4) of dietary lipid intake Phase 2: 1.7 (0.9) g/day, or 3.3% (2.4) of intake Phase 3: 0.9 (0.6) g/day, or 1.4% (0.7) of intake Differences between phases were not statistically significant. Total excretion of ¹³ C in stool also varied widely across patients (0%-44%) and did not differ between study phases. Correlation between fecal fat and ¹³ C (r=0.48; p<0.05) was observed. Lack of lipid digestion and absorption were assessed by measuring TG and FA fractions, respectively. Mean ¹³ C TG recovery (SD) (% of administered dose), number of patients excreting TG: <ul style="list-style-type: none"> Phase 1: 0.7% (1.6), n=3 Phase 2: 0.9% (2.8), n=1 Phase 3: no recovery from any subjects, differences between phases were NS 	Mean fecal fat was not elevated compared to published norms [191, 192] during any study phase. There was wide variation in fecal fat at presentation, and wide variations in stool ¹³ C across subjects. Authors indicate that this is the first such assessment in malnourished children; previous studies on healthy children from the UK demonstrated average excretion of 6% [190]. The majority of excreted ¹³ C was in the form of FA rather than TG. Authors interpreted this to reflect failure of lipid absorption in the face of adequate digestion/ hydrolysis. Each form (FA and TG) was found in decreasing values as the study phases progressed, suggesting improved digestion and absorption, although	Statistical methods might be inappropriate for a small sample. All subjects were treated with antibiotics including metronidazole for presumptive SBBO; this might have affected GCA testing.

Evidence Table 3. Markers of digestion.

Biomarkers in bold are categorized as primarily markers of digestion.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
			<p>proportion of ^{13}C in triglyceride (TG) and fatty acid (FA) fractions to distinguish excretion caused by impaired digestion (presence of TG) vs. poor absorption (presence of FA).</p> <p>*** To assess bile salt deconjugation in the bowel caused by SBBO; conducted after the TG assessment and a 3 day washout period.</p> <p>**** Expressed as a percentage of absorbed label (dose administered - label recovered in stool) to assess oxidation for acute energy needs.</p>	<p>^{13}C FA fraction in stool declined during rehabilitation.</p> <p>Mean ^{13}C FA recovery (SD):</p> <ul style="list-style-type: none"> Phase 1: 6.0% (7.3) Phase 2: 4.8% (3.7) Phase 3: 3.3% (3.8), differences between phases were NS <p>Mean FA values were ~9x (NS), 5x ($p < 0.001$), and 3x ($p < 0.05$) higher than mean TG values in Phases 1, 2, and 3, respectively.</p> <p>Following administration of labeled TP, absorbed ^{13}C label by breath analysis was ~5% (range 0%-21.2%) and similar across study phases.</p> <p>Following the administration of labeled GCA, there was either no or minimal recovery of ^{13}C in stool and $^{13}\text{CO}_2$ on breath (as % of dose administered) in all phases.</p>	<p>results did not differ significantly.</p> <p>Fecal fat was correlated with concentrations of ^{13}C in stool.</p> <p>There was no evidence of SBBO or bile acid malabsorption.</p> <p>$^{13}\text{CO}_2$ excretion following administration of ^{13}C TP was minimal, suggesting a propensity for deposition in adipose tissues rather than oxidation for immediate energy needs. The authors report that this breath test has not been widely used, but that healthy UK children have breath excretion values from 15%-43% [190], compared to a mean of 5% and range 0%-21% in this cohort; the latter findings were more similar to results from kwashiorkor patients where ^{13}C-labeled oleic acid was used as substrate [193].</p>	
<p>2000</p> <p>Nichols B et al.</p> <p>Contribution of villous atrophy to reduced intestinal maltase in infants with malnutrition</p>	<p>Sao Paulo, Brazil</p> <p>Cases were children (mean age 9.9 mo, SD 8.1) hospitalized with malnutrition refractory to dietary rehabilitation.</p> <p>Controls were</p>	<p>Case-control</p> <p>n=33; n=24 cases n=9 controls</p> <p>Subjects were</p>	<p><u>Jejunal capsule biopsy:</u></p> <ul style="list-style-type: none"> Histopathology* Maltase activity Intestinal messenger RNA (mRNA) abundances: <ul style="list-style-type: none"> Maltase-glucoamylase 	<p>Mean villous atrophy score (SD):</p> <ul style="list-style-type: none"> Cases: 2.6 (0.8) Controls: 1.2 (0.5), $p=0.006$ <p>WAZ score was correlated with villous atrophy ($r=0.65$, p-value not reported).</p> <p>13/25 [sic] cases and 0/5 controls had subnormal (defined</p>	<p>The malnourished children had significantly greater villous atrophy than the younger controls.</p> <p>Among the subset tested for mRNA messages, maltase activity as well as the mRNA</p>	<p>Tissue from patients requiring intestinal resection as part of their biliary atresia management provides an opportunity to assess presumably "normal" intestinal</p>

Evidence Table 3. Markers of digestion.

Biomarkers in bold are categorized as primarily markers of digestion.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
Jejunal biopsy, maltase activity, and enzyme messenger RNAs among malnourished and well-nourished children. Assessed association between maltase and villous atrophy and other mucosal intestinal markers indicative of loss of enterocytes and enterocytic function.	children (mean age 3.6 mo, SD 1.0) with HAZ and WAZ scores >-2 and normal intestinal mucosa on biopsy, hospitalized for Kasai procedure for biliary atresia.	matched on height and weight; ages differed within matched sets.	<p>(MGA)</p> <ul style="list-style-type: none"> • Sucrase-isomaltase (SI) • Villin, a structural protein expressed only in enterocytes • Sodium-activated luminal glucose-galactose transporter 1 (SGLT), a functional protein expressed only in enterocytes • β-actin <p>* Mucosal atrophy was scored on a scale of 1 (absence of atrophy compared to an organ donor) to 4 (similar to children with active CD).</p> <p>Histology among controls was on surgically resected tissue.</p>	<p>as <94 U/g protein) of maltase activity; mean maltase was 34% lower among cases ($p=0.11$). Maltase activity did not appear to decrease with WAZ score (further details not provided).</p> <p>However, in sub-analyses among those samples with an adequate β-actin, a housekeeping gene message, ($n=10$ cases, $n=9$ controls), cases' findings expressed as a mean percent of controls' (SD) included:</p> <ul style="list-style-type: none"> • Villous length (reciprocal of atrophy score): 38.9 (41.6), $p=0.004$ • Maltase activity: 37.1 (23.2), $p=0.001$ • MGA mRNA: 45.1 (36.4), $p=0.016$ • Villin mRNA: 52.5 (22.6), $p=0.003$ • SGLT mRNA: 66.6 (23.1), $p=0.057$ • β-actin: 88.2 (15.8), $p=0.189$ <p>Both villous length and maltase activity in a subset of cases were less than 40% of control values.</p> <p>MGA, villin, and SGLT mRNA abundances were correlated with villous atrophy score ($r=0.73$), ($r=0.76$), and ($r=0.54$), respectively (p-values not reported)¹.</p> <p>MGA mRNA abundance was</p>	<p>abundances for MGA, villin and SGLT were significantly correlated with case status and were correlated with villous atrophy.</p> <p>While maltase deficiency has been reported in malnutrition in other studies, authors assert that these are the first results that directly support the hypothesis that reductions in maltase activity are due to villous atrophy. This study also nicely correlates mRNA relative abundance with function.</p>	<p>architecture. However, unless they mocked up <i>ex vivo</i> mucosal biopsies in these controls, resections will have lower proportions of villous to submucosa tissue compared to cases' samples derived from mucosal biopsies. While this probably doesn't affect histology, it might affect enterocyte functional assays and mRNA determination, as transmural tissue will bring in more diverse populations of cells; only some of them might have transcripts of interest. However, the bias is likely in a direction that would reduce effect size.</p> <p>It was unclear if control inclusion criteria included absence of atrophy or if all potential controls lacked atrophy.</p> <p>Statistical methods</p>

¹ Villin and SGLT1 were assessed as a ratio with housekeeper gene β -actin.

Evidence Table 3. Markers of digestion.

Biomarkers in bold are categorized as primarily markers of digestion.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
				correlated with maltase activity (r=0.32).		might not have adequately taken into account the small sample size and matching scheme. Subsets of subjects were investigated for various tests. For example, 10 cases had mRNA analyses based on β -actin adequacy. Another instance of selected testing was the subset of 22 and 15 cases that had WAZ score to histology and mRNA correlation analyses, respectively. Rationale for subset selection was not thoroughly described.
2009 Ritchie et al. 13C-sucrose breath test: novel use of a noninvasive biomarker of environmental gut health Sucrose breath test (SBT) as a marker of small bowel mucosal	Darwin and Adelaide, Australia 4 mo-5 yr old Aboriginal children admitted to hospital with diarrhea. Two control groups: 1. Aboriginal controls admitted to hospital with non-GI symptoms (50% had	Case-control n=43; n=18 Aboriginal cases with AD n=25 controls: • 18 Aboriginal, without diarrhea • 7 non-Aboriginal, healthy	Blood Tests: • L:R (32 Aboriginal cases and controls tested) • C-reactive protein (CRP) • Mean Corpuscular Volume (MCV) • Hemoglobin Breath Test: ¹³C sucrose breath	20/32 (63%) of Aboriginal children had abnormal L:R ratios. Mean ¹ L:R (CI): • Diarrhea cases: 31.8 (24.9, 40.7) • Aboriginal controls without diarrhea: 11.4 (8.5, 15.5), significant difference (p<0.0001) SBT Mean (CI): • Diarrhea cases: 1.9% (0.9,	SBT values were significantly lower and L:R values were significantly higher among Aboriginal children with diarrhea than among those without GI symptoms. SBT was also significantly lower among Aboriginal controls than among non-Aboriginal children without diarrhea. This is	Abnormal L:R ratios were defined as >16; no reference or derivation was provided for this cut-point. L:R test was not conducted among the non-Aboriginal controls. SBT/ L:R correlation analysis

¹ Geometric mean.

Evidence Table 3. Markers of digestion.

Biomarkers in bold are categorized as primarily markers of digestion.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
damage vis a vis sucrase activity among an Australian Aboriginal population. Also compared SBT with serum lactulose:rhamnose ratio (L:R)	pneumonia) 2. Healthy, non-Aboriginal controls recruited from community		test (SBT)	<p>3.0), $p < 0.0001$ compared to non-Aboriginal controls and $p = 0.004$ compared to Aboriginal controls</p> <ul style="list-style-type: none"> Aboriginal controls: 4.1% (3.0, 5.2), $p = 0.032$ compared to non-Aboriginal controls Non-Aboriginal controls: 6.1% (4.8, 7.3) <p>Significant differences were observed between all three groups.</p> <p>SBT results were not associated with wasting or with patient age or breastfeeding status.</p> <p>SBT and L:R were inversely correlated ($r = 0.67$; CI: 0.42, 0.62; $p < 0.0001$). L:R explained 45% of the variance in SBT; diarrhea explained 28% of variance.</p> <p>SBT was associated with increased MCV, relative risk (CI)=3.9 (2.8, 5.0). SBT was not associated with hemoglobin or CRP.</p>	<p>consistent with previous reports of high prevalence of clinically silent TE in this population.</p> <p>SBT was significantly inversely correlated with L:R.</p>	<p>was based on data for Aboriginal cases and controls combined; stratified analysis was not reported and could be of interest considering the large difference in L:R observed between these groups.</p> <p>Associations of MCV, CRP, and hemoglobin with SBT after adjusting for potentially confounding variables were not reported.</p>

Notes: Some studies included subjects ≥ 5 yr of age. Where these studies provided data separately for children < 5 yr, we present results for only those subjects. Where these studies did not stratify results by age, but did report the number of children < 5 yr included in the study, we provide a breakdown of under-5s. All studies reporting lactulose:rhamnose ratio results presented values multiplied by a factor of 100 for ease of reporting.

Abbreviations: AD=acute diarrhea, ALT=alanine aminotransferase, AST=aspartate aminotransferase, CBC=complete blood count, CD=celiac disease, CI=95% confidence interval, Cr=creatinine, Δ =change in, EED=environmental enteric dysfunction, FTT=failure to thrive, GI=gastrointestinal, HAZ=height-for-age Z-(score), HDL=high density lipoproteins, HIV=human immunodeficiency virus, HLA=human leukocyte antigen, IEL=intraepithelial lymphocytes, IgA=immunoglobulin A, IgE=immunoglobulin E, IgG=immunoglobulin G, IgM=immunoglobulin M, IL=interleukin, IFN=interferon, LDL=low density lipoproteins, L:M=lactulose:mannitol ratio, mo=month(s), NS=not statistically significant, PD=persistent diarrhea, RCT=randomized controlled trial, SBBO=small bowel bacterial overgrowth, SD=standard deviation, SE=standard error, SES=socioeconomic status, Tc-99m=technetium 99, T3=triiodothyronine, T4=thyroxine, TE=tropical enteropathy, TGF=transforming growth factor, TNF=tumor necrosis factor, TS=tropical sprue, WAZ=weight-for-age Z-(score), WBC=white blood cell count, WFA=weight-for-age, WHZ=weight-for-height Z-(score), wk=week(s), yr=year(s)

5.4.1 Sucrose and Lactose Breath Tests

Three studies used breath tests to detect the presence of lactose (n=2) [102, 147] or sucrose (n=1) [159] in the intestines after administration of a loading dose activity. These disaccharides should, in normal intestinal health, be split by the brush border enzymes lactase or sucrase to glucose and galactose or fructose, respectively. While these breath tests also reflect intestinal capacity to absorb these monosaccharides, we classified them as markers of digestive function first and foremost, because enzymatic cleavage of the ingested sugars is a cardinal intestinal process required for absorption to take place. Breath tests can measure various molecules in exhaled breath, most commonly hydrogen. Normally, very little hydrogen is detected in breath after an overnight fast; however, hydrogen is produced when undigested substances such as lactose are fermented by intestinal bacteria. The sucrose breath test (SBT) assessed in this review measured exhaled CO₂, a normal by-product of disaccharide metabolism which will be found in reduced amounts if there is reduced sucrase activity. Because genetically ordained age-associated lactose intolerance becomes common beyond infancy in many populations irrespective of intestinal mucosal health, the possibility exists that sucrase activity might serve as a better marker of overall intestinal function because such age-related decline in tolerances are not known to be associated with sucrose.

CO₂ exhalation in the SBT was significantly lower among Aboriginal children with diarrhea compared to those without gastrointestinal symptoms, as well as among Aboriginal controls compared to non-Aboriginal children without diarrhea. SBT results were not associated with age, breastfeeding status, or wasting [159]. SBT results were significantly inversely correlated with L:R values (r=0.67), but this was assessed among all Aboriginal subjects (cases and controls) combined. L:R values differed largely between these groups; it would be useful to investigate the relationship between SBT and L:R stratified on diarrhea status. SBT results were also associated with one other marker, mean corpuscular volume, but were not associated with blood C-reactive protein, an index of systemic inflammation, or with hemoglobin, concentrations of which can be reduced for a variety of reasons, including acute and chronic systemic inflammation. While this study suggests that SBT is a promising diagnostic test for EED, this was the only

publication that analyzed the SBT in children in a developing country setting or among marginalized populations during the time period under review.

Two studies utilized hydrogen breath tests (HBT) to assess lactase function [102, 147]. Each study also assessed either lactulose or D-xylose as substrates using the HBT. These two substrates for breath hydrogen analyses are primarily used to identify small bowel bacterial overgrowth (SBBO) and malabsorption, respectively, and as such they are discussed in those sections. Prevalence of abnormal lactose absorption differed between these two studies. Lactose absorption among indigenous Brazilian children with mild malnutrition was abnormal in more than one fourth of the subjects [102]. In well-nourished Mexican children, HBT values in cases with asymptomatic giardiasis were only mildly elevated but remained below concentrations that have been used as criteria for lactose malabsorption [147]. Cases had HBTs before and after anti-giardiasis treatment. The pre-treatment HBT excretion was significantly higher compared to controls without giardiasis and to post-treatment values. The clinical relevance of such mildly elevated HBT results in asymptotically infected children remains unclear, however.

The discrepancy in results between the studies was unexpected, and the reason for it remains unclear. Both studies used the same cutoff for normal values, but the proportions of children with lactase deficiency were quite different. The differences might reflect numerous factors including differences in age, nutritional status, and age-related lactose intolerance. Another potential contributing factor is the exclusion of children with SBBO from the Mexican study but not from the Brazilian study, in which greater than 10% of the subjects had SBBO by lactulose HBT. An additional complication in assessing mucosal function, at least in children four years of age and older, is that there is a high prevalence of genetic lactase deficiency in many of the populations at risk for enteropathy, including in Latin America, Africa and Asia [259] and among Native Americans [260].

Neither of the HBT studies assessed the relationship of the test with growth outcomes in a statistically interpretable manner. While the Mexican study found normal D-xylose absorption by breath hydrogen testing in case (and control) subjects, neither this study nor the Brazilian study statistically analyzed the association between growth and the lactose HBT.

5.4.2 Stool Reducing Substances

Reducing substances are those that reduce copper salts in a hot solution to a chromogenic less oxidized state. These substances include glucose, lactose, fructose, galactose, and pentose. Like breath tests, reducing substances can indicate malabsorption, but also primarily identify maldigestion. This test has been used for decades to differentiate diarrhea secondary to infection from that caused by noninfectious intestinal dysfunction, particularly lactose intolerance. A condition of the test is that it must be performed on liquid stool.

Four studies [43, 58, 132, 138] assessed the prevalence of stool reducing substances to investigate digestive pathology. The proportion of positive tests for stool reducing substances among subjects varied widely across studies. Only 3.3% of Brazilian children hospitalized with malnutrition or persistent diarrhea had positive tests for stool reducing substances (definition of positive not provided) [138]. In contrast, tests in Haitian children with and without diarrhea were positive for stool reducing substances in one-third of those with diarrhea and cryptosporidiosis, in two-thirds of those with diarrhea but no evidence of *Cryptosporidium* infection, and in nearly half of controls without diarrhea [132], though the accuracy of this test on non-diarrheal stools is assumed to be inadequate because the non-absorbed sugars reportedly partition to the aqueous phase [261]. Hence, finding these sugars in solid stools, while unexpected, probably indicates of some degree of maldigestion. Again, cutoff points defining positivity were not provided, and there was no statistical difference between groups for this parameter ($p=0.2$).

Two studies investigated reducing substances among Aboriginal and non-Aboriginal Australian children with diarrhea; a positive result was defined as stool containing sugar concentrations $\geq 0.5\%$. In the first of these, one-quarter of Aboriginal diarrheal cases tested positive for stool reducing substances [58]. In the subsequent study by the same authors almost one-fifth of children with profuse diarrhea tested positive [43].

Only one study of reducing substances examined its association with clinical outcomes, and this study found that the marker was associated with severity of diarrheal illness [58]. The same study found

that among subjects with diarrhea, a positive test for reducing substances was associated with high L:R by univariate analysis, but the association did not hold up in their multivariate model. Another study also examined the association between reducing substances and urinary nitric oxide among Aboriginal and non-Aboriginal children with acute diarrhea, but found none [43].

5.4.3 Intestinal Disaccharidases

Two studies assessed intestinal disaccharidase activity as a marker of digestive pathology on jejunal specimens obtained by capsule biopsy--Bolivian children with persistent diarrhea and malnutrition [109] and Brazilian children with refractory malnutrition [53]. Of note, the latter study utilized a unique control group, children without severe malnutrition undergoing intestinal resection as part of the management of their biliary atresia. Both studies assessed the proportion of children with maltase activities that were below normal, and the Bolivian study also measured sucrase-isomaltase and lactase activities. Both studies reported similar prevalences of abnormally low maltase activity in approximately half of the subjects with enteric dysfunction, but only one of these studies provided a defined cut point for abnormal (<94U/g protein) [53]. The deficiency in other disaccharidase activities was not as prevalent as that of maltase. In addition to maltase activity, the Brazilian study also measured abundance of messenger RNA for maltase-glucoamylase (MGA) and sucrase-isomaltase in small intestinal tissue, and found that they were correlated with the activity of maltase at the messenger RNA abundance.

The Brazilian study found no association between WAZ score and tissue maltase activity (no other details were provided), while the Bolivian study found that intestinal lactase concentrations were significantly and positively associated with WAZ and less strongly associated with HAZ at admission. Unfortunately, they did not detail the magnitude of these associations or report if they assessed maltase and sucrase-isomaltase association with growth parameters. Because intestinal disaccharidase activity is, by its nature, measured on intestinal tissue, it was relatively straightforward for these studies to assess marker association with intestinal histopathology. Maltase-glucoamylase (MGA) mRNA abundances were strongly correlated with both maltase activity and villous atrophy. The Bolivian study did not attempt to correlate disaccharidase activity with histopathology.

5.4.4 ^{13}C Assessment in Stool after Lipid Administration

Two studies by the same group of investigators in the same setting [148, 149] with a total sample size of 32 severely malnourished children assessed digestion by administering radiolabeled lipids. They then measured the amount of radiolabel excreted in the stool in the forms of triglyceride (TG) and fatty acid (FA), with recovery of fatty acids interpreted to indicate adequate lipid breakdown but poor absorption while recovery of triglycerides marked poor digestive function. Both studies found widely varying ^{13}C in stool, although the variation was less marked in their later study; however the sample size was only eight patients [148].

In both of these studies, the majority of excreted ^{13}C was in the form of FA rather than TG, reflecting a failure of lipid absorption in the face of adequate digestion. Each labeled lipid form (FA and TG) was found in decreasing concentrations as the study progressed, suggesting improved digestion and absorption, although concentrations did not differ significantly with time.

The two studies differed in their findings related to small bowel bacterial overgrowth; the first study [149] found no evidence for bacterial overgrowth while the second [148] did, as measured by the recovery of label in the stool after ingestion of ^{13}C glycocholate.

The first of these studies [149] additionally investigated fecal fat as a marker and found that it was associated with concentrations of ^{13}C in stool.

5.4.5 Urinary Lactose:Lactulose Ratio

We considered serum and urinary lactose to be primarily measures of gut permeability, as described above. As a large molecule, lactose should not enter the system unless there is a permeability defect. It should be recognized, however, that presence of lactose in the serum or urine could be complicated by lactase deficiency. However, lactase deficiency without a permeability defect would not be expected to result in the presence of lactose in the blood or urine. When urinary lactose is normalized against another marker for permeability, the lactose:lactulose ratio is primarily a marker of lactose digestion. One study assessed this marker and found that nearly half of subjects had low lactase activity,

defined as lactose:lactulose ratio >0.4 [124]. Urinary lactose and lactose:lactulose ratios significantly decreased with age and were significantly elevated among breast-fed compared to non-breastfed infants, adjusting for age, despite similar intestinal permeability values as measured by L:M. The markers were not associated with sex, ethnicity, or location. Lactose and lactose:lactulose ratios were not associated with L:M.

5.4.6 Summary of Markers of Digestion

A broad range of markers was used to assess digestive function in children in resource-limited settings. Intestinal disaccharidases were affected in subjects with persistent diarrhea and/or malnutrition. The sucrose and lactose HBTs showed varying degrees of digestive disturbance across studies with subjects of differing health conditions. Results for maltase activities were consistent across the two studies in which they were sought in intestinal tissues. Several different methods were used to assess intestinal enzyme capacity, and results between methods were consistent where comparable.

Few markers of digestion were investigated in relation to biopsy or tests of intestinal permeability. Breath tests in particular lacked comparison to other standard markers.

Varying associations were observed between markers of digestion and growth parameters. The sucrose breath test was not associated with growth [159]. The studies of intestinal disaccharidases found different results for different enzymes; one study found no association between maltase and wasting while the other found an association between lactase and growth parameters [53, 109]. The relationship between abnormal markers of digestion and growth outcomes was not reported for either hydrogen breath tests or stool reducing substances.

The sucrose breath test results were significantly associated with the L:R; the concentration of exhaled hydrogen was inversely associated with the L:R [159]. This test might be useful as a noninvasive marker of enteric dysfunction, although replication of these results is needed before a judgment as to their value can be made.

5.5 Markers of Intestinal Inflammation and Intestinal Immune Activation

Eighteen studies utilized a variety of markers that reflect intestinal inflammation or immune activation among children in resource-limited settings. The data relevant to this review are listed for each of these studies in Evidence Table 4. Eight types of markers were assessed across the studies, most of which were examined in stool. Lactoferrin was the most commonly assessed marker among these reports; nine studies utilized it to assess intestinal inflammation. Additionally, fecal cytokines, leukocytes, and neopterin were measured in five [101, 131, 132, 137, 140], four [104, 138, 158, 169], and one [15] studies, respectively. Two studies by the same group of investigators assessed fecal IgE [142, 143]. Intestinal tissue cytokines, immune and inflammatory cell markers, and duodenal aspirate immunoglobulins were investigated in one study apiece.

Evidence Table 4. Markers of intestinal inflammation and intestinal immune activation.
Biomarkers in bold are primarily markers of gut inflammation and/or immune activation.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
<p>2003</p> <p>Alcantara CS et al.</p> <p>Interleukin-8, tumor necrosis factor-alpha, and lactoferrin in immunocompetent hosts with experimental and Brazilian children with acquired cryptosporidiosis</p> <p>Fecal cytokines and lactoferrin as markers of intestinal inflammation among children with and without <i>Cryptosporidium parvum</i>.</p>	<p>Fortaleza, Brazil</p> <p>3-43 mo olds recruited from a shantytown community who were screened for enteric pathogens.</p> <p>There was a high prevalence of malnutrition among the cases.</p> <p>(Adults experimentally exposed to <i>C. parvum</i> by ingestion were also studied; these data were not included in this review.)</p>	<p>Case-control</p> <p>n=32;</p> <p>n=17 cases with <i>C. parvum</i>:</p> <ul style="list-style-type: none"> • 4 with no diarrhea • 10 with AD • 3 with PD <p>n=15 controls with no diarrhea or enteric pathogens and comparable HAZ and WAZ scores to cases</p>	<p><u>Stool tests:</u></p> <ul style="list-style-type: none"> • Lactoferrin (17 cases and 15 controls tested) • IL-8 (13 cases and 15 controls tested) • TNF-α (10 cases and 0 controls tested) 	<p>Lactoferrin positive:</p> <ul style="list-style-type: none"> • 12/17 cases <ul style="list-style-type: none"> • 1/4 cases without diarrhea • 8/10 AD cases • 3/3 PD cases • 3/15 controls (p=0.006 compared to cases) <p>IL-8 detectable:</p> <ul style="list-style-type: none"> • 3/13 all cases <ul style="list-style-type: none"> • 0/2 cases without diarrhea • 3/10 AD cases • 0/1 PD cases • 6/16 controls (p=0.435 compared to cases) <p>TNF-α detectable:</p> <ul style="list-style-type: none"> • 0/10 cases 	<p>The proportion of children who tested positive for fecal lactoferrin was greater in those with cryptosporidiosis, especially those symptomatic with diarrhea, than in uninfected controls, although 20% of the control group tested positive.</p> <p>Fecal IL-8 did not differ between those with and without <i>Cryptosporidium</i> infection. TNF-α was not elevated among children with <i>Cryptosporidium</i> infection.</p>	<p>Direct comparisons between various stool tests were not reported.</p> <p>Lactoferrin results were graded based on agglutination reaction positivity with increasing dilution and were considered negative if there was no reaction at 1:25.</p> <p>Four subjects were breastfed and were tested for lactoferrin.</p>
<p>2009</p> <p>Amadi B et al.</p> <p>Reduced production of sulfated glycosaminoglycans occurs in Zambian children with kwashiorkor but not marasmus</p> <p>Duodenal biopsy including assessments of intestinal markers in children with PD and</p>	<p>Lusaka, Zambia</p> <p>12.2-19.8 mo olds with PD and malnutrition admitted to the malnutrition ward of a teaching hospital.</p>	<p>Case-control</p> <p>n=41*;</p> <p>n=41 cases with PD and malnutrition:</p> <ul style="list-style-type: none"> • 18 with marasmus • 8 with marasmic kwashiorkor • 15 with kwashiorkor <p>n=19 healthy control children from UK</p>	<p><u>Endoscopic duodenal biopsy:</u></p> <ul style="list-style-type: none"> • Histopathology • Densities in lamina propria and crypt epithelium: • Cell proteins: <ul style="list-style-type: none"> • Glycosaminoglycan (GAG) • Enterocyte heparan sulfate proteoglycan (HSPG) • Syndecan-1 • Inflammatory cell markers: <ul style="list-style-type: none"> • CD3 IEL • Ki67 • Human leukocyte 	<p>Biopsy findings among the Zambian compared to the UK children:</p> <ul style="list-style-type: none"> • Villous height reduced • Crypt depth increased • ~50% reduction in crypt:villous ratio • Values for lamina propria cell densities were not reported for UK subjects <p>No significant differences in crypt or villous measures or lamina propria cell densities were observed between nutritional groups or after nutritional rehabilitation.</p>	<p>Mucosal architecture was markedly abnormal compared to UK controls but did not vary between marasmus and kwashiorkor presentations of malnutrition.</p> <p>Inflammatory cell densities were generally higher compared to UK children and showed different</p>	<p>27 subjects were HIV positive; incidence was lower in the kwashiorkor group.</p>

Evidence Table 4. Markers of intestinal inflammation and intestinal immune activation.
 Biomarkers in bold are primarily markers of gut inflammation and/or immune activation.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
different forms of malnutrition		* UK subjects are presented in this table due to comparisons of interest made in the review. However we do not include these subjects in the sample size for this review.	antigen DR-1 (HLA-DR)	Intestinal markers: <ul style="list-style-type: none"> • Inflammatory markers were seen in higher densities compared to the UK children. There were significant differences between the different nutritional groups in the specific types of inflammatory markers. • There was a significant reduction in GAGs and HSPG in the kwashiorkor group compared to UK children, but no significant differences between kwashiorkor and other presentations of malnutrition. • There was no difference in epithelial syndecan-1 protein expression between the malnutrition groups (data not available for UK controls). 	patterns across the malnutrition presentations. Tissue concentrations of HSPG and GAG were reduced especially amongst children with kwashiorkor. Intestinal protein markers did not differ amongst the malnutrition groups.	
2000 Azim T et al. Immune response of Bangladeshi children with acute diarrhea who subsequently have persistent diarrhea Immune activation tests, as well as transferrin and albumin as markers of nutritional status among children with and without PD	Dhaka, Bangladesh 7-12 mo olds with 6-8 days of watery diarrhea attending the International Centre for Diarrheal Disease Research. Cases were those who went on to develop PD, controls were those who did not. An additional group of subjects without diarrhea were recruited from a nutrition follow-up	Case-control n=136; n=38 cases with PD n=98 controls: <ul style="list-style-type: none"> • 85 with AD • 13 with no diarrhea 	Blood tests: <ul style="list-style-type: none"> • IFN-γ • TNF-α • WBC (total and differential) • IgA • IgG • IgM • Transferrin • Albumin • Immune function tests: <ul style="list-style-type: none"> • Neutrophil polarization response to chemotactic factor • Neutrophil opsonization to yeast • Mononuclear cell proliferation, spontaneous and in response to stimuli with 	WBC total and differential, immunoglobulin subtypes, cytokines, transferrin, and albumin did not differ between cases with diarrhea or controls, nor did stool leukocyte or erythrocyte counts. The percentages of neutrophils that polarized in response to stimulation were significantly higher in subjects with AD or PD compared to those without diarrhea; there was no difference between the two diarrhea groups. Opsonization did not vary between any groups.	Some immune and inflammatory markers were associated with acute and/or persistent diarrhea. The only marker that was significantly associated with progression to PD was a negative DTH response to tuberculin antigen (odds ratio=3.8, CI: 1.4, 9.9). This was calculated from a logistic regression analysis that only	The number of controls was relatively small and their nutritional status was not reported.

Evidence Table 4. Markers of intestinal inflammation and intestinal immune activation.
 Biomarkers in bold are primarily markers of gut inflammation and/or immune activation.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
	unit. Prevalence of malnutrition was high in all groups.		mitogens <u>Skin Test:</u> <ul style="list-style-type: none"> • Delayed-type hypersensitivity response (DTH) to tuberculin, tetanus, diphtheria, <i>Streptococcus</i>, <i>Proteus</i>, <i>Candida</i>, and <i>Trichophyton</i> <u>Stool tests:</u> <ul style="list-style-type: none"> • Leukocytes • Red blood cells 	Monocyte spontaneous proliferation counts were less than half among children with no diarrhea compared to those with AD (p<0.001) or with PD (p=0.011); there was no difference between the two diarrhea groups. Monocyte proliferation in response to stimulation did not differ between the 3 groups. The proportion with DTH responses differed among the three groups only in response to tuberculin (p=0.021). More PD subjects had a negative tuberculin response than did subjects with AD (p=0.024).	included children with diarrhea.	
2007 Bushen OY et al. Heavy cryptosporidial infections in children in northeast Brazil: comparison of <i>Cryptosporidium hominis</i> and <i>Cryptosporidium parvum</i> Fecal lactoferrin as a marker of intestinal inflammation in children with <i>Cryptosporidium</i>	Goncalves Dias favela in Fortaleza, Brazil All newborns from an urban shantytown were recruited at birth and followed for up to 4 yr. This study included only children testing positive for <i>Cryptosporidium</i> .	Cohort n=42 (41 tested) Stools were collected at regular intervals as well as during episodes of diarrhea.	<u>Stool Test:</u> Lactoferrin	68.3% were lactoferrin-positive; there were no differences in positivity between subjects with <i>C. hominis</i> and <i>C. parvum</i> spp. 67.9% of lactoferrin-positive subjects had very high titers. Younger children were more often lactoferrin-positive (p=0.03). The difference was mediated by <i>C. parvum</i> ; 87.5% of ≤1 year olds compared to 40.0% of older children with <i>C. parvum</i> were lactoferrin-positive (p=0.04). There was no difference among those infected with <i>C. hominis</i> . Lactoferrin was correlated with symptomatic infection among those with <i>C. parvum</i> : 78.6% of	Lactoferrin was correlated with younger age and symptomatic infection among those infected with <i>C. parvum</i> . Lactoferrin did not significantly predict growth outcomes. <i>Cryptosporidium</i> species-specific differences were observed in lactoferrin results. In contrast to <i>C. parvum</i> , there was no association between lactoferrin and symptomatic/asymptomatic <i>C.</i>	Lactoferrin results were graded based on agglutination reaction positivity with increasing dilution and were considered negative if there was no reaction at 1:50 and highly positive at >1:400. Data were part of a larger study; similar data on lactoferrin in <i>Giardia</i> -infected children was published by A. Kohli, et al. (also included in this review), using a slightly different

Evidence Table 4. Markers of intestinal inflammation and intestinal immune activation.
 Biomarkers in bold are primarily markers of gut inflammation and/or immune activation.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
				<p>symptomatic children compared to no asymptomatic children had a positive test ($r=0.67$, $p=0.004^1$).</p> <p>Lactoferrin was not correlated with degree of oocyst shedding ($p=0.28$).</p> <p>Lactoferrin was correlated with ΔHAZ score among those with <i>C. parvum</i>, although this observation was not statistically significant ($r=-0.39$, $p=0.13$).</p>	<p><i>hominis</i> infection ($p=0.231$). In addition, similar proportions of asymptomatic children with <i>C. hominis</i> had high fecal lactoferrin titers as had undetectable results.</p>	<p>grading scale for reporting lactoferrin results [133]. Rather than exclude breastfed children, Bushen et al. stratified results on breastfeeding status and found no difference in positive/ negative results, including when examined among younger and older children.</p>
<p>2004</p> <p>Campbell DI et al.</p> <p>Intestinal inflammation measured by fecal neopterin in Gambian children with enteropathy: association with growth failure, <i>Giardia lamblia</i>, and intestinal permeability</p> <p>Fecal neopterin and L:M as markers of intestinal inflammation and permeability, respectively, and their correlation with growth status and</p>	<p>Keneba, Gambia</p> <p>2 mo olds from rural area followed until 15 mo of age.</p>	<p>Cohort</p> <p>n=72</p> <p>Subjects were evaluated with twice-weekly questionnaire to determine diarrhea morbidity, clinic assessments of growth, and screening laboratory tests every 2 mo.</p>	<p>Stool Test:</p> <p>Neopterin</p> <p>Urine Tests:</p> <ul style="list-style-type: none"> • Lactulose² • Mannitol • L:M 	<p>Mean neopterin concentration was negatively correlated with long-term height ($r=-0.29$, $p<0.009$) and weight ($r=-0.36$, $p<0.007$) gain, but not with giardiasis.</p> <p>Mean³ L:M (CI): 0.31 (0.26, 0.34).</p> <p>Mean excretion of lactulose (CI): 0.20 (0.18, 0.23).</p> <p>Mean excretion of mannitol (CI): 3.0 (2.8, 3.2).</p> <p>Mean L:M was negatively correlated with long-term height gain (r value not provided, $p<0.0001$), but was not correlated with presence of <i>Giardia</i>.</p> <p>L:M and fecal neopterin were</p>	<p>L:M and mean fecal neopterin concentration were not correlated.</p> <p>Mean L:M in the Gambian children was substantially higher than normal values in children in the UK. These high L:M ratios appear to be driven by mannitol excretion.</p>	<p>Study population might have some overlap with that of Campbell et al. also included in this review [110].</p>

¹ Reported results were adjusted for confounding variables, unless otherwise noted.

² Lactulose and mannitol results were expressed as % of dose administered.

³ Geometric mean.

Evidence Table 4. Markers of intestinal inflammation and intestinal immune activation.
Biomarkers in bold are primarily markers of gut inflammation and/or immune activation.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
<i>Giardia</i> recovery in the stool				not correlated (p=0.11).		
2003 Campbell DI et al. Chronic T cell-mediated enteropathy in rural west African children: relationship with nutritional status and small bowel function L:M as a marker of intestinal permeability, small bowel biopsy with assessment of intestinal immune markers, and computerized morphometric analysis among rural Gambian children with differing degrees of malnutrition and compared to well-nourished UK children	Fajara and Sibanar, The Gambia 6 mo-3 yr old hospital- and clinic-based cases from rural communities. Case groups based on differences in nutritional status: • WAZ score >-2, with GI complaints other than diarrhea • Grade I protein energy malnutrition (PEM) (WAZ score -2 to -4) and unresponsive to nutritional supplements, with or without diarrhea • Grade II PEM (WAZ score <-4) with or without diarrhea Controls from UK* who were well nourished children with GI complaints other than diarrhea and with normal endoscopy results	Case-control n=40 cases: • Group 1: n=4 • Group 2: n=11 (7 with diarrhea) • Group 3: n=25 (18 with diarrhea) n=34 with case tissue samples sufficient for cytokine immunoreactivity tests: • Group 1: n=3 • Group 2: n=8 • Group 3: n=23	<u>Endoscopic small bowel biopsy, site not specified:</u> • Histopathology • Morphometric assessment by computer analysis* • Intestinal tissue cytokines and immune markers: • CD-3 • CD-4 • CD-8 • CD-19 • CD-25 • HLA-DR • Perforin • γδ T-cell receptor • Syndecan-1 • TNF-α • IFN-γ • TGF-β • IL-10 <u>Urine Tests:</u> • Lactulose ¹ • Mannitol • L:M * Biopsy involved morphometric assessment by computer analysis of villous height, crypt depth, villous: crypt ratio, and intraepithelial lymphocyte (IEL) density (per 100 epithelial cells).	Crypt-hyperplasia and villous atrophy were observed among all Gambian subjects, and the degree of histopathology did not differ among cases with differing nutritional status, nor was there a correlation with diarrhea. IEL ² means were ~3-fold higher in Gambian than UK children. Median CD3, CD4, CD8, CD19, and CD25 cell counts were significantly higher (2-5x higher) among each case group compared to the UK controls. IEL, γδ, syndecan-1, HLA-DR, and perforin were detected among the Gambian children in varying degrees but were not reported for UK controls. Syndecan, CD3, and CD8 displayed a gradient proportional to malnutrition severity. All Gambian groups showed higher lamina propria cytokine-immunoreactive mononuclear cell density (~200-450/mm ²) than UK controls (30-80/mm ²). Among subjects with elevated cytokines, similar densities	All Gambian subjects had evidence of enteropathy with crypt-hyperplasia and villous atrophy, and mean IELs >2 SD above UK norms, independent of nutritional status and diarrhea history. Elevation of cell-mediated intestinal markers and mucosal proinflammatory cytokines was present across the 3 Gambian groups, variably correlated with nutritional status. L:M ratios were elevated in all Gambian groups, without apparent correlation to host nutritional status.	Statistical methodology was not sufficiently detailed to determine what was compared (e.g. type of central tendency measure and variance calculations for L:M not stated). Duration of diarrhea not specified, but assumed to be persistent. Mucosal lymphocyte densities, cytokine immunoreactivity, and L:M results were not stratified by history of diarrhea.

¹ Lactulose and mannitol results were expressed as % of dose administered.

² These figures are presumed to represent IEL means; however, this was not explicitly stated.

Evidence Table 4. Markers of intestinal inflammation and intestinal immune activation.
 Biomarkers in bold are primarily markers of gut inflammation and/or immune activation.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
	<p>were also studied.</p> <p>* UK subjects are presented in this table due to comparisons of interest made in the review. However we do not include these subjects in the sample size for this review.</p>			<p>were seen for both pro-inflammatory (IFN-γ and TNF-α) and putative regulatory (IL-10 and TGF-β) cytokines. Epithelial expression of TGF-β was also enhanced compared to UK controls, but subjects with poorer nutritional status had lower densities of mucosal TGF-β+ cells, with median densities of 420 and 250 cells/mm² in the grade I and grade II PEM groups, respectively.</p> <p>L:M values¹:</p> <ul style="list-style-type: none"> • Group 1: 0.53 (0.4-1.3) • Group 2: 0.47 (0.02-2.20) • Group 3: 0.73 (0.14-2.2) • Not assessed among the UK controls <p>Nutritional status was not associated with L:M, recoveries of lactulose or mannitol.</p> <p>L:M was correlated with mucosal B lymphocyte density (r=0.57, p<0.05), IEL (r=0.51, p<0.02), and perforin+ IEL (r=-0.64, p<0.03).</p>		
<p>2001</p> <p>Kapoor S et al.</p> <p>Giardiasis--clinical and diagnostic perspective</p> <p>Immunoglobulin concentrations in</p>	<p>New Delhi, India</p> <p><12 yr olds admitted to hospital with PD and <i>Giardia</i>.</p> <p>Controls had no diarrhea and were hospitalized for</p>	<p>Case-control</p> <p>n=40;</p> <p>n=30 cases with PD and <i>Giardia</i></p> <p>n=10 controls without diarrhea</p>	<p><u>Duodenal secretion aspirates:</u></p> <ul style="list-style-type: none"> • IgG • IgM • IgA <p><u>Blood Tests:</u></p> <ul style="list-style-type: none"> • IgG • IgM 	<p>Higher mean concentrations of IgM were found in duodenal aspirates of cases compared to controls (p<0.05).</p> <p>Mean concentrations of duodenal IgA and IgG did not differ between cases and controls.</p>	<p>Differences in immunoglobulin concentrations were limited among children with PD infected with <i>Giardia</i> compared to children without such conditions.</p>	<p>The number of controls was small due to constraints in obtaining duodenal aspirate from children without GI symptoms.</p>

¹ Not clearly indicated if these figures represent mean (CI) or another measure of central tendency.

Evidence Table 4. Markers of intestinal inflammation and intestinal immune activation.
Biomarkers in bold are primarily markers of gut inflammation and/or immune activation.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
duodenal fluid and serum among children with PD and <i>Giardia</i> infection compared to those without diarrhea	non-GI conditions. Most cases were <7 yr old, with n=19 <3 yr old. Ages of controls were not specified.		• IgA			
2006 Kirkpatrick BD et al. Childhood cryptosporidiosis is associated with a persistent systemic inflammatory response Fecal cytokines and lactoferrin as markers of intestinal mucosal inflammation among children with and without <i>Cryptosporidium</i> infection	Port-au-Prince, Haiti <36 month olds recruited from GHESKIO HIV Center ¹ with <i>Cryptosporidium</i> infection and healthy controls. Subjects were followed-up at 6 and 9 months after infection resolved. HIV status of subjects varied. There was a high prevalence of malnutrition in the study population.	Cohort n=73; n=42 cases with diarrhea and <i>Cryptosporidium</i> infection (18 with PD) n=31 healthy controls without diarrhea and <i>Cryptosporidium</i> -negative	<u>Stool Tests:</u> • Lactoferrin • Cytokines: • IFN-γ • TNF-α • TGF-β • IL-4 • IL-8 • IL-10	Proportion lactoferrin-positive at enrollment: • Cases: 51.2% • Controls: 4.0% Cases had higher concentrations of TNF- α than controls at enrollment (p=0.04), but no difference was observed at follow-up. Controls had almost 2x higher fecal IFN- γ at enrollment (p=0.1); the magnitude of difference increased (to almost 3x) and was statistically significant at the 6- and 9-month follow-up (p=0.01 and p=0.03, respectively). No differences in fecal concentrations of TGF- β , IL-8, IL-4, or IL-10 were noted between groups.	Lactoferrin was present among half of subjects with cryptosporidiosis and uncommon among those without such infection. Fecal TNF- α was higher among cases at enrollment but did not persist when infection resolved. Paradoxically, controls' comparatively higher fecal IFN- γ increased in both magnitude and degree of statistical significance at follow-up. Of the remaining fecal cytokines assessed, there were no differences between cases and controls.	Cut-off values for lactoferrin positivity were not provided. Breastfed children (>85% of cases and controls) were included in testing. Proportions at follow-up were not reported. The association of fecal cytokines and lactoferrin with growth parameters, history of PD, and HIV status were not reported, nor was their association with each other. Various markers of systemic inflammation, including serum cytokines, were measured but their relationship with markers of intestinal inflammation was not reported.

¹ The Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections.

Evidence Table 4. Markers of intestinal inflammation and intestinal immune activation.
Biomarkers in bold are primarily markers of gut inflammation and/or immune activation.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
<p>2002</p> <p>Kirkpatrick BD et al.</p> <p>Cryptosporidiosis stimulates an inflammatory intestinal response in malnourished Haitian children</p> <p>Stool lactoferrin, reducing substances, leukocytes and cytokines as markers of intestinal inflammation of children with and without <i>Cryptosporidium</i> infection</p>	<p>Port-au-Prince, Haiti</p> <p><18 mo olds from a low SES setting recruited from the rehydration unit of GHESKIO HIV Center¹ with diarrhea and <i>Cryptosporidium</i> infection. Controls recruited from an outpatient clinic without <i>Cryptosporidium</i> infection included those with and without diarrhea.</p>	<p>Case-control</p> <p>n=49;</p> <p>n=17 cases with <i>Cryptosporidium</i> and diarrhea (5 with PD)</p> <p>n=32 controls without <i>Cryptosporidium</i>;</p> <ul style="list-style-type: none"> • 17 with diarrhea (5 with PD) • 15 healthy 	<p>Stool Tests:</p> <ul style="list-style-type: none"> • Reducing substances (RS) • Lactoferrin • Cytokines: <ul style="list-style-type: none"> • TNF-α receptor I • IL-4 • IL-8 • IL-10 • IL-13 • IFN-γ <p>Blood Test:</p> <ul style="list-style-type: none"> • WBC 	<p>Proportion RS-positive:</p> <ul style="list-style-type: none"> • 33.3% cases • 64.7% diarrhea controls • 46.7% healthy controls, (p=0.2) <p>Proportion lactoferrin-positive:</p> <ul style="list-style-type: none"> • 83.3% cases • 60.0% diarrhea controls • 28.6% healthy controls, (p=0.01) <p>IFN-γ was not recovered in any stools.</p> <p>All other fecal cytokines were significantly associated with <i>Cryptosporidium</i> cases compared to diarrhea and healthy controls.</p> <p>Additionally, TNF-α receptor I, IL-8, and IL-13 were found in diarrhea and healthy controls, while IL-4 and IL-10 were not.</p> <p>Fecal lactoferrin was associated with the presence of TNF-α receptor I (point estimate not provided, p=0.03).</p> <p>Mean WBC counts were within normal range in all 3 groups.</p>	<p>Fecal lactoferrin was identified most often in children with diarrhea, especially in those with <i>Cryptosporidium</i>. While some fecal cytokines were detected in as many as 40% of healthy controls and 70% of controls with diarrhea, they were generally associated with <i>Cryptosporidium</i> infection. The other stool tests did not discriminate by diarrhea or <i>Cryptosporidium</i> status.</p>	<p>Reported results were not stratified by persistent vs. acute diarrhea status.</p> <p>Cut-off values for lactoferrin positivity were not described.</p> <p>Stools from children who were breastfeeding were not tested for lactoferrin.</p>
<p>2008</p> <p>Kohli A et al.</p> <p><i>Giardia duodenalis</i> assemblage, clinical presentation and</p>	<p>Goncalves Dias favela in Fortaleza, Brazil</p> <p>All newborns from an urban shantytown were</p>	<p>Cohort</p> <p>n=108 stool samples from 47 children</p> <p>Stools were</p>	<p>Stool Test:</p> <ul style="list-style-type: none"> • Lactoferrin 	<p>Proportion of positive lactoferrin results decreased with each new <i>Giardia</i> infection, p=0.015:</p> <p>1.1st infection: 74.0% (15.2% of those testing positive had high titers)</p>	<p>Increased concentrations of lactoferrin were observed more frequently with first time <i>Giardia</i> infections.</p>	<p>Lactoferrin results were graded based on agglutination reaction positivity with increasing dilution; the following scale was</p>

¹ The Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections.

Evidence Table 4. Markers of intestinal inflammation and intestinal immune activation.
Biomarkers in bold are primarily markers of gut inflammation and/or immune activation.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
<p>markers of intestinal inflammation in Brazilian children</p> <p>Fecal lactoferrin as a marker of intestinal inflammation in <i>Giardia</i>-infected children and its association with persistence of diarrhea</p>	<p>recruited at birth and followed for up to 4 yr. Those with <i>Giardia</i> recovered from stools were included in this study.</p>	<p>collected at regular intervals as well as during episodes of diarrhea.</p>		<p>2.2nd infection: 40.0% (5.3% of those testing positive had high titers) 3.3rd infection: 1 (20.0%) tested positive (at a high titers)</p> <p>Increasing titers of lactoferrin were associated with longer duration of diarrhea, p=0.017: <ul style="list-style-type: none"> Negative: 2.2 days Low: 9.7 days High: 14.6 days </p> <p>Lactoferrin results did not differ between symptomatic and asymptomatic children at first infection, but those with symptoms had positive results with recurrent infections with greater frequency (75.0% vs. 0 in asymptomatic repeat infections, p=0.017.)</p>	<p>Concentrations were associated with longer duration of diarrhea, although these results were not presented separately for first and recurrent infections.</p> <p>Stool lactoferrin might be useful in predicting duration of diarrheal illness in <i>G. duodenalis</i>-infected children.</p>	<p>used: <ul style="list-style-type: none"> High = positive at 1:400-1:3200 dilution Low = positive at 1:25-1:200 Negative = no reaction at 1:25 </p> <p>Stools from children who were breastfeeding were not tested.</p> <p>Data were part of a larger study; similar data on lactoferrin in <i>Cryptosporidium</i>-infected children were published by O.Y. Bushen, et al. (also included in this review); however, Bushen et al. used a slightly different grading scale for reporting lactoferrin results [108].</p>
<p>2010</p> <p>Lima AA et al.</p> <p>Effects of vitamin A supplementation on intestinal barrier function, growth, total parasitic, and specific <i>Giardia</i> spp</p>	<p>Fortaleza, Brazil</p> <p>2 mo-9 yr olds (mean 43 mo) from an impoverished urban community, eligible if HAZ score was <median for their community.</p>	<p>RCT</p> <p>n=79; n=40 received placebo (tocopherol) n=39 received vitamin A (retinyl</p>	<p>Urine Tests: <ul style="list-style-type: none"> Lactulose¹ Mannitol L:M </p> <p>Stool Tests: <ul style="list-style-type: none"> Lactoferrin Cytokines: <ul style="list-style-type: none"> IFN-γ </p>	<p>Median L:M at baseline was 0.089. There was no significant change in L:M at 4 mo follow-up within either treatment group.</p> <p>No significant difference in L:M was observed between treatment groups.</p>	<p>Frequency of stool lactoferrin varied between 23%-32%.</p> <p>While vitamin A supplementation was associated with reduced lactulose excretion, it was also</p>	<p>Authors did not report testing for associations between urinary markers of intestinal permeability and concentrations of fecal cytokines, or between these</p>

¹ For lactulose and mannitol results, excretion measurement was not specified.

Evidence Table 4. Markers of intestinal inflammation and intestinal immune activation.
Biomarkers in bold are primarily markers of gut inflammation and/or immune activation.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
<p>infections in Brazilian children: a prospective randomized, double-blind, placebo-controlled trial</p> <p>L:M as a marker of intestinal barrier function, and stool lactoferrin and specific intestinal immunological cytokines as markers of intestinal inflammation among nutritionally at-risk children who received either vitamin A or placebo</p>	<p>Subjects were screened for intestinal parasites, and longitudinal anthropometrics were assessed.</p>	<p>palmitate)</p> <p>Subjects were treated every 4 mo.</p>	<ul style="list-style-type: none"> • TNF-α • IL-4 • IL-10 	<p>Both median lactulose and mannitol excretions decreased at 4 mo follow-up among the vitamin A compared to the placebo group:</p> <ul style="list-style-type: none"> • Lactulose: 0.21 to 0.74, p=0.042 • Mannitol: 3.06 to 8.25, p=0.008 <p>Overall proportion of lactoferrin was 23% initially. At 1 mo follow-up, there was no difference in prevalence between vitamin A (33%) and placebo (31%) groups.</p> <p>Cytokine concentrations did not significantly differ between placebo and vitamin A groups.</p>	<p>associated with reduced mannitol excretion, with no overall effect on L:M.</p> <p>Vitamin A supplementation was not associated with presence of lactoferrin or intestinal cytokine response.</p>	<p>markers and growth parameters or parasitosis.</p> <p>Cut-point values for lactoferrin positivity and abnormal L:M were not described.</p> <p>Exclusively breastfed children were excluded from study participation due to assessment of stool lactoferrin.</p>
<p>2005</p> <p>Lima AA et al.</p> <p>Intestinal barrier function and weight gain in malnourished children taking glutamine-supplemented enteral formula</p> <p>L:M as a marker of intestinal permeability and various stool tests among children with malnutrition or PD who received either glycine or glutamine</p>	<p>Fortaleza, Brazil</p> <p>2-60 mo olds hospitalized with WAZ score <-2, ~70% of whom had PD.</p>	<p>RCT</p> <p>n=80;</p> <p>n=53 received supplemented formula</p> <ul style="list-style-type: none"> • 27 with glycine • 26 with glutamine <p>n=27 received nonsupplemented formula</p>	<p>Urine Tests*:</p> <ul style="list-style-type: none"> • Lactulose¹ • Mannitol • L:M <p>Stool Tests**:</p> <ul style="list-style-type: none"> • Lactoferrin • Leukocytes • Occult blood • Reducing substances (RS) <p>* n=80 tested at enrollment, n=65 tested at day 10.</p> <p>** n=60 tested.</p>	<p>Mean² L:M (SE):</p> <ul style="list-style-type: none"> • Glutamine group: <ul style="list-style-type: none"> • Baseline: 0.31 (0.10) (similar in all three groups) • Day 10: 0.10 (0.02); significant decrease, (p=0.01) • No significant decrease in L:M in glycine and nonsupplemented formula groups at day 10 <p>Mean lactulose (SE):</p> <ul style="list-style-type: none"> • Glutamine group: <ul style="list-style-type: none"> • Baseline: 0.97 (0.46) (similar in all three groups) • Day 10: NS decrease in all 3 groups 	<p>L:M significantly improved in the glutamine group only.</p> <p>>50% of subjects had intestinal inflammation by stool lactoferrin. Fecal leukocytes, RS, and occult blood were detected in fewer subjects than lactoferrin.</p>	<p>The relationship between stool markers and L:M was not reported.</p> <p>Data were not stratified by history of PD.</p> <p>Fecal fat was assessed, but results were not reported.</p> <p>Cut-off values for lactoferrin positivity were not described.</p> <p>Exclusively</p>

¹ Lactulose and mannitol results were expressed as % of dose administered.

² Type of mean not specified.

Evidence Table 4. Markers of intestinal inflammation and intestinal immune activation.
 Biomarkers in bold are primarily markers of gut inflammation and/or immune activation.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
supplemented formula or placebo				Mean mannitol (SE): <ul style="list-style-type: none"> • Glutamine group: <ul style="list-style-type: none"> • Baseline: 3.42 (0.64) (similar in all three groups) • Day 10: NS decrease in all 3 groups Proportion of stool markers at baseline among all subjects: <ul style="list-style-type: none"> • Lactoferrin: 53.3% • Leukocytes: 11.7% • RS: 3.3% • Occult blood: 5.0% 		breastfed children were excluded from study participation due to assessment of stool lactoferrin.
2006 Long KZ et al. The effect of vitamin A supplementation on the intestinal immune response in Mexican children is modified by pathogen infections and diarrhea Fecal cytokines as markers of intestinal mucosal immune activation in children with and without GI pathogens receiving vitamin A or placebo	Mexico City, Mexico All 5-15 mo olds within a periurban community were eligible to be screened for participation.	RCT n=505 stool samples from 127 children; n=243 stool samples from 57 who received vitamin A supplementation n=262 stool samples from 70 who received placebo Participants were followed regularly; diarrhea history was tracked and stool samples were tested.	<u>Stool Tests:</u> <u>Cytokines:</u> <ul style="list-style-type: none"> • IL-4 • IL-6 • IFN-γ 	Positive tests for fecal cytokines: <ul style="list-style-type: none"> • IL-4: ~55% • IFN-γ: ~50% • IL-6: ~40% There were no significant differences in proportions of these fecal cytokines between vitamin A-supplemented and placebo subjects. Vitamin A-supplemented children with diarrhea had lower median IFN-γ concentrations (odds ratio ¹ =0.51; CI: 0.26, 0.99) and higher IL-4 concentrations (odds ratio=2.14; CI: 0.94, 4.87) compared to children with diarrhea in the placebo group in a nonrandomized analysis. IL-6 concentrations did not differ in this analysis. There were no differences between the two groups among those	Differences in fecal cytokine concentrations due to vitamin A supplementation were observed only in the subset of subjects with GI infection or diarrhea.	Pre-intervention fecal cytokine concentrations were not reported. Differences in fecal cytokines between all subjects with and without GI infections or history of diarrhea were not directly reported; all differences were described in terms of vitamin A interaction.

¹ The odds ratios represent odds that a cytokine (categorized into three levels: undetectable, <median, >median) will have a higher value among vitamin A-supplemented children.

Evidence Table 4. Markers of intestinal inflammation and intestinal immune activation.
 Biomarkers in bold are primarily markers of gut inflammation and/or immune activation.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
				without diarrhea. Differences in median concentrations of fecal cytokines by types of enteric pathogens were also observed.		
2001 Mahmud MA et al. Sociodemographic, environmental and clinical risk factors for developing persistent diarrhea among infants in a rural community of Egypt Stool IgE as a marker of gastrointestinal allergy and its association with persistent vs. acute diarrhea	Bilbeis, Egypt Newborns recruited at birth from a rural village and followed for the first year of life. Surveillance of diarrhea symptoms identified 392 episodes of diarrhea, 41 (11%) of which were persistent.	Nested case-control within a cohort study n=392 episodes of diarrhea (including 41 episodes of PD) among 152 infants*) * Stool samples from each PD episode were counted as a case for analysis and compared to randomly selected AD episodes and to non-diarrheal samples.	<u>Stool Test:</u> IgE	Fecal IgE was detected more frequently in stools from episodes of PD compared to episodes of AD: odds ratio (CI) ¹ =3.3 (1.0, 10.9). Fecal IgE was detected more frequently in stools from episodes of PD than in stools from children without diarrhea: odds ratio (CI)=4.84 (1.1, 21.7).	Fecal IgE was detected 3 times more frequently during episodes of PD than AD and 5 times more frequently in PD stools than in stools from those without diarrhea.	Sampling was based on episodes of diarrhea within a cohort of infants; individual infants could have contributed more than one diarrheal episode. Additionally, it appears that an individual could also have been included as a case of PD, a control with AD, or a non-diarrhea stool within the same analysis. Study population appears to be the same as in another Mahmud, et al. study also included in this review which reported the prevalence of fecal IgE by gender and age within the cohort [143].
2001 Mahmud MA et al.	Bilbeis, Egypt Newborns recruited at birth from a rural	Cohort n=152 followed for 29,036	<u>Stool Test:</u> IgE	Overall incidence of fecal IgE: 0.39/child-year By age group:	Substantial incidence of fecal IgE was observed in this setting in	Study population appears to be the same population as in another

¹ Reported results were adjusted for confounding variables, unless otherwise noted.

Evidence Table 4. Markers of intestinal inflammation and intestinal immune activation.
 Biomarkers in bold are primarily markers of gut inflammation and/or immune activation.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
Increased fecal IgE among infants in a rural community of Egypt: an analysis of associated risk factors Fecal IgE as a marker of intestinal inflammation among children with diarrhea	village and followed for the first year of life.	infant days Stools were collected during episodes of diarrhea.		<ul style="list-style-type: none"> • < 3 mo: 0.28/child-yr • 3-6 mo: 0.42/child-yr • 6-9 mo: 0.16/child-yr • >9 mo: 0.12/child-yr Relative risks (CI): <ul style="list-style-type: none"> • 3-6 compared to >9 mo olds: 3.28 (1.03, 13.60) • Male gender: 1.82 (0.83, 4.18) 	infants. IgE incidence peaked at 3-6 mo of age. Male gender was associated with fecal IgE.	Mahmud, et al. reference also included in this review which assessed the relationship between fecal IgE and PD [142].
2001 Rabbani GH et al. Increased nitrite and nitrate concentrations in sera and urine of patients with cholera or shigellosis To assess and compare nitric oxide as a marker of intestinal inflammation among children with cholera or shigellosis or healthy controls. Evaluated to assess nitric oxide production during infection of small bowel without inflammatory lesion (e.g., cholera) and during infection causing colon inflammation (e.g., shigellosis).	Dhaka, Bangladesh 2-6 yr olds with cholera or shigellosis admitted to the hospital. Controls were recruited from the healthy attendants of patients or from children of hospital staff. Mean age (SD) in yr: <ul style="list-style-type: none"> • Shigellosis cases: 3.8 (1.2) • Cholera cases: 4.2 (1.4) • Controls: 4.7 (1.8) 	Case-control n=63; n=45 cases: <ul style="list-style-type: none"> • 24 with cholera • 21 with shigellosis n=18 healthy controls Samples were collected from cases on admission and upon discharge (after 7-10 days of treatment).	<u>Urine Test:</u> Nitric Oxide (NO)* <u>Blood Tests:</u> <ul style="list-style-type: none"> • Nitrite (NO₂) • Nitrate (NO₃) • WBC <u>Stool Test:</u> Leukocytes * Nitric oxide (NO) is an unstable free radical that is converted to nitrite and nitrate. Urine NO ₂ + NO ₃ were expressed as a ratio with urine creatinine in order to account for differences in urine concentration.	In children with shigellosis, median serum NO was ~8x higher at baseline than in controls and significantly differed from convalescent concentrations (p<0.01). Concentrations declined by 52% of baseline during the recovery period but did not return to values found in the controls (measure of statistical significance not reported). In children with cholera, median serum NO concentrations at baseline were ~4x higher than in control subjects. Recovery concentrations decreased 52% from baseline (p<0.01); convalescent values did not differ from the values in controls (p<0.4). Median urinary NO ratios were similar among those with <i>Shigella</i> and <i>V. cholerae</i> infection, both upon admission and discharge. Initial values were ~2x higher than upon discharge (p<0.05 and 0.01,	NO as measured by both serum and urinary NO ₂ and NO ₃ concentrations was significantly elevated at presentation during acute illness compared to 7-10 days after hospitalization in both cholera and shigellosis. Median serum NO concentrations in cholera patients were ~half of those with shigellosis both upon admission and upon discharge and concentrations were much higher in cases than in controls, Such striking differences were not observed for urinary NO results.	Some values reported in table format conflict with the text; columns of data appear to be transposed. Assessment for NO correlation with fecal leukocyte counts was not reported, nor was the correlation between urinary NO and total blood WBC.

Evidence Table 4. Markers of intestinal inflammation and intestinal immune activation.

Biomarkers in bold are primarily markers of gut inflammation and/or immune activation.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
				<p>respectively). Control median NO was of an intermediate concentration between cases' admission and discharge median concentrations; the difference between control and case admission values was NS.</p> <p>Mean blood WBC counts (SD):</p> <ul style="list-style-type: none"> • Shigellosis: 19.6 (3.3) • Cholera: 8.3 (2.8) • Controls: 7.1 (1.8) <p>Mean fecal WBC/high power field (SD):</p> <ul style="list-style-type: none"> • Shigellosis: 38 (17) • Cholera: 5 (2) • Controls: 3 (1) <p>Serum NO correlated with blood WBC count in shigellosis cases at baseline ($r^2=0.92$, $p<0.01$), but only to a slight degree upon discharge ($r^2=0.26$, no p-value reported) and there was no correlation among the cholera cases. Serum NO correlated with stool volume at presentation ($r^2=0.85$, statistically significant per authors, p-value not reported).</p>	Serum NO concentrations correlated with total blood WBC in shigellosis cases.	
<p>2006</p> <p>Samie A et al.</p> <p><i>Cryptosporidium</i> species: preliminary descriptions of the prevalence and genotype distribution among school</p>	<p>Vhembe, South Africa</p> <p>0.1-88 yr olds from semi-urban community included patients hospitalized with diarrhea or other GI complaints as well</p>	<p>Cross-sectional</p> <p>n=26 ≤5 yr old:</p> <ul style="list-style-type: none"> • 22 hospital-based subjects • 4 school-based subjects 	<p>Stool Test:</p> <p>Lactoferrin</p>	<p>16/22 patients and 0/4 students were lactoferrin positive.</p> <p>While examination of lactoferrin association with history of diarrhea or with <i>Cryptosporidium</i> infection was not reported, only 3/22 and 16/22 hospitalized patients and 2/4 and 3/4 school children</p>	<p>Lactoferrin prevalence was high among children hospitalized with diarrhea or other GI symptoms, regardless of <i>Cryptosporidium</i> status.</p>	<p>Among the entire study cohort of all ages, lactoferrin results were similar among hospitalized patients regardless of <i>Cryptosporidium</i> status (influence of HIV infection was</p>

Evidence Table 4. Markers of intestinal inflammation and intestinal immune activation.
 Biomarkers in bold are primarily markers of gut inflammation and/or immune activation.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
children and hospital patients in the Venda region, Limpopo Province, South Africa Stool lactoferrin as a marker of intestinal inflammation among hospitalized patients and school children	as students attending nearby schools.			were positive for <i>Cryptosporidium</i> and had a history of diarrhea, respectively.	Lactoferrin was not found among school-recruited children, most of whom did have a history of diarrhea. Two of the four school children were <i>Cryptosporidium</i> -positive.	not reported). Among school children, lactoferrin was more frequently found to be positive among those infected with <i>Cryptosporidium</i> ; statistical testing was not reported. Lactoferrin results were graded based on agglutination reaction positivity with increasing dilution and was considered negative if there was no reaction at 1:25. Some subjects were breastfed and were tested for lactoferrin.
2008 Vieira MM et al. Carotenoids, retinol, and intestinal barrier function in children from northeastern Brazil L:M as marker of intestinal barrier function, fecal lactoferrin and leukocytes as	Fortaleza, Brazil 2 mo-9 yr olds (mean age 41 mo) from an impoverished urban community, eligible if HAZ score <median for their community.	Cross-sectional n=102	<u>Urine Tests:</u> <ul style="list-style-type: none"> • Lactulose¹ • Mannitol • L:M (97 tested) <u>Stool Tests:</u> <ul style="list-style-type: none"> • Lactoferrin (93 tested) • Leukocytes <u>lood Tests:</u> <ul style="list-style-type: none"> • C-reactive protein (CRP) 	48.5% had abnormal L:M. L:M and excretion of each sugar separately did not vary with retinol concentration. L:M was associated with levels of common dietary carotenoids, primarily driven by lactulose. However, the association was not always statistically significant, and the direction of association varied depending on precursor.	Almost half of subjects had increased L:M, and ~40% of subjects had increased lactoferrin. While serum retinol concentrations were not associated with L:M, serum carotenoids were; authors suggest that these retinol	L:M threshold for abnormal values was defined as ≥ 0.0864 [214]. Cut-off values for lactoferrin positivity were not described. Relationships between acute phase proteins and measures of intestinal permeability or

¹ Lactulose and mannitol results were expressed as % of dose administered.

Evidence Table 4. Markers of intestinal inflammation and intestinal immune activation.

Biomarkers in bold are primarily markers of gut inflammation and/or immune activation.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
markers of intestinal inflammation, and CRP and AGP as acute phase reactants among children with varying vitamin A status			<ul style="list-style-type: none"> α-1-acid glycoprotein (AGP) 	<p>40% of stool samples were positive for lactoferrin.</p> <p>1% of stool samples were positive for fecal leukocytes.</p> <p>30% of stool samples were positive for parasites but this had no impact on L:M results, lactoferrin, or acute phase reactants.</p>	precursors might be more sensitive predictors of impaired intestinal function. However, the reported direction of association varied, making interpretation of these results unclear.	<p>inflammation were not reported. Relationships between L:M and lactoferrin or fecal leukocytes as well as those between retinol or carotenoids and lactoferrin or fecal leukocytes were not reported.</p> <p>Exclusively breastfed children were excluded from study participation due to assessment of stool lactoferrin.</p>

Notes: Some studies included subjects ≥5 yr of age. Where these studies provided data separately for children <5 yr, we present results for only those subjects. Where these studies did not stratify results by age, but did report the number of children <5 yr included in the study, we provide a breakdown of under-5s. All studies reporting lactulose: rhamnose ratio results presented values multiplied by a factor of 100 for ease of reporting.

Abbreviations: AD=acute diarrhea, ALT=alanine aminotransferase, AST=aspartate aminotransferase, CBC=complete blood count, CD=celiac disease, CI=95% confidence interval, Cr=creatinine, Δ=change in, EED=environmental enteric dysfunction, FTT=failure to thrive, GI=gastrointestinal, HAZ=height-for-age Z-(score), HDL=high density lipoproteins, HIV=human immunodeficiency virus, HLA=human leukocyte antigen, IEL=intraepithelial lymphocytes, IgA=immunoglobulin A, IgE=immunoglobulin E, IgG=immunoglobulin G, IgM=immunoglobulin M, IL=interleukin, IFN=interferon, LDL=low density lipoproteins, L:M=lactulose:mannitol ratio, mo=month(s), NS=not statistically significant, PD=persistent diarrhea, RCT=randomized controlled trial, SBBO=small bowel bacterial overgrowth, SD=standard deviation, SE=standard error, SES=socioeconomic status, Tc-99m=technetium 99, T3=triiodothyronine, T4=thyroxine, TE=tropical enteropathy, TGF=transforming growth factor, TNF=tumor necrosis factor, TS=tropical sprue, WAZ=weight-for-age Z-(score), WBC=white blood cell count, WFA=weight-for-age, WHZ=weight-for-height Z-(score), wk=week(s), yr=year(s)

5.5.1 Fecal Lactoferrin

Fecal lactoferrin reflects infiltration of intestinal mucosa by polymorphonuclear neutrophils. The lactoferrin test might be more sensitive than assays for detection of leukocytes in stool because the former does not rely on the detection of whole cells, or on visualizing technology and trained observers. Its usefulness as a marker is enhanced by its relative stability in feces at room temperature.

We reviewed nine studies that utilized stool lactoferrin as a measure of intestinal inflammation. Populations in two of these studies appear to overlap [108, 133].

5.5.1.1 Prevalence of Fecal Lactoferrin

The proportion of lactoferrin-positive stools varied widely across publications whose study populations also varied in terms of nutritional status and health conditions such as diarrhea symptoms and infection with enteric parasites. The proportion of subjects whose stools tested positive for lactoferrin ranged from 13 to 74% [132, 133].

Two studies assessed stools of children whose HAZ scores were below the median and found that 23 to 40% were lactoferrin-positive [137, 169]. Another study found that 53% of subjects with malnutrition or persistent diarrhea had lactoferrin in their stools [138]. Samie et al. measured lactoferrin in 26 stools of children hospitalized with diarrhea or other gastrointestinal complaints and in stools of four primary school children, three of whom had diarrhea at the time of testing [162]. None of the schoolchildren and 73% of the inpatients had lactoferrin in their stools.

Several studies measured stool lactoferrin in children with parasitic infections. The proportion of Brazilian children infected with *Giardia* whose stools tested lactoferrin-positive decreased with each subsequent infection [133]. At first infection, 74% of subjects' stools were lactoferrin positive, 15% of which had high lactoferrin concentrations, defined as 1:400-1:3200

dilution in an agglutination reaction. At second infection, 40% were positive, of which 5% had high concentrations of this marker. At third infection, 20% tested positive, all of which had a high concentration of lactoferrin. Interestingly, lactoferrin results did not differ between symptomatic and asymptomatic children at first colonization by these parasites, but those with symptoms were more likely to produce stools that tested positive with recurrent infections. In a study among children from an impoverished Brazilian community with HAZ scores less than the median, nearly one-third of stools were positive for parasites, but parasitic infection was not associated with presence of stool lactoferrin [169].

Four studies measured stool lactoferrin in children with *Cryptosporidium* infection. One study tested stool lactoferrin in infants and children with *Cryptosporidium parvum* diarrhea, controls with diarrhea of different etiology, and healthy controls [132]. Lactoferrin was detected in 60% of stools from *C. parvum*-infected cases, 35% of diarrhea control stools, and 13% of healthy control stools. This difference across groups was statistically significant. Two other studies also found that the proportion of subjects with lactoferrin-positive stools was about 50 percentage points higher among cases compared to controls [101, 131]. Bushen et al. reported lactoferrin results only on *Cryptosporidium*-infected children; 68% were positive for lactoferrin and 68% of these subjects tested positive at a high titer, defined as positive at >1:400 dilution [108]. There were no differences in prevalence of lactoferrin-positivity between subjects with *C. hominis* and *C. parvum* spp.

5.5.1.2 Associations between Fecal Lactoferrin and Growth or Other Outcomes

Fecal lactoferrin did not significantly predict growth outcomes in the one study that assessed this relationship [108]. This was also the only study to assess the marker's relationship to breastfeeding and age. While there was no association with breastfeeding, younger subjects' stools were significantly more likely to be lactoferrin-positive. This difference, however, was

mediated by *C. parvum*; there was no age-associated difference among those infected with *C. hominis*.

Three studies found significant associations between fecal lactoferrin and cryptosporidiosis [101, 131, 132]. A fourth study reported a high proportion of positive stools from infected subjects but did not enroll uninfected children, so assessment of association with presence of infection was not possible [108]. That study did, however, test the relationship of fecal lactoferrin with oocyst shedding and found no association. A fifth study that had a small proportion of subjects infected with *Cryptosporidium* species did not report examining for association with fecal lactoferrin and infection, but based on the numerical data presented such an association was not mathematically possible [162].

Fecal lactoferrin was used as an outcome measure in one intervention trial testing the efficacy of vitamin A supplementation on intestinal barrier function, growth, and intestinal parasite infections [137]. No difference was observed in fecal lactoferrin results among treatment and placebo groups.

5.5.1.3 Association between Fecal Lactoferrin and Other Markers

Despite the number of studies that utilized fecal lactoferrin, only one study examined the association between fecal lactoferrin and another biomarker and found that fecal lactoferrin was significantly associated with the presence of tumor necrosis factor- α receptor I (TNF- α RI). Although the investigators also tested for other fecal cytokines, leukocytes and reducing substances, they did not report attempts to associate lactoferrin presence or concentration and these other markers in these subjects [132].

5.5.1.4 Methodological Issues with the Fecal Lactoferrin Test

The stool lactoferrin assay was generally performed with commercial kits. Methods described were similar across studies and results graded based on agglutination reaction positivity with increasing dilution. Six studies did not clearly report their cutoff for a positive test

[131, 132, 137, 138, 162, 169]. Two studies defined a positive threshold as a titer of >1:50 [101, 108], another as >1:25 [133]. Two studies defined high titers of positivity to be values >1:400 [108, 133].

Ingestion of breast milk might cause lactoferrin to be detected in the stool, in the absence of intestinal inflammation. Most of the lactoferrin studies in this review did not discuss this potential issue within the context of their research. One study that tested a wide age range of subjects did not mention the breastfeeding status of those being tested [162]. Five of the studies excluded breastfeeding subjects from lactoferrin testing [132, 133, 137, 138, 169]. Several studies, however, tested fecal lactoferrin in subjects known to be breast feeding [101, 108, 131], and one of these studies assessed the association between breastfeeding and stool lactoferrin but found none [108].

5.5.2 Fecal Cytokines

Five studies [101, 131, 132, 137, 140] measured concentrations of stool cytokines as indicators of intestinal inflammation; four of these studies investigated fecal cytokines in relation to gastrointestinal infection [101, 131, 132, 140]. The most commonly measured fecal cytokines were IFN- γ , TNF- α or TNF- α RI, and IL-4; each was assessed in four studies. IL-8 and IL-10 were each measured in three studies, while TGF- β , IL-6 and IL-13 were each measured in one.

5.5.2.1 Prevalence of Fecal Cytokines

Three of the five studies of fecal cytokines reported the proportion of subjects with positive tests. The proportion of samples with detectable cytokines in stool varied widely by cytokine and by study, ranging from 3% for IL-4 [132] to 55%, also for IL-4 [140]. In a study of children with and without gastrointestinal pathogens, about half of the stool samples were positive for IL-4, IFN- γ , and/or IL-6, respectively [140]. In contrast, in a study that measured a panel of cytokines in the stools of children with and without diarrhea, IFN- γ was not recovered in any stools and IL-4 was only detected in 3% of samples [132]. Only IL-13 and TNF- α RI were

detected in a substantial proportion of these subjects' stools; the former was detected in 32% and the latter in 52%. IL-8 was detected in 15% and IL-10 in 12% of stools. At 4-month follow-up in a subset of subjects, IL-8 was found in 6% and IFN- γ , IL-4, and IL-10 were not found in any stools. Among subjects in whom TNF- α RI was detected in stool during acute infection, this cytokine persisted at lower concentrations in stools of 50% of cases but was not detected in stools of controls. Some subjects previously negative for fecal TNF- α RI were positive at follow-up. In a study of fecal IL-8 and TNF- α in children with or without *C. parvum* infection, IL-8 was detectable in 31% of subjects without significant differences based on infection status [101]. TNF- α was only investigated in infected children and was detected in stools of 40%, all of whom had acute diarrhea; however, none had high fecal concentrations of the cytokine.

5.5.2.2 Associations between Fecal Cytokines and Growth or Other Outcomes

None of the studies of fecal cytokines reported assessment of their relationship to growth outcomes in the children studied.

Three studies investigated the relationship between fecal cytokines and *Cryptosporidium* infection. While IFN- γ was not identified in any stools in a Haitian study, fecal TNF- α RI, IL-8, IL-13, IL-4 and IL-10 were significantly associated with *C. parvum* infection [132]. Interestingly, some of these cytokines (TNF- α RI, IL-8, IL-13) were found in children with non-*Cryptosporidium* diarrhea and in children without diarrhea while other cytokines (IL-4 & IL-10) were not. Fecal cytokines were not associated with presence of co-pathogens in the stool. A subsequent study by the same investigators measured concentrations of IFN- γ , TNF- α , TGF- β , IL-4, IL-8, and IL-10 at multiple time points over nine months in stools of children with and without *Cryptosporidium* infection [131]. In contrast to their previous study, there were no differences in fecal concentrations of TGF- β , IL-8, IL-4 or IL-10 between those children with and without *Cryptosporidium* infection. Also, in contrast to their previous study, IFN- γ was detected and concentrations in stools of controls were almost double those of cases at enrollment, but this

difference was not statistically significant. At six- and nine-month follow-up, however, concentrations in stools of controls increased to almost triple that of cases and the difference was significant. Fecal TNF- α was only assessed in the second study; those with cryptosporidiosis had significantly higher concentrations at enrollment, but this did not persist at follow-up, i.e., after infection had resolved. A Brazilian study only measured TNF- α among 10 *C. parvum*-infected children and found no samples with elevated concentrations. IL-8 was measured among those with and without *C. parvum* infection, but the proportions of those with detectable serum concentrations did not differ between the groups [101].

Two randomized, controlled trials of vitamin A supplementation used fecal cytokines as outcome measures [137, 140]. In one, IL-4, IL-6 and IFN- γ were measured as the primary endpoints of the intervention in children with and without gastrointestinal pathogens [140]. Overall no significant difference was observed in stool cytokine concentrations between vitamin A-supplemented and placebo subjects. However the relationship between fecal cytokine concentrations and vitamin A supplementation was modified by both gastrointestinal infection and diarrhea. Similarly in the second study, vitamin A supplementation was not associated with an intestinal cytokine response [137].

5.5.2.3 Associations between Fecal Cytokines and Other Markers

Fecal cytokines were compared to other markers in only one of these studies, finding that TNF- α RI was significantly associated with fecal lactoferrin [132].

5.5.3 Fecal Leukocytes

Four studies collected data on stool leukocytes. Two of these studies reported the proportion of tests positive for the presence of leukocytes. These values ranged from 1% among children with HAZ scores below the local median [169] to 11.7% among children hospitalized with malnutrition or persistent diarrhea [138]. Two studies compared fecal leukocytes across subject groups with different gastrointestinal conditions. In one study, where neither proportions

of positive nor fecal leukocyte counts were reported, the investigators found that fecal leukocytes did not differ between children with acute diarrhea, some of whom went on to develop persistent diarrhea, and controls without diarrhea [104]. The second of these two studies found that mean fecal leukocyte counts were nearly eight times higher in shigellosis cases than in cholera cases and nearly 13 times higher in shigellosis than in healthy controls [158].

5.5.4 Fecal Neopterin

One study measured fecal neopterin as an indicator of intestinal inflammation, following subjects from 2-15 months of age [15]. No association was observed between L:M and fecal neopterin. Mean neopterin concentrations were negatively associated with long-term height gain, but were not associated with *Giardia* recovery in stools.

5.5.5 Fecal IgE

Two studies assessed fecal IgE as a marker of intestinal inflammation; both appear to have been conducted on the same population. The first was a community-based cohort study that investigated incidence of fecal IgE by gender and age group [143]. The incidence of fecal IgE was substantial, at 0.39/child-years, and peaked at 3-6 months of age. The second study assessed the relationship between stool IgE and persistent and/or acute diarrhea [142]. Fecal IgE was detected greater than three times more frequently among stools from episodes of persistent diarrhea compared to stool from episodes of acute diarrhea (OR (95% CIs) =3.3 (1.0, 10.9)) and nearly five times more frequently in persistent diarrhea stools than in stools from those without diarrhea (OR (95% CIs) =4.8 (1.07, 21.7)).

5.5.6 Inflammatory Intestinal Cell Markers

One study assessed inflammatory cell markers in intestinal tissue [103]. Densities of cell proteins and inflammatory markers in the lamina propria and crypt epithelium in Zambian children with persistent diarrhea and different forms of malnutrition were compared across

groups and to those in healthy controls from the UK. Immunohistochemistry was performed on intestinal tissue obtained by endoscopic biopsy. The intestinal cell proteins studied were glycosaminoglycans (GAG), heparan sulfate proteoglycan (HSPG), and syndecan-1. The inflammatory cell markers measured were CD3⁺ intraepithelial lymphocytes (IEL), human leukocyte antigen DR-1 (HLA-DR), and Ki67, a crypt epithelial nuclear proliferative marker.

Inflammatory markers were observed at higher concentrations in the Zambian subjects than in the UK controls. There were significant differences in specific types of inflammatory markers across malnutrition groups. There was a significant reduction in intestinal GAG and HSPG in the kwashiorkor group compared to UK children, but there were no significant differences in these values between the children with kwashiorkor and those with other types of malnutrition. There was no difference in epithelial syndecan-1 protein expression between the malnutrition groups; data for this marker were not reported for the UK controls.

These markers were not compared to other types of markers of intestinal function.

5.5.7 Intestinal Tissue Cytokines and Immune Markers

While scintigraphy and counts of intraepithelial white blood cells (WBCs) and leukocyte presence in the lamina propria provide assessments of intestinal inflammation, scintigraphy can be used more broadly to study intestinal pathology and as such is listed in section VII on nonspecific markers of intestinal injury. Because WBCs are sought in biopsies along with assessments of intestinal architecture, histopathology, including assessment of WBC infiltration, is listed in section VII as well.

Only one study assessed intestinal tissue cytokines and immune markers. Markers were compared between rural Gambian children with differing degrees of malnutrition and UK control subjects with normal endoscopic results [111]. They assessed cytokine immunohistochemistry of intestinal tissue using antibodies against syndecan-1, perforin, $\gamma\delta$ T-cell receptor, CD-3, CD-4,

CD-8, CD-19, CD-25, HLA-DR, TNF- α , IFN- γ , TGF- β , and IL-10. Median CD3⁺, CD4⁺, CD8⁺, CD19⁺, and CD25⁺ cell counts were 2-5 times higher among each case group compared to the UK controls; these differences were statistically significant. IEL, $\gamma\delta$, syndecan-1, HLA-DR, and perforin were detected among the Gambian children in varying degrees but were not reported for UK controls. Syndecan, CD3, and CD8 displayed a gradient proportional to malnutrition severity. All Gambian groups had greater density of cytokine-immunoreactive mononuclear cells in the lamina propria than UK controls. Among subjects with elevated cytokines, similar densities were seen for both pro-inflammatory (IFN- γ and TNF- α) and putative regulatory (IL-10 and TGF- β) cytokines. Epithelial expression of TGF- β in Gambian subjects was also enhanced compared to UK controls, but subjects with poorer nutritional status had lower densities of mucosal TGF- β + cells. A marker of intestinal permeability, L:M was significantly associated with mucosal B lymphocyte, IEL, and perforin-positive IEL densities.

5.5.8 Duodenal Aspirates for Immunoglobulins

One study measured immunoglobulin concentrations in duodenal fluid as a marker of intestinal inflammation [128]. Concentrations of duodenal immunoglobulin were compared in hospitalized children with both persistent diarrhea and *Giardia* infection and controls without diarrhea or gastrointestinal infection. Significantly higher mean concentrations of IgM were found in duodenal aspirates of cases compared to controls. Mean concentrations of duodenal IgA and IgG did not differ between cases and controls, however.

5.5.9 Summary of Markers of Intestinal Inflammation

A variety of markers were assessed with a preponderance of studies using fecal lactoferrin. Lactoferrin was measured among study populations with varying characteristics. Lactoferrin results varied considerably as did results of other measures of intestinal inflammation.

Of note, among studies that met our review inclusion criteria, there was a complete absence of research utilizing fecal calprotectin (a protein produced by neutrophils and monocytes). This marker has been found in stools of patients with inflammatory bowel diseases in developed country settings during the time period of this review [262-264], but we found no analyses of its prevalence and potential role as a diagnostic tool in children with EED.

A threshold for normal for tests of intestinal inflammation was often not defined by authors. Generally data on these markers were not collected longitudinally so it is not clear how much intra-individual variation exists. Only one study statistically compared markers of intestinal inflammation to each other, and found a relationship between TNF- α R1 and lactoferrin [132]. None of the intestinal inflammation studies compared these markers to biopsy results or to other tests of intestinal dysfunction such as permeability or absorption.

An important consideration in evaluating these tests is the overall feasibility of performing them, especially in resource-limited settings. For example, stool is a somewhat easier analyte to obtain than blood (especially non-capillary assessments) and even urine among young children. Duodenal aspirates are, of course, more invasive tests and examination of intestinal tissue can only be performed on biopsy specimens, limiting their feasible use. Nonetheless, stool is an imperfect analyte. Production of sample cannot be scheduled, and the mechanics of obtaining the specimen are sometimes challenging, necessitating using adhesive bags or collection from diapers. In addition, stool is probably more biohazardous than blood, and certainly more than urine, and often elicits handling concerns by laboratory staff and couriers.

5.6 Markers of Systemic Inflammation and Systemic Immune Activation

Markers of systemic immune function and inflammatory response might provide informative indirect evidence of precursors to, or consequences of, small intestinal injury.

Indeed, the hypothesis that local inflammation could be reflected in systemic markers is intriguing. There is precedent for associations between markers of organ-specific inflammation and systemic inflammation, with the best studied being coronary artery and inflammatory bowel diseases. The atherosclerotic lesion in coronary artery disease and the small and/or large bowel inflammation in Crohn's disease and ulcerative colitis are characterized by acute and chronic inflammatory changes, and, as such, could be analogous to the lesions found in EED. By extension, there is ample evidence of an association between systemic markers of inflammation and acute coronary artery events, including myocardial infarction, sudden cardiac death, and cerebrovascular accidents, and of intestinal disease activity in inflammatory bowel diseases. Concentrations of circulating C-reactive protein (CRP) have, indeed, emerged as strong predictors of such events in adults, and complement the use of lipid profiles, which are a more specific biomarker of coronary artery disease [265-267]. Systemic CRP or erythrocyte sedimentation rates are indices of inflammatory bowel disease activity [268, 269].

In the case of EED, there is justification for seeking evidence of systemic inflammation as a biomarker, based on the precedent of coronary artery disease and inflammatory bowel diseases. However, there are additional justifications: the pathophysiology of environmental enteric dysfunction might result in, or be associated with, a hyperpermeable gut. Such increased bowel permeability would expose the host to a variety of injurious substances, most particularly microbial inflammatory drivers, and the host response could either be a surrogate for inflammation, or reflect the process that leads to enteric dysfunction. For example, one or more bacterial molecules could be absorbed, leading to a pro-inflammatory host response, as manifested by elevated CRP, but such a response could be an appropriate reaction to the gut that enables the molecules to be absorbed.

To hone in on assessments of systemic inflammation and immune function that could be helpful as markers of enteric dysfunction, we reviewed those studies that examined the markers

among children with presentations such as persistent diarrhea, or investigations of the markers in relationship to markers of intestinal inflammation or dysfunction.

It should be noted that there can be considerable overlap between the primary assignment of many of these markers of systemic inflammation and nutrient testing (e.g., serum albumin, total protein, hemoglobin, and blood counts.) For example, while hypoalbuminemia, hypo- or hypergammaglobulinemia, and impaired erythropoiesis are indicators of nutritional status, they can also reflect systemic immune activation [270-273]; as such, they were assigned to this section. For purposes of this review, if a test could be related to inflammatory activation and measured the product of a nutrient (such as hemoglobin) and not the nutrient itself (such as iron), then we included the test in our review.

We identified a diverse set of markers from 23 studies that we assigned to the category of systemic inflammation but which could serve as biomarkers for intestinal inflammation. Relevant data for each of the studies in this category can be found in Evidence Table 5. The most commonly employed markers were CRP, albumin, hemoglobin, transferrin, and varying total and immunoglobulin class concentrations. Additional markers included circulating cytokines and/or chemokines, total oxidant status, circulating α -1-acid glycoprotein (AGP), serum mannose-binding lectin, and urinary neopterin. Three studies assessed nitric oxide [43, 158] and plasma endotoxin and IgG endotoxin-core antibody [110], which are markers that could reflect systemic inflammation driven by intestinal processes. One study also included data on multiple markers of cellular, as well as humoral, immunity [104].

Although we did not systematically seek studies that assessed systemic marker association with nutritional status, among the studies that used markers of systemic inflammation or immune activation that were included in this review, seven assessed systemic inflammatory markers in relation to anthropometric indices [43, 110, 122, 123, 130, 150, 151]. The relationships varied widely across markers and sometimes across different growth

parameters for the same marker. Some data associated circulating markers of systemic inflammation and stunting; the markers with the strongest associations were albumin and α -1-acid glycoprotein, each in an inverse relationship [123].

Six studies investigated association of systemic markers with persistent diarrhea [104, 106, 107, 114, 130, 166]. Those identified at significantly lower concentrations in children with persistent diarrhea relative to children without diarrhea included: serum total protein [106, 107], hemoglobin [106, 166], mean corpuscular volume (MCV) and mean corpuscular hemoglobin (MCH) [166], lymphocyte counts [166], and anti-oxidant concentrations [107]. Albumin concentrations were also lower in children with persistent diarrhea; this relationship was statistically significant in one study [106] but not in another [166]. Sample size differences could explain the effect discrepancy with six 6-24 month olds with persistent diarrhea in the latter [166] compared to 96 6-36 month olds in the former [106]. While albumin concentrations are known to increase with increasing age, the slightly older cohort in the study that found an association is unlikely to explain the discrepancy in results.

Markers found at higher levels in children with persistent diarrhea compared to those with no diarrhea were total oxidant status, thiobarbituric reactive substances, and DNA damage [107]. In addition, assays of neutrophil polarization and monocyte spontaneous proliferation showed increased responsiveness in children with acute or persistent diarrhea relative to those without diarrhea [104]. A negative delayed-type hypersensitivity response to tuberculin antigen was also associated with progression from acute to persistent diarrhea [104].

Only one study utilizing markers of systemic inflammation investigated both growth outcomes and persistent diarrhea; this was in relation to serum mannose-binding lectin [130], which was not significantly associated with either.

Five studies investigated the relationship of systemic inflammatory markers to gut permeability. Associations were found between IgG, IgA, IgM, and IgG endotoxin core antibody

and intestinal function as measured by the L:M ratio [110] and between hemoglobin concentration and the lactose:creatinine ratio [151]. Additionally a correlation was observed between urinary nitric oxide and the serum L:R ratio [43]. In contrast, anemia and mean corpuscular volume (MCV) were not associated with serum L:R [58], and associations were not found between the L:M ratio and other markers such as α -1-acid glycoprotein (AGP), total IgG, albumin, or hemoglobin concentrations [123]. Furthermore, only one of these studies included biopsy, but the authors did not report assessing the relationship between markers of systemic inflammation and histology [146].

Evidence Table 5. Markers of systemic inflammation and systemic immune activation.

Biomarkers in bold are primarily markers of systemic inflammation and/or immune activation.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
<p>2000</p> <p>Azim T et al.</p> <p>Immune response of Bangladeshi children with acute diarrhea who subsequently have persistent diarrhea</p> <p>Immune response tests, as well as transferrin and albumin as markers of nutritional status among children with and without PD</p>	<p>Dhaka, Bangladesh</p> <p>7-12 mo olds with 6-8 days of watery diarrhea attending the International Centre for Diarrheal Disease Research.</p> <p>Cases were those who went on to develop PD, controls were those who did not.</p> <p>An additional group of subjects without diarrhea were recruited from a nutrition follow-up unit.</p> <p>Prevalence of malnutrition was high in all groups.</p>	<p>Case-control</p> <p>n=136;</p> <p>n=38 cases with PD</p> <p>n=98 controls:</p> <ul style="list-style-type: none"> • 85 with AD • 13 with no diarrhea 	<p><u>Blood tests:</u></p> <ul style="list-style-type: none"> • IFN-γ • TNF-α • WBC (total and differential) • IgA • IgG • IgM • Transferrin • Albumin <p>Immune function tests:</p> <ul style="list-style-type: none"> • Neutrophil polarization response to chemotactic factor • Neutrophil opsonization to yeast • Mononuclear cell proliferation, spontaneous and in response to stimuli with mitogens <p><u>Skin Test:</u></p> <ul style="list-style-type: none"> • Delayed-type hypersensitivity response (DTH) to tuberculin, tetanus, diphtheria, <i>Streptococcus</i>, <i>Proteus</i>, <i>Candida</i>, and <i>Trichophyton</i> <p><u>Stool tests:</u></p> <ul style="list-style-type: none"> • Leukocytes • Red blood cells 	<p>WBC total and differential, immunoglobulin subtypes, cytokines, transferrin, and albumin did not differ between cases with diarrhea or controls, nor did stool leukocyte or erythrocyte counts.</p> <p>The percentages of neutrophils that polarized in response to stimulation were significantly higher in subjects with AD or PD compared to those without diarrhea; there was no difference between the two diarrhea groups.</p> <p>Opsonization did not vary between any groups.</p> <p>Monocyte spontaneous proliferation counts were less than half among children with no diarrhea compared to those with AD (p<0.001) or with PD (p=0.011); there was no difference between the two diarrhea groups.</p> <p>Monocyte proliferation in response to stimulation did not differ between the 3 groups.</p> <p>The proportion with DTH responses differed among the three groups only in response to tuberculin (p=0.021). More PD subjects had a negative tuberculin response than did subjects with AD (p=0.024).</p>	<p>Some immune and inflammatory markers were associated with acute and/or persistent diarrhea.</p> <p>The only marker that was significantly associated with progression to PD was a negative DTH response to tuberculin antigen (odds ratio=3.8, CI: 1.4, 9.9). This was calculated from a logistic regression analysis that only included children with diarrhea.</p>	<p>The number of controls was relatively small and their nutritional status was not reported.</p>

Evidence Table 5. Markers of systemic inflammation and systemic immune activation.

Biomarkers in bold are primarily markers of systemic inflammation and/or immune activation.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
<p>2003</p> <p>Bitarakwate E et al.</p> <p>Serum zinc status of children with persistent diarrhoea admitted to the diarrhoea management unit of Mulago Hospital, Uganda</p> <p>Serum protein, albumin, and hemoglobin among children with and without PD</p>	<p>Kampala and Mpigi, Uganda</p> <p>6-36 mo olds with PD, recruited from hospital, and healthy controls recruited mainly from the local population.</p>	<p>Case-control</p> <p>n=192;</p> <p>n=96 cases with PD</p> <p>n=96 healthy controls</p>	<p><u>Blood Tests:</u></p> <ul style="list-style-type: none"> • Albumin • Total protein • Hemoglobin 	<p>PD cases:</p> <p>7.47.9% low serum protein</p> <p>8.69.7% low serum albumin</p> <p>9.Low mean hemoglobin (10.5 g/dL)</p> <p>For controls, means of all three laboratory values were within normal range; percent of subjects with abnormal values are not reported.</p> <p>All three test results were significantly lower in children with PD than in controls (p< 0.01 for each comparison).</p>	<p>Decreased albumin, serum total protein and hemoglobin concentrations were associated with PD.</p>	
<p>2010</p> <p>Bukhari AS et al.</p> <p>DNA damage and plasma homocysteine concentrations are associated with serum metabolites and mineral constituents' profiles in children with persistent diarrhea</p> <p>Serum proteins, metabolites, and levels of DNA damage among children with and without PD</p>	<p>Faisalabad, Pakistan</p> <p>3-6 yr olds admitted to hospital with PD and healthy controls.</p>	<p>Case-control</p> <p>n=72;</p> <p>n=36 cases with PD</p> <p>n=36 healthy controls</p>	<p><u>Blood Tests:</u></p> <p>Serum proteins and metabolites:</p> <ul style="list-style-type: none"> • Albumin • Globulin • Homocysteine • Total protein • Total cholesterol, HDL, LDL, triglycerides • AST, ALT • T3, T4 • Total oxidant status (TOS), Total anti-oxidant status (TAS), and thiobarbituric reactive substances (TBARS) • DNA damage to lymphocytes 	<p>Mean values significantly higher among PD cases than in healthy controls:</p> <p>10.LDL</p> <p>11.Homocysteine</p> <p>12.TOS</p> <p>13.TBARS</p> <p>14.DNA damage</p> <p>Mean values significantly lower among PD cases than in healthy controls:</p> <p>15.Total protein</p> <p>16.T4</p> <p>17.TAS</p>	<p>Multiple serum markers were associated with PD, especially DNA damage to lymphocytes (p=0.0001).</p> <p>The authors speculate that zinc deficiency, more commonly found in the children with PD, might be responsible for increased homocysteine concentrations and play an important role in mediating DNA damage.</p>	<p>Control recruitment strategy was not well described.</p> <p>TOS, TBARS and TAS were incompletely defined.</p> <p>Some values differed by gender in both the case and control groups:</p> <p>18.Triglycerides</p> <p>19.Total cholesterol</p> <p>20.HDL</p> <p>21.T3</p> <p>Multiple markers studied; analyses did not appear to address potential confounding.</p>

Evidence Table 5. Markers of systemic inflammation and systemic immune activation.

Biomarkers in bold are primarily markers of systemic inflammation and/or immune activation.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
<p>2003</p> <p>Campbell DI et al.</p> <p>Growth faltering in rural Gambian infants is associated with impaired small intestinal barrier function, leading to endotoxemia and systemic inflammation</p> <p>L:M as a marker of intestinal permeability and its relationship with various inflammatory markers and endotoxin</p>	<p>Keneba, The Gambia</p> <p>All 2-11 mo olds were recruited from this rural village and followed up to 14 mo of age.</p>	<p>Cohort</p> <p>n=71</p>	<p><u>Urine Tests:</u></p> <ul style="list-style-type: none"> • Lactulose¹ (53 tested) • Mannitol (52 tested) • L:M (52 tested) <p><u>Blood tests:</u></p> <ul style="list-style-type: none"> • Albumin • CBC • C-reactive protein (CRP) • IgA • IgM • IgG • Plasma endotoxin • IgG endotoxin-core antibody 	<p>At 8 wk of age:</p> <ul style="list-style-type: none"> • Mean² L:M: 0.169 (CI: 0.145, 0.198; range: 0.058-0.657) • Mean lactulose recovery: 0.202 (SD=0.159; range: 0.009-0.640) • Mean mannitol recovery: 3.80 (SD=2.35; range: 0.52-8.58) <p>L:M more than doubled between 12 wk-1 yr of age (r=0.44, p<0.001) and was driven by both increasing lactulose (r=0.18, p<0.001) and decreasing mannitol (r=-0.14, p<0.01) excretion with age.</p> <p>WAZ and HAZ scores were negatively correlated with L:M (r=-0.41, p<0.001), and primarily driven by lactulose excretion (r=-0.39, p<0.001).</p> <p>Laboratory values were consistent with chronic, low level immunostimulation:</p> <ul style="list-style-type: none"> • 50% of platelet and 39% of leukocyte counts were elevated, especially mean lymphocyte counts which were almost twice expected values [198]. • While the mean³ CRP was within the normal range, 25% of values were above the upper limit of normal (5 mg/L), and 17% were >10 mg/L [198]. • Mean IgG, IgA and IgM concentrations were near normal at 8 wk of age, but increased rapidly; all three were elevated above expected values in all other 	<p>Mean L:M ratios were elevated at 8 weeks of age, and more than doubled in the first year of life.</p> <p>Many markers of inflammation and endotoxin release were significantly correlated with L:M and lactulose recovery.</p> <p>Poor growth was significantly correlated with L:M ratios, primarily due to lactulose excretion.</p> <p>Authors postulate that while general markers of inflammation cannot be specifically ascribed to a gut source, endotoxin and its related core antibody are potentially a direct measure of intestinal inflammation due to gut gram negatives as a primary source of endotoxin release among subjects without sources of</p>	<p>Presence of malaria parasites was assessed by blood smear at each study visit; the only parameter associated with malaria was CRP. Authors did not report investigating relationships between certain serum parameters (blood counts, CRP concentrations) and L:M.</p> <p>Study population might have overlap with that of Campbell et al. 2004 also included in this review [15].</p>

¹ For lactulose and mannitol results, excretion measurement was not specified.

² Geometric mean.

³ Geometric mean.

Evidence Table 5. Markers of systemic inflammation and systemic immune activation.

Biomarkers in bold are primarily markers of systemic inflammation and/or immune activation.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
				<p>age groups [198, 199].</p> <ul style="list-style-type: none"> • Mean¹ free plasma endotoxin concentration was twice the upper limit of normal [200] and IgG endotoxin-core antibody concentrations were also elevated [198]. • However, mean albumin concentrations (and concentrations within SD) were generally within normal range [198]. <p>L:M was correlated with IgG and IgA (r=0.41 and 0.41, respectively, p<0.001), and IgM (r=0.28, p<0.02).</p> <p>IgG and IgA were also correlated with lactulose recovery (r=0.26 and 0.25, respectively, p<0.02).</p> <p>IgG endotoxin core antibody concentration was correlated with L:M and driven by lactulose recovery, (r=0.35, p<0.005 for both).</p> <p>Endotoxin concentrations were correlated with lactulose recovery (r=0.36, p<0.02) only.</p>	extra-intestinal gram negative infection.	
<p>2002</p> <p>Clark TD et al.</p> <p>Risk factors and cumulative incidence of anaemia among human immunodeficiency virus-infected children in Uganda</p>	<p>Kampala, Uganda</p> <p>9 mo old HIV-infected children followed at Mulago hospital until 36 mo of age.</p> <p>More than 40% were stunted and/or underweight at</p>	<p>Cohort</p> <p>n=225</p>	<p>Blood Test:</p> <p>Hemoglobin</p>	<p>While chronic diarrhea was associated with moderate anemia in a univariate analysis (odds ratio=2.5, CI: 1.0, 6.3), it was either not associated with moderate anemia (hemoglobin <9 g/dL) in a multivariate model or not included in the model</p>	<p>While there was a high prevalence of anemia (<11 g/dL) and moderate anemia (<9 g/dL) (92% and 35% at 9 months, respectively) among this cohort of HIV-infected children, chronic diarrhea</p>	<p>The association between chronic diarrhea and other assessed hematologic markers (any degree of anemia, mean corpuscular volume, and mean corpuscular hemoglobin</p>

¹ Geometric mean.

Evidence Table 5. Markers of systemic inflammation and systemic immune activation.

Biomarkers in bold are primarily markers of systemic inflammation and/or immune activation.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
Association of chronic diarrhea with moderate anemia in HIV-infected children	enrollment.				appears to have not been associated with anemia in the multivariate analysis. However, the text did not specifically state whether chronic diarrhea was tested in the multivariate model.	concentration) was not reported.
2008 Goto R et al. Impact of anti- <i>Giardia</i> and anthelmintic treatment on infant growth and intestinal permeability in rural Bangladesh: a randomised double-blind controlled study L:M as a marker of intestinal permeability, IgG as a marker of chronic immune stimulation, and α -1-acid glycoprotein as an acute phase reactant among children undergoing anti-parasitic presumptive treatment vs. placebo. Also assessed markers' associations with	Dhamrai Upazila, Bangladesh 3-15 mo olds from a rural area were enrolled and followed in a 9-mo trial. There was a high prevalence of malnutrition in the study population.	RCT n=222* n=75 received anti- <i>Giardia</i> and anthelmintic treatment n=59 received anti- <i>Giardia</i> treatment only n=88 received placebo * Those who fully participated and for whom data were analyzed are included in this review.	<u>Urine Test:</u> L:M <u>Blood Tests:</u> • α-1-acid glycoprotein (AGP) • IgG • Albumin	Mean L:M ¹ (SD) at baseline was 0.18 (0.24) in treatment groups, with no significant difference in placebo group or in testing post-intervention. Proportion with elevated L:M at any study time point varied between 58%-74%. >57% consistently elevated L:M ratios. Seasonal variation in L:M was observed (p <0.001), with highest mean values in the monsoon season. L:M was associated with Δ WAZ and Δ WHZ scores at 24 weeks (p=0.001 and p<0.001, respectively, point estimates not provided.) Serum immune marker values were similar in all groups and did not change substantially with interventions. AGP concentrations were negatively associated with Δ WAZ score at 24 weeks (p=0.004, point estimate not provided), and were associated with Δ WHZ score at 12 weeks but not at 24 weeks.	High L:M ratios overall with substantial seasonal and within-infant variability. Interventions did not impact L:M or serum immune markers. There was improvement in weight with better L:M values, the degree to which this occurred was not reported.	High L:M ratios were defined as greater than the upper CI for UK infants. Same study population as reported by this group in another study also included in this review [123].

¹ Geometric mean.

Evidence Table 5. Markers of systemic inflammation and systemic immune activation.

Biomarkers in bold are primarily markers of systemic inflammation and/or immune activation.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
growth parameters. 2008 Goto R et al. Impact of intestinal permeability, inflammation status and parasitic infections on infant growth faltering in rural Bangladesh L:M as a marker of intestinal permeability, IgG as a marker of chronic immune stimulation, and α -1-acid glycoprotein as an acute phase reactant. Also assessed laboratory values' associations with giardiasis and growth parameters.	Dhamrai Upazila, Bangladesh 3-15 mo olds from a rural area were enrolled and followed in a 9-mo trial. There was a high prevalence of malnutrition in the study population.	Longitudinal data extracted from an RCT [123] n=298 Urine and blood samples were collected every 3 mo and anthropometric measurements were collected monthly.	<u>Urine Test:</u> L:M <u>Blood Tests:</u> • α -1-acid glycoprotein (AGP) • IgG • Albumin • Hemoglobin	Mean ¹ L:M: 0.15 L:M showed a decreasing trend with age (p=0.003), and was associated with female gender (p=0.004), HAZ score (p=0.039), and WAZ score (p=0.019), but not with giardiasis or any of the serum immune markers. IgG, AGP, and albumin were associated with giardiasis, but hemoglobin was not. Mean circulating albumin concentration was normal for age [203]. Compared to UK age-matched reference [199], rate of rise in IgG with increasing age was similar, but concentrations were consistently ~3g/L higher. IgG was not associated with growth parameters. Albumin was associated with HAZ score only (p=0.016). AGP was inversely associated with HAZ (p=0.011) and WAZ (p=0.005) scores	Mean L:M was elevated. L:M was not associated with any of the tested serum markers of inflammation or with giardiasis. IgG rose with increasing age at the rate expected (compared to UK norms) [199] but at higher concentrations across all ages.	Helminthiasis prevalence was very low; testing for association with markers was not performed. Giardiasis was defined as presence of a <i>Giardia</i> -specific IgM response. Same study population as reported by this group in another study also included in this review [122]. Cut-off values representing elevated concentrations have not been determined for AGP. UK norms for 10 mo olds-adults are 0.88 g/L mean (0.21 SD) [204].
2007 Jain S et al. Fecal occult blood screening in children with severe malnutrition Fecal occult blood	Delhi, India Children (ages unspecified) admitted with severe malnutrition and age-matched healthy controls recruited from an immunization clinic.	Case-control n=80; n=50 cases with severe malnutrition n=30 healthy controls	<u>Stool Test:</u> Occult blood <u>Blood Test:</u> Hemoglobin	Fecal occult blood test was positive in 30/50 (60%) cases and 0/30 controls. Among cases positive for fecal occult blood, 20 (66.7%) were found to have hemoglobin <8 g/dL. Enteric infections: • Parasitic infections were detected	A high proportion of severely malnourished children had a positive fecal occult blood test, compared with no positives among healthy controls.	Among cases, half had a presenting complaint of diarrhea (duration not specified), but the authors did not report results stratified by diarrhea duration.

¹ Geometric mean.

Evidence Table 5. Markers of systemic inflammation and systemic immune activation.

Biomarkers in bold are primarily markers of systemic inflammation and/or immune activation.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
among severely malnourished children compared to healthy controls				<p>in 14/50 (28%) of cases, 12 (85.7%) of whom tested positive for fecal occult blood.</p> <ul style="list-style-type: none"> Bacterial infections were detected in 18/50 (36%) of cases, 13 (72.2%) of whom tested positive for fecal occult blood. Of the remaining 18 for whom an enteric pathogen was not identified, 5 (27.8%) tested positive for fecal blood. <p>Among the 30 cases with fecal occult blood, 16 were breastfed, 11 were fed cow's milk, and 3 were fed formula.</p>	<p>Malnourished children with identifiable pathogens more often tested positive for fecal occult blood, although approximately 25% of those without an identifiable pathogen also tested positive.</p> <p>Presence of fecal blood did not appear to vary by feeding mode (e.g. breast milk, cow's milk, or formula), although data presented were limited.</p>	<p>Authors did not provide differences in proportions of occult blood among those with and without specific enteric pathogens.</p> <p>Statistical analysis was not provided; data were reported as proportions only.</p> <p>Matching scheme was not defined.</p>
<p>2001</p> <p>Kapoor S et al.</p> <p>Giardiasis--clinical and diagnostic perspective</p> <p>Immunoglobulin concentrations in duodenal fluid and serum among children with PD and <i>Giardia</i> infection compared to those without diarrhea</p>	<p>New Delhi, India</p> <p><12 yr olds admitted to hospital with PD and <i>Giardia</i>.</p> <p>Controls had no diarrhea and were hospitalized for non-GI conditions.</p> <p>Most cases were <7 yr old, with n=19 <3 yr old. Ages of controls were not specified.</p>	<p>Case-control</p> <p>n=40;</p> <p>n=30 cases with PD and <i>Giardia</i></p> <p>n=10 controls without diarrhea</p>	<p><u>Duodenal secretion aspirates:</u></p> <ul style="list-style-type: none"> IgG IgM IgA <p><u>Blood Tests:</u></p> <ul style="list-style-type: none"> IgG IgM IgA 	<p>Higher mean concentrations of IgM were found in duodenal aspirates of cases compared to controls (p<0.05).</p> <p>Mean concentrations of duodenal IgA and IgG did not differ between cases and controls.</p>	<p>Differences in immunoglobulin concentrations were limited among children with PD infected with <i>Giardia</i> compared to children without such conditions.</p>	<p>The number of controls was small due to constraints in obtaining duodenal aspirate from children without GI symptoms.</p>
<p>2006</p> <p>Kirkpatrick BD et al.</p> <p>Serum mannose-binding lectin</p>	<p>Port-au-Prince, Haiti</p> <p><36 mo old inner-city residents recruited from the rehydration unit at the State</p>	<p>Case-control</p> <p>n=99;</p> <p>n=49 cases with <i>Cryptosporidium</i></p>	<p><u>Blood Test:</u></p> <p>Mannose-binding lectin (MBL)</p>	<p>Serum MBL concentrations were lower in cases than in healthy controls (p=0.002) and diarrhea controls (p=0.045).</p> <p>Percentage MBL-deficient:</p>	<p>While cryptosporidiosis was associated with MBL deficiency, MBL concentrations were not significantly</p>	<p>MBL deficiency was defined as concentrations ≤ 70 ng/mL.</p>

Evidence Table 5. Markers of systemic inflammation and systemic immune activation.

Biomarkers in bold are primarily markers of systemic inflammation and/or immune activation.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
<p>deficiency is associated with cryptosporidiosis in young Haitian children</p> <p>Mannose-binding lectin as a marker of innate immune activation among children with and without <i>Cryptosporidium</i> infection</p>	<p>University Hospital or from GHESKIO HIV Center¹.</p> <p>All subjects were HIV-negative.</p>	<p>infection (22 with PD)</p> <p>n=9 diarrhea controls negative for <i>Cryptosporidium</i></p> <p>n=41 healthy controls without diarrhea and <i>Cryptosporidium</i>-negative</p>		<ul style="list-style-type: none"> • 36.7% cases • 9.8% healthy controls • 0 diarrhea controls <p>Cryptosporidiosis was associated with MBL deficiency (odds ratio=22.4; CI: 3.1, 160.8²).</p> <p>Among cases, the proportion of those with PD was nearly double among those with MBL deficiency compared to those without MBL deficiency, but these results were not significant (p=0.13). MBL deficiency was not associated with duration of diarrhea (p=0.37) among those with cryptosporidiosis nor with anthropometric status among either cases or controls.</p>	<p>associated with mean duration of diarrhea or history of PD.</p>	
<p>2002</p> <p>Kirkpatrick BD et al.</p> <p>Cryptosporidiosis stimulates an inflammatory intestinal response in malnourished Haitian children</p> <p>Stool lactoferrin, reducing substances, leukocytes and cytokines as markers of intestinal inflammation of children with and without</p>	<p>Port-au-Prince, Haiti</p> <p><18 mo olds from a low SES setting recruited from the rehydration unit of GHESKIO HIV Center³ with diarrhea and <i>Cryptosporidium</i> infection. Controls recruited from an outpatient clinic without <i>Cryptosporidium</i> infection included those with and without diarrhea.</p>	<p>Case-control</p> <p>n=49;</p> <p>n=17 cases with <i>Cryptosporidium</i> and diarrhea (5 with PD)</p> <p>n=32 controls without <i>Cryptosporidium</i>;</p> <ul style="list-style-type: none"> • 17 with diarrhea (5 with PD) • 15 healthy 	<p><u>Stool Tests:</u></p> <ul style="list-style-type: none"> • Reducing substances (RS) • Lactoferrin • Cytokines: <ul style="list-style-type: none"> • TNF-α receptor I • IL-4 • IL-8 • IL-10 • IL-13 • IFN-γ <p><u>Blood Test:</u></p> <ul style="list-style-type: none"> • WBC 	<p>Proportion RS-positive:</p> <ul style="list-style-type: none"> • 33.3% cases • 64.7% diarrhea controls • 46.7% healthy controls, (p=0.2) <p>Proportion lactoferrin-positive:</p> <ul style="list-style-type: none"> • 83.3% cases • 60.0% diarrhea controls • 28.6% healthy controls, (p=0.01) <p>IFN-γ was not recovered in any stools.</p> <p>All other fecal cytokines were significantly associated with <i>Cryptosporidium</i> cases compared to diarrhea and healthy controls.</p> <p>Additionally, TNF-α receptor I, IL-8, IL-13 were found in diarrhea and healthy controls, while IL-4 and IL-10</p>	<p>Fecal lactoferrin was identified most often in children with diarrhea, especially in those with <i>Cryptosporidium</i>. While some fecal cytokines were detected in as many as 40% of healthy controls and 70% of controls with diarrhea, they were generally associated with <i>Cryptosporidium</i> infection. The other stool tests did not discriminate by diarrhea or</p>	<p>Reported results were not stratified by persistent vs. acute diarrhea status.</p> <p>Cut-off values for lactoferrin positivity were not described.</p> <p>Stools from children who were breastfeeding were not tested for lactoferrin.</p>

¹ The Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections.

² Reported results were adjusted for confounding variables, unless otherwise noted.

³ The Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections.

Evidence Table 5. Markers of systemic inflammation and systemic immune activation.

Biomarkers in bold are primarily markers of systemic inflammation and/or immune activation.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
<i>Cryptosporidium</i> infection				were not. Fecal lactoferrin was associated with the presence of TNF- α receptor I (point estimate not provided, $p=0.03$). Mean WBC counts were within normal range in all 3 groups.	<i>Cryptosporidium</i> status.	
2003 Kukuruzovic R et al. Increased nitric oxide production in acute diarrhea is associated with abnormal gut permeability, hypokalemia and malnutrition in tropical Australian aboriginal children Nitric oxide (NO) as a marker of intestinal permeability and inflammation, and lactulose:rhamnose ratio (L:R) as a marker of intestinal permeability and the relationship between NO and L:R, growth parameters, mean corpuscular volume (as a surrogate of iron deficiency), and stool reducing substances among children with and without diarrhea	Darwin, Australia 1-6 yr old Aboriginal and non-Aboriginal hospital inpatients. Subjects were grouped as follows: • Children with AD • Children with no diarrhea but with non-GI infectious conditions • Children without GI or infectious conditions	Case-control n=318; n=169 cases with AD (154 Aboriginal) n=149 controls: • 73 with non-GI infections (49 Aboriginal) 76 with no infections (29 Aboriginal)	Urine Test: Nitric Oxide (NO)* Blood Tests: • L:R • Mean corpuscular volume (MCV) Stool Test: Reducing substances (RS)** (169 cases tested) * NO is an unstable free radical and is converted to nitrite and nitrate. Urine nitrate (NO ₃) + nitrite (NO ₂) was expressed as a ratio with urine creatinine (NO ₂ + NO ₃ :Cr) in order to account for differences in urine concentration. ** Measured only among children with profuse diarrhea.	NO among Aboriginal children with diarrhea was >3x higher than any other group and >5x higher than in non-Aboriginal controls. • NO was >3x and >2x higher among Aboriginal than non-Aboriginal children in the diarrhea ($p<0.001$) and no infections groups ($p<0.001$), respectively, but there was no difference between them in the non-GI infections group. • NO was >3x and ~2x higher in the diarrhea compared to the no infections group among Aboriginals ($p<0.001$) and non-Aboriginals ($p<0.03$), respectively. • NO was virtually the same among the Aboriginal non-GI infections and no infections groups, as well as among the non-Aboriginal diarrhea and non-GI infections groups. 112/152 (74%) and 31/169 (18%) of children with AD had abnormal L:R ratios and positive stool RS, respectively. NO and L:R were measured at "convalescence" on Day 5 among those with diarrhea: the mean improvement in NO was 21.7%	NO ₂ + NO ₃ :Cr ratio, as a measure of endogenous nitric oxide production, was used as a marker of gut permeability and inflammation, with an attempt to identify how much more it reflects as response to inflammation from GI vs. non-GI infections. Among non-Aboriginal controls, NO production was the same among those with diarrhea and non-GI infections (and higher compared to controls). NO was highest by far among Aboriginal children with diarrhea compared to any other group. Authors suggest that high basal concentrations of NO among Aboriginal children	Positive stool RS was defined as $\geq 0.5\%$. Abnormal L:R was defined as >7.6; no reference or derivation was provided for this cut-point. Study population appears to be the same as in another Kukuruzovic, et al. study also included in this review which assessed serum lactulose:rhamnose as a marker of intestinal permeability [58].

Evidence Table 5. Markers of systemic inflammation and systemic immune activation.

Biomarkers in bold are primarily markers of systemic inflammation and/or immune activation.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
				<p>compared with 54.6% for L:R (p=0.01).</p> <p>NO and L:R were correlated (n=193, r=0.37, p<0.001)¹; the correlation was stronger for lactulose (effect ratio=1.47, p<0.001) than for rhamnose (effect ratio=0.80, p=0.02²).</p> <p>NO was not correlated with stool RS³ or MCV, but was correlated with lower WAZ score (effect ratio=0.88, p=0.05).</p>	<p>due to (clinically silent) enteropathy could explain the concentrations seen among Aboriginal controls in this study.</p> <p>NO appeared to decrease significantly more slowly than L:R among children recovering from diarrhea.</p> <p>NO was found to correlate with L:R. NO was more strongly correlated with lactulose than rhamnose.</p>	
<p>2002</p> <p>Kukuruzovic RH et al.</p> <p>Small bowel intestinal permeability in Australian Aboriginal children</p> <p>Serum lactulose: rhamnose ratio (L:R), serum lactose, and stool reducing substances as markers of intestinal</p>	<p>Darwin, Australia</p> <p>Cases were Aboriginal and non-Aboriginal children admitted to hospital with diarrhea. Controls were Aboriginal and non-Aboriginal children admitted without GI illnesses.</p>	<p>Case-control</p> <p>n=375 admissions for 306 children;</p> <p>n=285 case admissions for AD (264 Aboriginal)</p> <p>n=90 control admissions with no diarrhea (74 Aboriginal)</p>	<p>Blood Tests:</p> <ul style="list-style-type: none"> • Lactose • Lactulose⁴ • Rhamnose • L:R • Hemoglobin • Mean corpuscular volume (MCV) <p>Stool Test:</p> <p>Reducing substances (RS)*</p> <p>L:R testing was</p>	<p>27/75 (36%) of Aboriginal controls and 0 non-Aboriginal controls had abnormal L:R ratios.</p> <p>Mean⁵ L:R at baseline:</p> <p>Cases:</p> <ul style="list-style-type: none"> • Aboriginal: 16.4 • Non-Aboriginal: 7.9, p=0.002 compared to Aboriginal cases <p>Controls:</p> <ol style="list-style-type: none"> 1. Aboriginal: 4.6 2. Non-Aboriginal: 2.5, p=0.02 compared to Aboriginal controls <p>Mean improvement¹ in L:R (CI) at day 5 among those with repeat testing:</p>	<p>Mean L:R ratios of Aboriginal children were approximately double those of non-Aboriginal children both among those with and without diarrhea, consistent with authors' suggestion that clinically silent enteropathy is prevalent among Aboriginal children.</p> <p>Mean L:R significantly</p>	<p>Positive stool RS was defined as $\geq 0.5\%$.</p> <p>Abnormal L:R was defined as >5.6, derived from 2 SD above the arithmetic mean for non-Aboriginal controls in this study. The rationale for the choice of 2 SD above the arithmetic, instead of the geometric, mean is not clear.</p>

¹ Reported results appear to have been adjusted for age and race.

² Reported results were adjusted for age and race.

³ Reported results among children with diarrhea were adjusted for age and race.

⁴ Lactulose and rhamnose results were expressed as % of dose administered.

⁵ Geometric mean.

Evidence Table 5. Markers of systemic inflammation and systemic immune activation.

Biomarkers in bold are primarily markers of systemic inflammation and/or immune activation.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
permeability among Aboriginal and non-Aboriginal children with and without diarrhea			<p>repeated on day 5 for a subset of Aboriginal subjects:</p> <ul style="list-style-type: none"> • 174/264 admissions for acute diarrhea • 25/74 control admissions <p>* Measured only among children with profuse diarrhea when "clinically indicated." Number tested not provided.</p>	<ul style="list-style-type: none"> • Aboriginal cases: 14.6 (11.2, 18.0) • Aboriginal controls: -0.63 (-4.0, 2.7) <p>Mean lactulose recovery²:</p> <ul style="list-style-type: none"> • Cases day 1: 0.085 (0.070–0.103) • Cases day 5: 0.039 (0.033–0.046) • Controls: 0.024 (0.019–0.029) <p>All 3 values significantly differed from one another.</p> <p>Mean rhamnose recovery:</p> <ul style="list-style-type: none"> • Cases day 1: 0.479 (0.424–0.542) • Cases day 5: 0.555 (0.498–0.616) • Controls: 0.585 (0.500–0.685) <p>These values did not significantly differ from one another.</p> <p>Confidence intervals (CIs) in the authors' graphical representation of mean L:R at admission did not overlap, and the difference in means was particularly evident between Aboriginal and non-Aboriginal subjects.</p> <p>Factors associated with L:R among cases were³:</p> <ul style="list-style-type: none"> • Acidosis (p=0.007) • Hypokalemia (p=0.035) • Diarrhea severity (p=0.001) <p>Age and malnutrition were not associated with L:R.</p>	<p>improved over 5 days among Aboriginal cases. Children with severe diarrhea had higher mean L:R.</p> <p>Higher case L:R was driven more by high lactulose than by low rhamnose. Similarly, improvement in L:R among cases was primarily due to decreased lactulose.</p> <p>Stool RS and serum lactose were found in approximately one-quarter and one-third of Aboriginal cases, respectively. The latter was weakly associated with increased lactulose.</p>	<p>Proportions of cases with abnormal concentrations were not reported.</p> <p>Analysis included data for 69 children with repeat admissions; this might violate independence assumptions for their statistical analysis methods.</p> <p>Repeat L:R testing was conducted on controls of both racial groups, but among cases it was only conducted on Aboriginal cases.</p> <p>This study appears to report on the same population as in the Kukuruzovic, et al. 2003 reference also included in this review, which assessed nitric oxide excretion [43].</p> <p>Authors reiterate the advantages of serum over timed</p>

¹ Improvement in L:R appears to have been calculated as baseline L:R minus repeat L:R, as described in another publication in this review; however, this was not expressly stated. Reference 134. Kukuruzovic RH, Brewster DR. Milk formulas in acute gastroenteritis and malnutrition: a randomized trial. J Paediatr Child Health. 2002. 38(6):571-577.

² Figures reported parenthetically after the mean percent recoveries of lactulose and rhamnose were not specified as ranges or CIs.

³ Reported results were adjusted for confounding variables, unless otherwise noted.

Evidence Table 5. Markers of systemic inflammation and systemic immune activation.

Biomarkers in bold are primarily markers of systemic inflammation and/or immune activation.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
				<p>38% and 27% of Aboriginal cases had positive serum lactose and stool RS, respectively. 12% of Aboriginal and non-Aboriginal controls combined had lactosemia.</p> <p>Presence of lactosemia was associated with L:R, adjusted relative risk (CI)=1.06 (1.03, 1.10)¹. Stool RS, anemia, and MCV were not associated with L:R.</p>		urine collection for assessment of L:R, as discussed in another publication in this review [125].
<p>2001</p> <p>Mittal SK et al.</p> <p>Tropical sprue in north Indian children</p> <p>D-xylose and duodenal biopsy as markers of TS</p>	<p>New Delhi, India</p> <p>0-15 yr old gastroenterology clinic patients with PD.</p> <p>Those with abnormal morphology on biopsy, abnormal D-xylose test, and clinical response to antibiotics were diagnosed as having TS.</p> <p>Those with abnormal morphology and response to gluten-free diet were diagnosed with CD. We include data on these subjects for comparative reasons.</p>	<p>Case-series</p> <p>n=94; (38 with repeat biopsies)</p> <p><5 yr old: n=44</p>	<p><u>Duodenal biopsy, method not specified:</u></p> <p>Histopathology</p> <p>Blood Tests:</p> <ul style="list-style-type: none"> • Hemoglobin • D-xylose* <p>* Not specified whether from urine or serum, and units of measurement not provided.</p>	<p>36 (38.3%) were diagnosed with TS including 14/44 (31.8%) who were under 5 years of age.</p> <p>18 (19.1%) were diagnosed with CD.</p> <p>Degree of villous atrophy among TS vs. CD patients:</p> <ul style="list-style-type: none"> • Mild in 8/36 (22.2%) vs. 0 • Moderate in 23/36 (63.9%) vs. 4/18 (22.2%) • Severe in 5/36 (13.9%) vs. 14/18 (77.8%) <p>Mean hemoglobin concentration (range) among TS patients was 8.3 g/dL (5.5-11) and did not differ from values of those with CD.</p> <p>Among the 22 TS patients, repeat biopsies showed:</p> <ul style="list-style-type: none"> • 16 with normalization • 5 with improvement • 1 worsened despite marked clinical improvement <p>The D-xylose test was abnormal in all TS patients by diagnostic definition.</p>	<p>More than half of the GI clinic patients with PD had some degree of villous atrophy.</p> <p>More than one-third and almost one-fifth of subjects were diagnosed with TS and CD, respectively.</p> <p>By study diagnostic definition, all TS patients improved with treatment. Among those who had repeat biopsies, almost three-quarters showed normalization of histology, while 23% had partial improvement and 1 patient had worsened pathology.</p>	<p>Biopsy results were not provided for patients without TS or CD.</p> <p>It was unclear if there were patients with abnormal D-xylose and histology who did not respond to antibiotic therapy and therefore were not diagnosed with TS.</p> <p>Cut-off points used to define abnormal D-xylose tests were not provided.</p>

¹ Reported results were adjusted for severity of diarrhea, acidosis, hypokalemia, and age.

Evidence Table 5. Markers of systemic inflammation and systemic immune activation.

Biomarkers in bold are primarily markers of systemic inflammation and/or immune activation.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
<p>2001</p> <p>Northrop-Clewes CA et al.</p> <p>Anthelmintic treatment of rural Bangladeshi children: effect on host physiology, growth, and biochemical status</p> <p>L:M as a marker of intestinal permeability, and α 1-antichymotrypsin as a marker of inflammation and immune activation to treatment among children randomized to bimonthly antihelminthics or placebo.</p>	<p>Jamalpur district, northern Bangladesh</p> <p>2-5 yr olds from poor rural villages, sampled randomly from a larger cohort study.</p> <p>Stools were assessed for helminthiasis and giardiasis. Growth was followed longitudinally.</p>	<p>RCT*</p> <p>n=109;</p> <p>n=54 received bimonthly empiric antihelminthic treatment</p> <p>n=55 received placebo</p> <p>* Randomized at the village level.</p>	<p>Blood Tests:</p> <ul style="list-style-type: none"> α 1-antichymotrypsin (ACT) Albumin Total protein <p>Urine Test:</p> <p>L:M</p> <p>Among 93 subjects with L:M at baseline:</p> <ul style="list-style-type: none"> 46 received treatment 47 received placebo <p>Among 66 subjects with repeated L:M testing:</p> <ul style="list-style-type: none"> 34 received treatment 32 received placebo 	<p>Mean L:M¹ at baseline:</p> <ul style="list-style-type: none"> Treatment: 0.22 Placebo: 0.25 <p>Seasonal variation in L:M was observed, with highest values following the monsoon season.</p> <p>Within-subject L:M analysis showed no significant association with intestinal helminthiasis and no significant improvement in treatment or placebo groups over 1 yr. L:M was generally not associated with giardiasis (with the exception of one group at one study interval).</p> <p>L:M was inversely correlated with ΔHAZ and ΔWAZ scores at some of the follow-up intervals ($r=-0.22$, $p<0.02$ and $r=-0.21$, $p<0.05$, respectively, at 12 mo follow-up visit).</p> <p>Mean serum ACT, albumin and total protein were within normal ranges and were not associated with growth parameters. ACT and albumin concentrations did not significantly change with treatment, whereas total protein concentrations did ($p<0.001$).</p>	<p>L:M ratios were high overall and demonstrated seasonal variation.</p> <p>Intra-individual L:M values did not change significantly over time, nor were they associated with helminthiasis or consistently associated with giardiasis.</p> <p>Inverse correlations were seen between L:M and growth parameters.</p> <p>Serum markers were within normal range. The only significant change in these markers was a decrease in total protein in the treatment group without concomitant change in albumin; this suggested a decrease in globulins (not directly measured), perhaps due to decreased inflammation.</p>	<p>Baseline study data were lost, so analysis began with samples taken at month 2.</p> <p>The relationship between the serum markers and intestinal permeability was not reported.</p>
<p>2009</p> <p>Panter-Brick C et al.</p>	<p>Kathmandu, Nepal</p> <p>3-18 mo olds in two</p>	<p>Cohort</p> <p>n=86;</p>	<p>Urine Test:</p> <p>Lactose:Cr</p>	<p>Mean² Lactose:Cr (CI):</p> <ul style="list-style-type: none"> Squatter: 0.14 (0.12, 0.16) Middle Class: 0.08 (0.07, 0.10) 	<p>Authors speculate that Lactose:Cr accounted for less of</p>	<p>Specific sugar excretion was normalized to</p>

¹ Geometric mean.

² Geometric mean.

Evidence Table 5. Markers of systemic inflammation and systemic immune activation.

Biomarkers in bold are primarily markers of systemic inflammation and/or immune activation.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
<p>Pathways leading to early growth faltering: An investigation into the importance of mucosal damage and immunostimulation in different socio-economic groups in Nepal</p> <p>Lactose:creatinine ratio (Lactose:Cr) as a marker of intestinal permeability and hemoglobin, albumin, α-1-acid glycoprotein, and IgG as markers of immunostimulation. The latter were also assessed for their relationship to nutritional status.</p>	<p>cohorts:</p> <ul style="list-style-type: none"> All children in target age range from four squatter settlements Randomly selected, age-matched cohort from lower middle-class, periurban households 	<p>n=48 in squatter cohort</p> <p>n=38 in lower middle-class cohort</p>	<p><u>Blood Test:</u> Hemoglobin</p>	<ul style="list-style-type: none"> Statistically significant difference between the 2 groups among the 6-12 mo olds ($p=0.007$) and 18-24 mo olds ($p=0.002$), but not among 12-18 mo olds. For both SES groups, Lactose:Cr values decreased with increasing age ($p<0.001$). <p>HAZ, WAZ, WHZ, and ΔWAZ scores were strongly associated with mean Lactose:Cr ($p<0.001$ each) as was ΔHAZ score ($p=0.004$); ΔWHZ score was not. The strength and magnitude of association between ΔWAZ score and Lactose:Cr was most pronounced among the wealthier cohort and there was no association between ΔHAZ score and Lactose:Cr among the squatter children.</p> <p>Hemoglobin concentrations were inversely related to Lactose:Cr ($r^2=0.018$, $p<0.001$).</p>	<p>the deterioration in nutritional status among the squatter children because of several factors, including poorer nutritional intake, that impact the nutritional status of children with lower socio-economic status.</p>	<p>urinary creatinine to control for variation in renal function.</p> <p>Authors suggest that while Lactose:Cr might not be as accurate as L:M, it might be a more field-friendly assessment of mucosal damage compared to L:M, requiring only spot urine collection and no substrate dosing. However, L:M was not assessed in this study; direct comparison of the two tests was not possible.</p> <p>While hemoglobin concentration was inversely related to Lactose:Cr, testing for associations of other measured blood markers (IgG, AGP and albumin) with Lactose:Cr was not reported.</p>
<p>2001</p> <p>Rabbani GH et al.</p> <p>Increased nitrite and nitrate concentrations in sera and urine of patients with cholera</p>	<p>Dhaka, Bangladesh</p> <p>2-6 yr olds with cholera or shigellosis admitted to the hospital.</p> <p>Controls were</p>	<p>Case-control</p> <p>n=63;</p> <p>n=45 cases:</p> <ul style="list-style-type: none"> 24 with cholera 21 with shigellosis 	<p><u>Urine Test:</u> Nitric Oxide (NO)*</p> <p><u>Blood Tests:</u></p> <ul style="list-style-type: none"> Nitrite (NO₂) Nitrate (NO₃) WBC 	<p>In children with shigellosis, median serum NO was ~8x higher at baseline than in controls and significantly differed from convalescent concentrations ($p<0.01$). Concentrations declined by 52% of baseline during the recovery period but did not return to values found in the controls (measure of</p>	<p>NO as measured by both serum and urinary NO₂ and NO₃ concentrations was significantly elevated at presentation during acute illness compared to 7-10 days after</p>	<p>Some values reported in table format conflict with the text; columns of data appear to be transposed.</p> <p>Assessment for NO correlation with</p>

Evidence Table 5. Markers of systemic inflammation and systemic immune activation.

Biomarkers in bold are primarily markers of systemic inflammation and/or immune activation.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
<p>or shigellosis</p> <p>To assess and compare nitric oxide as a marker of intestinal inflammation among children with cholera or shigellosis or healthy controls. Evaluated to assess nitric oxide production during infection of small bowel without inflammatory lesion (e.g., cholera) and during infection causing colon inflammation (e.g., shigellosis).</p>	<p>recruited from the healthy attendants of patients or from children of hospital staff.</p> <p>Mean age (SD) in yr:</p> <ul style="list-style-type: none"> • Shigellosis cases: 3.8 (1.2) • Cholera cases: 4.2 (1.4) • Controls: 4.7 (1.8) 	<p>n=18 healthy controls</p> <p>Samples were collected from cases on admission and upon discharge (after 7-10 days of treatment).</p>	<p><u>Stool Test:</u> Leukocytes</p> <p>* Nitric oxide (NO) is an unstable free radical that is converted to nitrite and nitrate. Urine NO₂ + NO₃ were expressed as a ratio with urine creatinine in order to account for differences in urine concentration.</p>	<p>statistical significance not reported).</p> <p>In children with cholera, median serum NO concentrations at baseline were ~4x higher than in control subjects. Recovery concentrations decreased 52% from baseline (p<0.01); convalescent values did not differ from the values in controls (p<0.4).</p> <p>Median urinary NO ratios were similar among those with <i>Shigella</i> and <i>V. cholerae</i> infection, both upon admission and discharge. Initial values were ~2x higher than upon discharge (p<0.05 and 0.01, respectively). Control median NO was of an intermediate concentration between cases' admission and discharge median concentrations; the difference between control and case admission values was NS.</p> <p>Mean blood WBC counts (SD):</p> <ul style="list-style-type: none"> • Shigellosis: 19.6 (3.3) • Cholera: 8.3 (2.8) • Controls: 7.1 (1.8) <p>Mean fecal WBC/high power field (SD):</p> <ul style="list-style-type: none"> • Shigellosis: 38 (17) • Cholera: 5 (2) • Controls: 3 (1) <p>Serum NO correlated with blood WBC count in shigellosis cases at baseline (r²=0.92, p<0.01), but only to a slight degree upon discharge (r²=0.26, no p-value reported) and there was no correlation among the cholera cases. Serum NO correlated with stool volume at presentation</p>	<p>hospitalization in both cholera and shigellosis.</p> <p>Median serum NO concentrations in cholera patients were ~half of those with shigellosis both upon admission and upon discharge and concentrations were much higher in cases than in controls. Such striking differences were not observed for urinary NO results.</p> <p>Serum NO concentrations correlated with total blood WBC in shigellosis cases.</p>	<p>fecal leukocyte counts was not reported, nor was the correlation between urinary NO and total blood WBC.</p>

Evidence Table 5. Markers of systemic inflammation and systemic immune activation.

Biomarkers in bold are primarily markers of systemic inflammation and/or immune activation.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
				($r^2=0.85$, statistically significant per authors, p-value not reported).		
<p>2009</p> <p>Ritchie BK et al.</p> <p>13C-sucrose breath test: novel use of a noninvasive biomarker of environmental gut health</p> <p>Sucrose breath test (SBT) as a marker of small bowel mucosal damage vis a vis sucrose activity among an Australian Aboriginal population. Also compared SBT with serum lactulose:rhamnose ratio (L:R)</p>	<p>Darwin and Adelaide, Australia</p> <p>4 mo-5 yr old Aboriginal children admitted to hospital with diarrhea.</p> <p>Two control groups:</p> <ul style="list-style-type: none"> Aboriginal controls admitted to hospital with non-GI symptoms (50% had pneumonia) Healthy, non-Aboriginal controls recruited from community 	<p>Case-control</p> <p>n=43;</p> <p>n=18 Aboriginal cases with AD</p> <p>n=25 controls:</p> <ul style="list-style-type: none"> 18 Aboriginal, without diarrhea 7 non-Aboriginal, healthy 	<p>Blood Tests:</p> <ul style="list-style-type: none"> L:R (32 Aboriginal cases and controls tested) C-reactive protein (CRP) Mean Corpuscular Volume (MCV) Hemoglobin <p>Breath Test: ¹³C sucrose breath test (SBT)</p>	<p>20/32 (63%) of Aboriginal children had abnormal L:R ratios.</p> <p>Mean¹ L:R (CI):</p> <ul style="list-style-type: none"> Diarrhea cases: 31.8 (24.9, 40.7) Aboriginal controls without diarrhea: 11.4 (8.5, 15.5), significant difference (p<0.0001) <p>SBT Mean (CI):</p> <ul style="list-style-type: none"> Diarrhea cases: 1.9% (0.9, 3.0), p<0.0001 compared to non-Aboriginal controls and p=0.004 compared to Aboriginal controls Aboriginal controls: 4.1% (3.0, 5.2), p=0.032 compared to non-Aboriginal controls Non-Aboriginal controls: 6.1% (4.8, 7.3) Significant differences were observed between all three groups. <p>SBT results were not associated with wasting or with patient age or breastfeeding status.</p> <p>SBT and L:R were inversely correlated (r=0.67; CI: 0.42, 0.62; p<0.0001). L:R explained 45% of the variance in SBT; diarrhea explained 28% of variance.</p> <p>SBT was associated with increased MCV, relative risk (CI)=3.9 (2.8, 5.0).</p>	<p>SBT values were significantly lower and L:R values were significantly higher among Aboriginal children with diarrhea than among those without GI symptoms. SBT was also significantly lower among Aboriginal controls than among non-Aboriginal children without diarrhea. This is consistent with previous reports of high prevalence of clinically silent TE in this population.</p> <p>SBT was significantly inversely correlated with L:R.</p>	<p>Abnormal L:R ratios were defined as >16; no reference or derivation was provided for this cut-point.</p> <p>L:R test was not conducted among the non-Aboriginal controls.</p> <p>SBT/L:R correlation analysis was based on data for Aboriginal cases and controls combined; stratified analysis was not reported and could be of interest considering the large difference in L:R observed between these groups.</p> <p>Associations of MCV, CRP, and hemoglobin with SBT after adjusting for potentially confounding variables were not reported.</p>

¹ Geometric mean.

Evidence Table 5. Markers of systemic inflammation and systemic immune activation.

Biomarkers in bold are primarily markers of systemic inflammation and/or immune activation.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
				SBT was not associated with hemoglobin or CRP.		
2001 Rollins NC et al. Feeding mode, intestinal permeability, and neopterin excretion: A longitudinal study in infants of HIV-infected South African women L:M as a marker of gut mucosal integrity and urinary neopterin excretion as a marker of cell-mediated immunity in infants with and without HIV infection	Durban, South Africa 1, 6, and 14 wk old infants born to HIV-infected mothers.	Cohort n=272	<u>Urine Tests:</u> • Lactulose ¹ • Mannitol • L:M • Neopterin	Mean ² L:M (CI): • HIV-infected subjects: • 1 wk: 0.12 (0.06, 0.27) • 6 wk: 0.24 (0.15, 0.38) • 14 wk: 0.24 (0.14, 0.44) • Uninfected subjects: • 1 wk: 0.13 (0.09, 0.19) • 6 wk: 0.08 (0.06, 0.11) • 14 wk: 0.09 (0.07, 0.13) HIV-infection by 14 wk of age was significantly associated with increased L:M. A non-significant, positive trend in neopterin excretion was observed among HIV-infected infants.	L:M was generally normal (compared to UK values) for non-HIV-infected infants, but significantly increased among HIV-infected subjects, especially after 6 weeks. The increased L:M in HIV-infected infants was primarily driven by lactulose rather than mannitol. Higher neopterin excretion by HIV-infected infants was observed but this was not statistically significant.	Assessment of association between L:M and neopterin was not reported.
2000 Rollins NC et al. Vitamin A supplementation of South African children with diarrhea: optimum timing for improving biochemical and clinical recovery and subsequent vitamin A status	Durban, South Africa 6-60 mo old inpatients or outpatients with severe diarrhea.	RCT n=139; n=66 received vitamin A on admission (group 1) n=73 received vitamin A after clinical improvement (group 2)	<u>Urine Tests:</u> • Lactulose ³ • Mannitol • L:M • Neopterin <u>Blood Tests:</u> • C-reactive protein (CRP) • α-1 acid glycoprotein (AGP)	Mean ⁴ L:M: • Group 1: • Day 0: ~1.8 • Day 3: ~2.4 • Group 2: • Day 0: ~1.2 • Day 3: ~0.7 There were no differences in mean L:M between groups or within groups between days 0 and 3, although there was a significant difference in paired analysis within individuals at the two time points (data not	Mean L:M ratios were very high (~10x) (at baseline and at day 3 in both groups) compared to other studies in this review. Study authors suggested (via personal correspondence) that this could have been due to the severity of illness in the sample	Urine testing could only be conducted in the laboratory on certain days; hence only a subset of subjects underwent those tests. Group 2 patients had significantly higher CRP, non-significantly higher WBCs and AGP, and lower retinol

¹ Lactulose and mannitol results were expressed in mg.

² Geometric mean.

³ For lactulose, mannitol, and neopterin results, excretion measurement was not specified.

⁴ Geometric mean.

Evidence Table 5. Markers of systemic inflammation and systemic immune activation.

Biomarkers in bold are primarily markers of systemic inflammation and/or immune activation.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
L:M as a marker of intestinal permeability and urinary neopterin, serum α -1 acid glycoprotein, and C-reactive protein as markers of inflammation among children with severe diarrhea		Treatment involved vitamin A supplementation either on the day of admission or after acute diarrheal symptoms had resolved.	49 subjects received urine testing: <ul style="list-style-type: none"> • Group 1: n=25 • Group 2: n=24 Blood and urine were tested on days 0 and 3.	<p>presented, and direction, magnitude and degree of significance not reported).</p> <p>Lactulose and mannitol excretion were assessed only in the paired analysis. Lactulose excretion decreased between days 0 and 3 (magnitude of effect and degree of significance not reported), while mannitol excretion showed no change.</p> <p>Mean¹ neopterin and AGP concentrations did not differ between groups or within groups on the different study days or in the paired analysis. When initial CRP (~2x higher in Group 2 compared to Group 1, p<0.004) was taken into account, mean CRP on day 3 did not differ between the 2 groups. However in the paired analysis, CRP concentrations were significantly different between days 0 and 3.</p>	<p>population (children hospitalized for diarrhea).</p> <p>Vitamin A administration did not result in significant improvement in L:M, neopterin, or AGP regardless of timing of vitamin A administration.</p>	<p>and retinol-binding protein concentration compared to group 1 at baseline. Authors note that these parameters suggest that Group 2 patients might have been more ill at baseline. For the subset of 49 patients undergoing urine testing, the mean² L:M and neopterin concentrations were lower among Group 2 than Group 1 subjects (NS). However, baseline differences in acute phase and vitamin A markers at baseline were not reported separately for these 49 subjects.</p> <p>Data for lactulose and mannitol excretion were not reported separately. Rationale for additional analyses of these molecules expressed as ratios with creatinine was not explained.</p>

¹ Geometric mean.

² Geometric mean.

Evidence Table 5. Markers of systemic inflammation and systemic immune activation.

Biomarkers in bold are primarily markers of systemic inflammation and/or immune activation.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
						Authors suggest that their 3-day testing period (based on their previous work in a different setting [207] might have been too short to identify effect as demonstrated by McCullough et al. at 10 days after presentation [208].
<p>2003</p> <p>Soliman SM et al.</p> <p>Role of micronutrient mixture in acute and persistent diarrhea in infants and its impact on nutritional status</p> <p>Blood cell and albumin markers among infants with acute, persistent or no diarrhea, and effects on these markers after 10 days of supplementation with micronutrient mixture (containing vitamin A, zinc and other micronutrients) among subjects with and without diarrhea</p>	<p>Cairo, Egypt</p> <p>6-24 mo olds with diarrhea were recruited from Al-Sahel teaching hospital malnutrition clinic.</p> <p>5/6 PD cases and 10/14 AD cases had some degree of malnutrition.</p> <p>Infants with PD had significantly lower vitamin A and zinc stores compared to controls. Those with AD had significantly lower vitamin A stores.</p>	<p>Case-control</p> <p>n=30;</p> <p>n=20 cases:</p> <ul style="list-style-type: none"> • 6 with PD • 14 with AD <p>n=10 healthy controls*</p> <p>* Controls were age- and sex-matched to cases.</p>	<p><u>Blood Tests:</u></p> <ul style="list-style-type: none"> • Complete blood count and differential • Red cell measures: <ul style="list-style-type: none"> • Mean corpuscular volume (MCV) • Mean corpuscular hemoglobin (MCH) • Mean corpuscular hemoglobin concentration (MCHC) • Transferrin saturation • Albumin 	<p>Mean baseline hemoglobin was significantly lower in infants with AD and PD ($p < 0.05$ for each group) than in controls</p> <p>Mean MCV and MCH were lower in those with AD ($p < 0.025$ and $p < 0.01$, respectively) and PD ($p < 0.01$ for both markers) compared to controls.</p> <p>Mean lymphocyte counts among PD cases were low compared to those of controls ($p < 0.01$).</p> <p>Other markers did not vary significantly at baseline. However, among infants with PD, mean albumin was abnormally low, although it was not significantly different compared to controls or those with AD.</p> <p>Mean albumin (g/dL) (SE):</p> <ul style="list-style-type: none"> • PD: 2.9 (0.27) • AD: 3.29 (0.25) • Controls: 3.37 (0.21) <p>Following micronutrient supplementation, mean hemoglobin, MCV, lymphocyte counts and albumin increased in both diarrhea</p>	<p>Albumin and many hematologic markers were low at baseline among infants with diarrhea, especially in those with PD, compared to those without diarrhea; some of these differences were statistically significant. Parameters generally normalized after micronutrient supplementation.</p>	<p>Information on control recruitment and anthropometrics were not specified.</p> <p>Sample size was small when stratified by case/control groups, especially for PD cases (n=6). Controls were reported to have been matched to cases, yet there were half the number of controls than cases and statistical testing (student's t-test) was not commensurate with matched case-control methodology.</p>

Evidence Table 5. Markers of systemic inflammation and systemic immune activation.

Biomarkers in bold are primarily markers of systemic inflammation and/or immune activation.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
				groups to concentrations on par with control baseline concentrations (albeit increases were NS except within the PD group). MCH improved to concentrations on par with the control group only among the infants with AD.		
<p>2008</p> <p>Vieira MM et al.</p> <p>Carotenoids, retinol, and intestinal barrier function in children from northeastern Brazil</p> <p>L:M as marker of intestinal barrier function, fecal lactoferrin and leukocytes as markers of intestinal inflammation, and CRP and AGP as acute phase reactants among children with varying vitamin A status</p>	<p>Fortaleza, Brazil</p> <p>2 mo-9 yr olds (mean age 41 mo) from an impoverished urban community, eligible if HAZ score <median for their community.</p>	<p>Cross-sectional</p> <p>n=102</p>	<p><u>Urine Tests:</u></p> <ul style="list-style-type: none"> • Lactulose¹ • Mannitol • L:M (97 tested) <p><u>Stool Tests:</u></p> <ul style="list-style-type: none"> • Lactoferrin (93 tested) • Leukocytes <p><u>Blood Tests:</u></p> <ul style="list-style-type: none"> • C-reactive protein (CRP) • α-1-acid glycoprotein (AGP) 	<p>48.5% had abnormal L:M.</p> <p>L:M and excretion of each sugar separately did not vary with retinol concentration.</p> <p>L:M was associated with levels of common dietary carotenoids, primarily driven by lactulose. However, the association was not always statistically significant, and the direction of association varied depending on precursor.</p> <p>40% of stool samples were positive for lactoferrin.</p> <p>1% of stool samples were positive for fecal leukocytes.</p> <p>30% of stool samples were positive for parasites but this had no impact on L:M results, lactoferrin, or acute phase reactants.</p>	<p>Almost half of subjects had increased L:M, and ~40% of subjects had increased lactoferrin.</p> <p>While serum retinol concentrations were not associated with L:M, serum carotenoids were; authors suggest that these retinol precursors might be more sensitive predictors of impaired intestinal function. However, the reported direction of association varied, making interpretation of these results unclear.</p>	<p>L:M threshold for abnormal values was defined as >0.0864 [214]. Cut-off values for lactoferrin positivity were not described.</p> <p>Relationships between acute phase proteins and measures of intestinal permeability or inflammation were not reported.</p> <p>Relationships between L:M and lactoferrin or fecal leukocytes as well as those between retinol or carotenoids and lactoferrin or fecal leukocytes were not reported.</p> <p>Exclusively breastfed children were excluded from study participation due to assessment of stool lactoferrin.</p>

¹ Lactulose and mannitol results were expressed as % of dose administered.

Evidence Table 5. Markers of systemic inflammation and systemic immune activation.

Biomarkers in bold are primarily markers of systemic inflammation and/or immune activation.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
<p>2007</p> <p>Williams EA et al.</p> <p>A double-blind, placebo-controlled, glutamine-supplementation trial in growth-faltering Gambian infants</p> <p>L:M and plasma immunoglobulins and acute phase reactant proteins (albumin, C-reactive protein, and alpha-1-antichymotrypsin) in community-based Gambian infants enrolled in a glutamine trial</p>	<p>West Kiang region, Gambia</p> <p>4-10 mo olds from a rural area followed during the 5-month rainy season and for 6 months afterward.</p>	<p>Cohort</p> <p>n=72</p> <p>Glutamine or placebo of nonessential amino acids was orally administered twice daily during rainy season; L:M ratio was measured monthly, and plasma samples were collected 3 times.</p>	<p><u>Urine Tests:</u></p> <ul style="list-style-type: none"> • Lactulose¹ • Mannitol • L:M <p><u>Blood markers</u></p> <ul style="list-style-type: none"> • C-reactive protein (CRP) • Alpha-1 anti-chymotrypsin (ACT) • IgA • IgG • IgM • Albumin 	<p>Mean² L:M (CI):</p> <ul style="list-style-type: none"> • Baseline: <ul style="list-style-type: none"> • Glutamine group: 0.33 (0.25, 0.43) • Placebo group: 0.33 (0.26, 0.41) • Post-intervention: <ul style="list-style-type: none"> • Glutamine group: 0.29 (0.23, 0.35) • Placebo group: 0.26 (0.21, 0.32) <p>Mean excretion of lactulose (CI):</p> <ul style="list-style-type: none"> • Baseline: <ul style="list-style-type: none"> • Glutamine group: 0.21 (0.16, 0.28) • Placebo group: 0.20 (0.15, 0.26) • Post-intervention: <ul style="list-style-type: none"> • Glutamine group: 0.17 (0.13, 0.21) • Placebo group: 0.14 (0.11, 0.18) <p>Mean excretion of mannitol (CI):</p> <ul style="list-style-type: none"> • Baseline: <ul style="list-style-type: none"> • Glutamine group: 2.65 (2.02, 3.48) • Placebo group: 2.50 (1.87, 3.36) • Post-intervention: <ul style="list-style-type: none"> • Glutamine group: 2.48 (1.99, 3.11) • Placebo group: 2.14 (1.62, 2.82) <p>L:M values did not differ significantly between treatment groups before or following intervention. However, a</p>	<p>L:M values were elevated in this population, with no significant change after the intervention.</p> <p>None of the plasma markers differed significantly between treatment and placebo groups, either at baseline or at the end of supplementation.</p> <p>Growth outcomes did not differ significantly across treatment groups.</p>	<p>The relationships between L:M and growth parameters, immuno-globulins, and acute phase proteins were not reported.</p>

¹ Lactulose and mannitol results were expressed as % of dose administered.

² Geometric mean.

Evidence Table 5. Markers of systemic inflammation and systemic immune activation.

Biomarkers in bold are primarily markers of systemic inflammation and/or immune activation.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
				<p>repeated measures ANOVA showed that during supplementation, L:M values were borderline elevated among the glutamine-supplemented group relative to the placebo group ($p=0.05$), counter to expectation.</p> <p>Neither ACT, CRP, albumin, nor immunoglobulins IgA, IgG, or IgM differed significantly between treatment and placebo groups, either at baseline or at the end of supplementation.</p> <p>Mean levels of IgA and IgG increased during the study ($p<0.001$), while IgM levels did not. Concentrations of each of these immunoglobulins did not differ between treatment and placebo groups.</p> <p>Plasma albumin, ACT, and CRP values showed no change over the course of the study.</p> <p>Proportions of children with elevated CRP ranged from 30-41% at different collection time points. The glutamine intervention had no effect on proportion of children with elevated CRP.</p> <p>Treatment and placebo groups experienced decreases in WAZ, HAZ, and MUAC coinciding with the rainy season; however, there was no significant difference observed between the groups for any of these parameters.</p> <p>Treatment and placebo groups did not differ in morbidity indices (i.e.</p>		

Evidence Table 5. Markers of systemic inflammation and systemic immune activation.

Biomarkers in bold are primarily markers of systemic inflammation and/or immune activation.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
				percentage of time reported with a particular illness or illness overall).		

Notes: Some studies included subjects ≥ 5 yr of age. Where these studies provided data separately for children < 5 yr, we present results for only those subjects. Where these studies did not stratify results by age, but did report the number of children < 5 yr included in the study, we provide a breakdown of under-5s. All studies reporting lactulose:ramnose ratio results presented values multiplied by a factor of 100 for ease of reporting.

Abbreviations: AD=acute diarrhea, ALT=alanine aminotransferase, AST=aspartate aminotransferase, CBC=complete blood count, CD=celiac disease, CI=95% confidence interval, Cr=creatinine, Δ =change in, EED=environmental enteric dysfunction, FTT=failure to thrive, GI=gastrointestinal, HAZ=height-for-age Z-(score), HDL=high density lipoproteins, HIV=human immunodeficiency virus, HLA=human leukocyte antigen, IEL=intraepithelial lymphocytes, IgA=immunoglobulin A, IgE=immunoglobulin E, IgG=immunoglobulin G, IgM=immunoglobulin M, IL=interleukin, IFN=interferon, LDL=low density lipoproteins, L:M=lactulose:mannitol ratio, mo=month(s), NS=not statistically significant, PD=persistent diarrhea, RCT=randomized controlled trial, SBBO=small bowel bacterial overgrowth, SD=standard deviation, SE=standard error, SES=socioeconomic status, Tc-99m=technetium 99, T3=triiodothyronine, T4=thyroxine, TE=tropical enteropathy, TGF=transforming growth factor, TNF=tumor necrosis factor, TS=tropical sprue, WAZ=weight-for-age Z-(score), WBC=white blood cell count, WFA=weight-for-age, WHZ=weight-for-height Z-(score), wk=week(s), yr=year(s)

5.7 Markers of Microbial Drivers

Markers of microbial environments, such small bowel bacterial overgrowth (SBBO), were reviewed, while markers for specific enteric organisms were beyond the scope of this review. The data from each of the studies relevant to this review are listed in Evidence Table 6.

Evidence Table 6. Markers of microbial drivers.

Biomarkers in bold are primarily markers of microbial drivers.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
<p>2002</p> <p>Alves GM et al.</p> <p>Nutritional status and breath hydrogen test with lactose and lactulose in Terena Indian children</p> <p>Lactose hydrogen breath test (HBT) as a marker of lactase activity, and lactulose HBT as a marker of SBBO</p>	<p>Limão Verde and Córrego Seco, Mato Grosso do Sul, Brazil</p> <p>All children <10 yr old were recruited from these rural villages.</p>	<p>Cross-sectional</p> <p>n=264;</p> <p><5 yr old: n=145</p> <p>(However results were provided by <4 and ≥4 yr old age groups.)</p>	<p>Breath Tests:</p> <ul style="list-style-type: none"> Lactose HBT (251 tested) Lactulose HBT (252 tested) 	<p>Lactose HBT:</p> <ul style="list-style-type: none"> Elevated: 27.1% among all subjects Borderline: 43.0% among all subjects 0% of subjects <4 yr had elevated or borderline results <p>Lactulose HBT positive:</p> <ul style="list-style-type: none"> 11.5% of all subjects 8.6% of subjects <4 yr 	<p>The prevalence of lactase deficiency as measured by lactose HBT was >25%, but non-existent among those <4 yr of age.</p> <p>Prevalence of SBBO as assessed by lactulose HBT was ~10%.</p>	<p>Assessment of association between lactulose and lactose absorption was not reported.</p>
<p>2000</p> <p>Fagundes-Neto U et al.</p> <p>Studies of the small bowel surface by scanning electron microscopy in infants with persistent diarrhea</p> <p>Scanning electron microscope (SEM) and light microscope (LM) analyses of small intestinal biopsy among infants with PD with and without SBBO</p>	<p>Sao Paulo, Brazil</p> <p>2-10 mo olds with PD and protein calorie malnutrition consecutively admitted to Sao Paulo Hospital.</p>	<p>Case-series</p> <p>n=16</p>	<p><u>Jejunal secretions aspirate:</u></p> <p>Bacterial concentrations</p> <p><u>Jejunal tethered capsule biopsy:</u></p> <p>Histopathology by LM and SEM</p> <p><u>Rectal tethered capsule biopsy:</u></p> <p>Histopathology</p>	<p>68.7% had bacterial overgrowth (concentration >10⁴ colonies/mL): 3 had enteropathogenic <i>E. coli</i> while the rest had colonic microflora.</p> <p>All small intestine specimens had morphological abnormalities on LM:</p> <ul style="list-style-type: none"> 43.7% moderate villous atrophy 56.3% subtotal villous atrophy <p>SEM revealed abnormalities of varying intensity:</p> <ul style="list-style-type: none"> Among the 11 with SBBO, villous atrophy ranged from Grade II (n=4), Grade III (n=2), to Grade IV (n=3). For the 5 subjects without SBBO, villous atrophy ranged from Grade I (n=1) to Grade 2 (n=4). A mucous-fibrinoid pseudo-membrane over enterocytes was noted in 7 of the 11 with SBBO and none of the others. Other abnormalities noted on SEM included: Mucus and debris covered large 	<p>Histological abnormalities were noted in all subjects by LM and SEM.</p> <p>Degree of villous atrophy noted on SEM seemed to be correlated with SBBO (no statistical tests were reported).</p> <p>Authors speculate that the mucous-fibrinoid pseudo-membrane partially covering enterocytes is consistent with a malabsorptive process, with the findings of fat droplets on enterocytes surfaces, and with the state of malnutrition of the subjects.</p>	<p>Inconsistent reporting of proportions of histopathologic findings among all subjects and by SBBO status; assessment of potential relationship with SBBO between different histologic findings was not possible.</p>

Evidence Table 6. Markers of microbial drivers.

Biomarkers in bold are primarily markers of microbial drivers.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
				<p>areas of the villous surface</p> <ul style="list-style-type: none"> • Derangement of the enterocytes (in some cases cell borders were not clearly defined) • Reduced height and number (or absence in some places) of microvilli • Lymphocytes and fat droplets were observed over the surface of enterocytes (18%)¹ <p>10 subjects had colitis on rectal biopsy; this was not associated with SBBO or degree of small intestinal pathology on SEM.</p>		
<p>2002</p> <p>Murphy JL et al.</p> <p>Maldigestion and malabsorption of dietary lipid during severe childhood malnutrition</p> <p>Stool recovery of radiolabeled products as markers of lipid digestion and absorption, and bile salt deconjugation as a marker of SBBO among children with severe malnutrition</p>	<p>Kingston, Jamaica</p> <p>5-23 mo olds admitted to the Tropical Metabolism Research Unit of the University of the West Indies with severe malnutrition.</p>	<p>Case-series</p> <p>n=24</p> <p>Subjects were divided into 3 groups of 8 children, each group receiving a different labeled triglyceride.</p> <p>Data were collected in three separate phases as described above in JL Murphy et al. 2001 [149].</p>	<p>Stool Tests:</p> <ul style="list-style-type: none"> • Total and fractionated ¹³C following ingestion of one of three ¹³C labeled triglycerides (TG): trilaurin, triolein, or trilinolein* • ¹³C stool assay following administration of labeled fatty acid ¹³C glycocholate** <p>* To assess fat excretion as a % of dose administered. Also assessed proportion of ¹³C in triglyceride (TG) and fatty acid (FA) fractions to distinguish excretion</p>	<p>Median total stool excretion of ¹³C in phase 1 was 9% (range: 1%-29%) and did not vary between TG groups.</p> <p>Median ¹³C excretion dropped 33%-99% in phase 2 and 86%-95% in phase 3 compared to phase 1 (p<0.05 each).</p> <p>Over the study period, there were significant associations between total lipid and the amount of ¹³C labeled TGs in stool for some groups, but not for others.</p> <p>Median ¹³C in TG and FA was similar across TG groups in all phases. ¹³C FA recovery was similar and reduced by ~2/3 compared to Phase 1. ¹³C TG was not detectable in Phases 2 or 3. Statistical comparisons between phases were not reported.</p> <p>¹³C after radiolabeled glycocholate</p>	<p>High concentrations of ¹³C (compared to healthy UK children) [190] were observed in half of the subjects at admission, reflecting impaired digestion or absorption.</p> <p>The differences in stool ¹³C were wide but not as extreme as in a previous study by same investigators (also examined in this review) using a different TG (tripalmitin) substrate [149].</p> <p>¹³C excretion did not significantly differ between TG groups</p>	<p>Authors state that the study was not powered to compare the different TGs, but they contend that medium chain trilaurin did not appear to be processed differently than the longer chain TGs triolein and trilinolein.</p> <p>Authors did not describe the method used to assign subjects to different TG groups.</p> <p>While it was noted that some subjects had positive stool cultures, details</p>

1 These SEM results were not presented separately for those with and without SBBO.

Evidence Table 6. Markers of microbial drivers.

Biomarkers in bold are primarily markers of microbial drivers.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
			<p>caused impaired digestion (presence of TG) vs. poor absorption (presence of FA).</p> <p>** To assess bile salt deconjugation in the bowel caused by SBBO; conducted after the TG assessment and a 3 day washout period.</p>	<p>administration was detected in stool at quantities considered to be in excess of the 7% recovery of dose administered upper limit of normal in U.S. adults in [189]:</p> <ul style="list-style-type: none"> • Phase 1: 13/24 (54%) • Phase 2: 5/24 (20.8%) • Phase 3: 3/24 (12.5%) 	<p>and declined with improving clinical course.</p> <p>Similar to their previous study, significantly more ¹³C in stool was recovered as FA than TG, reflecting impaired absorption over poor lipid digestion/ hydrolysis. Unlike in their previous study, there was evidence of SBBO as measured post-ingestion of ¹³C glycocholate.</p>	<p>were not provided on the nature of the enteric infections.</p>
<p>2001</p> <p>Murphy JL et al.</p> <p>Gastrointestinal handling and metabolic disposal of ¹³C-labelled tripalmitin during rehabilitation from childhood malnutrition</p> <p>Fecal fat, stool recovery of radiolabeled products, and breath tests as markers of lipid digestion and absorption and bile salt deconjugation as a marker of SBBO among children with severe</p>	<p>Kingston, Jamaica</p> <p>7-23 mo olds with malnutrition admitted to the University of the West Indies.</p>	<p>Case-series</p> <p>n=8</p> <p>Data were collected in three separate phases (each lasting 9 days):</p> <ul style="list-style-type: none"> • Within 48 hours of admission • During early rehabilitation • During late rehabilitation 	<p>Stool Tests:</p> <ul style="list-style-type: none"> • Fecal fat* • Total and fractionated ¹³C assay after administration of ¹³C tripalmitin (TP)** • ¹³C assay after administration of ¹³C glycocholate (GCA)*** <p>Breath Tests:</p> <ul style="list-style-type: none"> • ¹³CO₂ after administration of ¹³C glycocholate (GCA)*** • ¹³CO₂ after administration of ¹³C TP**** <p>* In 72 hour stool</p>	<p>Mean fecal fat (SD):</p> <ul style="list-style-type: none"> • Phase 1: 2.4 g/day (3.6) or 5.9% (9.4) of dietary lipid intake • Phase 2: 1.7 (0.9) g/day, or 3.3% (2.4) of intake • Phase 3: 0.9 (0.6) g/day, or 1.4% (0.7) of intake • Differences between phases were not statistically significant. <p>Total excretion of ¹³C in stool also varied widely across patients (0%-44%) and did not differ between study phases.</p> <p>Correlation between fecal fat and ¹³C (r=0.48; p<0.05) was observed.</p> <p>Lack of lipid digestion and absorption were assessed by measuring TG and FA fractions, respectively. Mean ¹³C TG recovery (SD) (% of administered dose), number of patients excreting TG:</p>	<p>Mean fecal fat was not elevated compared to published norms [191, 192] during any study phase.</p> <p>There was wide variation in fecal fat at presentation, and wide variations in stool ¹³C across subjects. Authors indicate that this is the first such assessment in malnourished children; previous studies on healthy children from the UK demonstrated average excretion of 6% [190].</p>	<p>Statistical methods might be inappropriate for a small sample.</p> <p>All subjects were treated with antibiotics including metronidazole for presumptive SBBO; this might have affected GCA testing.</p>

Evidence Table 6. Markers of microbial drivers.

Biomarkers in bold are primarily markers of microbial drivers.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
malnutrition			<p>collection (measured as total grams and as % of dietary fat intake).</p> <p>** To assess fat excretion as a % of dose administered. Also assessed proportion of ¹³C in triglyceride (TG) and fatty acid (FA) fractions to distinguish excretion caused by impaired digestion (presence of TG) vs. poor absorption (presence of FA).</p> <p>*** To assess bile salt deconjugation in the bowel caused by SBBO; conducted after the TG assessment and a 3 day washout period.</p> <p>**** Expressed as a percentage of absorbed label (dose administered - label recovered in stool) to assess oxidation for acute energy needs.</p>	<ul style="list-style-type: none"> • Phase 1: 0.7% (1.6), n=3 • Phase 2: 0.9% (2.8), n=1 • Phase 3: no recovery from any subjects, differences between phases were NS <p>¹³C FA fraction in stool declined during rehabilitation. Mean ¹³C FA recovery (SD):</p> <ul style="list-style-type: none"> • Phase 1: 6.0% (7.3) • Phase 2: 4.8% (3.7) • Phase 3: 3.3% (3.8), differences between phases were NS <p>Mean FA values were ~9x (NS), 5x (p<0.001), and 3x (p<0.05) higher than mean TG values in Phases 1, 2, and 3, respectively.</p> <p>Following administration of labeled TP, absorbed ¹³C label by breath analysis was ~5% (range 0%-21.2%) and similar across study phases.</p> <p>Following the administration of labeled GCA, there was either no or minimal recovery of ¹³C in stool and ¹³CO₂ on breath (as % of dose administered) in all phases.</p>	<p>The majority of excreted ¹³C was in the form of FA rather than TG. Authors interpreted this to reflect failure of lipid absorption in the face of adequate digestion/hydrolysis. Each form (FA and TG) was found in decreasing values as the study phases progressed, suggesting improved digestion and absorption, although results did not differ significantly.</p> <p>Fecal fat was correlated with concentrations of ¹³C in stool. There was no evidence of SBBO or bile acid malabsorption.</p> <p>¹³CO₂ excretion following administration of ¹³C TP was minimal, suggesting a propensity for deposition in adipose tissues rather than oxidation for immediate energy needs. The authors report that this breath test has not been widely</p>	

Evidence Table 6. Markers of microbial drivers.

Biomarkers in bold are primarily markers of microbial drivers.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
					used, but that healthy UK children have breath excretion values from 15%-43% [190], compared to a mean of 5% and range 0%-21% in this cohort; the latter findings were more similar to results from kwashiorkor patients where ¹³ C-labeled oleic acid was used as substrate [193].	

Notes: Some studies included subjects ≥5 yr of age. Where these studies provided data separately for children <5 yr, we present results for only those subjects. Where these studies did not stratify results by age, but did report the number of children <5 yr included in the study, we provide a breakdown of under-5s. All studies reporting lactulose:ramnose ratio results presented values multiplied by a factor of 100 for ease of reporting.

Abbreviations: AD=acute diarrhea, ALT=alanine aminotransferase, AST=aspartate aminotransferase, CBC=complete blood count, CD=celiac disease, CI=95% confidence interval, Cr=creatinine, Δ=change in, EED=environmental enteric dysfunction, FTT=failure to thrive, GI=gastrointestinal, HAZ=height-for-age Z-(score), HDL=high density lipoproteins, HIV=human immunodeficiency virus, HLA=human leukocyte antigen, IEL=intraepithelial lymphocytes, IgA=immunoglobulin A, IgE=immunoglobulin E, IgG=immunoglobulin G, IgM=immunoglobulin M, IL=interleukin, IFN=interferon, LDL=low density lipoproteins, L:M=lactulose:mannitol ratio, mo=month(s), NS=not statistically significant, PD=persistent diarrhea, RCT=randomized controlled trial, SBBO=small bowel bacterial overgrowth, SD=standard deviation, SE=standard error, SES=socioeconomic status, Tc-99m=technetium 99, T3=triiodothyronine, T4=thyroxine, TE=tropical enteropathy, TGF=transforming growth factor, TNF=tumor necrosis factor, TS=tropical sprue, WAZ=weight-for-age Z-(score), WBC=white blood cell count, WFA=weight-for-age, WHZ=weight-for-height Z-(score), wk=week(s), yr=year(s)

5.7.1 Lactulose Hydrogen Breath Test (HBT)

Alves et al. utilized the lactulose hydrogen breath test (HBT) to measure of lactose absorption and the lactulose HBT as a measure of SBBO in a community-based study of indigenous children in Brazil [102]. Prevalence of SBBO in the study subjects was 12% among subjects below four years of age, and overall 9% had SBBO. The authors did not report on the relationship between lactulose and lactose absorption.

In a study of intestinal function among well-nourished children with asymptomatic giardiasis and healthy controls in Mexico, Moya-Camarena et al. utilized the lactulose HBT and the indican test to exclude subjects with SBBO. No further data were reported on results of the lactulose HBT; therefore we did not include this study in this section of our review [147].

5.7.2 $^{13}\text{CO}_2$ in Breath or Stool after Administration of ^{13}C Glycocholate as Marker for SBBO

Murphy et al. [149] assessed gastrointestinal function by stool tests with [149] or without [148] breath tests in children hospitalized for rehabilitation of malnutrition. The $^{13}\text{CO}_2$ breath test was performed after administering ^{13}C glycocholate (GCA) to assess bile salt deconjugation in the bowel caused by SBBO. The test was conducted after a similar assessment with triglyceride and a subsequent 3-day washout period. Results were expressed as percent of administered dose. In their initial study, following the administration of labeled GCA, there was no or minimal recovery of ^{13}C in stool and $^{13}\text{CO}_2$ on breath in all study phases. The authors interpreted these results to indicate that the GCA was not malabsorbed and that the subjects did not show evidence of bile salt deconjugation. In the subsequent larger study, however, ^{13}C from labeled GCA was recovered in the stool in more than one-third of the children, indicating the presence of SBBO [148].

5.7.3 Intestinal Aspirates for Bacterial Concentrations

Fagundes-Neto et al. analyzed jejunal aspirates and small intestinal biopsies of hospitalized infants with persistent diarrhea and malnutrition by scanning electron microscopy (SEM) and light microscopy [118]. Based on bacterial concentration in jejunal aspirates, more than two-thirds of subjects had bacterial overgrowth (concentration $>10^4$ colonies/mL), and three were infected with enteropathogenic *E. coli* while the rest had colonic microflora in their small bowel. Histological abnormalities were noted in all subjects by light microscopy and SEM. The degree of villous atrophy noted on SEM seemed to correlate with SBBO, but statistical testing was not provided.

Fagundes-Neto et al. also reported a mucous-fibrinoid pseudo-membrane that partially covered enterocytes [118]. They speculated that it could indicate a malabsorptive process, based on the findings of fat droplets on enterocyte surfaces and the malnourished condition of the subjects.

Reporting of proportions of histopathologic findings among all subjects and by SBBO status, as well as statistical assessment of potential correlation with SBBO between different histologic findings, would have benefitted the analysis.

5.8 Markers of Nonspecific Intestinal Injury

The matter of small bowel biopsies and EED is complex. From initial investigations nearly five decades ago, the histopathologic appearance of the small bowel defined the entity. Sentinel papers from Southeast Asia and elsewhere formed the basis of our understanding of the entity on which we have focused in this review [274, 275]. Also, there is an extensive tradition of pathological assessments of the bowel and other organs in a variety of syndromes and diseases, and histological assessment is often considered the gold standard to which biomarkers are compared. Histology certainly can inform the nature of lesions. In the digestive system, microscopic evaluation of tissue

can often help differentiate infectious from noninfectious inflammations, assess the degree of allergic reaction if present, suggest the principal effector cells, and identify malignant potential (rare in these subjects). Specific diagnoses can also be made by histologic evaluation of the small bowel; well-known examples are celiac disease and Crohn's disease.

In view of the potential value of relating biopsies to biomarkers, we sought to find any relation between this putatively definitive test (small bowel biopsy) and any laboratory test or abnormality. The data relevant to this review are listed for each of these 18 biopsy studies in Evidence Table 7. We also include other markers of non-specific intestinal injury in Evidence Table 7, including three studies utilizing fecal occult blood or red blood cells and one employing Tc-99m dextran scintigraphy.

Evidence Table 7. Markers of non-specific intestinal injury.

Biomarkers in bold are primarily markers of non-specific intestinal injury.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
<p>2009</p> <p>Amadi B et al.</p> <p>Reduced production of sulfated glycosaminoglycans occurs in Zambian children with kwashiorkor but not marasmus</p> <p>Duodenal biopsy including assessments of intestinal markers in children with PD and different forms of malnutrition</p>	<p>Lusaka, Zambia</p> <p>12.2-19.8 mo olds with PD and malnutrition admitted to the malnutrition ward of a teaching hospital.</p>	<p>Case-control</p> <p>n=41*; n=41 cases with PD and malnutrition: • 18 with marasmus • 8 with marasmic kwashiorkor • 15 with kwashiorkor</p> <p>n=19 healthy control children from UK</p> <p>* UK subjects are presented in this table due to comparisons of interest made in the review. However we do not include these subjects in the sample size for this review.</p>	<p><u>Endoscopic duodenal biopsy:</u></p> <ul style="list-style-type: none"> • Histopathology • Densities in lamina propria and crypt epithelium: • Cell proteins: <ul style="list-style-type: none"> • Glycosaminoglycan (GAG) • Enterocyte heparan sulfate proteoglycan (HSPG) • Syndecan-1 • Inflammatory cell markers: <ul style="list-style-type: none"> • CD3 IEL • Ki67 • Human leukocyte antigen DR-1 (HLA-DR) 	<p>Biopsy findings among the Zambian compared to the UK children:</p> <ul style="list-style-type: none"> • Villous height reduced • Crypt depth increased • ~50% reduction in crypt:villous ratio • Values for lamina propria cell densities were not reported for UK subjects <p>No significant differences in crypt or villous measures or lamina propria cell densities were observed between nutritional groups or after nutritional rehabilitation.</p> <p>Intestinal markers:</p> <ul style="list-style-type: none"> • Inflammatory markers were seen in higher densities compared to the UK children. There were significant differences between the different nutritional groups in the specific types of inflammatory markers. • There was a significant reduction in GAGs and HSPG in the kwashiorkor group compared to UK children, but no significant differences between kwashiorkor and other presentations of malnutrition. • There was no difference in epithelial syndecan-1 protein expression between the malnutrition groups (data not available for UK controls). 	<p>Mucosal architecture was markedly abnormal compared to UK controls but did not vary between marasmus and kwashiorkor presentations of malnutrition.</p> <p>Inflammatory cell densities were generally higher compared to UK children and showed different patterns across the malnutrition presentations.</p> <p>Tissue concentrations of HSPG and GAG were reduced especially amongst children with kwashiorkor. Intestinal protein markers did not differ amongst the malnutrition groups.</p>	<p>27 subjects were HIV positive; incidence was lower in the kwashiorkor group.</p>
<p>2000</p> <p>Azim T et al.</p>	<p>Dhaka, Bangladesh</p> <p>7-12 mo olds with 6-8 days of watery</p>	<p>Case-control</p> <p>n=136;</p>	<p><u>Blood tests:</u></p> <ul style="list-style-type: none"> • IFN-γ • TNF-α • WBC (total and 	<p>WBC total and differential, immunoglobulin subtypes, cytokines, transferrin, and albumin did not differ between</p>	<p>Some immune and inflammatory markers were associated with</p>	<p>The number of controls was relatively small and their nutritional</p>

Evidence Table 7. Markers of non-specific intestinal injury.

Biomarkers in bold are primarily markers of non-specific intestinal injury.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
<p>Immune response of Bangladeshi children with acute diarrhea who subsequently have persistent diarrhea</p> <p>Immune activation tests, as well as transferrin and albumin as markers of nutritional status among children with and without PD</p>	<p>diarrhea attending the International Centre for Diarrheal Disease Research.</p> <p>Cases were those who went on to develop PD, controls were those who did not.</p> <p>An additional group of subjects without diarrhea were recruited from a nutrition follow-up unit.</p> <p>Prevalence of malnutrition was high in all groups.</p>	<p>n=38 cases with PD</p> <p>n=98 controls:</p> <ul style="list-style-type: none"> • 85 with AD • 13 with no diarrhea 	<p>differential)</p> <ul style="list-style-type: none"> • IgA • IgG • IgM • Transferrin • Albumin • Immune function tests: <ul style="list-style-type: none"> • Neutrophil polarization response to chemotactic factor • Neutrophil opsonization to yeast • Mononuclear cell proliferation, spontaneous and in response to stimuli with mitogens <p><u>Skin Test:</u></p> <ul style="list-style-type: none"> • Delayed-type hypersensitivity response (DTH) to tuberculin, tetanus, diphtheria, <i>Streptococcus</i>, <i>Proteus</i>, <i>Candida</i>, and <i>Trichophyton</i> <p><u>Stool tests:</u></p> <ul style="list-style-type: none"> • Leukocytes • Red blood cells 	<p>cases with diarrhea or controls, nor did stool leukocyte or erythrocyte counts.</p> <p>The percentages of neutrophils that polarized in response to stimulation were significantly higher in subjects with AD or PD compared to those without diarrhea; there was no difference between the two diarrhea groups.</p> <p>Opsonization did not vary between any groups.</p> <p>Monocyte spontaneous proliferation counts were less than half among children with no diarrhea compared to those with AD (p<0.001) or with PD (p=0.011); there was no difference between the two diarrhea groups.</p> <p>Monocyte proliferation in response to stimulation did not differ between the 3 groups.</p> <p>The proportion with DTH responses differed among the three groups only in response to tuberculin (p=0.021). More PD subjects had a negative tuberculin response than did subjects with AD (p=0.024).</p>	<p>acute and/or persistent diarrhea.</p> <p>The only marker that was significantly associated with progression to PD was a negative DTH response to tuberculin antigen (odds ratio=3.8, CI: 1.4, 9.9). This was calculated from a logistic regression analysis that only included children with diarrhea.</p>	<p>status was not reported.</p>
<p>2005</p> <p>Bhatnagar S et al.</p> <p>Celiac disease with mild to moderate histological changes</p>	<p>Delhi, India</p> <p>1-18 yr olds with a presentation consistent with CD (combination of chronic diarrhea,</p>	<p>Case-series</p> <p>n=107</p>	<p><u>Endoscopic duodenal biopsy:</u></p> <p>Histopathology</p>	<p>70 had normal histology (defined as crypt:villous ratio 1:2-3, absence of lymphoid lamina propria infiltration, and minimal intraepithelial lymphocytes (IEL).</p> <p>37 had mild changes (defined as</p>	<p>More than one quarter of children with chronic diarrhea had normal small intestinal mucosa; at follow-up their</p>	

Evidence Table 7. Markers of non-specific intestinal injury.

Biomarkers in bold are primarily markers of non-specific intestinal injury.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
<p>is a common cause of chronic diarrhea in Indian children</p> <p>Duodenal biopsy among children with chronic diarrhea</p>	<p>abdominal distension, and growth failure), recruited from a pediatric gastroenterology clinic.</p> <p>Subjects negative for CD-specific antibodies were of interest for this review.</p>			<p>mild blunting of villi with crypt:villous ratio of 1:1*). A specific etiology was identified in only n=5:</p> <ul style="list-style-type: none"> • 2 with giardiasis • 1 with lymphangiectasia • 2 with chronic pancreatitis <p>Only children with CD had moderate or severe histologic changes.</p> <p>* Along with increased IEL and lymphocytic lamina propria infiltration.</p>	<p>growth had improved and their diarrhea had resolved.</p> <p>No definitive diagnosis was reached for 86% of subjects with abnormal histology (albeit most had mild findings).</p>	
<p>2003</p> <p>Bustos M et al.</p> <p>Disaccharidase deficiency in Bolivian children with persistent diarrhea</p> <p>Jejunal biopsy and disaccharidase activities in children with PD and different forms of malnutrition</p>	<p>Cochabamba, Bolivia</p> <p>3-34 mo old Amerindians hospitalized with PD and moderate or severe malnutrition in an urban setting.</p>	<p>Cohort</p> <p>n=42 cases with PD and malnutrition:</p> <ul style="list-style-type: none"> • 2 with kwashiorkor • 20 with marasmus • 20 with marasmic-kwashiorkor <p>Children were assessed on admission and at three weeks, after diarrhea had resolved and anthropometrics were improving.</p>	<p><u>Jejunal tethered capsule biopsy:</u></p> <ul style="list-style-type: none"> • Histopathology • Disaccharidase activity: <ul style="list-style-type: none"> • Lactase • Sucrose-Isomaltase • Maltase <p>Histology was scored on a scale of 1 (normal) to 4 (severe morphological damage or flat mucosa).</p>	<p>Most subjects had mild to moderate (score of 2-3) histological abnormalities, with one kwashiorkor patient having completely flat villi.</p> <p>Second biopsy showed a trend of improved mucosa, but difference was not significant based on histology score, intraepithelial lymphocyte density, or degree of infiltration of lamina propria.</p> <p>Percentages with enzymatic activity below normal at baseline, discharge:</p> <ul style="list-style-type: none"> • Lactase: 64%, 59% • Sucrase-isomaltase: 97%, 90% • Maltase: 45%, 52% <p>All changes were statistically significant.</p> <p>Lactase recovery was associated with admission HAZ (p=0.05) and WAZ (p=0.03) scores.</p>	<p>Patients had diminished intestinal disaccharidase activity and substantial pathology on biopsy at admission and at three weeks, despite clinical improvements and tolerance of lactose-containing formula.</p>	<p>Spanish language article.</p> <p>Values for subnormal disaccharidase activity were not provided.</p> <p>The magnitude of lactase inverse association with growth parameters was not reported. Authors did not report whether they had tested for associations between maltase or sucrose-isomaltase and growth parameters.</p>

Evidence Table 7. Markers of non-specific intestinal injury.

Biomarkers in bold are primarily markers of non-specific intestinal injury.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
				Despite continued high disaccharidase deficiency prevalence at discharge, all children tolerated the lactose-containing formula challenge.		
2003 Campbell DI et al. Chronic T cell-mediated enteropathy in rural west African children: relationship with nutritional status and small bowel function L:M as a marker of intestinal permeability, small bowel biopsy with assessment of intestinal immune markers, and computerized morphometric analysis among rural Gambian children with differing degrees of malnutrition and compared to well-nourished UK children	Fajara and Sibinar, The Gambia 6 mo-3 yr old hospital- and clinic-based cases from rural communities. Case groups based on differences in nutritional status: 1. WAZ score >-2, with GI complaints other than diarrhea 2. Grade I protein energy malnutrition (PEM) (WAZ score -2 to -4) and unresponsive to nutritional supplementation, with or without diarrhea 3. Grade II PEM (WAZ score <-4) with or without diarrhea Controls from UK* who were well nourished children with GI complaints other than diarrhea and with normal endoscopy results	Case-control n=40 cases: • Group 1: n=4 • Group 2: n=11 (7 with diarrhea) • Group 3: n=25 (18 with diarrhea) n=34 with case tissue samples sufficient for cytokine immunoreactivity tests: • Group 1: n=3 • Group 2: n=8 • Group 3: n=23	<u>Endoscopic small bowel biopsy, site not specified:</u> • Histopathology • Morphometric assessment by computer analysis* • Intestinal tissue cytokines and immune markers: • CD-3 • CD-4 • CD-8 • CD-19 • CD-25 • HLA-DR • Perforin • $\gamma\delta$ T-cell receptor • Syndecan-1 • TNF- α • IFN- γ • TGF- β • IL-10 <u>Urine Tests:</u> • Lactulose ¹ • Mannitol • L:M * Biopsy involved morphometric assessment by computer analysis of	Crypt-hyperplasia and villous atrophy were observed among all Gambian subjects, and the degree of histopathology did not differ among cases with differing nutritional status, nor was there a correlation with diarrhea. IEL ² means were ~3-fold higher in Gambian than UK children. Median CD3, CD4, CD8, CD19, and CD25 cell counts were significantly higher (2-5x higher) among each case group compared to the UK controls. IEL, $\gamma\delta$, syndecan-1, HLA-DR, and perforin were detected among the Gambian children in varying degrees but were not reported for UK controls. Syndecan, CD3, and CD8 displayed a gradient proportional to malnutrition severity. All Gambian groups showed higher lamina propria cytokine-immunoreactive mononuclear cell density (~200-450/mm ²) than UK controls (30-80/mm ²). Among subjects with elevated cytokines, similar densities were seen for both pro-inflammatory	All Gambian subjects had evidence of enteropathy with crypt-hyperplasia and villous atrophy, and mean IELs >2 SD above UK norms, independent of nutritional status. Elevation of cell-mediated intestinal markers and mucosal proinflammatory cytokines was present across the 3 Gambian groups, variably correlated with nutritional status. L:M ratios were elevated in all Gambian groups, without apparent correlation to host nutritional status.	Statistical methodology was not sufficiently detailed to determine what was compared (e.g. type of central tendency measure and variance calculations for L:M not stated) Duration of diarrhea not specified, but assumed to be persistent. Mucosal lymphocyte densities, cytokine immunoreactivity, and L:M results not stratified by history of diarrhea.

¹ Lactulose and mannitol results were expressed as % of dose administered.

² These figures are presumed to represent IEL means, however, this was not explicitly stated.

Evidence Table 7. Markers of non-specific intestinal injury.

Biomarkers in bold are primarily markers of non-specific intestinal injury.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
	<p>were also studied.</p> <p>* UK subjects are presented in this table due to comparisons of interest made in the review. However we do not include these subjects in the sample size for this review.</p>		villous height, crypt depth, villous:crypt ratio, and intraepithelial lymphocyte (IEL) density (per 100 epithelial cells).	<p>(IFN-γ and TNF-α) and putative regulatory (IL-10 and TGF-β) cytokines. Epithelial expression of TGF-β was also enhanced compared to UK controls, but subjects with poorer nutritional status had lower densities of mucosal TGF-β+ cells, with median densities of 420 and 250 cells/mm² in the grade I and grade II PEM groups, respectively.</p> <p>L:M values¹:</p> <ul style="list-style-type: none"> • Group 1: 0.53 (0.4-1.3) • Group 2: 0.47 (0.02-2.20) • Group 3: 0.73 (0.14-2.2) • Not assessed among the UK controls <p>Nutritional status was not associated with L:M, recoveries of lactulose or mannitol.</p> <p>L:M was correlated with mucosal B lymphocyte density (r=0.57, p<0.05), IEL (r=0.51, p<0.02), and perforin+ IEL (r=-0.64, p<0.03).</p>		
<p>2006</p> <p>El Mouzan MI et al.</p> <p>Endoscopic duodenal biopsy in children</p> <p>Duodenal biopsy among children with suspected intestinal disease</p>	<p>Riyadh, Saudi Arabia</p> <p>1.5 mo-18 yr olds referred to hospital for endoscopy with duodenal biopsy.</p> <p>78% of subjects were <12 yr old; results not presented by age.</p>	<p>Retrospective case-series</p> <p>n=241 cases:</p> <ul style="list-style-type: none"> • 102 with PD • 116 with unexplained short stature • 11 with refractory rickets • 12 with other conditions 	<p><u>Endoscopic duodenal biopsy:</u></p> <ul style="list-style-type: none"> • Gross endoscopic visualization • Histopathology 	<p>14% had abnormalities on endoscopic visualization:</p> <ul style="list-style-type: none"> • 1% had esophagitis • 6% had gastritis, 7 (47%) of which were <i>H. pylori</i> positive • 7% had duodenitis <p>Biopsy results:</p> <ul style="list-style-type: none"> • PD: <ul style="list-style-type: none"> • 26% normal • 29% chronic non-specific duodenitis 	<p>Villous atrophy was identified not only among 40% of children with PD, but also among 22%, 9%, and 17% of those with short stature, rickets, and other conditions, respectively.</p> <p>Authors argue that</p>	<p>Specific results for the 2 patients with protein losing enteropathy were not reported.</p> <p>For 27% of cases, the only histopathology finding was chronic non-specific duodenitis; the</p>

¹ Not clearly indicated if these figures represent mean (CI) or another measure of central tendency.

Evidence Table 7. Markers of non-specific intestinal injury.

Biomarkers in bold are primarily markers of non-specific intestinal injury.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
		(including 2 with protein losing enteropathy)		<ul style="list-style-type: none"> • 40% villous atrophy • 5% other* <ul style="list-style-type: none"> • Short stature: <ul style="list-style-type: none"> • 56% normal • 22% chronic non-specific duodenitis • 22% villous atrophy • Rickets: <ul style="list-style-type: none"> • 55% normal • 36% chronic non-specific duodenitis • 9% villous atrophy • Other: <ul style="list-style-type: none"> • 25% normal • 50% chronic non-specific duodenitis • 17% villous atrophy • 8% other* <p>* 3 lymphangiectasia, 2 <i>Giardia</i>, 1 <i>Mycobacterium avium intracellulare</i>. Findings were reported according to presenting symptoms.</p>	<p>endoscopic biopsy is superior to “blind” capsule biopsy in developing country settings and allows for visualization of the intestine.</p> <p>Endoscopic visualization results were not reported by condition nor in relation to histopathology results; it is difficult to assess the value added compared to biopsy alone.</p>	<p>diagnostic, prognostic, and therapeutic utility of identification is unclear.</p>
<p>2000</p> <p>Fagundes-Neto U et al.</p> <p>Studies of the small bowel surface by scanning electron microscopy in infants with persistent diarrhea</p> <p>Scanning electron microscope (SEM) and light microscope (LM) analyses of</p>	<p>Sao Paulo, Brazil</p> <p>2-10 mo olds with PD and protein calorie malnutrition consecutively admitted to Sao Paulo Hospital.</p>	<p>Case-series</p> <p>n=16</p>	<p><u>Jejunal secretions aspirate:</u> Bacterial concentrations</p> <p><u>Jejunal tethered capsule biopsy:</u> Histopathology by LM and SEM</p> <p><u>Rectal tethered capsule biopsy:</u> Histopathology</p>	<p>68.7% had bacterial overgrowth (concentration $>10^4$ colonies/mL): 3 had enteropathogenic <i>E. coli</i> while the rest had colonic microflora.</p> <p>All small intestine specimens had morphological abnormalities on LM:</p> <ul style="list-style-type: none"> • 43.7% moderate villous atrophy • 56.3% subtotal villous atrophy <p>SEM revealed abnormalities of varying intensity:</p> <ul style="list-style-type: none"> • Among the 11 with SBBO, 	<p>Histological abnormalities were noted in all subjects by LM and SEM.</p> <p>Degree of villous atrophy noted on SEM seemed to be correlated with SBBO (no statistical tests were reported).</p> <p>Authors speculate that the mucous-fibrinoid pseudo-</p>	<p>Inconsistent reporting of proportions of histopathologic findings among all subjects and by SBBO status; assessment of potential relationship with SBBO between different histologic findings was not possible.</p>

Evidence Table 7. Markers of non-specific intestinal injury.

Biomarkers in bold are primarily markers of non-specific intestinal injury.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
small intestinal biopsy among infants with PD with and without SBBO				<p>villous atrophy ranged from Grade II (n=4), Grade III (n=2), to Grade IV (n=3).</p> <ul style="list-style-type: none"> • For the 5 subjects without SBBO, villous atrophy ranged from Grade I (n=1) to Grade 2 (n=4). • A mucous-fibrinoid pseudo-membrane over enterocytes was noted in 7 of the 11 with SBBO and none of the others. <p>Other abnormalities noted on SEM included:</p> <ul style="list-style-type: none"> • Mucus and debris covered large areas of the villous surface • Derangement of the enterocytes (in some cases cell borders were not clearly defined) • Reduced height and number (or absence in some places) of microvilli • Lymphocytes and fat droplets were observed over the surface of enterocytes (18%)¹ <p>10 subjects had colitis on rectal biopsy; this was not associated with SBBO or degree of small intestinal pathology on SEM.</p>	membrane partially covering enterocytes is consistent with a malabsorptive process, with the findings of fat droplets on enterocytes surfaces, and with the state of malnutrition of the subjects.	
2001 Gandolfi L et al. Antiendomysial antibody test reliability in children with frequent	Brasilia, Brazil 6 mo-13 yr olds with acute, persistent or chronic diarrhea, and/or malnutrition being seen at the pediatric	Cross-sectional n=31	Jejunal capsule biopsy: Histopathology	<p>30/31 (96.8%) had abnormal histopathology:</p> <ul style="list-style-type: none"> • Suggesting non-specific inflammatory abnormalities in 27 (87.1%) subjects. • Demonstrating grade 3 mucosal abnormalities in all malnourished 1 yr olds 	The vast majority of children with clinically severe diarrhea and/or malnutrition had some degree of abnormality on jejunal biopsy.	Biopsies of interest were not provided in subject-specific detail (e.g. characteristics of the 27 children with non-specific inflammation were

¹ These SEM results were not presented separately for those with and without SBBO.

Evidence Table 7. Markers of non-specific intestinal injury.

Biomarkers in bold are primarily markers of non-specific intestinal injury.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
diarrhea and malnutrition: is it celiac disease Jejunal biopsy among children with PD and/or malnutrition	gastroenterology service of a university hospital and determined to have disease severity warranting biopsy. Subjects negative for CD-specific antibodies were of interest for this review.			negative for enteric parasites.		not detailed (e.g. presence of parasites, degree of malnutrition and/or diarrhea).
2000 Hafeez A et al. An audit of pediatric upper gastrointestinal endoscopies Duodenal biopsy among children with PD or growth problems	Islamabad, Pakistan 2 mo-12 yr olds referred from various hospitals to KRL Hospital Islamabad for abdominal pain, PD, short stature, FTT, GI bleeding, or anemia. The subjects of interest for this review were those with PD or growth problems.	Case-series n=41; • 28 with PD • 9 with FTT • 4 with short stature	<u>Endoscopic duodenal Biopsy:</u> • Gross endoscopic visualization • Histopathology	Positive histopathologic findings were identified in: • 21/28 with PD • 7/9 with FTT • 3/4 with short stature More abnormalities were found via histology than visualization, and findings did not necessarily correlate.	75% of the PD and 77% and the short stature/FTT patients had abnormalities by endoscopy. Authors assert the importance of biopsies among children with indications for endoscopy, due to lack of correlation between them and increased identification of abnormalities by biopsy.	There was possible bias in the manner of selection for endoscopy. 14 biopsies were unable to be analyzed (from 100 endoscopies). Authors did not report the endoscopic appearance of the mucosa. Histology findings were reported by specimen (with multiple specimens from some patients), not by condition or by patient, so specific results could not be interpreted in regards to this review.
2007 Jain S et al.	Delhi, India Children (ages	Case-control n=80;	<u>Stool Test:</u> Occult blood	Fecal occult blood test was positive in 30/50 (60%) cases and 0/30 controls.	A high proportion of severely malnourished	Among cases, half had a presenting complaint of

Evidence Table 7. Markers of non-specific intestinal injury.

Biomarkers in bold are primarily markers of non-specific intestinal injury.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
<p>Fecal occult blood screening in children with severe malnutrition</p> <p>Fecal occult blood among severely malnourished children compared to healthy controls</p>	<p>unspecified) admitted with severe malnutrition and age-matched healthy controls recruited from an immunization clinic.</p>	<p>n=50 cases with severe malnutrition</p> <p>n=30 healthy controls</p>	<p>Blood Test: Hemoglobin</p>	<p>Among cases positive for fecal occult blood, 20 (66.7%) were found to have hemoglobin <8 g/dL.</p> <p>Enteric infections:</p> <ul style="list-style-type: none"> Parasitic infections were detected in 14/50 (28%) of cases, 12 (85.7%) of whom tested positive for fecal occult blood. Bacterial infections were detected in 18/50 (36%) of cases, 13 (72.2%) of whom tested positive for fecal occult blood. Of the remaining 18 for whom an enteric pathogen was not identified, 5 (27.8%) tested positive for fecal blood. <p>Among the 30 cases with fecal occult blood, 16 were breastfed, 11 were fed cow's milk, and 3 were fed formula.</p>	<p>children had a positive fecal occult blood test, compared with no positives among healthy controls.</p> <p>Malnourished children with identifiable pathogens more often tested positive for fecal occult blood, although approximately 25% of those without an identifiable pathogen also tested positive.</p> <p>Presence of fecal blood did not appear to vary by feeding mode (e.g. breast milk, cow's milk, or formula), although data presented were limited.</p>	<p>diarrhea (duration not specified), but the authors did not report results stratified by diarrhea duration.</p> <p>Authors did not provide differences in proportions of occult blood among those with and without specific enteric pathogens.</p> <p>Statistical analysis was not provided; data were reported as proportions only.</p> <p>Matching scheme was not defined.</p>
<p>2002</p> <p>Kapoor, S et al.</p> <p>Detecting protein losing enteropathy by Tc-99m dextran scintigraphy: A novel experience</p> <p>Tc-99m dextran scintigraphy as a marker of protein-</p>	<p>New Delhi, India</p> <p>2-12 yr olds selected from hospitalized patients with symptoms suspicious for protein-losing enteropathy (hypoalbuminemia and edema).</p>	<p>Case-series</p> <p>n=3 <5 yr old</p>	<p>Tc-99m dextran scintigraphy</p>	<p>Abnormal Tc-99m dextran uptake was positive in one child found to have subtotal villous atrophy on biopsy and another thought to have abdominal tuberculosis.</p> <p>The child with the negative scan had marasmus and partial villous atrophy on biopsy.</p>	<p>Scintigraphy might be a useful, noninvasive method for detecting intestinal pathology.</p>	<p>This pilot study had a small sample size of 8 children, and only 3 were younger than 5 years.</p>

Evidence Table 7. Markers of non-specific intestinal injury.

Biomarkers in bold are primarily markers of non-specific intestinal injury.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
losing enteropathy or intestinal inflammation						
2004 Laadhar A et al. Determination of anti-transglutaminase antibodies in the diagnosis of celiac disease in children: results of a five year prospective study Duodenal biopsy among patients with suspected CD	Sfax, Tunisia Children admitted for endoscopic biopsy for symptoms of CD (not specified). Subjects of interest for this review were those who tested negative for CD-specific serology and who did not meet the study diagnostic criteria for CD--subtotal or total villous atrophy consistent with Marsh stages 3 or 4. Controls were aged 3 mo-17 yr (mean 4.5 yr).	Case-control n=99	<u>Endoscopic duodenal biopsy:</u> Histopathology	Of 99 subjects not meeting diagnostic criteria for CD, endoscopic biopsies revealed: <ul style="list-style-type: none"> • 76 had normal morphology of the intestinal mucosa • 7 had elevated densities of intraepithelial lymphocytes • 10 had partial villous atrophy (Marsh stage 2) • 6 had various other conditions such as giardiasis or gastritis 	Among 169 children with symptoms of CD, 41% had subtotal or total villous atrophy, 10% had partial villous atrophy or inflammatory findings, and 45% had normal biopsies.	Article in French. Prevalence of CD antibodies did not clearly align with case/control designation. Because of the way the results were reported, we could not extract data on those who tested negative for CD-specific serology and who had Marsh stages 3 or 4 histopathology. Methods section described obtaining duodenal biopsies, while results and conclusion sections specify that jejunal specimens were obtained.
2006 Leite CA et al. Functional, microbiological and morphological intestinal findings among human immunodeficiency virus infected children	Sao Paulo, Brazil 5 mo-12 yr old (median 24 mo) HIV-infected subjects recruited from a hospital and clinic. All subjects had some degree of protein-energy malnutrition.	Cohort n=11; n=5 patients with current or recent episode of diarrhea n=6 patients with no diarrhea in the 30 days preceding enrollment	<u>Blood Test:</u> D-xylose (9 tested) <u>Biopsy of small intestine by tethered capsule or endoscopy:</u> Histopathology (10 tested) <u>Rectal biopsy:</u>	100% had low D-xylose absorption: <ul style="list-style-type: none"> • Mean: 15.6 mg/dL • SD: 5 • Range: 8.9-24.4 • Median: 14.2 Small intestinal biopsy: <ul style="list-style-type: none"> • 100% had some degree of villous atrophy based on a I-IV grading system: <ul style="list-style-type: none"> • Grade I: 3 • Grade I/II: 2 	There was a high prevalence (100%) of abnormal D-xylose results among HIV-infected children, regardless of diarrhea status. All patients also had cellular infiltration of the lamina propria and varying degrees of	Portuguese language article. D-xylose <25 mg/dL was defined as indicative of malabsorption. This value is higher than what some references have noted as a cut-point [186].

Evidence Table 7. Markers of non-specific intestinal injury.

Biomarkers in bold are primarily markers of non-specific intestinal injury.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
Small intestinal and rectal biopsy to assess morphology and D-xylose as a marker of malabsorption among HIV-infected children			Histopathology (6 tested)	<ul style="list-style-type: none"> Grade II: 1 Grade II/III: 1 Grade III/IV: 1 2 samples were too superficial to assess Intraepithelial lymphocytes were increased in half of the biopsies. Lymphocytic and polymorphonuclear (PMN) infiltration of the lamina propria were present in 10/10 and 7/10 biopsies, respectively. <p>Rectal biopsy:</p> <ul style="list-style-type: none"> 100% had normal architecture Lymphocytic and PMN infiltration were present in 6/6 and 4/6, respectively. 	villous atrophy. There was no correlation between D-xylose and degree of villous atrophy on biopsy.	Investigators used a well-articulated system of grading villous atrophy. Results were not presented by diarrhea status, perhaps due to small sample size.
<p>2005</p> <p>Lima AA et al.</p> <p>Intestinal barrier function and weight gain in malnourished children taking glutamine-supplemented enteral formula</p> <p>L:M as a marker of intestinal permeability and various stool tests among children with malnutrition or PD who received either glycine or glutamine</p>	Fortaleza, Brazil 2-60 mo olds hospitalized with WAZ score <-2, ~70% of whom had PD.	RCT n=80; n=53 received supplemented formula • 27 with glycine • 26 with glutamine n=27 received nonsupplemented formula	<p>Urine Tests*:</p> <ul style="list-style-type: none"> Lactulose¹ Mannitol L:M <p>Stool Tests**:</p> <ul style="list-style-type: none"> Lactoferrin Leukocytes Occult blood Reducing substances (RS) <p>* n=80 tested at enrollment, n=65 tested at day 10.</p> <p>** n=60 tested.</p>	<p>Mean² L:M (SE):</p> <ul style="list-style-type: none"> Glutamine group: <ul style="list-style-type: none"> Baseline: 0.31 (0.10) (similar in all three groups) Day 10: 0.10 (0.02); significant decrease, (p=0.01) No significant decrease in L:M in glycine and nonsupplemented formula groups at day 10 <p>Mean lactulose (SE):</p> <ul style="list-style-type: none"> Glutamine group: <ul style="list-style-type: none"> Baseline: 0.97 (0.46) (similar in all three groups) Day 10: NS decrease in all 3 groups 	L:M significantly improved in the glutamine group only. >50% of subjects had intestinal inflammation by stool lactoferrin. Fecal leukocytes, RS, and occult blood were detected in fewer subjects than lactoferrin.	The relationship between stool markers and L:M was not reported. Data were not stratified by history of PD. Fecal fat was assessed, but results were not reported. Cut-off values for lactoferrin positivity were not described. Exclusively

¹ Lactulose and mannitol results were expressed as % of dose administered.

² Type of mean not specified.

Evidence Table 7. Markers of non-specific intestinal injury.

Biomarkers in bold are primarily markers of non-specific intestinal injury.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
supplemented formula or placebo				<p>Mean mannitol (SE):</p> <ul style="list-style-type: none"> • Glutamine group: <ul style="list-style-type: none"> • Baseline: 3.42 (0.64) (similar in all three groups) • Day 10: NS decrease in all 3 groups <p>Proportion of stool markers at baseline among all subjects:</p> <ul style="list-style-type: none"> • Lactoferrin: 53.3% • Leukocytes: 11.7% • RS: 3.3% • Occult blood: 5.0% 		breastfed children were excluded from study participation due to assessment of stool lactoferrin.
<p>2001</p> <p>Mishra OP et al.</p> <p>Endoscopic and histopathological evaluation of preschool children with chronic diarrhea</p> <p>Duodenal biopsy among patients with chronic diarrhea</p>	<p>Varanasi, India</p> <p>1-5 yr olds with PD selected randomly from an outpatient population in a urban setting.</p> <p>A high proportion of the children had varying degrees of protein energy malnutrition.</p>	<p>Case-series</p> <p>n=30 with endoscopy performed</p>	<p><u>Endoscopic duodenal biopsy:</u></p> <ul style="list-style-type: none"> • Gross endoscopic visualization • Histopathology 	<p>7 (23.3%) had grossly abnormal endoscopic findings:</p> <ul style="list-style-type: none"> • 5 (16.7%) with chronic duodenitis • 1 with duodenitis with multiple erosions • 1 with duodenitis with hemorrhagic gastritis <p>22 (73.3%) had abnormal histopathology:</p> <ul style="list-style-type: none"> • 1. 17 (56.7%) with villous atrophy with mononuclear cell infiltration • 1 (3.3%) with villous atrophy and eosinophilic infiltration • 2 (6.7%) with villous atrophy and mononuclear and eosinophilic infiltration • 2 (6.7%) with only mononuclear cell infiltration <p>Mean duration of diarrhea (SD) was not associated with gross endoscopic findings but did vary by histopathology:</p> <ul style="list-style-type: none"> • Normal histopathology: 9.0 wk (6.0), n=8 • Mononuclear cell infiltration: 9.0 wk (6.0), n=2 	<p>Grossly abnormal endoscopic appearance was found in one-quarter of children with chronic diarrhea assessed by endoscopy.</p> <p>Three-quarters had abnormal histology. More than half had villous atrophy with mononuclear cell infiltration; these patients had >1 month longer duration of diarrhea than those with either normal histology or mononuclear cell infiltration without villous atrophy.</p> <p>Age, enteropathogen recovery, and degree of malnutrition were not associated with</p>	<p>Authors do not report assessing relationship between gross endoscopic findings and histopathology.</p> <p>Number of patients with villous atrophy and both mononuclear and eosinophilic infiltration was very small (n=2), yet authors report a significant difference in their duration of diarrhea relative to those with normal histopathology.</p>

Evidence Table 7. Markers of non-specific intestinal injury.

Biomarkers in bold are primarily markers of non-specific intestinal injury.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
				<ul style="list-style-type: none"> Villous atrophy with mononuclear cell infiltration: 14.9 wk (5.3), n=17, p<0.02 compared to normal histopathology Villous atrophy with mononuclear and eosinophilic infiltration: 21.5 wk (2.1), n=2, p<0.02 compared to normal histopathology Villous atrophy with eosinophilic infiltration: 6.0 wk, n=1 <p>No consistent pattern was observed between gross endoscopic findings or histopathological lesions and age, WFA, or type of enteropathogen recovered in stools.</p>	gross endoscopic or histopathological findings.	
<p>2001</p> <p>Mittal SK et al.</p> <p>Tropical sprue in north Indian children</p> <p>D-xylose and duodenal biopsy as markers of TS</p>	<p>New Delhi, India</p> <p>0-15 yr old gastroenterology clinic patients with PD.</p> <p>Those with abnormal morphology on biopsy, abnormal D-xylose test, and clinical response to antibiotics were diagnosed as having TS.</p> <p>Those with abnormal morphology and response to gluten-</p>	<p>Case-series</p> <p>n=94; (38 with repeat biopsies)</p> <p><5 yr old: n=44</p>	<p><u>Duodenal biopsy, method not specified:</u></p> <p>Histopathology</p> <p><u>Blood Tests:</u></p> <ul style="list-style-type: none"> Hemoglobin D-xylose* <p>* Not specified whether from urine or serum, and units of measurement not provided.</p>	<p>36 (38.3%) were diagnosed with TS including 14/44 (31.8%) who were under 5 years of age.</p> <p>18 (19.1%) were diagnosed with CD.</p> <p>Degree of villous atrophy among TS vs. CD patients:</p> <ul style="list-style-type: none"> Mild in 8/36 (22.2%) vs. 0 Moderate in 23/36 (63.9%) vs. 4/18 (22.2%) Severe in 5/36 (13.9%) vs. 14/18 (77.8%) <p>Mean hemoglobin concentration (range) among TS patients was 8.3 g/dL (5.5-11) and did not differ from values of those with CD.</p> <p>Among the 22 TS patients,</p>	<p>More than half of the GI clinic patients with PD had some degree of villous atrophy.</p> <p>More than one-third and almost one-fifth of subjects were diagnosed with TS and CD, respectively.</p> <p>By study diagnostic definition, all TS patients improved with treatment. Among those who had repeat biopsies, almost three-quarters showed</p>	<p>Biopsy results were not provided for patients without TS or CD.</p> <p>It was unclear if there were patients with abnormal D-xylose and histology who did not respond to antibiotic therapy and therefore were not diagnosed with TS.</p> <p>Cut-off points used to define abnormal D-xylose tests were not provided.</p>

Evidence Table 7. Markers of non-specific intestinal injury.

Biomarkers in bold are primarily markers of non-specific intestinal injury.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
	free diet were diagnosed with CD. We include data on these subjects for comparative reasons.			repeat biopsies showed: <ul style="list-style-type: none"> • 16 with normalization • 5 with improvement • 1 worsened despite marked clinical improvement <p>The D-xylose test was abnormal in all TS patients by diagnostic definition.</p>	normalization of histology, while 23% had partial improvement and 1 patient had worsened pathology.	
2000 Nichols B et al. Contribution of villous atrophy to reduced intestinal maltase in infants with malnutrition Jejunal biopsy, maltase activity, and enzyme messenger RNAs among malnourished and well-nourished children. Assessed association between maltase and villous atrophy and other mucosal intestinal markers indicative of loss of enterocytes and enterocytic function.	Sao Paulo, Brazil Cases were children (mean age 9.9 mo, SD 8.1) hospitalized with malnutrition refractory to dietary rehabilitation. Controls were children (mean age 3.6 mo, SD 1.0) with HAZ and WAZ scores >-2 and normal intestinal mucosa on biopsy, hospitalized for Kasai procedure for biliary atresia.	Case-control n=33; n=24 cases n=9 controls Subjects were matched on height and weight; ages differed within matched sets.	<u>Jejunal capsule biopsy:</u> <ul style="list-style-type: none"> • Histopathology* • Maltase activity • Intestinal messenger RNA (mRNA) abundances: <ul style="list-style-type: none"> • Maltase-glucoamylase (MGA) • Sucrase-isomaltase (SI) • Villin, a structural protein expressed only in enterocytes • Sodium-activated luminal glucose-galactose transporter 1 (SGLT), a functional protein expressed only in enterocytes • β-actin <p>* Mucosal atrophy was scored on a scale of 1 (absence of atrophy compared to an organ donor) to 4 (similar to children with active CD).</p> <p>Histology among controls was on surgically resected tissue.</p>	Mean villous atrophy score (SD): <ul style="list-style-type: none"> • Cases: 2.6 (0.8) • Controls: 1.2 (0.5), p=0.006 <p>WAZ score was correlated with villous atrophy (r=0.65, p-value not reported).</p> <p>13/25 [sic] cases and 0/5 controls had subnormal (defined as <94 U/g protein) of maltase activity; mean maltase was 34% lower among cases (p=0.11). Maltase activity did not appear to decrease with WAZ score (further details not provided).</p> <p>However, in sub-analyses among those samples with an adequate β-actin, a housekeeping gene message, (n=10 cases, n=9 controls), cases' findings expressed as a mean percent of controls' (SD) included: <ul style="list-style-type: none"> • Villous length (reciprocal of atrophy score): 38.9 (41.6), p=0.004 • Maltase activity: 37.1 (23.2), p=0.001 • MGA mRNA: 45.1 (36.4), p=0.016 • Villin mRNA: 52.5 (22.6), p=0.003 </p>	The malnourished children had significantly greater villous atrophy than the younger controls. Among the subset tested for mRNA messages, maltase activity as well as the mRNA abundances for MGA, villin and SGLT were significantly correlated with case status and were correlated with villous atrophy. While maltase deficiency has been reported in malnutrition in other studies, authors assert that these are the first results that directly support the hypothesis that reductions in maltase activity are due to villous atrophy. This study	Tissue from patients requiring intestinal resection as part of their biliary atresia management provides an opportunity to assess presumably "normal" intestinal architecture. However, unless they mocked up <i>ex vivo</i> mucosal biopsies in these controls, resections will have lower proportions of villous to submucosa tissue compared to cases' biopsies. While this probably doesn't affect histology, it might affect enterocyte functional assays and mRNA determination, as transmural tissue will bring in more diverse populations

Evidence Table 7. Markers of non-specific intestinal injury.

Biomarkers in bold are primarily markers of non-specific intestinal injury.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
				<ul style="list-style-type: none"> • SGLT mRNA: 66.6 (23.1), p=0.057 • β-actin: 88.2 (15.8), p=0.189 <p>Both villous length and maltase activity in a subset of cases were less than 40% of control values.</p> <p>MGA, villin, and SGLT mRNA abundances were correlated with villous atrophy score (r=0.73), (r=0.76), and (r=0.54), respectively (p-values not reported)¹.</p> <p>MGA mRNA abundance was correlated with maltase activity (r=0.32).</p>	<p>also nicely correlates mRNA relative abundance with function.</p>	<p>of cells; only some of them might have transcripts of interest. However, the bias is likely in a direction that would reduce effect size.</p> <p>It was unclear if control inclusion criteria included absence of atrophy or if all potential controls lacked atrophy.</p> <p>Statistical methods might not have adequately taken into account the small sample size and matching scheme.</p> <p>Subsets of subjects were investigated for various tests. For example, 10 cases had mRNA analyses based on β-actin adequacy. Another instance of selected testing was the subset of 22 and 15 cases that had WAZ score to histology and mRNA correlation analyses,</p>

¹ Villin and SGLT1 were assessed as a ratio with housekeeper gene β -actin.

Evidence Table 7. Markers of non-specific intestinal injury.

Biomarkers in bold are primarily markers of non-specific intestinal injury.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
						respectively. Rationale for subset selection was not thoroughly described.
<p>2003</p> <p>Pires AL et al.</p> <p>Digital morphometric and stereologic analysis of small intestinal mucosa in well-nourished and malnourished children with persistent diarrhea</p> <p>Computerized morphometric and stereologic assessments in proximal small intestine biopsy in subjects with PD</p>	<p>Porto Alegre, Brazil</p> <p>6 mo-5 yr old inpatients from an urban setting who underwent biopsy as part of a work-up for PD.</p> <p>There was a high proportion of children with malnutrition in this study population.</p>	<p>Cross-sectional, retrospective</p> <p>n=65</p>	<p><u>Small intestinal biopsies, site and method not specified*</u>:</p> <ul style="list-style-type: none"> • Mucosal morphometric assessment by computer analysis (62 tested): <ul style="list-style-type: none"> • Villous height • Crypt depth • Villous:crypt ratio • Mucosal thickness • Digital assessment (500x magnification) (65 tested): <ul style="list-style-type: none"> • Enterocyte height • Enterocyte nucleus height • Brush border height • Stereological analysis to assess mucosal surface area (62 tested) <p>* From stored specimens previously assessed by micrometer.</p>	<p>Computerized mucosal measures were similar to those by micrometer and were not associated with nutritional status.</p> <p>Digitally assessed enterocyte height, enterocyte brush border, and enterocyte nucleus height correlations:</p> <ul style="list-style-type: none"> • WAZ score: r=0.25 (p=0.038), r=0.26 (p=0.03), and r=0.24, (p=0.05), respectively • WHZ score: r=0.29 (p=0.02), r=0.27 (p=0.03), and r=0.16 (p=0.19), respectively • HAZ score: r=0.16 (0.18), r=0.23 (p=0.06), r=0.23 (0.06) <p>There was no correlation between mucosal surface area and growth parameters.</p>	<p>Enterocyte measures show some correlation with WAZ and WHZ scores, but not with HAZ score. However, surface area and villous:crypt ratios were not correlated with any growth parameter.</p>	
<p>2008</p> <p>Poddar U et al.</p> <p>Is tissue transglutaminase autoantibody the best for diagnosing celiac disease in children of developing countries</p>	<p>Chandigarh, India</p> <p><14 yr (mean age 6.9 yr) presenting with symptoms consistent with CD (PD, FTT, and/or pallor)</p> <p>Subjects negative for CD were of interest for this</p>	<p>Case-control</p> <p>n=28 controls;</p> <ul style="list-style-type: none"> • 22 with giardiasis • 1 with TS • 5 with SBBO 	<p><u>Endoscopic duodenal biopsy:</u></p> <p>Histopathology</p>	<p>Duodenal biopsy of those with giardiasis showed nonspecific chronic inflammation of lamina propria; there was no evidence of villous atrophy.</p>	<p>Duodenal biopsy demonstrated histological changes accompanying <i>Giardia</i> infection.</p>	<p>Authors did not report the biopsy findings in the TS or SBBO patients.</p>

Evidence Table 7. Markers of non-specific intestinal injury.

Biomarkers in bold are primarily markers of non-specific intestinal injury.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
Duodenal biopsies in controls with giardiasis, TS, and SBBO	review.					
2002 Poddar U et al. Celiac disease in India: Are they true cases of celiac disease Duodenal biopsy, D-xylose, and fecal fat in children with symptoms of CD but normal mucosal biopsy results	Chandigarh, India 18 mo-14 yr olds with PD, FTT, or pallor from a hospital pediatric gastroenterology unit. Subjects with normal crypt:villous ratio on biopsy were of interest for this review.	Case-control n=47	<u>Endoscopic duodenal biopsy:</u> Histopathology <u>Stool Tests:</u> • Fecal fat* • D-xylose** * In 72-hour stool collection. ** Not specified whether from urine or serum, and units of measurement not provided.	38% had chronic inflammatory cell infiltrates in the lamina propria. 55% had abnormal D-xylose concentrations. 20% had abnormal fecal fat test. No results beyond proportion positive were reported for any of the above markers.	Among controls with normal mucosal architecture by biopsy, more than one-third had PD. D-xylose and fecal fat might not correlate well with duodenal biopsy results.	Relationships between fecal fat, D-xylose and biopsy results were not reported. While 38% of controls had PD, results for the markers studied were not stratified by PD for this group. Seven children with biopsies consistent with CD did not respond to gluten-free diet and were excluded from the study. Cut-off points used to define abnormal D-xylose tests were not provided.
2008 Sherwani K et al. Prevalence of iron deficiency anemia in chronic diarrhoea and celiac disease - A western UP experience Duodenal biopsy in	Aligarh, India 1-12 yr olds (mean age 51.2 mo) from an urban setting with PD recruited from pediatric outpatient and inpatient units. Those with negative CD work-up were	Cross-sectional n=19	<u>Duodenal biopsy, method not specified:</u> Histopathology	Six patients had partial villous atrophy and non-specific duodenitis by biopsy.	Biopsy identified abnormal histopathology in approximately 1/3 of patients who did not have CD, but did not identify PD etiology in the remainder who did not have CD.	The 6 children with partial villous atrophy were thought to have SBBO as they recovered after treatment with broad spectrum antibiotics.

Evidence Table 7. Markers of non-specific intestinal injury.

Biomarkers in bold are primarily markers of non-specific intestinal injury.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
patients with PD	subjects of interest for this review.					
2003 Tassara O et al. Gastrointestinal diseases in children infected with the human immunodeficiency virus Endoscopy and biopsy among HIV-infected children	Santiago, Chile 0-12 yr old (median 9 mo) HIV-infected children treated in hospital. A high proportion had PD.	Cross-sectional n=11	<u>Endoscopic upper GI biopsy</u> including esophagus, stomach, and/or duodenum: • Gross endoscopic visualization • Histopathology	Macroscopic inflammatory changes were observed on endoscopy in the esophagus, stomach or duodenum in 2 subjects. Biopsies of esophagus, stomach or duodenum showed inflammatory changes of varying degree in all 11 subjects.	Biopsy results might show inflammatory damage in cases with no macroscopic damage visible.	Spanish language article. Inflammatory changes identified in the digestive system were not specified by site (i.e. esophagus, stomach or duodenum). Results were not stratified by presenting symptoms, including PD.

Notes: Some studies included subjects ≥ 5 yr of age. Where these studies provided data separately for children < 5 yr, we present results for only those subjects. Where these studies did not stratify results by age, but did report the number of children < 5 yr included in the study, we provide a breakdown of under-5s. All studies reporting lactulose: rhamnose ratio results presented values multiplied by a factor of 100 for ease of reporting.

Abbreviations: AD=acute diarrhea, ALT=alanine aminotransferase, AST=aspartate aminotransferase, CBC=complete blood count, CD=celiac disease, CI=95% confidence interval, Cr=creatinine, Δ =change in, EED=environmental enteric dysfunction, FTT=failure to thrive, GI=gastrointestinal, HAZ=height-for-age Z-(score), HDL=high density lipoproteins, HIV=human immunodeficiency virus, HLA=human leukocyte antigen, IEL=intraepithelial lymphocytes, IgA=immunoglobulin A, IgE=immunoglobulin E, IgG=immunoglobulin G, IgM=immunoglobulin M, IL=interleukin, IFN=interferon, LDL=low density lipoproteins, L:M=lactulose:mannitol ratio, mo=month(s), NS=not statistically significant, PD=persistent diarrhea, RCT=randomized controlled trial, SBBO=small bowel bacterial overgrowth, SD=standard deviation, SE=standard error, SES=socioeconomic status, Tc-99m=technetium 99, T3=triiodothyronine, T4=thyroxine, TE=tropical enteropathy, TGF=transforming growth factor, TNF=tumor necrosis factor, TS=tropical sprue, WAZ=weight-for-age Z-(score), WBC=white blood cell count, WFA=weight-for-age, WHZ=weight-for-height Z-(score), wk=week(s), yr=year(s)

Our findings indicate a profound lack of enteric histologic data on pediatric populations in resource-limited settings. Specifically, only 18 of the 77 studies that we reviewed contained any biopsy materials, and only three of these 18 publications also included any non-intestinal tissue candidate biomarkers [111, 136, 155]. Furthermore, only two [111, 136] of these three studies attempted to statistically relate the less invasive, non-intestinal markers to histologic findings; the only significant association reported was between L:M and intestinal tissue inflammation on histopathology. Moreover, only 718 subjects aged 0-18 years were represented among the 18 biopsy studies. Ages were mixed in many studies, such that it was impossible to discern which subjects were in the age range of maximal interest in this review (i.e., under five years of age), and indications for the biopsies were quite diffuse (e.g., diarrhea, poorly specified abdominal symptoms). Therefore, the subject population and data availability were suboptimal for the purposes of this review. In addition, none of the studies that included biopsies related the findings to the outcome of most considerable interest, i.e., stunting.

Prospectively collected small bowel biopsies may provide useful data, guide biomarker development and validation, and reveal information about the cause(s) and pathophysiology of EED. Appropriate conditions are necessary for biopsy studies to be illuminating. For example, the context in which subjects and controls are selected is vital. Regarding cases, a rigorous clinical case definition must be established that defines growth faltering and minimal extent of intestinal functional abnormalities. Exclusion criteria should also be established for disorders that might mimic EED, such as celiac disease or inflammatory bowel disease. The pathology associated with these disorders, however, could inform biomarker association with intestinal dysfunction not specific to, but nevertheless relevant to and sensitive for EED. Such markers could be part of a set of markers used to diagnose EED. However, the usefulness of a biopsy to guide biomarker development and validation depends on several factors. Ideally, the lesion should be from treatment-naïve hosts; this does bring up an ethical dilemma, however. For

example, placement of a patient on gluten free diet, even briefly, or treating a patient with possible inflammatory bowel disease, prior to biopsies can obscure findings and render the histopathologic evaluation less valuable. Second, biopsies obtained under protocol must take into account the distribution of the lesion, so as to confirm the negative predictive value of any set of biopsies. Two disorders provide some guidance in this realm. For celiac disease, the lesion is surprisingly non-uniform [276-279], and multiple biopsies must be sought to avoid beta error. A similar situation applies to gastric biopsies for *Helicobacter pylori* detection [280-286]. A comparison group is also necessary, and to date, most “normal” or “control” tissues were from children in developed country settings. Hence, the abnormalities noted in children’s biopsies cannot be attributed to the disease process (enteropathy), or its consequences (stunting, most particularly), rather than to residence in an area in which such disorders are common. In other words, biopsy association with disease is, based on the available literature, no more strong than EED association with geography.

A case could be made that biopsies are part of a routine evaluation of a child with failure to thrive, and a recent publication from North America suggests that this diagnostic modality is commonly employed in the evaluation of stunting disorders [287]. However, the precise diagnostic yield of a biopsy is not stated in this publication, nor are the data weighted by the symptoms or the age of the children. At this time, it remains uncertain how generalizable the utility of these recommendations is in settings where EED is common.

The safety of a biopsy also needs to be considered in pondering the value of tissue assessment, or of biomarker discovery or validation. If a biopsy is obtained as part of an evaluation of poor growth, then the small risk of the biopsy usually is less than the potential benefit. However, this calculus assumes that substantial pre-procedure and post-procedure care is available to mitigate the likelihood of complications. The use of anesthesia in inpatient or

outpatient settings is safe, but should conform to the highest grade of safety [288]. An additional concern is that endoscopy of the duodenum carries a risk of causing intramural hematomas, estimated at 0.08% of upper endoscopic procedures in the United States [289, 290]. This complication results in small bowel obstruction, severe pain, and Ampulla of Vater obstruction and requires management involving prolonged hospitalization and total parenteral nutrition and/or or naso-enteral feeds. Coagulopathies such as von Willebrand Disease, other platelet disorders, and vitamin K deficiency (the risk of which is increased in chronic diarrhea and malabsorption) [291, 292] are thought to contribute to approximately half of endoscopy-related duodenal hematomas [289, 290, 293-307]. Among von Willebrand Disease variants, only severe (type 3) disease can be readily identified by available screening tests (prothrombin time) although such assessments can be used to pre-endoscopically identify treatment-responsive vitamin D deficiency.

If biopsies are obtained as part of a research protocol to identify markers that predict clinically consequential EED (and even if biopsies are only used for clinical care), it is necessary to assemble a panel of individuals whose tissues are evaluated in parallel, but who do not have the most consequential of the complications of putative enteropathy, namely, stunting (assuming this remains the outcome of greatest concern). It would not be possible to recruit healthy control children for biopsies, because the procedure would offer limited benefit—especially in relation to potential harm. However, some surrogate controls might arise as adventitiously obtained tissue becomes available either during operations or other endoscopic procedures, and the use of small bowel obtained at time of portoenterostomy is a particularly inspired choice [53].

Caveats must be attached to any histologic assessment of the guts in children being evaluated for enteropathy as part of a care plan. It is very unlikely that intestinal biopsies would

be used as a diagnostic procedure at the beginning of an evaluation for malnutrition or poor growth. More likely, it would be a procedure of last resort, after less invasive evaluation failed to establish an etiology, and after attempts at nutritional and intestinal rehabilitation are undertaken and prove unsuccessful. However, as noted above, the empiric treatment of consequential intestinal dysfunction might change the pathology, and thereby diminish the diagnostic value of the procedure. Also, if biopsies are obtained, and subjected to analysis, it is critical that the materials be handled in a systematic manner, and processed per protocol, so as to maximize the data that they generate.

In summary, there is no evidence to date that biopsies have been used to define the entity of childhood EED, because inadequate controls have been studied (children without evidence of functional impairment of gut function living in the same environment). There is no evidence that the biopsies relate to the outcome of greatest concern, namely, stunting. The data obtained from biopsies could be falsely normal, because of attempts at intestinal rehabilitation that will presumably precede the endoscopy. This negative assessment does not mean that biopsies are without worth, only that their value as providing case-defining information, or guiding biomarker discovery or validation, has yet to be made. However, if biopsies are obtained, it is critical that they be performed in a rigorous, disciplined and ethical manner, and that the data to be obtained are maximized.

5.9 Markers of Extra-Small Intestinal Function

We included markers of non-small intestinal organ function as these might provide important indirect assessments of precursors to or resultants of small intestinal injury. We reviewed those markers that were examined among children with presentations potentially consistent with enteropathy, such as persistent diarrhea, or were examined in relationship to

markers of intestinal inflammation or dysfunction. The data relevant to this review are listed for each of these studies in Evidence Table 8.

Evidence Table 8. Markers of extra-small intestinal function.

Biomarkers in bold are primarily markers of extra-small-intestinal function.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
<p>2010</p> <p>Bukhari AS et al.</p> <p>DNA damage and plasma homocysteine concentrations are associated with serum metabolites and mineral constituents' profiles in children with persistent diarrhea</p> <p>Serum proteins, metabolites, and levels of DNA damage among children with and without PD</p>	<p>Faisalabad, Pakistan</p> <p>3-6 yr olds admitted to hospital with PD and healthy controls.</p>	<p>Case-control</p> <p>n=72;</p> <p>n=36 cases with PD</p> <p>n=36 healthy controls</p>	<p><u>Blood Tests:</u></p> <p>Serum proteins and metabolites:</p> <ul style="list-style-type: none"> • Albumin • Globulin • Homocysteine • Total protein • Total cholesterol, HDL, LDL, triglycerides • AST, ALT • T3, T4 • Total oxidant status (TOS), Total anti-oxidant status (TAS), and thiobarbituric reactive substances (TBARS) <p>DNA damage to lymphocytes</p>	<p>Mean values significantly higher among PD cases than in healthy controls:</p> <ul style="list-style-type: none"> • LDL • Homocysteine • TOS • TBARS • DNA damage <p>Mean values significantly lower among PD cases than in healthy controls:</p> <ul style="list-style-type: none"> • Total protein • T4 • TAS 	<p>Multiple serum markers were associated with PD, especially DNA damage to lymphocytes (p=0.0001).</p> <p>The authors speculate that zinc deficiency, more commonly found in the children with PD, might be responsible for increased homocysteine concentrations and play an important role in mediating DNA damage.</p>	<p>Control recruitment strategy was not well described.</p> <p>TOS, TBARS and TAS were incompletely defined.</p> <p>Some values differed by gender in both the case and control groups:</p> <ul style="list-style-type: none"> • Triglycerides • Total cholesterol • HDL • T3 <p>Multiple markers studied; analyses did not appear to address potential confounding.</p>
<p>2000</p> <p>Fagundes-Neto U et al.</p> <p>Studies of the small bowel surface by scanning electron microscopy in infants with persistent diarrhea</p> <p>Scanning electron microscope (SEM) and light microscope (LM) analyses of small intestinal biopsy among infants with PD with and without SBBO</p>	<p>Sao Paulo, Brazil</p> <p>2-10 mo olds with PD and protein calorie malnutrition consecutively admitted to Sao Paulo Hospital.</p>	<p>Case-series</p> <p>n=16</p>	<p><u>Jejunal secretions aspirate:</u></p> <p>Bacterial concentrations</p> <p><u>Jejunal tethered capsule biopsy:</u></p> <p>Histopathology by LM and SEM</p> <p><u>Rectal tethered capsule biopsy:</u></p> <p>Histopathology</p>	<p>68.7% had bacterial overgrowth (concentration >10⁴ colonies/mL): 3 had enteropathogenic <i>E. coli</i> while the rest had colonic microflora.</p> <p>All small intestine specimens had morphological abnormalities on LM:</p> <ul style="list-style-type: none"> • 43.7% moderate villous atrophy • 56.3% subtotal villous atrophy <p>SEM revealed abnormalities of varying intensity:</p> <ul style="list-style-type: none"> • Among the 11 with SBBO, villous atrophy ranged from Grade II (n=4), Grade III (n=2), to Grade IV (n=3). • For the 5 subjects without SBBO, villous atrophy ranged from Grade I (n=1) to Grade 2 (n=4). • A mucous-fibrinoid pseudo- 	<p>Histological abnormalities were noted in all subjects by LM and SEM.</p> <p>Degree of villous atrophy noted on SEM seemed to be correlated with SBBO (no statistical tests were reported).</p> <p>Authors speculate that the mucous-fibrinoid pseudo-membrane partially covering enterocytes is consistent with a malabsorptive</p>	<p>Inconsistent reporting of proportions of histopathologic findings among all subjects and by SBBO status; assessment of potential relationship with SBBO between different histologic findings was not possible.</p>

Evidence Table 8. Markers of extra-small intestinal function.

Biomarkers in bold are primarily markers of extra-small-intestinal function.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
				<p>membrane over enterocytes was noted in 7 of the 11 with SBBO and none of the others.</p> <p>Other abnormalities noted on SEM included:</p> <ul style="list-style-type: none"> • Mucus and debris covered large areas of the villous surface • Derangement of the enterocytes (in some cases cell borders were not clearly defined) • Reduced height and number (or absence in some places) of microvilli • Lymphocytes and fat droplets were observed over the surface of enterocytes (18%)¹ <p>10 subjects had colitis on rectal biopsy; this was not associated with SBBO or degree of small intestinal pathology on SEM.</p>	<p>process, with the findings of fat droplets on enterocytes surfaces, and with the state of malnutrition of the subjects.</p>	
<p>2005</p> <p>Galpin L et al.</p> <p>Effect of <i>Lactobacillus</i> GG on intestinal integrity in Malawian children at risk of tropical enteropathy</p> <p>L:M and sucrose: lactulose ratio (SUC:L) as markers of intestinal and gastric permeability, respectively, in</p>	<p>Mwenye, Malawi</p> <p>36-60 mo olds recruited from a rural community, excluding children with severe acute malnutrition or severe chronic illnesses.</p> <p>Subjects were considered at risk for EED due to residence in a location with high prevalence of EED.</p>	<p>RCT</p> <p>n=164;</p> <p>n=81 received <i>Lactobacillus</i> GG (80 completed the study)</p> <p>n=83 received placebo (81 completed the study)</p> <p>Subjects received 30-days of</p>	<p>Urine Tests:</p> <ul style="list-style-type: none"> • Lactulose² • Mannitol • Sucrose (SUC) • L:M • SUC:L 	<p>At enrollment:</p> <ul style="list-style-type: none"> • 73% had L:M >0.10 • 40% had L:M >0.20 • Mean³ L:M (SD): <ul style="list-style-type: none"> • Treatment: 0.18 (0.16) • Placebo: 0.22 (0.20) • Mean lactulose (SD) in treatment group: 0.25 (0.17) • Mean mannitol (SD) in treatment group: 8.0 (4.5) • Mean SUC:L (SD): <ul style="list-style-type: none"> • Treatment: 0.58 (0.64) • Placebo: 0.60 (0.64) <p>Mean excretion of sucrose (SD) increased from 0.057 (0.042) to 0.078 (0.058) in the treatment group</p>	<p>A high baseline prevalence of abnormal L:M was observed, with no change after intervention.</p> <p>High mannitol excretion (relative to UK norms) drove the abnormal L:M.</p> <p>There was little effect on SUC:L with intervention; sucrose excretion increased in both</p>	<p>Difficult to interpret sucrose tests because there are limited data on laboratory values for these tests in young children.</p>

¹ These SEM results were not presented separately for those with and without SBBO.

² Lactulose, mannitol, and sucrose results were expressed as % of dose administered.

³ Arithmetic mean.

Evidence Table 8. Markers of extra-small intestinal function.

Biomarkers in bold are primarily markers of extra-small-intestinal function.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
asymptomatic children presumed at risk of EED	Presumed that if SBBO is etiology for EED, treatment with <i>Lactobacillus</i> will result in improved gut integrity.	<i>Lactobacillus</i> GG or placebo. Only the 161 subjects who completed the study had repeat testing.		(p=0.01), but similar results were observed in the placebo group. Otherwise there were no changes in lactulose, mannitol, L:M, or SUC:L after treatment or placebo.	treatment and control groups.	
2006 Leite CA et al. Functional, microbiological and morphological intestinal findings among human immunodeficiency virus infected children Small intestinal and rectal biopsy to assess morphology and D-xylose as a marker of malabsorption among HIV-infected children	Sao Paulo, Brazil 5 mo-12 yr old (median 24 mo) HIV-infected subjects recruited from a hospital and clinic. All subjects had some degree of protein-energy malnutrition.	Cohort n=11; n=5 patients with current or recent episode of diarrhea n=6 patients with no diarrhea in the 30 days preceding enrollment	<u>Blood Test:</u> D-xylose (9 tested) <u>Biopsy of small intestine by tethered capsule or endoscopy:</u> Histopathology (10 tested) <u>Rectal biopsy:</u> Histopathology (6 tested)	100% had low D-xylose absorption: • Mean: 15.6 mg/dL • SD: 5 • Range: 8.9-24.4 • Median: 14.2 Small intestinal biopsy: • 100% had some degree of villous atrophy based on a I-IV grading system: • Grade I: 3 • Grade I/II: 2 • Grade II: 1 • Grade II/III: 1 • Grade III/IV: 1 • 2 samples were too superficial to assess • Intraepithelial lymphocytes were increased in half of the biopsies. • Lymphocytic and polymorphonuclear (PMN) infiltration of the lamina propria were present in 10/10 and 7/10 biopsies, respectively. Rectal biopsy: • 100% had normal architecture Lymphocytic and PMN infiltration were present in 6/6 and 4/6, respectively.	There was a high prevalence (100%) of abnormal D-xylose results among HIV-infected children, regardless of diarrhea status. All patients also had cellular infiltration of the lamina propria and varying degrees of villous atrophy. There was no correlation between D-xylose and degree of villous atrophy on biopsy.	Portuguese language article. D-xylose <25 mg/dL was defined as indicative of malabsorption. This value is higher than what some references have noted as a cut-point [186]. Investigators used a well-articulated system of grading villous atrophy. Results were not presented by diarrhea status, perhaps due to small sample size.
2003 Tassara O et al. Gastrointestinal diseases in children infected with the	Santiago, Chile 0-12 yr old (median 9 mo) HIV-infected children treated in hospital. A high proportion had PD.	Cross-sectional n=11	<u>Endoscopic upper GI biopsy</u> including esophagus, stomach, and/or duodenum: • Gross endoscopic visualization	Macroscopic inflammatory changes were observed on endoscopy in the esophagus, stomach or duodenum in 2 subjects. Biopsies of esophagus, stomach or duodenum showed inflammatory	Biopsy results might show inflammatory damage in cases with no macroscopic damage visible.	Spanish language article. Inflammatory changes identified in the digestive system were not

Evidence Table 8. Markers of extra-small intestinal function.

Biomarkers in bold are primarily markers of extra-small-intestinal function.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
human immunodeficiency virus Endoscopy and biopsy among HIV-infected children			• Histopathology	changes of varying degree in all 11 subjects.		specified by site (i.e. esophagus, stomach or duodenum). Results were not stratified by presenting symptoms, including PD.
2009 Trehan I et al. A randomized, double-blind, placebo-controlled trial of rifaximin, a nonabsorbable antibiotic, in the treatment of tropical enteropathy L:M, sucrose:lactulose, and sucralose:lactulose as markers of small intestinal, gastric, and colonic permeability, respectively, among those receiving rifaximin or placebo	Limela, Malawi All 3-5 yr olds from the village were recruited.	RCT n=144; n=72 received rifaximin for 7 days n=72 received placebo It was presumed that if SBBO is the etiology for enteropathy, treatment with rifaximin would result in improved intestinal integrity.	<u>Urine Tests</u> • Lactulose ¹ • Mannitol • Sucrose (SUC) • Sucralose (SCL) • L:M • Sucrose:lactulose ratio (SUC:L) • Sucralose:lactulose ratio (SCL:L) Subjects were tested before and after treatment.	At enrollment: • Mean mannitol (SD): • Treatment: 9.57 (5.24) • Placebo: 10.29 (6.62) • Mean lactulose (SD): • Treatment: 0.30 (0.18) • Placebo: 0.34 (0.25) • Mean SUC (SD): • Treatment: 0.062 (0.04) • Placebo: 0.074 (0.058) • Mean SCL (SD): • Treatment: 0.51 (0.29) • Placebo: 0.58 (0.53) • Mean L:M (SD): • Treatment: 0.18 (0.12) • Placebo: 0.17 (0.09) • Mean SUC:L (SD): • Treatment: 0.50 (0.34) • Placebo: 0.64 (0.90) • Mean SCL:L (SD): • Treatment: 0.42 (0.32) • Placebo: 0.39 (0.23) • For both groups combined: • 76% had L:M >0.10 • 34% had L:M >0.20 No significant post- intervention differences were observed in any fractional sugar excretion or dual sugar test, including among children	There was a high proportion with elevated L:M which did not change with rifaximin treatment. Baseline L:M measurements in this study resembled those of another Malawian population in similar environmental conditions [120]. SCL excretion in this population was similar to that found in healthy American children (0.4%), while SCL:L was comparatively lower (0.8) and driven by lactulose [210]. SCL:L might be a better marker of colonic permeability [211-213]. Results from this study potentially indicate that colonic	Methodological differences in specimen collection and testing, in particular for SCL excretion, might account for some differences in values compared to other studies. This was the first use of SCL for site-specific absorption testing in a developing country setting.

¹ Lactulose, mannitol, SUC, and SCL results were expressed as % of dose administered.

Evidence Table 8. Markers of extra-small intestinal function.

Biomarkers in bold are primarily markers of extra-small-intestinal function.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
				with elevated pre-intervention L:M.	permeability was normal. Few data exist on SUC excretion. Results in this trial are similar to those found in another Malawian population (0.06% SUC excretion) [120] and high compared to healthy older children from developed country settings (0.02-0.03%) [210, 212].	

Notes: Some studies included subjects ≥ 5 yr of age. Where these studies provided data separately for children < 5 yr, we present results for only those subjects. Where these studies did not stratify results by age, but did report the number of children < 5 yr included in the study, we provide a breakdown of under-5s. All studies reporting lactulose:rhamnose ratio results presented values multiplied by a factor of 100 for ease of reporting.

Abbreviations: AD=acute diarrhea, ALT=alanine aminotransferase, AST=aspartate aminotransferase, CBC=complete blood count, CD=celiac disease, CI=95% confidence interval, Cr=creatinine, Δ =change in, EED=environmental enteric dysfunction, FTT=failure to thrive, GI=gastrointestinal, HAZ=height-for-age Z-(score), HDL=high density lipoproteins, HIV=human immunodeficiency virus, HLA=human leukocyte antigen, IEL=intraepithelial lymphocytes, IgA=immunoglobulin A, IgE=immunoglobulin E, IgG=immunoglobulin G, IgM=immunoglobulin M, IL=interleukin, IFN=interferon, LDL=low density lipoproteins, L:M=lactulose:mannitol ratio, mo=month(s), NS=not statistically significant, PD=persistent diarrhea, RCT=randomized controlled trial, SBBO=small bowel bacterial overgrowth, SD=standard deviation, SE=standard error, SES=socioeconomic status, Tc-99m=technetium 99, T3=triiodothyronine, T4=thyroxine, TE=tropical enteropathy, TGF=transforming growth factor, TNF=tumor necrosis factor, TS=tropical sprue, WAZ=weight-for-age Z-(score), WBC=white blood cell count, WFA=weight-for-age, WHZ=weight-for-height Z-(score), wk=week(s), yr=year(s)

One study assessed markers of liver and thyroid function among hospitalized persistent diarrhea cases and healthy controls [107]. These authors found that thyroid hormones were significantly lower in children with diarrhea than in controls. Liver tests showed associations in conflicting directions.

The remaining five studies examined tests related to segments of the gastrointestinal tract outside of the small bowel [13, 118, 120, 136, 167]. Three of these performed endoscopy and/or biopsy on the esophagus, stomach, and/or rectum [118, 136, 167]. In a study of 11 HIV-infected malnourished children rectal biopsy tissue uniformly demonstrated normal architecture, but increased lymphocytic and neutrophilic infiltration. Duodenal biopsies were also infiltrated with these cells but all subjects had additionally some degree of abnormal architecture [136]. Another case series found macroscopic inflammatory changes in 18% of endoscopies and 100% of biopsies of the upper gastrointestinal tract in eight children with HIV infection, many of whom had persistent diarrhea [167]. However, the investigators did not report whether these findings were identified in the esophagus, stomach and/or duodenum. A third study in this category found that nearly two-thirds of subjects had evidence of colitis based on rectal biopsy; this was not associated with small bowel bacterial overgrowth or degree of small intestinal pathology observed by scanning electron microscope [118].

Tests of small intestinal permeability have been described in a previous section (5.3), but certain dual-sugar permeability tests are more specific for evaluating colonic or gastric function. These markers include urinary sucrose, urinary sucralose, the urinary sucrose:lactulose ratio (SUC:L), and the urinary sucralose:lactulose ratio (SCL:L). Sucrose excretion and sucrose:lactulose (SUC:L) were components of a panel of urinary excretion tests that comprised the clinical endpoints as measures of gastric permeability for two community-based intervention studies, one of which additionally tested sucralose excretion and sucralose:lactulose (SCL:L) as measures of colonic permeability. The first of these studies was

a randomized, controlled trial of *Lactobacillus* GG [120]. The mean excretion of sucrose increased in the treatment group following treatment, but similar results were observed in the placebo group. Following the intervention, there was no change in the mean SUC:L in either group. The second of these studies was a randomized, controlled trial that assessed L:M, SUC:L, and SCL:L responses to treatment with rifaximin, a nonabsorbable antibiotic. The investigators hypothesized that if small bowel bacterial overgrowth played an etiologic role in enteropathy, treatment with the antibiotic would result in improvements in measurements of permeability [13]. Sucralose excretion in this population was similar to that found in healthy American children while SCL:L was comparatively lower and driven by lactulose [210]. These results were similar to those found in another Malawian population [120] in where excretion values were 2-3 fold greater than those excreted by healthy older children from developed countries [210, 212]. No significant post-intervention differences were observed for any of these markers. The authors asserted that this was the first use of sucralose for site-specific absorption testing in a developing country setting. Few data exist on sucrose excretion, but overall values for sucrose excretion were similar across the two studies.

5.10 Relationships between Markers of EED, Including Histopathology

Biomarkers provide, by definition, “read-outs” or values that are related to one or more host processes. Here we review inter-marker relationships, independent of host outcomes (which are reviewed below).

Only four studies included assessments of “noninvasive” biomarkers (i.e., those not requiring the introduction of an endoscope or tube into the small bowel (e.g., for visualization, to obtain duodenal fluid or biopsy tissue) as well as intestinal histopathology [111, 136, 155]; only two of these studies compared histopathology to less invasive markers. Leite et al. assessed

the relationship of D-xylose and the degree of villous blunting and found no association [136]. Campbell et al. found that L:M was associated with various findings on scanning electronic microscopy (SEM) and was correlated with mucosal B lymphocyte density, intraepithelial lymphocyte (IEL) density, and the presence of perforin-positive IELs [111].

An additional three studies compared endoscopic visualization or markers in intestinal tissue obtained by biopsy to standard light microscopic histopathology [53, 118, 126]. Neither endoscopic [126] nor SEM [118] findings were associated with histopathology on light microscopy. However, intestinal maltase activity, as well as intestinal mRNA abundances for maltase-glucoamylase and the enterocyte-specific proteins villin and sodium-activated luminal glucose-galactose transporter 1, were correlated with villous atrophy [53].

Twelve studies [15, 43, 58, 110, 123-125, 132, 149, 151, 158, 159] compared 15 different non-intestinal tissue markers to each other. Four of these studies assessed serum L:R to other markers and found relationships with sucrose breath values [159], serum lactose [58], urinary nitrites [43], and urinary L:R [125], but did not demonstrate associations with stool reducing substances [58] or serum red blood cell markers [58]. Three other studies assessed urinary L:M to other markers and found no associations with fecal neopterin [15], urinary lactose or lactose:lactulose [124], or a variety of systemic immune/inflammatory markers including AGP, total IgG, albumin, and hemoglobin [123]. However, one additional study did find that L:M was associated with not only total serum IgM and IgA levels, but also IgG [110]. This study also found a correlation between L:M values and IgG endotoxin core antibody concentrations, and additionally found urinary lactulose excretion to correlate with circulating IgG endotoxin core antibody and endotoxin concentrations. Other studies found that urinary lactose:creatinine was inversely related to hemoglobin [151] and that fecal lactoferrin was related to TNF- α receptor I [132]. Others found no relationship between urinary nitrite and stool reducing substances [43] or between sucrose breath test and hemoglobin or C-reactive protein [159].

5.11 Relationships between EED Biomarkers and Growth or Other Outcomes of Interest

We sought to find biomarkers of processes relevant to consequential outcomes in the host. In the context of EED, the outcome of greatest proximate interest is growth failure, specifically linear growth failure, but other potential injuries (e.g., persistent diarrhea) and distal consequences (e.g., delayed cognitive development) were also considered.

Eight studies attempted to associate various markers with persistent diarrhea, six of which found such an association. In five of the six studies, these were systemic markers such as serum proteins or indices of serum white or red blood cells [106, 107, 142, 166, 308]. A sixth study found that concentrations of immunoglobulin in duodenal aspirates were associated with persistent diarrhea among children infected with *Giardia* [128]. A study of mannose-binding lectin (MBL) found that while a deficiency of the marker was associated with cryptosporidiosis, MBL concentrations were not significantly associated with either duration of diarrhea or persistent diarrhea [130]. While the eighth study did assess for hemoglobin association with persistent diarrhea, it was not clear from the reporting of their multivariate results if there was an association [114].

Fourteen studies [101, 103, 111, 113, 117, 121, 126, 131-133, 138, 154, 155, 167] included subjects with and without persistent diarrhea but did not statistically assess relationships between markers and this outcome, although five of these studies [101, 103, 117, 126, 155] did present data stratified by the outcome of persistent diarrhea.

While acute diarrhea is not a cardinal EED symptom, we included it as an outcome of interest when looking at studies that sought its association with biomarkers of enteric dysfunction. Our rationale was that intestinal damage or pathophysiology resulting from acute enteric processes might still provide meaningful insights into the utility of various markers in

representing pathologic gut processes. Eight studies [43, 58, 116, 124, 125, 159, 166, 308] investigated the relationship between markers and acute diarrhea. It should be noted that some of these studies included children with persistent diarrhea, but did not stratify results according to acute or persistent presentations; we include all of these studies under the heading “acute diarrhea”. Most of these studies found associations between acute diarrhea and the markers investigated. One of these studies [125] found a relationship between acute diarrhea and both urinary and serum L:R while another [58], a study limited to serum L:R testing, found associations between diarrhea and serum L:R and lactulose. However, Goto et al. [124] did not find an association between the L:M ratio and acute diarrhea.

Studies also found associations between acute diarrhea and other tests specific for intestinal function, such as the sucrose breath test [159], and fecal fat [116]. Association was also observed for two markers of innate immunity, neutrophil polarization in response to a chemotactic factor and monocyte spontaneous proliferation assays [104], as well as nitric oxide production [43]. While one study found associations between acute diarrhea and various red blood cell parameters [166], another [104] found a lack of association between acute diarrhea and other systemic markers such as white blood cells, transferrin, serum albumin, cytokines, and immunoglobulin subtypes.

Sixteen [15, 101, 108, 121, 130-134, 136, 140, 152, 158, 162, 168, 172] studies had subjects with and without acute diarrhea but did not statistically analyze the relationship between markers and acute diarrhea, although three [101, 152, 162] presented data stratified by acute diarrhea status. In two studies [101, 162], a high proportion of those with acute diarrhea were lactoferrin positive. One of these studies [101] also found that a low proportion of cases with acute diarrhea were positive for stool IL-8, but all of the individuals positive for stool IL-8 had acute diarrhea. The study [152] utilizing the D-xylose test found that of the eight children

with abnormal results, one had diarrhea and of 19 children with diarrhea, only one had an abnormal result for D-xylose.

Thirteen studies included children with symptomatic or clinically silent giardiasis [15, 105, 116, 117, 122-124, 128, 133, 137, 147, 150, 154]; diagnostic methods to identify *Giardia* varied between microscopy and antigen testing. Seven of these studies investigated the relationship between markers and giardiasis [15, 116, 123, 124, 128, 147, 150] and five found an association between at least one marker and the infection [116, 123, 124, 128, 147], although the studies commonly reported associations between one biomarker and not others. Some studies found serum total IgG and AGP [123], and lactose hydrogen breath test results [147] were significantly higher in asymptomatic, *Giardia*-infected children than in uninfected controls. Significantly higher mean concentrations of total IgM were found in duodenal aspirates of *Giardia* cases with persistent diarrhea compared to controls without diarrhea [128]. In a study that included subjects with and without diarrhea, giardiasis was associated with the presence of fecal fat, and this association held across four testing methods [116]. In contrast, a study of a fecal marker of inflammation, neopterin, did not find an association with *Giardia* infection [15]. The relationship between *Giardia* infection and a urinary marker of intestinal permeability differed across studies. While Goto et al. found an association between giardiasis and mean urinary L:M value in one study [124], they did not find this association in a subsequently published study [123]. Campbell et al. did not find an association between *Giardia* infection and urinary L:M [15], and another report found that urinary L:M was not consistently associated with giardiasis [150]. The relationship between circulating markers and *Giardia* infection varied by marker; specifically, an association was observed between infection and serum albumin but not hemoglobin concentrations [123]. Six studies [105, 117, 122, 133, 137, 154] that included both infected and uninfected subjects did not statistically investigate the relationship between *Giardia* infection and these markers, although two [105, 117] of these studies did present data stratified

by infection status and a third [154] provided a general description of the histopathology in infected subjects. These three studies investigated cases with intestinal symptoms consistent with celiac disease and referred for duodenal biopsy. Among the children that were not diagnosed as having celiac disease, the studies reported widely varying percentages of subjects with *Giardia* infection: 0.8% [117], 5.4% [105], and 78.6% [154].

Eight studies presented data on children with asymptomatic and/or symptomatic cryptosporidiosis. Five of these [101, 130-132, 172] tested the association of *Cryptosporidium* infection with various markers, three of which were conducted in Haiti by the same group [130-132]. Fecal lactoferrin [101, 132] serum mannose-binding lectin deficiency [130], and mean urinary L:M [172] were associated with cryptosporidiosis. A sixth study tested longitudinally collected stools of Brazilian children for *Cryptosporidium* and presented the results for the children with infection, finding that stool lactoferrin was strongly associated with symptomatic infection in children with *C. parvum* but not *C. hominis* [108].

In the three cryptosporidiosis studies that included testing for various fecal cytokines, results were mixed. For example, two studies found no association between infection and IL-8 [101, 131], IL-4 [131], or IL-10 [131], while associations were identified with each of these cytokines, as well as with IL-13, in one of the studies from Haiti [132]. One of the studies from Haiti found an association between fecal IFN- γ and control status rather than among those with *Cryptosporidium* infection [131], while the other did not detect IFN- γ in the stools of any subjects [132].

In two additional studies of subjects with and without *Cryptosporidium* infection, abnormal D-xylose results were found more often among infected children [152], while fecal lactoferrin did not appear to be related to infection status based on the numbers reported in the study, although statistical testing of the relationship was not described [162].

Sixteen studies assessed the association of markers of intestinal function with nutritional status outcomes [15, 43, 53, 108-112, 122-124, 139, 145, 150, 151, 153]. The anthropometric assessments used in these investigations varied, and the results for given measures were mixed. We describe the results of the eight studies that measured the relationship between L:M and anthropometrics above (see Table 15) [15, 110-112, 122-124, 150].

Urinary lactose:creatinine [151], stool neopterin [15], and intestinal lactase activity [109] were associated with all anthropometric indices investigated while stool lactoferrin [108] and intestinal maltase activity were not [53]. Results for urinary nitric oxide and WAZ correlation were of borderline statistical significance (effect ratio 0.88, $p=0.05$) [43].

Four studies examined the association between histopathology and growth parameters [53, 111, 145, 153]; two studies identified no relationship between weight-for-age measures [111, 145], while one reported that WAZ score was correlated with degree of villous atrophy [53]. Examination of tissue by digital morphometry in another study produced ambiguous results [153]. One of these studies also examined the relationship of weight-for-age with endoscopic visualization of the intestine and found no association [145]. Campbell et al. found varying results when assessing the relationship of different intestinal tissue cytokines and immune markers with WAZ score [111].

Chapter 6. Conclusions and Future Implications

6.1 Summary of Findings

The 77 references from the years 2000 to 2010 provide a robust body of knowledge on biomarkers and diagnostic tests that could be useful in the quest to identify EED pathology, especially actionable EED, the entity most in need of identification to mitigate its long-term and life-threatening consequences.

Markers of permeability were the most frequently utilized biomarkers in the studies that we reviewed and the urinary L:M test was the most common of those measures. Lactoferrin, as well as other stool markers of intestinal inflammation, were also frequently assessed. Marker results varied greatly in terms of indicating the presence of intestinal dysfunction and degree of dysfunction when positive. This is not unexpected given the diverse populations that were studied, including different settings and subject presentations (e.g., asymptomatic children as well as those with various symptoms). In 20 of the 25 studies using the L:M test, the permeability ratio was noted to be elevated. As mentioned in the L:M section in Chapter 5, interpretation and comparison across studies in this review were hampered by variations in the way data were reported.

6.2 Future Biomarker and Diagnostics Research

This analysis was a comprehensive attempt to identify the most promising biomarkers or diagnostic tests on which to base future efforts and analyses of EED. Our review found many different biomarkers, across a wide range of diagnostic categories that have been deployed to

assess enteric function in children in resource-poor settings. However, regrettably, the extant literature does not permit us to recommend a specific technology or biomarker that can be used as a standard for the diagnosis of EED. There are many reasons for this difficulty:

1. The “tests” and the studies in which they were used were not developed with a biomarker concept in mind. The assays were performed chiefly to corroborate processes and were related to various host characteristics, but the relation to gut dysfunction was inferred without validation. While the preponderance of tests reported plausibly relate to gut dysfunction, their association with this particular pathophysiology was not proven.
2. The disorder of interest is poorly defined. It is clear that there is considerable and convergent evidence of abnormal digestive systems in the population of interest (children in low-income settings), and that there is an outcome (i.e., stunting) that is conceivably related to dysfunction of the gut, but the link has not been made conclusively.
3. Histopathological evidence of gut inflammation, which has been considered to prove the presence of EED, is an elusive gold standard (see discussion below on small bowel biopsies). Only two studies related histopathology to specific extra-intestinal markers. The L:M was found to correlate with intestinal inflammatory cell infiltration [111], while D-xylose was not associated with degree of villous atrophy [136]. Moreover, there is no evidence that histopathology is related to the ultimate outcome of interest, namely stunting, or other consequential host injury such as vaccine failure or increased susceptibility to infections.
4. The data presented in the publications that we analyzed often did not reflect high-grade subject reporting. For example, we often encountered data reported only in

terms of p-values and lacking reporting of effect sizes. In the field of randomized controlled trials, adherence to Consolidated Standards of Reporting Trials (CONSORT) Statement guidelines [309, 310] has improved the quality of clinical trials [311-313]. The effect of the non-systematic reporting of data in the biomarker field is that populations are not well described, methodology is not always discernible, and statistical tests are not completely described. The data that result might either obscure, or overstate, the value of the tests being assessed. We applaud efforts to standardize the quality of reporting of tests and biomarkers [314].

5. More data were certainly available than were reported. For example, there is value to the separate and simultaneous reporting of the lactulose and mannitol clearances, but such values were often not provided. Some studies reported a biomarker as significantly associated with an outcome of interest or correlated with another marker. However, often they did not mention whether other outcomes or biomarkers examined in the study were related to the biomarker of interest, leaving the reader unsure of whether these relationships were assessed at all or if only select (e.g., positive) findings were reported. Correlation analyses between the tests employed in the study were rarely reported. The publications that we reviewed did not report utilization of supplementary data deposition resources (e.g., supplementary or web-linked tables). However, such on-line registries for meta-data have only recently been made widely available by journals, better enabling capacity for all data to be fully utilized to answer questions that may not have been primary to the published study.
6. The biomarker studies that we analyzed, in the main, were often research project-driven. They were rarely scrutinized in the context of modern test-development standards. Many potential aspects critical to the clinical usefulness of a test, and to

the interpretation of the reported data, were not addressed. These include matters pertaining to the following: specimen transport, physical condition of the specimen (e.g., water content of stool), specimen processing prior to assay performance, temperature sensitivity, dynamic range of the test result, inhibitors (or molecules that could cause false positives) in the analyte, durability of the assays, inter-laboratory variability, biologic perturbations in specimens that often contain bacteria (stool and possibly urine), and assessments of the distribution of values in normal groups. An additional concern is that the target biomarker is presumed to be stable in the body fluid assayed, but this is rarely documented. We would encourage the broader use of spiking experiments, whereby the target molecule is added to the specimen of interest, and, ideally, recovered quantitatively. These study design, subject characterization, laboratory and analyte specification, and analysis and reporting considerations should be well addressed in future biomarker development work.

The multitude of test methods and procedures utilized, the disparate nature of the studies, and the limited testing for correlation with outcomes of interest (e.g., clinical signs of EED, histopathology or other markers of EED, or clinical outcomes of EED, such as stunting,) restrict our ability to declare any markers as clear lead candidates that warrant major or exclusive investment in the next phase of EED biomarker research.

It is important to note that our analysis was focused only on literature produced during the last eleven years. We acknowledge that it is possible that additional information could be extracted from studies published during prior years. In fact, we identified more references that were potentially relevant to our review question from the period 1990-1999 than for the period 2000-2010. However, a review of 10 randomly selected articles published between 1990-1999 and relevant to our review question (Appendix 3) did not add significant information compared to the 77 more recent publications included in the systematic review. Also, the aforementioned

structural issues in the reporting of the data in the studies from the 11-year period used in this systematic review (e.g., small sample sizes, study design and reporting issues) were also evident in the earlier studies. Moreover, even though EED research was more prevalent in the 1970s and 1980s, secular trends in nutritional, socioeconomic, and disease conditions, as well as laboratory, epidemiologic, and biostatistical method improvements as well as potential shifts in etiologies raise concerns about data comparability across large intervals of time.

It is quite likely that combinations of complementary markers might be required for different purposes. For instance, specific growth measures are used for population screening (e.g., height-for-age Z-scores to identify prevalence of stunting within given populations), and differ from those used for individual clinical management (i.e., growth monitoring). Another paradigm might be to use a highly sensitive screen for enteropathy, followed by more specific reflexive testing. An example in clinical medicine would be HIV screening followed by protein immunoblot (Western blot) assay for specific antigenic reactivity. The situation might, however, be more complicated for EED, as there is unlikely to be a unifactorial process or driver. Ideally, forthcoming research will identify a marker or markers that can serve related but differing functions. The marker or set of markers might also vary according to the function desired. For EED, we foresee multiple potential points of testing. First, in an individual, a biomarker could be used to detect early pathologic or functional changes, at an actionable stage before stunting and its consequences ensue. Second, a biomarker could be used to monitor clinical progression/recovery to determine intervention effectiveness. Third, a biomarker could be used to measure population prevalence to determine those populations where focused attention could mitigate morbidity and mortality from enteropathy and stunting.

It is possible that a marker of end-pathway processes common to non-EED forms of enteropathy will have more utility than EED-specific biomarkers. However, we wish to note that the “re-purposing” of biomarkers of other enteropathies will not result in an EED-specific marker.

This issue would be most relevant if there is geographic overlap between EED and other enteropathies of childhood, most notably celiac disease, as might be the case in South Asia as evidenced by recent studies from India [315].

Different approaches probably need to be tested or developed in parallel to find the optimal biomarkers for enteropathy, and in particular, to identify the optimal biomarkers to detect enteropathy that results in adverse consequences for the host (mostly likely stunting). Such strategies could consist of broad screening and biomarker discovery, using agnostic methodologies (e.g., proteomics, genomics, and metabolomics). It is important to note that biomarker discovery requires disciplined approaches, strong statistical support to identify attributable risk to a specific biomarker and to avoid false discoveries, as well as validation cohorts. Underlying any such discovery and validation is the obligation to be absolutely certain that the core data and specimens are of the highest quality. To date, cohorts have been small, specimens not uniformly collected and handled, and outcomes have been nebulous. These problems need to be remedied before applying novel analytics to the problem of enteropathy. However, the MAL-ED [316] and other cohorts might provide sufficient rigor and resources to begin to answer these questions.

If a perfect, or even an adequate single biomarker, cannot be found, an alternative might be the development of an “enteropathy index” which integrates a constellation of clinical symptoms and signs and/or set of markers. Variations of the “enteropathy index” might need to accommodate the processes of screening, diagnosing dysfunction in individual cases, and monitoring this condition and its consequences. For example, we divided the markers into eight categories, representing different enteric functions or expressions. An “enteropathy index” might be represented by “stacking” one marker from each of three or more categories such as lactoferrin (intestinal inflammation) + L:M (primarily permeability but mannitol excretion provides a measure of absorptive function) + lactose hydrogen breath test (digestion). We wish to note

that a recent publication by Kosek, et al. [317] provides data in support of this concept, proposing the use of three stool markers (neopterin, myeloperoxidase, and alpha-1-antitrypsin) reflective of inflammatory and permeability processes.

In considering data to be obtained from biopsy specimens, it will be important to balance information to be gleaned against the small risk related to the procedure. Based on current state of knowledge, it is not known when enteric functional deficits related to environmental enteropathy occur in temporal relation to histopathologic changes. When EED research does incorporate obtaining biopsies, such issues should be considered. Given the challenges in obtaining pediatric biopsies, any future EED biopsy research should include ascertainment of the relationship between histopathology and growth, in addition to utilization of histopathology as a “gold standard” by which less invasive biomarker performance is gauged.

Whichever of these biomarker discovery and validation strategies is employed, we urge rigorous adherence to standards for the design and reporting of biomarker studies. The “STAndards for the Reporting of Diagnostic accuracy studies” or “STARD” initiative provides an excellent framework and checklist for diagnostic accuracy studies, allowing readers to assess for potential bias in a study (internal validity) and to evaluate generalizability (external validity). The STARD initiative is akin to the CONSORT statement for randomized controlled trials [318] and provides an excellent structure for consideration for development of biomarker discovery study design and reporting guidelines [319].

In reviewing these studies, it appears that many tests were compromised by choice of analyte, and independent of processes, it is important, looking forward, to consider the body substance analyzed, and the benefits and drawbacks of each. These are summarized in Table 16.

Table 16. Analyte attributes.

Comments on attributes of analyte, relevant to current and future biomarker assessments.

Attribute	Blood	Urine	Stool	Breath	Biopsies	Saliva
Invasiveness ¹	High	Low	Low	Med	High	Med
Steady state assessment ²	Yes	Sometimes	Sometimes	Yes	Yes	Yes
Requires processing before freezing or long-term storage ³	Yes	No	No	No	Yes	No
Schedulable ⁴	Yes	No	No	Yes	Yes	Yes
Consent issues ⁵	Medium	Low	Low	Low	High	Low
Components of analyte that can be studied	Plasma, serum, white cells, red cells, host nucleic acids	Mostly urine	Stool, microbes	Gas	Bulk tissues, cells, microbes	Saliva, microbes
Technology to obtain ⁶	Low	Low	Low	Med	High	Med (if special swabs employed)
Biohazardous ⁷	High	Low	Low	Med	High	Low
Offensive ⁸	Med	Low	High	Med	Med	Med
Ability to collect and bring from home ⁹	No	Yes	Yes	No	No	Yes
Provenance ¹⁰	Good	Fair	Fair	Good	Good	Fair

¹ Invasiveness is defined as "low" if analyte is produced spontaneously by subject, "medium" if a special apparatus or collection device is needed to obtain the specimen and "high" if mucosa or integument is breached to obtain.

² Steady state is assessed ("yes") if the substance studied is likely to remain stable on an hour-to-hour basis, and not assessed ("no") if substance studied is capable of changing profoundly in a short interval.

³ Processing (e.g., physical separation by centrifugation of components) is generally performed before long-term storage.

⁴ Schedulable samplings are those that can be arranged and obtained in advance, i.e., are not generally produced on command by children.

⁵ Consent issues are "low" if the substance is spontaneously produced without any physical risk to the subject, "medium" if obtaining the substance has a degree of physical discomfort or anxiety risk such as a hematoma or pain from a phlebotomy, and "high" if there is any possibility of injury that could result in hospitalization.

⁶ "Low" technology describes minimally expensive materials that are easily obtainable, such as needles and syringes; "medium" cost pertains to special-order items, such as breath hydrogen bags; and "high" cost pertains to materials obtained in an inpatient setting using sophisticated technology, such as endoscopic and biopsy equipment.

⁷ Materials are considered to have "low" biohazard risk if the likelihood of contracting a life-threatening infection are nil if the substance is placed on an open cut or inhaled; "medium" if a serious but rarely life threatening infection would result if the substance is placed on an open cut or inhaled (breath is placed in this category because of the possibility of tuberculosis or other infections spread via respiratory droplets); and "high" if a life-threatening infection, most notably HIV, would result if the substance is placed on an open cut or inhaled.

⁸ Offensiveness relates to a general reaction to a worker's skin coming in contact with the substance accidentally.

⁹ Materials can be brought from home for analysis, with a modest amount of instruction and materials.

¹⁰ Provenance relates to low, medium, or high risk of accidental or intentional substitution by a research subject or patient or family.

As can be seen, each body substance has strengths and drawbacks in research studies and clinical practice, and much of the literature chose specimens to analyze based either on precedent or lack of suitable alternatives. In reviewing the tests, blood has many commendable attributes, but the requirement to breach the skin to obtain the specimen adds an extreme, and often limiting, constraint to sampling. We wish to propose for consideration the use of transcutaneous technology to evaluate blood components. These devices are quite successful in measuring blood gases (oxygen and carbon dioxide), bilirubin, and glucose, and their methodology might be adaptable to either endogenous targets (e.g., iron) or challenge substances (D-xylose), and therefore have a high likelihood of playing a useful role in detecting and monitoring enteropathy.

In all assessments, it is important to recognize that normal or reference values are highly abstract concepts. Often, normal values were obtained from studying cohorts of children in developed countries, and there are rarely opportunities to establish normal values based on putatively normal subjects in the same environment, and of the same genetic makeup, as the subjects studied for enteropathy. Unless and until methodology and sampling of subjects are used to establish such norms, it will be difficult to calibrate the magnitude of abnormality. This problem is compounded by definitional issues in pathology. While we believe that intestinal inflammation is quite likely undesirable, we cannot state with certainty that an inflamed mucosa is wholly deleterious for children in resource-poor settings. Specifically, it is possible that low-to-moderate-grade inflammation of the gut is a homeostatic mechanism in environments in which enteric pathogens are ubiquitous.

The obstacles we encountered in this review suggest opportunities to adhere to publication standards in future reports of biomarker research related to EED. We were largely hindered by inadequate definitions and reporting incompleteness. The STARD guidelines are a very good basis for subsequent reports, but might need to be adapted in consideration of the

biomarker field. Specifically, processes that are interrogated by the biomarker should be clearly described, if known, and if not known, then that should be stated. Rigorous statistics should be applied for two overriding reasons: first, it is critical that point estimates (including percent attribution where study design allows for calculation) and confidence intervals should be reported in addition to the less informative p-values; second, in the assessment of multiple biomarkers identified in agnostic discovery projects, it is important to incorporate statistically valid safeguards against false discovery via multiple comparisons.

We also believed that the authors of the texts we reviewed generally obtained more data than they reported, probably because of page limitations or focus of the paper. Very few of the publications reported data that were obtained exclusively in the context of biomarker development or evaluation; many of the reports produced biomarker data in the context of other studies. Also, there was sparse use of online repositories for storage of meta-data. As such, considerable opportunities to review relevant data for biomarkers might have been lost. Certainly, there are increasing capacities to archive ancillary data for interrogation by other investigators. We are encouraged by this trend and believe that complete data deposition should be considered a “best practice” of future enteropathy-biomarker projects. Furthermore, systematic deposition is best facilitated, for ease of input as well as extraction of data, by placement in the public domain.

In addition to more rigorous and transparent provision of study design and major findings, it is apparent that future research in the field will be handicapped by current journal publication constraints. Specifically, biomarker studies in human populations are likely to generate volumes of data that are well in excess of the word and table limits of standard journal articles. This is especially regrettable, because the cost of accruing human cohorts is increasing, and therefore there is an obligation to make the most of the data that are produced henceforth. We propose that a biomarker data repository be established, and used to advance

research in this field, and to be accessible for future data queries. We do acknowledge, however, that the establishment, preservation, and curation of data require resources that are often not provided to the projects in which the data are generated. Nonetheless, a standardized, disciplined, and logical deposition and maintenance of data while studies are performed will reduce the expense of archiving the material after the study. Such investments will enhance and expedite biomarker research and application for reducing the burden of stunting.

APPENDICES

Appendix 1. Search terms for EED articles of interest.

Search terms for EED alone are in gray, malnutrition outcomes are in pink. A combined strategy, denoted in yellow was utilized for searches in the smaller WHO databases.

PubMed TE/ED

completed April 1, 2010 (24156 Citations)

Step 1 (24875 Citations)

("Viruses" [Mesh] OR "Bacteria" [Mesh] OR "Parasites" [Mesh]) AND "Intestinal Diseases" [Mesh]

Step 2 (2789652 Citations)

("malnutrition" OR "undernutrition" OR "micronutrient" OR "nutritional deficiency" OR "Nutrition Disorders" [Mesh] OR "child development" [Mesh] OR environmental OR recurrent OR recurring OR persistent OR chronic OR "Communicable Disease Control" [Mesh] OR handwashing OR "hand washing" OR toilet* OR sanitation OR hygiene OR drinking)

Step 3 (478234 Citations)

(enteropathy OR enteropathies OR diarrhea OR diarrhoea OR diarrhoeal OR diarrheal OR "Malabsorption Syndromes" [Mesh])

Step 2 AND 3 combined (93491 Citations)

Step 4 (759 Citations)

("Diarrhea" [Mesh] AND "chronic disease" [Mesh]) 1, 378

Step 5

("environmental enteropathies" OR "environmental enteropathy" OR "tropical enteropathy" OR "tropical enteropathies" OR "sprue, tropical " [MeSH] OR "tropical sprue" OR " Idiopathic Tropical Malabsorption Syndromes" OR " Idiopathic Tropical Malabsorption Syndrome")

Step 6 (37074 Citations)

"Intestinal Absorption" [Mesh]

Step 1 OR (Step 2 AND 3) OR Step 4 OR Step 5 OR Step6 (148353 Citations)

Step 7 (1826934 Citations)

"Child" [Mesh] OR "Maternal-Child Health Centers" [Mesh] OR "Child Nutrition Sciences" [Mesh] OR "Child Health Services" [Mesh] OR "Child Nutritional Physiological Phenomena" [Mesh] OR "Child Nutrition Disorders" [Mesh] OR "Child Mortality" [Mesh] OR "Child Welfare" [Mesh] OR "Child Care" [Mesh] OR "Child Reactive Disorders" [Mesh] OR "Child Guidance" [Mesh] OR "Child Reactive Disorders" [Mesh] OR "Child Behavior Disorders" [Mesh] OR "Child, Orphaned" [Mesh] OR "Child, Institutionalized" [Mesh] OR "Child, Hospitalized" [Mesh] OR "Child Development" [Mesh] OR "Child Behavior" [Mesh] OR "Developmental Disabilities" [Mesh] OR "Mental Disorders Diagnosed in Childhood" [Mesh] OR "Disabled Children" [Mesh] OR "children" [TIAB] OR "newborn*" [TIAB] OR "childhood" [TIAB] OR "baby" [TIAB] OR "babies" [TIAB] OR "toddler" [TIAB] OR "toddlers" [TIAB] OR "infants" [TIAB] OR "infant" [TIAB] OR "infantile" [TIAB] OR "young patient" [TIAB] OR "young patients" [TIAB] OR "Pediatric Nursing" [Mesh] OR "Pediatric Assistants" [Mesh] OR "Hospitals, Pediatric" [Mesh] OR "Intensive Care Units, Pediatric" [Mesh] OR "Pediatrics" [Mesh] OR "Pediatricians" [TIAB] OR "paediatricians" [TIAB] OR "Pediatrician" [TIAB] OR "paediatrician" [TIAB] OR "Pediatrics" [TIAB] OR "paediatrics" [TIAB] OR "Pediatric" [TIAB] OR "paediatric" [TIAB]

Step 1 OR (Step 2 AND 3) OR Step 4 OR Step 5 OR Step6 AND Step7 (24156 Citations)

EMBASE TE/ED

completed April 1, 2010 (20052 Citations)

Step 1 (39771 Citations)

'gastroenteritis'/exp OR 'gastroenteritis' OR 'protein losing gastroenteropathy'/exp OR 'protein losing gastroenteropathy' OR 'celiac disease'/exp OR 'celiac disease' OR 'tropical sprue'/exp OR 'tropical sprue' OR 'infantile gastroenteritis'/exp OR 'infantile gastroenteritis' OR 'acute gastroenteritis'/exp OR 'acute gastroenteritis' OR 'viral gastroenteritis'/exp OR 'viral gastroenteritis' OR 'persistent diarrhea' OR 'persistent diarrhoea' OR 'recurrent diarrhea' OR 'recurrent diarrhoea'

Step 2 (4062 Citations)

'intestine mucosa permeability'/exp OR 'small intestine absorption'/exp

Step 3 (745 Citations)

'environmental enteropathies' OR 'environmental enteropathy' OR 'tropical enteropathy' OR 'tropical enteropathies' OR 'tropical sprue'/exp OR 'tropical sprue' OR 'idiopathic tropical malabsorption syndromes' OR 'idiopathic tropical malabsorption syndrome'

OR

Step 4 (3611 citations)

('chronic disease'/exp AND 'diarrhea'/exp) OR 'chronic diarrhea'/exp

Step 5 (3156573 Citations)

'child'/exp OR 'child' OR 'children'/exp OR 'children' OR 'youth'/exp OR 'youth' OR youth* OR newborn* OR 'newborn'/exp OR 'newborn' OR 'new born' OR 'childhood disease'/exp OR 'childhood disease' OR 'baby'/exp OR 'baby' OR babies OR 'infant'/exp OR 'infant' OR infant* OR childhood* OR toddler* OR kid OR kids OR 'young patient' OR boy* OR girl* OR 'young age' OR pediater* OR paediatric* OR 'child death'/exp OR 'child death' OR 'child health'/exp OR 'child health' OR 'child care'/exp OR 'child care' OR 'childhood mortality'/exp OR 'childhood mortality' OR 'child hospitalization'/exp OR 'child hospitalization' OR 'pediatric hospital'/exp OR 'pediatric hospital' OR child*

(Step 1 OR Step 2 OR Step 3 OR Step 4) AND Step 5 (20052 Citations)

Global Health TE/ED

completed June 1, 2010 (7825 citations)

Step 1 (232244 Citations)

(child or children or newborn\$ or childhood or baby or babies or toddler or toddlers or infants or infant or infantile or "young patients" or "young patient" or pediatrics or pediatric or paediatric or paediatrics or girls or sons or daughters or "child welfare" or "rearing practices" or unicef or paediatric\$ or "child development" or "child nutrition" or "child health" or kid or kids or pediatricians or paediatricians).af.

Step 2 (4555 Citations)

(enteropathy or scouring).id. OR ("chronic infections" and diarrhoea).de. OR (diarrhea and "nutritional status").id. OR ("tropical sprue\$" or "tropical enteropath\$" or "environmental enteropath\$" or "persistent diarrhea\$" or "Persistent diarrhoea\$" or "chronic diarrhoea\$" or "chronic diarrhea\$" or "intestinal inflamm*" or "intestinal permeability").af.

Step 3 (620850 Citations)

(undernutrition or "tropical countries" or "tropical zones" or "parasitic infections").id. or (tropics or "bacterial diseases").de. or (vv600 or vv210 or hh600 or ll822 or vv130).cc.

Step 4 (28447 Citations)

("intestinal mucosa" or "small intestine" or "gastroenteritis" or intestines or "intestinal diseases" or "intestinal absorption").de. or (Intestines or "gastrointestinal tract").id.

Step 1 AND (Step 2 OR (Step 3 AND Step 4)) (10242 Citations)

Step 5 (*Journals indexed by PubMed and Embase removed) (2417 Citations)

"Journal of Pediatric Gastroenterology and Nutrition" [Journals] OR Journal of Clinical Microbiology" [Journals] OR"Archives of Disease in Childhood" [Journals] OR"Pediatric Infectious Disease Journal" [Journals] OR"Journal of Infectious Diseases" [Journals] OR"Journal of Pediatrics" [Journals] OR

"Clinical Infectious Diseases" [Journals] OR"Infection and Immunity" [Journals] OR

"Journal of Medical Virology" [Journals] OR"Transactions of the Royal Society of Tropical Medicine and Hygiene" [Journals] OR"Journal of Nutrition" [Journals] OR "East African Medical Journal" [Journals]

"BMC Infectious Diseases" [Journals] OR"American Journal of Tropical Medicine and Hygiene" [Journals] OR"Pediatric Research" [Journals] OR"Archives de Pediatrie" [Journals] OR

"Journal of Paediatrics and Child Health" [Journals] OR"Asian Pacific Journal of Allergy and Immunology" [Journals] OR"Journal of Tropical Pediatrics" [Journals]

Step 1 AND (Step 2 OR (Step 3 AND Step 4) NOT Step 5 (7825 Citations)

PubMed Malnutrition

completed April 19, 2010 (23238 Citations)

Step 1 (2540333 Citations)

"developing country" [tiab] OR "developing countries" [tiab] OR "developing nation" [tiab] OR "developing nations" [tiab] OR "developing population" [tiab] OR "developing populations" [tiab] OR "developing world" [tiab] OR "less developed country" [tiab] OR "less developed countries" [tiab] OR "less developed nation" [tiab] OR "less developed nations" [tiab] OR "less developed population" [tiab] OR "less developed populations" [tiab] OR "less developed world" [tiab] OR "lesser developed country" [tiab] OR "lesser developed countries" [tiab] OR "lesser developed nation" [tiab] OR "lesser developed nations" [tiab] OR "lesser developed population" [tiab] OR "lesser developed populations" [tiab] OR "lesser developed world" [tiab] OR "under developed country" [tiab] OR "under developed countries" [tiab] OR "under developed nation" [tiab] OR "under developed nations" [tiab] OR "under developed population" [tiab] OR "under developed populations" [tiab] OR "under developed world" [tiab] OR "underdeveloped country" [tiab] OR "underdeveloped countries" [tiab] OR "underdeveloped nation" [tiab] OR "underdeveloped nations" [tiab] OR "underdeveloped population" [tiab] OR "underdeveloped populations" [tiab]

OR "underdeveloped world" [tiab] OR "middle income country" [tiab] OR "middle income countries" [tiab] OR "middle income nation" [tiab] OR "middle income nations" [tiab] OR "middle income population" [tiab] OR "middle income populations" [tiab] OR "low income country" [tiab] OR "low income countries" [tiab] OR "low income nation" [tiab] OR "low income nations" [tiab] OR "low income population" [tiab] OR "low income populations" [tiab] OR "lower income country" [tiab] OR "lower income countries" [tiab] OR "lower income nation" [tiab] OR "lower income nations" [tiab] OR "lower income population" [tiab] OR "lower income populations" [tiab] OR "underserved country" [tiab] OR "underserved countries" [tiab] OR "underserved nation" [tiab] OR "underserved nations" [tiab] OR "underserved population" [tiab] OR "underserved populations" [tiab] OR "underserved world" [tiab] OR "under served country" [tiab] OR "under served countries" [tiab] OR "under served nation" [tiab] OR "under served nations" [tiab] OR "under served population" [tiab] OR "under served populations" [tiab] OR "under served world" [tiab] OR "deprived country" [tiab] OR "deprived countries" [tiab] OR "deprived nation" [tiab] OR "deprived nations" [tiab] OR "deprived population" [tiab] OR "deprived populations" [tiab] OR "deprived world" [tiab] OR "poor country" [tiab] OR "poor countries" [tiab] OR "poor nation" [tiab] OR "poor nations" [tiab] OR "poor population" [tiab] OR "poor populations" [tiab] OR "poor world" [tiab] OR "poorer country" [tiab] OR "poorer countries" [tiab] OR "poorer nation" [tiab] OR "poorer nations" [tiab] OR "poorer population" [tiab] OR "poorer populations" [tiab] OR "poorer world" [tiab] OR "developing economy" [tiab] OR "developing economies" [tiab] OR "less developed economy" [tiab] OR "less developed economies" [tiab] OR "lesser developed economy" [tiab] OR "lesser developed economies" [tiab] OR "under developed economy" [tiab] OR "under developed economies" [tiab] OR "underdeveloped economy" [tiab] OR "underdeveloped economies" [tiab] OR "middle income economy" [tiab] OR "middle income economies" [tiab] OR "low income economy" [tiab] OR "low income economies" [tiab] OR "lower income economy" [tiab] OR "lower income economies" [tiab] OR "low gdp" [tiab] OR "low gnp" [tiab] OR "low gross domestic" [tiab] OR "low gross national" [tiab] OR "lower gdp" [tiab] OR "lower gnp" [tiab] OR "lower gross domestic" [tiab] OR "lower gross national" [tiab] OR Imic [tiab] OR Imics [tiab] OR "third world" [tiab] OR "lami country" [tiab] OR "lami countries" [tiab] OR "transitional country" [tiab] OR "transitional countries" [tiab] OR "developing country" [ot] OR "developing countries" [ot] OR "developing nation" [ot] OR "developing nations" [ot] OR "developing population" [ot] OR "developing populations" [ot] OR "developing world" [ot] OR "less developed country" [ot] OR "less developed countries" [ot] OR "less developed nation" [ot] OR "less developed nations" [ot] OR "less developed population" [ot] OR "less developed populations" [ot] OR "less developed world" [ot] OR "lesser developed country" [ot] OR "lesser developed countries" [ot] OR "lesser developed nation" [ot] OR "lesser developed nations" [ot] OR "lesser developed population" [ot] OR "lesser developed populations" [ot] OR "lesser developed world" [ot] OR "under developed country" [ot] OR "under developed countries" [ot] OR "under developed nation" [ot] OR "under developed nations" [ot] OR "under developed population" [ot] OR "under developed populations" [ot] OR "under developed world" [ot] OR "underdeveloped country" [ot] OR "underdeveloped countries" [ot] OR "underdeveloped nation" [ot] OR "underdeveloped nations" [ot] OR "underdeveloped population" [ot] OR "underdeveloped populations" [ot] OR "underdeveloped world" [ot] OR "middle income country" [ot] OR "middle income countries" [ot] OR "middle income nation" [ot] OR "middle income nations" [ot] OR "middle income population" [ot] OR "middle income populations" [ot] OR "low

income country" [ot] OR "low income countries" [ot] OR "low income nation" [ot] OR "low income nations" [ot] OR "low income population" [ot] OR "low income populations" [ot] OR "lower income country" [ot] OR "lower income countries" [ot] OR "lower income nation" [ot] OR "lower income nations" [ot] OR "lower income population" [ot] OR "lower income populations" [ot] OR "underserved country" [ot] OR "underserved countries" [ot] OR "underserved nation" [ot] OR "underserved nations" [ot] OR "underserved population" [ot] OR "underserved populations" [ot] OR "underserved world" [ot] OR "under served country" [ot] OR "under served countries" [ot] OR "under served nation" [ot] OR "under served nations" [ot] OR "under served population" [ot] OR "under served populations" [ot] OR "under served world" [ot] OR "deprived country" [ot] OR "deprived countries" [ot] OR "deprived nation" [ot] OR "deprived nations" [ot] OR "deprived population" [ot] OR "deprived populations" [ot] OR "deprived world" [ot] OR "poor country" [ot] OR "poor countries" [ot] OR "poor nation" [ot] OR "poor nations" [ot] OR "poor population" [ot] OR "poor populations" [ot] OR "poor world" [ot] OR "poorer country" [ot] OR "poorer countries" [ot] OR "poorer nation" [ot] OR "poorer nations" [ot] OR "poorer population" [ot] OR "poorer populations" [ot] OR "poorer world" [ot] OR "developing economy" [ot] OR "developing economies" [ot] OR "less developed economy" [ot] OR "less developed economies" [ot] OR "lesser developed economy" [ot] OR "lesser developed economies" [ot] OR "under developed economy" [ot] OR "under developed economies" [ot] OR "underdeveloped economy" [ot] OR "underdeveloped economies" [ot] OR "middle income economy" [ot] OR "middle income economies" [ot] OR "low income economy" [ot] OR "low income economies" [ot] OR "lower income economy" [ot] OR "lower income economies" [ot] OR "low gdp" [ot] OR "low gnp" [ot] OR "low gross domestic" [ot] OR "low gross national" [ot] OR "lower gdp" [ot] OR "lower gnp" [ot] OR "lower gross domestic" [ot] OR "lower gross national" [ot] OR Imic [ot] OR Imics [ot] OR "third world" [ot] OR "lami country" [ot] OR "lami countries" [ot] OR "transitional country" [ot] OR "transitional countries" [ot] OR Africa [pl] OR Asia [pl] OR Caribbean [pl] OR West Indies [pl] OR South America [pl] OR Latin America [pl] OR Central America [pl] OR Afghanistan [pl] OR Albania [pl] OR Algeria [pl] OR Angola [pl] OR Antigua [pl] OR Barbuda [pl] OR Argentina [pl] OR Armenia [pl] OR Armenian [pl] OR Aruba [pl] OR Azerbaijan [pl] OR Bahrain [pl] OR Bangladesh [pl] OR Barbados [pl] OR Benin [pl] OR Byelarus [pl] OR Byelorussian [pl] OR Belarus [pl] OR Belorussian [pl] OR Belorussia [pl] OR Belize [pl] OR Bhutan [pl] OR Bolivia [pl] OR Bosnia [pl] OR Herzegovina [pl] OR Hercegovina [pl] OR Botswana [pl] OR Brazil [pl] OR Bulgaria [pl] OR Burkina Faso [pl] OR Burkina Fasso [pl] OR Upper Volta [pl] OR Burundi [pl] OR Urundi [pl] OR Cambodia [pl] OR Khmer Republic [pl] OR Kampuchea [pl] OR Cameroon [pl] OR Cameroons [pl] OR Cameron [pl] OR Camerons [pl] OR Cape Verde [pl] OR Central African Republic [pl] OR Chad [pl] OR Chile [pl] OR China [pl] OR Colombia [pl] OR Comoros [pl] OR Comoro Islands [pl] OR Comores [pl] OR Mayotte [pl] OR Congo [pl] OR Zaire [pl] OR Costa Rica [pl] OR Cote d'Ivoire [pl] OR Ivory Coast [pl] OR Croatia [pl] OR Cuba [pl] OR Cyprus [pl] OR Czechoslovakia [pl] OR Czech Republic [pl] OR Slovakia [pl] OR Slovak Republic [pl] OR Djibouti [pl] OR French Somaliland [pl] OR Dominica [pl] OR Dominican Republic [pl] OR East Timor [pl] OR East Timur [pl] OR Timor Leste [pl] OR Ecuador [pl] OR Egypt [pl] OR United Arab Republic [pl] OR El Salvador [pl] OR Eritrea [pl] OR Estonia [pl] OR Ethiopia [pl] OR Fiji [pl] OR Gabon [pl] OR Gabonese Republic [pl] OR Gambia [pl] OR Gaza [pl] OR Georgia Republic [pl] OR Georgian Republic [pl] OR Ghana [pl] OR Gold Coast [pl] OR Greece [pl] OR Grenada [pl] OR Guatemala [pl] OR Guinea [pl] OR Guam [pl] OR Guiana [pl]

OR Guyana [pl] OR Haiti [pl] OR Honduras [pl] OR Hungary [pl] OR India [pl] OR Maldives [pl]
OR Indonesia [pl] OR Iran [pl] OR Iraq [pl] OR Isle of Man [pl] OR Jamaica [pl] OR Jordan [pl]
OR Kazakhstan [pl] OR Kazakh [pl] OR Kenya [pl] OR Kiribati [pl] OR Korea [pl] OR Kosovo [pl]
OR Kyrgyzstan [pl] OR Kirghizia [pl] OR Kyrgyz Republic [pl] OR Kirghiz [pl] OR Kirgizstan [pl]
OR "Lao PDR" [pl] OR Laos [pl] OR Latvia [pl] OR Lebanon [pl] OR Lesotho [pl] OR Basutoland
[pl] OR Liberia [pl] OR Libya [pl] OR Lithuania [pl] OR Macedonia [pl] OR Madagascar [pl] OR
Malagasy Republic [pl] OR Malaysia [pl] OR Malaya [pl] OR Malay [pl] OR Sabah [pl] OR
Sarawak [pl] OR Malawi [pl] OR Nyasaland [pl] OR Mali [pl] OR Malta [pl] OR Marshall Islands
[pl] OR Mauritania [pl] OR Mauritius [pl] OR Agalega Islands [pl] OR Mexico [pl] OR Micronesia
[pl] OR Middle East [pl] OR Moldova [pl] OR Moldovia [pl] OR Moldovian [pl] OR Mongolia [pl]
OR Montenegro [pl] OR Morocco [pl] OR Ifni [pl] OR Mozambique [pl] OR Myanmar [pl] OR
Myanma [pl] OR Burma [pl] OR Namibia [pl] OR Nepal [pl] OR Netherlands Antilles [pl] OR New
Caledonia [pl] OR Nicaragua [pl] OR Niger [pl] OR Nigeria [pl] OR Northern Mariana Islands [pl]
OR Oman [pl] OR Muscat [pl] OR Pakistan [pl] OR Palau [pl] OR Palestine [pl] OR Panama [pl]
OR Paraguay [pl] OR Peru [pl] OR Philippines [pl] OR Philipines [pl] OR Phillipines [pl] OR
Phillippines [pl] OR Poland [pl] OR Portugal [pl] OR Puerto Rico [pl] OR Romania [pl] OR
Rumania [pl] OR Roumania [pl] OR Russia [pl] OR Russian [pl] OR Rwanda [pl] OR Ruanda [pl]
OR Saint Kitts [pl] OR St Kitts [pl] OR Nevis [pl] OR Saint Lucia [pl] OR St Lucia [pl] OR Saint
Vincent [pl] OR St Vincent [pl] OR Grenadines [pl] OR Samoa [pl] OR Samoan Islands [pl] OR
Navigator Island [pl] OR Navigator Islands [pl] OR Sao Tome [pl] OR Saudi Arabia [pl] OR
Senegal [pl] OR Serbia [pl] OR Montenegro [pl] OR Seychelles [pl] OR Sierra Leone [pl] OR
Slovenia [pl] OR Sri Lanka [pl] OR Ceylon [pl] OR Solomon Islands [pl] OR Somalia [pl] OR
Sudan [pl] OR Suriname [pl] OR Surinam [pl] OR Swaziland [pl] OR Syria [pl] OR Tajikistan [pl]
OR Tadzhiistan [pl] OR Tadjikistan [pl] OR Tadhik [pl] OR Tanzania [pl] OR Thailand [pl] OR
Togo [pl] OR Togolese Republic [pl] OR Tonga [pl] OR Trinidad [pl] OR Tobago [pl] OR Tunisia
[pl] OR Turkey [pl] OR Turkmenistan [pl] OR Turkmen [pl] OR Uganda [pl] OR Ukraine [pl] OR
Uruguay [pl] OR USSR [pl] OR Soviet Union [pl] OR Union of Soviet Socialist Republics [pl] OR
Uzbekistan [pl] OR Uzbek OR Vanuatu [pl] OR New Hebrides [pl] OR Venezuela [pl] OR
Vietnam [pl] OR Viet Nam [pl] OR West Bank [pl] OR Yemen [pl] OR Yugoslavia [pl] OR Zambia
[pl] OR Zimbabwe [pl] OR Rhodesia [pl] OR Africa [tiab] OR Asia [tiab] OR Caribbean [tiab] OR
West Indies [tiab] OR South America [tiab] OR Latin America [tiab] OR Central America [tiab]
OR Afghanistan [tiab] OR Albania [tiab] OR Algeria [tiab] OR Angola [tiab] OR Antigua [tiab] OR
Barbuda [tiab] OR Argentina [tiab] OR Armenia [tiab] OR Armenian [tiab] OR Aruba [tiab] OR
Azerbaijan [tiab] OR Bahrain [tiab] OR Bangladesh [tiab] OR Barbados [tiab] OR Benin [tiab] OR
Byelarus [tiab] OR Byelorussian [tiab] OR Belarus [tiab] OR Belorussian [tiab] OR Belorussia
[tiab] OR Belize [tiab] OR Bhutan [tiab] OR Bolivia [tiab] OR Bosnia [tiab] OR Herzegovina [tiab]
OR Hercegovina [tiab] OR Botswana [tiab] OR Brazil [tiab] OR Bulgaria [tiab] OR Burkina Faso
[tiab] OR Burkina Fasso [tiab] OR Upper Volta [tiab] OR Burundi [tiab] OR Urundi [tiab] OR
Cambodia [tiab] OR Khmer Republic [tiab] OR Kampuchea [tiab] OR Cameroon [tiab] OR
Camerouns [tiab] OR Cameron [tiab] OR Camerons [tiab] OR Cape Verde [tiab] OR Central
African Republic [tiab] OR Chad [tiab] OR Chile [tiab] OR China [tiab] OR Colombia [tiab] OR
Comoros [tiab] OR Comoro Islands [tiab] OR Comores [tiab] OR Mayotte [tiab] OR Congo [tiab]
OR Zaire [tiab] OR Costa Rica [tiab] OR Cote d'Ivoire [tiab] OR Ivory Coast [tiab] OR Croatia
[tiab] OR Cuba [tiab] OR Cyprus [tiab] OR Czechoslovakia [tiab] OR Czech Republic [tiab] OR

Slovakia [tiab] OR Slovak Republic [tiab] OR Djibouti [tiab] OR French Somaliland [tiab] OR Dominica [tiab] OR Dominican Republic [tiab] OR East Timor [tiab] OR East Timur [tiab] OR Timor Leste [tiab] OR Ecuador [tiab] OR Egypt [tiab] OR United Arab Republic [tiab] OR El Salvador [tiab] OR Eritrea [tiab] OR Estonia [tiab] OR Ethiopia [tiab] OR Fiji [tiab] OR Gabon [tiab] OR Gabonese Republic [tiab] OR Gambia [tiab] OR Gaza [tiab] OR Georgia Republic [tiab] OR Georgian Republic [tiab] OR Ghana [tiab] OR Gold Coast [tiab] OR Greece [tiab] OR Grenada [tiab] OR Guatemala [tiab] OR Guinea [tiab] OR Guam [tiab] OR Guiana [tiab] OR Guyana [tiab] OR Haiti [tiab] OR Honduras [tiab] OR Hungary [tiab] OR India [tiab] OR Maldives [tiab] OR Indonesia [tiab] OR Iran [tiab] OR Iraq [tiab] OR Isle of Man [tiab] OR Jamaica [tiab] OR Jordan [tiab] OR Kazakhstan [tiab] OR Kazakh [tiab] OR Kenya [tiab] OR Kiribati [tiab] OR Korea [tiab] OR Kosovo [tiab] OR Kyrgyzstan [tiab] OR Kirghizia [tiab] OR Kyrgyz Republic [tiab] OR Kirghiz [tiab] OR Kirgizstan [tiab] OR "Lao PDR" [tiab] OR Laos [tiab] OR Latvia [tiab] OR Lebanon [tiab] OR Lesotho [tiab] OR Basutoland [tiab] OR Liberia [tiab] OR Libya [tiab] OR Lithuania [tiab] OR Macedonia [tiab] OR Madagascar [tiab] OR Malagasy Republic [tiab] OR Malaysia [tiab] OR Malaya [tiab] OR Malay [tiab] OR Sabah [tiab] OR Sarawak [tiab] OR Malawi [tiab] OR Nyasaland [tiab] OR Mali [tiab] OR Malta [tiab] OR Marshall Islands [tiab] OR Mauritania [tiab] OR Mauritius [tiab] OR Agalega Islands [tiab] OR Mexico [tiab] OR Micronesia [tiab] OR Middle East [tiab] OR Moldova [tiab] OR Moldovia [tiab] OR Moldovian [tiab] OR Mongolia [tiab] OR Montenegro [tiab] OR Morocco [tiab] OR Ifni [tiab] OR Mozambique [tiab] OR Myanmar [tiab] OR Myanma [tiab] OR Burma [tiab] OR Namibia [tiab] OR Nepal [tiab] OR Netherlands Antilles [tiab] OR New Caledonia [tiab] OR Nicaragua [tiab] OR Niger [tiab] OR Nigeria [tiab] OR Northern Mariana Islands [tiab] OR Oman [tiab] OR Muscat [tiab] OR Pakistan [tiab] OR Palau [tiab] OR Palestine [tiab] OR Panama [tiab] OR Paraguay [tiab] OR Peru [tiab] OR Philippines [tiab] OR Philipines [tiab] OR Phillipines [tiab] OR Phillippines [tiab] OR Poland [tiab] OR Portugal [tiab] OR Puerto Rico [tiab] OR Romania [tiab] OR Rumania [tiab] OR Roumania [tiab] OR Russia [tiab] OR Russian [tiab] OR Rwanda [tiab] OR Ruanda [tiab] OR Saint Kitts [tiab] OR St Kitts [tiab] OR Nevis [tiab] OR Saint Lucia [tiab] OR St Lucia [tiab] OR Saint Vincent [tiab] OR St Vincent [tiab] OR Grenadines [tiab] OR Samoa [tiab] OR Samoan Islands [tiab] OR Navigator Island [tiab] OR Navigator Islands [tiab] OR Sao Tome [tiab] OR Saudi Arabia [tiab] OR Senegal [tiab] OR Serbia [tiab] OR Montenegro [tiab] OR Seychelles [tiab] OR Sierra Leone [tiab] OR Slovenia [tiab] OR Sri Lanka [tiab] OR Ceylon [tiab] OR Solomon Islands [tiab] OR Somalia [tiab] OR Sudan [tiab] OR Suriname [tiab] OR Surinam [tiab] OR Swaziland [tiab] OR Syria [tiab] OR Tajikistan [tiab] OR Tadzhikistan [tiab] OR Tadjikistan [tiab] OR Tadhik [tiab] OR Tanzania [tiab] OR Thailand [tiab] OR Togo [tiab] OR Togolese Republic [tiab] OR Tonga [tiab] OR Trinidad [tiab] OR Tobago [tiab] OR Tunisia [tiab] OR Turkey [tiab] OR Turkmenistan [tiab] OR Turkmen [tiab] OR Uganda [tiab] OR Ukraine [tiab] OR Uruguay [tiab] OR USSR [tiab] OR Soviet Union [tiab] OR Union of Soviet Socialist Republics [tiab] OR Uzbekistan [tiab] OR Uzbek OR Vanuatu [tiab] OR New Hebrides [tiab] OR Venezuela [tiab] OR Vietnam [tiab] OR Viet Nam [tiab] OR West Bank [tiab] OR Yemen [tiab] OR Yugoslavia [tiab] OR Zambia [tiab] OR Zimbabwe [tiab] OR Rhodesia [tiab] OR Africa [ot] OR Asia [ot] OR Caribbean [ot] OR West Indies [ot] OR South America [ot] OR Latin America [ot] OR Central America [ot] OR Afghanistan [ot] OR Albania [ot] OR Algeria [ot] OR Angola [ot] OR Antigua [ot] OR Barbuda [ot] OR Argentina [ot] OR Armenia [ot] OR Armenian [ot] OR Aruba [ot] OR Azerbaijan [ot] OR Bahrain [ot] OR Bangladesh [ot] OR Barbados [ot] OR Benin [ot] OR

Byelarus [ot] OR Byelorussian [ot] OR Belarus [ot] OR Belorussian [ot] OR Belorussia [ot] OR Belize [ot] OR Bhutan [ot] OR Bolivia [ot] OR Bosnia [ot] OR Herzegovina [ot] OR Hercegovina [ot] OR Botswana [ot] OR Brazil [ot] OR Bulgaria [ot] OR Burkina Faso [ot] OR Burkina Fasso [ot] OR Upper Volta [ot] OR Burundi [ot] OR Urundi [ot] OR Cambodia [ot] OR Khmer Republic [ot] OR Kampuchea [ot] OR Cameroon [ot] OR Cameroons [ot] OR Cameron [ot] OR Camerons [ot] OR Cape Verde [ot] OR Central African Republic [ot] OR Chad [ot] OR Chile [ot] OR China [ot] OR Colombia [ot] OR Comoros [ot] OR Comoro Islands [ot] OR Comores [ot] OR Mayotte [ot] OR Congo [ot] OR Zaire [ot] OR Costa Rica [ot] OR Cote d'Ivoire [ot] OR Ivory Coast [ot] OR Croatia [ot] OR Cuba [ot] OR Cyprus [ot] OR Czechoslovakia [ot] OR Czech Republic [ot] OR Slovakia [ot] OR Slovak Republic [ot] OR Djibouti [ot] OR French Somaliland [ot] OR Dominica [ot] OR Dominican Republic [ot] OR East Timor [ot] OR East Timur [ot] OR Timor Leste [ot] OR Ecuador [ot] OR Egypt [ot] OR United Arab Republic [ot] OR El Salvador [ot] OR Eritrea [ot] OR Estonia [ot] OR Ethiopia [ot] OR Fiji [ot] OR Gabon [ot] OR Gabonese Republic [ot] OR Gambia [ot] OR Gaza [ot] OR "Georgia Republic" [ot] OR "Georgian Republic" [ot] OR Ghana [ot] OR Gold Coast [ot] OR Greece [ot] OR Grenada [ot] OR Guatemala [ot] OR Guinea [ot] OR Guam [ot] OR Guiana [ot] OR Guyana [ot] OR Haiti [ot] OR Honduras [ot] OR Hungary [ot] OR India [ot] OR Maldives [ot] OR Indonesia [ot] OR Iran [ot] OR Iraq [ot] OR Isle of Man [ot] OR Jamaica [ot] OR Jordan [ot] OR Kazakhstan [ot] OR Kazakh [ot] OR Kenya [ot] OR Kiribati [ot] OR Korea [ot] OR Kosovo [ot] OR Kyrgyzstan [ot] OR Kirghizia [ot] OR Kyrgyz Republic [ot] OR Kirghiz [ot] OR Kirgizstan [ot] OR "Lao PDR" [ot] OR Laos [ot] OR Latvia [ot] OR Lebanon [ot] OR Lesotho [ot] OR Basutoland [ot] OR Liberia [ot] OR Libya [ot] OR Lithuania [ot] OR Macedonia [ot] OR Madagascar [ot] OR Malagasy Republic [ot] OR Malaysia [ot] OR Malaya [ot] OR Malay [ot] OR Sabah [ot] OR Sarawak [ot] OR Malawi [ot] OR Nyasaland [ot] OR Mali [ot] OR Malta [ot] OR Marshall Islands [ot] OR Mauritania [ot] OR Mauritius [ot] OR Agalega Islands [ot] OR Mexico [ot] OR Micronesia [ot] OR Middle East [ot] OR Moldova [ot] OR Moldovia [ot] OR Moldovian [ot] OR Mongolia [ot] OR Montenegro [ot] OR Morocco [ot] OR Ifni [ot] OR Mozambique [ot] OR Myanmar [ot] OR Myanma [ot] OR Burma [ot] OR Namibia [ot] OR Nepal [ot] OR Netherlands Antilles [ot] OR New Caledonia [ot] OR Nicaragua [ot] OR Niger [ot] OR Nigeria [ot] OR Northern Mariana Islands [ot] OR Oman [ot] OR Muscat [ot] OR Pakistan [ot] OR Palau [ot] OR Palestine [ot] OR Panama [ot] OR Paraguay [ot] OR Peru [ot] OR Philippines [ot] OR Philipines [ot] OR Phillipines [ot] OR Phillippines [ot] OR Poland [ot] OR Portugal [ot] OR Puerto Rico [ot] OR Romania [ot] OR Rumania [ot] OR Roumania [ot] OR Russia [ot] OR Russian [ot] OR Rwanda [ot] OR Ruanda [ot] OR Saint Kitts [ot] OR St Kitts [ot] OR Nevis [ot] OR Saint Lucia [ot] OR St Lucia [ot] OR Saint Vincent [ot] OR St Vincent [ot] OR Grenadines [ot] OR Samoa [ot] OR Samoan Islands [ot] OR Navigator Island [ot] OR Navigator Islands [ot] OR Sao Tome [ot] OR Saudi Arabia [ot] OR Senegal [ot] OR Serbia [ot] OR Montenegro [ot] OR Seychelles [ot] OR Sierra Leone [ot] OR Slovenia [ot] OR Sri Lanka [ot] OR Ceylon [ot] OR Solomon Islands [ot] OR Somalia [ot] OR Sudan [ot] OR Suriname [ot] OR Surinam [ot] OR Swaziland [ot] OR Syria [ot] OR Tajikistan [ot] OR Tadjhikistan [ot] OR Tadjikistan [ot] OR Tadjhik [ot] OR Tanzania [ot] OR Thailand [ot] OR Togo [ot] OR Togolese Republic [ot] OR Tonga [ot] OR Trinidad [ot] OR Tobago [ot] OR Tunisia [ot] OR Turkey [ot] OR Turkmenistan [ot] OR Turkmen [ot] OR Uganda [ot] OR Ukraine [ot] OR Uruguay [ot] OR USSR [ot] OR Soviet Union [ot] OR Union of Soviet Socialist Republics [ot] OR Uzbekistan [ot] OR Uzbek OR Vanuatu [ot] OR New Hebrides [ot] OR Venezuela [ot] OR Vietnam [ot] OR Viet Nam [ot] OR West Bank [ot] OR

Yemen [ot] OR Yugoslavia [ot] OR Zambia [ot] OR Zimbabwe [ot] OR Rhodesia [ot] OR Developing Countries [Mesh:noexp] OR Africa [Mesh:noexp] OR Africa, Northern [Mesh:noexp] OR Africa South of the Sahara [Mesh:noexp] OR Africa, Central [Mesh:noexp] OR Africa, Eastern [Mesh:noexp] OR Africa, Southern [Mesh:noexp] OR Africa, Western [Mesh:noexp] OR Asia [Mesh:noexp] OR Asia, Central [Mesh:noexp] OR Asia, Southeastern [Mesh:noexp] OR Asia, Western [Mesh:noexp] OR Caribbean Region [Mesh:noexp] OR West Indies [Mesh:noexp] OR South America [Mesh:noexp] OR Latin America [Mesh:noexp] OR Central America [Mesh:noexp] OR Afghanistan [Mesh:noexp] OR Albania [Mesh:noexp] OR Algeria [Mesh:noexp] OR American Samoa [Mesh:noexp] OR Angola [Mesh:noexp] OR "Antigua and Barbuda" [Mesh:noexp] OR Argentina [Mesh:noexp] OR Armenia [Mesh:noexp] OR Azerbaijan [Mesh:noexp] OR Bahrain [Mesh:noexp] OR Bangladesh [Mesh:noexp] OR Barbados [Mesh:noexp] OR Benin [Mesh:noexp] OR Byelarus [Mesh:noexp] OR Belize [Mesh:noexp] OR Bhutan [Mesh:noexp] OR Bolivia [Mesh:noexp] OR Bosnia-Herzegovina [Mesh:noexp] OR Botswana [Mesh:noexp] OR Brazil [Mesh:noexp] OR Bulgaria [Mesh:noexp] OR Burkina Faso [Mesh:noexp] OR Burundi [Mesh:noexp] OR Cambodia [Mesh:noexp] OR Cameroon [Mesh:noexp] OR Cape Verde [Mesh:noexp] OR Central African Republic [Mesh:noexp] OR Chad [Mesh:noexp] OR Chile [Mesh:noexp] OR China [Mesh:noexp] OR Colombia [Mesh:noexp] OR Comoros [Mesh:noexp] OR Congo [Mesh:noexp] OR Costa Rica [Mesh:noexp] OR Cote d'Ivoire [Mesh:noexp] OR Croatia [Mesh:noexp] OR Cuba [Mesh:noexp] OR Cyprus [Mesh:noexp] OR Czechoslovakia [Mesh:noexp] OR Czech Republic [Mesh:noexp] OR Slovakia [Mesh:noexp] OR Djibouti [Mesh:noexp] OR "Democratic Republic of the Congo" [Mesh:noexp] OR Dominica [Mesh:noexp] OR Dominican Republic [Mesh:noexp] OR East Timor [Mesh:noexp] OR Ecuador [Mesh:noexp] OR Egypt [Mesh:noexp] OR El Salvador [Mesh:noexp] OR Eritrea [Mesh:noexp] OR Estonia [Mesh:noexp] OR Ethiopia [Mesh:noexp] OR Fiji [Mesh:noexp] OR Gabon [Mesh:noexp] OR Gambia [Mesh:noexp] OR "Georgia (Republic)" [Mesh:noexp] OR Ghana [Mesh:noexp] OR Greece [Mesh:noexp] OR Grenada [Mesh:noexp] OR Guatemala [Mesh:noexp] OR Guinea [Mesh:noexp] OR Guinea-Bissau [Mesh:noexp] OR Guam [Mesh:noexp] OR Guyana [Mesh:noexp] OR Haiti [Mesh:noexp] OR Honduras [Mesh:noexp] OR Hungary [Mesh:noexp] OR India [Mesh:noexp] OR Indonesia [Mesh:noexp] OR Iran [Mesh:noexp] OR Iraq [Mesh:noexp] OR Jamaica [Mesh:noexp] OR Jordan [Mesh:noexp] OR Kazakhstan [Mesh:noexp] OR Kenya [Mesh:noexp] OR Korea [Mesh:noexp] OR Kosovo [Mesh:noexp] OR Kyrgyzstan [Mesh:noexp] OR Laos [Mesh:noexp] OR Latvia [Mesh:noexp] OR Lebanon [Mesh:noexp] OR Lesotho [Mesh:noexp] OR Liberia [Mesh:noexp] OR Libya [Mesh:noexp] OR Lithuania [Mesh:noexp] OR Macedonia [Mesh:noexp] OR Madagascar [Mesh:noexp] OR Malaysia [Mesh:noexp] OR Malawi [Mesh:noexp] OR Mali [Mesh:noexp] OR Malta [Mesh:noexp] OR Mauritania [Mesh:noexp] OR Mauritius [Mesh:noexp] OR Mexico [Mesh:noexp] OR Micronesia [Mesh:noexp] OR Middle East [Mesh:noexp] OR Moldova [Mesh:noexp] OR Mongolia [Mesh:noexp] OR Montenegro [Mesh:noexp] OR Morocco [Mesh:noexp] OR Mozambique [Mesh:noexp] OR Myanmar [Mesh:noexp] OR Namibia [Mesh:noexp] OR Nepal [Mesh:noexp] OR Netherlands Antilles [Mesh:noexp] OR New Caledonia [Mesh:noexp] OR Nicaragua [Mesh:noexp] OR Niger [Mesh:noexp] OR Nigeria [Mesh:noexp] OR Oman [Mesh:noexp] OR Pakistan [Mesh:noexp] OR Palau [Mesh:noexp] OR Panama [Mesh:noexp] OR Papua New Guinea [Mesh:noexp] OR Paraguay [Mesh:noexp] OR Peru [Mesh:noexp] OR Philippines [Mesh:noexp] OR Poland [Mesh:noexp] OR Portugal

[Mesh:noexp] OR Puerto Rico [Mesh:noexp] OR Romania [Mesh:noexp] OR Russia [Mesh:noexp] OR "Russia (Pre-1917)" [Mesh:noexp] OR Rwanda [Mesh:noexp] OR "Saint Kitts and Nevis" [Mesh:noexp] OR Saint Lucia [Mesh:noexp] OR "Saint Vincent and the Grenadines" [Mesh:noexp] OR Samoa [Mesh:noexp] OR Saudi Arabia [Mesh:noexp] OR Senegal [Mesh:noexp] OR Serbia [Mesh:noexp] OR Montenegro [Mesh:noexp] OR Seychelles [Mesh:noexp] OR Sierra Leone [Mesh:noexp] OR Slovenia [Mesh:noexp] OR Sri Lanka [Mesh:noexp] OR Somalia [Mesh:noexp] OR South Africa [Mesh:noexp] OR Sudan [Mesh:noexp] OR Suriname [Mesh:noexp] OR Swaziland [Mesh:noexp] OR Syria [Mesh:noexp] OR Tajikistan [Mesh:noexp] OR Tanzania [Mesh:noexp] OR Thailand [Mesh:noexp] OR Togo [Mesh:noexp] OR Tonga [Mesh:noexp] OR "Trinidad and Tobago" [Mesh:noexp] OR Tunisia [Mesh:noexp] OR Turkey [Mesh:noexp] OR Turkmenistan [Mesh:noexp] OR Uganda [Mesh:noexp] OR Ukraine [Mesh:noexp] OR Uruguay [Mesh:noexp] OR USSR [Mesh:noexp] OR Uzbekistan [Mesh:noexp] OR Vanuatu [Mesh:noexp] OR Venezuela [Mesh:noexp] OR Vietnam [Mesh:noexp] OR Yemen [Mesh:noexp] OR Yugoslavia [Mesh:noexp] OR Zambia [Mesh:noexp] OR Zimbabwe [Mesh:noexp] OR "tropical climate" OR "tropical climate" [MeSH] OR "Vulnerable Populations" [Mesh] OR "American Native Continental Ancestry Group" [Mesh] OR "Oceanic Ancestry Group" [Mesh] OR "aboriginals" [all fields] OR "aboriginals" [all fields] OR "native americans" [all fields] OR "native american" [all fields] OR "first nations" [all fields] OR inuit [all fields] OR eskimo [all fields] OR eskimos [all fields] OR maori [all fields] OR "Health Services, Indigenous" [MeSH]

Step 2 (53847 Citations)

"Growth Disorders" [Mesh:NoExp] OR "Body Weight Changes" [Mesh] OR "Child Nutrition Disorders" [Mesh] OR "Infant Nutrition Disorders" [Mesh]

Step 1 AND Step 2 (7592 Citations)

Step 3 (73672 Citations)

"Failure to Thrive" [Mesh] OR "Body Height" [Mesh] OR "Thinness" [Mesh] OR "Starvation" [Mesh] OR "Protein Deficiency" [Mesh] OR "Malnutrition" [Mesh] OR "Malnutrition" [Mesh] OR "stunting" [all fields] OR "stunted" [all fields] OR "wasted" [TIAB] OR "wasting" [TIAB] OR "height for age" [all fields] OR "weight for age" [all fields] OR "weight for height" [all fields] OR "growth faltering" [all fields] OR "underweight" [all fields] OR "under weight" [all fields] OR "short stature" [all fields]

(Step 1 AND Step 2) OR Step 3 (79085 Citations)

Step 4 (1848948 Citations)

'Child' [Mesh] OR 'Maternal-Child Health Centers' [Mesh] OR 'Child Nutrition Sciences' [Mesh] OR 'Child Health Services' [Mesh] OR 'Child Nutritional Physiological Phenomena' [Mesh] OR 'Child Nutrition Disorders' [Mesh] OR 'Child Mortality' [Mesh] OR 'Child Welfare' [Mesh] OR 'Child Care' [Mesh] OR 'Child Reactive Disorders' [Mesh] OR 'Child Guidance' [Mesh] OR 'Child Reactive Disorders' [Mesh] OR 'Child Behavior Disorders' [Mesh] OR 'Child, Orphaned' [Mesh]

OR 'Child, Institutionalized' [Mesh] OR 'Child, Hospitalized' [Mesh] OR 'Child Development' [Mesh] OR 'Child Behavior' [Mesh] OR 'Developmental Disabilities' [Mesh] OR 'Mental Disorders Diagnosed in Childhood' [Mesh] OR 'Disabled Children' [Mesh] OR 'children' [TIAB] OR 'newborn*' [TIAB] OR 'childhood' [TIAB] OR 'baby' [TIAB] OR 'babies' [TIAB] OR 'toddler' [TIAB] OR 'toddlers' [TIAB] OR 'infants' [TIAB] OR 'infant' [TIAB] OR 'infantile' [TIAB] OR 'young patient' [TIAB] OR 'young patients' [TIAB] OR 'Pediatric Nursing' [Mesh] OR 'Pediatric Assistants' [Mesh] OR 'Hospitals, Pediatric' [Mesh] OR 'Intensive Care Units, Pediatric' [Mesh] OR 'Pediatrics' [Mesh] OR 'Pediatricians' [TIAB] OR 'paediatricians' [TIAB] OR 'Pediatrician' [TIAB] OR 'paediatrician' [TIAB] OR 'Pediatrics' [TIAB] OR 'paediatrics' [TIAB] OR 'Pediatric' [TIAB] OR 'paediatric' [TIAB]

Step 4 AND ((Step 1 AND Step 2) OR Step 3(34445 Citations))

Step 5 (2329420 Citations)

"Congenital Abnormalities" [Mesh] OR "Genetic Diseases, Inborn" [Mesh] OR "Endocrine System Diseases" [Mesh] OR "Hormones, Hormone Substitutes, and Hormone Antagonists" [Mesh] OR "Kidney Diseases" [Mesh]

(Step 4 AND ((Step 1 AND Step 2) OR Step 3)) NOT Step 5 23238 Citations

EMBASE Malnutrition

completed April 19, 2010 (17,634 Citations)

Step 1 (3,164,283 citations)

'child'/exp OR 'child' OR 'children'/exp OR 'children' OR 'youth'/exp OR 'youth' OR youth* OR newborn* OR 'newborn'/exp OR 'newborn' OR 'new born' OR 'childhood disease'/exp OR 'childhood disease' OR 'baby'/exp OR 'baby' OR babies OR 'infant'/exp OR 'infant' OR infant* OR childhood* OR toddler* OR kid OR kids OR 'young patient' OR boy* OR girl* OR 'young age' OR pediatr* OR paediatr* OR 'child death'/exp OR 'child death' OR 'child health'/exp OR 'child health' OR 'child care'/exp OR 'child care' OR 'childhood mortality'/exp OR 'childhood mortality' OR 'child hospitalization'/exp OR 'child hospitalization' OR 'pediatric hospital'/exp OR 'pediatric hospital' OR child*

Step 2 (4,437,122 Citations)

Afghanistan or Albania or Algeria or Angola or Antigua or Barbuda or Argentina or Armenia or Armenian or Aruba or Azerbaijan or Bahrain or Bangladesh or Barbados or Benin or Byelarus or Byelorussian or Belarus or Belorussian or Belorussia or Belize or Bhutan or Bolivia or Bosnia or Herzegovina or Hercegovina or Botswana or Brazil or Bulgaria or 'Burkina Faso' or 'Burkina Fasso' or 'Upper Volta' or Burundi or Urundi or Cambodia or 'Khmer Republic' or Kampuchea or Cameroon or Cameroons or Cameron or Camerons or 'Cape Verde' or 'Central African

Republic' or Chad or Chile or China or Colombia or Comoros or 'Comoro Islands' or Comores or Mayotte or Congo or Zaire or 'Costa Rica' or 'Cote d Ivoire' or 'Ivory Coast' or Croatia or Cuba or Cyprus or Czechoslovakia or 'Czech Republic' or Slovakia or 'Slovak Republic' or Djibouti or 'French Somaliland' or Dominica or 'Dominican Republic' or 'East Timor' or 'East Timur' or 'Timor Leste' or Ecuador or Egypt or 'United Arab Republic' or 'El Salvador' or Eritrea or Estonia or Ethiopia or Fiji or Gabon or 'Gabonese Republic' or Gambia or Gaza or 'Georgia Republic' or 'Georgian Republic' or Ghana or 'Gold Coast' or Greece or Grenada or Guatemala or Guinea or Guam or Guiana or Guyana or Haiti or Honduras or Hungary or India or Maldives or Indonesia or Iran or Iraq or Jamaica or Jordan or Kazakhstan or Kazakh or Kenya or Kiribati or Korea or Kosovo or Kyrgyzstan or Kirghizia or Kyrgyz or Kirghiz or Kirgizstan or 'Lao PDR' or Laos or Latvia or Lebanon or Lesotho or Basutoland or Liberia or Libya or Lithuania or Macedonia or Madagascar or Malagasy or Malaysia or Malaya or Malay or Sabah or Sarawak or Malawi or Nyasaland or Mali or Malta or 'Marshall Islands' or Mauritania or Mauritius or 'Agalega Islands' or Mexico or Micronesia or 'Middle East' or Moldova or Moldavia or Moldovan or Mongolia or Montenegro or Morocco or Ifni or Mozambique or Myanmar or Myanma or Burma or Namibia or Nepal or 'Netherlands Antilles' or 'New Caledonia' or Nicaragua or Niger or Nigeria or 'Mariana Islands' or Oman or Muscat or Pakistan or Palau or Palestine or Panama or Paraguay or Peru or Philippines or Philipines or Phillipines or Phillippines or Poland or Portugal or 'Puerto Rico' or Romania or Rumania or Roumania or Russia or Russian or Rwanda or Ruanda or 'Saint Kitts' or 'St Kitts' or Nevis or 'Saint Lucia' or 'St Lucia' or 'Saint Vincent' or 'St Vincent' or Grenadines or Samoa or 'Samoa Islands' or 'Navigator Island' or 'Navigator Islands' or 'Sao Tome' or 'Saudi Arabia' or Senegal or Serbia or Montenegro or Seychelles or 'Sierra Leone' or Slovenia or 'Sri Lanka' or Ceylon or 'Solomon Islands' or Somalia or Sudan or Suriname or Surinam or Swaziland or Syria or Tajikistan or Tadjhikistan or Tadjikistan or Tadjhik or Tanzania or Thailand or Togo or Togolese or Tonga or Trinidad or Tobago or Tunisia or Turkey or Turkmenistan or Turkmen or Uganda or Ukraine or Uruguay or USSR or 'Soviet Union' or 'Union of Soviet Socialist Republics' or Uzbekistan or Uzbek or Vanuatu or 'New Hebrides' or Venezuela or Vietnam or 'Viet Nam' or 'West Bank' or Yemen or Yugoslavia or Zambia or Zimbabwe or Rhodesia OR ((developing or 'less developed' or 'under developed' or underdeveloped or 'middle income' or 'low income' or 'lower income' or underserved or 'under served' or deprived or poor*) and (countn* or nation* or population* or world)) OR ((developing or 'less developed' or 'lesser developed' or 'under developed' or underdeveloped or middle income or 'lower income' or 'lower income') AND (economy or economies)) OR (low* NEAR (gdp or gnp or gross domestic or gross national)) OR (low NEAR/3 middle) OR (Imic OR Imics OR third AND world OR 'lami countries' OR 'lami country') OR (transitional AND countn*) OR 'tropic climate'/exp OR 'aborigine'/exp OR 'American Indian'/exp OR 'Eskimo'/exp OR 'Maori'/exp OR 'indigenous people'/exp

Step 3 (141,231 Citations)

'thinness' OR 'stunted' OR 'stunting' OR 'growth faltering' OR 'wasted' OR 'height for age' OR 'weight for age' OR 'weight for height' OR 'underweight' OR 'under weight' OR 'growth failure' OR 'protein deficiency'/exp OR 'starvation'/exp OR 'underweight'/exp OR 'lean body weight'/exp OR 'weight change'/exp OR 'growth curve'/exp OR 'growth inhibition'/exp OR 'growth rate'/exp OR 'postnatal growth'/exp OR 'failure to thrive'/exp OR 'wasting syndrome'/exp OR 'malnutrition'/de or 'developmental, age and growth parameters'/de OR 'growth disorder'/de OR 'body height'/exp OR 'body height'/exp

Step 1 AND Step 2 AND Step 3 (24,575 Citations)

Step 4

'genetic and familial disorders'/exp OR 'congenital disorder'/exp OR 'endocrine disease'/exp OR 'hormones and agents acting on the endocrine system'/exp OR 'urogenital tract disease'/exp OR 'neoplasm'/exp

(Step 1 AND Step 2 AND Step 3) NOT Step 4 (16,833 Citations)

Step 5 (13,130 Citations)

'growth retardation'/exp

Step 1 and Step 2 and Step 5 (2,321 Citations)

Step 6 (5,6000,005)

'genetic and familial disorders'/exp OR 'congenital disorder'/exp OR 'hormones and agents acting on the endocrine system'/exp OR 'urogenital tract disease'/exp OR 'neoplasm'/exp

(Step 1 and Step 2 and Step 3) NOT Step 6 (801 Citations)

((Step 1 AND Step 2 AND Step 3) NOT Step 4) OR ((Step 1 and Step 2 and Step 5) NOT Step 6) (17,634 Citations)

WHO LILACS Database (TE/ED and Malnutrition)

completed June 17, 2010 (1617 Citations)

("tropical sprue" OR "tropical enteropathy" OR "environmental enteropathy" OR "persistent diarrhea" OR "Persistent diarrhoea" or "chronic diarrhoea" or "chronic diarrhea" OR "tropical malabsorption syndrome" OR Stunting OR wasting OR underweight OR "height for age" OR "weight for height" OR "weight for age" OR malnutrition) and (Child OR Children OR newborn OR childhood OR baby OR babies OR toddler OR toddlers OR infants OR infant OR infantile OR young patient OR young patients OR Pediatricians OR paediatricians OR Pediatrician OR paediatrician OR Pediatrics OR paediatrics OR Pediatric OR paediatric)

WHO SE Asia Database (IMSEAR) (TE/ED and Malnutrition)

completed June 17, 2010 (1335 Citations)

((("tropical sprue" OR "tropical enteropathy" OR "environmental enteropathy" OR "persistent diarrhea" OR "Persistent diarrhoea" or "chronic diarrhoea" or "chronic diarrhea" OR "tropical malabsorption syndrome" OR Stunting OR wasting OR underweight OR "height for age" OR "weight for height" OR "weight for age" OR malnutrition) AND (Child OR Children OR newborn

OR childhood OR baby OR babies OR toddler OR toddlers OR infants OR infant OR infantile OR young patient OR young patients OR Pediatricians OR paediatricians OR Pediatrician OR paediatrician OR Pediatrics OR paediatrics OR Pediatric OR paediatric))

WHO Western Pacific Region Index Medicus (WPRIM) (TE/ED and Malnutrition)

completed June 17, 2010 (685 Citations)

"tropical sprue" OR "tropical enteropathy" OR "environmental enteropathy" OR "persistent diarrhea" OR "Persistent diarrhoea" or "chronic diarrhoea" or "chronic diarrhea" OR "tropical malabsorption syndrome" OR Stunting OR wasting OR underweight OR "height for age" OR "weight for height" OR "weight for age" OR malnutrition

WHO EMRO (IMEMR) (TE/ED and Malnutrition)

completed June 17, 2010 (459 Citations)

Child OR Children OR newborn OR childhood OR baby OR babies OR toddler OR toddlers OR infants OR infant OR infantile OR young patient OR young patients OR Pediatricians OR paediatricians OR Pediatrician OR paediatrician OR Pediatrics OR paediatrics OR Pediatric OR paediatric [KeyWords] and "tropical sprue" OR "tropical enteropathy" OR "environmental enteropathy" OR "persistent diarrhea" OR "Persistent diarrhoea" or "chronic diarrhoea" or "chronic diarrhea" OR "tropical malabsorption syndrome" OR Stunting OR wasting OR underweight OR "height for age" OR "weight for height" OR "weight for age" OR malnutrition [KeyWords]

WHO African Index Medicus (TE/ED and Malnutrition)

completed June 17, 2010 (70 Citations)

"tropical sprue" OR "tropical enteropathy" OR "environmental enteropathy" OR "persistent diarrhea" OR "Persistent diarrhoea" or "chronic diarrhoea" or "chronic diarrhea" OR "tropical malabsorption syndrome" OR Stunting OR wasting OR underweight OR "height for age" OR "weight for height" OR "weight for age" OR malnutrition

Appendix 2. References used to test systematic search.

These papers were used to confirm inclusiveness in search criteria, and to confirm that filters do not inadvertently exclude relevant work.

Reference	Setting and why selected
Brown KH, Khatun M, Ahmed G. Relationship of the xylose absorption status of children in Bangladesh to their absorption of macronutrients from local diets. <i>Am J Clin Nut.</i> 1981;34(8):1540-7.	Setting: Bangladesh Reason for selection: Biomarker and physiologic test studied
Fagundes-Neto U, Viaro T, Wehba J, Patrício FR, Machado NL. Tropical enteropathy (environmental enteropathy) in early childhood: a syndrome caused by contaminated environment. <i>J Trop Pediatr.</i> 1984;30(4):204-9.	Setting: Brazil Reason for selection: Biomarkers, pathophysiologic correlates
Solomons NW, Mazariegos M, Brown KH, Klasing K. The underprivileged, developing country child: environmental contamination and growth failure revisited. <i>Nutr Rev</i> 1993;51(11):327-32.	Setting: Review Reason for selection: Addresses pathophysiology and epidemiology
Fagundes-Neto U, Martins MC, Lima FL, Patricio FR, Toledo MR. Asymptomatic environmental enteropathy among slum-dwelling infants. <i>J Am Coll Nutr</i> 1994;13(1):51-6.	Setting: Brazil Reason for selection: Pathophysiology
Bhutta ZA, Hendricks KM. Nutritional management of persistent diarrhea in childhood: a perspective from the developing world. <i>J Pediatr Gastroenterol Nutr</i> 1996;22(1):17-37.	Setting: Review Reason for selection: Therapy and epidemiology
Menzies IS, Zuckerman MJ, Nukajam WS, Somasundaram SG, Murphy B, Jenkins AP, et al. Geography of intestinal permeability and absorption. <i>Gut</i> 1999;44(4):483-9 ¹ .	Setting: Qatar Reason for selection: Pathophysiology
Campbell DI, Elia M, Lunn PG. Growth faltering in rural Gambian infants is associated with impaired small intestinal barrier function, leading to endotoxemia and systemic inflammation. <i>J Nutr.</i> 2003;133(5):1332-8.	Setting: Gambia Reason for selection: Biomarkers related to stunting
Kukuruzovic R, Brewster DR, Gray E, Anstey NM. Increased nitric oxide production in acute diarrhoea is associated with abnormal gut permeability, hypokalaemia and malnutrition in tropical Australian aboriginal children. <i>Trans R Soc Trop Med Hyg.</i> 2003;97(1):115-20.	Setting: Australian Aboriginal children Reason for selection: Relates a relevant biomarker (NO production) to lactulose/rhamnose test of intestinal permeability
Solomons NW. Environmental contamination and chronic inflammation influence human growth potential. <i>J Nutr</i> 2003;133(5):1237 ² .	Setting: Commentary Reason for selection: Risk factors

¹ The reference was not captured in the umbrella search of multiple databases with both TE/ED and stunting search terms (i.e., PubMed + EMBASE + GH—TE/ED + stunting).

² The reference was captured in the PubMed stunting search but lost when the child filter was added.

Reference	Setting and why selected
Campbell DI, McPhail G, Lunn PG, Elia M, Jeffries DJ. Intestinal inflammation measured by fecal neopterin in Gambian children with enteropathy: association with growth failure, <i>Giardia lamblia</i> , and intestinal permeability. J Pediatr Gastroenterol Nutr. 2004;39(2):153-7.	Setting: Gambia Reason for selection: Marker of gut inflammation in children and inflammation is related to another biomarker (lactulose:mannitol ratio) and growth of children in study
Salazar-Lindo E, Allen S, Brewster DR, Elliott EJ, Fasano A, Phillips AD, et al. Intestinal infections and environmental enteropathy: Working Group report of the second World Congress of Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr 2004;39 Suppl 2:S662-9.	Setting: Review Reason for selection: Broadly inclusive of topics of interest
Lima AA, Brito LF, Ribeiro HB, Martins MC, Lustosa AP, Rocha EM, et al. Intestinal barrier function and weight gain in malnourished children taking glutamine supplemented enteral formula. J Pediatr Gastroenterol Nutr 2005;40(1):28-35.	Setting: Brazil Reason for selection: Pathophysiology and treatment
Bhutta ZA. Effect of infections and environmental factors on growth and nutritional status in developing countries. J Pediatr Gastroenterol Nutr 2006;43 Suppl 3:S13-21 ³ .	Setting: Review Reason for selection: Epidemiology and causative factors
Bhutta ZA, Nelson EA, Lee WS, Tarr PI, Zablach R, Phua KB, et al. Recent advances and evidence gaps in persistent diarrhea. J Pediatr Gastroenterol Nutr 2008;47(2):260-5.	Setting: Review Reason for selection: Broadly inclusive data
Botero-Garcés JH, García-Montoya GM, Grisales-Patiño D, Aguirre-Acevedo DC, Alvarez-Urbe MC. <i>Giardia intestinalis</i> and nutritional status in children participating in the complementary nutrition program, Antioquia, Colombia, May to October 2006. Rev Inst Med Trop Sao Paulo. 2009;51(5):155-62.	Setting: Colombia Reason for selection: Studies relation between a specific agent and nutritional status
Goto R, Mascie-Taylor CG, Lunn PG. Impact of intestinal permeability, inflammation status and parasitic infections on infant growth faltering in rural Bangladesh 2009: Br J Nutr. 2009;101(10):1509-16.	Setting: Rural Bangladesh Reason for selection: Biomarkers associated with stunting
Humphrey JH. Child undernutrition, tropical enteropathy, toilets, and handwashing. Lancet 2009;374(9694):1032-5.	Setting: Review Reason for selection: Environmental factors
Ritchie BK, Brewster DR, Davidson GP, Tran CD, McNeil Y, Hawkes JS, et al. 13C-sucrose breath test: novel use of a noninvasive biomarker of environmental gut health. Pediatrics. 2009;124(2):620-6.	Setting: Australian Aboriginal children Reason for selection: Novel biomarker (exhaled isotope) to test intestinal permeability

³ The reference was captured in the search with only the stunting term.

Appendix 3. Summary of sampled references published between 1990-1999.

Method: An index of records determined to be relevant to this systematic review was sorted by year. From this ordering, every 10th article was sampled.

1. Khoshoo V, Bhan MK, Jain R, Jayashree S, Bhandari N, Sazawal S, et al. Intestinal glucoamylase and other disaccharidases in children with protracted diarrhoea. Indian J Med Res. 1990;92:1-4.

Sample size: 42 (all < 5 years of age)

Subjects: Persistent or chronic diarrhea and malnutrition

Markers: Jejunal biopsy, brush border disaccharidase activity, and correlation of latter with degree of mucosal injury

Relevance to 2000-2010 set: Disaccharidase activity was investigated in one study from the previous decade; this study adds assessment of its relationship with histology.

2. Saavedra JM, Brown KH. Nonabsorbable marker and single, random stool samples used for measuring intestinal absorption of macronutrients in infants and children. Am J Clin Nutr. 1991;53(3):790-94.

Sample size: 21 (all < 5 years of age)

Subjects: Malnourished

Markers: Fecal excretion of polyethylene glycol as a marker of intestinal absorption and in comparison to standard balance test

Relevance to 2000-2010 set: These tests of absorption were not included in the previous decade article set.

3. Sullivan PB, Lunn PG, Northrop-Clewes C, Crowe PT, Marsh MN, Neale G. Persistent diarrhea and malnutrition--the impact of treatment on small bowel structure and permeability. J Pediatr Gastroenterol Nutr. 1992;14(2):208-15.

Sample size: 20 (all < 5 years of age)

Subjects: Persistent or chronic diarrhea, most also malnourished

Markers: Lactulose and mannitol fractional excretion, L:M, and jejunal biopsy; compared L:M with biopsy results

Relevance to 2000-2010 set: The L:M test was reported in 25 studies in later decade, but none compared it to histology.

4. Baqui AH, Sack RB, Black RE, Chowdhury HR, Yunus M, Siddique AK. Cell-mediated immune deficiency and malnutrition are independent risk factors for persistent diarrhea in Bangladeshi children. Am J Clin Nutr. 1993;58(4):543-48.

Sample size: 705 (all < 5 years of age)

Subjects: Persistent diarrhea, malnutrition, or asymptomatic

Markers: Cell-mediated immune response with multiple-antigen skin test

Relevance to 2000-2010 set: A similar study was published in the 2000-2010 publication set.

5. Roy SK, Akramuzzaman SM, Haider R, Khatun M, Akbar MS, Eeckels R. Persistent diarrhoea: efficacy of a rice-based diet and role of nutritional status in recovery and nutrient absorption. Br J Nutr. 1994;71(1):123-34.

Sample size: 51 (all < 5 years of age)

Subjects: Persistent diarrhea (many also malnourished) and controls with previous history of acute diarrhea

Markers: Comparison of nutrient absorption in cases and controls determined by 72-hour balance study and recovery of cases following rice-based diet therapy

Relevance to 2000-2010 set: The 72 hour balance study was not reported in studies reviewed from the later decade.

6. Kallas MR, Patricio FR, Fagundes-Neto U. [Morphometrics of the small intestine in children with diarrhea due to classical enteropathogenic *Escherichia coli* and to environmental asymptomatic enteropathy]. *Rev Assoc Med Bras.* 1995;41(3):162-166. Portuguese.
Sample size: 46 (likely most or all subjects < 5 years of age; mean age was under 7 months)
Subjects: Acute or persistent diarrhea with stool culture positive for EPEC (cases) or asymptomatic children negative for EPEC (controls)
Markers: Small intestine biopsy and morphometry
Relevance to 2000-2010 set: Histology was examined in 18 studies in the 2000-2010 set with one study also using morphometric assessment.
7. Cooper ES, Ramdath DD, Whyte-Alleng C, Howell S, Serjeant BE. Plasma proteins in children with trichuris dysentery syndrome. *J Clin Pathol.* 1997;50(3):236-240.
Sample size: 89 (many older than 5 years of age)
Subjects: Chronic diarrhea with and without *Trichuris* dysentery syndrome and healthy controls
Markers: Blood markers: alpha-1-antitrypsin, ceruloplasmin, albumin, globulin, fibrinogen, fibronectin, ferritin, transferrin, plasma viscosity, hemoglobin, leukocytes, and CRP
Relevance to 2000-2010 set: Primarily assessed markers of systemic inflammation that were reviewed in assessments of articles from the previous decade. The remaining markers are primarily assessments of hepatic function and were not assessed in the 2000-2010 set.
8. Brooks SE, Reid WA. Scanning electron microscopy of the jejunum in children with protein-energy malnutrition. *West Indian Med J.* 1997;46(1):15-21.
Sample size: 7 (all < 5 years of age)
Subjects: Fatal severe kwashiorkor or marasmic kwashiorkor
Markers: Scanning electron microscopy (SEM) and light microscopy on jejunal biopsy sections taken by autopsy and fixed within 75 minutes after death
Relevance to 2000-2010 set: In the later decade publications, SEM and light microscopy were used in one study to investigate jejunal morphology in 16 infants with persistent diarrhea, many of whom also had small bowel bacterial overgrowth (as measured by jejunal secretion) and/or exhibited some degree of malnutrition.
9. Abbas KA, Bilal R, Sajjad MI, Latif Z, Mirza NH. Fat absorption in persistent diarrhoea using ¹³C-labelled trioctanoin breath test. *J Trop Pediatr.* 1999;45(2):87-94.
Sample size: 10 (all < 5 years of age)
Subjects: Persistent diarrhea (some with malnutrition) and asymptomatic controls
Markers: Fat absorption by breath test after ¹³C-labelled trioctanoin administration
Relevance to 2000-2010 set: 2 studies in the 1990-1999 publication set assessed fat absorption although not by breath test with this specific medium chain fatty acid.
10. Taniguchi K, Rikimaru T, Yartey JE, Akpedonu P, Armar-Klemesu MA, Nkrumah FK, et al. Immunological background in children with persistent diarrhea in Ghana. *Pediatr Int.* 1999;41(2):162-167.
Sample size: 85 (all < 5 years of age)
Subjects: Persistent or acute diarrhea
Markers: A variety of serum markers of systemic inflammation and immune response were compared between persistent and acute diarrhea cases, including: albumin, pre-albumin, total protein, transferrin, IgA & IgG subclass fractions, natural killer cells, lymphocyte immunophenotypes, and T-cell activation.
Relevance to 2000-2010 set: Many of these systemic markers were examined in the 2000-2010 set, although some were not.

Appendix 4. Sample REDCap template.

Data Export Tool

Use the page below to select fields you wish to extract from the project. Each row contains language from the original data collection instrument, plus a parenthetical listing of the actual project field name.

You may use the buttons at the top of the form to select or deselect all fields for a given data collection instrument, duplicate your last data retrieval, or select all fields in the project for export. Once all fields are selected, go to the bottom of this page and click the Submit button. After submitting this page, wait for a page to appear allowing you to save the file to your computer. The files are comma-delimited and may be read into SPSS, Excel, R, SAS or other analysis packages. If any fields in the project have been tagged as Identifiers, those particular fields will be displayed below in red.

Use the buttons below to select fields by form - or click individual fields below. Click the SUBMIT button at bottom of page to finalize data export procedure.

Every field in the project

Repeat field selection from your last export

Form: Study Id Info


Form: Study Data

Form: Summary Synthesis

Form: Study Id Info	
Record number (<i>record_number</i>)	<input checked="" type="checkbox"/>
Copyright (<i>copyright_agreement</i>)	<input type="checkbox"/>
Year of publication (<i>publication_year</i>)	<input checked="" type="checkbox"/>
Authors (<i>authors</i>)	<input checked="" type="checkbox"/>
Journal (<i>journal</i>)	<input checked="" type="checkbox"/>
Title (<i>title</i>)	<input checked="" type="checkbox"/>
PMID (<i>pmid</i>)	<input type="checkbox"/>
Source spreadsheet number (<i>spreadsheet_name</i>)	<input type="checkbox"/>

Summary Synthesis

 Download form as PDF  PDF with saved data

 Editing existing Record number **444**

Record number	444
Does this study directly compare a diagnostic method to biopsy (using the latter as a gold standard)?	<input type="radio"/> Yes <input checked="" type="radio"/> No
Does this study compare a dx method to other, non-biopsy dx methods?	<input type="radio"/> Yes <input checked="" type="radio"/> No
Comments on evidence quality	limitations: studies of biopsy samples too small for in-depth glyco-biological analysis with current technology. Analysis of staining intensity, even with computerized densitometry, is a relatively crude approach to a complex biosynthetic process. Potential sources of artifact may arise during tissue handling or staining.
Any points about this article that could be pertinent for other systematic review questions	topic area III, II
Synthesis: relevant conclusions for our review <small>* must provide value</small>	Zambian children w/ PD and malnutrition had greater inflam cell densities than did those UK controls. Marasmic children had greater inflammatory cell densities than did those with kwashiorkor. Expression of both HSPG and GAGs was similar between marasmic and UK children but

Appendix 5. Highly considered but excluded references.

Reference	Country	Reason for exclusion
Altuntas B, Filik B, Ensari A, Zorlu P, Teziç T. Can zinc deficiency be used as a marker for the diagnosis of celiac disease in Turkish children with short stature? <i>Pediatr Int.</i> 2000;42(6):682-684.	Turkey	Biopsy data were the same as previously reported in a 1998 publication ¹ that was included in this review. This 2000 publication adds no new data of relevance to this review.
Bahia M, Rabello A, Brasileiro Filho G, Penna FJ. Serum anti gliadin antibody levels as a screening criterion before jejunal biopsy indication for celiac disease in a developing country. <i>Braz J Med Biol Res.</i> 2001;34(11):1415-1420.	Brazil	The only outcomes of interest to this review that were reported on for subjects of interest (controls that did not have celiac disease) were that their jejunal biopsy results were “normal,” and no other data or specific information was reported that pertained to this review.
Bay A, Oner AF, Celebi V, Uner A. Evaluation of vitamin K deficiency in children with acute and intractable diarrhea. <i>Adv Ther.</i> 2006;23(3):469-474.	Turkey	Outcomes were primarily related to micronutrient (vitamin K) deficiency or malabsorption.
Cooke ML, Goddard EA, Brown RA. Endoscopy findings in HIV-infected children from sub-Saharan Africa. <i>J Trop Pediatr.</i> 2009;55(4):238-243.	South Africa	Most subjects had upper gastrointestinal conditions that were not of interest to this review. Only 3 subjects had diarrhea, and it was unlikely that they were all under 5 yr.
Kelly P, Musuku J, Kafwembe E, Libby G, Zulu I, Murphy J, et al. Impaired bioavailability of vitamin A in adults and children with persistent diarrhoea in Zambia. <i>Aliment Pharmacol Ther.</i> 2001;15(7):973-979.	Zambia	Change in serum retinol status was assessed following administration of oral vitamin A to adult cases (males hospitalized with persistent diarrhea (PD)) (n=15), controls (males hospitalized with conditions other than PD) (n=24) and cases under 2 yr hospitalized with PD and malnutrition (n=11). While the children with PD did have similar degrees of change in serum retinol after vitamin A administration compared to the adult controls, the study did not include childhood controls. Without childhood controls and with limited sample size of children, interpretation and generalization of findings to childhood enteric function is limited.
Kukuruzovic R, Robins-Browne RM, Anstey NM, Brewster DR. Enteric pathogens, intestinal permeability and nitric oxide	Australia	Data on outcomes of interest to this review were not reported.

¹ Altuntas B, Kansu A, Ensari A, Girgin N. Celiac disease in Turkish short-statured children and the value of anti gliadin antibody in diagnosis. *Acta Paediatr Jpn.* 1998;40(5):457-460.

Reference	Country	Reason for exclusion
production in acute gastroenteritis. <i>Pediatr Infect Dis J.</i> 2002;21(8):730-739.		
Kumar R, Marwaha N, Marwaha RK, Garewal G. Vitamin K deficiency in diarrhoea. <i>Indian J Pediatr.</i> 2001;68(3):235-238.	India	Outcomes were primarily related to micronutrient (vitamin K) deficiency or malnutrition.
Manary MJ, Hotz C, Krebs NF, Gibson RS, Westcott JE, Arnold T, et al. Dietary phytate reduction improves zinc absorption in Malawian children recovering from tuberculosis but not in well children. <i>J Nutr.</i> 2000;130(12):2959-2964.	Malawi	Subjects ranged in age from 3-13 yr, but based on the group means and standard deviations for age, there were likely to be few subjects under age 5 years.
Thacher TD, Obadofin MO, O'Brien KO, Abrams SA. The effect of vitamin D2 and vitamin D3 on intestinal calcium absorption in Nigerian children with rickets. <i>J Clin Endocrinol Metab.</i> 2009;94(9):3314-3321.	Nigeria	Study assessed differences in calcium uptake with varying vitamin D preparations and was not an assessment of intestinal function.
Ukarapol N, Lertprasertsuk N, Fuchs GJ, Wongsawasdi L, Sirisanthana V. Impact of gastrointestinal endoscopy on HIV-infected children. <i>Dig Endosc.</i> 2004;16(1):26-29.	Thailand	Study described 13 colonoscopy or sigmoidoscopy and 10 gastroduodenoscopy sessions for 14 patients resulting in 7 possible assessments of the small intestine. However results were aggregated across gastrointestinal anatomical sites, and it was difficult to extract results of interest to this review.
Walkowiak J, Herzig KH. Fecal elastase-1 is decreased in villous atrophy regardless of the underlying disease. <i>Eur J Clin Invest.</i> 2001;31(5):425-430.	Poland	The age range of all subjects (n=54) was 2-16 yr with a mean of 7.0 yr, SE=0.5. The sample size of children of any age with presentations of interest to this review was n=18. The high mean age of subjects coupled with small sample size suggest that few children with presentations meeting inclusion criteria were likely under 5 yr. In addition, it was unclear if the study setting met developing country setting inclusion criteria.
Yachha SK, Aggarwal R, Srinivas S, Srivastava A, Somani SK, Itha S. Antibody testing in Indian children with celiac disease. <i>Indian J Gastroenterol.</i> 2006;25(3):132-135.	India	While some subjects in this study were under 5 yr of age, the subjects of interest to this review (i.e., the children without celiac disease who had small intestinal biopsies) were all aged ≥ 5 yr.

Appendix 6. Review articles with information of relevance to the systematic review.

-
- Bhatnagar S. Laboratory diagnosis of persistent and chronic diarrhea. *IJPP*. 2003;5(2):125-132.
-
- Bhutta ZA, Nelson EA, Lee WS, Tarr PI, Zablath R, Phua KB, et al. Recent advances and evidence gaps in persistent diarrhea. *J Pediatr Gastroenterol and Nutr*. 2008;47(2):260-265.
-
- Bhutta ZA. Effect of infections and environmental factors on growth and nutritional status in developing countries. *J Pediatr Gastroenterol Nutr*. 2006 Dec;43: Suppl 3:S13-21.
-
- Bickler SW. Tropical enteropathy protects against Western diseases in environments of poor sanitation. *Med Hypotheses*. 2006;67(1):146-150.
-
- Brewster DR. Critical appraisal of the management of severe malnutrition: 3. Complications. *J Paediatr Child Health*. 2006;42(10):583-593.
-
- Brewster DR, Manary MJ, Menzies IS, O'Loughlin EV, Henry RL. Intestinal permeability in kwashiorkor. *Arch Dis Child*. 1997; Mar;76(3):236-41.
-
- Butler RN. Non-invasive tests in animal models and humans: a new paradigm for assessing efficacy of biologics including prebiotics and probiotics. *Curr Pharm Des*. 2008;14(14):1341-50.
-
- Davidson G, Kritas S, Butler R. Stressed mucosa. *Nestle Nutr Workshop Ser Pediatr Program*. 2007;59:133-142; discussion 143-146.
-
- Gibbons T, Fuchs GJ. Chronic enteropathy: clinical aspects. *Nestle Nutr Workshop Ser Pediatr Program*. 2007;59:89-101; discussion 102-104.
-
- Guerrant RL, Oriá RB, Moore SR, Oriá MO, Lima AA. Malnutrition as an enteric infectious disease with long-term effects on child development. *Nutr Rev*. 2008;66(9):487-505.
-
- Humphrey JH. Child undernutrition, tropical enteropathy, toilets, and handwashing. *Lancet*. 2009;374(9694):1032-35.
-
- Mehta S. Celiac disease in India. *Indian J Gastroenterol*. 2008;27(1):43.
-
- Petri WA Jr, Miller M, Binder HJ, Levine MM, Dillingham R, Guerrant RL. Enteric infections, diarrhea, and their impact on function and development. *J Clin Invest*. 2008;118(4):1277-90.
-
- Prentice AM, Darboe MK. Growth and host-pathogen interactions. *Nestle Nutr Workshop Ser Pediatr Program*. 2007;61:197-210.
-
- Ramakrishna BS, Venkataraman S, Mukhopadhyaya A. Tropical malabsorption. *Postgrad Med J*. 2006; 82(974):779-787.
-
- Solon JA, Morgan G, Prentice A. Mucosal immunity in severely malnourished Gambian children. *J Pediatr*. 2006; 149(5) Suppl:S100-S106.
-
- Sondheimer JM. Glutamine for childhood malnutrition: Probably not needed. *J Pediatr Gastroenterol and Nutr*. 2005;40(1):24-25.
-
- Sullivan PB. Studies of the small intestine in persistent diarrhea and malnutrition: the Gambian experience. *J Pediatr Gastroenterol Nutr*. 2002;34 Suppl 1:S11-13.
-
- Taren DL. Diarrhea and other gastrointestinal diseases. In: Gershwin ME, Nestel P, Keen CL, editors. *Handbook of Nutrition and Immunity*. Humana Press; 2004;287-302.
-
- Velasco-Benitez CA. Digestive, hepatic, and nutritional manifestations in Latin American children with HIV/AIDS. *J Pediatr Gastroenterol Nutr*. 2008;47 Suppl 1:S24-26.
-

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
<p>2003</p> <p>Alcantara CS et al.</p> <p>Interleukin-8, tumor necrosis factor-alpha, and lactoferrin in immunocompetent hosts with experimental and Brazilian children with acquired cryptosporidiosis</p> <p>Fecal cytokines and lactoferrin as markers of intestinal inflammation among children with and without <i>Cryptosporidium parvum</i>.</p>	<p>Fortaleza, Brazil</p> <p>3-43 mo olds recruited from a shantytown community who were screened for enteric pathogens.</p> <p>There was a high prevalence of malnutrition among the cases.</p> <p>(Adults experimentally exposed to <i>C. parvum</i> by ingestion were also studied; these data were not included in this review.)</p>	<p>Case-control</p> <p>n=32;</p> <p>n=17 cases with <i>C. parvum</i>:</p> <ul style="list-style-type: none"> • 4 with no diarrhea • 10 with AD • 3 with PD <p>n=15 controls with no diarrhea or enteric pathogens and comparable HAZ and WAZ scores to cases</p>	<p><u>Stool tests:</u></p> <ul style="list-style-type: none"> • Lactoferrin (17 cases and 15 controls tested) • IL-8 (13 cases and 15 controls tested) • TNF-α (10 cases and 0 controls tested) 	<p>Lactoferrin positive:</p> <ul style="list-style-type: none"> • 12/17 cases <ul style="list-style-type: none"> • 1/4 cases without diarrhea • 8/10 AD cases • 3/3 PD cases • 3/15 controls (p=0.006 compared to cases) <p>IL-8 detectable:</p> <ul style="list-style-type: none"> • 3/13 all cases <ul style="list-style-type: none"> • 0/2 cases without diarrhea • 3/10 AD cases • 0/1 PD cases • 6/16 controls (p=0.435 compared to cases) <p>TNF-α detectable:</p> <ul style="list-style-type: none"> • 0/10 cases 	<p>The proportion of children who tested positive for fecal lactoferrin was greater in those with cryptosporidiosis, especially those symptomatic with diarrhea, than in uninfected controls, although 20% of the control group tested positive.</p> <p>Fecal IL-8 did not differ between those with and without <i>Cryptosporidium</i> infection. TNF-α was not elevated among children with <i>Cryptosporidium</i> infection.</p>	<p>Direct comparisons between various stool tests were not reported.</p> <p>Lactoferrin results were graded based on agglutination reaction positivity with increasing dilution and were considered negative if there was no reaction at 1:25.</p> <p>Four subjects were breastfed and were tested for lactoferrin.</p>
<p>2002</p> <p>Alves GM et al.</p> <p>Nutritional status and breath hydrogen test with lactose and lactulose in Terena Indian children</p> <p>Lactose hydrogen breath test (HBT) as a marker of lactase activity, and lactulose HBT as a marker of</p>	<p>Limão Verde and Córrego Seco, Mato Grosso do Sul, Brazil</p> <p>All children <10 yr old were recruited from these rural villages.</p>	<p>Cross-sectional</p> <p>n=264;</p> <p><5 yr old: n=145</p> <p>(However results were provided by <4 and \geq4 yr old age groups.)</p>	<p><u>Breath Tests:</u></p> <ul style="list-style-type: none"> • Lactose HBT (251 tested) • Lactulose HBT (252 tested) 	<p>Lactose HBT:</p> <ul style="list-style-type: none"> • Elevated: 27.1% among all subjects • Borderline: 43.0% among all subjects • 0% of subjects <4 yr had elevated or borderline results <p>Lactulose HBT positive:</p> <ul style="list-style-type: none"> • 11.5% of all subjects • 8.6% of subjects <4 yr 	<p>The prevalence of lactase deficiency as measured by lactose HBT was >25%, but non-existent among those <4 yr of age.</p> <p>Prevalence of SBBO as assessed by lactulose HBT was ~10%.</p>	<p>Assessment of association between lactulose and lactose absorption was not reported.</p>

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
SBBO						
<p>2009</p> <p>Amadi B et al.</p> <p>Reduced production of sulfated glycosaminoglycans occurs in Zambian children with kwashiorkor but not marasmus</p> <p>Duodenal biopsy including assessments of intestinal markers in children with PD and different forms of malnutrition</p>	<p>Lusaka, Zambia</p> <p>12.2-19.8 mo olds with PD and malnutrition admitted to the malnutrition ward of a teaching hospital.</p>	<p>Case-control</p> <p>n=41*;</p> <p>n=41 cases with PD and malnutrition:</p> <ul style="list-style-type: none"> • 18 with marasmus • 8 with marasmic kwashiorkor • 15 with kwashiorkor <p>n=19 healthy control children from UK</p> <p>* UK subjects are presented in this table due to comparisons of interest made in the review. However we do not include these subjects in the sample size for this review.</p>	<p><u>Endoscopic duodenal biopsy:</u></p> <ul style="list-style-type: none"> • Histopathology • Densities in lamina propria and crypt epithelium: • Cell proteins: <ul style="list-style-type: none"> • Glycosaminoglycan (GAG) • Enterocyte heparan sulfate proteoglycan (HSPG) • Syndecan-1 • Inflammatory cell markers: <ul style="list-style-type: none"> • CD3 IEL • Ki67 • Human leukocyte antigen DR-1 (HLA-DR) 	<p>Biopsy findings among the Zambian compared to the UK children:</p> <ul style="list-style-type: none"> • Villous height reduced • Crypt depth increased • ~50% reduction in crypt:villous ratio • Values for lamina propria cell densities were not reported for UK subjects <p>No significant differences in crypt or villous measures or lamina propria cell densities were observed between nutritional groups or after nutritional rehabilitation.</p> <p>Intestinal markers:</p> <ul style="list-style-type: none"> • Inflammatory markers were seen in higher densities compared to the UK children. There were significant differences between the different nutritional groups in the specific types of inflammatory markers. • There was a significant reduction in GAGs and HSPG in the kwashiorkor group compared to UK children, but no significant differences between kwashiorkor and other presentations of malnutrition. • There was no difference in 	<p>Mucosal architecture was markedly abnormal compared to UK controls but did not vary between marasmus and kwashiorkor presentations of malnutrition.</p> <p>Inflammatory cell densities were generally higher compared to UK children and showed different patterns across the malnutrition presentations.</p> <p>Tissue concentrations of HSPG and GAG were reduced especially amongst children with kwashiorkor. Intestinal protein markers did not differ amongst the malnutrition groups.</p>	<p>27 subjects were HIV positive; incidence was lower in the kwashiorkor group.</p>

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
				epithelial syndecan-1 protein expression between the malnutrition groups (data not available for UK controls).		
<p>2000</p> <p>Azim T et al.</p> <p>Immune response of Bangladeshi children with acute diarrhea who subsequently have persistent diarrhea</p> <p>Immune activation tests, as well as transferrin and albumin as markers of nutritional status among children with and without PD</p>	<p>Dhaka, Bangladesh</p> <p>7-12 mo olds with 6-8 days of watery diarrhea attending the International Centre for Diarrheal Disease Research.</p> <p>Cases were those who went on to develop PD, controls were those who did not.</p> <p>An additional group of subjects without diarrhea were recruited from a nutrition follow-up unit.</p> <p>Prevalence of malnutrition was high in all groups.</p>	<p>Case-control</p> <p>n=136;</p> <p>n=38 cases with PD</p> <p>n=98 controls:</p> <ul style="list-style-type: none"> • 85 with AD • 13 with no diarrhea 	<p><u>Blood tests:</u></p> <ul style="list-style-type: none"> • IFN-γ • TNF-α • WBC (total and differential) • IgA • IgG • IgM • Transferrin • Albumin • Immune function tests: <ul style="list-style-type: none"> • Neutrophil polarization response to chemotactic factor • Neutrophil opsonization to yeast • Mononuclear cell proliferation, spontaneous and in response to stimuli with mitogens <p><u>Skin Test:</u></p> <ul style="list-style-type: none"> • Delayed-type hypersensitivity response (DTH) to tuberculin, tetanus, diphtheria, <i>Streptococcus</i>, <i>Proteus</i>, <i>Candida</i>, and <i>Trichophyton</i> 	<p>WBC total and differential, immunoglobulin subtypes, cytokines, transferrin, and albumin did not differ between cases with diarrhea or controls, nor did stool leukocyte or erythrocyte counts.</p> <p>The percentages of neutrophils that polarized in response to stimulation were significantly higher in subjects with AD or PD compared to those without diarrhea; there was no difference between the two diarrhea groups.</p> <p>Opsonization did not vary between any groups.</p> <p>Monocyte spontaneous proliferation counts were less than half among children with no diarrhea compared to those with AD (p<0.001) or with PD (p=0.011); there was no difference between the two diarrhea groups.</p> <p>Monocyte proliferation in response to stimulation did not differ between the 3 groups.</p> <p>The proportion with DTH</p>	<p>Some immune and inflammatory markers were associated with acute and/or persistent diarrhea.</p> <p>The only marker that was significantly associated with progression to PD was a negative DTH response to tuberculin antigen (odds ratio=3.8, CI: 1.4, 9.9). This was calculated from a logistic regression analysis that only included children with diarrhea.</p>	<p>The number of controls was relatively small and their nutritional status was not reported.</p>

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
			<u>Stool tests:</u> <ul style="list-style-type: none"> • Leukocytes • Red blood cells 	<p>responses differed among the three groups only in response to tuberculin ($p=0.021$). More PD subjects had a negative tuberculin response than did subjects with AD ($p=0.024$).</p>		
<p>2005</p> <p>Bhatnagar S et al.</p> <p>Celiac disease with mild to moderate histological changes is a common cause of chronic diarrhea in Indian children</p> <p>Duodenal biopsy among children with chronic diarrhea</p>	<p>Delhi, India</p> <p>1-18 yr olds with a presentation consistent with CD (combination of chronic diarrhea, abdominal distension, and growth failure), recruited from a pediatric gastroenterology clinic.</p> <p>Subjects negative for CD-specific antibodies were of interest for this review.</p>	<p>Case-series</p> <p>n=107</p>	<p><u>Endoscopic duodenal biopsy:</u></p> <p>Histopathology</p>	<p>70 had normal histology (defined as crypt:villous ratio 1:2-3, absence of lymphoid lamina propria infiltration, and minimal intraepithelial lymphocytes (IEL).</p> <p>37 had mild changes (defined as mild blunting of villi with crypt:villous ratio of 1:1*). A specific etiology was identified in only n=5:</p> <ul style="list-style-type: none"> • 2 with giardiasis • 1 with lymphangiectasia • 2 with chronic pancreatitis <p>Only children with CD had moderate or severe histologic changes.</p> <p>* Along with increased IEL and lymphocytic lamina propria infiltration.</p>	<p>More than one quarter of children with chronic diarrhea had normal small intestinal mucosa; at follow-up their growth had improved and their diarrhea had resolved.</p> <p>No definitive diagnosis was reached for 86% of subjects with abnormal histology (albeit most had mild findings).</p>	
<p>2003</p> <p>Bitarakwate E et al.</p> <p>Serum zinc status of children with persistent diarrhea admitted to the diarrhea management unit of Mulago Hospital, Uganda</p>	<p>Kampala and Mpigi, Uganda</p> <p>6-36 mo olds with PD, recruited from hospital, and healthy controls recruited mainly from the local population.</p>	<p>Case-control</p> <p>n=192;</p> <p>n=96 cases with PD</p> <p>n=96 healthy controls</p>	<p><u>Blood Tests:</u></p> <ul style="list-style-type: none"> • Albumin • Total protein • Hemoglobin 	<p>PD cases:</p> <ul style="list-style-type: none"> • 47.9% low serum protein • 69.7% low serum albumin • Low mean hemoglobin (10.5 g/dL) <p>For controls, means of all three laboratory values were within normal range; percent of subjects with abnormal values are not reported.</p>	<p>Decreased albumin, serum total protein and hemoglobin concentrations were associated with PD.</p>	

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
Serum protein, albumin, and hemoglobin among children with and without PD				All three test results were significantly lower in children with PD than in controls ($p < 0.01$ for each comparison).		
<p>2010</p> <p>Bukhari AS et al.</p> <p>DNA damage and plasma homocysteine concentrations are associated with serum metabolites and mineral constituents' profiles in children with persistent diarrhea</p> <p>Serum proteins, metabolites, and levels of DNA damage among children with and without PD</p>	<p>Faisalabad, Pakistan</p> <p>3-6 yr olds admitted to hospital with PD and healthy controls.</p>	<p>Case-control</p> <p>n=72;</p> <p>n=36 cases with PD</p> <p>n=36 healthy controls</p>	<p><u>Blood Tests:</u></p> <p>Serum proteins and metabolites:</p> <ul style="list-style-type: none"> • Albumin • Globulin • Homocysteine • Total protein • Total cholesterol, HDL, LDL, triglycerides • AST, ALT • T3, T4 • Total oxidant status (TOS), Total anti-oxidant status (TAS), and thiobarbituric reactive substances (TBARS) • DNA damage to lymphocytes 	<p>Mean values significantly higher among PD cases than in healthy controls:</p> <ul style="list-style-type: none"> • LDL • Homocysteine • TOS • TBARS • DNA damage <p>Mean values significantly lower among PD cases than in healthy controls:</p> <ul style="list-style-type: none"> • Total protein • T4 • TAS 	<p>Multiple serum markers were associated with PD, especially DNA damage to lymphocytes ($p=0.0001$).</p> <p>The authors speculate that zinc deficiency, more commonly found in the children with PD, might be responsible for increased homocysteine concentrations and play an important role in mediating DNA damage.</p>	<p>Control recruitment strategy was not well described.</p> <p>TOS, TBARS and TAS were incompletely defined.</p> <p>Some values differed by gender in both the case and control groups:</p> <ul style="list-style-type: none"> • Triglycerides • Total cholesterol • HDL • T3 <p>Multiple markers studied; analyses did not appear to address potential confounding.</p>
<p>2007</p> <p>Bushen OY et al.</p> <p>Heavy cryptosporidial infections in children in northeast Brazil: comparison of</p>	<p>Goncalves Dias favela in Fortaleza, Brazil</p> <p>All newborns from an urban shantytown were recruited at birth</p>	<p>Cohort</p> <p>n=42 (41 tested)</p> <p>Stools were collected at</p>	<p><u>Stool Test:</u></p> <p>Lactoferrin</p>	<p>68.3% were lactoferrin-positive; there were no differences in positivity between subjects with <i>C. hominis</i> and <i>C. parvum</i> spp.</p> <p>67.9% of lactoferrin-positive subjects had very high titers.</p>	<p>Lactoferrin was correlated with younger age and symptomatic infection among those infected with <i>C. parvum</i>.</p>	<p>Lactoferrin results were graded based on agglutination reaction positivity with increasing dilution and</p>

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
<p><i>Cryptosporidium hominis</i> and <i>Cryptosporidium parvum</i></p> <p>Fecal lactoferrin as a marker of intestinal inflammation in children with <i>Cryptosporidium</i></p>	<p>and followed for up to 4 yr.</p> <p>This study included only children testing positive for <i>Cryptosporidium</i>.</p>	<p>regular intervals as well as during episodes of diarrhea.</p>		<p>Younger children were more often lactoferrin-positive (p=0.03). The difference was mediated by <i>C. parvum</i>; 87.5% of ≤1 year olds compared to 40.0% of older children with <i>C. parvum</i> were lactoferrin-positive (p=0.04). There was no difference among those infected with <i>C. hominis</i>.</p> <p>Lactoferrin was correlated with symptomatic infection among those with <i>C. parvum</i>: 78.6% of symptomatic children compared to no asymptomatic children had a positive test (r=0.67, p=0.004¹).</p> <p>Lactoferrin was not correlated with degree of oocyst shedding (p=0.28).</p> <p>Lactoferrin was correlated with ΔHAZ score among those with <i>C. parvum</i>, although this observation was not statistically significant (r=-0.39, p=0.13).</p>	<p>Lactoferrin did not significantly predict growth outcomes.</p> <p><i>Cryptosporidium</i> species-specific differences were observed in lactoferrin results. In contrast to <i>C. parvum</i>, there was no association between lactoferrin and symptomatic / asymptomatic <i>C. hominis</i> infection (p=0.231). In addition, similar proportions of asymptomatic children with <i>C. hominis</i> had high fecal lactoferrin titers as had undetectable results.</p>	<p>were considered negative if there was no reaction at 1:50 and highly positive at >1:400.</p> <p>Data were part of a larger study; similar data on lactoferrin in <i>Giardia</i>-infected children was published by A. Kohli, et al. (also included in this review), using a slightly different grading scale for reporting lactoferrin results [133]. Rather than exclude breastfed children, Bushen et al. stratified results on breastfeeding status and found no difference in positive/negative results, including when examined among younger and older children.</p>

¹ Reported results were adjusted for confounding variables, unless otherwise noted.

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
<p>2003</p> <p>Bustos M et al.</p> <p>Disaccharidase deficiency in Bolivian children with persistent diarrhea</p> <p>Jejunal biopsy and disaccharidase activities in children with PD and different forms of malnutrition</p>	<p>Cochabamba, Bolivia</p> <p>3-34 mo old Amerindians hospitalized with PD and moderate or severe malnutrition in an urban setting.</p>	<p>Cohort</p> <p>n=42 cases with PD and malnutrition:</p> <ul style="list-style-type: none"> • 2 with kwashiorkor • 20 with marasmus • 20 with marasmic-kwashiorkor <p>Children were assessed on admission and at three weeks, after diarrhea had resolved and anthropometrics were improving.</p>	<p><u>Jejunal tethered capsule biopsy:</u></p> <ul style="list-style-type: none"> • Histopathology • Disaccharidase activity: <ul style="list-style-type: none"> • Lactase • Sucrose-Isomaltase • Maltase <p>Histology was scored on a scale of 1 (normal) to 4 (severe morphological damage or flat mucosa).</p>	<p>Most subjects had mild to moderate (score of 2-3) histological abnormalities, with one kwashiorkor patient having completely flat villi.</p> <p>Second biopsy showed a trend of improved mucosa, but difference was not significant based on histology score, intraepithelial lymphocyte density, or degree of infiltration of lamina propria.</p> <p>Percentages with enzymatic activity below normal at baseline, discharge:</p> <ul style="list-style-type: none"> • Lactase: 64%, 59% • Sucrase-isomaltase: 97%, 90% • Maltase: 45%, 52% <p>All changes were statistically significant.</p> <p>Lactase recovery was associated with admission HAZ (p=0.05) and WAZ (p=0.03) scores.</p> <p>Despite continued high disaccharidase deficiency prevalence at discharge, all children tolerated the lactose-containing formula challenge.</p>	<p>Patients had diminished intestinal disaccharidase activity and substantial pathology on biopsy at admission and at three weeks, despite clinical improvements and tolerance of lactose-containing formula.</p>	<p>Spanish language article.</p> <p>Values for subnormal disaccharidase activity were not provided.</p> <p>The magnitude of lactase inverse association with growth parameters was not reported. Authors did not report whether they had tested for associations between maltase or sucrose-isomaltase and growth parameters.</p>
<p>2004</p> <p>Campbell DI et al.</p>	<p>Keneba, Gambia</p> <p>2 mo olds from rural area followed</p>	<p>Cohort</p> <p>n=72</p>	<p><u>Stool Test:</u> Neopterin</p>	<p>Mean neopterin concentration was negatively correlated with long-term height (r=-0.29, p<0.009) and weight</p>	<p>L:M and mean fecal neopterin concentration were not correlated.</p>	<p>Study population might have some overlap with that</p>

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
<p>Intestinal inflammation measured by fecal neopterin in Gambian children with enteropathy: association with growth failure, <i>Giardia lamblia</i>, and intestinal permeability</p> <p>Fecal neopterin and L:M as markers of intestinal inflammation and permeability, respectively, and their correlation with growth status and <i>Giardia</i> recovery in the stool</p>	until 15 mo of age.	Subjects were evaluated with twice-weekly questionnaire to determine diarrhea morbidity, clinic assessments of growth, and screening laboratory tests every 2 mo.	<p><u>Urine Tests:</u></p> <ul style="list-style-type: none"> • Lactulose² • Mannitol • L:M 	<p>($r=-0.36$, $p<0.007$) gain, but not with giardiasis.</p> <p>Mean³ L:M (CI): 0.31 (0.26, 0.34).</p> <p>Mean excretion of lactulose (CI): 0.20 (0.18, 0.23).</p> <p>Mean excretion of mannitol (CI): 3.0 (2.8, 3.2).</p> <p>Mean L:M was negatively correlated with long-term height gain (r value not provided, $p<0.0001$), but was not correlated with presence of <i>Giardia</i>.</p> <p>L:M and fecal neopterin were not correlated ($p=0.11$).</p>	Mean L:M in the Gambian children was substantially higher than normal values in children in the UK. These high L:M ratios appear to be driven by mannitol excretion.	of Campbell et al. also included in this review [110].
<p>2003</p> <p>Campbell DI et al.</p> <p>Growth faltering in rural Gambian infants is associated with impaired small intestinal barrier function, leading to endotoxemia and systemic inflammation</p> <p>L:M as a marker of intestinal permeability</p>	<p>Keneba, The Gambia</p> <p>All 2-11 mo olds were recruited from this rural village and followed up to 14 mo of age.</p>	<p>Cohort</p> <p>n=71</p>	<p><u>Urine Tests:</u></p> <ul style="list-style-type: none"> • Lactulose⁴ (53 tested) • Mannitol (52 tested) • L:M (52 tested) <p><u>Blood tests:</u></p> <ul style="list-style-type: none"> • Albumin • CBC • C-reactive protein (CRP) • IgA 	<p>At 8 wk of age:</p> <ul style="list-style-type: none"> • Mean⁵ L:M: 0.169 (CI: 0.145, 0.198; range: 0.058-0.657) • Mean lactulose recovery: 0.202 (SD=0.159; range: 0.009-0.640) • Mean mannitol recovery: 3.80 (SD=2.35; range: 0.52-8.58) <p>L:M more than doubled between 12 wk-1 yr of age ($r=0.44$, $p<0.001$) and was driven by both increasing</p>	<p>Mean L:M ratios were elevated at 8 weeks of age, and more than doubled in the first year of life.</p> <p>Many markers of inflammation and endotoxin release were significantly correlated with L:M and lactulose recovery.</p>	<p>Presence of malaria parasites was assessed by blood smear at each study visit; the only parameter associated with malaria was CRP.</p> <p>Authors did not report investigating</p>

² Lactulose and mannitol results were expressed as % of dose administered.

³ Type of mean not specified.

⁴ For lactulose and mannitol results, excretion measurement was not specified.

⁵ Geometric mean.

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
and its relationship with various inflammatory markers and endotoxin			<ul style="list-style-type: none"> • IgM • IgG • Plasma endotoxin • IgG endotoxin-core antibody 	<p>lactulose ($r=0.18$, $p<0.001$) and decreasing mannitol ($r=-0.14$, $p<0.01$) excretion with age.</p> <p>WAZ and HAZ scores were negatively correlated with L:M ($r=-0.41$, $p<0.001$), and primarily driven by lactulose excretion ($r=-0.39$, $p<0.001$).</p> <p>Laboratory values were consistent with chronic, low level immunostimulation:</p> <ul style="list-style-type: none"> • 50% of platelet and 39% of leukocyte counts were elevated, especially mean lymphocyte counts which were almost twice expected values [198]. • While the mean⁶ CRP was within the normal range, 25% of values were above the upper limit of normal (5 mg/L), and 17% were >10 mg/L [198]. • Mean IgG, IgA and IgM concentrations were near normal at 8 wk of age, but increased rapidly; all three were elevated above expected values in all other age groups [198, 199]. • Mean⁷ free plasma endotoxin concentration was twice the upper limit of normal [200] and IgG endotoxin-core antibody concentrations were also 	<p>Poor growth was significantly correlated with L:M ratios, primarily due to lactulose excretion.</p> <p>Authors postulate that while general markers of inflammation cannot be specifically ascribed to a gut source, endotoxin and its related core antibody are potentially a direct measure of intestinal inflammation due to gut gram negatives as a primary source of endotoxin release among subjects without sources of extra-intestinal gram negative infection.</p>	<p>relationships between certain serum parameters (blood counts, CRP concentrations) and L:M.</p> <p>Study population might have overlap with that of Campbell et al. 2004 also included in this review [15].</p>

⁶ Geometric mean.

⁷ Geometric mean.

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
				<p>elevated [198].</p> <ul style="list-style-type: none"> • However, mean albumin concentrations (and concentrations within SD) were generally within normal range [198]. <p>L:M was correlated with IgG and IgA (r=0.41 and 0.41, respectively, p<0.001), and IgM (r=0.28, p<0.02).</p> <p>IgG and IgA were also correlated with lactulose recovery (r=0.26 and 0.25, respectively, p<0.02).</p> <p>IgG endotoxin core antibody concentration was correlated with L:M and driven by lactulose recovery, (r=0.35, p<0.005 for both).</p> <p>Endotoxin concentrations were correlated with lactulose recovery (r=0.36, p<0.02) only.</p>		
<p>2003</p> <p>Campbell DI et al.</p> <p>Chronic T cell-mediated enteropathy in rural west African children: relationship with nutritional status</p>	<p>Fajara and Sibanar, The Gambia</p> <p>6 mo-3 yr old hospital- and clinic-based cases from rural communities.</p>	<p>Case-control</p> <p>n=40 cases:</p> <ul style="list-style-type: none"> • Group 1: n=4 • Group 2: n=11 (7 with diarrhea) • Group 3: n=25 (18 	<p><u>Endoscopic small bowel biopsy, site not specified:</u></p> <ul style="list-style-type: none"> • Histopathology • Morphometric assessment by computer analysis* • Intestinal tissue cytokines and 	<p>Crypt-hyperplasia and villous atrophy were observed among all Gambian subjects, and the degree of histopathology did not differ among cases with differing nutritional status, nor was there a correlation with diarrhea.</p>	<p>All Gambian subjects had evidence of enteropathy with crypt-hyperplasia and villous atrophy, and mean IELs >2 SD above UK norms,</p>	<p>Statistical methodology was not sufficiently detailed to determine what was compared (e.g. type of central tendency</p>

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
<p>and small bowel function</p> <p>L:M as a marker of intestinal permeability, small bowel biopsy with assessment of intestinal immune markers, and computerized morphometric analysis among rural Gambian children with differing degrees of malnutrition and compared to well-nourished UK children</p>	<p>Case groups based on differences in nutritional status:</p> <ol style="list-style-type: none"> 1. WAZ score >-2, with GI complaints other than diarrhea 2. Grade I protein energy malnutrition (PEM) (WAZ score -2 to -4) and unresponsive to nutritional supplements, with or without diarrhea 3. Grade II PEM (WAZ score <-4) with or without diarrhea <p>Controls from UK* who were well nourished children with GI complaints other than diarrhea and with normal endoscopy results were also studied.</p> <p>* UK subjects are presented in this</p>	<p>with diarrhea)</p> <p>n=34 with case tissue samples sufficient for cytokine immunoreactivity tests:</p> <ul style="list-style-type: none"> • Group 1: n=3 • Group 2: n=8 • Group 3: n=23 	<p>immune markers:</p> <ul style="list-style-type: none"> • CD-3 • CD-4 • CD-8 • CD-19 • CD-25 • HLA-DR • Perforin • $\gamma\delta$ T-cell receptor • Syndecan-1 • TNF-α • IFN-γ • TGF-β • IL-10 <p><u>Urine Tests:</u></p> <ul style="list-style-type: none"> • Lactulose⁸ • Mannitol • L:M <p>* Biopsy involved morphometric assessment by computer analysis of villous height, crypt depth, villous:crypt ratio, and intraepithelial lymphocyte (IEL) density (per 100 epithelial cells).</p>	<p>IEL⁹ means were ~3-fold higher in Gambian than UK children.</p> <p>Median CD3, CD4, CD8, CD19, and CD25 cell counts were significantly higher (2-5x higher) among each case group compared to the UK controls.</p> <p>IEL, $\gamma\delta$, syndecan-1, HLA-DR, and perforin were detected among the Gambian children in varying degrees but were not reported for UK controls. Syndecan, CD3, and CD8 displayed a gradient proportional to malnutrition severity.</p> <p>All Gambian groups showed higher lamina propria cytokine-immunoreactive mononuclear cell density (~200-450/mm²) than UK controls (30-80/mm²).</p> <p>Among subjects with elevated cytokines, similar densities were seen for both pro-inflammatory (IFN-γ and TNF-α) and putative regulatory (IL-10 and TGF-β) cytokines. Epithelial expression of TGF-β was also enhanced compared to UK controls, but subjects with</p>	<p>independent of nutritional status and diarrhea history.</p> <p>Elevation of cell-mediated intestinal markers and mucosal proinflammatory cytokines was present across the 3 Gambian groups, variably correlated with nutritional status.</p> <p>L:M ratios were elevated in all Gambian groups, without apparent correlation to host nutritional status.</p>	<p>measure and variance calculations for L:M not stated).</p> <p>Duration of diarrhea not specified, but assumed to be persistent.</p> <p>Mucosal lymphocyte densities, cytokine immunoreactivity, and L:M results were not stratified by history of diarrhea.</p>

⁸ Lactulose and mannitol results were expressed as % of dose administered.

⁹ These figures are presumed to represent IEL means; however, this was not explicitly stated.

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
	table due to comparisons of interest made in the review. However we do not include these subjects in the sample size for this review.			<p>poorer nutritional status had lower densities of mucosal TGF-β+ cells, with median densities of 420 and 250 cells/mm² in the grade I and grade II PEM groups, respectively.</p> <p>L:M values¹⁰:</p> <ul style="list-style-type: none"> • Group 1: 0.53 (0.4-1.3) • Group 2: 0.47 (0.02-2.20) • Group 3: 0.73 (0.14-2.2) • Not assessed among the UK controls <p>Nutritional status was not associated with L:M, recoveries of lactulose or mannitol.</p> <p>L:M was correlated with mucosal B lymphocyte density (r=0.57, p<0.05), IEL (r=0.51, p<0.02), and perforin+ IEL (r=-0.64, p<0.03).</p>		
2002 Campbell DI et al. Age-related association of small intestinal mucosal enteropathy with nutritional status in	Keneba, The Gambia and surrounding villages 2-60 yr olds randomly selected from rural communities.	Cohort n=162; <5 yr old: n=26 (23 were re-assessed)	<u>Urine Tests:</u> • Lactulose ¹¹ • Mannitol • L:M	<p>Mean¹² L:M (SE) in 2-5 yr old group: 0.353 (0.022).</p> <p>Mean lactulose and mannitol % recovery was ~0.45 and ~0.65, respectively.</p> <p>L:M was highest in 2-5 yr age group and decreased with</p>	Mean L:M in asymptomatic 2 to 5 yr olds was high and decreased significantly with increasing age, but never fell within expected range of values.	Subjects were free from diarrhea symptoms for at least one week prior to urinary assessments. The authors

¹⁰ Not clearly indicated if these figures represent mean (CI) or another measure of central tendency.

¹¹ Lactulose and mannitol results were expressed as % of dose administered.

¹² Type of mean not specified.

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
<p>rural Gambian children</p> <p>L:M and urinary lactulose and mannitol recovery as a marker of intestinal permeability and its association with nutritional status at varying ages. Also assessed correlation of change in L:M with nutritional status at 3.5 mo re-visit.</p>				<p>increasing age (up to age 20) ($p < 0.001$), but never fell within referenced UK normal ranges [201].</p> <p>Most of the improvement in L:M was driven by a reduction in lactulose excretion ($p < 0.001$), which fell within expected UK ranges by age 10 yr.</p> <p>In contrast, although mannitol excretion slightly decreased with age, this trend did not reach statistical significance. In fact, excretion proportions were at all times $\frac{1}{2}$ - $\frac{1}{3}$ of expected UK values [201].</p> <p>L:M was inversely correlated with HAZ score¹³ ($r = -0.31$, $p < 0.001$), but not with WAZ or body mass index (BMI) Z scores. The correlation with HAZ score was mainly due to the higher lactulose excretion in subjects with poorer HAZ scores ($r = -0.22$, $p = 0.001$) and held across all age groups.</p> <p>There was a small improvement in mean L:M (SE) between the two study time points from 0.198 (0.018) to 0.172 (0.010) ($p = 0.026$ for change in L:M), driven by an improvement in mannitol recovery with no change in lactulose excretion.</p>	<p>Among all age groups, L:M showed significant intra-subject correlation between tests conducted 3.5 months apart.</p> <p>Among all age groups, L:M was significantly inversely correlated with HAZ score, primarily driven by lactulose excretion.</p>	<p>sought correlation between the mean L:M of the two visits and ΔBMIZ, ΔHAZ and ΔWAZ scores, but statistical calculations were not provided.</p>

¹³ Reported results were adjusted for age, sex, and visit.

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
				<p>Indices of intestinal permeability within subjects showed a high degree of correlation between the two visits:</p> <ul style="list-style-type: none"> • Lactulose: $r=0.55$, $p<0.001$ • Mannitol: $r=0.24$, $p<0.05$ • L:M: $r=0.66$, $p<0.001$ <p>Change in measures between visits (analysis not stratified by age):</p> <ul style="list-style-type: none"> • Mean L:M (SD): <ul style="list-style-type: none"> • Visit 1: -1.62 (0.66) • Visit 2: -1.76 (0.55), ($p=0.026$) • Mean mannitol recovery (SD): <ul style="list-style-type: none"> • Visit 1: 5.25 (2.69) • Visit 2: 6.28 (3.03), ($p=0.006$) • Mean lactulose recovery (SD): <ul style="list-style-type: none"> • Visit 1: 0.28 (0.20) • Visit 2: 0.29 (0.18), NS (p-value not specified) 		
<p>2003</p> <p>Chen P et al.</p> <p>Association of vitamin A and zinc status with altered intestinal permeability: analyses of cohort data from northeastern Brazil</p>	<p>Goncalves Dias favela in Fortaleza, Brazil</p> <p>2-97 mo olds recruited from an urban shantytown.</p>	<p>Cohort</p> <p>$n=75$ with pre-supplement L:M and retinol concentrations measured:</p> <ul style="list-style-type: none"> • 51 with pre-supplement circulating 	<p><u>Urine Tests:</u></p> <ul style="list-style-type: none"> • Lactulose¹⁴ • Mannitol • L:M 	<p>Baseline mean (SD):</p> <ul style="list-style-type: none"> • L:M¹⁵: 0.29 (0.16) • Lactulose: 0.54 (0.29) • Mannitol: 2.07 (0.88) <p>L:M was not correlated with age. L:M was inversely correlated with retinol ($r=-0.55$, $p<0.0005$), including after adjustment for zinc</p>	<p>Supplementation of vitamin A and zinc resulted in significant improvements in L:M among the cohort of children with a history of PD or low WAZ score who received post-</p>	<p>Longitudinal data were not reported stratifying on underlying condition (i.e. PD history vs. WAZ score).</p> <p>Follow-up data</p>

¹⁴ For lactulose and mannitol results, excretion measurement was not specified.

¹⁵ Type of mean not specified.

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
L:M as a marker of intestinal permeability pre- and post-vitamin A and zinc supplementation among children with history of PD or low WAZ score		<p>zinc concentration s measured</p> <ul style="list-style-type: none"> • 20 with post-intervention* longitudinal follow-up of subset with history of PD or low WAZ score <p>* These subjects received a single oral dose of vitamin A and a 2-wk course of daily zinc supplements.</p>		<p>concentration and stratification on retinol concentrations.</p> <p>Retinol was correlated with mannitol ($r=0.28$, $p=0.017$) and lactulose ($r=-0.22$, $p<0.063$) excretion.</p> <p>Lactulose, mannitol and their combined ratio were not correlated with zinc concentrations.</p> <p>L:M improved after supplementation for the cohort of 20 children followed longitudinally with PD or low WAZ score: L:M mean (SD):</p> <ul style="list-style-type: none"> • Pre-treatment: 0.28 (0.12) • Post-treatment: 0.19 (0.07) <p>However, lactulose and mannitol excretion did not change significantly.</p>	<p>supplementation assessment. Less than one-third of the subjects had post-intervention L:M assessments.</p>	<p>on L:M were not provided for the children with normal WAZ score or no history of PD.</p> <p>Unclear how long after supplementation the L:M testing was done.</p> <p>Post-supplementation L:M results in the text of the publication differed somewhat from what was reported in the publication table.</p>
<p>2002</p> <p>Clark TD et al.</p> <p>Risk factors and cumulative incidence of anemia among human immunodeficiency virus-infected children in Uganda</p> <p>Association of chronic diarrhea with moderate anemia in HIV-infected children</p>	<p>Kampala, Uganda</p> <p>9 mo old HIV-infected children followed at Mulago hospital until 36 mo of age.</p> <p>More than 40% were stunted and/or underweight at enrollment.</p>	<p>Cohort</p> <p>n=225</p>	<p><u>Blood Test:</u> Hemoglobin</p>	<p>While chronic diarrhea was associated with moderate anemia in a univariate analysis (odds ratio=2.5, CI: 1.0, 6.3), it was either not associated with moderate anemia (hemoglobin <9 g/dL) in a multivariate model or not included in the model</p>	<p>While there was a high prevalence of anemia (<11 g/dL) and moderate anemia (<9 g/dL) (92% and 35% at 9 months, respectively) among this cohort of HIV-infected children, chronic diarrhea appears to have not been associated with anemia in the multivariate</p>	<p>The association between chronic diarrhea and other assessed hematologic markers (any degree of anemia, mean corpuscular volume, and mean corpuscular hemoglobin concentration) was not reported.</p>

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
					analysis. However, the text did not specifically state whether chronic diarrhea was tested in the multivariate model.	
<p>2007</p> <p>Darboe MK et al.</p> <p>Effectiveness of an early supplementation scheme of high-dose vitamin A versus standard WHO protocol in Gambian mothers and infants: a randomised controlled trial</p> <p>L:M as a marker of intestinal epithelial integrity among infants receiving high-dose vitamin A or standard vitamin A protocol</p>	<p>Keneba, The Gambia</p> <p>Subjects recruited at birth from rural community. Age range during study was 0-12 mo.</p>	<p>RCT</p> <p>n=197</p> <p>n=99 received high dose vitamin A protocol</p> <p>n=98 received standard dose vitamin A protocol</p>	<p><u>Urine Test:</u> L:M</p>	<p>Mean¹⁶ L:M and proportion with values >0.30 among those receiving standard doses of vitamin A, by age:</p> <ul style="list-style-type: none"> • 2 mo: 0.195, 12% • 5 mo: 0.197, 13% • 7 mo: 0.212, 22% • 9 mo: 0.286, 30% • 12 mo: 0.322, 34% <p>Mean L:M differed between the two groups only at 7 mo (0.276 in high-dose vitamin A group, p=0.014), although there was no difference in percentages with L:M >0.30.</p>	<p>L:M values rose by ~50% from age 2 mo to 1 yr and were not affected by dosing of vitamin A.</p>	<p>The L:M normal cutoff was defined higher than for most other L:M studies, as 0.30. This was derived from the mean plus 2 SD from a study of UK infants [202]</p>
<p>2002</p> <p>Dini E et al.</p> <p>Sudan III and steatocrit in the detection of fecal fat in malnourished children</p> <p>Fecal fat by four different testing methods as a marker</p>	<p>Caracas, Venezuela</p> <p>6 mo-9 yr olds with recruited from an outpatient nutrition center and well-nourished controls.</p>	<p>Case-control</p> <p>n=129;</p> <p>n=99 cases:</p> <ul style="list-style-type: none"> • 30 with subclinical malnutrition • 34 with mild malnutrition • 30 with moderate 	<p><u>Stool Test:</u> Fecal fat, by method:</p> <ul style="list-style-type: none"> • Sudan III classic • Sudan III modified • Steatocrit classic • Steatocrit acid <p>Each subject underwent testing for</p>	<p>Proportions testing positive for fecal fat ranged from 33%-41% overall, depending on test method used.</p> <p>The proportion testing positive varied by nutritional status across testing methods:</p> <ul style="list-style-type: none"> • 80%-100% of severely malnourished subjects had a positive test 	<p>A majority of children studied tested negative for fecal fat.</p> <p>The highest percent testing positive was in those with severe malnutrition, followed by those with subclinical-</p>	<p>Spanish language article.</p> <p>Control recruitment strategy was not well described.</p> <p>Proportions positive for fecal fat by history of diarrhea (current</p>

¹⁶ Geometric mean.

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
<p>of malabsorption among children with varying nutritional status and well-nourished controls</p>		<p>malnutrition <ul style="list-style-type: none"> • 5 with severe malnutrition n=30 controls</p>	<p>all four methods.</p>	<ul style="list-style-type: none"> • Similar proportions of subjects with subclinical, mild or moderate malnutrition tested positive, ranging from 30%-47% • 13%-27% of controls tested positive <p>These differences appeared to be significant, but statistical comparison results were not entirely clear.</p> <p>Fecal fat did not vary based on quantity of fat intake.</p> <p>By all four methods, a high percentage of children with parasites tested positive (~60%) compared to children without parasites (25%).</p> <p>Associations were observed between infection with <i>Giardia lamblia</i> or <i>Blastocystis hominis</i> and fecal fat ($p < 0.05$); this held true across diagnostic methods.</p> <p>The presence of diarrhea at time of testing was positively associated with fecal fat by all test methods ($p < 0.02$ for all except steatocrit classic, $p = 0.06$).</p> <p>The relationship between fecal fat and history of diarrhea in the year prior to testing varied by test method:</p> <ul style="list-style-type: none"> • Sudan III classic: $p = 0.134$ 	<p>moderate malnutrition. Controls had the lowest percent testing positive.</p> <p>Subjects with enteric parasites or those experiencing diarrhea at time of testing excreted fat significantly more often than uninfected children without diarrhea, although the magnitude of difference was not reported.</p> <p>There was some variation between the different testing methods, for example their relationship with a history of diarrhea in the year prior to testing.</p>	<p>or previous) were not provided. Authors reported percent agreement between tests but did not report results of statistical testing of these estimates.</p> <p>Test results varied by subject characteristics; however, assessments adjusting for potential confounding were not reported.</p>

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
				<ul style="list-style-type: none"> • Sudan III modified: p<0.001 • Steatocrit classic: p=0.14 • Steatocrit acid: p=0.015 <p>Agreement between all four methods was 72%. Agreement between at least three was 91.5%.</p>		
<p>2006</p> <p>El Mouzan MI et al.</p> <p>Endoscopic duodenal biopsy in children</p> <p>Duodenal biopsy among children with suspected intestinal disease</p>	<p>Riyadh, Saudi Arabia</p> <p>1.5 mo-18 yr olds referred to hospital for endoscopy with duodenal biopsy.</p> <p>78% of subjects were <12 yr old; results not presented by age.</p>	<p>Retrospective case-series</p> <p>n=241 cases:</p> <ul style="list-style-type: none"> • 102 with PD • 116 with unexplained short stature • 11 with refractory rickets • 12 with other conditions (including 2 with protein losing enteropathy) 	<p><u>Endoscopic duodenal biopsy:</u></p> <ul style="list-style-type: none"> • Gross endoscopic visualization • Histopathology 	<p>14% had abnormalities on endoscopic visualization:</p> <ul style="list-style-type: none"> • 1% had esophagitis • 6% had gastritis, 7 (47%) of which were <i>H. pylori</i> positive • 7% had duodenitis <p>Biopsy results:</p> <ul style="list-style-type: none"> • PD: <ul style="list-style-type: none"> • 26% normal • 29% chronic non-specific duodenitis • 40% villous atrophy • 5% other* • Short stature: <ul style="list-style-type: none"> • 56% normal • 22% chronic non-specific duodenitis • 22% villous atrophy • Rickets: <ul style="list-style-type: none"> • 55% normal • 36% chronic non-specific duodenitis • 9% villous atrophy • Other: <ul style="list-style-type: none"> • 25% normal • 50% chronic non-specific duodenitis 	<p>Villous atrophy was identified not only among 40% of children with PD, but also among 22%, 9%, and 17% of those with short stature, rickets, and other conditions, respectively.</p> <p>Authors argue that endoscopic biopsy is superior to “blind” capsule biopsy in developing country settings and allows for visualization of the intestine.</p> <p>Endoscopic visualization results were not reported by condition nor in relation to histopathology results; it is difficult to assess the value added compared to biopsy alone.</p>	<p>Specific results for the 2 patients with protein losing enteropathy were not reported.</p> <p>For 27% of cases, the only histopathology finding was chronic non-specific duodenitis; the diagnostic, prognostic, and therapeutic utility of identification is unclear.</p>

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
				<ul style="list-style-type: none"> • 17% villous atrophy • 8% other* <p>* 3 lymphangiectasia, 2 <i>Giardia</i>, 1 <i>Mycobacterium avium intracellulare</i>. Findings were reported according to presenting symptoms.</p>		
<p>2000</p> <p>Fagundes-Neto U et al.</p> <p>Studies of the small bowel surface by scanning electron microscopy in infants with persistent diarrhea</p> <p>Scanning electron microscope (SEM) and light microscope (LM) analyses of small intestinal biopsy among infants with PD with and without SBBO</p>	<p>Sao Paulo, Brazil</p> <p>2-10 mo olds with PD and protein calorie malnutrition consecutively admitted to Sao Paulo Hospital.</p>	<p>Case-series</p> <p>n=16</p>	<p><u>Jejunal secretions aspirate:</u> Bacterial concentrations</p> <p><u>Jejunal tethered capsule biopsy:</u> Histopathology by LM and SEM</p> <p><u>Rectal tethered capsule biopsy:</u> Histopathology</p>	<p>68.7% had bacterial overgrowth (concentration >10⁴ colonies/mL): 3 had enteropathogenic <i>E. coli</i> while the rest had colonic microflora.</p> <p>All small intestine specimens had morphological abnormalities on LM:</p> <ul style="list-style-type: none"> • 43.7% moderate villous atrophy • 56.3% subtotal villous atrophy <p>SEM revealed abnormalities of varying intensity:</p> <ul style="list-style-type: none"> • Among the 11 with SBBO, villous atrophy ranged from Grade II (n=4), Grade III (n=2), to Grade IV (n=3). • For the 5 subjects without SBBO, villous atrophy ranged from Grade I (n=1) to Grade 2 (n=4). • A mucous-fibrinoid pseudo-membrane over enterocytes was noted in 7 of the 11 with SBBO and none of the others. <p>Other abnormalities noted on SEM included:</p>	<p>Histological abnormalities were noted in all subjects by LM and SEM.</p> <p>Degree of villous atrophy noted on SEM seemed to be correlated with SBBO (no statistical tests were reported).</p> <p>Authors speculate that the mucous-fibrinoid pseudo-membrane partially covering enterocytes is consistent with a malabsorptive process, with the findings of fat droplets on enterocytes surfaces, and with the state of malnutrition of the subjects.</p>	<p>Inconsistent reporting of proportions of histopathologic findings among all subjects and by SBBO status; assessment of potential relationship with SBBO between different histologic findings was not possible.</p>

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
				<ul style="list-style-type: none"> • Mucus and debris covered large areas of the villous surface • Derangement of the enterocytes (in some cases cell borders were not clearly defined) • Reduced height and number (or absence in some places) of microvilli • Lymphocytes and fat droplets were observed over the surface of enterocytes (18%)¹⁷ <p>10 subjects had colitis on rectal biopsy; this was not associated with SBBO or degree of small intestinal pathology on SEM.</p>		
<p>2001</p> <p>Filteau SM et al.</p> <p>The effect of antenatal vitamin A and (beta)-carotene supplementation on gut integrity of infants of HIV-infected South African women</p> <p>L:M as a marker of intestinal permeability among infants of HIV-infected mothers</p>	<p>Durban, South Africa</p> <p>Pregnant, HIV-infected women between 28-32 wk gestation recruited from antenatal clinic. Infants were followed until 14 wk of age.</p>	<p>RCT</p> <p>n=238</p> <p>n=119 received vitamin A supplements (26 with HIV infection)</p> <p>n=119 received placebo (29 with HIV infection)</p>	<p><u>Urine Tests:</u></p> <ul style="list-style-type: none"> • Lactulose¹⁸ • Mannitol • L:M <p>Subjects tested:</p> <ul style="list-style-type: none"> • 1 wk: <ul style="list-style-type: none"> • Treatment: n=104 • Placebo: n=104 • 6 wk: <ul style="list-style-type: none"> • Treatment: n=100 • Placebo: n=105 • 14 wk: <ul style="list-style-type: none"> • Treatment: n=99 	<p>Mean L:M¹⁹ (CI) at 1 wk among infants without reports of illness was 0.12 (0.08, 0.17). L:M did not change with increasing age and did not significantly increase with reported morbidity.</p> <p>While a history of ever having been breastfed was an important contributor to L:M at 1 wk ($\Delta R^2=0.22$, $p=0.008$), a significant effect was not seen at 6 and 14 weeks²⁰. Current feeding status had a modest effect on L:M only at</p>	<p>Mean L:M overall was within normal range. However, mean L:M for placebo-treated, HIV-infected infants by 14 weeks was significantly elevated to almost 0.5.</p> <p>While HIV infection did not affect mannitol excretion, it was associated with increased</p>	<p>Specific sugar excretion was normalized to urinary creatinine to control for variation in renal function.</p>

¹⁷ These SEM results were not presented separately for those with and without SBBO.

¹⁸ For lactulose and mannitol results, excretion measurement was not specified.

¹⁹ Geometric mean.

²⁰ Reported results were adjusted for confounding variables, unless otherwise noted.

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
enrolled in a vitamin A trial		Treatment involved maternal vitamin A supplements during pregnancy and at delivery.	<ul style="list-style-type: none"> • Placebo: n=95 	<p>14 wk ($\Delta R^2=0.06$, $p=0.04$).</p> <p>Birth weight contributed significantly at 1 wk ($\Delta R^2=0.07$, $p=0.02$), but current weight did not contribute significantly to L:M at any time point.</p> <p>HIV infection status by 14 wk was the major factor contributing to L:M at 6 wk ($\Delta R^2=0.22$, $p=0.008$) and 14 wk ($\Delta R^2=0.21$, $p=0.01$).</p> <p>Maternal HIV viral load during pregnancy was not consistently significantly correlated with infant L:M. Maternal lymphocyte counts and plasma retinol concentrations were not associated with infant L:M.</p> <p>While maternal vitamin A supplementation had no effect on L:M of uninfected infants, it appeared to prevent the increase in L:M of HIV-infected infants²¹:</p> <p>Mean²² L:M (CI):</p> <ul style="list-style-type: none"> • Uninfected: <ul style="list-style-type: none"> • Vitamin A group: 0.11 (0.08, 0.15) • Placebo group: 0.09 (0.06, 0.12) • HIV-infected: 	lactulose excretion.	

²¹ Reported results were adjusted for confounding variables included an interaction with HIV infection.

²² Geometric mean.

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
				<ul style="list-style-type: none"> Vitamin A group: 0.17 (0.13, 0.23) Placebo group: 0.50 (0.37, 0.68) <p>Mannitol was not affected by vitamin A. HIV infection was not consistently significantly associated with mannitol across age groups.</p> <p>Lactulose also did not consistently differ between treatment groups or by HIV-status, although vitamin A prevention of increase in lactulose among HIV-infected infants neared significance at 14 wk (p=0.058)²³.</p>		
<p>2005</p> <p>Galpin L et al.</p> <p>Effect of <i>Lactobacillus</i> GG on intestinal integrity in Malawian children at risk of tropical enteropathy</p> <p>L:M and sucrose: lactulose ratio (SUC:L) as markers of intestinal and gastric permeability, respectively, in asymptomatic children presumed at risk of</p>	<p>Mwenye, Malawi</p> <p>36-60 mo olds recruited from a rural community, excluding children with severe acute malnutrition or severe chronic illnesses.</p> <p>Subjects were considered at risk for EED due to residence in a location with high prevalence of EED.</p>	<p>RCT</p> <p>n=164;</p> <p>n=81 received <i>Lactobacillus</i> GG (80 completed the study)</p> <p>n=83 received placebo (81 completed the study)</p> <p>Subjects received 30-</p>	<p><u>Urine Tests:</u></p> <ul style="list-style-type: none"> Lactulose²⁴ Mannitol Sucrose (SUC) L:M SUC:L 	<p>At enrollment:</p> <ul style="list-style-type: none"> 73% had L:M >0.10 40% had L:M >0.20 Mean²⁵ L:M (SD): <ul style="list-style-type: none"> Treatment: 0.18 (0.16) Placebo: 0.22 (0.20) Mean lactulose (SD) in treatment group: 0.25 (0.17) Mean mannitol (SD) in treatment group: 8.0 (4.5) Mean SUC:L (SD): <ul style="list-style-type: none"> Treatment: 0.58 (0.64) Placebo: 0.60 (0.64) <p>Mean excretion of sucrose (SD) increased from 0.057 (0.042) to 0.078 (0.058) in the treatment group (p=0.01), but</p>	<p>A high baseline prevalence of abnormal L:M was observed, with no change after intervention.</p> <p>High mannitol excretion (relative to UK norms) drove the abnormal L:M.</p> <p>There was little effect on SUC:L with intervention; sucrose excretion increased in both treatment and</p>	<p>Difficult to interpret sucrose tests because there are limited data on laboratory values for these tests in young children.</p>

²³ P-values are from reported results that were adjusted for confounding variables.

²⁴ Lactulose, mannitol, and sucrose results were expressed as % of dose administered.

²⁵ Arithmetic mean.

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
EED	Presumed that if SBBO is etiology for EED, treatment with <i>Lactobacillus</i> will result in improved gut integrity.	days of <i>Lactobacillus</i> GG or placebo. Only the 161 subjects who completed the study had repeat testing.		similar results were observed in the placebo group. Otherwise there were no changes in lactulose, mannitol, L:M, or SUC:L after treatment or placebo.	control groups.	
2001 Gandolfi L et al. Antiendomysial antibody test reliability in children with frequent diarrhea and malnutrition: is it celiac disease Jejunal biopsy among children with PD and/or malnutrition	Brasilia, Brazil 6 mo-13 yr olds with acute, persistent or chronic diarrhea, and/or malnutrition being seen at the pediatric gastroenterology service of a university hospital and determined to have disease severity warranting biopsy. Subjects negative for CD-specific antibodies were of interest for this review.	Cross-sectional n=31	<u>Jejunal capsule biopsy:</u> Histopathology	30/31 (96.8%) had abnormal histopathology: <ul style="list-style-type: none"> • Suggesting non-specific inflammatory abnormalities in 27 (87.1%) subjects. • Demonstrating grade 3 mucosal abnormalities in all malnourished 1 yr olds negative for enteric parasites. 	The vast majority of children with clinically severe diarrhea and/or malnutrition had some degree of abnormality on jejunal biopsy.	Biopsies of interest were not provided in subject-specific detail (e.g. characteristics of the 27 children with non-specific inflammation were not detailed (e.g. presence of parasites, degree of malnutrition and/or diarrhea).
2008 R. Goto, et al. Impact of anti- <i>Giardia</i> and anthelmintic treatment on infant	Dhamrai Upazila, Bangladesh 3-15 mo olds from a rural area were enrolled and followed in a 9-mo	RCT n=222* n=75 received anti- <i>Giardia</i> and	<u>Urine Test:</u> L:M <u>Blood Tests:</u> • α -1-acid glycoprotein (AGP)	Mean L:M ²⁶ (SD) at baseline was 0.18 (0.24) in treatment groups, with no significant difference in placebo group or in testing post-intervention. Proportion with elevated L:M	High L:M ratios overall with substantial seasonal and within-infant variability.	High L:M ratios were defined as greater than the upper CI for UK infants. Same study

²⁶ Geometric mean.

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
<p>growth and intestinal permeability in rural Bangladesh: a randomised double-blind controlled study</p> <p>L:M as a marker of intestinal permeability, IgG as a marker of chronic immune stimulation, and α-1-acid glycoprotein as an acute phase reactant among children undergoing anti-parasitic presumptive treatment vs. placebo. Also assessed markers' associations with growth parameters.</p>	<p>trial.</p> <p>There was a high prevalence of malnutrition in the study population.</p>	<p>anthelmintic treatment</p> <p>n=59 received anti-<i>Giardia</i> treatment only</p> <p>n=88 received placebo</p> <p>* Those who fully participated and for whom data were analyzed are included in this review.</p>	<ul style="list-style-type: none"> • IgG • Albumin 	<p>at any study time point varied between 58%-74%. >57% consistently elevated L:M ratios.</p> <p>Seasonal variation in L:M was observed ($p < 0.001$), with highest mean values in the monsoon season.</p> <p>L:M was associated with ΔWAZ and ΔWHZ scores at 24 weeks ($p=0.001$ and $p<0.001$, respectively, point estimates not provided.)</p> <p>Serum immune marker values were similar in all groups and did not change substantially with interventions.</p> <p>AGP concentrations were negatively associated with ΔWAZ score at 24 weeks ($p=0.004$, point estimate not provided), and were associated with ΔWHZ score at 12 weeks but not at 24 weeks.</p>	<p>Interventions did not impact L:M or serum immune markers.</p> <p>There was improvement in weight with better L:M values, the degree to which this occurred was not reported.</p>	<p>population as reported by this group in another study also included in this review [123].</p>
<p>2008</p> <p>Goto R et al.</p> <p>Impact of intestinal permeability, inflammation status and parasitic infections on infant</p>	<p>Dhamrai Upazila, Bangladesh</p> <p>3-15 mo olds from a rural area were enrolled and followed in a 9-mo trial.</p>	<p>Longitudinal data extracted from an RCT [122]</p> <p>n=298</p> <p>Urine and</p>	<p><u>Urine Test:</u> L:M</p> <p><u>Blood Tests:</u></p> <ul style="list-style-type: none"> • α-1-acid glycoprotein (AGP) • IgG • Albumin 	<p>Mean²⁷ L:M: 0.15</p> <p>L:M showed a decreasing trend with age ($p=0.003$), and was associated with female gender ($p=0.004$), HAZ score ($p=0.039$), and WAZ score ($p=0.019$), but not with giardiasis or any of the serum</p>	<p>Mean L:M was elevated. L:M was not associated with any of the tested serum markers of inflammation or with giardiasis.</p> <p>IgG rose with</p>	<p>Helminthiasis prevalence was very low; testing for association with markers was not performed.</p> <p>Giardiasis was</p>

²⁷ Geometric mean.

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
<p>growth faltering in rural Bangladesh</p> <p>L:M as a marker of intestinal permeability, IgG as a marker of chronic immune stimulation, and α-1-acid glycoprotein as an acute phase reactant. Also assessed laboratory values' associations with giardiasis and growth parameters.</p>	<p>There was a high prevalence of malnutrition in the study population.</p>	<p>blood samples were collected every 3 mo and anthropometric measurements were collected monthly.</p>	<ul style="list-style-type: none"> • Hemoglobin 	<p>immune markers.</p> <p>IgG, AGP, and albumin were associated with giardiasis, but hemoglobin was not.</p> <p>Mean circulating albumin concentration was normal for age [203]. Compared to UK age-matched reference [199], rate of rise in IgG with increasing age was similar, but concentrations were consistently ~3g/L higher.</p> <p>IgG was not associated with growth parameters. Albumin was associated with HAZ score only (p=0.016). AGP was inversely associated with HAZ (p=0.011) and WAZ (p=0.005) scores.</p>	<p>increasing age at the rate expected (compared to UK norms) [199] but at higher concentrations across all ages.</p>	<p>defined as presence of a <i>Giardia</i>-specific IgM response.</p> <p>Same study population as reported by this group in another study also included in this review [122].</p> <p>Cut-off values representing elevated concentrations have not been determined for AGP. UK norms for 10 mo olds-adults are 0.88 g/L mean (0.21 SD) [204].</p>
<p>2002</p> <p>Goto R et al.</p> <p>Poor intestinal permeability in mildly stunted Nepali children: Associations with weaning practices and <i>Giardia lamblia</i> infection</p> <p>L:M as a marker of</p>	<p>Kathmandu, Nepal</p> <p>0-5 yr olds (mean age 3.8 yr) from two urban squatter settlements.</p> <p>37% and 33% of subjects were stunted and underweight,</p>	<p>Cross-sectional</p> <p>n=210</p>	<p><u>Urine Tests:</u></p> <ul style="list-style-type: none"> • Lactulose²⁸ • Mannitol • Lactose²⁹ (168 tested) • L:M (158 tested) • Lactose:lactulose ratio (157 tested) 	<p>L:M:</p> <ul style="list-style-type: none"> • 92% had values >UK norms • Mean³⁰ L:M (SD, range): 0.26 (0.21, 0.04-1.71). • <i>Giardia</i>-infected versus uninfected means: 0.43 vs. 0.25, p=0.014 <p>The duration of ingestion of solid foods (with or without concurrent breastfeeding) was not associated with L:M in multivariate analysis.</p>	<p>L:M ratios were high overall.</p> <p>Wide individual variation was observed in L:M ratios.</p> <p>L:M was associated with giardiasis but not helminthiasis.</p>	<p>Low lactase activity was defined as lactose:lactulose ratio >0.4.</p> <p>Specific L:M data by WAZ and HAZ scores were not reported, although authors state</p>

²⁸ Lactulose and mannitol results were expressed as % of dose administered.

²⁹ Lactose results were expressed in mg/L.

³⁰ Geometric mean.

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
intestinal permeability, and assessment of association with giardiasis, helminthiasis, nutritional practices, and growth status.	respectively.			<p>L:M was correlated with longer duration of breastfeeding ($r=0.27$, $p<0.019$). Specifically, children who breastfed for >2 yr had higher L:M ratios than children who breastfed for shorter times (data not provided).</p> <p>L:M was not associated with:</p> <ul style="list-style-type: none"> • History of diarrhea in the week preceding testing • Helminthiasis • Age • WAZ or HAZ scores <p>Lactulose excretion ranged from 0.02–15.00. Mannitol excretion ranged from 0.5–15.00.</p> <p>47% showed low lactase activity. Lactose values and lactose:lactulose ratios decreased with age ($R^2=28\%$, $p<0.0001$), but were not associated with sex, ethnicity, and location nor were they associated with L:M.</p> <p>Mean³¹ urinary lactose concentrations (mg/L) by feeding mode:</p> <ul style="list-style-type: none"> • Breastfed: 172.5 • Non-breastfed: 44.5, $p<0.0001$ corrected for infant age 	<p>Urinary lactose concentrations and lactose:lactulose ratios were significantly higher in breastfed subjects than in those that were not breastfed, despite similar intestinal permeability values.</p> <p>There were some unexpected findings: the duration of breastfeeding, and not the timing of introduction of solid foods, was correlated with L:M, and the correlation was direct, not inverse. Authors speculate that this could be due to higher mean age of their cohort compared to another study that demonstrated beneficial effect of duration of breastfeeding on reduced L:M in Guatemala [205].</p>	that L:M was not associated with “growth status.”

³¹ Geometric mean.

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
				<p>Mean³² lactose:lactulose ratio by feeding mode:</p> <ul style="list-style-type: none"> Breastfed: 2.76 Non-breastfed: 0.31, p<0.0001 corrected for infant age <p>Mean L:M by feeding mode:</p> <ul style="list-style-type: none"> Breastfed: 0.23 Non-breastfed: 0.28, non-significant, p-value not specified 		
<p>2000</p> <p>Haase A et al.</p> <p>Dual sugar permeability testing in diarrheal disease</p> <p>Lactulose:rhamnose ratio (L:R) as a marker of intestinal permeability in children with or without diarrhea. Also directly compared blood and urine methods of L:R testing in a subset of subjects.</p>	<p>Darwin, Australia</p> <p>Cases were >4 mo olds admitted to Royal Darwin Hospital with diarrhea. Controls were patients admitted with non-GI illness.</p> <p>More than 75% of cases and controls were Aboriginal.</p>	<p>Case-control</p> <p>n=264;</p> <p>n=150 cases with AD</p> <p>n=114 controls with no diarrhea</p>	<p><u>Blood Test:</u> L:R</p> <p><u>Urine Test:</u> L:R</p> <p>Among cases:</p> <ul style="list-style-type: none"> 24 had both blood and urine L:R 98 had blood L:R only 28 had urine L:R only <p>Among controls:</p> <ul style="list-style-type: none"> 25 had both blood and urine L:R 36 had blood L:R only 53 had urine L:R only <p>A total of 49 subjects were tested with both blood and urine L:R methods to allow direct</p>	<p>Among the subset with both blood and urine specimens:</p> <ul style="list-style-type: none"> Urine L:R: <ul style="list-style-type: none"> Mean³³ (CI): <ul style="list-style-type: none"> Cases: 12.4 (9.3, 16.5) Controls: 6.7 (5.0, 8.8), p=0.004 Distribution across ratios: <ul style="list-style-type: none"> Low: n=31 Intermediate: n=9 High: n=9 Blood L:R: <ul style="list-style-type: none"> Mean³⁴ (CI): <ul style="list-style-type: none"> Cases: 9.4 (6.7, 13.1) Controls: 5.9 (4.4, 7.8), p=0.04 Distribution across ratios: <ul style="list-style-type: none"> Low: n=27 Intermediate: n=11 High: n=11 	<p>Children with diarrhea had significantly higher L:R ratios by both blood and urine testing compared with controls without GI illness.</p> <p>There was substantial agreement between urine and blood L:R tests in the same subjects.</p> <p>Urine has been an established substrate for sugar excretion assessment as an indication of intestinal permeability.</p>	<p>Authors used data from non-diarrheal controls from their clinical practice to derive cut-points for L:R ratios used in this study:</p> <ul style="list-style-type: none"> Blood L:R: <ul style="list-style-type: none"> Low= <7 Intermediate= 7-12.5 High= >12.5 Urinary L:R: <ul style="list-style-type: none"> Low= <10 Intermediate= 10-18 High= >18 <p>Controls were significantly</p>

³² Geometric mean.

³³ Geometric mean.

³⁴ Geometric mean.

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
			comparison of values.	<p>Among subjects with only urine tested: Mean³⁵ urine L:R (CI):</p> <ul style="list-style-type: none"> • Cases: 15.7 (12.6, 19.6) • Controls: 6.7 (5.7, 8.0), p<0.0001 <p>Among subjects with only blood tested: Mean³⁶ blood L:R (CI):</p> <ul style="list-style-type: none"> • Cases: 12.8 (10.3, 16.0) • Controls: 3.7 (2.8, 4.9), p<0.0001 <p>Even though blood L:R was consistently lower than urine L:R by a geometric mean (CI) of 1.09 (1.02, 1.16), there was strong correlation between L:R ratios in blood and urine as measured by:</p> <ul style="list-style-type: none"> • Concordance correlation coefficient for agreement (CI) of 0.76 (0.64, 0.88) • Kappa statistic (CI) of 0.71 (0.51, 0.92) (when L:R ratios are divided into 3 ordered categories) • Sensitivity and specificity of blood tests of 81% (25/31) and 89% (16/18), respectively, when using the urine testing as the standard. <p>The failure rate* for serum</p>	<p>However, timed collection of urine is not a trivial task, especially among female children, and contamination with stool is problematic, especially in children with diarrhea. However, the much lower concentrations of probe sugars in blood compared to urine had posed a challenge to sensitive detection in blood. High performance liquid chromatography (HPLC) methods, as used in this study, now provide a more sensitive method of assessing blood specimens.</p> <p>The failure rate of L:R blood testing was significantly lower than that of urine testing.</p>	<p>older than the cases, but authors suggest that age differences do not impact L:R test performance.</p> <p>Numbers of subjects do not always match up (e.g. numerator in test failure rate calculations does not match other such reported numbers).</p> <p>Analyses of those subjects who had both blood and urine testing were conducted on combined cases and controls. Analyses of those with and without diarrhea would have been of interest. One would expect children with diarrhea to have higher rates of urine</p>

³⁵ Geometric mean.

³⁶ Geometric mean.

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
				<p>L:R testing (20/197, 10%) was lower than for urine testing (86/234, 37%) (p<0.0001).</p> <p>* Defined as emesis with rhamnose/lactulose oral challenge (same dose for urine and serum testing), urine leakage or contamination with stool, or plasma quantity from blood draw of insufficient quantity for analysis.</p>		<p>test failure due to contamination with stool and to have higher failure rates using either analytes due to higher rates of emesis.</p> <p>Spot blood testing might be more feasible than timed urine collections, but HPLC might not be feasible in resource-poor settings.</p> <p>This study appears to report on the same population as two other studies in this review which also assessed serum L:R as a marker of intestinal permeability [43, 58].</p>
<p>2000 Hafeez A et al. An audit of pediatric upper gastrointestinal endoscopies</p>	<p>Islamabad, Pakistan 2 mo-12 yr olds referred from various hospitals to KRL Hospital Islamabad for</p>	<p>Case-series n=41; • 28 with PD • 9 with FTT • 4 with short stature</p>	<p><u>Endoscopic duodenal Biopsy:</u> • Gross endoscopic visualization • Histopathology</p>	<p>Positive histopathologic findings were identified in: • 21/28 with PD • 7/9 with FTT • 3/4 with short stature</p> <p>More abnormalities were found via histology than</p>	<p>75% of the PD and 77% and the short stature/FTT patients had abnormalities by endoscopy. Authors assert the</p>	<p>There was possible bias in the manner of selection for endoscopy. 14 biopsies were unable to be analyzed (from</p>

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
Duodenal biopsy among children with PD or growth problems	abdominal pain, PD, short stature, FTT, GI bleeding, or anemia. The subjects of interest for this review were those with PD or growth problems.			visualization, and findings did not necessarily correlate.	importance of biopsies among children with indications for endoscopy, due to lack of correlation between them and increased identification of abnormalities by biopsy.	100 endoscopies). Authors did not report the endoscopic appearance of the mucosa. Histology findings were reported by specimen (with multiple specimens from some patients), not by condition or by patient, so specific results could not be interpreted in regards to this review.

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
<p>2007</p> <p>Jain S et al.</p> <p>Fecal occult blood screening in children with severe malnutrition</p> <p>Fecal occult blood among severely malnourished children compared to healthy controls</p>	<p>Delhi, India</p> <p>Children (ages unspecified) admitted with severe malnutrition and age-matched healthy controls recruited from an immunization clinic.</p>	<p>Case-control</p> <p>n=80;</p> <p>n=50 cases with severe malnutrition</p> <p>n=30 healthy controls</p>	<p><u>Stool Test:</u> Occult blood</p> <p><u>Blood Test:</u> Hemoglobin</p>	<p>Fecal occult blood test was positive in 30/50 (60%) cases and 0/30 controls.</p> <p>Among cases positive for fecal occult blood, 20 (66.7%) were found to have hemoglobin <8 g/dL.</p> <p>Enteric infections:</p> <ul style="list-style-type: none"> • Parasitic infections were detected in 14/50 (28%) of cases, 12 (85.7%) of whom tested positive for fecal occult blood. • Bacterial infections were detected in 18/50 (36%) of cases, 13 (72.2%) of whom tested positive for fecal occult blood. • Of the remaining 18 for whom an enteric pathogen was not identified, 5 (27.8%) tested positive for fecal blood. <p>Among the 30 cases with fecal occult blood, 16 were breastfed, 11 were fed cow's milk, and 3 were fed formula.</p>	<p>A high proportion of severely malnourished children had a positive fecal occult blood test, compared with no positives among healthy controls.</p> <p>Malnourished children with identifiable pathogens more often tested positive for fecal occult blood, although approximately 25% of those without an identifiable pathogen also tested positive.</p> <p>Presence of fecal blood did not appear to vary by feeding mode (e.g. breast milk, cow's milk, or formula), although data presented were limited.</p>	<p>Among cases, half had a presenting complaint of diarrhea (duration not specified), but the authors did not report results stratified by diarrhea duration.</p> <p>Authors did not provide differences in proportions of occult blood among those with and without specific enteric pathogens.</p> <p>Statistical analysis was not provided; data were reported as proportions only.</p> <p>Matching scheme was not defined.</p>

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
<p>2002</p> <p>Kapoor S et al.</p> <p>Detecting protein losing enteropathy by Tc-99m dextran scintigraphy: A novel experience</p> <p>Tc-99m dextran scintigraphy as a marker of protein-losing enteropathy or intestinal inflammation</p>	<p>New Delhi, India</p> <p>2-12 yr olds selected from hospitalized patients with symptoms suspicious for protein-losing enteropathy (hypoalbuminemia and edema).</p>	<p>Case-series</p> <p>n=3 <5 yr old</p>	<p>Tc-99m dextran scintigraphy</p>	<p>Abnormal Tc-99m dextran uptake was positive in one child found to have subtotal villous atrophy on biopsy and another thought to have abdominal tuberculosis.</p> <p>The child with the negative scan had marasmus and partial villous atrophy on biopsy.</p>	<p>Scintigraphy might be a useful, noninvasive method for detecting intestinal pathology.</p>	<p>This pilot study had a small sample size of 8 children, and only 3 were younger than 5 years.</p>
<p>2001</p> <p>Kapoor S et al.</p> <p>Giardiasis--clinical and diagnostic perspective</p> <p>Immunoglobulin concentrations in duodenal fluid and serum among children with PD and <i>Giardia</i> infection compared to those without diarrhea</p>	<p>New Delhi, India</p> <p><12 yr olds admitted to hospital with PD and <i>Giardia</i>.</p> <p>Controls had no diarrhea and were hospitalized for non-GI conditions.</p> <p>Most cases were <7 yr old, with n=19 <3 yr old. Ages of controls were not specified.</p>	<p>Case-control</p> <p>n=40;</p> <p>n=30 cases with PD and <i>Giardia</i></p> <p>n=10 controls without diarrhea</p>	<p><u>Duodenal secretion aspirates:</u></p> <ul style="list-style-type: none"> • IgG • IgM • IgA <p><u>Blood Tests:</u></p> <ul style="list-style-type: none"> • IgG • IgM • IgA 	<p>Higher mean concentrations of IgM were found in duodenal aspirates of cases compared to controls (p<0.05).</p> <p>Mean concentrations of duodenal IgA and IgG did not differ between cases and controls.</p>	<p>Differences in immunoglobulin concentrations were limited among children with PD infected with <i>Giardia</i> compared to children without such conditions.</p>	<p>The number of controls was small due to constraints in obtaining duodenal aspirate from children without GI symptoms.</p>
<p>2006</p> <p>Kirkpatrick BD et al.</p> <p>Serum mannose-binding lectin deficiency is associated with</p>	<p>Port-au-Prince, Haiti</p> <p><36 mo old inner-city residents recruited from the rehydration unit at the State</p>	<p>Case-control</p> <p>n=99;</p> <p>n=49 cases with <i>Cryptosporidium</i> infection (22 with PD)</p>	<p><u>Blood Test:</u></p> <p>Mannose-binding lectin (MBL)</p>	<p>Serum MBL concentrations were lower in cases than in healthy controls (p=0.002) and diarrhea controls (p=0.045).</p> <p>Percentage MBL-deficient:</p> <ul style="list-style-type: none"> • 36.7% cases 	<p>While cryptosporidiosis was associated with MBL deficiency, MBL concentrations were not significantly</p>	<p>MBL deficiency was defined as concentrations ≤ 70 ng/mL.</p>

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
<p>cryptosporidiosis in young Haitian children</p> <p>Mannose-binding lectin as a marker of innate immune response among children with and without <i>Cryptosporidium</i> infection</p>	<p>University Hospital or from GHESKIO HIV Center³⁷.</p> <p>All subjects were HIV-negative.</p>	<p>n=9 diarrhea controls negative for <i>Cryptosporidium</i></p> <p>n=41 healthy controls without diarrhea and <i>Cryptosporidium</i>-negative</p>		<ul style="list-style-type: none"> • 9.8% healthy controls • 0 diarrhea controls <p>Cryptosporidiosis was associated with MBL deficiency (odds ratio=22.4; CI: 3.1, 160.8³⁸).</p> <p>Among cases, the proportion of those with PD was nearly double among those with MBL deficiency compared to those without MBL deficiency, but these results were not significant (p=0.13). MBL deficiency was not associated with duration of diarrhea (p=0.37) among those with cryptosporidiosis nor with anthropometric status among either cases or controls.</p>	<p>associated with mean duration of diarrhea or history of PD.</p>	
<p>2006</p> <p>Kirkpatrick BD et al.</p> <p>Childhood cryptosporidiosis is associated with a persistent systemic inflammatory response</p> <p>Fecal cytokines and lactoferrin as markers of intestinal</p>	<p>Port-au-Prince, Haiti</p> <p><36 month olds recruited from GHESKIO HIV Center³⁹ with <i>Cryptosporidium</i> infection and healthy controls.</p> <p>Subjects were followed-up at 6 and 9 months after</p>	<p>Cohort</p> <p>n=73;</p> <p>n=42 cases with diarrhea and <i>Cryptosporidium</i> infection (18 with PD)</p> <p>n=31 healthy controls without diarrhea and <i>Cryptosporidium</i>-</p>	<p><u>Stool Tests:</u></p> <ul style="list-style-type: none"> • Lactoferrin • Cytokines: <ul style="list-style-type: none"> • IFN-γ • TNF-α • TGF-β • IL-4 • IL-8 • IL-10 	<p>Proportion lactoferrin-positive at enrollment:</p> <ul style="list-style-type: none"> • Cases: 51.2% • Controls: 4.0% <p>Cases had higher concentrations of TNF-α than controls at enrollment (p=0.04), but no difference was observed at follow-up.</p> <p>Controls had almost 2x higher fecal IFN-γ at enrollment (p=0.1); the</p>	<p>Lactoferrin was present among half of subjects with cryptosporidiosis and uncommon among those without such infection.</p> <p>Fecal TNF-α was higher among cases at enrollment but did</p>	<p>Cut-off values for lactoferrin positivity were not provided.</p> <p>Breastfed children (>85% of cases and controls) were included in testing. Proportions at follow-up were not reported.</p> <p>The association of fecal cytokines and</p>

³⁷ The Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections.

³⁸ Reported results were adjusted for confounding variables, unless otherwise noted.

³⁹ The Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections.

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
mucosal inflammation among children with and without <i>Cryptosporidium</i> infection	infection resolved. HIV status of subjects varied. There was a high prevalence of malnutrition in the study population.	negative		magnitude of difference increased (to almost 3x) and was statistically significant at the 6- and 9-month follow-up (p=0.01 and p=0.03, respectively). No differences in fecal concentrations of TGF- β , IL-8, IL-4, or IL-10 were noted between groups.	not persist when infection resolved. Paradoxically, controls' comparatively higher fecal IFN- γ increased in both magnitude and degree of statistical significance at follow-up. Of the remaining fecal cytokines assessed, there were no differences between cases and controls.	lactoferrin with growth parameters, history of PD, and HIV status were not reported, nor was their association with each other. Various markers of systemic inflammation, including serum cytokines, were measured but their relationship with markers of intestinal inflammation was not reported.
2002 Kirkpatrick BD et al. Cryptosporidiosis stimulates an inflammatory intestinal response in malnourished Haitian children Stool lactoferrin, reducing substances, leukocytes and cytokines as markers of intestinal inflammation of	Port-au-Prince, Haiti <18 mo olds from a low SES setting recruited from the rehydration unit of GHESKIO HIV Center ⁴⁰ with diarrhea and <i>Cryptosporidium</i> infection. Controls recruited from an outpatient clinic without <i>Cryptosporidium</i> infection included those with and	Case-control n=49; n=17 cases with <i>Cryptosporidium</i> and diarrhea (5 with PD) n=32 controls without <i>Cryptosporidium</i> ; • 17 with diarrhea (5 with PD) • 15 healthy	<u>Stool Tests:</u> • Reducing substances (RS) • Lactoferrin • Cytokines: • TNF- α receptor I • IL-4 • IL-8 • IL-10 • IL-13 • IFN- γ <u>Blood Test:</u> WBC	Proportion RS-positive: • 33.3% cases • 64.7% diarrhea controls • 46.7% healthy controls, (p=0.2) Proportion lactoferrin-positive: • 83.3% cases • 60.0% diarrhea controls • 28.6% healthy controls, (p=0.01) IFN- γ was not recovered in any stools. All other fecal cytokines were significantly	Fecal lactoferrin was identified most often in children with diarrhea, especially in those with <i>Cryptosporidium</i> . While some fecal cytokines were detected in as many as 40% of healthy controls and 70% of controls with diarrhea, they were generally associated with	Reported results were not stratified by persistent vs. acute diarrhea status. Cut-off values for lactoferrin positivity were not described. Stools from children who were breastfeeding were not tested for lactoferrin.

⁴⁰ The Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections.

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
children with and without <i>Cryptosporidium</i> infection	without diarrhea.			<p>associated with <i>Cryptosporidium</i> cases compared to diarrhea and healthy controls.</p> <p>Additionally, TNF-α receptor I, IL-8, and IL-13 were found in diarrhea and healthy controls, while IL-4 and IL-10 were not.</p> <p>Fecal lactoferrin was associated with the presence of TNF-α receptor I (point estimate not provided, $p=0.03$).</p> <p>Mean WBC counts were within normal range in all 3 groups.</p>	<i>Cryptosporidium</i> infection. The other stool tests did not discriminate by diarrhea or <i>Cryptosporidium</i> status.	
<p>2008</p> <p>Kohli A et al.</p> <p><i>Giardia duodenalis</i> assemblage, clinical presentation and markers of intestinal inflammation in Brazilian children</p> <p>Fecal lactoferrin as a marker of intestinal inflammation in <i>Giardia</i>-infected children and its association with persistence of diarrhea</p>	<p>Goncalves Dias favela in Fortaleza, Brazil</p> <p>All newborns from an urban shantytown were recruited at birth and followed for up to 4 yr. Those with <i>Giardia</i> recovered from stools were included in this study.</p>	<p>Cohort</p> <p>n=108 stool samples from 47 children</p> <p>Stools were collected at regular intervals as well as during episodes of diarrhea.</p>	<p><u>Stool Test:</u> Lactoferrin</p>	<p>Proportion of positive lactoferrin results decreased with each new <i>Giardia</i> infection, $p=0.015$:</p> <ul style="list-style-type: none"> 1st infection: 74.0% (15.2% of those testing positive had high titers) 2nd infection: 40.0% (5.3% of those testing positive had high titers) 3rd infection: 1 (20.0%) tested positive (at a high titers) <p>Increasing titers of lactoferrin were associated with longer duration of diarrhea, $p=0.017$:</p> <ul style="list-style-type: none"> Negative: 2.2 days Low: 9.7 days High: 14.6 days 	<p>Increased concentrations of lactoferrin were observed more frequently with first time <i>Giardia</i> infections. Concentrations were associated with longer duration of diarrhea, although these results were not presented separately for first and recurrent infections.</p> <p>Stool lactoferrin might be useful in predicting</p>	<p>Lactoferrin results were graded based on agglutination reaction positivity with increasing dilution; the following scale was used:</p> <ul style="list-style-type: none"> High = positive at 1:400-1:3200 dilution Low = positive at 1:25-1:200 Negative = no reaction at 1:25 <p>Stools from children who were breastfeeding were not tested.</p>

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
				<p>Lactoferrin results did not differ between symptomatic and asymptomatic children at first infection, but those with symptoms had positive results with recurrent infections with greater frequency (75.0% vs. 0 in asymptomatic repeat infections, p=0.017.)</p>	<p>duration of diarrheal illness in <i>G. duodenalis</i>-infected children.</p>	<p>Data were part of a larger study; similar data on lactoferrin in <i>Cryptosporidium</i>-infected children were published by O.Y. Bushen, et al. (also included in this review); however, Bushen et al. used a slightly different grading scale for reporting lactoferrin results [108].</p>
<p>2003</p> <p>Kukuruzovic RH et al.</p> <p>Increased nitric oxide production in acute diarrhea is associated with abnormal gut permeability, hypokalemia and malnutrition in tropical Australian aboriginal children</p> <p>Nitric oxide (NO) as a marker of intestinal permeability and inflammation, and lactulose:rhamnose ratio (L:R) as a marker of intestinal permeability and the relationship</p>	<p>Darwin, Australia</p> <p>1-6 yr old Aboriginal and non-Aboriginal hospital inpatients.</p> <p>Subjects were grouped as follows:</p> <ol style="list-style-type: none"> 1. Children with AD 2. Children with no diarrhea but with non-GI infectious conditions 3. Children without GI or infectious conditions 	<p>Case-control</p> <p>n=318;</p> <p>n=169 cases with AD (154 Aboriginal)</p> <p>n=149 controls:</p> <ul style="list-style-type: none"> • 73 with non-GI infections (49 Aboriginal) • 76 with no infections (29 Aboriginal) 	<p><u>Urine Test:</u> Nitric Oxide (NO)*</p> <p><u>Blood Tests:</u> L:R Mean corpuscular volume (MCV)</p> <p><u>Stool Test:</u> Reducing substances (RS)** (169 cases tested)</p> <p>* NO is an unstable free radical and is converted to nitrite and nitrate. Urine nitrate (NO₃)+ nitrite (NO₂) was expressed as a ratio with urine creatinine (NO₂ + NO₃:Cr) in order to account for</p>	<p>NO among Aboriginal children with diarrhea was >3x higher than any other group and >5x higher than in non-Aboriginal controls.</p> <ul style="list-style-type: none"> • NO was >3x and >2x higher among Aboriginal than non-Aboriginal children in the diarrhea (p<0.001) and no infections groups (p<0.001), respectively, but there was no difference between them in the non-GI infections group. • NO was >3x and ~2x higher in the diarrhea compared to the no infections group among Aboriginals (p<0.001) and non-Aboriginals (p<0.03), respectively. • NO was virtually the same among the Aboriginal non-GI infections and no 	<p>NO₂ + NO₃:Cr ratio, as a measure of endogenous nitric oxide production, was used as a marker of gut permeability and inflammation, with an attempt to identify how much more it reflects as response to inflammation from GI vs. non-GI infections.</p> <p>Among non-Aboriginal controls, NO production was the same among those with diarrhea and non-GI infections (and higher compared</p>	<p>Positive stool RS was defined as ≥0.5%.</p> <p>Abnormal L:R was defined as >7.6; no reference or derivation was provided for this cut-point.</p> <p>Study population appears to be the same as in another Kukuruzovic, et al. study also included in this review which assessed serum lactulose:rhamnose as a marker of intestinal permeability [58].</p>

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
<p>between NO and L:R, growth parameters, mean corpuscular volume (as a surrogate of iron deficiency), and stool reducing substances among children with and without diarrhea</p>			<p>differences in urine concentration.</p> <p>** Measured only among children with profuse diarrhea.</p>	<p>infections groups, as well as among the non-Aboriginal diarrhea and non-GI infections groups.</p> <p>112/152 (74%) and 31/169 (18%) of children with AD had abnormal L:R ratios and positive stool RS, respectively.</p> <p>NO and L:R were measured at “convalescence” on Day 5 among those with diarrhea: the mean improvement in NO was 21.7% compared with 54.6% for L:R (p=0.01).</p> <p>NO and L:R were correlated (n=193, r=0.37, p<0.001)⁴¹; the correlation was stronger for lactulose (effect ratio=1.47, p<0.001) than for rhamnose (effect ratio=0.80, p=0.02⁴²).</p> <p>NO was not correlated with stool RS⁴³ or MCV, but was correlated with lower WAZ score (effect ratio=0.88, p=0.05).</p>	<p>to controls). NO was highest by far among Aboriginal children with diarrhea compared to any other group. Authors suggest that high basal concentrations of NO among Aboriginal children due to (clinically silent) enteropathy could explain the concentrations seen among Aboriginal controls in this study.</p> <p>NO appeared to decrease significantly more slowly than L:R among children recovering from diarrhea. NO was found to correlate with L:R. NO was more strongly correlated with lactulose than rhamnose.</p>	

⁴¹ Reported results appear to have been adjusted for age and race.

⁴² Reported results were adjusted for age and race.

⁴³ Reported results among children with diarrhea were adjusted for age and race.

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
<p>2002</p> <p>Kukuruzovic RH et al.</p> <p>Milk formulas in acute gastroenteritis and malnutrition: a randomized trial</p> <p>Lactulose:rhamnose ratio (L:R) as a marker of intestinal permeability among children with diarrhea and/or malnutrition treated with milk formulas of varying composition and osmolality</p>	<p>Darwin, Australia</p> <p>Inpatient Aboriginal children <3 yr old with AD and/or WAZ score <-2.</p> <p>60% of subjects had low WAZ score and 90% had diarrhea.</p>	<p>RCT</p> <p>n=177;</p> <p>n=60 received De-Lact formula</p> <p>n=65 received O-Lac formula</p> <p>n=52 received Alfaré formula</p> <p>Subjects were treated with one of three low-lactose formulas:</p> <ul style="list-style-type: none"> • De-Lact, low-osmolality lactose-free formula • O-Lac, lactose-free formula • Alfaré, partially hydrolyzed formula 	<p><u>Blood Test:</u> L:R</p> <p>L:R testing was repeated in 150 subjects at day 5:</p> <ul style="list-style-type: none"> • De-Lact: n=48 • O-Lac: n=52 • Alfaré: n=50 	<p>Baseline mean⁴⁴ L:R (CI) in De-Lact group was 14.9 (10.4, 21.5), with no difference between groups.</p> <p>The mean improvement* in L:R (CI) was 13.0 (9.3, 16.6) with some significant differences between the various formulas:</p> <ul style="list-style-type: none"> • De-Lact: 18.6 (10.6, 26.6) • O-Lac: 12.0 (7.5, 16.6), p=0.15 compared to De-Lact • Alfaré: 8.5 (2.1, 14.9), p=0.049 compared to De-Lact <p>* Improvement in L:R was calculated as baseline L:R minus repeat L:R.</p>	<p>Authors noted that treatment with all of the low-lactose formulas studied resulted in improved L:R among this population at risk for enteropathy and growth failure. Improvement was most marked with the low osmolality formula, De-Lact.</p>	<p>Reported results did not appear to be harmonized with the method described for calculating improvement in L:R.</p> <p>Fully breastfed children were excluded.</p> <p>The study did not include a control arm (of standard care) to which change in L:R could be compared.</p> <p>Authors reiterate the advantages of serum over timed urine collection for assessment of L:R as discussed in another publication in this review [125].</p>

⁴⁴ Geometric mean.

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
<p>2002</p> <p>Kukuruzovic RH et al.</p> <p>Small bowel intestinal permeability in Australian Aboriginal children</p> <p>Serum lactulose: rhamnose ratio (L:R), serum lactose, and stool reducing substances as markers of intestinal permeability among Aboriginal and non-Aboriginal children with and without diarrhea</p>	<p>Darwin, Australia</p> <p>Cases were Aboriginal and non-Aboriginal children admitted to hospital with diarrhea. Controls were Aboriginal and non-Aboriginal children admitted without GI illnesses.</p>	<p>Case-control</p> <p>n=375 admissions for 306 children;</p> <p>n=285 case admissions for AD (264 Aboriginal)</p> <p>n=90 control admissions with no diarrhea (74 Aboriginal)</p>	<p><u>Blood Tests:</u></p> <ul style="list-style-type: none"> • Lactose • Lactulose⁴⁵ • Rhamnose • L:R • Hemoglobin • Mean corpuscular volume (MCV) <p><u>Stool Test:</u> Reducing substances (RS)*</p> <p>L:R testing was repeated on day 5 for a subset of Aboriginal subjects:</p> <ul style="list-style-type: none"> • 174/264 admissions for acute diarrhea • 25/74 control admissions <p>* Measured only among children with profuse diarrhea when "clinically indicated." Number tested not provided.</p>	<p>27/75 (36%) of Aboriginal controls and 0 non-Aboriginal controls had abnormal L:R ratios.</p> <p>Mean⁴⁶ L:R at baseline: Cases:</p> <ul style="list-style-type: none"> • Aboriginal: 16.4 • Non-Aboriginal: 7.9, p=0.002 compared to Aboriginal cases <p>Controls:</p> <ul style="list-style-type: none"> • Aboriginal: 4.6 • Non-Aboriginal: 2.5, p=0.02 compared to Aboriginal controls <p>Mean improvement⁴⁷ in L:R (CI) at day 5 among those with repeat testing:</p> <ul style="list-style-type: none"> • Aboriginal cases: 14.6 (11.2, 18.0) • Aboriginal controls: -0.63 (-4.0, 2.7) <p>Mean lactulose recovery⁴⁸:</p> <ul style="list-style-type: none"> • Cases day 1: 0.085 (0.070–0.103) • Cases day 5: 0.039 (0.033–0.046) • Controls: 0.024 (0.019–0.029) <p>All 3 values significantly differed from one another.</p> <p>Mean rhamnose recovery:</p>	<p>Mean L:R ratios of Aboriginal children were approximately double those of non-Aboriginal children both among those with and without diarrhea, consistent with authors' suggestion that clinically silent enteropathy is prevalent among Aboriginal children.</p> <p>Mean L:R significantly improved over 5 days among Aboriginal cases. Children with severe diarrhea had higher mean L:R.</p> <p>Higher case L:R was driven more by high lactulose than by low rhamnose. Similarly, improvement in</p>	<p>Positive stool RS was defined as $\geq 0.5\%$.</p> <p>Abnormal L:R was defined as >5.6, derived from 2 SD above the arithmetic mean for non-Aboriginal controls in this study. The rationale for the choice of 2 SD above the arithmetic, instead of the geometric, mean is not clear. Proportions of cases with abnormal concentrations were not reported.</p> <p>Analysis included data for 69 children with repeat admissions; this might violate independence assumptions for their statistical analysis methods.</p> <p>Repeat L:R testing was conducted on</p>

⁴⁵ Lactulose and rhamnose results were expressed as % of dose administered.

⁴⁶ Geometric mean.

⁴⁷ Improvement in L:R appears to have been calculated as baseline L:R minus repeat L:R, as described in another publication in this review; however, this was not expressly stated. Reference 134. Kukuruzovic, R.H. and D.R. Brewster, *Milk formulas in acute gastroenteritis and malnutrition: a randomized trial*. J Paediatr Child Health, 2002. **38**(6): p. 571-577.

⁴⁸ Figures reported parenthetically after the mean percent recoveries of lactulose and rhamnose were not specified as ranges or CIs.

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
				<ul style="list-style-type: none"> • Cases day 1: 0.479 (0.424–0.542) • Cases day 5: 0.555 (0.498–0.616) • Controls: 0.585 (0.500–0.685) <p>These values did not significantly differ from one another.</p> <p>Confidence intervals (CIs) in the authors' graphical representation of mean L:R at admission did not overlap, and the difference in means was particularly evident between Aboriginal and non-Aboriginal subjects.</p> <p>Factors associated with L:R among cases were⁴⁹:</p> <ul style="list-style-type: none"> • Acidosis (p=0.007) • Hypokalemia (p=0.035) • Diarrhea severity (p=0.001) <p>Age and malnutrition were not associated with L:R.</p> <p>38% and 27% of Aboriginal cases had positive serum lactose and stool RS, respectively. 12% of Aboriginal and non-Aboriginal controls combined had lactosemia.</p> <p>Presence of lactosemia was associated with L:R,</p>	<p>L:R among cases was primarily due to decreased lactulose.</p> <p>Stool RS and serum lactose were found in approximately one-quarter and one-third of Aboriginal cases, respectively. The latter was weakly associated with increased lactulose.</p>	<p>controls of both racial groups, but among cases it was only conducted on Aboriginal cases.</p> <p>This study appears to report on the same population as in the Kukuruzovic, et al. 2003 reference also included in this review, which assessed nitric oxide excretion [43].</p> <p>Authors reiterate the advantages of serum over timed urine collection for assessment of L:R, as discussed in another publication in this review [125].</p>

⁴⁹ Reported results were adjusted for confounding variables, unless otherwise noted.

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
				<p>adjusted relative risk (CI)=1.06 (1.03, 1.10)⁵⁰. Stool RS, anemia, and MCV were not associated with L:R.</p>		

⁵⁰ Reported results were adjusted for severity of diarrhea, acidosis, hypokalemia, and age.

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
<p>2004</p> <p>Laadhar L et al.</p> <p>Determination of anti-transglutaminase antibodies in the diagnosis of celiac disease in children: results of a five year prospective study</p> <p>Duodenal biopsy among patients with suspected CD</p>	<p>Sfax, Tunisia</p> <p>Children admitted for endoscopic biopsy for symptoms of CD (not specified).</p> <p>Subjects of interest for this review were those who tested negative for CD-specific serology and who did not meet the study diagnostic criteria for CD--subtotal or total villous atrophy consistent with Marsh stages 3 or 4.</p> <p>Controls were aged 3 mo-17 yr (mean 4.5 yr).</p>	<p>Case-control</p> <p>n=99</p>	<p><u>Endoscopic duodenal biopsy:</u> Histopathology</p>	<p>Of 99 subjects not meeting diagnostic criteria for CD, endoscopic biopsies revealed:</p> <ul style="list-style-type: none"> • 76 had normal morphology of the intestinal mucosa • 7 had elevated densities of intraepithelial lymphocytes • 10 had partial villous atrophy (Marsh stage 2) • 6 had various other conditions such as giardiasis or gastritis 	<p>Among 169 children with symptoms of CD, 41% had subtotal or total villous atrophy, 10% had partial villous atrophy or inflammatory findings, and 45% had normal biopsies.</p>	<p>Article in French.</p> <p>Prevalence of CD antibodies did not clearly align with case/control designation. Because of the way the results were reported, we could not extract data on those who tested negative for CD-specific serology and who had Marsh stages 3 or 4 histopathology.</p> <p>Methods section described obtaining duodenal biopsies, while results and conclusion sections specify that jejunal specimens were obtained.</p>

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
<p>2006</p> <p>Leite CA et al.</p> <p>Functional, microbiological and morphological intestinal findings among human immunodeficiency virus infected children</p> <p>Small intestinal and rectal biopsy to assess morphology and D-xylose as a marker of malabsorption among HIV-infected children</p>	<p>Sao Paulo, Brazil</p> <p>5 mo-12 yr old (median 24 mo) HIV-infected subjects recruited from a hospital and clinic.</p> <p>All subjects had some degree of protein-energy malnutrition.</p>	<p>Cohort</p> <p>n=11;</p> <p>n=5 patients with current or recent episode of diarrhea</p> <p>n=6 patients with no diarrhea in the 30 days preceding enrollment</p>	<p><u>Blood Test:</u> D-xylose (9 tested)</p> <p><u>Biopsy of small intestine by tethered capsule or endoscopy:</u> Histopathology (10 tested)</p> <p><u>Rectal biopsy:</u> Histopathology (6 tested)</p>	<p>100% had low D-xylose absorption:</p> <ul style="list-style-type: none"> • Mean: 15.6 mg/dL • SD: 5 • Range: 8.9-24.4 • Median: 14.2 <p>Small intestinal biopsy:</p> <ul style="list-style-type: none"> • 100% had some degree of villous atrophy based on a I-IV grading system: <ul style="list-style-type: none"> • Grade I: 3 • Grade I/II: 2 • Grade II: 1 • Grade II/III: 1 • Grade III/IV: 1 • 2 samples were too superficial to assess <ul style="list-style-type: none"> • Intraepithelial lymphocytes were increased in half of the biopsies. • Lymphocytic and polymorphonuclear (PMN) infiltration of the lamina propria were present in 10/10 and 7/10 biopsies, respectively. <p>Rectal biopsy:</p> <ul style="list-style-type: none"> • 100% had normal architecture • Lymphocytic and PMN infiltration were present in 6/6 and 4/6, respectively. 	<p>There was a high prevalence (100%) of abnormal D-xylose results among HIV-infected children, regardless of diarrhea status.</p> <p>All patients also had cellular infiltration of the lamina propria and varying degrees of villous atrophy.</p> <p>There was no correlation between D-xylose and degree of villous atrophy on biopsy.</p>	<p>Portuguese language article.</p> <p>D-xylose <25 mg/dL was defined as indicative of malabsorption. This value is higher than what some references have noted as a cut-point [186].</p> <p>Investigators used a well-articulated system of grading villous atrophy.</p> <p>Results were not presented by diarrhea status, perhaps due to small sample size.</p>

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
<p>2010</p> <p>Lima AA et al.</p> <p>Effects of vitamin A supplementation on intestinal barrier function, growth, total parasitic, and specific <i>Giardia</i> spp infections in Brazilian children: a prospective randomized, double-blind, placebo-controlled trial</p> <p>L:M as a marker of intestinal barrier function, and stool lactoferrin and specific intestinal immunological cytokines as markers of intestinal inflammation among nutritionally at-risk children who received either vitamin A or placebo</p>	<p>Fortaleza, Brazil</p> <p>2 mo-9 yr olds (mean 43 mo) from an impoverished urban community, eligible if HAZ score was <median for their community.</p> <p>Subjects were screened for intestinal parasites, and longitudinal anthropometrics were assessed.</p>	<p>RCT</p> <p>n=79;</p> <p>n=40 received placebo (tocopherol)</p> <p>n=39 received vitamin A (retinyl palmitate)</p> <p>Subjects were treated every 4 mo.</p>	<p><u>Urine Tests:</u></p> <ul style="list-style-type: none"> • Lactulose⁵¹ • Mannitol • L:M <p><u>Stool Tests:</u></p> <ul style="list-style-type: none"> • Lactoferrin • Cytokines: <ul style="list-style-type: none"> • IFN-γ • TNF-α • IL-4 • IL-10 	<p>Median L:M at baseline was 0.089. There was no significant change in L:M at 4 mo follow-up within either treatment group.</p> <p>No significant difference in L:M was observed between treatment groups.</p> <p>Both median lactulose and mannitol excretions decreased at 4 mo follow-up among the vitamin A compared to the placebo group:</p> <ul style="list-style-type: none"> • Lactulose: 0.21 to 0.74, p=0.042 • Mannitol: 3.06 to 8.25, p=0.008 <p>Overall proportion of lactoferrin was 23% initially. At 1 mo follow-up, there was no difference in prevalence between vitamin A (33%) and placebo (31%) groups.</p> <p>Cytokine concentrations did not significantly differ between placebo and vitamin A groups.</p>	<p>Frequency of stool lactoferrin varied between 23%-32%.</p> <p>While vitamin A supplementation was associated with reduced lactulose excretion, it was also associated with reduced mannitol excretion, with no overall effect on L:M.</p> <p>Vitamin A supplementation was not associated with presence of lactoferrin or intestinal cytokine response.</p>	<p>Authors did not report testing for associations between urinary markers of intestinal permeability and concentrations of fecal cytokines, or between these markers and growth parameters or parasitosis.</p> <p>Cut-point values for lactoferrin positivity and abnormal L:M were not described.</p> <p>Exclusively breastfed children were excluded from study participation due to assessment of stool lactoferrin.</p>

⁵¹ For lactulose and mannitol results, excretion measurement was not specified.

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
<p>2005</p> <p>Lima AA et al.</p> <p>Intestinal barrier function and weight gain in malnourished children taking glutamine-supplemented enteral formula</p> <p>L:M as a marker of intestinal permeability and various stool tests among children with malnutrition or PD who received either glycine or glutamine supplemented formula or placebo</p>	<p>Fortaleza, Brazil</p> <p>2-60 mo olds hospitalized with WAZ score <-2, ~70% of whom had PD.</p>	<p>RCT</p> <p>n=80;</p> <p>n=53 received supplemented formula</p> <ul style="list-style-type: none"> • 27 with glycine • 26 with glutamine <p>n=27 received nonsupplemented formula</p>	<p><u>Urine Tests*</u>:</p> <ul style="list-style-type: none"> • Lactulose⁵² • Mannitol • L:M <p><u>Stool Tests**</u>:</p> <ul style="list-style-type: none"> • Lactoferrin • Leukocytes • Occult blood • Reducing substances (RS) <p>* n=80 tested at enrollment, n=65 tested at day 10.</p> <p>** n=60 tested.</p>	<p>Mean⁵³ L:M (SE):</p> <ul style="list-style-type: none"> • Glutamine group: <ul style="list-style-type: none"> • Baseline: 0.31 (0.10) (similar in all three groups) • Day 10: 0.10 (0.02); significant decrease, (p=0.01) • No significant decrease in L:M in glycine and nonsupplemented formula groups at day 10 <p>Mean lactulose (SE):</p> <ul style="list-style-type: none"> • Glutamine group: <ul style="list-style-type: none"> • Baseline: 0.97 (0.46) (similar in all three groups) • Day 10: NS decrease in all 3 groups <p>Mean mannitol (SE):</p> <ul style="list-style-type: none"> • Glutamine group: <ul style="list-style-type: none"> • Baseline: 3.42 (0.64) (similar in all three groups) • Day 10: NS decrease in all 3 groups <p>Proportion of stool markers at baseline among all subjects:</p> <ul style="list-style-type: none"> • Lactoferrin: 53.3% • Leukocytes: 11.7% • RS: 3.3% • Occult blood: 5.0% 	<p>L:M significantly improved in the glutamine group only.</p> <p>>50% of subjects had intestinal inflammation by stool lactoferrin. Fecal leukocytes, RS, and occult blood were detected in fewer subjects than lactoferrin.</p>	<p>The relationship between stool markers and L:M was not reported.</p> <p>Data were not stratified by history of PD.</p> <p>Fecal fat was assessed, but results were not reported.</p> <p>Cut-off values for lactoferrin positivity were not described.</p> <p>Exclusively breastfed children were excluded from study participation due to assessment of stool lactoferrin.</p>

⁵² Lactulose and mannitol results were expressed as % of dose administered.

⁵³ Type of mean not specified.

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
<p>2007</p> <p>Lima NL et al.</p> <p>Wasting and intestinal barrier function in children taking alanyl-glutamine-supplemented enteral formula</p> <p>L:M as a marker of intestinal permeability in assessing alanyl-glutamine supplement to improve intestinal barrier function in malnourished children compared to glycine-containing placebo supplement</p>	<p>Parque Universitario, Fortaleza, Brazil</p> <p>6 mo-8 yr olds (mean age 3.5 yr) from an urban setting with HAZ, WAZ, or WHZ scores <-1.</p>	<p>RCT</p> <p>n=107;</p> <p>n=51 received alanyl-glutamine treatment</p> <p>n=56 received glycine placebo</p>	<p><u>Urine Tests:</u></p> <ul style="list-style-type: none"> • Lactulose⁵⁴ • Mannitol • L:M 	<p>L:M median (range) at baseline:</p> <ul style="list-style-type: none"> • Treatment: 0.0385 (0.8922 [sic]) • Placebo: 0.0302 (5.5812 [sic]) <p>Lactulose and mannitol excretion both significantly decreased in the treatment group only (p=0.05 for both sugars)⁵⁵. L:M did not change significantly within or across groups days after treatment.</p> <p>Lactulose excretion was not associated with WHZ, WAZ or HAZ scores in either group⁵⁶. Mannitol was not associated with growth parameters in the control group, but was associated with WHZ (r²=-0.386, p=0.027) and WAZ (r²=-0.385, p=0.027) scores in the supplemented group. Data for L:M and growth parameter association was not provided.</p>	<p>Even though lactulose excretion improved in the treatment group, mannitol excretion worsened with overall L:M not changing.</p> <p>Lactulose, mannitol and L:M did not change significantly in the placebo group.</p>	<p>Authors state that L:M median and range values were within the confidence interval for values of healthy children in the study community; no reference was cited.</p> <p>Although the authors defined persistent and chronic diarrhea in their methods, they did not report data stratified according to these conditions.</p> <p>Authors provide negative R² values when reporting Pearson's correlation analysis results; these likely actually represent r values.</p>
<p>2006</p> <p>Long KZ et al.</p> <p>The effect of vitamin A supplementation on the intestinal</p>	<p>Mexico City, Mexico</p> <p>All 5-15 mo olds within a periurban community were eligible to be</p>	<p>RCT</p> <p>n=505 stool samples from 127 children;</p> <p>n=243 stool</p>	<p><u>Stool Tests:</u></p> <p><u>Cytokines:</u></p> <ul style="list-style-type: none"> • IL-4 • IL-6 • IFN-γ 	<p>Positive tests for fecal cytokines:</p> <ul style="list-style-type: none"> • IL-4: ~55% • IFN-γ: ~50% • IL-6: ~40% <p>There were no significant</p>	<p>Differences in fecal cytokine concentrations due to vitamin A supplementation were observed only in the subset</p>	<p>Pre-intervention fecal cytokine concentrations were not reported. Differences in fecal cytokines between all subjects with</p>

⁵⁴ For lactulose and mannitol results, excretion measurement was not specified.

⁵⁵ Reported results were adjusted for age and season.

⁵⁶ Reported results were adjusted for age and season.

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
<p>immune response in Mexican children is modified by pathogen infections and diarrhea</p> <p>Fecal cytokines as markers of intestinal mucosal immune activation in children with and without GI pathogens receiving vitamin A or placebo</p>	<p>screened for participation.</p>	<p>samples from 57 who received vitamin A supplementation</p> <p>n=262 stool samples from 70 who received placebo</p> <p>Participants were followed regularly; diarrhea history was tracked and stool samples were tested.</p>		<p>differences in proportions of these fecal cytokines between vitamin A-supplemented and placebo subjects.</p> <p>Vitamin A-supplemented children with diarrhea had lower median IFN-γ concentrations (odds ratio⁵⁷=0.51; CI: 0.26, 0.99) and higher IL-4 concentrations (odds ratio=2.14; CI: 0.94, 4.87) compared to children with diarrhea in the placebo group in a nonrandomized analysis. IL-6 concentrations did not differ in this analysis. There were no differences between the two groups among those without diarrhea.</p> <p>Differences in median concentrations of fecal cytokines by types of enteric pathogens were also observed.</p>	<p>of subjects with GI infection or diarrhea.</p>	<p>and without GI infections or history of diarrhea were not directly reported; all differences were described in terms of vitamin A interaction.</p>
<p>2005</p> <p>López de Romaña D et al.</p> <p>Longitudinal measurements of zinc absorption in Peruvian children consuming wheat</p>	<p>Lima, Peru</p> <p>3-4 yr olds residing in a poor community at the periphery of Lima with stunting and moderate anemia as a surrogate risk factor for zinc</p>	<p>RCT</p> <p>n=41; (31 completed both initial and follow-up absorption assay at 2 mo)</p> <p>Group 1:</p>	<p><u>Urine Test:</u> Zinc excretion to measure fractional absorption of zinc (FAZ) and total absorbed zinc (TAZ) following radiolabeled zinc administration</p>	<p>Mean zinc parameters (SD) at initial assessment:</p> <ul style="list-style-type: none"> • FAZ: <ul style="list-style-type: none"> • Group 1: 0.34 (0.11) • Group 2: 0.24 (0.05) • Group 3: 0.13 (0.04) • TAZ (mg/d): <ul style="list-style-type: none"> • Group 1: 0.71 (0.18) • Group 2: 1.11 (0.21) • Group 3: 1.34 (0.47) 	<p>Despite a reduction in FAZ with increasing fortification, TAZ increased as more zinc was consumed and with increasing concentrations of zinc fortification.</p>	<p>Intestinal function could play a role in zinc (or other micronutrient) absorption; such factors were not explored in this study.</p> <p>The principal aim</p>

⁵⁷ The odds ratios represent odds that a cytokine (categorized into three levels: undetectable, <median, >median) will have a higher value among vitamin A-supplemented children.

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
<p>products fortified with iron only or iron and 1 of 2 amounts of zinc</p> <p>Zinc absorption among stunted, anemic children receiving zinc as well as iron and/or iron/zinc-fortified foods</p>	<p>deficiency.</p>	<p>n=14 received wheat flour with iron fortification only (10 completed follow-up)</p> <p>Group 2: n=12 received wheat flour with iron and 3mg zinc/100g flour (9 completed follow-up)</p> <p>Group 3: n=15 wheat flour with iron and 9mg zinc/100g flour (12 completed follow-up)</p>		<p>Neither mean FAZ nor TAZ changed significantly at subsequent assessments in any treatment group.</p> <p>In both the initial and subsequent assays, mean TAZ from zinc-fortified meals increased with increasing amounts of fortification ($p < 0.001$). However mean FAZ was inversely related to zinc intake from these meals ($p < 0.001$).</p> <p>Nonfortified dinner FAZ and TAZ were significantly lower in the group receiving the most zinc-supplementation at the initial assay ($p = 0.015$ and $p = 0.012$, respectively) despite no difference in zinc intakes from the unfortified dinner by treatment group. This relationship between groups was not observed at the second assay; however, a significant decrease of 16% in mean FAZ and TAZ from the unfortified dinners was observed between initial and subsequent assays ($p < 0.001$). Mean plasma zinc concentrations did not differ between treatment groups throughout the study period. The proportion with low fasting plasma zinc concentrations ($< 65 \mu\text{g/dL}$)</p>	<p>Authors speculate that reduction in FAZ with increasing fortification could be due to factors such as saturation kinetics.</p> <p>Authors described a unexpected finding: subjects consuming more zinc from the zinc-fortified breakfast and lunch meals absorbed less zinc from the unfortified dinners during the initial absorption assay.</p>	<p>of this study was to determine appropriate extent of zinc fortification of a staple food in a specific community; we present only results relevant to this review.</p>

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
				was lower at the end of the study (3.3% vs. 20.5% initially, p=0.046).		
<p>2001</p> <p>Mahmud MA et al.</p> <p>Sociodemographic, environmental and clinical risk factors for developing persistent diarrhea among infants in a rural community of Egypt</p> <p>Stool IgE as a marker of gastrointestinal allergy and its association with persistent vs. acute diarrhea</p>	<p>Bilbeis, Egypt</p> <p>Newborns recruited at birth from a rural village and followed for the first year of life.</p> <p>Surveillance of diarrhea symptoms identified 392 episodes of diarrhea, 41 (11%) of which were persistent.</p>	<p>Nested case-control within a cohort study</p> <p>n=392 episodes of diarrhea (including 41 episodes of PD) among 152 infants*)</p> <p>* Stool samples from each PD episode were counted as a case for analysis and compared to randomly selected AD episodes and to non-diarrheal samples.</p>	<p><u>Stool Test:</u> IgE</p>	<p>Fecal IgE was detected more frequently in stools from episodes of PD compared to episodes of AD: odds ratio (CI)⁵⁸=3.3 (1.0, 10.9).</p> <p>Fecal IgE was detected more frequently in stools from episodes of PD than in stools from children without diarrhea: odds ratio (CI)=4.84 (1.1, 21.7).</p>	<p>Fecal IgE was detected 3 times more frequently during episodes of PD than AD and 5 times more frequently in PD stools than in stools from those without diarrhea.</p>	<p>Sampling was based on episodes of diarrhea within a cohort of infants; individual infants could have contributed more than one diarrheal episode. Additionally, it appears that an individual could also have been included as a case of PD, a control with AD, or a non-diarrhea stool within the same analysis.</p> <p>Study population appears to be the same as in another Mahmud, et al. study also included in this review which reported the prevalence of fecal IgE by gender and age within the cohort [143].</p>
<p>2001</p> <p>Mahmud MA et al.</p>	<p>Bilbeis, Egypt</p> <p>Newborns recruited at birth</p>	<p>Cohort</p> <p>n=152 followed for</p>	<p><u>Stool Test:</u> IgE</p>	<p>Overall incidence of fecal IgE: 0.39/child-year</p> <p>By age group:</p>	<p>Substantial incidence of fecal IgE was observed in this setting in</p>	<p>Study population appears to be the same population as in another</p>

⁵⁸ Reported results were adjusted for confounding variables, unless otherwise noted.

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
<p>Increased fecal IgE among infants in a rural community of Egypt: an analysis of associated risk factors</p> <p>Fecal IgE as a marker of intestinal inflammation among children with diarrhea</p>	<p>from a rural village and followed for the first year of life.</p>	<p>29,036 infant days</p> <p>Stools were collected during episodes of diarrhea.</p>		<ul style="list-style-type: none"> • < 3 mo: 0.28/child-yr • 3-6 mo: 0.42/child-yr • 6-9 mo: 0.16/child-yr • >9 mo: 0.12/child-yr <p>Relative risks (CI):</p> <ul style="list-style-type: none"> • 3-6 compared to >9 mo olds : 3.28 (1.03, 13.60) • Male gender: 1.82 (0.83, 4.18) 	<p>infants.</p> <p>IgE incidence peaked at 3-6 mo of age.</p> <p>Male gender was associated with fecal IgE.</p>	<p>Mahmud, et al. reference also included in this review which assessed the relationship between fecal IgE and PD [142].</p>
<p>2002</p> <p>Manary ML et al.</p> <p>Zinc homeostasis in Malawian children consuming a high-phytate, maize-based diet</p> <p>Zinc absorption in a sample of 10 asymptomatic children</p>	<p>Blantyre, Malawi</p> <p>2–5 yr olds (mean age 43.6 mo, SD 7.7) from rural area attending immunization clinic.</p> <p>There was a high prevalence of stunting and low plasma zinc in this series.</p>	<p>Case-series</p> <p>n=10</p>	<p><u>Stool Test:</u> Endogenous fecal zinc (EFZ)</p> <p><u>Urine Test:</u> Zinc excretion to measure fractional absorption (FAZ) and total absorption (TAZ) following radiolabeled zinc administration.</p>	<p>Mean (SD):</p> <ul style="list-style-type: none"> • FAZ: 0.24 (0.04) • TAZ (mg/d): 1.30 (0.33) • EFZ (mg/d): 1.15 (0.33) <p>Language in the discussion section strongly suggests, but does not explicitly state, that TAZ and EFZ were not correlated. Correlation analysis for these parameters was not reported.</p>	<p>EFZ was higher than would be expected for a zinc deficient cohort, and EFZ was not correlated with TAZ as would have been expected. While high-phytate diets leading to poor zinc absorption might explain these findings, the authors note that in a previous study (among a somewhat older age group) there were no differences in EFZ among children consuming high- or low-phytate diets [187]. They note that such perturbations in EFZ have also</p>	<p>Authors note that the lack of comparable data from children of the age range in this study limits data interpretation. They also provide results per body weight due to presumed relationship; validity of such measures has not been established.</p> <p>Authors comment that the methods used for calculating absorption measures are sensitive and accurate, but quite difficult to conduct, especially among children.</p>

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
					<p>been reported in children with enteropathy due to cystic fibrosis [188] and suggest that a similar process could be going on in these Malawian children due to TE.</p>	
<p>2001</p> <p>Mishra OP et al.</p> <p>Endoscopic and histopathological evaluation of preschool children with chronic diarrhea</p> <p>Duodenal biopsy among patients with chronic diarrhea</p>	<p>Varanasi, India</p> <p>1-5 yr olds with PD selected randomly from an outpatient population in an urban setting.</p> <p>A high proportion of the children had varying degrees of protein energy malnutrition.</p>	<p>Case-series</p> <p>n=30 with endoscopy performed</p>	<p><u>Endoscopic duodenal biopsy:</u></p> <ul style="list-style-type: none"> • Gross endoscopic visualization • Histopathology 	<p>7 (23.3%) had grossly abnormal endoscopic findings:</p> <ul style="list-style-type: none"> • 5 (16.7%) with chronic duodenitis • 1 with duodenitis with multiple erosions • 1 with duodenitis with hemorrhagic gastritis <p>22 (73.3%) had abnormal histopathology:</p> <ul style="list-style-type: none"> • 17 (56.7%) with villous atrophy with mononuclear cell infiltration • 1 (3.3%) with villous atrophy and eosinophilic infiltration • 2 (6.7%) with villous atrophy and mononuclear and eosinophilic infiltration • 2 (6.7%) with only mononuclear cell infiltration <p>Mean duration of diarrhea (SD) was not associated with gross endoscopic</p>	<p>Grossly abnormal endoscopic appearance was found in one-quarter of children with chronic diarrhea assessed by endoscopy. Three-quarters had abnormal histology. More than half had villous atrophy with mononuclear cell infiltration; these patients had >1 month longer duration of diarrhea than those with either normal histology or mononuclear cell infiltration without villous atrophy.</p> <p>Age, enteropathogen recovery, and WFA were not</p>	<p>Authors do not report assessing relationship between gross endoscopic findings and histopathology.</p> <p>Number of patients with villous atrophy and both mononuclear and eosinophilic infiltration was very small (n=2), yet authors report a significant difference in their duration of diarrhea relative to those with normal histopathology.</p>

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
				<p>findings but did vary by histopathology:</p> <ul style="list-style-type: none"> • Normal histopathology: 9.0 wk (6.0), n=8 • Mononuclear cell infiltration: 9.0 wk (6.0), n=2 • Villous atrophy with mononuclear cell infiltration: 14.9 wk (5.3), n=17, p<0.02 compared to normal histopathology • Villous atrophy with mononuclear and eosinophilic infiltration: 21.5 wk (2.1), n=2, p<0.02 compared to normal histopathology • Villous atrophy with eosinophilic infiltration: 6.0 wk, n=1 <p>No consistent pattern was observed between gross endoscopic findings or histopathological lesions and age, degree of malnutrition, or type of enteropathogen recovered in stools.</p>	<p>associated with gross endoscopic or histopathological findings.</p>	
<p>2001 Mittal SK et al. Tropical sprue in north Indian children D-xylose and duodenal biopsy as</p>	<p>New Delhi, India 0-15 yr old gastroenterology clinic patients with PD. Those with</p>	<p>Case-series n=94; (38 with repeat biopsies) <5 yr old: n=44</p>	<p><u>Duodenal biopsy, method not specified:</u> Histopathology <u>Blood Tests:</u> • Hemoglobin • D-xylose*</p>	<p>36 (38.3%) were diagnosed with TS including 14/44 (31.8%) who were under 5 years of age. 18 (19.1%) were diagnosed with CD. Degree of villous atrophy</p>	<p>More than half of the GI clinic patients with PD had some degree of villous atrophy. More than one-third and almost one-fifth of</p>	<p>Biopsy results were not provided for patients without TS or CD. It was unclear if there were patients with abnormal D-xylose and</p>

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
markers of TS	<p>abnormal morphology on biopsy, abnormal D-xylose test, and clinical response to antibiotics were diagnosed as having TS.</p> <p>Those with abnormal morphology and response to gluten-free diet were diagnosed with CD. We include data on these subjects for comparative reasons.</p>		<p>* Not specified whether from urine or serum, and units of measurement not provided.</p>	<p>among TS vs. CD patients:</p> <ul style="list-style-type: none"> • Mild in 8/36 (22.2%) vs. 0 • Moderate in 23/36 (63.9%) vs. 4/18 (22.2%) • Severe in 5/36 (13.9%) vs. 14/18 (77.8%) <p>Mean hemoglobin concentration (range) among TS patients was 8.3 g/dL (5.5-11) and did not differ from values of those with CD.</p> <p>Among the 22 TS patients, repeat biopsies showed:</p> <ul style="list-style-type: none"> • 16 with normalization • 5 with improvement • 1 worsened despite marked clinical improvement <p>The D-xylose test was abnormal in all TS patients by diagnostic definition.</p>	<p>subjects were diagnosed with TS and CD, respectively.</p> <p>By study diagnostic definition, all TS patients improved with treatment. Among those who had repeat biopsies, almost three-quarters showed normalization of histology, while 23% had partial improvement and 1 patient had worsened pathology.</p>	<p>histology who did not respond to antibiotic therapy and therefore were not diagnosed with TS.</p> <p>Cut-off points used to define abnormal D-xylose tests were not provided.</p>
<p>2002</p> <p>Moya-Camarena SY et al.</p> <p>Effects of asymptomatic <i>Giardia intestinalis</i> infection on carbohydrate absorption in well-nourished Mexican children</p>	<p>Hermosillo, Sonora, Mexico</p> <p>3-6 yr olds in a periurban setting attending preschool centers meeting inclusion criteria of no GI symptoms, no antibiotics in the preceding 3 wk, and no SBBO by lactulose HBT and</p>	<p>Case-control</p> <p>n=13;</p> <p><5 yr old: n=5</p> <p>n=7 asymptomatic cases infected only with <i>G. intestinalis</i></p> <p>n=6 controls</p>	<p><u>Breath Tests</u>*:</p> <ul style="list-style-type: none"> • Lactose HBT • D-Xylose HBT** <p><u>Urine Test</u>:</p> <p>D-xylose**.⁵⁹</p> <p>* Reported as parts per million (ppm) post-substrate ingestion after subtraction of baseline, pre-</p>	<p>Mean lactose HBT (SE):</p> <ul style="list-style-type: none"> • Cases pre-treatment: 3.6 (0.75) ppm • Cases post-treatment: - 0.85 (0.75) ppm (p<0.05 compared to pre-treatment) • Controls: 0.19 (0.81) ppm (p<0.05 compared to pre-treatment cases) <p>Mean xylose HBT (SE):</p> <ul style="list-style-type: none"> • Cases pre-treatment: 2.2 (0.69) ppm for infected 	<p>Lactose HBT concentrations were normal according to established cut-points among all subjects.</p> <p>However, lactose HBT was significantly higher among cases compared to controls and</p>	<p>Statistical methods might not have been adequate to account for intra-subject correlation when comparing the same group of subjects (cases) before and after treatment.</p> <p>Investigators wished to exclude children with</p>

⁵⁹ D-xylose results were expressed as % of dose administered.

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
Lactose hydrogen breath test (HBT) as a marker of lactose absorption, and xylose breath test and urinary excretion as markers of xylose absorption in well-nourished children with asymptomatic giardiasis and non-infected controls	Indican test.	without <i>Giardia</i> Cases were evaluated before and 3 wk after treatment with tinidazole. Post-treatment stools were verified for absence of parasites.	substrate H ₂ concentrations. A positive HBT is considered to be a rise of ≥ 20 ppm in breath H ₂ above baseline H ₂ concentration. ** Investigators did not specify the xylose enantiomer used, however test functionality characteristics lead us to assume that it was the dextrorotary (D) enantiomer.	group <ul style="list-style-type: none"> Cases post-treatment: - 4.16 (0.69) ppm ($p < 0.05$ compared to pre-treatment) Controls: 1.13 (0.74) ppm (NS compared to pre-treatment cases) Mean urinary excretion of xylose (SE) among cases pre-treatment and post-treatment was 34% (3) and 46% (11), respectively (NS), well above cut-offs indicative of malabsorption.	there was also a significant decrease in lactose HBT among cases after treatment. The clinical relevance of such mildly elevated HBT results in asymptotically infected children is unclear. Results did not demonstrate xylose malabsorption by either urinary or breath measures among any group. While urinary results did not differ before and after treatment, case xylose HBT was significantly lower after treatment; again the clinical significance of such results is not apparent.	SBBO. As such, inclusion criteria restricted participants to those with adequate production of H ₂ following ingestion of lactulose and with minimal urinary indoxyl sulfate excretion. The number of children excluded due to failure to meet these criteria was not reported.
2002 Murphy JL et al. Maldigestion and malabsorption of dietary lipid during severe childhood	Kingston, Jamaica 5-23 mo olds admitted to the Tropical Metabolism Research Unit of the University of	Case-series n=24 Subjects were divided into 3 groups of 8	<u>Stool Tests:</u> <ul style="list-style-type: none"> Total and fractionated ¹³C following ingestion of one of three ¹³C labeled triglycerides (TG): trilaurin, triolein, or trilinolein* 	Median total stool excretion of ¹³ C in phase 1 was 9% (range: 1%-29%) and did not vary between TG groups. Median ¹³ C excretion dropped 33%-99% in phase 2 and 86%-95% in phase 3	High concentrations of ¹³ C (compared to healthy UK children) [190] were observed in half of the subjects at	Authors state that the study was not powered to compare the different TGs, but they contend that medium chain trilaurin did not

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
<p>malnutrition</p> <p>Stool recovery of radiolabeled products as markers of lipid digestion and absorption, and bile salt deconjugation as a marker of SBBO among children with severe malnutrition</p>	<p>the West Indies with severe malnutrition.</p>	<p>children, each group receiving a different labeled triglyceride.</p> <p>Data were collected in three separate phases as described above in JL Murphy et al. 2001 [149].</p>	<ul style="list-style-type: none"> • ¹³C stool assay following administration of labeled fatty acid ¹³C glycocholate** <p>* To assess fat excretion as a % of dose administered. Also assessed proportion of ¹³C in triglyceride (TG) and fatty acid (FA) fractions to distinguish excretion caused impaired digestion (presence of TG) vs. poor absorption (presence of FA).</p> <p>** To assess bile salt deconjugation in the bowel caused by SBBO; conducted after the TG assessment and a 3 day washout period.</p>	<p>compared to phase 1 (p<0.05 each).</p> <p>Over the study period, there were significant associations between total lipid and the amount of ¹³C labeled TGs in stool for some groups, but not for others.</p> <p>Median ¹³C in TG and FA was similar across TG groups in all phases. ¹³C FA recovery was similar and reduced by ~2/3 compared to Phase 1. ¹³C TG was not detectable in Phases 2 or 3. Statistical comparisons between phases were not reported.</p> <p>¹³C after radiolabeled glycocholate administration was detected in stool at quantities considered to be in excess of the 7% recovery of dose administered upper limit of normal in U.S. adults in [189]:</p> <ul style="list-style-type: none"> • Phase 1: 13/24 (54%) • Phase 2: 5/24 (20.8%) • Phase 3: 3/24 (12.5%) 	<p>admission, reflecting impaired digestion or absorption.</p> <p>The differences in stool ¹³C were wide but not as extreme as in a previous study by same investigators (also examined in this review) using a different TG (tripalmitin) substrate [149].</p> <p>¹³C excretion did not significantly differ between TG groups and declined with improving clinical course.</p> <p>Similar to their previous study, significantly more ¹³C in stool was recovered as FA than TG, reflecting impaired absorption over poor lipid digestion/ hydrolysis. Unlike in their previous study, there was evidence of SBBO as</p>	<p>appear to be processed differently than the longer chain TGs triolein and triolinolein.</p> <p>Authors did not describe the method used to assign subjects to different TG groups.</p> <p>While it was noted that some subjects had positive stool cultures, details were not provided on the nature of the enteric infections.</p>

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
					measured post-ingestion of ¹³ C glycocholate.	
<p>2001</p> <p>Murphy JL et al.</p> <p>Gastrointestinal handling and metabolic disposal of ¹³C-labelled tripalmitin during rehabilitation from childhood malnutrition</p> <p>Fecal fat, stool recovery of radiolabeled products, and breath tests as markers of lipid digestion and absorption and bile salt deconjugation as a marker of SBBO among children with severe malnutrition</p>	<p>Kingston, Jamaica</p> <p>7-23 mo olds with malnutrition admitted to the University of the West Indies.</p>	<p>Case-series</p> <p>n=8</p> <p>Data were collected in three separate phases (each lasting 9 days):</p> <ol style="list-style-type: none"> 1. Within 48 hours of admission 2. During early rehabilitation 3. During late rehabilitation 	<p><u>Stool Tests:</u></p> <ul style="list-style-type: none"> • Fecal fat* • Total and fractionated ¹³C assay after administration of ¹³C tripalmitin (TP)** • ¹³C assay after administration of ¹³C glycocholate (GCA)*** <p><u>Breath Tests:</u></p> <ul style="list-style-type: none"> • ¹³CO₂ after administration of ¹³C glycocholate (GCA)*** • ¹³CO₂ after administration of ¹³C TP**** <p>* In 72 hour stool collection (measured as total grams and as % of dietary fat intake).</p> <p>** To assess fat excretion as a % of dose administered. Also assessed proportion of ¹³C in triglyceride (TG) and fatty acid (FA) fractions to distinguish</p>	<p>Mean fecal fat (SD):</p> <ul style="list-style-type: none"> • Phase 1: 2.4 g/day (3.6) or 5.9% (9.4) of dietary lipid intake • Phase 2: 1.7 (0.9) g/day, or 3.3% (2.4) of intake • Phase 3: 0.9 (0.6) g/day, or 1.4% (0.7) of intake • Differences between phases were not statistically significant. <p>Total excretion of ¹³C in stool also varied widely across patients (0%-44%) and did not differ between study phases.</p> <p>Correlation between fecal fat and ¹³C (r=0.48; p<0.05) was observed.</p> <p>Lack of lipid digestion and absorption were assessed by measuring TG and FA fractions, respectively. Mean ¹³C TG recovery (SD) (% of administered dose), number of patients excreting TG:</p> <ul style="list-style-type: none"> • Phase 1: 0.7% (1.6), n=3 • Phase 2: 0.9% (2.8), n=1 • Phase 3: no recovery from any subjects, differences between phases were NS <p>¹³C FA fraction in stool</p>	<p>Mean fecal fat was not elevated compared to published norms [191, 192] during any study phase.</p> <p>There was wide variation in fecal fat at presentation, and wide variations in stool ¹³C across subjects. Authors indicate that this is the first such assessment in malnourished children; previous studies on healthy children from the UK demonstrated average excretion of 6% [190].</p> <p>The majority of excreted ¹³C was in the form of FA rather than TG. Authors interpreted this to reflect failure of lipid absorption in the face of adequate digestion/ hydrolysis. Each form (FA and TG)</p>	<p>Statistical methods might be inappropriate for a small sample.</p> <p>All subjects were treated with antibiotics including metronidazole for presumptive SBBO; this might have affected GCA testing.</p>

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
			<p>excretion caused by impaired digestion (presence of TG) vs. poor absorption (presence of FA).</p> <p>*** To assess bile salt deconjugation in the bowel caused by SBBO; conducted after the TG assessment and a 3 day washout period.</p> <p>**** Expressed as a percentage of absorbed label (dose administered - label recovered in stool) to assess oxidation for acute energy needs.</p>	<p>declined during rehabilitation.</p> <p>Mean ¹³C FA recovery (SD):</p> <ul style="list-style-type: none"> • Phase 1: 6.0% (7.3) • Phase 2: 4.8% (3.7) • Phase 3: 3.3% (3.8), differences between phases were NS <p>Mean FA values were ~9x (NS), 5x (p<0.001), and 3x (p<0.05) higher than mean TG values in Phases 1, 2, and 3, respectively.</p> <p>Following administration of labeled TP, absorbed ¹³C label by breath analysis was ~5% (range 0%-21.2%) and similar across study phases.</p> <p>Following the administration of labeled GCA, there was either no or minimal recovery of ¹³C in stool and ¹³CO₂ on breath (as % of dose administered) in all phases.</p>	<p>was found in decreasing values as the study phases progressed, suggesting improved digestion and absorption, although results did not differ significantly.</p> <p>Fecal fat was correlated with concentrations of ¹³C in stool. There was no evidence of SBBO or bile acid malabsorption.</p> <p>¹³CO₂ excretion following administration of ¹³C TP was minimal, suggesting a propensity for deposition in adipose tissues rather than oxidation for immediate energy needs. The authors report that this breath test has not been widely used, but that healthy UK children have breath excretion</p>	

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
					values from 15%-43% [190], compared to a mean of 5% and range 0%-21% in this cohort; the latter findings were more similar to results from kwashiorkor patients where ¹³ C-labeled oleic acid was used as substrate [193].	
<p>2000</p> <p>Nichols B et al.</p> <p>Contribution of villous atrophy to reduced intestinal maltase in infants with malnutrition</p> <p>Jejunal biopsy, maltase activity, and enzyme messenger RNAs among malnourished and well-nourished children. Assessed association between maltase and villous atrophy and other mucosal intestinal markers indicative of loss of enterocytes and enterocytic function.</p>	<p>Sao Paulo, Brazil</p> <p>Cases were children (mean age 9.9 mo, SD 8.1) hospitalized with malnutrition refractory to dietary rehabilitation.</p> <p>Controls were children (mean age 3.6 mo, SD 1.0) with HAZ and WAZ scores >-2 and normal intestinal mucosa on biopsy, hospitalized for Kasai procedure for biliary atresia.</p>	<p>Case-control</p> <p>n=33; n=24 cases n=9 controls</p> <p>Subjects were matched on height and weight; ages differed within matched sets.</p>	<p><u>Jejunal capsule biopsy:</u></p> <ul style="list-style-type: none"> • Histopathology* • Maltase activity • Intestinal messenger RNA (mRNA) abundances: <ul style="list-style-type: none"> • Maltase-glucoamylase (MGA) • Sucrase-isomaltase (SI) • Villin, a structural protein expressed only in enterocytes • Sodium-activated luminal glucose-galactose transporter 1 (SGLT), a functional protein expressed only in enterocytes 	<p>Mean villous atrophy score (SD):</p> <ul style="list-style-type: none"> • Cases: 2.6 (0.8) • Controls: 1.2 (0.5), p=0.006) <p>WAZ score was correlated with villous atrophy (r=0.65, p- value not reported).</p> <p>13/25 [sic] cases and 0/5 controls had subnormal (defined as <94 U/g protein) of maltase activity; mean maltase was 34% lower among cases (p=0.11). Maltase activity did not appear to decrease with WAZ score (further details not provided).</p> <p>However, in sub-analyses among those samples with an adequate β-actin, a housekeeping gene message, (n=10 cases, n=9 controls), cases' findings</p>	<p>The malnourished children had significantly greater villous atrophy than the younger controls.</p> <p>Among the subset tested for mRNA messages, maltase activity as well as the mRNA abundances for MGA, villin and SGLT were significantly correlated with case status and were correlated with villous atrophy.</p> <p>While maltase deficiency has been reported in malnutrition in</p>	<p>Tissue from patients requiring intestinal resection as part of their biliary atresia management provides an opportunity to assess presumably "normal" intestinal architecture. However, unless they mocked up <i>ex vivo</i> mucosal biopsies in these controls, resections will have lower proportions of villous to submucosa tissue compared to cases' samples derived from mucosal biopsies. While this probably doesn't affect histology, it might affect</p>

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
			<ul style="list-style-type: none"> • β-actin <p>* Mucosal atrophy was scored on a scale of 1 (absence of atrophy compared to an organ donor) to 4 (similar to children with active CD).</p> <p>Histology among controls was on surgically resected tissue.</p>	<p>expressed as a mean percent of controls' (SD) included:</p> <ul style="list-style-type: none"> • Villous length (reciprocal of atrophy score): 38.9 (41.6), $p=0.004$ • Maltase activity: 37.1 (23.2), $p=0.001$ • MGA mRNA: 45.1 (36.4), $p=0.016$ • Villin mRNA: 52.5 (22.6), $p=0.003$ • SGLT mRNA: 66.6 (23.1), $p=0.057$ • β-actin: 88.2 (15.8), $p=0.189$ <p>Both villous length and maltase activity in a subset of cases were less than 40% of control values.</p> <p>MGA, villin, and SGLT mRNA abundances were correlated with villous atrophy score ($r=0.73$), ($r=0.76$), and ($r=0.54$), respectively (p-values not reported)⁶⁰.</p> <p>MGA mRNA abundance was correlated with maltase activity ($r=0.32$).</p>	<p>other studies, authors assert that these are the first results that directly support the hypothesis that reductions in maltase activity are due to villous atrophy. This study also nicely correlates mRNA relative abundance with function.</p>	<p>enterocyte functional assays and mRNA determination, as transmural tissue will bring in more diverse populations of cells; only some of them might have transcripts of interest. However, the bias is likely in a direction that would reduce effect size.</p> <p>It was unclear if control inclusion criteria included absence of atrophy or if all potential controls lacked atrophy.</p> <p>Statistical methods might not have adequately taken into account the small sample size and matching scheme.</p> <p>Subsets of subjects were investigated for various tests. For example, 10 cases had mRNA analyses based on β-actin adequacy. Another instance of</p>

⁶⁰ Villin and SGLT1 were assessed as a ratio with housekeeper gene β -actin.

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
						selected testing was the subset of 22 and 15 cases that had WAZ score to histology and mRNA correlation analyses, respectively. Rationale for subset selection was not thoroughly described.
<p>2001</p> <p>Northrop-Clewes CA et al.</p> <p>Anthelmintic treatment of rural Bangladeshi children: effect on host physiology, growth, and biochemical status</p> <p>L:M as a marker of intestinal permeability, and α 1-antichymotrypsin as a marker of inflammation and immune response to treatment among children randomized to bimonthly antihelmintics or placebo.</p>	<p>Jamalpur district, northern Bangladesh</p> <p>2-5 yr olds from poor rural villages, sampled randomly from a larger cohort study.</p> <p>Stools were assessed for helminthiasis and giardiasis. Growth was followed longitudinally.</p>	<p>RCT*</p> <p>n=109;</p> <p>n=54 received bimonthly empiric antihelminthic treatment</p> <p>n=55 received placebo</p> <p>* Randomized at the village level.</p>	<p><u>Blood Tests:</u></p> <ul style="list-style-type: none"> • α 1-antichymotrypsin (ACT) • Albumin • Total protein <p><u>Urine Test:</u></p> <p>L:M</p> <p>Among 93 subjects with L:M at baseline:</p> <ul style="list-style-type: none"> • 46 received treatment • 47 received placebo <p>Among 66 subjects with repeated L:M testing:</p> <ul style="list-style-type: none"> • 34 received treatment • 32 received placebo 	<p>Mean L:M⁶¹ at baseline:</p> <ul style="list-style-type: none"> • Treatment: 0.22 • Placebo: 0.25 <p>Seasonal variation in L:M was observed, with highest values following the monsoon season.</p> <p>Within-subject L:M analysis showed no significant association with intestinal helminthiasis and no significant improvement in treatment or placebo groups over 1 yr. L:M was generally not associated with giardiasis (with the exception of one group at one study interval).</p> <p>L:M was inversely correlated with ΔHAZ and ΔWAZ scores at some of the follow-up intervals ($r=-0.22$, $p<0.02$ and $r=-0.21$,</p>	<p>L:M ratios were high overall and demonstrated seasonal variation.</p> <p>Intra-individual L:M values did not change significantly over time, nor were they associated with helminthiasis or consistently associated with giardiasis.</p> <p>Inverse correlations were seen between L:M and growth parameters.</p> <p>Serum markers were within normal range.</p>	<p>Baseline study data were lost, so analysis began with samples taken at month 2.</p> <p>The relationship between the serum markers and intestinal permeability was not reported.</p>

⁶¹ Geometric mean.

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
				<p>p<0.05, respectively, at 12 mo follow-up visit).</p> <p>Mean serum ACT, albumin and total protein were within normal ranges and were not associated with growth parameters. ACT and albumin concentrations did not significantly change with treatment, whereas total protein concentrations did (p<0.001).</p>	The only significant change in these markers was a decrease in total protein in the treatment group without concomitant change in albumin; this suggested a decrease in globulins (not directly measured), perhaps due to decreased inflammation.	
<p>2009</p> <p>Panter-Brick C et al.</p> <p>Pathways leading to early growth faltering: An investigation into the importance of mucosal damage and immunostimulation in different socio-economic groups in Nepal</p> <p>Lactose:creatinine ratio (Lactose:Cr) as a marker of intestinal permeability and</p>	<p>Kathmandu, Nepal</p> <p>3-18 mo olds in two cohorts:</p> <ol style="list-style-type: none"> All children in target age range from four squatter settlements Randomly selected, age-matched cohort from lower middle-class, periurban households 	<p>Cohort</p> <p>n=86;</p> <p>n=48 in squatter cohort</p> <p>n=38 in lower middle-class cohort</p>	<p><u>Urine Test:</u> Lactose:Cr</p> <p><u>Blood Test:</u> • Hemoglobin</p>	<p>Mean⁶² Lactose:Cr (CI):</p> <ul style="list-style-type: none"> Squatter: 0.14 (0.12, 0.16) Middle Class: 0.08 (0.07, 0.10) Statistically significant difference between the 2 groups among the 6-12 mo olds (p=0.007) and 18-24 mo olds (p=0.002), but not among 12-18 mo olds. For both SES groups, Lactose:Cr values decreased with increasing age (p<0.001). <p>HAZ, WAZ, WHZ, and ΔWAZ scores were strongly associated with mean Lactose:Cr (p<0.001 each)</p>	<p>Authors speculate that Lactose:Cr accounted for less of the deterioration in nutritional status among the squatter children because of several factors, including poorer nutritional intake, that impact the nutritional status of children with lower socio-economic status.</p>	<p>Specific sugar excretion was normalized to urinary creatinine to control for variation in renal function.</p> <p>Authors suggest that while Lactose:Cr might not be as accurate as L:M, it might be a more field-friendly assessment of mucosal damage compared to L:M, requiring only spot urine collection and no substrate</p>

⁶² Geometric mean.

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
hemoglobin, albumin, α -1-acid glycoprotein, and IgG as markers of immunostimulation. The latter were also assessed for their relationship to nutritional status.				<p>as was ΔHAZ score ($p=0.004$); ΔWHZ score was not. The strength and magnitude of association between ΔWAZ score and Lactose:Cr was most pronounced among the wealthier cohort and there was no association between ΔHAZ score and Lactose:Cr among the squatter children.</p> <p>Hemoglobin concentrations were inversely related to Lactose:Cr ($r^2=0.018$, $p<0.001$).</p>		<p>dosing. However, L:M was not assessed in this study; direct comparison of the two tests was not possible.</p> <p>While hemoglobin concentration was inversely related to Lactose:Cr, testing for associations of other measured blood markers (IgG, AGP and albumin) with Lactose:Cr were not reported.</p>
<p>2001</p> <p>Perin NM et al.</p> <p>Intestinal absorption of D-xylose in children infected with the human immunodeficiency virus</p> <p>D-xylose as a marker of intestinal absorption among HIV-infected children with and without GI symptoms</p>	<p>Florianopolis, Brazil</p> <p>18 mo-14 yr old HIV-infected children with GI and non-GI symptoms of HIV infection recruited from a pediatric AIDS center.</p>	<p>Cross-sectional</p> <p>n=104</p>	<p><u>Blood Test:</u> D-xylose</p>	<p>Prevalence of an abnormal D-xylose result was 7.7%.</p> <p>Mean D-xylose (SD, range): 42.8mg/dL (14.4mg/dL, 16-73 mg/dL)</p> <p>D-xylose was not associated with age.</p> <p>Of the 8 children with abnormal results, 1 had diarrhea. Of 19 with diarrhea, 1 had an abnormal result.</p> <p>Of those with abnormal results, 50% had <i>Cryptosporidium</i> infection. Of the 33 subjects with <i>Cryptosporidium</i> infection, 4 had abnormal D-xylose</p>	<p>D-xylose showed substantial variation across individuals.</p>	<p>Portuguese language article.</p> <p>D-xylose <25 mg/dL was defined as indicative of malabsorption.</p>

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
				results.		
<p>2003</p> <p>Pires AL et al.</p> <p>Digital morphometric and stereologic analysis of small intestinal mucosa in well-nourished and malnourished children with persistent diarrhea</p> <p>Computerized morphometric and stereologic assessments in proximal small intestine biopsy in subjects with PD</p>	<p>Porto Alegre, Brazil</p> <p>6 mo-5 yr old inpatients from an urban setting who underwent biopsy as part of a work-up for PD.</p> <p>There was a high proportion of children with malnutrition in this study population.</p>	<p>Cross-sectional, retrospective</p> <p>n=65</p>	<p><u>Small intestinal biopsies, site and method not specified*</u>:</p> <ul style="list-style-type: none"> • Mucosal morphometric assessment by computer analysis (62 tested): <ul style="list-style-type: none"> • Villous height • Crypt depth • Villous:crypt ratio • Mucosal thickness • Digital assessment (500x magnification) (65 tested): <ul style="list-style-type: none"> • Enterocyte height • Enterocyte nucleus height • Brush border height • Stereological analysis to assess mucosal surface area (62 tested) <p>* From stored specimens previously assessed by micrometer.</p>	<p>Computerized mucosal measures were similar to those by micrometer and were not associated with nutritional status.</p> <p>Digitally assessed enterocyte height, enterocyte brush border, and enterocyte nucleus height correlations:</p> <ul style="list-style-type: none"> • WAZ score: r=0.25 (p=0.038), r=0.26 (p=0.03), and r=0.24, (p=0.05), respectively • WHZ score: r=0.29 (p=0.02), r=0.27 (p=0.03), and r=0.16 (p=0.19), respectively • HAZ score: r=0.16 (0.18), r=0.23 (p=0.06), r=0.23 (0.06) <p>There was no correlation between mucosal surface area and growth parameters.</p>	<p>Enterocyte measures show some correlation with WAZ and WHZ scores, but not with HAZ score. However, surface area and villous:crypt ratios were not correlated with any growth parameter.</p>	
<p>2008</p> <p>Poddar U et al.</p>	<p>Chandigarh, India</p> <p><14 yr (mean age</p>	<p>Case-control</p> <p>n=28 controls;</p>	<p><u>Endoscopic duodenal biopsy:</u></p> <p>Histopathology</p>	<p>Duodenal biopsy of those with giardiasis showed nonspecific chronic</p>	<p>Duodenal biopsy demonstrated histological</p>	<p>Authors did not report the biopsy findings in the TS</p>

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
<p>Is tissue transglutaminase autoantibody the best for diagnosing celiac disease in children of developing countries</p> <p>Duodenal biopsies in controls with giardiasis, TS, and SBBO</p>	<p>6.9 yr) presenting with symptoms consistent with CD (PD, FTT, and/or pallor)</p> <p>Subjects negative for CD were of interest for this review.</p>	<ul style="list-style-type: none"> • 22 with giardiasis • 1 with TS • 5 with SBBO 		<p>inflammation of lamina propria; there was no evidence of villous atrophy.</p>	<p>changes accompanying <i>Giardia</i> infection.</p>	<p>or SBBO patients.</p>
<p>2002</p> <p>Poddar U et al.</p> <p>Celiac disease in India: Are they true cases of celiac disease?</p> <p>Duodenal biopsy, D-xylose, and fecal fat in children with symptoms of CD but normal mucosal biopsy results</p>	<p>Chandigarh, India</p> <p>18 mo-14 yr olds with PD, FTT, or pallor from a hospital pediatric gastroenterology unit.</p> <p>Subjects with normal crypt:villous ratio on biopsy were of interest for this review.</p>	<p>Case-control</p> <p>n=47</p>	<p><u>Endoscopic duodenal biopsy:</u> Histopathology</p> <p><u>Stool Tests:</u></p> <ul style="list-style-type: none"> • Fecal fat* • D-xylose** <p>* In 72-hour stool collection.</p> <p>** Not specified whether from urine or serum, and units of measurement not provided.</p>	<p>38% had chronic inflammatory cell infiltrates in the lamina propria.</p> <p>55% had abnormal D-xylose concentrations.</p> <p>20% had abnormal fecal fat test.</p> <p>No results beyond proportion positive were reported for any of the above markers.</p>	<p>Among controls with normal mucosal architecture by biopsy, more than one-third had PD.</p> <p>D-xylose and fecal fat might not correlate well with duodenal biopsy results.</p>	<p>Relationships between fecal fat, D-xylose and biopsy results were not reported.</p> <p>While 38% of controls had PD, results for the markers studied were not stratified by PD for this group.</p> <p>Seven children with biopsies consistent with CD did not respond to gluten-free diet and were excluded from the study.</p> <p>Cut-off points used to define abnormal D-xylose tests were not provided.</p>

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
<p>2000</p> <p>Quadro L et al.</p> <p>Retinol and retinol-binding protein: gut integrity and circulating immunoglobulins</p> <p>L:M as a marker of small intestinal permeability, and its correlation with serum retinol among mildly malnourished children</p>	<p>Goncalves Dias favela in Fortaleza, Brazil</p> <p>1-9 yr olds with mild malnutrition selected from a large cohort of children from an urban slum. They were recruited at birth and followed longitudinally.</p> <p>19 (63%) had some degree of vitamin A deficiency—all of these had mild deficiency, except for 2 with moderately low concentrations.</p>	<p>Cross-sectional</p> <p>n =30</p>	<p><u>Urine Tests:</u></p> <ul style="list-style-type: none"> • Lactulose⁶³ • Mannitol • L:M 	<p>80% of subjects had abnormal L:M, defined as ≥ 0.030.</p> <p>Serum retinol was:</p> <ul style="list-style-type: none"> • Inversely correlated with L:M ($r=0.46$, $p=0.012$) • Directly correlated with mannitol ($r=0.66$, $p<0.01$) • Not correlated with lactulose (data not reported) 	<p>Children with low serum retinol had higher L:M, apparently mediated by mannitol excretion.</p>	<p>The L:M normal cutoff was defined lower than for most other L:M studies, as 0.030. The authors reference several studies regarding use of this cut point.</p>

⁶³ Lactulose and mannitol results were expressed as % of dose administered.

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
<p>2004</p> <p>Rabbani GH et al.</p> <p>Green banana and pectin improve small intestinal permeability and reduce fluid loss in Bangladeshi children with persistent diarrhea</p> <p>L:M as a marker of intestinal permeability among infants with PD who are treated with green banana, pectin, or rice diet</p>	<p>Dhaka, Bangladesh</p> <p>5-12 mo old males admitted to the hospital of the International Centre for Diarrhoeal Disease Research with PD but without other concurrent illnesses.</p>	<p>RCT</p> <p>n=57;</p> <p>n=19 received green banana and rice</p> <p>n=17 received pectin and rice</p> <p>n=21 received rice alone (placebo)</p>	<p>Urine Tests:</p> <ul style="list-style-type: none"> • Lactulose⁶⁴ • Mannitol • L:M 	<p>Mean L:M⁶⁵ (SD) by treatment group, pre- and post-treatment:</p> <ul style="list-style-type: none"> • Banana: pre=0.50 (0.14), post=0.21 (0.12), p<0.01 • Pectin: pre=0.54 (0.17), post=0.23 (0.09), p<0.01 • Placebo: pre=0.41 (0.11), post=0.45 (0.13), p>0.6 <p>Lactulose and mannitol excretion did not differ between groups at baseline.</p> <p>Lactulose excretion was not significantly reduced after intervention in the placebo group. Mean (SD):</p> <ul style="list-style-type: none"> • Pre-treatment: 1.45 (0.12) • Post-treatment: 1.35 (0.15) <p>Both treatment groups had 70-80% reduced lactulose excretion following treatment (p<0.01).</p> <p>Mannitol excretion increased in all groups compared to their pre-treatment values, but only significantly so in the banana and pectin groups (p<0.05).</p> <p>Mean mannitol % excretion (SD), pre- vs. post-treatment:</p> <ul style="list-style-type: none"> • Banana: 1.82 (0.13) vs. 	<p>L:M values were high at baseline among the study population of inpatient young children with PD. Mean L:M significantly improved with the green banana or pectin intervention but were still above normal range following 7 days of treatment. The improvements in L:M were driven by both mannitol and lactulose, with the latter having an impact of greater magnitude.</p> <p>Authors cite studies postulating that the effectiveness of green banana in reducing diarrheal fluid loss is due to its high content of amylase-resistant starch, which undergoes bacterial fermentation into</p>	

⁶⁴ Lactulose and mannitol results were expressed as % of dose administered.

⁶⁵ Type of mean not specified.

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
				<p>3.21 (0.16)</p> <ul style="list-style-type: none"> • Pectin: 1.91 (0.12) vs. 3.2 (0.18) • Placebo: 2.10 (0.11) vs. 2.33 (0.18) <p>The banana and pectin groups stopped having diarrhea more often compared to controls (e.g. $p < 0.01$ by day 4). Among the banana and pectin groups, stool reductions were associated with percent change in L:M before and after treatment ($R^2 = 0.84$ for pectin and $R^2 = 0.86$ for banana; $p < 0.05$ for each).</p>	<p>short-chain fatty acids in the colon, stimulating colonic salt and water absorption. Pectin is thought to work by a similar mechanism. Authors also suggest that short chain fatty acids might affect entero-hormones and growth factors, resulting in the observed changes in intestinal permeability [206].</p>	
<p>2001</p> <p>Rabbani GH et al.</p> <p>Increased nitrite and nitrate concentrations in sera and urine of patients with cholera or shigellosis</p> <p>To assess and compare nitric oxide as a marker of intestinal inflammation among children with cholera</p>	<p>Dhaka, Bangladesh</p> <p>2-6 yr olds with cholera or shigellosis admitted to the hospital.</p> <p>Controls were recruited from the healthy attendants of patients or from children of hospital staff.</p> <p>Mean age (SD) in</p>	<p>Case-control</p> <p>n=63;</p> <p>n=45 cases:</p> <ul style="list-style-type: none"> • 24 with cholera • 21 with shigellosis <p>n=18 healthy controls</p> <p>Samples were collected from cases on admission</p>	<p><u>Urine Test:</u> Nitric Oxide (NO)*</p> <p><u>Blood Tests:</u></p> <ul style="list-style-type: none"> • Nitrite (NO₂) • Nitrate (NO₃) • WBC <p><u>Stool Test:</u> Leukocytes</p> <p>* Nitric oxide (NO) is an unstable free radical that is</p>	<p>In children with shigellosis, median serum NO was ~8x higher at baseline than in controls and significantly differed from convalescent concentrations ($p < 0.01$). Concentrations declined by 52% of baseline during the recovery period but did not return to values found in the controls (measure of statistical significance not reported).</p> <p>In children with cholera, median serum NO concentrations at baseline</p>	<p>NO as measured by both serum and urinary NO₂ and NO₃ concentrations was significantly elevated at presentation during acute illness compared to 7-10 days after hospitalization in both cholera and shigellosis.</p> <p>Median serum NO concentrations in</p>	<p>Some values reported in table format conflict with the text; columns of data appear to be transposed.</p> <p>Assessment for NO correlation with fecal leukocyte counts was not reported, nor was the correlation between urinary NO and total blood WBC.</p>

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
<p>or shigellosis or healthy controls. Evaluated to assess nitric oxide production during infection of small bowel without inflammatory lesion (e.g., cholera) and during infection causing colon inflammation (e.g., shigellosis).</p>	<p>yr:</p> <ul style="list-style-type: none"> • Shigellosis cases: 3.8 (1.2) • Cholera cases: 4.2 (1.4) • Controls: 4.7 (1.8) 	<p>and upon discharge (after 7-10 days of treatment).</p>	<p>converted to nitrite and nitrate. Urine NO₂ + NO₃ were expressed as a ratio with urine creatinine in order to account for differences in urine concentration.</p>	<p>were ~4x higher than in control subjects. Recovery concentrations decreased 52% from baseline (p<0.01); convalescent values did not differ from the values in controls (p<0.4).</p> <p>Median urinary NO ratios were similar among those with <i>Shigella</i> and <i>V. cholerae</i> infection, both upon admission and discharge. Initial values were ~2x higher than upon discharge (p<0.05 and 0.01, respectively). Control median NO was of an intermediate concentration between cases' admission and discharge median concentrations; the difference between control and case admission values was NS.</p> <p>Mean blood WBC counts (SD):</p> <ul style="list-style-type: none"> • Shigellosis: 19.6 (3.3) • Cholera: 8.3 (2.8) • Controls: 7.1 (1.8) <p>Mean fecal WBC/high power field (SD):</p> <ul style="list-style-type: none"> • Shigellosis: 38 (17) • Cholera: 5 (2) • Controls: 3 (1) <p>Serum NO correlated with blood WBC count in shigellosis cases at baseline (r²=0.92, p<0.01), but only</p>	<p>cholera patients were ~half of those with shigellosis both upon admission and upon discharge and concentrations were much higher in cases than in controls, Such striking differences were not observed for urinary NO results.</p> <p>Serum NO concentrations correlated with total blood WBC in shigellosis cases.</p>	

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
				to a slight degree upon discharge ($r^2=0.26$, no p-value reported) and there was no correlation among the cholera cases. Serum NO correlated with stool volume at presentation ($r^2=0.85$, statistically significant per authors, p-value not reported).		
<p>2009</p> <p>Ritchie BK et al.</p> <p>13C-sucrose breath test: novel use of a noninvasive biomarker of environmental gut health</p> <p>Sucrose breath test (SBT) as a marker of small bowel mucosal damage vis a vis sucrase activity among an Australian Aboriginal population. Also compared SBT with serum lactulose:rhamnose ratio (L:R)</p>	<p>Darwin and Adelaide, Australia</p> <p>4 mo-5 yr old Aboriginal children admitted to hospital with diarrhea.</p> <p>Two control groups:</p> <ol style="list-style-type: none"> 1. Aboriginal controls admitted to hospital with non-GI symptoms (50% had pneumonia) 2. Healthy, non-Aboriginal controls recruited from community 	<p>Case-control</p> <p>n=43;</p> <p>n=18 Aboriginal cases with AD</p> <p>n=25 controls:</p> <ul style="list-style-type: none"> • 18 Aboriginal, without diarrhea • 7 non-Aboriginal, healthy 	<p><u>Blood Tests:</u></p> <ul style="list-style-type: none"> • L:R (32 Aboriginal cases and controls tested) • C-reactive protein (CRP) • Mean Corpuscular Volume (MCV) • Hemoglobin <p><u>Breath Test:</u></p> <p>¹³C sucrose breath test (SBT)</p>	<p>20/32 (63%) of Aboriginal children had abnormal L:R ratios.</p> <p>Mean⁶⁶ L:R (CI):</p> <ul style="list-style-type: none"> • Diarrhea cases: 31.8 (24.9, 40.7) • Aboriginal controls without diarrhea: 11.4 (8.5, 15.5), significant difference ($p<0.0001$) <p>SBT Mean (CI):</p> <ul style="list-style-type: none"> • Diarrhea cases: 1.9% (0.9, 3.0), $p<0.0001$ compared to non-Aboriginal controls and $p=0.004$ compared to Aboriginal controls • Aboriginal controls: 4.1% (3.0, 5.2), $p=0.032$ compared to non-Aboriginal controls • Non-Aboriginal controls: 6.1% (4.8, 7.3) <p>Significant differences were observed between all three groups.</p>	<p>SBT values were significantly lower and L:R values were significantly higher among Aboriginal children with diarrhea than among those without GI symptoms. SBT was also significantly lower among Aboriginal controls than among non-Aboriginal children without diarrhea. This is consistent with previous reports of high prevalence of clinically silent TE in this population.</p> <p>SBT was significantly inversely</p>	<p>Abnormal L:R ratios were defined as >16; no reference or derivation was provided for this cut-point.</p> <p>L:R test was not conducted among the non-Aboriginal controls.</p> <p>SBT/L:R correlation analysis was based on data for Aboriginal cases and controls combined; stratified analysis was not reported and could be of interest considering the large difference in L:R observed between these groups.</p> <p>Associations of</p>

⁶⁶ Geometric mean.

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
				<p>SBT results were not associated with wasting or with patient age or breastfeeding status.</p> <p>SBT and L:R were inversely correlated ($r=0.67$; CI: 0.42, 0.62; $p<0.0001$). L:R explained 45% of the variance in SBT; diarrhea explained 28% of variance.</p> <p>SBT was associated with increased MCV, relative risk (CI)=3.9 (2.8, 5.0). SBT was not associated with hemoglobin or CRP.</p>	correlated with L:R.	MCV, CRP, and hemoglobin with SBT after adjusting for potentially confounding variables were not reported.
<p>2001</p> <p>Rollins NC et al.</p> <p>Feeding mode, intestinal permeability, and neopterin excretion: A longitudinal study in infants of HIV-infected South African women</p> <p>L:M as a marker of gut mucosal integrity and urinary neopterin excretion as a marker of cell-mediated immunity in infants with and</p>	<p>Durban, South Africa</p> <p>1, 6, and 14 wk old infants born to HIV-infected mothers.</p>	<p>Cohort</p> <p>n=272</p>	<p><u>Urine Tests:</u></p> <ul style="list-style-type: none"> • Lactulose⁶⁷ • Mannitol • L:M • Neopterin 	<p>Mean⁶⁸ L:M (CI):</p> <ul style="list-style-type: none"> • HIV-infected subjects: <ul style="list-style-type: none"> • 1 wk: 0.12 (0.06, 0.27) • 6 wk: 0.24 (0.15, 0.38) • 14 wk: 0.24 (0.14, 0.44) • Uninfected subjects: <ul style="list-style-type: none"> • 1 wk: 0.13 (0.09, 0.19) • 6 wk: 0.08 (0.06, 0.11) • 14 wk: 0.09 (0.07, 0.13) <p>HIV-infection by 14 wk of age was significantly associated with increased L:M.</p> <p>A non-significant, positive trend in neopterin excretion was observed among HIV-</p>	<p>L:M was generally normal (compared to UK values) for non-HIV-infected infants, but significantly increased among HIV-infected subjects, especially after 6 weeks.</p> <p>The increased L:M in HIV-infected infants was primarily driven by lactulose rather than mannitol.</p>	<p>Assessment of association between L:M and neopterin was not reported.</p>

⁶⁷ Lactulose and mannitol results were expressed in mg.

⁶⁸ Geometric mean.

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
without HIV infection				infected infants.	Higher neopterin excretion by HIV-infected infants was observed but this was not statistically significant.	
<p>2000</p> <p>Rollins NC et al.</p> <p>Vitamin A supplementation of South African children with diarrhea: optimum timing for improving biochemical and clinical recovery and subsequent vitamin A status</p> <p>L:M as a marker of intestinal permeability and urinary neopterin, serum α-1 acid glycoprotein, and C-reactive protein as markers of inflammation among children with severe diarrhea</p>	<p>Durban, South Africa</p> <p>6-60 mo old inpatients or outpatients with severe diarrhea.</p>	<p>RCT</p> <p>n=139;</p> <p>n=66 received vitamin A on admission (group 1)</p> <p>n=73 received vitamin A after clinical improvement (group 2)</p> <p>Treatment involved vitamin A supplementation either on the day of admission or after acute diarrheal symptoms had resolved.</p>	<p><u>Urine Tests:</u></p> <ul style="list-style-type: none"> • Lactulose⁶⁹ • Mannitol • L:M • Neopterin <p><u>Blood Tests:</u></p> <ul style="list-style-type: none"> • C-reactive protein (CRP) • α-1 acid glycoprotein (AGP) <p>49 subjects received urine testing:</p> <ul style="list-style-type: none"> • Group 1: n=25 • Group 2: n=24 <p>Blood and urine were tested on days 0 and 3.</p>	<p>Mean⁷⁰ L:M:</p> <ul style="list-style-type: none"> • Group 1: <ul style="list-style-type: none"> • Day 0: ~1.8 • Day 3: ~2.4 • Group 2: <ul style="list-style-type: none"> • Day 0: ~1.2 • Day 3: ~0.7 <p>There were no differences in mean L:M between groups or within groups between days 0 and 3, although there was a significant difference in paired analysis within individuals at the two time points (data not presented, and direction, magnitude and degree of significance not reported).</p> <p>Lactulose and mannitol excretion were assessed only in the paired analysis. Lactulose excretion decreased between days 0 and 3 (magnitude of effect and degree of significance not reported), while mannitol excretion showed no change.</p>	<p>Mean L:M ratios were very high (~10x) (at baseline and at day 3 in both groups) compared to other studies in this review. Study authors suggested (via personal correspondence) that this could have been due to the severity of illness in the sample population (children hospitalized for diarrhea).</p> <p>Vitamin A administration did not result in significant improvement in L:M, neopterin, or AGP regardless of timing of vitamin A administration.</p>	<p>Urine testing could only be conducted in the laboratory on certain days; hence only a subset of subjects underwent those tests.</p> <p>Group 2 patients had significantly higher CRP, non-significantly higher WBCs and AGP, and lower retinol and retinol-binding protein concentration compared to group 1 at baseline. Authors note that these parameters suggest that Group 2 patients might have been more ill at baseline. For the subset of 49 patients undergoing urine testing, the mean⁷² L:M and neopterin concentrations</p>

⁶⁹ For lactulose, mannitol, and neopterin results, excretion measurement was not specified.

⁷⁰ Geometric mean.

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
				<p>Mean⁷¹ neopterin and AGP concentrations did not differ between groups or within groups on the different study days or in the paired analysis. When initial CRP (~2x higher in Group 2 compared to Group 1, p<0.004) was taken into account, mean CRP on day 3 did not differ between the 2 groups. However in the paired analysis, CRP concentrations were significantly different between days 0 and 3.</p>		<p>were lower among Group 2 than Group 1 subjects (NS). However, baseline differences in acute phase and vitamin A markers at baseline were not reported separately for these 49 subjects.</p> <p>Data for lactulose and mannitol excretion were not reported separately. Rationale for additional analyses of these molecules expressed as ratios with creatinine was not explained.</p> <p>Authors suggest that their 3-day testing period (based on their previous work in a different setting [207] might have been too short to identify effect as demonstrated by McCullough et al. at 10 days after presentation [208].</p>

⁷² Geometric mean.

⁷¹ Geometric mean.

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
<p>2006</p> <p>Samie A et al.</p> <p><i>Cryptosporidium</i> species: preliminary descriptions of the prevalence and genotype distribution among school children and hospital patients in the Venda region, Limpopo Province, South Africa</p> <p>Stool lactoferrin as a marker of intestinal inflammation among hospitalized patients and school children</p>	<p>Vhembe, South Africa</p> <p>0.1-88 yr olds from semi-urban community included patients hospitalized with diarrhea or other GI complaints as well as students attending nearby schools.</p>	<p>Cross-sectional</p> <p>n=26 ≤5 yr old:</p> <ul style="list-style-type: none"> • 22 hospital-based subjects • 4 school-based subjects 	<p><u>Stool Test:</u> Lactoferrin</p>	<p>16/22 patients and 0/4 students were lactoferrin positive.</p> <p>While examination of lactoferrin association with history of diarrhea or with <i>Cryptosporidium</i> infection was not reported, only 3/22 and 16/22 hospitalized patients and 2/4 and 3/4 school children were positive for <i>Cryptosporidium</i> and had a history of diarrhea, respectively.</p>	<p>Lactoferrin prevalence was high among children hospitalized with diarrhea or other GI symptoms, regardless of <i>Cryptosporidium</i> status.</p> <p>Lactoferrin was not found among school-recruited children, most of whom did have a history of diarrhea. Two of the four school children were <i>Cryptosporidium</i>-positive.</p>	<p>Among the entire study cohort of all ages, lactoferrin results were similar among hospitalized patients regardless of <i>Cryptosporidium</i> status (influence of HIV infection was not reported). Among school children, lactoferrin was more frequently found to be positive among those infected with <i>Cryptosporidium</i>; statistical testing was not reported.</p> <p>Lactoferrin results were graded based on agglutination reaction positivity with increasing dilution and was considered negative if there was no reaction at 1:25.</p> <p>Some subjects were breastfed and were tested for lactoferrin.</p>
<p>2004</p> <p>Sarker SA et al.</p>	<p>Dhaka, Bangladesh</p> <p>2-5 yr old</p>	<p>Case-control</p> <p>n=25:</p>	<p><u>Blood Test:</u> Iron (absorption test)</p>	<p>Mean⁷³ iron absorption from ferrous (Fe) sulfate and Fe fumarate:</p> <ul style="list-style-type: none"> • Uninfected children: 	<p>Iron absorption from Fe fumarate was significantly lower than from</p>	<p>Data on iron absorption among 2-5 yr olds are limited, making</p>

⁷³ Geometric mean.

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
<p><i>Helicobacter pylori</i> infection, iron absorption, and gastric acid secretion in Bangladeshi children</p> <p>Iron absorption among children with iron deficiency anemia with and without <i>H. pylori</i> infection</p>	<p>apparently healthy children from a periurban setting, screened for iron deficiency and <i>H. pylori</i>.</p>	<p>n=13 cases infected with <i>H. pylori</i></p> <p>n=12 controls not infected with <i>H. pylori</i></p>		<p>15.6% and 5.4%, (p<0.001)</p> <ul style="list-style-type: none"> • Infected children before treatment: 19.7% and 5.3%, (p<0.0001) • Infected children after treatment: 22.5% and 6.4%, (p<0.0001) • <i>H. pylori</i> treatment did not significantly affect absorption (Fe sulfate or fumarate), p=0.3 	<p>Fe sulfate.</p> <p>Results do not support the hypothesis that <i>H. pylori</i> infection influences absorption of water-soluble (Fe sulfate) or non-water-soluble (Fe fumarate) iron compounds.</p>	<p>comparison of results from this study setting difficult.</p>
<p>2006</p> <p>Sheng XY et al.</p> <p>Major variables of zinc homeostasis in Chinese toddlers</p> <p>Differences in zinc absorption in healthy toddlers with a high prevalence of zinc deficiency.</p>	<p>Xi-Chou (town) & Yun-Nan (province), China</p> <p>19-25 mo olds recruited from a remote small town and 2 surrounding rural villages.</p> <p>48% of children had plasma zinc concentrations below 2.5th percentile. Dietary zinc intake was low.</p> <p>There was a high prevalence of stunting among the subjects.</p>	<p>Cross-sectional</p> <p>n=43</p>	<p><u>Stool Test:</u> Endogenous fecal zinc (EFZ)</p> <p><u>Urine Test:</u> Zinc excretion to measure fractional absorption of zinc (FAZ) and total absorbed zinc (TAZ) following radiolabeled zinc administration</p>	<p>Mean (SD):</p> <ul style="list-style-type: none"> • FAZ: 0.35 (0.12) • AZ (mg/d): 0.63 (0.24) • EFZ (mg/d): 0.67 (0.23) <p>The quantity of absorbed zinc was lower than physiologic requirements.</p> <p>There was no statistically significant difference in any laboratory value between the town and village groups.</p> <p>Zinc absorption was ~80% of estimated physiologic requirement and equivalent to the amount of endogenous zinc excreted via the intestine; it was expected that absorbed zinc would exceed excreted zinc [144, 187, 194, 195].</p>	<p>Zinc absorption was lower than physiologic requirements and EFZ was higher than expected.</p> <p>The authors note that the results are difficult to explain and specifically state that they do not think (though without clear justification) that enteropathy is prevalent in the population and therefore could not be a contributing factor.</p>	
<p>2008</p> <p>Sherwani K et al.</p>	<p>Aligarh, India</p> <p>1-12 yr olds (mean age 51.2 mo) from</p>	<p>Cross-sectional</p> <p>n=19</p>	<p><u>Duodenal biopsy, method not specified:</u> Histopathology</p>	<p>Six patients had partial villous atrophy and non-specific duodenitis by biopsy.</p>	<p>Biopsy identified abnormal histopathology in approximately 1/3</p>	<p>The 6 children with partial villous atrophy were thought to have</p>

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
<p>Prevalence of iron deficiency anemia in chronic diarrhoea and celiac disease - A western UP experience</p> <p>Duodenal biopsy in patients with PD</p>	<p>an urban setting with PD recruited from pediatric outpatient and inpatient units.</p> <p>Those with negative CD work-up were subjects of interest for this review.</p>				<p>of patients who did not have CD, but did not identify PD etiology in the remainder who did not have CD.</p>	<p>SBBO as they recovered after treatment with broad spectrum antibiotics.</p>
<p>2003</p> <p>Soliman SM et al.</p> <p>Role of micronutrient mixture in acute and persistent diarrhea in infants and its impact on nutritional status</p> <p>Blood cell and albumin markers among infants with acute, persistent or no diarrhea, and effects on these markers after 10 days of supplementation with micronutrient mixture (containing vitamin A, zinc and other micronutrients) among subjects with and without diarrhea</p>	<p>Cairo, Egypt</p> <p>6-24 mo olds with diarrhea were recruited from Al-Sahel teaching hospital malnutrition clinic.</p> <p>5/6 PD cases and 10/14 AD cases had some degree of malnutrition.</p> <p>Infants with PD had significantly lower vitamin A and zinc stores compared to controls. Those with AD had significantly lower vitamin A stores.</p>	<p>Case-control</p> <p>n=30;</p> <p>n=20 cases:</p> <ul style="list-style-type: none"> • 6 with PD • 14 with AD <p>n=10 healthy controls*</p> <p>* Controls were age- and sex-matched to cases.</p>	<p><u>Blood Tests:</u></p> <ul style="list-style-type: none"> • Complete blood count and differential • Red cell measures: <ul style="list-style-type: none"> • Mean corpuscular volume (MCV) • Mean corpuscular hemoglobin (MCH) • Mean corpuscular hemoglobin concentration (MCHC) • Transferrin saturation • Albumin 	<p>Mean baseline hemoglobin was significantly lower in infants with AD and PD ($p<0.05$ for each group) than in controls</p> <p>Mean MCV and MCH were lower in those with AD ($p<0.025$ and $p<0.01$, respectively) and PD ($p<0.01$ for both markers) compared to controls.</p> <p>Mean lymphocyte counts among PD cases were low compared to those of controls ($p<0.01$).</p> <p>Other markers did not vary significantly at baseline. However, among infants with PD, mean albumin was abnormally low, although it was not significantly different compared to controls or those with AD. Mean albumin (g/dL) (SE):</p> <ul style="list-style-type: none"> • PD: 2.9 (0.27) • AD: 3.29 (0.25) • Controls: 3.37 (0.21) 	<p>Albumin and many hematologic markers were low at baseline among infants with diarrhea, especially in those with PD, compared to those without diarrhea; some of these differences were statistically significant. Parameters generally normalized after micronutrient supplementation.</p>	<p>Information on control recruitment and anthropometrics were not specified.</p> <p>Sample size was small when stratified by case/control groups, especially for PD cases (n=6). Controls were reported to have been matched to cases, yet there were half the number of controls than cases and statistical testing (student's t-test) was not commensurate with matched case-control methodology.</p>

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
				Following micronutrient supplementation, mean hemoglobin, MCV, lymphocyte counts and albumin increased in both diarrhea groups to concentrations on par with control baseline concentrations (albeit increases were NS except within the PD group). MCH improved to concentrations on par with the control group only among the infants with AD.		
<p>2003</p> <p>Tassara O et al.</p> <p>Gastrointestinal diseases in children infected with the human immunodeficiency virus</p> <p>Endoscopy and biopsy among HIV-infected children</p>	<p>Santiago, Chile</p> <p>0-12 yr old (median 9 mo) HIV-infected children treated in hospital. A high proportion had PD.</p>	<p>Cross-sectional</p> <p>n=11</p>	<p><u>Endoscopic upper GI biopsy</u> including esophagus, stomach, and/or duodenum:</p> <ul style="list-style-type: none"> Gross endoscopic visualization Histopathology 	<p>Macroscopic inflammatory changes were observed on endoscopy in the esophagus, stomach or duodenum in 2 subjects.</p> <p>Biopsies of esophagus, stomach or duodenum showed inflammatory changes of varying degree in all 11 subjects.</p>	<p>Biopsy results might show inflammatory damage in cases with no macroscopic damage visible.</p>	<p>Spanish language article.</p> <p>Inflammatory changes identified in the digestive system were not specified by site (i.e. esophagus, stomach or duodenum).</p> <p>Results were not stratified by presenting symptoms, including PD.</p>
<p>2000</p> <p>Thurnham DI et al.</p> <p>Innate immunity, gut integrity, and vitamin A in Gambian and Indian</p>	<p>Orissa State, India</p> <p>Subjects were recruited from 2 sources:</p> <ol style="list-style-type: none"> Hospital-based infants admitted for "diarrheal or 	<p>RCT</p> <p>n=174;</p> <p>n=94 hospital-based</p> <ul style="list-style-type: none"> 31 received vitamin A at day 	<p><u>Urine Test:</u></p> <p>L:M</p> <p>For hospital-based subjects, L:M was assessed at baseline, discharge from</p>	<p>Mean L:M was ~3-fold higher among hospitalized compared to clinic patients at baseline. Within the allocation groups, mean baseline L:M did not differ for either the hospitalized or clinic subjects.</p>	<p>Mean L:M values, including post-intervention values, were 2-5 times higher than those observed in the UK [209].</p>	<p>Precise numerical values were not reported, rather L:M results were portrayed in figures with units expressed in mg, making it difficult to</p>

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
<p>infants</p> <p>L:M as a marker of intestinal integrity among children receiving vitamin A supplementation</p>	<p>respiratory disease,” mean age 9 mo</p> <p>2. Clinic-based infants with “minor ailments”, age not specified</p>	<p>1</p> <ul style="list-style-type: none"> • 32 received vitamin A at discharge (up to day 5) • 31 received placebo <p>n=80 clinic-based*</p> <p>Clinic-based subjects were randomized to receive vitamin A weekly for 8 wk or placebo.</p> <p>* Number of subjects in each treatment group was not specified.</p>	<p>hospital, and 10 or 30 days after discharge.</p> <p>For clinic-based subjects, L:M was assessed at baseline, 4, and 8 wk.</p>	<p>Among the hospital cohort, mean L:M declined significantly in the two vitamin A groups compared to the placebo group, and remained lower at day 30 among the treatment groups, but the difference was no longer significant compared to the placebo group.</p> <p>Among the clinic cohort, mean L:M reduction was accelerated in vitamin A-supplemented children. However, mean L:M did not significantly differ between treatment groups at any time point.</p> <p>The rate of decline in L:M was most steep among the vitamin A-treated hospitalized patients, in whom the mean L:M value decreased by 63% over 30 days, followed by placebo-treated hospitalized patients, with a decrease of 38% over 30 days. Mean L:M decreased by 57% in the vitamin A-treated clinic patients, while there was no change in L:M among the clinic placebo group.</p>	<p>L:M reduction was accelerated among vitamin A-supplemented children, but end-of-study mean values did not differ statistically between allocation groups in either the clinic or the hospital cohorts.</p>	<p>compare these results to those of other studies.</p> <p>Information on study design, such as randomization scheme, was limited.</p> <p>The article also reported re-analyzed data from a 1991 report from The Gambia [209].</p>

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
<p>2009</p> <p>Trehan I et al.</p> <p>A randomized, double-blind, placebo-controlled trial of rifaximin, a nonabsorbable antibiotic, in the treatment of tropical enteropathy</p> <p>L:M, sucrose:lactulose, and sucralose:lactulose as markers of small intestinal, gastric, and colonic permeability, respectively, among those receiving rifaximin or placebo</p>	<p>Limela, Malawi</p> <p>All 3-5 yr olds from the village were recruited.</p>	<p>RCT</p> <p>n=144;</p> <p>n=72 received rifaximin for 7 days</p> <p>n=72 received placebo</p> <p>It was presumed that if SBBO is the etiology for enteropathy, treatment with rifaximin would result in improved intestinal integrity.</p>	<p><u>Urine Tests</u></p> <ul style="list-style-type: none"> • Lactulose⁷⁴ • Mannitol • Sucrose (SUC) • Sucralose (SCL) • L:M • Sucrose:lactulose ratio (SUC:L) • Sucralose:lactulose ratio (SCL:L) <p>Subjects were tested before and after treatment.</p>	<p>At enrollment:</p> <ul style="list-style-type: none"> • Mean mannitol (SD): <ul style="list-style-type: none"> • Treatment: 9.57 (5.24) • Placebo: 10.29 (6.62) • Mean lactulose (SD): <ul style="list-style-type: none"> • Treatment: 0.30 (0.18) • Placebo: 0.34 (0.25) • Mean SUC (SD): <ul style="list-style-type: none"> • Treatment: 0.062 (0.04) • Placebo: 0.074 (0.058) • Mean SCL (SD): <ul style="list-style-type: none"> • Treatment: 0.51 (0.29) • Placebo: 0.58 (0.53) • Mean L:M⁷⁵ (SD): <ul style="list-style-type: none"> • Treatment: 0.18 (0.12) • Placebo: 0.17 (0.09) • Mean SUC:L (SD): <ul style="list-style-type: none"> • Treatment: 0.50 (0.34) • Placebo: 0.64 (0.90) • Mean SCL:L (SD): <ul style="list-style-type: none"> • Treatment: 0.42 (0.32) • Placebo: 0.39 (0.23) • For both groups combined: <ul style="list-style-type: none"> • 76% had L:M >0.10 • 34% had L:M >0.20 <p>No significant post-intervention differences were observed in any fractional sugar excretion or dual sugar test, including among children with elevated pre-intervention L:M.</p>	<p>There was a high proportion with elevated L:M which did not change with rifaximin treatment.</p> <p>Baseline L:M measurements in this study resembled those of another Malawian population in similar environmental conditions [120].</p> <p>SCL excretion in this population was similar to that found in healthy American children (0.4%), while SCL:L was comparatively lower (0.8) and driven by lactulose [210]. SCL:L might be a better marker of colonic permeability [211-213]. Results from this study potentially indicate that colonic</p>	<p>Methodological differences in specimen collection and testing, in particular for SCL excretion, might account for some differences in values compared to other studies.</p> <p>This was the first use of SCL for site-specific absorption testing in a developing country setting.</p>

⁷⁴ Lactulose, mannitol, SUC, and SCL results were expressed as % of dose administered.

⁷⁵ Type of mean for sugar ratios not specified.

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
					<p>permeability was normal.</p> <p>Few data exist on SUC excretion. Results in this trial are similar to those found in another Malawian population (0.06% SUC excretion) [120] and high compared to healthy older children from developed country settings (0.02-0.03%) [210, 212].</p>	
<p>2008</p> <p>Vieira MM et al.</p> <p>Carotenoids, retinol, and intestinal barrier function in children from northeastern Brazil</p> <p>L:M as marker of intestinal barrier function, fecal lactoferrin and leukocytes as markers of intestinal inflammation, and CRP and AGP as acute phase reactants among</p>	<p>Fortaleza, Brazil</p> <p>2 mo-9 yr olds (mean age 41 mo) from an impoverished urban community, eligible if HAZ score <median for their community.</p>	<p>Cross-sectional</p> <p>n=102</p>	<p><u>Urine Tests:</u></p> <ul style="list-style-type: none"> • Lactulose⁷⁶ • Mannitol • L:M (97 tested) <p><u>Stool Tests:</u></p> <ul style="list-style-type: none"> • Lactoferrin (93 tested) • Leukocytes <p><u>Blood Tests:</u></p> <ul style="list-style-type: none"> • C-reactive protein (CRP) • α-1-acid glycoprotein (AGP) 	<p>48.5% had abnormal L:M.</p> <p>L:M and excretion of each sugar separately did not vary with retinol concentration.</p> <p>L:M was associated with levels of common dietary carotenoids, primarily driven by lactulose. However, the association was not always statistically significant, and the direction of association varied depending on precursor.</p> <p>40% of stool samples were positive for lactoferrin.</p>	<p>Almost half of subjects had increased L:M, and ~40% of subjects had increased lactoferrin.</p> <p>While serum retinol concentrations were not associated with L:M, serum carotenoids were; authors suggest that these retinol precursors might be more sensitive predictors of</p>	<p>L:M threshold for abnormal values was defined as ≥ 0.0864 [214]. Cut-off values for lactoferrin positivity were not described.</p> <p>Relationships between acute phase proteins and measures of intestinal permeability or inflammation were not reported. Relationships between L:M and lactoferrin or fecal</p>

⁷⁶ Lactulose and mannitol results were expressed as % of dose administered.

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
children with varying vitamin A status				1% of stool samples were positive for fecal leukocytes. 30% of stool samples were positive for parasites but this had no impact on L:M results, lactoferrin, or acute phase reactants.	impaired intestinal function. However, the reported direction of association varied, making interpretation of these results unclear.	leukocytes as well as those between retinol or carotenoids and lactoferrin or fecal leukocytes were not reported. Exclusively breastfed children were excluded from study participation due to assessment of stool lactoferrin.
2007 Williams EA et al. A double-blind, placebo-controlled, glutamine-supplementation trial in growth-faltering Gambian infants L:M and plasma immunoglobulins and acute phase reactant proteins (albumin, C-reactive protein, and alpha-1-antichymotrypsin) in community-based Gambian infants enrolled in a glutamine trial	West Kiang region, Gambia 4-10 mo olds from a rural area followed during the 5-month rainy season and for 6 months afterward.	Cohort n=72 Glutamine or placebo of nonessential amino acids was orally administered twice daily during rainy season; L:M ratio was measured monthly, and plasma samples were collected 3 times.	<u>Urine Tests:</u> • Lactulose ⁷⁶ • Mannitol • L:M <u>Blood markers</u> • C-reactive protein (CRP) • Alpha-1 antichymotrypsin (ACT) • IgA • IgG • IgM • Albumin	Mean ⁷⁷ L:M (CI): • Baseline: • Glutamine group: 0.33 (0.25, 0.43) • Placebo group: 0.33 (0.26, 0.41) • Post-intervention: • Glutamine group: 0.29 (0.23, 0.35) • Placebo group: 0.26 (0.21, 0.32) Mean excretion of lactulose (CI): • Baseline: • Glutamine group: 0.21 (0.16, 0.28) • Placebo group: 0.20 (0.15, 0.26) • Post-intervention: • Glutamine group: 0.17 (0.13, 0.21) • Placebo group: 0.14	L:M values were elevated in this population, with no significant change after the intervention. None of the plasma markers differed significantly between treatment and placebo groups, either at baseline or at the end of supplementation. Growth outcomes did not differ significantly across treatment groups.	The relationships between L:M and growth parameters, immuno-globulins, and acute phase proteins were not reported.

⁷⁷ Geometric mean

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
				<p>(0.11, 0.18)</p> <p>Mean excretion of mannitol (CI):</p> <ul style="list-style-type: none"> • Baseline: <ul style="list-style-type: none"> • Glutamine group: 2.65 (2.02, 3.48) • Placebo group: 2.50 (1.87, 3.36) • Post-intervention: <ul style="list-style-type: none"> • Glutamine group: 2.48 (1.99, 3.11) • Placebo group: 2.14 (1.62, 2.82) <p>L:M values did not differ significantly between treatment groups before or following intervention. However, a repeated measures ANOVA showed that during supplementation, L:M values were borderline elevated among the glutamine-supplemented group relative to the placebo group (p=0.05), counter to expectation.</p> <p>Neither ACT, CRP, albumin, nor immunoglobulins IgA, IgG, or IgM differed significantly between treatment and placebo groups, either at baseline or at the end of supplementation.</p> <p>Mean levels of IgA and IgG increased during the study (p <0.001), while IgM levels</p>		

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
				<p>did not. Concentrations of each of these immunoglobulins did not differ between treatment and placebo groups.</p> <p>Plasma albumin, ACT, and CRP values showed no change over the course of the study.</p> <p>Proportions of children with elevated CRP ranged from 30-41% at different collection time points. The glutamine intervention had no effect on proportion of children with elevated CRP.</p> <p>Treatment and placebo groups experienced decreases in WAZ, HAZ, and MUAC coinciding with the rainy season; however, there was no significant difference observed between the groups for any of these parameters.</p> <p>Treatment and placebo groups did not differ in morbidity indices (i.e. percentage of time reported with a particular illness or illness overall).</p>		
<p>2000 Willumsen JF et al. Subclinical mastitis as a risk factor for</p>	<p>Durban, South Africa HIV-infected breastfeeding mothers and their</p>	<p>Cross-sectional analysis of baseline data prior to randomization for an RCT</p>	<p><u>Urine Test:</u> L:M</p>	<p>There was no significant association between L:M and subclinical mastitis as measured by milk Na/K.</p>	<p>Subclinical mastitis was not associated with magnitude of L:M.</p>	<p>Actual L:M values were not reported but are found in a companion study, also included in this review [119].</p>

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
<p>mother-infant HIV transmission</p> <p>L:M as a marker of infant intestinal permeability and its relationship with subclinical maternal mastitis</p>	<p>infants followed up to 14 wk of age.</p> <p>Women recruited from antenatal clinic via a vitamin A supplementation trial to reduce mother-to-child HIV transmission.</p>	<p>n=104 mothers</p> <p>n=108 infants (4 pairs of twins), (26 were HIV-infected by 3 mo of age)</p>				<p>The study group in Willumsen, et al. represents a subsample of the study population reported in the companion study.</p>
<p>2000</p> <p>Zhang Y et al.</p> <p>Lactulose-mannitol intestinal permeability test in children with diarrhea caused by rotavirus and <i>Cryptosporidium</i></p> <p>L:M as a marker of intestinal permeability in children with diarrhea</p>	<p>Lima, Peru</p> <p>0-36 mo olds with watery diarrhea admitted to oral rehydration unit of hospital.</p>	<p>Case-control</p> <p>n=36;</p> <p>n=29 cases:</p> <ul style="list-style-type: none"> • 15 with <i>C. parvum</i> alone • 7 with rotavirus alone • 7 with bacteria (alone or with rotavirus or <i>Cryptosporidium</i>) <p>n=7 controls with unknown etiology</p>	<p><u>Urine Test:</u> L:M</p> <p>Enrollment and convalescent (at day 20) L:M ratios were assessed.</p>	<p>Mean⁷⁸ L:M (SE) at day 1, day 20:</p> <ul style="list-style-type: none"> • Rotavirus only: 0.67 (0.38), 0.19 (0.09) • <i>Cryptosporidium</i> only: 0.76 (0.43), 0.28 (0.14) • Bacterial infection: ranged from 0.2-0.87, 0.11-0.99 • Unknown etiology: 0.26 (0.12), 0.29 (0.18) <p>Mean L:M ratios significantly differed between the unknown etiology and both the rotavirus (p< 0.01) and <i>Cryptosporidium</i> groups (p<0.05) at baseline, but not at day 20.</p> <p>Mean L:M ratios decreased between baseline and day 20 for both the rotavirus (p<0.001) and <i>Cryptosporidium</i> (p<0.05) groups.</p> <p>Among the group of subjects with enteric bacterial infections, the</p>	<p>L:M ratios were significantly elevated in children with rotavirus or <i>Cryptosporidium</i> infection compared to those with diarrhea not caused by rotavirus, <i>Cryptosporidium</i>, or identifiable bacteria.</p> <p>Mean L:M did not change significantly among those with diarrhea of unknown etiology, but did significantly decrease among those infected with rotavirus or <i>Cryptosporidium</i>, reaching ratios</p>	

⁷⁸ Arithmetic mean.

Appendix 7. Evidence table of all studies included in the review.

Reference and Study Outcomes of Diagnostic Interest	Location and Target Population	Design and Sample Size	Biomarker	Results	Conclusion	Comments
				causative agents identified and mean L:M ratios (baseline, day 20) were: <i>Campylobacter jejuni</i> and rotavirus infection (0.86, 0.18), <i>C. jejuni</i> and <i>Cryptosporidium</i> infection (0.87, 0.53), <i>Salmonella</i> sp. (0.2, 0.11), <i>C. jejuni</i> (0.69, 0.99), and <i>Aeromonas</i> sp. (0.38, 0.11). The L:M ratios of this group of seven infants were not included in the statistical analyses.	similar to those with diarrhea of unknown etiology.	

Notes: Some studies included subjects ≥ 5 yr of age. Where these studies provided data separately for children < 5 yr, we present results for only those subjects. Where these studies did not stratify results by age, but did report the number of children < 5 yr included in the study, we provide a breakdown of under-5s. All studies reporting lactulose:rhamnose ratio results presented values multiplied by a factor of 100 for ease of reporting. Further details on L:M studies can be found in Table 14.

Abbreviations: AD=acute diarrhea, ALT=alanine aminotransferase, AST=aspartate aminotransferase, CBC=complete blood count, CD=celiac disease, CI=95% confidence interval, Cr=creatinine, Δ =change in, EED=environmental enteric dysfunction, FTT=failure to thrive, GI=gastrointestinal, HAZ=height-for-age Z-(score), HDL=high density lipoproteins, HIV=human immunodeficiency virus, HLA=human leukocyte antigen, IEL=intraepithelial lymphocytes, IgA=immunoglobulin A, IgE=immunoglobulin E, IgG=immunoglobulin G, IgM=immunoglobulin M, IL=interleukin, IFN=interferon, LDL=low density lipoproteins, L:M=lactulose:mannitol ratio, mo=month(s), NS=not statistically significant, PD=persistent diarrhea, RCT=randomized controlled trial, SBBO=small bowel bacterial overgrowth, SD=standard deviation, SE=standard error, SES=socioeconomic status, Tc-99m=technetium 99, T3=triiodothyronine, T4 = thyroxine, TE=tropical enteropathy, TGF=transforming growth factor, TNF=tumor necrosis factor, TS=tropical sprue, WAZ=weight-for-age Z-(score), WBC=white blood cell count, WFA=weight-for-age, WHZ=weight-for-height Z-(score), wk=week(s), yr=year(s)

REFERENCES

1. Butterworth CE, Jr., Perez-Santiago E. Pathologic changes in jejunal biopsies from sprue patients; a preliminary report. *Am J Dig Dis.* 1957;2(11):659-62.
2. Hillary W. Observations on the changes of the air and the concomitant epidemical diseases in the island of Barbados, to which is added a treatise on the putrid bilious fever, commonly called the yellow fever: and such other diseases as are indigenous or endemical, in the West India Islands. 2nd ed. London: Hawes, Clarke, and Collins; 1766.
3. Booth CC. The 1st description of tropical sprue (William Hillary). *Gut.* 1964;5:45-50.
4. Manson P. Notes on Sprue in China, Imperial Maritime Customs, Special Series No. 2, Medical Reports for the Half Year Ended 31 March 1880 (19th issue). Shanghai: Statistical Department of the Inspectorate in General. 1880:33-7.
5. Ayrey F. Outbreaks of sprue during the Burma Campaign. *Trans R Soc Trop Med Hyg.* 1947;41:377-406.
6. Girdwood RH. Fifty years after: some experiences of the medical care of prisoners of war. *Scott Med J.* 1993;38(4):120-4.
7. Bartholomew C. William Hillary and sprue in the Caribbean: 230 years later. *Gut.* 1989;30 Spec No:17-21.
8. Ramakrishna BS, Venkataraman S, Mukhopadhyaya A. Tropical malabsorption. *Postgrad Med J.* 2006;82(974):779-87.
9. Mathan VI, Baker SJ. An epidemic of tropical sprue in southern India. I. Clinical features. *Ann Trop Med Parasitol.* 1970;64(4):439-51.
10. Cook GC. Malabsorption. *Br Med J.* 1967;11(1):613-7.
11. Falaiye JM. Present status of subclinical intestinal malabsorption in the tropics. *Br Med J.* 1971;20(4):454-8.
12. Moshal MG, Hift W, Kallichurum S, Pillay K. Endemic tropical sprue in Africa. *J Trop Med Hyg.* 1975;78:2-5.
13. Trehan I, Shulman RJ, Ou CN, Maleta K, Manary MJ. A randomized, double-blind, placebo-controlled trial of rifaximin, a nonabsorbable antibiotic, in the treatment of tropical enteropathy. *Am J Gastroenterol.* 2009;104(9):2326-33.
14. Kelly P, Menzies I, Crane R, Zulu I, Nickols C, Feakins R, et al. Responses of small intestinal architecture and function over time to environmental factors in a tropical population. *Am J Trop Med Hyg.* 2004;70(4):412-9.
15. Campbell DI, McPhail G, Lunn PG, Elia M, Jeffries DJ. Intestinal inflammation measured by fecal neopterin in Gambian children with enteropathy: association with growth failure, *Giardia lamblia*, and intestinal permeability. *J Pediatr Gastroenterol Nutr.* 2004;39(2):153-7.
16. Keusch GT, Rosenberg IH, Denno DM, Duggan C, Guerrant RL, Lavery JV, et al. Implications of acquired environmental enteric dysfunction for growth and stunting in infants and children living in low- and middle-income countries. *Food Nutr Bull.* 2013;34(3):357-64.

17. Fagundes-Neto U, Viaro T, Wehba J, da Silva Patricio FR, Machado NL. Tropical enteropathy (environmental enteropathy) in early childhood: a syndrome caused by contaminated environment. *J Trop Pediatr*. 1984;30:204-9.
18. Salazar-Lindo E, Allen S, Brewster DR, Elliott EJ, Fasano A, Phillips AD, et al. Intestinal infections and environmental enteropathy: Working Group report of the second World Congress of Pediatric Gastroenterology, Hepatology, and Nutrition. *J Pediatr Gastroenterol Nutr*. 2004;39 Suppl 2:S662-9.
19. Keusch GT, Denno DM, Black RE, Duggan C, Guerrant RL, Lavery JV, et al. Environmental enteric dysfunction: pathogenesis, diagnosis, and clinical consequences. *Clin Infect Dis*. 2014;59 Suppl 4:S207-12.
20. Snyder JD, Merson MH. The magnitude of the global problem of acute diarrhoeal disease: a review of active surveillance data. *Bull World Health Organ*. 1982;60(4):605-13.
21. Walker CL, Rudan I, Liu L, Nair H, Theodoratou E, Bhutta ZA, et al. Global burden of childhood pneumonia and diarrhoea. *Lancet*. 2013;381(9875):1405-16.
22. Victora CG, Bryce J, Fontaine O, Monasch R. Reducing deaths from diarrhoea through oral rehydration therapy. *Bull World Health Organ*. 2000;78(10):1246-55.
23. Munos MK, Walker CL, Black RE. The effect of oral rehydration solution and recommended home fluids on diarrhoea mortality. *Int J Epidemiol*. 2010;39 Suppl 1:i75-87.
24. UNICEF/WHO. Diarrhoea: Why children are still dying and what can be done. Geneva: 2009.
25. Feng XL, Theodoratou E, Liu L, Chan KY, Hipgrave D, Scherpbier R, et al. Social, economic, political and health system and program determinants of child mortality reduction in China between 1990 and 2006: A systematic analysis. *J Glob Health*. 2012;2(1):010405.
26. UNICEF/WHO. Progress on Drinking Water and Sanitation – 2014 Update. Geneva: 2014.
27. Pruss-Ustun A, Bartram J, Clasen T, Colford JM, Jr., Cumming O, Curtis V, et al. Burden of disease from inadequate water, sanitation and hygiene in low- and middle-income settings: a retrospective analysis of data from 145 countries. *Trop Med Int Health*. 2014;19(8):894-905.
28. Bain R, Cronk R, Hossain R, Bonjour S, Onda K, Wright J, et al. Global assessment of exposure to faecal contamination through drinking water based on a systematic review. *Trop Med Int Health*. 2014;19(8):917-27.
29. Freeman MC, Stocks ME, Cumming O, Jeandron A, Higgins JP, Wolf J, et al. Hygiene and health: systematic review of handwashing practices worldwide and update of health effects. *Trop Med Int Health*. 2014;19(8):906-16.
30. Wolf J, Pruss-Ustun A, Cumming O, Bartram J, Bonjour S, Cairncross S, et al. Assessing the impact of drinking water and sanitation on diarrhoeal disease in low- and middle-income settings: systematic review and meta-regression. *Trop Med Int Health*. 2014;19(8):928-42.
31. Bhutta ZA, Bird SM, Black RE, Brown KH, Gardner JM, Hidayat A, et al. Therapeutic effects of oral zinc in acute and persistent diarrhea in children in developing countries: pooled analysis of randomized controlled trials. *Am J Clin Nutr*. 2000;72(6):1516-22.
32. Bhutta ZA, Black RE, Brown KH, Gardner JM, Gore S, Hidayat A, et al. Prevention of diarrhea and pneumonia by zinc supplementation in children in developing countries: pooled analysis of randomized controlled trials. Zinc Investigators' Collaborative Group. *J Pediatr*. 1999;135(6):689-97.
33. Walker CL, Black RE. Zinc for the treatment of diarrhoea: effect on diarrhoea morbidity, mortality and incidence of future episodes. *Int J Epidemiol*. 2010;39 Suppl 1:i63-9.

34. Glass RI, Bresee JS, Turcios R, Fischer TK, Parashar UD, Steele AD. Rotavirus vaccines: targeting the developing world. *J Infect Dis*. 2005;192 Suppl 1:S160-6.
35. Tate JE, Panozzo CA, Payne DC, Patel MM, Cortese MM, Fowlkes AL, et al. Decline and change in seasonality of US rotavirus activity after the introduction of rotavirus vaccine. *Pediatrics*. 2009;124(2):465-71.
36. Gurgel RG, Bohland AK, Vieira SC, Oliveira DM, Fontes PB, Barros VF, et al. Incidence of rotavirus and all-cause diarrhea in northeast Brazil following the introduction of a national vaccination program. *Gastroenterology*. 2009;137(6):1970-5.
37. Lopez AL, Clemens JD, Deen J, Jodar L. Cholera vaccines for the developing world. *Hum Vaccin*. 2008;4(2):165-9.
38. Sur D, Ochiai RL, Bhattacharya SK, Ganguly NK, Ali M, Manna B, et al. A cluster-randomized effectiveness trial of Vi typhoid vaccine in India. *N Engl J Med*. 2009;361(4):335-44.
39. What We Do: Enteric and Diarrheal Diseases Strategy Overview. Gates Foundation website. Accessed September 30, 2014. Available from: <http://www.gatesfoundation.org/What-We-Do/Global-Health/Enteric-and-Diarrheal-Diseases>
40. Boschi-Pinto C, Lanata CF, Black RE. The global burden of childhood diarrhoea. In: Ehiri JE, Meremikwu M, editors. *International Maternal and Child Health*. Washington, DC: Springer; 2009. p. 225-43.
41. Checkley W, Buckley G, Gilman RH, Assis AM, Guerrant RL, Morris SS, et al. Multi-country analysis of the effects of diarrhoea on childhood stunting. *Int J Epidemiol*. 2008;37(4):816-30.
42. Tormo R, Polanco I, Salazar-Lindo E, Goulet O. Acute infectious diarrhoea in children: new insights in antisecretory treatment with racecadotril. *Acta Paediatr*. 2008;97(8):1008-15.
43. Kukuruzovic R, Brewster DR, Gray E, Anstey NM. Increased nitric oxide production in acute diarrhoea is associated with abnormal gut permeability, hypokalaemia and malnutrition in tropical Australian aboriginal children. *Trans R Soc Trop Med Hyg*. 2003;97(1):115-20.
44. Brewster DR, Manary MJ, Menzies IS, O'Loughlin EV, Henry RL. Intestinal permeability in kwashiorkor. *Arch Dis Child*. 1997;76(3):236-41.
45. Humphrey JH. Child undernutrition, tropical enteropathy, toilets, and handwashing. *Lancet*. 2009;374(9694):1032-5.
46. Fontaine O, Kosek M, Bhatnagar S, Boschi-Pinto C, Chan KY, Duggan C, et al. Setting research priorities to reduce global mortality from childhood diarrhoea by 2015. *PLoS Med*. 2009;6(3):e41.
47. Kosek M, Lanata CF, Black RE, Walker DG, Snyder JD, Salam MA, et al. Directing diarrhoeal disease research towards disease-burden reduction. *J Health Popul Nutr*. 2009;27(3):319-31.
48. Moore SR, Lima AA, Conaway MR, Schorling JB, Soares AM, Guerrant RL. Early childhood diarrhoea and helminthiasis associate with long-term linear growth faltering. *Int J Epidemiol*. 2001;30(6):1457-64.
49. Petri WA, Jr., Miller M, Binder HJ, Levine MM, Dillingham R, Guerrant RL. Enteric infections, diarrhea, and their impact on function and development. *J Clin Invest*. 2008;118:1277-90.
50. Lorntz B, Soares AM, Moore SR, Pinkerton R, Gansneder B, Bovbjerg VE, et al. Early childhood diarrhea predicts impaired school performance. *Pediatr Infect Dis J*. 2006;25(6):513-20.

51. Steiner TS, Lima AA, Nataro JP, Guerrant RL. Enteroaggregative *Escherichia coli* produce intestinal inflammation and growth impairment and cause interleukin-8 release from intestinal epithelial cells. *J Infect Dis.* 1998;177(1):88-96.
52. Lunn PG. The impact of infection and nutrition on gut function and growth in childhood. *Proc Nutr Soc.* 2000;59(1):147-54.
53. Nichols BL, Nichols VN, Putman M, Avery SE, Fraley JK, Quaroni A, et al. Contribution of villous atrophy to reduced intestinal maltase in infants with malnutrition. *J Pediatr Gastroenterol Nutr.* 2000;30(5):494-502.
54. Veitch AM, Kelly P, Zulu IS, Segal I, Farthing MJ. Tropical enteropathy: a T-cell-mediated crypt hyperplastic enteropathy. *Eur J Gastroenterol Hepatol.* 2001;13(10):1175-81.
55. Keusch GT. Subclinical malabsorption in Thailand. I. Intestinal absorption in Thai children. *Am J Clin Nutr.* 1972;25(10):1062-6.
56. Brewster DR. *Intestinal Permeability in Protein-Energy Malnutrition.* Oxford: Oxford University Press; 2000.
57. Menzies IS, Zuckerman MJ, Nukajam WS, Somasundaram SG, Murphy B, Jenkins AP, et al. Geography of intestinal permeability and absorption. *Gut.* 1999;44(4):483-9.
58. Kukuruzovic RH, Brewster DR. Small bowel intestinal permeability in Australian Aboriginal children. *J Pediatr Gastroenterol Nutr.* 2002;35(2):206-12.
59. Marchetti G, Tincati C, Silvestri G. Microbial translocation in the pathogenesis of HIV infection and AIDS. *Clin Microbiol Rev.* 2013;26(1):2-18.
60. Thayu M, Denson LA, Shults J, Zemel BS, Burnham JM, Baldassano RN, et al. Determinants of changes in linear growth and body composition in incident pediatric Crohn's disease. *Gastroenterology.* 2010;139(2):430-8.
61. Hibbert JM, Hsu LL, Bhatena SJ, Irune I, Sarfo B, Creary MS, et al. Proinflammatory cytokines and the hypermetabolism of children with sickle cell disease. *Exp Biol Med (Maywood).* 2005;230(1):68-74.
62. Denno D. Global child health. *Pediatr Rev.* 2011;32(2):e25-38.
63. Guerrant RL, Oria RB, Moore SR, Oria MOB, Lima AAM. Malnutrition as an enteric infectious disease with long-term effects on child development. *Nutr Rev.* 2008;66(9):487-505.
64. Mata L. Diarrheal disease as a cause of malnutrition. *Am J Trop Med Hyg.* 1992;47(1 Pt 2):16-27.
65. Black RE, Victora CG, Walker SP, Bhutta ZA, Christian P, de Onis M, et al. Maternal and child undernutrition and overweight in low-income and middle-income countries. *Lancet.* 2013;382(9890):427-51.
66. Guerrant RL, Schorling JB, McAuliffe JF, de Souza MA. Diarrhea as a cause and an effect of malnutrition: diarrhea prevents catch-up growth and malnutrition increases diarrhea frequency and duration. *Am J Trop Med Hyg.* 1992;47(1 Pt 2):28-35.
67. Schorling JB, Guerrant RL. Diarrhoea and catch-up growth. *Lancet.* 1990;335(8689):599-600.
68. Guerrant RL, Kosek M, Lima AA, Lorntz B, Guyatt HL. Updating the DALYs for diarrhoeal disease. *Trends Parasitol.* 2002;18(5):191-3.
69. Niehaus MD, Moore SR, Patrick PD, Derr LL, Lorntz B, Lima AA, et al. Early childhood diarrhea is associated with diminished cognitive function 4 to 7 years later in children in a northeast Brazilian shantytown. *Am J Trop Med Hyg.* 2002;66(5):590-3.

70. Bhutta ZA, Ghishan F, Lindley K, Memon IA, Mittal S, Rhoads JM. Persistent and chronic diarrhea and malabsorption: Working Group report of the second World Congress of Pediatric Gastroenterology, Hepatology, and Nutrition. *J Pediatr Gastroenterol Nutr.* 2004;39 Suppl 2:S711-6.
71. Berkman DS, Lescano AG, Gilman RH, Lopez SL, Black MM. Effects of stunting, diarrhoeal disease, and parasitic infection during infancy on cognition in late childhood: a follow-up study. *Lancet.* 2002;359(9306):564-71.
72. UNICEF. *The State of the World's Children 2007: Executive Summary.* UNICEF, 2006.
73. Walker SP, Wachs TD, Grantham-McGregor S, Black MM, Nelson CA, Huffman SL, et al. Inequality in early childhood: risk and protective factors for early child development. *Lancet.* 2011;378(9799):1325-38.
74. Pongcharoen T, Ramakrishnan U, DiGirolamo AM, Winichagoon P, Flores R, Singkhornard J, et al. Influence of prenatal and postnatal growth on intellectual functioning in school-aged children. *Arch Pediatr Adolesc Med.* 2012;166(5):411-6.
75. Martorell R, Horta BL, Adair LS, Stein AD, Richter L, Fall CH, et al. Weight gain in the first two years of life is an important predictor of schooling outcomes in pooled analyses from five birth cohorts from low- and middle-income countries. *J Nutr.* 2010;140(2):348-54.
76. Adair LS, Fall CH, Osmond C, Stein AD, Martorell R, Ramirez-Zea M, et al. Associations of linear growth and relative weight gain during early life with adult health and human capital in countries of low and middle income: findings from five birth cohort studies. *Lancet.* 2013;382(9891):525-34.
77. Black RE, Allen LH, Bhutta ZA, Caulfield LE, de Onis M, Ezzati M, et al. Maternal and child undernutrition: global and regional exposures and health consequences. *Lancet.* 2008;371(9608):243-60.
78. Lee AC, Darmstadt GL, Khatri SK, LeClerq SC, Shrestha SR, Christian P. Maternal-fetal disproportion and birth asphyxia in rural Sarlahi, Nepal. *Arch Pediatr Adolesc Med.* 2009;163(7):616-23.
79. Subramanian SV, Ackerson LK, Davey Smith G, John NA. Association of maternal height with child mortality, anthropometric failure, and anemia in India. *JAMA.* 2009;301(16):1691-701.
80. Brantley RK, Williams KR, Silva TM, Sstrom M, Thielman NM, Ward H, et al. AIDS-associated diarrhea and wasting in Northeast Brazil is associated with subtherapeutic plasma levels of antiretroviral medications and with both bovine and human subtypes of *Cryptosporidium parvum*. *Braz J Infect Dis.* 2003;7(1):16-22.
81. Ogra PL, Okayasu H, Czerkinsky C, Sutter RW. Mucosal immunity to poliovirus. *Expert Rev Vaccines.* 2011;10(10):1389-92.
82. Dewey KG, Adu-Afarwah S. Systematic review of the efficacy and effectiveness of complementary feeding interventions in developing countries. *Matern Child Nutr.* 2008;4 Suppl 1:24-85.
83. Church PC, Guan J, Walters TD, Frost K, Assa A, Muise AM, et al. Infliximab maintains durable response and facilitates catch-up growth in luminal pediatric Crohn's disease. *Inflamm Bowel Dis.* 2014;20(7):1177-86.
84. Field M. Intestinal secretion: effect of cyclic AMP and its role in cholera. *N Engl J Med.* 1971;284:1137-44.

85. Sawaya AL, Martins PA, Baccin Martins VJ, Florencio TT, Hoffman D, do Carmo PFM, et al. Malnutrition, long-term health and the effect of nutritional recovery. *Nestle Nutr Workshop Ser Pediatr Program*. 2009;63:95-105; -8, 259-68.
86. Silva EC, Martins IS, de Araujo EA. [Metabolic syndrome and short stature in adults from the metropolitan area of Sao Paulo city (SP, Brazil)]. *Cien Saude Colet*. 2011;16(2):663-8.
87. Solomons NW. Environmental contamination and chronic inflammation influence human growth potential. *J Nutr*. 2003;133(5):1237.
88. Bickler SW, DeMaio A. Western diseases: current concepts and implications for pediatric surgery research and practice. *Pediatr Surg Int*. 2008;24(3):251-5.
89. Bouree P. [Tropical sprue]. *Presse Med*. 2007;36(4 Pt 2):723-6.
90. Owens SR, Greenson JK. The pathology of malabsorption: current concepts. *Histopathology*. 2007;50(1):64-82.
91. Nath SK. Tropical sprue. *Curr Gastroenterol Rep*. 2005;7(5):343-9.
92. Chang F, Mahadeva U, Deere H. Pathological and clinical significance of increased intraepithelial lymphocytes (IELs) in small bowel mucosa. *APMIS*. 2005;113(6):385-99.
93. Mathan VI. Diarrhoeal diseases. *Br Med Bull*. 1998;54(2):407-19.
94. Country and Lending Groups. World Bank website. Accessed June 1, 2010. Available from: <http://data.worldbank.org/about/country-classifications/country-and-lending-groups>
95. Country Classifications: a Short History. World Bank website. Accessed June 1, 2010. Available from: <http://data.worldbank.org/about/country-classifications/a-short-history>
96. Mathai J, Raju B, Bavdekar A. Chronic and persistent diarrhea in infants and young children: status statement. *Indian Pediatr*. 2011;48(1):37-42.
97. Pai CG, Khandige GK. Is Crohn's disease rare in India? *Indian J Gastroenterol*. 2000;19(1):17-20.
98. Koepsell TD, Weiss NS. Chapter 10: Measurement Error. *Epidemiologic Methods: Studying the Occurrence of Illness*. New York: Oxford University Press; 2003.
99. Higgins JPT, Green S. *Cochrane Handbook for Systematic Reviews of Interventions*. West Sussex: Wiley Blackwell; 2008.
100. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform*. 2009;42(2):377-81.
101. Alcantara CS, Yang CH, Steiner TS, Barrett LJ, Lima AA, Chappell CL, et al. Interleukin-8, tumor necrosis factor-alpha, and lactoferrin in immunocompetent hosts with experimental and Brazilian children with acquired cryptosporidiosis. *Am J Trop Med Hyg*. 2003;68(3):325-8.
102. Alves GM, de Moraes MB, Fagundes-Neto U. [Nutritional status and breath hydrogen test with lactose and lactulose in Terena Indian children]. *J Pediatr (Rio J)*. 2002;78(2):113-9.
103. Amadi B, Fagbemi AO, Kelly P, Mwiya M, Torrente F, Salvestrini C, et al. Reduced production of sulfated glycosaminoglycans occurs in Zambian children with kwashiorkor but not marasmus. *Am J Clin Nutr*. 2009;89(2):592-600.
104. Azim T, Islam LN, Sarker MS, Ahmad SM, Hamadani JD, Faruque SM, et al. Immune response of Bangladeshi children with acute diarrhea who subsequently have persistent diarrhea. *J Pediatr Gastroenterol Nutr*. 2000;31(5):528-35.

105. Bhatnagar S, Gupta SD, Mathur M, Phillips AD, Kumar R, Knutton S, et al. Celiac disease with mild to moderate histologic changes is a common cause of chronic diarrhea in Indian children. *J Pediatr Gastroenterol Nutr.* 2005;41(2):204-9.
106. Bitarakwate E, Mworozzi E, Kekitiinwa A. Serum zinc status of children with persistent diarrhoea admitted to the diarrhoea management unit of Mulago Hospital, Uganda. *Afr Health Sci.* 2003;3(2):54-60.
107. Bukhari AS, Jalal F, Nagra SA, Rajoka MI. DNA damage and plasma homocysteine levels are associated with serum metabolites and mineral constituents' profiles in children with persistent diarrhea. *Afr J Biotechnol.* 2010;9(3):357-61.
108. Bushen OY, Kohli A, Pinkerton RC, Dupnik K, Newman RD, Sears CL, et al. Heavy cryptosporidial infections in children in northeast Brazil: comparison of *Cryptosporidium hominis* and *Cryptosporidium parvum*. *Trans R Soc Trop Med Hyg.* 2007;101(4):378-84.
109. Bustos WM, Weisstaub NG, Araya QM. [Disaccharidase deficiency in Bolivian children with persistent diarrhea.] *Rev Chil Pediatr.* 2003;74(4):398-404.
110. Campbell DI, Elia M, Lunn PG. Growth faltering in rural Gambian infants is associated with impaired small intestinal barrier function, leading to endotoxemia and systemic inflammation. *J Nutr.* 2003;133(5):1332-8.
111. Campbell DI, Murch SH, Elia M, Sullivan PB, Sanyang MS, Jobarteh B, et al. Chronic T cell-mediated enteropathy in rural west African children: relationship with nutritional status and small bowel function. *Pediatr Res.* 2003;54(3):306-11.
112. Campbell DI, Lunn PG, Elia M. Age-related association of small intestinal mucosal enteropathy with nutritional status in rural Gambian children. *Br J Nutr.* 2002;88(5):499-505.
113. Chen P, Soares AM, Lima AA, Gamble MV, Schorling JB, Conway M, et al. Association of vitamin A and zinc status with altered intestinal permeability: analyses of cohort data from northeastern Brazil. *J Health Popul Nutr.* 2003;21(4):309-15.
114. Clark TD, Mmiro F, Ndugwa C, Perry RT, Jackson JB, Melikian G, et al. Risk factors and cumulative incidence of anaemia among human immunodeficiency virus-infected children in Uganda. *Ann Trop Paediatr.* 2002;22(1):11-7.
115. Darboe MK, Thurnham DI, Morgan G, Adegbola RA, Secka O, Solon JA, et al. Effectiveness of an early supplementation scheme of high-dose vitamin A versus standard WHO protocol in Gambian mothers and infants: a randomised controlled trial. *Lancet.* 2007;369(9579):2088-96.
116. Dini E, Toro O, Azuaje A. Sudan III y esteatocrito en la detección de grasa fecal en niños desnutridos. *GEN.* 2002;56(2):73-83.
117. El Mouzan MI, Assiri AM, Al Herbish AS, Al Sohaibani MO. Endoscopic duodenal biopsy in children. *Saudi J Gastroenterol.* 2006;12(1):31-3.
118. Fagundes-Neto U, De Martini-Costa S, Pedroso MZ, Scaletsky IC. Studies of the small bowel surface by scanning electron microscopy in infants with persistent diarrhea. *Braz J Med Biol Res.* 2000;33(12):1437-42.
119. Filteau SM, Rollins NC, Coutsooudis A, Sullivan KR, Willumsen JF, Tomkins AM. The effect of antenatal vitamin A and (beta)-carotene supplementation on gut integrity of infants of HIV-infected South African women. *J Pediatr Gastroenterol Nutr.* 2001;32(4):464-70.

120. Galpin L, Manary MJ, Fleming K, Ou CN, Ashorn P, Shulman RJ. Effect of *Lactobacillus* GG on intestinal integrity in Malawian children at risk of tropical enteropathy. *Am J Clin Nutr*. 2005;82(5):1040-5.
121. Gandolfi L, Catassi C, Garcia S, Modelli IC, Campos Jr D, Pratesi R. Antiendomysial antibody test reliability in children with frequent diarrhea and malnutrition: is it celiac disease. *J Pediatr Gastroenterol Nutr*. 2001;33(4):483-7.
122. Goto R, Mascie-Taylor CG, Lunn PG. Impact of anti-*Giardia* and anthelmintic treatment on infant growth and intestinal permeability in rural Bangladesh: a randomised double-blind controlled study. *Trans R Soc Trop Med Hyg*. 2008;103(5):520-9.
123. Goto R, Mascie-Taylor CG, Lunn PG. Impact of intestinal permeability, inflammation status and parasitic infections on infant growth faltering in rural Bangladesh. *Br J Nutr*. 2008;101(10):1509-16.
124. Goto R, Panter-Brick C, Northrop-Clewes CA, Manahdhar R, Tuladhar NR. Poor intestinal permeability in mildly stunted Nepali children: associations with weaning practices and *Giardia lamblia* infection. *Br J Nutr*. 2002;88(2):141-9.
125. Haase AM, Kukuruzovic RH, Dunn K, Bright A, Brewster DR. Dual sugar permeability testing in diarrheal disease. *J Pediatr*. 2000;136(2):232-7.
126. Hafeez A, Ali S, Hassan M. An audit of pediatric upper gastrointestinal endoscopies. *J Coll Physicians Surg Pak*. 2000;10(1):13-5.
127. Jain S, Das S, Gupta P. Fecal occult blood screening in children with severe malnutrition. *Indian Pediatr*. 2007;44(12):913-5.
128. Kapoor L, Chowdhary A, Malhotra VL, Bhatt V. Giardiasis--clinical and diagnostic perspective. *J Commun Dis*. 2001;33(2):72-7.
129. Kapoor S, Ratan SK, Kashyap R, Mittal SK, Rajeshwari K, Rawat H, et al. Detecting protein losing enteropathy by Tc-99m dextran scintigraphy: a novel experience. *Indian J Pediatr*. 2002;69(9):761-4.
130. Kirkpatrick BD, Huston CD, Wagner D, Noel F, Rouzier P, Pape JW, et al. Serum mannose-binding lectin deficiency is associated with cryptosporidiosis in young Haitian children. *Clin Infect Dis*. 2006;43(3):289-94.
131. Kirkpatrick BD, Noel F, Rouzier PD, Powell JL, Pape JW, Bois G, et al. Childhood cryptosporidiosis is associated with a persistent systemic inflammatory response. *Clin Infect Dis*. 2006;43(5):604-8.
132. Kirkpatrick BD, Daniels MM, Jean SS, Pape JW, Karp C, Littenberg B, et al. Cryptosporidiosis stimulates an inflammatory intestinal response in malnourished Haitian children. *J Infect Dis*. 2002;186(1):94-101.
133. Kohli A, Bushen OY, Pinkerton RC, Houpt E, Newman RD, Sears CL, et al. *Giardia duodenalis* assemblage, clinical presentation and markers of intestinal inflammation in Brazilian children. *Trans R Soc Trop Med Hyg*. 2008;102(7):718-25.
134. Kukuruzovic RH, Brewster DR. Milk formulas in acute gastroenteritis and malnutrition: a randomized trial. *J Paediatr Child Health*. 2002;38(6):571-7.
135. Laadhar L, Bouaziz N, Ben Ayed M, Chaabouni M, Boudawara T, Hachicha M, et al. [Determination of anti-transglutaminase antibodies in the diagnosis of coeliac disease in children: results of a five years prospective study]. *Ann Biol Clin (Paris)*. 2004;62(4):431-6.

136. Leite CA, Succi RC, Patricio FR, Fagundes-Neto U. [Functional, microbiological and morphological intestinal findings among human immunodeficiency virus infected children]. *Arq Gastroenterol.* 2006;43(4):310-5.
137. Lima AA, Soares AM, Lima NL, Mota RM, Maciel BL, Kvalsund MP, et al. Effects of vitamin A supplementation on intestinal barrier function, growth, total parasitic, and specific *Giardia* spp infections in Brazilian children: a prospective randomized, double-blind, placebo-controlled trial. *J Pediatr Gastroenterol Nutr.* 2010;50(3):309-15.
138. Lima AA, Brito LF, Ribeiro HB, Martins MC, Lustosa AP, Rocha EM, et al. Intestinal barrier function and weight gain in malnourished children taking glutamine supplemented enteral formula. *J Pediatr Gastroenterol Nutr.* 2005;40(1):28-35.
139. Lima NL, Soares AM, Mota RM, Monteiro HS, Guerrant RL, Lima AA. Wasting and intestinal barrier function in children taking alanyl-glutamine-supplemented enteral formula. *J Pediatr Gastroenterol Nutr.* 2007;44(3):365-74.
140. Long KZ, Estrada-Garcia T, Rosado JL, Ignacio Santos J, Haas M, Firestone M, et al. The effect of vitamin A supplementation on the intestinal immune response in Mexican children is modified by pathogen infections and diarrhea. *J Nutr.* 2006;136(5):1365-70.
141. López de Romaña D, Salazar M, Hambidge KM, Penny ME, Peerson JM, Krebs NF, et al. Longitudinal measurements of zinc absorption in Peruvian children consuming wheat products fortified with iron only or iron and 1 of 2 amounts of zinc. *Am J Clin Nutr.* 2005;81(3):637-47.
142. Mahmud MA, Hossain MM, Huang DB, Habib M, DuPont HL. Sociodemographic, environmental and clinical risk factors for developing persistent diarrhoea among infants in a rural community of Egypt. *J Health Popul Nutr.* 2001;19(4):313-9.
143. Mahmud MA, Marshall GD, Jr., Hossain MM, Huang DB, Habib M, DuPont HL. Increased fecal IgE among infants in a rural community of Egypt: an analysis of associated risk factors. *J Trop Pediatr.* 2001;47(6):339-44.
144. Manary MJ, Hotz C, Krebs NF, Gibson RS, Westcott JE, Broadhead RL, et al. Zinc homeostasis in Malawian children consuming a high-phytate, maize-based diet. *Am J Clin Nutr.* 2002;75(6):1057-61.
145. Mishra OP, Dhawan T, Singla PN, Dixit VK, Arya NC, Nath G. Endoscopic and histopathological evaluation of preschool children with chronic diarrhoea. *J Trop Pediatr.* 2001;47(2):77-80.
146. Mittal SK, Rajeshwari K, Kalra KK, Srivastava S, Malhotra V. Tropical sprue in north Indian children. *Trop Gastroenterol.* 2001;22(3):146-8.
147. Moya-Camarena SY, Sotelo N, Valencia ME. Effects of asymptomatic *Giardia intestinalis* infection on carbohydrate absorption in well-nourished Mexican children. *Am J Trop Med Hyg.* 2002;66(3):255-9.
148. Murphy JL, Badaloo AV, Chambers B, Forrester TE, Wootton SA, Jackson AA. Maldigestion and malabsorption of dietary lipid during severe childhood malnutrition. *Arch Dis Child.* 2002;87(6):522-5.
149. Murphy JL, Robinson EN, Forrester TE, Wootton SA, Jackson AA. Gastrointestinal handling and metabolic disposal of ¹³C-labelled tripalmitin during rehabilitation from childhood malnutrition. *Br J Nutr.* 2001;85(6):705-13.

150. Northrop-Clewes CA, Rousham EK, Mascie-Taylor CN, Lunn PG. Anthelmintic treatment of rural Bangladeshi children: effect on host physiology, growth, and biochemical status. *Am J Clin Nutr.* 2001;73(1):53-60.
151. Panter-Brick C, Lunn PG, Langford RM, Maharjan M, Manandhar DS. Pathways leading to early growth faltering: An investigation into the importance of mucosal damage and immunostimulation in different socio-economic groups in Nepal. *Br J Nutr.* 2009;101(4):558-67.
152. Perin NM, Pires MM, Nassar SM. [Intestinal absorption of D-xylose in children infected with the human immunodeficiency virus]. *Arq Gastroenterol.* 2001;38(4):261-8.
153. Pires AL, da Silveira TR, da Silva VD. [Digital morphometric and stereologic analysis of small intestinal mucosa in well-nourished and malnourished children with persistent diarrhea]. *J Pediatr (Rio J).* 2003;79(4):329-36.
154. Poddar U, Thapa BR, Nain CK, Singh K. Is tissue transglutaminase autoantibody the best for diagnosing celiac disease in children of developing countries? *J Clin Gastroenterol.* 2008;42(2):147-51.
155. Poddar U, Thapa BR, Nain CK, Prasad A, Singh K. Celiac disease in India: Are they true cases of celiac disease? *J Pediatr Gastroenterol Nutr.* 2002;35(4):508-12.
156. Quadro L, Gamble MV, Vogel S, Lima AA, Piantedosi R, Moore SR, et al. Retinol and retinol-binding protein: gut integrity and circulating immunoglobulins. *J Infect Dis.* 2000;182 Suppl 1:S97-S102.
157. Rabbani GH, Teka T, Saha SK, Zaman B, Majid N, Khatun M, et al. Green banana and pectin improve small intestinal permeability and reduce fluid loss in Bangladeshi children with persistent diarrhea. *Dig Dis Sci.* 2004;49(3):475-84.
158. Rabbani GH, Islam S, Chowdhury AK, Mitra AK, Miller MJ, Fuchs G. Increased nitrite and nitrate concentrations in sera and urine of patients with cholera or shigellosis. *Am J Gastroenterol.* 2001;96(2):467-72.
159. Ritchie BK, Brewster DR, Davidson GP, Tran CD, McNeil Y, Hawkes JS, et al. 13C-sucrose breath test: novel use of a noninvasive biomarker of environmental gut health. *Pediatrics.* 2009;124(2):620-6.
160. Rollins NC, Filteau SM, Coutsooudis A, Tomkins AM. Feeding mode, intestinal permeability, and neopterin excretion: a longitudinal study in infants of HIV-infected South African women. *J Acquir Immune Defic Syndr.* 2001;28(2):132-9.
161. Rollins NC, Filteau SM, Elson I, Tomkins AM. Vitamin A supplementation of South African children with severe diarrhea: optimum timing for improving biochemical and clinical recovery and subsequent vitamin A status. *Pediatr Infect Dis J.* 2000;19(4):284-9.
162. Samie A, Bessong PO, Obi CL, Sevilleja JEAD, Stroup S, Hout E, et al. *Cryptosporidium* species: preliminary descriptions of the prevalence and genotype distribution among school children and hospital patients in the Venda region, Limpopo Province, South Africa. *Exp Parasitol.* 2006;114(4):314-22.
163. Sarker SA, Davidsson L, Mahmud H, Walczyk T, Hurrell RF, Gyr N, et al. *Helicobacter pylori* infection, iron absorption, and gastric acid secretion in Bangladeshi children. *Am J Clin Nutr.* 2004;80(1):149-53.
164. Sheng XY, Hambidge KM, Zhu XX, Ni JX, Bailey KB, Gibson RS, et al. Major variables of zinc homeostasis in Chinese toddlers. *Am J Clin Nutr.* 2006;84(2):389-94.

165. Sherwani RK, Alam S, Akhtar K, Abid B, Rahman K, Mehdi R. Prevalence of iron deficiency anemia in chronic diarrhoea and celiac disease - a western UP experience. *Indian J Hematol Blood Transfus.* 2008;24(1):12-5.
166. Soliman SM, Helwa AH, Al Shafei MM, Al Okbi SY. Role of micronutrient mixture in acute and persistent diarrhea in infants and its impact on nutritional status. *Pol J Food Nutr Sci.* 2003;12(3):83-8.
167. Tassara R, Alarcon T, Larranaga C, Wu E, Alvarez AM. [Digestive pathology in children infected with the human immunodeficiency virus (HIV), in Santiago de Chile]. *Rev Med Chil.* 2003;131(1):19-24.
168. Thurnham DI, Northrop-Clewes CA, McCullough FS, Das BS, Lunn PG. Innate immunity, gut integrity, and vitamin A in Gambian and Indian infants. *J Infect Dis.* 2000;182 Suppl 1:S23-8.
169. Vieira MM, Paik J, Blaner WS, Soares AM, Mota RM, Guerrant RL, et al. Carotenoids, retinol, and intestinal barrier function in children from northeastern Brazil. *J Pediatr Gastroenterol Nutr.* 2008;47(5):652-9.
170. Williams EA, Elia M, Lunn PG. A double-blind, placebo-controlled, glutamine-supplementation trial in growth-faltering Gambian infants. *Am J Clin Nutr.* 2007;86(2):421-7.
171. Willumsen BM, Filteau SM, Coutsooudis A, Uebel KE, Newell ML, Tomkins AM. Subclinical mastitis as a risk factor for mother-infant HIV transmission. *Adv Exp Med Biol.* 2000;478:211-23.
172. Zhang Y, Lee B, Thompson M, Glass R, Cama RI, Figueroa D, et al. Lactulose-mannitol intestinal permeability test in children with diarrhea caused by rotavirus and *Cryptosporidium*. Diarrhea Working Group, Peru. *J Pediatr Gastroenterol Nutr.* 2000;31(1):16-21.
173. Ngure FM, Humphrey JH, Mbuya MN, Majo F, Mutasa K, Govha M, et al. Formative research on hygiene behaviors and geophagy among infants and young children and implications of exposure to fecal bacteria. *Am J Trop Med Hyg.* 2013;89(4):709-16.
174. Xylose structure. Accessed October 25, 2012. Available from: <http://commons.wikimedia.org/w/index.php?title=File:D-Xylose.svg&page=1>
175. Lactose structure. Accessed October 25, 2012. Available from: http://en.wikipedia.org/w/index.php?title=File:Lactose_Haworth.svg&page=1
176. Lactulose structure. Accessed October 25, 2012. Available from: https://en.wikipedia.org/wiki/File:Lactulose_structure.svg
177. Mannitol structure. Accessed October 25, 2012. Available from: http://en.wikipedia.org/wiki/File:Mannitol_structure.png
178. Alpha-L-Rhamnopyranose structure. Accessed October 25, 2012. Available from: <http://de.wikipedia.org/w/index.php?title=Datei:Alpha-L-Rhamnopyranose.svg&page=1&filetimestamp=20111208092120>
179. Sucralose structure. Accessed October 25, 2012. Available from: <http://en.wikipedia.org/wiki/File:Sucralose2.png>
180. Saccharose structure. Accessed October 25, 2012. Available from: <http://en.wikipedia.org/w/index.php?title=File:Saccharose2.svg&page=1>
181. Nicolaysen R. Studies upon the mode of action of vitamin D: The absorption of calcium chloride, xylose and sodium sulphate from isolated loops of the small intestine and of calcium chloride from the abdominal cavity in the rat. *Biochem J.* 1937;31(2):323-8.

182. Helmer OM, Fouts PJ. Gastro-Intestinal Studies. VII. The Excretion of Xylose in Pernicious Anemia. *J Clin Invest.* 1937;16(3):343-9.
183. Tveito K, Brunborg C, Bratlie J, Askedal M, Sandvik L, Lundin KE, et al. Intestinal malabsorption of D-xylose: comparison of test modalities in patients with celiac disease. *Scand J Gastroenterol.* 2010;45(11):1289-94.
184. Peeters M, Hiele M, Ghooys Y, Huysmans V, Geboes K, Vantrappen G, et al. Test conditions greatly influence permeation of water soluble molecules through the intestinal mucosa: need for standardisation. *Gut.* 1994;35(10):1404-8.
185. Denno DM, VanBuskirk K, Nelson ZC, Musser CA, Hay Burgess DC, Tarr PI. Use of the lactulose to mannitol ratio to evaluate childhood environmental enteric dysfunction: a systematic review. *Clin Infect Dis.* 2014;59 Suppl 4:S213-9.
186. Fischbach FT, Dunning III MB, editors. *Manual of Laboratory and Diagnostic Tests.* 8th ed. Philadelphia: Lippincott Williams and Wilkins; 2009.
187. Manary MJ, Hotz C, Krebs NF, Gibson RS, Westcott JE, Arnold T, et al. Dietary phytate reduction improves zinc absorption in Malawian children recovering from tuberculosis but not in well children. *J Nutr.* 2000;130(12):2959-64.
188. Krebs NF, Westcott JE, Arnold TD, Kluger BM, Accurso FJ, Miller LV, et al. Abnormalities in zinc homeostasis in young infants with cystic fibrosis. *Pediatr Res.* 2000;48(2):256-61.
189. Schoeller DA, Klein PD, MacLean WC, Jr., Watkins JB, van Santen E. Fecal ¹³C analysis for the detection and quantitation of intestinal malabsorption. Limits of detection and application to disorders of intestinal cholyglycine metabolism. *J Lab Clin Med.* 1981;97(3):440-8.
190. Murphy JL, Laiho KM, Jones AE, Wootton SA. Metabolic handling of ¹³C labelled tripalmitin in healthy controls and patients with cystic fibrosis. *Arch Dis Child.* 1998;79(1):44-7.
191. Silverman A, Roy CC. *Pediatric Clinical Gastroenterology.* 3rd ed. St. Louis: C. V. Mosby; 1983.
192. Shmerling DH, Forrer JC, Prader A. Fecal fat and nitrogen in healthy children and in children with malabsorption or maldigestion. *Pediatrics.* 1970;46(5):690-5.
193. Iputo JE, Wong WW, Klein PD. Impaired lipidoxidation in kwashiorkor. *Nutr Res.* 1998;18:1187-201.
194. Krebs NF, Hambidge KM, Westcott JE, Miller LV, Sian L, Bell M, et al. Exchangeable zinc pool size in infants is related to key variables of zinc homeostasis. *J Nutr.* 2003;133(5 Suppl 1):1498S-501S.
195. Mazariegos M, Hambidge KM, Krebs NF, Westcott JE, Lei S, Grunwald GK, et al. Zinc absorption in Guatemalan schoolchildren fed normal or low-phytate maize. *Am J Clin Nutr.* 2006;83(1):59-64.
196. Pitkanen E. The conversion of D-xylose into D-threitol in patients without liver disease and in patients with portal liver cirrhosis. *Clin Chim Acta.* 1977;80(1):49-54.
197. Fordtran JS, Clodi PH, Soergel KH, Ingelfinger FJ. Sugar absorption tests, with special reference to 3-O-methyl-D-glucose and D-xylose. *Ann Intern Med.* 1962;57:883-91.
198. Hughes E. *Normal Values.* London: Lancet Publishing Group; 1996.
199. Meites S, editor. *Pediatric Clinical Chemistry: reference (normal) values.* 3rd ed. Washington, DC: AACC Press; 1989.
200. Yao YM, Yu Y, Wang P, Tian HM, Sheng ZY. Elevated serum neopterin level: its relation to endotoxaemia and sepsis in patients with major burns. *Eur J Clin Invest.* 1996;26:224-30.

201. Travis S, Menzies I. Intestinal permeability: functional assessment and significance. *Clin Sci (Lond)*. 1992;82(5):471-88.
202. Lunn PG, Northrop-Clewes CA, Downes RM. Recent developments in the nutritional management of diarrhoea. 2. Chronic diarrhoea and malnutrition in The Gambia: studies on intestinal permeability. *Trans R Soc Trop Med Hyg*. 1991;85(1):8-11.
203. Arcara KM, Tschudy MM, Johns Hopkins Hospital. Children's Medical and Surgical Center. The Harriet Lane Handbook. 19th ed. Philadelphia, PA: Mosby/Elsevier; 2011.
204. Sann L, Bienvenu J, Lahet C, Divry P, Cotte J, Bethenod M. Serum orosomucoid concentration in newborn infants. *Eur J Pediatr*. 1981;136(2):181-5.
205. Goto K, Chew F, Torun B, Peerson JM, Brown KH. Epidemiology of altered intestinal permeability to lactulose and mannitol in Guatemalan infants. *J Pediatr Gastroenterol Nutr*. 1999;28(3):282-90.
206. Longo WE, Ballantyne GH, Savoca PE, Adrian TE, Bilchik AJ, Modlin IM. Short-chain fatty acid release of peptide YY in the isolated rabbit distal colon. *Scand J Gastroenterol*. 1991;26(4):442-8.
207. Willumsen JF, Darling JC, Kitundu JA, Kingamkono RR, Msengi AE, Mduma B, et al. Dietary management of acute diarrhoea in children: effect of fermented and amylase-digested weaning foods on intestinal permeability. *J Pediatr Gastroenterol Nutr*. 1997;24(3):235-41.
208. McCullough FSW, Northrop-Clewes CA, Das BS, Thurnham DI. Effect of vitamin A supplementation of hospitalized Indian infants with gastrointestinal and respiratory infections [Abstract T29, p. 80]. Presented at the Nineteenth International Vitamin A Consultative Group Meeting; 1999; Durban, South Africa.
209. Lunn PG, Northrop-Clewes CA, Downes RM. Intestinal permeability, mucosal injury, and growth faltering in Gambian infants. *Lancet*. 1991;338(8772):907-10.
210. Meddings JB, Sutherland LR, Byles NI, Wallace JL. Sucrose: a novel permeability marker for gastroduodenal disease. *Gastroenterology*. 1993;104(6):1619-26.
211. Meddings JB, Gibbons I. Discrimination of site-specific alterations in gastrointestinal permeability in the rat. *Gastroenterology*. 1998;114(1):83-92.
212. Shulman RJ, Eakin MN, Czyzewski DI, Jarrett M, Ou CN. Increased gastrointestinal permeability and gut inflammation in children with functional abdominal pain and irritable bowel syndrome. *J Pediatr*. 2008;153(5):646-50.
213. Anderson AD, Jain PK, Fleming S, Poon P, Mitchell CJ, MacFie J. Evaluation of a triple sugar test of colonic permeability in humans. *Acta Physiol Scand*. 2004;182(2):171-7.
214. Barboza Junior MS, Silva TM, Guerrant RL, Lima AA. Measurement of intestinal permeability using mannitol and lactulose in children with diarrheal diseases. *Braz J Med Biol Res*. 1999;32(12):1499-504.
215. Northrop CA, Lunn PG, Behrens RH. Automated enzymatic assays for the determination of intestinal permeability probes in urine. 1. Lactulose and lactose. *Clin Chim Acta*. 1990;187(2):79-87.
216. Lunn PG, Northrop CA, Northrop AJ. Automated enzymatic assays for the determination of intestinal permeability probes in urine. 2. Mannitol. *Clin Chim Acta*. 1989;183(2):163-70.
217. Juby LD, Rothwell J, Axon AT. Lactulose/mannitol test: an ideal screen for celiac disease. *Gastroenterology*. 1989;96(1):79-85.

218. Lunn PG, Northrop-Clewes CA. Intestinal permeability: update on the enzymatic assay of mannitol. *Clin Chim Acta*. 1992;205(1-2):151-2.
219. Freeman JV, Cole TJ, Chinn S, Jones PR, White EM, Preece MA. Cross sectional stature and weight reference curves for the UK, 1990. *Arch Dis Child*. 1995;73(1):17-24.
220. Weaver LT. The impact of milk and weaning diet on gastrointestinal permeability in English and Gambian infants. *Trans R Soc Trop Med Hyg*. 1988;82(5):784-9.
221. Sullivan PB, Lunn PG, Northrop-Clewes C, Crowe PT, Marsh MN, Neale G. Persistent diarrhea and malnutrition--the impact of treatment on small bowel structure and permeability. *J Pediatr Gastroenterol Nutr*. 1992;14(2):208-15.
222. Beattie RM, Walker-Smith JA, Murch SH. Indications for investigation of chronic gastrointestinal symptoms. *Arch Dis Child*. 1995;73(4):354-5.
223. Catassi C, Bonucci A, Coppa GV, Carlucci A, Giorgi PL. Intestinal permeability changes during the first month: effect of natural versus artificial feeding. *J Pediatr Gastroenterol Nutr*. 1995;21(4):383-6.
224. Catassi C, Pierani P, Natalini G, Gabrielli O, Coppa GV, Giorgi PL. Clinical application of a simple HPLC method for the sugar intestinal permeability test. *J Pediatr Gastroenterol Nutr*. 1991;12(2):209-12.
225. Shulman RJ, Schanler RJ, Lau C, Heitkemper M, Ou CN, Smith EO. Early feeding, antenatal glucocorticoids, and human milk decrease intestinal permeability in preterm infants. *Pediatr Res*. 1998;44(4):519-23.
226. van Elburg RM, Uil JJ, Kokke FTM, Et al. Repeatability of the sugar-absorption test, using lactulose and mannitol, for measuring intestinal permeability of sugars. *J Pediatr Gastroenterol Nutr*. 1995;20(2):184-8.
227. Ford RP, Menzies IS, Phillips AD, Walker-Smith JA, Turner MW. Intestinal sugar permeability: relationship to diarrhoeal disease and small bowel morphology. *J Pediatr Gastroenterol Nutr*. 1985;4(4):568-74.
228. Akram S, Mourani S, Ou CN, Rognerud C, Sadiq R, Goodgame RW. Assessment of intestinal permeability with a two-hour urine collection. *Dig Dis Sci*. 1998;43(9):1946-50.
229. Rousham EK, Northrop-Clewes CA, Lunn PG. Maternal reports of child illness and the biochemical status of the child: the use of morbidity interviews in rural Bangladesh. *Br J Nutr*. 1998;80(5):451-6.
230. Blood J, Ingle AR, Allison N, Davies GR, Hill PG. Rapid enzymatic method for the measurement of mannitol in urine. *Ann Clin Biochem*. 1991;28 (Pt 4):401-6.
231. Behrens RH, Lunn PG, Northrop CA, Hanlon PW, Neale G. Factors affecting the integrity of the intestinal mucosa of Gambian children. *Am J Clin Nutr*. 1987;45(6):1433-41.
232. Northrop CA, Lunn PG, Wainwright M, Evans J. Plasma albumin concentrations and intestinal permeability in Bangladeshi children infected with *Ascaris lumbricoides*. *Trans R Soc Trop Med Hyg*. 1987;81(5):811-5.
233. Bao Y, Silva TM, Guerrant RL, Lima AM, Fox JW. Direct analysis of mannitol, lactulose and glucose in urine samples by high-performance anion-exchange chromatography with pulse amperometric detection. Clinical evaluation of intestinal permeability in human immunodeficiency virus infection. *J Chromatogr B Biomed Appl*. 1996;685(1):105-12.

234. Lima AA, Silva TM, Gifoni AM, Barrett LJ, McAuliffe IT, Bao Y, et al. Mucosal injury and disruption of intestinal barrier function in HIV-infected individuals with and without diarrhea and cryptosporidiosis in northeast Brazil. *Am J Gastroenterol.* 1997;92(10):1861-6.
235. Deitch EA. Intestinal permeability is increased in burn patients shortly after injury. *Surgery.* 1990;107(4):411-6.
236. Ukabam SO, Cooper BT. Small intestinal permeability to mannitol, lactulose, and polyethylene glycol 400 in celiac disease. *Dig Dis Sci.* 1984;29(9):809-16.
237. Wyatt J, Vogelsang H, Hubl W, Waldhoer T, Lochs H. Intestinal permeability and the prediction of relapse in Crohn's disease. *Lancet.* 1993;341(8858):1437-9.
238. Pearson AD, Eastham EJ, Laker MF, Craft AW, Nelson R. Intestinal permeability in children with Crohn's disease and coeliac disease. *Br Med J (Clin Res Ed).* 1982;285(6334):20-1.
239. Behrens RH, Docherty H, Elia M, Neale G. A simple enzymatic method for the assay of urinary lactulose. *Clin Chim Acta.* 1984;137(3):361-7.
240. Yamanaka K. D-mannitol dehydrogenase from *Leuconostoc mesenteroides*. *Methods Enzymol.* 1975;41:138-42.
241. Roy SK, Behrens RH, Haider R, Akramuzzaman SM, Mahalanabis D, Wahed MA, et al. Impact of zinc supplementation on intestinal permeability in Bangladeshi children with acute diarrhoea and persistent diarrhoea syndrome. *J Pediatr Gastroenterol Nutr.* 1992;15(3):289-96.
242. Scarpignato C, Pelosini I. Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic. *Digestion.* 2006;73 Suppl 1:13-27.
243. Laker MF, Bull HJ, Menzies IS. Evaluation of mannitol for use as a probe marker of gastrointestinal permeability in man. *Eur J Clin Invest.* 1982;12(6):485-91.
244. Menzies IS, Jenkins AP, Heduan E, Catt SD, Segal MB, Creamer B. The effect of poorly absorbed solute on intestinal absorption. *Scand J Gastroenterol.* 1990;25(12):1257-64.
245. Miller MA, Parkman HP, Urbain JL, Brown KL, Donahue DJ, Knight LC, et al. Comparison of scintigraphy and lactulose breath hydrogen test for assessment of orocecal transit: lactulose accelerates small bowel transit. *Dig Dis Sci.* 1997;42(1):10-8.
246. Milnes JP, Walters AJ, Andrews DJ, Low-Beer TS. Urinary infection may invalidate the double-sugar test of intestinal permeability. *Scand J Gastroenterol.* 1988;23(7):885-90.
247. Begum HA. Effect of food supplementation on the growth of infants in rural Bangladesh [PhD thesis]. Cambridge: University of Cambridge; 2004.
248. Stephenson LS, Latham MC, Kinoti SN, Kurz KM, Brigham H. Improvements in physical fitness of Kenyan schoolboys infected with hookworm, *Trichuris trichiura* and *Ascaris lumbricoides* following a single dose of albendazole. *Trans R Soc Trop Med Hyg.* 1990;84(2):277-82.
249. Adams EJ, Stephenson LS, Latham MC, Kinoti SN. Physical activity and growth of Kenyan school children with hookworm, *Trichuris trichiura* and *Ascaris lumbricoides* infections are improved after treatment with albendazole. *J Nutr.* 1994;124(8):1199-206.
250. Hadju V, Stephenson LS, Abadi K, Mohammed HO, Bowman DD, Parker RS. Improvements in appetite and growth in helminth-infected schoolboys three and seven weeks after a single dose of pyrantel pamoate. *Parasitology.* 1996;113 (Pt 5):497-504.

251. Howden CW, Robertson C, Duncan A, Morris AJ, Russell RI. Comparison of different measurements of intestinal permeability in inflammatory bowel disease. *Am J Gastroenterol*. 1991;86(10):1445-9.
252. Cox MA, Iqbal TH, Cooper BT, Lewis KO. An analytical method for the quantitation of mannitol and disaccharides in serum: a potentially useful technique in measuring small intestinal permeability in vivo. *Clin Chim Acta*. 1997;263(2):197-205.
253. Fleming SC, Duncan A, Russell RI, Laker MF. Measurement of sugar probes in serum: an alternative to urine measurement in intestinal permeability testing. *Clin Chem*. 1996;42(3):445-8.
254. Cox MA, Lewis KO, Cooper BT. Measurement of small intestinal permeability markers, lactulose, and mannitol in serum: results in celiac disease. *Dig Dis Sci*. 1999;44(2):402-6.
255. Fleming SC, Kynaston JA, Laker MF, Pearson AD, Kapembwa MS, Griffin GE. Analysis of multiple sugar probes in urine and plasma by high-performance anion-exchange chromatography with pulsed electrochemical detection. Application in the assessment of intestinal permeability in human immunodeficiency virus infection. *J Chromatogr*. 1993;640(1-2):293-7.
256. Sorensen SH, Proud FJ, Rutgers HC, Markwell P, Adam A, Batt RM. A blood test for intestinal permeability and function: a new tool for the diagnosis of chronic intestinal disease in dogs. *Clin Chim Acta*. 1997;264(1):103-15.
257. Seguin P, Kleiber A, Chanavaz C, Morcet J, Malledant Y. Determination of capillary hemoglobin levels using the HemoCue system in intensive care patients. *J Crit Care*. 2011;26(4):423-7.
258. Kukuruzovic RH, Haase A, Dunn K, Bright A, Brewster DR. Intestinal permeability and diarrhoeal disease in Aboriginal Australians. *Arch Dis Child*. 1999;81(4):304-8.
259. Scrimshaw NS, Murray EB. The acceptability of milk and milk products in populations with a high prevalence of lactose intolerance. *Am J Clin Nutr*. 1988;48(4 Suppl):1079-159.
260. Newcomer AD, Thomas PJ, McGill DB, Hofmann AF. Lactase deficiency: a common genetic trait of the American Indian. *Gastroenterology*. 1977;72(2):234-7.
261. Test ID: UREDF; Reducing Substance, Feces. Mayo Medical Laboratories website. Accessed June 29, 2015. Available from: <http://www.mayomedicallaboratories.com/test-catalog/Clinical+and+Interpretive/83255>
262. Tibble J, Teahon K, Thjodleifsson B, Roseth A, Sigthorsson G, Bridger S, et al. A simple method for assessing intestinal inflammation in Crohn's disease. *Gut*. 2000;47(4):506-13.
263. Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. *Gastroenterology*. 2000;119(1):15-22.
264. D'Haens G, Ferrante M, Vermeire S, Baert F, Noman M, Moortgat L, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. *Inflamm Bowel Dis*. 2012;18(12):2218-24.
265. Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. *Lancet*. 2010;375(9709):132-40.

266. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. *Circulation*. 2003;107(3):363-9.
267. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Jr., Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. *N Engl J Med*. 2008;359(21):2195-207.
268. Turner D, Mack DR, Hyams J, LeLeiko N, Otle A, Markowitz J, et al. C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) or both? A systematic evaluation in pediatric ulcerative colitis. *J Crohns Colitis*. 2011;5(5):423-9.
269. Kellermayer R, Mir SA, Nagy-Szakal D, Cox SB, Dowd SE, Kaplan JL, et al. Microbiota separation and C-reactive protein elevation in treatment-naive pediatric granulomatous Crohn disease. *J Pediatr Gastroenterol Nutr*. 2012;55(3):243-50.
270. McMillan DC, Watson WS, O'Gorman P, Preston T, Scott HR, McArdle CS. Albumin concentrations are primarily determined by the body cell mass and the systemic inflammatory response in cancer patients with weight loss. *Nutr Cancer*. 2001;39(2):210-3.
271. Maher FT, Snell AM, Mann FD. Turbidimetric estimation of serum colloids in the differential diagnosis of hepatobiliary disease. *Gastroenterology*. 1949;12(3):394-408.
272. Zitrin CM, Lincoln EM, Saifer A, Lewkowicz S. Serum gamma globulin in childhood tuberculosis. *Am Rev Tuberc*. 1956;74(1):15-28.
273. Sihler KC, Raghavendran K, Westerman M, Ye W, Napolitano LM. Hepcidin in trauma: linking injury, inflammation, and anemia. *J Trauma*. 2010;69(4):831-7.
274. Lindenbaum J, Alam AK, Kent TH. Subclinical small-intestinal disease in East Pakistan. *Br Med J*. 1966;2(5530):1616-9.
275. Baker SJ, Mathan VI. Syndrome of tropical sprue in South India. *Am J Clin Nutr*. 1968;21(9):984-93.
276. Bonamico M, Mariani P, Thanasi E, Ferri M, Nenna R, Tiberti C, et al. Patchy villous atrophy of the duodenum in childhood celiac disease. *J Pediatr Gastroenterol Nutr*. 2004;38(2):204-7.
277. Ravelli A, Bolognini S, Gambarotti M, Villanacci V. Variability of histologic lesions in relation to biopsy site in gluten-sensitive enteropathy. *Am J Gastroenterol*. 2005;100(1):177-85.
278. Hopper AD, Cross SS, Sanders DS. Patchy villous atrophy in adult patients with suspected gluten-sensitive enteropathy: is a multiple duodenal biopsy strategy appropriate? *Endoscopy*. 2008;40(3):219-24.
279. Oxentenko AS, Grisolano SW, Murray JA, Burgart LJ, Dierkhising RA, Alexander JA. The insensitivity of endoscopic markers in celiac disease. *Am J Gastroenterol*. 2002;97(4):933-8.
280. Siddique I, Al-Mekhaizeem K, Alateeqi N, Memon A, Hasan F. Diagnosis of *Helicobacter pylori*: improving the sensitivity of CLOtest by increasing the number of gastric antral biopsies. *J Clin Gastroenterol*. 2008;42(4):356-60.
281. Eshun JK, Black DD, Casteel HB, Horn H, Beavers-May T, Jetton CA, et al. Comparison of immunohistochemistry and silver stain for the diagnosis of pediatric *Helicobacter pylori* infection in urease-negative gastric biopsies. *Pediatr Dev Pathol*. 2001;4(1):82-8.
282. Goel N, Sherwal BL, Patwari AK, Bajaj P, Choudhury M. Evaluation of invasive and non-invasive diagnostic modalities for *Helicobacter pylori* infection in children. *Indian Pediatr*. 2003;40(2):141-6.

283. Ni YH, Lin JT, Huang SF, Yang JC, Chang MH. Accurate diagnosis of *Helicobacter pylori* infection by stool antigen test and 6 other currently available tests in children. *J Pediatr*. 2000;136(6):823-7.
284. Ogata SK, Kawakami E, Patricio FR, Pedroso MZ, Santos AM. Evaluation of invasive and non-invasive methods for the diagnosis of *Helicobacter pylori* infection in symptomatic children and adolescents. *Sao Paulo Med J*. 2001;119(2):67-71.
285. Vinette KM, Gibney KM, Proujansky R, Fawcett PT. Comparison of PCR and clinical laboratory tests for diagnosing *H. pylori* infection in pediatric patients. *BMC Microbiol*. 2004;4:5.
286. Yanez P, la Garza AM, Perez-Perez G, Cabrera L, Munoz O, Torres J. Comparison of invasive and noninvasive methods for the diagnosis and evaluation of eradication of *Helicobacter pylori* infection in children. *Arch Med Res*. 2000;31(4):415-21.
287. Volonaki E, Sebire NJ, Borrelli O, Lindley KJ, Elawad M, Thapar N, et al. Gastrointestinal endoscopy and mucosal biopsy in the first year of life: indications and outcome. *J Pediatr Gastroenterol Nutr*. 2012;55(1):62-5.
288. Guidelines for Ambulatory Anesthesia and Surgery, Committee of Origin: Ambulatory Surgical Care. Approved by the American Society for Anesthesiology House of Delegates on October 15, 2003, and last amended on October 22, 2008.
289. Dunkin D, Benkov KJ, Rosenberg HK. Duodenal and rectal hematomas complicating endoscopic biopsy: use of sonography in pediatrics. *J Ultrasound Med*. 2009;28(11):1575-80.
290. Guzman C, Bousvaros A, Buonomo C, Nurko S. Intraduodenal hematoma complicating intestinal biopsy: case reports and review of the literature. *Am J Gastroenterol*. 1998;93(12):2547-50.
291. Bay A, Oner AF, Celebi V, Uner A. Evaluation of vitamin K deficiency in children with acute and intractable diarrhea. *Adv Ther*. 2006;23(3):469-74.
292. Kumar R, Marwaha N, Marwaha RK, Garewal G. Vitamin K deficiency in diarrhoea. *Indian J Pediatr*. 2001;68(3):235-8.
293. Almeida Cunha RP, Alves FP, Rocha AM, Rocha GA, Camargo LM, Nogueira PO, et al. Prevalence and risk factors associated with *Helicobacter pylori* infection in native populations from Brazilian Western Amazon. *Trans R Soc Trop Med Hyg*. 2003;97(4):382-6.
294. Muhsen K, Goren S, Cohen D. *Helicobacter pylori* infection in early childhood and growth at school age. *Helicobacter*. 2015;20(6):410-7.
295. Muhsen K, Jurban M, Goren S, Cohen D. Incidence, age of acquisition and risk factors of *Helicobacter pylori* infection among Israeli Arab infants. *J Trop Pediatr*. 2012;58(3):208-13.
296. Nguyen TV, Bengtsson C, Nguyen GK, Yin L, Hoang TT, Phung DC, et al. Age as risk factor for *Helicobacter pylori* recurrence in children in Vietnam. *Helicobacter*. 2012;17(6):452-7.
297. Rowland M, Daly L, Vaughan M, Higgins A, Bourke B, Drumm B. Age-specific incidence of *Helicobacter pylori*. *Gastroenterology*. 2006;130(1):65-72.
298. Antoniou D, Zarifi M, Gentimi F, Christopoulos-Geroulanos G. Sonographic diagnosis and monitoring of an intramural duodenal hematoma following upper endoscopic biopsy in a child. *J Clin Ultrasound*. 2009;37(9):534-8.
299. Bechtel K, Moss RL, Leventhal JM, Spiro D, Abo A. Duodenal hematoma after upper endoscopy and biopsy in a 4-year-old girl. *Pediatr Emerg Care*. 2006;22(9):653-4.

300. Borsaru AD, Nandurkar D. Intramural duodenal haematoma presenting as a complication after endoscopic biopsy. *Australas Radiol.* 2007;51(4):378-80.
301. Camarero C, Herrera D, Corbaton J, Mingo A, Olivares F, Roldan B. Intramural haematoma of the duodenum following endoscopic biopsy: an unusual complication of non-therapeutic endoscopy in children. *Eur J Pediatr.* 2004;163(7):418-9.
302. Diniz-Santos DR, de Andrade Cairo RC, Braga H, Araujo-Neto C, Paes IB, Silva LR. Duodenal hematoma following endoscopic duodenal biopsy: a case report and review of the existing literature. *Can J Gastroenterol.* 2006;20(1):39-42.
303. Dumitriu D, Menten R, Smets F, Clapuyt P. Postendoscopic duodenal hematoma in children: ultrasound diagnosis and follow-up. *J Clin Ultrasound.* 2014;42(9):550-3.
304. Eichele DD, Ross M, Tang P, Hutchins GF, Mailliard M. Spontaneous intramural duodenal hematoma in type 2B von Willebrand disease. *World J Gastroenterol.* 2013;19(41):7205-8.
305. Ghersin E, Gaitini D, Wills O, Soudack M, Engel A. Intramural duodenal hematoma mimicking an intestinal mass on sonography. *J Ultrasound Med.* 2002;21(6):693-5.
306. Winckworth LC, Tricot T, Fertleman C, Blumberg R. An unusual complication of endoscopic intestinal biopsy. *J Paediatr Child Health.* 2011;47(11):842.
307. Hameed S, McHugh K, Shah N, Arthurs OJ. Duodenal haematoma following endoscopy as a marker of coagulopathy. *Pediatr Radiol.* 2014;44(4):392-7.
308. Azim T, Ahmad SM, Sefat EK, Sarker MS, Unicomb LE, De S, et al. Immune response of children who develop persistent diarrhea following rotavirus infection. *Clin Diagn Lab Immunol.* 1999;6(5):690-5.
309. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. *JAMA.* 1996;276(8):637-9.
310. Moher D, Schulz KF, Altman DG, Consort Group. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. *Ann Intern Med.* 2001;134(8):657-62.
311. Hopewell S, Dutton S, Yu LM, Chan AW, Altman DG. The quality of reports of randomised trials in 2000 and 2006: comparative study of articles indexed in PubMed. *Br Med J.* 2010;340:c723.
312. Mills EJ, Wu P, Gagnier J, Devereaux PJ. The quality of randomized trial reporting in leading medical journals since the revised CONSORT statement. *Contemp Clin Trials.* 2005;26(4):480-7.
313. Plint AC, Moher D, Morrison A, Schulz K, Altman DG, Hill C, et al. Does the CONSORT checklist improve the quality of reports of randomised controlled trials? A systematic review. *Med J Aust.* 2006;185(5):263-7.
314. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. *Clin Chem.* 2003;49(1):7-18.
315. Makharia GK, Verma AK, Amarchand R, Bhatnagar S, Das P, Goswami A, et al. Prevalence of celiac disease in the northern part of India: a community based study. *J Gastroenterol Hepatol.* 2011;26(5):894-900.
316. Mal-Ed Network Investigators. The MAL-ED study: a multinational and multidisciplinary approach to understand the relationship between enteric pathogens, malnutrition, gut

- physiology, physical growth, cognitive development, and immune responses in infants and children up to 2 years of age in resource-poor environments. *Clin Infect Dis*. 2014;59 Suppl 4:S193-206.
317. Kosek M, Haque R, Lima A, Babji S, Shrestha S, Qureshi S, et al. Fecal markers of intestinal inflammation and permeability associated with the subsequent acquisition of linear growth deficits in infants. *Am J Trop Med Hyg*. 2013;88(2):390-6.
 318. Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. *Ann Intern Med*. 2010;152(11):726-32.
 319. STARD Report. EQUATOR (Enhancing the QUALity and Transparency Of health Research) website. Accessed September 19, 2014. Available from: <http://www.stard-statement.org/>